Surgical Catheters Market to Reach US$ 9.25 Billion by 2034 Driven by Rising Demand 2026-10-28 · PR News Releaser · Healthcare, Medical devices https://www.prnewsreleaser.com/news/480339 The global Surgical Catheters Market is experiencing steady growth as demand for surgical procedures and catheter-based medical interventions continues to support market expansion. The Surgical Catheters Market size is expected to reach US$ 9.25 billion by 2034 from US$ 5.2 ... Read more ———————————————————————————————————————————————————————————— Filipino Students Win International Award for Tech Designed to Ease Nurses’ Workload 2026-10-28 · EIN Presswire · Healthcare, Oil & gas https://www.einpresswire.com/article/952808347/filipino-students-win-international-award-for-tech-designed-to-ease-nurses-workload Project CARED was among four winners of the WRO STEM Entrepreneur Program, powered by Aramco, receiving $5,000 and six months of mentoring to further develop their patient-monitoring system. Three Filipino students developed CARED, a patient-monitoring system that combines routine measurements into one device designed to reduce repetitive work for nurses. Three students developed CARED in response to the heavy worklo ———————————————————————————————————————————————————————————— IMDA and NUH Partner in First Open Innovation Platform Collaboration in Public Healthcare 2026-10-28 · PR Newswire · SaaS, Healthcare, Education https://www.prnewswire.com/news-releases/imda-and-nuh-partner-in-first-open-innovation-platform-collaboration-in-public-healthcare-302921923.html Partnership accelerates healthcare innovation by connecting real-world hospital needs with technology expertise SINGAPORE, Oct. 28, 2026 -- The Infocomm Media Development Authority (IMDA) and the National University Hospital (NUH), through its Kent Ridge Office of Innovation... ———————————————————————————————————————————————————————————— Appian and PSI CRO Form Strategic Partnership to Advance AI-driven Clinical Trial Operations 2026-10-28 · PR Newswire · Finance, AI, SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/appian-and-psi-cro-form-strategic-partnership-to-advance-ai-driven-clinical-trial-operations-302921701.html First joint project launches a broader platform strategy for process orchestration across the clinical trial lifecycle BERLIN, Oct. 28, 2026 -- Appian (Nasdaq: APPN) and PSI CRO announced today the launch of their first joint AI-powered process orchestration solution. The new... ———————————————————————————————————————————————————————————— NWB Finland Oy Announces AINA Natural Water Coming Soon to Walmart.com 2026-10-28 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Media, Travel, Food & drink, Sports, Sustainability, Marketing & advertising, Chemicals & materials https://newsworthy.ai/news/202610283095/nwb-finland-oy-announces-aina-natural-water-coming-soon-to-walmartcom Boca Raton, Florida Wednesday Oct 28, 2026 @ 5:00 AM Eastern — NWB Finland Oy is continuing its planned U.S. rollout of AINA Natural Water, announcing that the Finnish premium water brand is coming soon to Walmart.com. The upcoming Walmart.com availability represents another step in NWB Finland Oy's strategy to introduce AINA Natural Water to U.S. consumers through established e-commerce platforms. The announcement follows the company's plans to bring AINA to OneLavi.com as part of its initial U.S. market introduction. "Walmart.com represents another important opportunity to introduce AINA Natural Water to American consumers," said Marita Weiman, Quality Assurance Manager at NWB Finland Oy. "Our goal is to make Northern Finland's naturally filtered water accessible through familiar shopping platforms while introducing consumers to the convenience and sustainability considerations behind our packaging." Bringing Northern Finland's Water to More U.S. Consumers AINA Natural Water originates in the Pudasjärvi region of Northern Finland, where groundwater is naturally filtered through layers of soil, sand and rock before undergoing mechanical filtration and packaging. The water contains approximately 32 mg/L of Total Dissolved Solids (TDS). Its naturally low mineral content contributes to a soft, neutral taste and clean finish without an aftertaste. Unlike premium water brands that rely primarily on individual plastic bottles, AINA is packaged in 5-liter and 10-liter bag-in-box formats. The larger formats are designed for convenient everyday use while requiring substantially less plastic than comparable volumes packaged in individual plastic bottles. The packaging makes AINA suitable for households, offices, hospitality environments and gatherings where convenient access to drinking water is important. Building a Broader U.S. E-Commerce Presence NWB Finland Oy's planned expansion to Walmart.com follows its announcement that AINA Natural Water is coming soon to OneLavi.com, a marketplace offering health, wellness and lifestyle products. Together, these planned e-commerce channels represent an important part of the company's strategy to establish AINA in the U.S. market and introduce consumers to a premium water brand that combines Northern Finnish origin with an alternative approach to packaging. NWB Finland Oy also participated in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where the company introduced AINA Natural Water and its distinctive bag-in-box format to U.S. retail buyers. "We are taking a step-by-step approach to building AINA's presence in the United States," Weiman said. "Expanding our planned availability to Walmart.com is another way to reach consumers who appreciate quality drinking water, everyday convenience and packaging designed to reduce reliance on individual plastic bottles." The AINA Difference Northern Finland Source: Naturally filtered groundwater from the Pudasjärvi region of Northern Finland. Sustainability-Focused Packaging: Designed to use substantially less plastic than comparable volumes of individually bottled water. Naturally Low Mineral Content: Approximately 32 mg/L TDS. Clean, Neutral Taste: A soft drinking experience with no aftertaste. Convenient Everyday Formats: Offered in 5-liter and 10-liter bag-in-box packaging. Additional details about AINA Natural Water's availability on Walmart.com will be announced as the company's U.S. rollout progresses. About NWB Finland Oy NWB Finland Oy is a Finland-based company focused on sustainable beverage packaging and natural water solutions. Headquartered in Pudasjärvi, Finland, the company was founded with a mission to develop environmentally responsible alternatives to traditional beverage packaging while delivering premium-quality products to consumers around the world. Its flagship brand, AINA Natural Water, features naturally filtered groundwater sourced from Northern Finland, a region known for its pristine natural environment and abundant groundwater resources. The water is packaged in innovative bag-in-box formats designed to reduce plastic consumption while providing a convenient solution for households, businesses, hospitality venues, and events. NWB Finland Oy's long-term vision is to make Northern Finland's natural groundwater available to consumers globally while continuing to invest in sustainable packaging solutions that support both consumer needs and environmental responsibility. ———————————————————————————————————————————————————————————— Ebola: 20 contacts released from quarantine in Kenya, amid vaccine ‘hope’ in Democratic Republic of the (DR) Congo 2026-10-28 · APO Group · SaaS, Healthcare, Education, Travel, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/ebola-20-contacts-released-from-quarantine-in-kenya-amid-vaccine-hope-in-democratic-republic-of-the-dr-congo?lang=en They were discharged on Monday, according to the UN World Health Organization (WHO), which has been assisting the Kenyan authorities with Ebola preparedness since the Democratic Republic of the Congo (DRC) declared an outbreak on 15 May.   Another 98 contacts remain in quarantine.  No risk to the community  The people who are now back at home remained asymptomatic during quarantine and underwent standard protocols, including a final health assessment, counselling on post-discharge precautions and follow-up where required before being released.  “We ask communities to welcome them home warmly,” said Dr Patrick Amoth, Kenya’s director general for health. “Having completed 21 days without symptoms, they pose no risk of infection to anyone.”  The WHO representative to Kenya, Dr Neema Rusibamayila Kimambo, echoed his message.  “People who complete quarantine have helped protect their families, their communities and the whole country,” she said.   Rush to trace contacts  Kenya confirmed its first Ebola case on 6 October – a Kenyan man who had been working in the DRC, where the caseload is approaching the 10,000 mark.  He flew back to Kenya via Uganda on 3 October and died in a Nairobi hospital two days later.  The Ministry of Health conducted robust contact tracing of anyone who may have been exposed, including family members, airline passengers and crew, airport workers and medical personnel. By 22 October, all contacts were traced – both in Kenya and abroad – and placed in quarantine.    As of Monday, eight contacts had developed symptoms and were confirmed positive for Ebola disease through laboratory testing. They were immediately transferred to the Ebola treatment centre in Nairobi.   Praise and support  In total, Kenya has reported nine confirmed Ebola cases and two deaths. All are part of one connected group and there is no evidence that the virus has spread to the community.    “WHO commends the Ministry of Health, the Kenya National Public Health Institute, national and county health teams for their work in responding quickly to every new case,” said Dr. Kimambo.  The UN agency continues to support Kenya in all aspects of Ebola response, including coordination, disease surveillance, contact tracing, laboratory testing, case management, infection prevention and control, health screening at points of entry, risk communication and community engagement.  Although there is no licensed vaccine or specific treatment for Bundibugyo virus disease, WHO stressed that early detection and supportive care improve chances of recovery.   DRC vaccine trial  Meanwhile, “a crucial clinical trial” was launched in the DRC on Friday to determine if vaccines can provide protection against the disease, said WHO’s Dr. Meg Doherty, speaking from the eastern city of Bunia to journalists in Geneva.  The TUMAINI trial platform is designed so that several vaccine candidates can be evaluated within one research framework using a strategy called the ring vaccination approach involving contacts of people with a confirmed case of Ebola.  “Tumaini actually means ‘hope’ in Swahili, and is giving us some hope,” said Dr. Doherty, director of WHO’s Department of Science for Health. ​ A moving experience   The first vaccine under evaluation is Ervebo which has been effective against Ebola caused by the Zaire virus. It is not yet known if it will have any protective effect against the Bundibugyo strain.  Dr. Doherty attended the launch, where four people were vaccinated.  “It was moving to see this trial begin, just as it has been deeply sad to see the effect of this outbreak on communities,” she said.    “I lived and worked in DRC nearly 40 years ago, and it is quite heartbreaking to see this beautiful country challenged by outbreaks on top of humanitarian crises.”  Evaluations and recommendations  Last week, WHO convened technical advisory groups that evaluated the evidence on two vaccines designed specifically against Bundibugyo virus: ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and mRNA-1469 developed by the American company Moderna.  Recommendations will be published this week.  “In the meantime, rings are being set up, with people who have a family member sick with Ebola, or who have been exposed to the virus another way,” she said, noting that two rings are currently in place and several more are being prepared.  “Community members are already walking into the site asking to be enrolled, highlighting the intense need for an efficacious vaccine,” she added.  ‘An important step’    Dr. Doherty explained that a decade ago, WHO and partners used the ring vaccination approach in Guinea during the West African Ebola outbreak to help establish the efficacy of the Ervebo vaccine.   “Today, scientists are building on that experience to seek answers about the Bundibugyo virus,” she said.  The trial is led by the Congolese authorities and is integrated into the ongoing response to the outbreak. It is being managed by the National Public Health and Biomedical Research Institute, known by the French acronym IRNRB.   “We do not yet know for certain when results will begin to emerge. We expect it will take several months,” she said.  “But already, having this trial in place is an important step towards gathering scientific data that will help policy makers reach decisions on vaccine use, and we anticipate, to protect people in this outbreak and future outbreaks.”  Dr Doherty noted that several other vaccines are under development, “and as they go through their initial studies, if they look promising, they too could be brought into this vaccine platform trial.”  Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— Auction Direct USA in Raleigh, North Carolina, Offers Professional Oil Change Services for Used Car Owners 2026-10-28 · PR Newswire · Healthcare, Energy, Automotive https://www.prnewswire.com/news-releases/auction-direct-usa-in-raleigh-north-carolina-offers-professional-oil-change-services-for-used-car-owners-302921786.html RALEIGH, N.C., Oct. 28, 2026 -- Auction Direct USA in Raleigh, North Carolina, offers professional oil change services to help used car owners maintain engine performance, improve reliability and support long-term vehicle health. Auction Direct USA in Raleigh, North Carolina,... ———————————————————————————————————————————————————————————— Dr. Bobak Parang Announced as Recipient of Rising Tide/LUNGevity Research Award for Overcoming Drug Resistance 2026-10-28 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/dr-bobak-parang-announced-as-recipient-of-rising-tidelungevity-research-award-for-overcoming-drug-resistance-302921344.html $600K+ investment leverages combination of FDA approved treatments to overcome drug resistance in EGFR-positive lung cancer WASHINGTON, Oct. 28, 2026 -- A groundbreaking clinical trial aimed at overcoming drug resistance in EGFR-positive non-small cell lung cancer (NSCLC),... ———————————————————————————————————————————————————————————— LUNGevity Invests $1M+ in High-Priority Research to Expand Lung Cancer Workforce & Improve Patient Care 2026-10-28 · PR Newswire · Healthcare, Jobs & workplace https://www.prnewswire.com/news-releases/lungevity-invests-1m-in-high-priority-research-to-expand-lung-cancer-workforce--improve-patient-care-302921257.html New awards support research spanning early detection, immunotherapy resistance, predictive biomarkers, and personalized treatment WASHINGTON, Oct. 28, 2026 -- LUNGevity Foundation has announced the recipients of six research awards aimed at strengthening the lung cancer... ———————————————————————————————————————————————————————————— Global Injection Pen Market Set to Expand at a 7.14% CAGR During 2023–2031 2026-10-28 · PR News Releaser · Healthcare, Biotech & pharma, Medical devices https://www.prnewsreleaser.com/news/480246 The Injection Pen Market is expanding as demand for convenient, accurate, and patient-friendly drug delivery systems continues to increase. Injection pens are medical devices designed to administer controlled doses of injectable medications, offering an alternative to traditional syringes for many ... Read more ———————————————————————————————————————————————————————————— CELSET Launches SOLTOX, a Korean Botulinum Toxin Type A Brand, for International Markets 2026-10-28 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/celset-launches-soltox-a-korean-botulinum-toxin-type-a-brand-for-international-markets-302921881.html SEOUL, South Korea, Oct. 28, 2026 -- CELSET INC., a Korean biotechnology company specializing in medical aesthetics, has launched SOLTOX, its botulinum toxin type A brand, introducing a Korean botulinum toxin brand to the international medical aesthetics industry. SOLTOX is... ———————————————————————————————————————————————————————————— Custom LSR Molding Supplier Hongrita at FAKUMA: From Mold Design to Integrated Production 2026-10-28 · EIN Presswire · Healthcare, Retail, Automotive, Industrial, Consumer goods https://www.einpresswire.com/article/952797349/custom-lsr-molding-supplier-hongrita-at-fakuma-from-mold-design-to-integrated-production HONG KONG, HONG KONG, CHINA, October 28, 2026 / EINPresswire.com / -- Choosing a Custom LSR Molding Supplier is no longer only a question of who can build a mold. For medical, baby-care, automotive, and precision consumer products, the harder question is whether one manufacturing partner can translate a design into a stable process, control liquid silicone rubber at production scale, integrate secondary operations, a ———————————————————————————————————————————————————————————— TNT Creatine Earns Best Seller Spotlight on OneLavi 2026-10-28 · Newsworthy.ai · AI, SaaS, Healthcare, Energy, Retail, Sports, Industrial, Marketing & advertising, Consumer goods https://newsworthy.ai/news/202610283096/tnt-creatine-earns-best-seller-spotlight-on-onelavi Boca Raton, Florida Wednesday Oct 28, 2026 @ 4:00 AM Eastern — True Nutrition Technology (TNT), the German sports nutrition brand trusted by more than 500,000 customers, announced that its Creatine Monohydrate Creapure® Powder (100 Servings) is featured in the Best Sellers section on the homepage of OneLavi.com, a U.S. online retailer specializing in health, wellness, beauty, and lifestyle products. The prominent homepage placement marks another milestone in TNT's expansion into the United States, bringing additional visibility to one of the brand's core sports nutrition products. Founded in 2020, OneLavi offers a curated selection of international and domestic brands across nutrition, skincare, beauty, and wellness. Its homepage features a Best Sellers section highlighting selected products for customers exploring the retailer's growing catalog. "Seeing our creatine featured among OneLavi's best sellers is exciting for our team," said Markus Himmelstoss, Co-Founder of True Nutrition Technology. "We've spent years building TNT around product quality, transparency, and German manufacturing standards. It's encouraging to see our brand gaining visibility as we introduce our products to more consumers in the United States." A German Sports Nutrition Brand Gains U.S. Visibility Founded by former athletes Michael Weigl and Markus Himmelstoss, TNT has built a customer base of more than 500,000 through its focus on sports nutrition products manufactured under strict German quality standards. The brand's Creatine Monohydrate Creapure® Powder is made in Germany using Creapure®, a creatine ingredient recognized for its high purity and manufacturing standards. Each container provides 100 servings, with 5 grams of creatine monohydrate per serving. The product is vegan, micronized for easy mixing, and independently lab tested. Creatine is one of the most extensively studied ingredients in sports nutrition, with research supporting its role in improving performance during repeated bouts of high-intensity exercise. Why Creatine Remains a Sports Nutrition Staple Creatine has become a popular addition to training routines among athletes, fitness enthusiasts, and active adults. Unlike pre-workout products typically consumed before exercise, creatine is commonly taken daily as part of an ongoing nutrition and training program. Its established research history, straightforward use, and compatibility with different training programs have helped make creatine a widely recognized category in sports nutrition. TNT's approach emphasizes ingredient quality, independent testing, and clear product information, allowing consumers to make informed decisions about the products they incorporate into their routines. Featured on OneLavi's Homepage OneLavi's Best Sellers section introduces visitors to a selection of products across the retailer's health, beauty, and wellness categories. TNT's featured placement brings a German performance nutrition product into a broader shopping environment that includes nutrition, skincare, collagen, and other wellness products. The recognition also reflects TNT's strategy of expanding beyond its established European customer base and introducing its products through U.S. e-commerce platforms. "Our goal is to make TNT products accessible to more American consumers while maintaining the same quality standards that helped us grow in Germany," Himmelstoss added. "Being featured on OneLavi's homepage is another positive step in that direction." Available Now on OneLavi TNT Creatine Monohydrate Creapure® Powder (100 Servings) is available for purchase on OneLavi.com. Product: TNT Creatine Monohydrate Creapure® Powder, 100 Servings Retailer: OneLavi.com TNT's Synapsensause Pre-Workout is also available through OneLavi, providing U.S. consumers with additional options from the German sports nutrition brand. TNT continues expanding its U.S. presence through e-commerce and retail distribution initiatives, including product availability on Amazon. About TNT (True Nutrition Technology) Founded in Germany by former athletes Michael Weigl and Markus Himmelstoss, TNT (True Nutrition Technology) is a leading sports nutrition brand trusted by more than 500,000 customers. Since 2012, TNT has produced premium supplements under strict German quality standards, with every product independently lab-tested for safety, purity, and transparency. TNT’s core product lineup includes Creatine Monohydrate Creapure®, CLEAR WHEY Protein, and Synapsensause Pre-Workout-three performance-focused supplements widely used by athletes to support strength, recovery, energy, and training intensity. From advanced protein blends to innovative vegan formulations, TNT develops evidence-based nutrition designed to help athletes and everyday individuals perform at their best. More than just supplements, TNT represents a passion for sport, health, and performance. Built on German precision and a culture of honesty, TNT continues to expand globally with one mission: delivering the highest quality nutrition-for us, and for you. ———————————————————————————————————————————————————————————— Photoplethysmography Biosensors Market Demand for Continuous Physiological Data 2026-10-28 · Express Press Release · Healthcare, Consumer electronics https://express-press-release.net/news/2026/10/28/1779045 The growth of wearable health technology is creating new demand for sensors that can collect physiological information conveniently and non-invasively. Photoplethysmography (PPG) biosensors are becoming [read full press release...] ———————————————————————————————————————————————————————————— Nxera Pharma Secures Exclusive Rights to Fabry Disease Phase 3 Oral Therapy Candidate Lucerastat for Japan and Selected Asia Pacific Markets 2026-10-28 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/28/3389900/0/en/nxera-pharma-secures-exclusive-rights-to-fabry-disease-phase-3-oral-therapy-candidate-lucerastat-for-japan-and-selected-asia-pacific-markets.html Tokyo, Japan and Cambridge, UK, 28 October 2026 – Nxera Pharma Co., Ltd. ("Nxera" or the "Company"; TSE: 4565) today announces that it has exercised its option to license lucerastat from Idorsia Ltd ("Idorsia"; SIX: IDIA) and has entered into a co-development and commercialization agreement (the "Agreement"). Under the Agreement, Nxera will hold exclusive rights to develop and commercialize lucerastat in Japan, South Korea, Taiwan and selected other Asia Pacific markets, excluding China (the "Territory"). ———————————————————————————————————————————————————————————— Inside the USD 4.0 Billion Opportunity: A Strategic Look at the 3D Printing Metal Market 2026-10-28 · Express Press Release · Healthcare, Automotive, Industrial, Aerospace & defense, Medical devices https://express-press-release.net/news/2026/10/28/1779030 Metal additive manufacturing has moved well beyond the prototyping bench. Aerospace primes, medical device makers and automotive suppliers now use it to produce complex, lightweight, [read full press release...] ———————————————————————————————————————————————————————————— New Book Classification Examines How an Insured Patient Was Made Self-Pay at Mayo Clinic—and Fought Back 2026-10-28 · 24-7 Press Release · Healthcare https://www.24-7pressrelease.com/press-release/539981/new-book-classification-examines-how-an-insured-patient-was-made-self-pay-at-mayo-clinicand-fought-back Thomas E. Zordani's November 1 nonfiction release reconstructs the records, financial classifications, disputed communications, and internal processes behind a failed Mayo Clinic appointment that became an extensive investigation ———————————————————————————————————————————————————————————— Scott Zack's Creek Equity Details Healthcare Services Portfolio Spanning Supply Chain, Pharmacy Benefits, and Medical Courier Logistics 2026-10-28 · 24-7 Press Release · Healthcare, Logistics https://www.24-7pressrelease.com/press-release/539802/scott-zacks-creek-equity-details-healthcare-services-portfolio-spanning-supply-chain-pharmacy-benefits-and-medical-courier-logistics Bloomfield Hills investment company's operating businesses serve hospitals, health systems, laboratories, employers, and benefit funds across Michigan and beyond. ———————————————————————————————————————————————————————————— Corporate Detox Provides Energy Reset from Cubicle to Corner Office 2026-10-28 · Express Press Release · Healthcare, Energy https://express-press-release.net/news/2026/10/28/1779014 Basking Ridge, NJ, 2026-10-28 — The day-to-day grind can take its toll. Relationships suffer, health is spotty, sleep is interrupted. Something is off [read full press release...] ———————————————————————————————————————————————————————————— Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma 2026-10-28 · PressReach · Healthcare, Medical devices https://pressreach.com/roche-strengthens-cancer-diagnostic-portfolio-with-launch-of-test-for-differential-diagnosis-of-mesothelioma The VENTANA BAP1 (SP527) test helps confidently distinguish malignant mesothelioma from lung, breast and stomach cancers, as well as benign tissue growth in the chest or abdomen. Most patients are diagnosed with mesothelioma late, resulting in a median overall survival of just 12 to 18 months.1 Roche's comprehensive cancer diagnostic portfolio delivers end-to-end clinical answers … Continue reading "Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma" ———————————————————————————————————————————————————————————— Jiahui Launches International Cell Therapy Center to Expand Global Access to CAR-T Treatment 2026-10-28 · PR Newswire · Healthcare, Automotive, Biotech & pharma https://www.prnewswire.com/news-releases/jiahui-launches-international-cell-therapy-center-to-expand-global-access-to-car-t-treatment-302921799.html SHANGHAI, Oct. 28, 2026 -- Jiahui International Hospital launched Jiahui International Cell Therapy Center, building on landmark CAR-T cases and multidisciplinary expertise to serve patients from China and abroad. The center was unveiled at the inaugural Jiahui International... ———————————————————————————————————————————————————————————— Sensorion Announces its Participation in the European Society of Gene & Cell Therapy (ESGCT) Annual Congress 2026-10-28 · Business Wire · Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/sensorion-announces-participation-european-society-063000978.html MONTPELLIER, France & CAMBRIDGE, Mass., October 28, 2026--Regulatory News: Sensorion (FR001401A9Z0 – ALSEN) ("the Company"), a pioneering clinical-stage biotechnology company that develops novel therapies to restore hearing and to treat and prevent hearing loss disorders, today announced its participat ———————————————————————————————————————————————————————————— GB Health Clinic helps adults navigate midlife changes with hormone replacement therapy and weight management Care. 2026-10-28 · EIN Presswire · Healthcare, Energy https://www.einpresswire.com/article/952695119/gb-health-clinic-helps-adults-navigate-midlife-changes-with-hormone-replacement-therapy-and-weight-management-care GB Health Clinic offers personalized hormone replacement and weight-loss care for adults navigating hormonal and weight-related changes in midlife. MELBOURNE, FL, UNITED STATES, October 28, 2026 / EINPresswire.com / -- Adults experiencing changes in energy, sleep, mood, body composition, or other aspects of well-being during midlife may benefit from a personalized approach to hormone and weight management. GB Health ———————————————————————————————————————————————————————————— Iroko Psychiatry Provides Personalized Depression Care for Adults in Mansfield, Texas. 2026-10-28 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952692071/iroko-psychiatry-provides-personalized-depression-care-for-adults-in-mansfield-texas Iroko Psychiatry offers adults in Mansfield personalized depression care, psychiatric evaluations, and treatment planning tailored to individual needs. MANSFIELD, TX, UNITED STATES, October 28, 2026 / EINPresswire.com / -- Adults experiencing depression in Mansfield, Texas, can access personalized psychiatric support through Iroko Psychiatry , a mental health practice providing individualized, evidence-based care. Th ———————————————————————————————————————————————————————————— Torrance Mental Health Provider Offers Personalized ADHD Support for Adults and Children 2026-10-28 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952689009/torrance-mental-health-provider-offers-personalized-adhd-support-for-adults-and-children Acen Integrative Psychiatry provides individualized mental health care, ADHD assessment, and medication management for patients across age groups. TORRANCE , CA, UNITED STATES, October 28, 2026 / EINPresswire.com / -- Acen Integrative Psychiatry provides personalized mental health services for children, adolescents, and adults living with attention-deficit/hyperactivity disorder (ADHD), offering assessment and treatm ———————————————————————————————————————————————————————————— Medidata Named by IDC MarketScape™ as a Leader in Worldwide Life Sciences R&D RWD/RWE Data Platforms, Technology Solutions, and Consulting Services 2026-10-28 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/28/3389859/0/en/medidata-named-by-idc-marketscape-as-a-leader-in-worldwide-life-sciences-r-d-rwd-rwe-data-platforms-technology-solutions-and-consulting-services.html Medidata is the only company exclusively dedicated to clinical trial technology recognized in the Leaders category Medidata is the only company exclusively dedicated to clinical trial technology recognized in the Leaders category ———————————————————————————————————————————————————————————— Materialise Reports Third Quarter 2026 Results 2026-10-28 · Business Wire · Finance, Healthcare, Industrial, Software & IT, Medical devices https://finance.yahoo.com/healthcare/articles/materialise-reports-third-quarter-2026-060000100.html Regulated information 1 LEUVEN, Belgium, October 28, 2026--Materialise NV (Euronext & NASDAQ:MTLS), a global leader in 3D-printed medical devices and software, and a pioneer in additive manufacturing software and services, today announced its financial results for the third quarter ended September 30, ———————————————————————————————————————————————————————————— Dassault Systèmes Takes Its Life Sciences Ambition to the Next Level with a Unified AI Platform Connecting Science, Medicine and Patients 2026-10-28 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/dassault-syst-mes-takes-life-060000948.html Dassault Systèmes takes decisive step in its life sciences strategy to empower faster discovery, better therapies and smarter decisions Dassault Systèmes completes the acquisition of ArisGlobal; will now create a unified AI-native platform for life sciences connecting the therapeutic lifecycle Dr. Ashwini Zenooz, formerly ———————————————————————————————————————————————————————————— Evaluating a Medical-Grade Manufacturing for Freeze-Dried Powders Supplier in China: JiKe Quality Analysis 2026-10-28 · EIN Presswire · Healthcare, Industrial, Biotech & pharma https://www.einpresswire.com/article/952740536/evaluating-a-medical-grade-manufacturing-for-freeze-dried-powders-supplier-in-china-jike-quality-analysis GUANGZHOU, GUANGDONG, CHINA, October 28, 2026 / EINPresswire.com / -- What specific technical parameters distinguish a cosmetic freeze-drying workshop built to pharmaceutical standards from standard manufacturing environments? As topical formulations integrate delicate bioactive peptides, recombinant proteins, and sensitive antioxidant complexes, traditional liquid emulsions often face physical stability limitations ———————————————————————————————————————————————————————————— From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatment 2026-10-28 · PR Newswire · Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/from-china-to-the-global-stage-hengrui-showcases-innovative-research-at-esmo-congress-2026-exploring-new-approaches-to-oncology-treatment-302921584.html Record 64 Research Presentations Highlight Hengrui's Oncology R&D Strength and Growing International Reach MADRID and SHANGHAI, Oct. 27, 2026 -- The European Society for Medical Oncology (ESMO) Congress 2026 recently concluded in Madrid. As a leading innovator in China's... ———————————————————————————————————————————————————————————— Hims & Hers Health, Inc. Securities Fraud Class Action Result of Deceptive Privacy and Billing Practices and Over 14% Stock Decline - Investors may Contact Lewis Kahn, Esq., at Kahn Swick & Foti, LLC 2026-10-28 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/28/3389827/6713/en/hims-hers-health-inc-securities-fraud-class-action-result-of-deceptive-privacy-and-billing-practices-and-over-14-stock-decline-investors-may-contact-lewis-kahn-esq-at-kahn-swick-fo.html Hims & Hers Health (HIMS) Investors Have Opportunity to Lead Securities Fraud Lawsuit ———————————————————————————————————————————————————————————— My ESA Therapist Addresses Growing Consumer Questions About Online ESA Letter Services 2026-10-28 · Newsworthy.ai · AI, SaaS, Healthcare, Real estate, Retail, Marketing & advertising, Internet & apps https://newsworthy.ai/news/202610283112/my-esa-therapist-addresses-growing-consumer-questions-about-online-esa-letter-services 780 Lynnhaven Pkwy #400, Virginia Beach, VA 23452, United States Tuesday Oct 27, 2026 @ 10:00 PM Eastern — As more individuals explore online options for emotional support animal (ESA) evaluations, questions about provider qualifications, assessment procedures, documentation requirements, and service legitimacy have become important considerations for consumers. My ESA Therapist is highlighting the value of consumer awareness to help individuals better understand online ESA letter services and make informed decisions before beginning an evaluation. An emotional support animal may provide comfort and emotional support to an individual experiencing a mental health-related disability. However, obtaining documentation for an emotional support animal is not simply a matter of purchasing a certificate or registering a pet online. Understanding the role of a qualified mental health professional, the purpose of an evaluation, and the applicable housing rules can help consumers avoid misleading claims and unrealistic expectations. Understanding What Online ESA Letter Services Actually Provide Online ESA letter services connect individuals with mental health professionals who may evaluate whether an emotional support animal is appropriate for their circumstances. Depending on the provider, these services may include an initial screening, a professional consultation, an assessment of the individual's needs, and documentation when clinically appropriate. Consumers should understand that an online evaluation does not automatically guarantee an ESA letter. A qualified professional must determine whether the individual's circumstances support the recommendation. A service that promises approval to every applicant without meaningful assessment deserves careful scrutiny. My ESA Therapist emphasizes the importance of understanding the difference between a professional evaluation and commercial products that offer registration certificates, identification cards, or other materials without establishing whether an individual qualifies for an emotional support animal recommendation. These distinctions are particularly important for people who are unfamiliar with the process and may assume that every website offering ESA-related products provides the same type of service. Why Provider Credentials Matter One of the most important considerations when comparing online ESA letter services is the professional responsible for conducting the evaluation and issuing any resulting documentation. Consumers should look for clear information about provider qualifications, professional licensing, and the process used to determine eligibility. They should also understand whether the professional is authorized to provide services in the individual's state. State requirements can differ, and some jurisdictions have additional rules governing emotional support animal documentation. For example, California has specific requirements relevant to ESA documentation and professional relationships. Consumers seeking an ESA letter in California should review the applicable state rules rather than assuming that a service operating online automatically satisfies them. Before scheduling an evaluation, individuals can ask who will conduct the consultation, what information may be required, how the assessment works, and whether the provider follows applicable state and professional standards. Transparent answers to these questions can help consumers distinguish professional services from providers that rely primarily on marketing promises. Recognizing Warning Signs Before Paying for a Service The availability of online services can make it easier for consumers to explore their options, but it also creates a need for careful decision-making. Several warning signs deserve attention when researching online ESA letter services. Guaranteed approval without an evaluation: A promise that every applicant will receive a letter regardless of individual circumstances may indicate that the service does not prioritize professional assessment. Unclear provider information: Consumers should be cautious when a website does not explain who conducts evaluations, how credentials can be verified, or which professional is responsible for the resulting documentation. Confusing registration with professional documentation: Purchasing an ESA registration, certificate, or identification card does not, by itself, establish eligibility for an emotional support animal accommodation. Unclear pricing or refund policies: Before submitting payment, consumers should review the total cost, any additional charges, cancellation terms, and the circumstances under which a refund may be available. Unrealistic housing promises: No service should imply that its documentation guarantees approval in every housing situation. Housing providers may assess accommodation requests under applicable laws, and specific circumstances can affect the outcome. Reviewing these issues before making a payment can help individuals reduce the risk of unnecessary expenses and misunderstandings. Understanding ESA Letters and Housing Rights Many consumers seek an emotional support animal letter because they want to request an accommodation from a housing provider. However, the rules governing assistance animals are not identical across every setting. Under the federal Fair Housing Act, qualifying individuals may request reasonable accommodations involving assistance animals in covered housing situations. Emotional support animals may qualify under these provisions when the applicable legal requirements are met. A housing provider may request reliable information when a disability or disability-related need for an animal is not apparent or already known. However, the documentation and information that may appropriately be requested depend on the circumstances. Consumers should avoid assuming that a particular certificate or registration automatically establishes a right to an accommodation. ESA letters also differ from service animal requirements under the Americans with Disabilities Act. Emotional support animals are not generally considered service animals under the ADA, and the legal protections applicable to service animals in public places do not automatically extend to ESAs. Understanding these distinctions can help consumers identify the type of documentation they need and avoid relying on inaccurate online claims. Questions Consumers Should Ask Before Choosing an Online ESA Service A few practical questions can help individuals assess whether an online ESA service is appropriate for their needs: Who will conduct my evaluation, and can I verify their professional credentials? Is the professional authorized to provide services in my state? What does the evaluation involve, and what information will I need to provide? Will a licensed mental health professional determine whether an ESA recommendation is appropriate? What are the total costs, cancellation conditions, and refund policies? How is my personal and mental health information collected, stored, and protected? What documentation may be provided if the professional determines that I qualify? Are the service's claims consistent with applicable housing laws and state requirements? Consumers should feel comfortable asking these questions before committing to a service. A transparent provider should explain its process clearly without pressuring individuals to purchase documentation. My ESA Therapist Encourages Informed Decisions My ESA Therapist connects individuals with licensed mental health professionals for emotional support animal evaluations and provides educational resources related to ESAs, housing, and emotional well-being. Through its consumer-awareness focus, the organization encourages individuals to understand the purpose of an ESA evaluation, verify professional qualifications, review service terms, and learn about the rules that may apply to their circumstances. The organization also emphasizes that an emotional support animal recommendation should be based on an appropriate professional assessment rather than a guaranteed commercial outcome. Consumers benefit from understanding both the potential role of an emotional support animal in their lives and the responsibilities involved in requesting an accommodation. As online ESA letter services continue to attract attention, access to clear, accurate information remains an important part of responsible decision-making. By asking informed questions and evaluating providers carefully, individuals can approach the process with more realistic expectations and a better understanding of their options. About My ESA Therapist My ESA Therapist provides access to licensed mental health professionals for emotional support animal evaluations and offers educational resources concerning emotional support animals, housing-related considerations, and emotional well-being. The organization aims to help individuals better understand the ESA evaluation process and make informed decisions about seeking professional guidance. Media Contact: My ESA Therapist Website: https://myesatherapist.com/ ———————————————————————————————————————————————————————————— Jetour UAE and Medcare Hospitals Drove Breast Health Awareness Through ‘Drive with Purpose’ Pinktober Campaign 2026-10-28 · Arab Newswire · Healthcare, Automotive https://arabnewswire.com/jetour-uae-and-medcare-hospitals-drove-breast-health-awareness-through-drive-with-purpose-pinktober-campaign/ Dubai, UAE –- Elite Group Holding and Jetour UAE, in partnership with Medcare Hospitals, marked Breast Cancer Awareness Month with “Drive with Purpose,” a month-long campaign aimed at raising awareness about breast health and encouraging women to prioritise regular screenings and early detection. ———————————————————————————————————————————————————————————— Ocrevus Market Size to Reach 0.04 Billion by 2030 with 4 CAGR 2026-10-28 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/952277425/ocrevus-market-size-to-reach-0-04-billion-by-2030-with-4-cagr Ocrevus Market Report Ocrevus Market Report Share Ocrevus Market Report Size The Business Research Company’s Ocrevus Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 28, 2026 / EINPresswire.com / -- The treatment landscape for multiple sclerosis is evolving rapidly, with innovative drug formulations enhancing patient convenience and expandi ———————————————————————————————————————————————————————————— Newsweek Places KFSH in Top 4% of World's Smart Hospitals for Digital Maturity and AI 2026-10-28 · GlobeNewswire · AI, Healthcare https://www.globenewswire.com/news-release/2026/10/28/3389816/0/en/newsweek-places-kfsh-in-top-4-of-world-s-smart-hospitals-for-digital-maturity-and-ai.html RIYADH, Saudi Arabia, Oct. 27, 2026 -- King Faisal Specialist Hospital & Research Centre (KFSH) is one of only 15 hospitals worldwide to receive both the maximum five-ribbon digital maturity rating and the new Leader in AI Innovation distinction in Newsweek's World's Best Smart Hospitals 2027, placing it among fewer than 4% of the leading 410 hospitals ranked across 33 countries, joining a small global group setting the pace in digital and AI-enabled care. ———————————————————————————————————————————————————————————— M-M-R II Market Revenue To Cross $0.6 Billion By 2030 Supported By Rising Demand 2026-10-28 · EIN Presswire · Finance, Healthcare https://www.einpresswire.com/article/952312157/m-m-r-ii-market-revenue-to-cross-0-6-billion-by-2030-supported-by-rising-demand M-M-R II Market M-M-R II Market Report M-M-R II Market Share The Business Research Company’s M-M-R II Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 28, 2026 / EINPresswire.com / -- The global M-M-R II market is experiencing steady growth, supported by strong scientific immunization frameworks and consistent public health commitments. This vacci ———————————————————————————————————————————————————————————— Longevity BioTech Market Outlook 2030: Market Size, CAGR, Trends And Forecast Analysis 2026-10-28 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/952280716/longevity-biotech-market-outlook-2030-market-size-cagr-trends-and-forecast-analysis Longevity BioTech Market Longevity BioTech Market Report Longevity BioTech Market Analysis The Business Research Company’s Longevity BioTech Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 28, 2026 / EINPresswire.com / -- The longevity biotechnology sector is gaining momentum as innovations in anti-aging therapies and regenerative medicine draw t ———————————————————————————————————————————————————————————— Latest Data of Orelabrutinib Presented at the European Society for Medical Oncology (ESMO) Congress 2026 2026-10-28 · GlobeNewswire · Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/28/3389813/0/en/latest-data-of-orelabrutinib-presented-at-the-european-society-for-medical-oncology-esmo-congress-2026.html BEIJING, Oct. 27, 2026 -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that latest data of orelabrutinib, its novel BTK inhibitor, were presented at the European Society for Medical Oncology (ESMO) Congress 2026. ———————————————————————————————————————————————————————————— Grünenthal presents Phase III results for Qutenza® in post-surgical neuropathic pain at IASP 2026 World Congress on Pain 2026-10-28 · Pressat · SaaS, Healthcare, Education, Food & drink, Biotech & pharma, Government & policy https://pressat.co.uk/releases/grnenthal-presents-phase-iii-results-for-qutenzar-in-post-surgical-neuropathic-pain-at-iasp-2026-world-congress-on-pain-05e0a4aa865d3e0831e7d39b686b271b/ Wednesday 28 October, 2026 Aachen, Germany, 28 October 2026 – The trial (n=409) showed that Qutenza® “Post-surgical neuropathic pain can be difficult to manage with current treatment options, and there is an urgent need for patient-centred, effective solutions. The RISE trial provides encouraging evidence that Qutenza® can deliver clinically meaningful and sustained pain reduction for up to 42 weeks, having shown a greater reduction in average pain intensity than the control,” said Prof. Patrice Forget, MD, PhD, FFPMRCA, Clinical Chair (full professor) in Anaesthesia, University of Aberdeen, and Honorary Consultant, NHS Grampian, Aberdeen, UK. “As IASP shines a global spotlight on neuropathic pain at this year's congress, findings such as these are important to help improve outcomes for patients and reduce the burden of pain on families and healthcare systems.” “Post-surgical neuropathic pain has been relatively understudied and continues to go under-recognised in clinical practice,” said Uli Brödl, Chief Scientific Officer, Grünenthal. “These results build on the robust body of evidence for Qutenza® and reinforce its potential to provide meaningful, long-lasting pain relief for people living with pain.” Post-surgical neuropathic pain is a poorly recognised potential complication of surgery that can result in devastating outcomes. It affects millions of patients every year, with pain lasting for months or years post-procedure.1 It can also have a significant mental health impact, with patients reporting feeling extremely depressed or anxious, and having problems with daily activities.[4] Qutenza® is already approved in Europe for the treatment of peripheral neuropathic pain in adults, either alone or in combination with other medicinal products for the treatment of pain.[5] It is also approved in the US for the treatment of neuropathic pain associated with postherpetic neuralgia and for the treatment of neuropathic pain associated with diabetic peripheral neuropathy (DPN) of the feet in adults.[6] About the RISE trial2,3 The RISE (AV-001) trial is a Phase III multi-centre, randomised, double-blind, parallel-group trial to confirm the efficacy and safety of Qutenza 179mg cutaneous patch versus a low-dose capsaicin control patch in people with moderate to severe post-surgical neuropathic pain. It included eligible adults with a 24-hour average pain intensity (API) score of 4 or more, a pain duration of 6 to 60 months after index surgery and a DN4 (Douleur Neuropathique 4) Interview score of 3 or more. Participants were randomly assigned to receive treatment with either a 60-minute Qutenza patch (8%) or a low-dose capsaicin control patch (0.04%). The trial had two primary endpoints: Change in 24-hour API from baseline to the average score of the entire period between Week 2 and Week 12. Change in 24-hour API from baseline to the average score at Week 12. The primary sponsor of the trial is Averitas Pharma, Inc., Grünenthal’s U.S. subsidiary. About post-surgical neuropathic pain The signs and symptoms of peri- and post-surgical pain can vary based on the person and the severity of the injury caused in surgery. Reported symptoms include pain caused by stimuli that are normally painless (allodynia), abnormally increased sensitivity to pain (hyperalgesia), tingling, numbness, phantom pain and scar pain.[8],[9],[10] About Qutenza® Qutenza® Qutenza® About Grünenthal Grünenthal is headquartered in Aachen, Germany, and has affiliates in 28 countries across Europe, Latin America, and the U.S. Our products are available in approx. 100 countries. In 2025, Grünenthal employed around 4,100 people and achieved revenues of €1.8 billion. Follow us on LinkedIn For further information, please contact: Matt Crabb, Head of Global Communications (Interim) at Grünenthal matt.crabb@grunenthal.com ### References [1] Gregory P & Settles K. Pract Pain Manag. 2013;13(9):1–6. [2] Wallace M et al. Efficacy of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026. [3] Wallace M et al. Safety and tolerability of high-concentration capsaicin patch in post-surgical neuropathic pain (RISE). Presented at the International Association for the Study of Pain World Congress 2026. [4] Santos MP, Lemos F, Gomes J, Romao JM, Veiga D. Br J Pain 2024;18(1):42–56. [5] European Medicines Agency. Qutenza 179 mg cutaneous patch SmPC. Available at: https://www.medicines.org.uk/emc/product/573/smpc [6] US Food and Drug Administration. Qutenza® Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022395s019lbl.pdf [7] [8] Werner MU & Kongsgaard UE. Br J Anaesth. 2014;113(1):1–4. [9] Macrae WA. Br J Anaesth. 2008;101:77–86. [10] Searle RD & Simpson KH. Contin Educ Anaesth Crit Care Pain. 2010;10:12–14. ———————————————————————————————————————————————————————————— Badger Bob's Services Voted Top-Rated AC Repair Company in Sarasota in 2026 2026-10-28 · 1888 Press Release · Healthcare https://www.1888pressrelease.com/badger-bob-s-services-voted-top-rated-ac-repair-company-in-s-pr-773706.html Badger Bob's Services was recognized as a top-rated AC repair company in Sarasota for 2026, highlighting its commitment to reliable HVAC services, quality repairs, and customer satisfaction. ———————————————————————————————————————————————————————————— Arthritis & Joint Pain Center of Rochester Discusses Factors to Consider Before Knee Replacement Surgery 2026-10-28 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/952653320/arthritis-joint-pain-center-of-rochester-discusses-factors-to-consider-before-knee-replacement-surgery Options for chronic knee pain Patient education focuses on knee osteoarthritis, available treatment approaches, and considerations involved in deciding whether surgery is appropriate. FAIRPORT, NY, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Rochester Arthritis & Joint Pain Center , serving patients in Rochester, New York, is providing information to help individuals with chronic knee pain better understa ———————————————————————————————————————————————————————————— Lynk Pharmaceuticals Reports Positive Long-Term Phase III Results for Zemprocitinib in bDMARDs-Inadequate Responders with Moderate-to-Severe Rheumatoid Arthritis 2026-10-28 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/lynk-pharmaceuticals-reports-positive-long-term-phase-iii-results-for-zemprocitinib-in-bdmards-inadequate-responders-with-moderate-to-severe-rheumatoid-arthritis-302920881.html HANGZHOU, China, SHANGHAI and BOSTON, Oct. 27, 2026 -- Lynk Pharmaceuticals Co., Ltd. ("Lynk Pharmaceuticals"), a clinical-stage innovative drug development company focused on immune and inflammatory diseases, today announced positive long-term results from its pivotal Phase... ———————————————————————————————————————————————————————————— Wheelchair-Bound to Walking: Guntur Neurosurgeon Reports 5-Year Spine Surgery Outcome at SBNS 100 2026-10-28 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952214661/wheelchair-bound-to-walking-guntur-neurosurgeon-reports-5-year-spine-surgery-outcome-at-sbns-100 Dr. Mohana Rao Patibandla presenting his neurosurgical work at SBNS100, celebrating 100 years of British neurosurgery, at the QEII Centre, London, October 2026. Dr. Mohana Rao Patibandla, Founder and Chief Neurosurgeon of Dr. Rao’s Hospital, participating in the Society of British Neurological Surgeons’ centenary meeting in London. Photo credit: Special Arrangement / The Hindu. From wheelchair-bound to walking again: ———————————————————————————————————————————————————————————— Smile Dental Care Earns a 95 Dental.me Score and 5.0 Rating Behind Dr. Helen Pavon Pozo's Integral Approach 2026-10-27 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952706157/smile-dental-care-earns-a-95-dental-me-score-and-5-0-rating-behind-dr-helen-pavon-pozo-s-integral-approach Dental treatment room with chair and city view window at Smile Dental Care in Miami Dentist in mask examining an older patient's teeth in treatment chair at Smile Dental Care Smile Dental Care in Miami, FL SMILE DENTAL CARE — Dental.me Verified, Score 95 The Miami practice pairs comprehensive family dentistry — from implants to emergency care — with Saturday hours and a whole-patient philosophy. A healthy smile goes ———————————————————————————————————————————————————————————— HIMS Deadline: HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit 2026-10-27 · PR Newswire · Finance, Healthcare, Legal https://www.prnewswire.com/news-releases/hims-deadline-hims-investors-have-opportunity-to-lead-hims--hers-health-inc-securities-fraud-lawsuit-302919010.html NEW YORK, Oct. 27, 2026 -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the "Class Period"), of the important November 2, 2026... ———————————————————————————————————————————————————————————— UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3389774/0/en/urogen-pharma-to-report-third-quarter-2026-financial-results-on-wednesday-november-4th-2026.html Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET Conference Call and Webcast Scheduled for Wednesday, November 4th, 2026, at 10:00 AM ET ———————————————————————————————————————————————————————————— Zura Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) 2026-10-27 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/zura-bio-reports-inducement-grants-220000723.html HENDERSON, Nev., October 27, 2026--Zura Bio Limited (Nasdaq: ZURA) ("Zura" or the "Company"), a clinical-stage biotechnology company developing novel and differentiated medicines to meaningfully improve the lives of patients with serious and debilitating autoimmune and inflammatory diseases, today rep ———————————————————————————————————————————————————————————— MGMT Digital Discusses Behavioral Health Marketing on Recovery.com’s Podcast 2026-10-27 · EIN Presswire · Healthcare, Media, Marketing & advertising https://www.einpresswire.com/article/952682362/mgmt-digital-discusses-behavioral-health-marketing-on-recovery-com-s-podcast MGMT Digital Logo Agency executives Zach Gross and Jake Gorman discuss ethical marketing, building trust, and helping treatment providers connect with people seeking care. We built MGMT Digital to help treatment providers show up honestly, set real expectations, and earn the confidence of the people reaching out for help.” — Zach Gross, Founder and CEO of MGMT Digital MADISON, WI, UNITED STATES, October 27, 2026 / EI ———————————————————————————————————————————————————————————— Macnica SLVS-EC IP Brings Sony's New IMX742 Sensor to Single-Use Endoscope Designs 2026-10-27 · PRWeb · Healthcare, Media, Consumer electronics, Medical devices https://www.prweb.com/releases/macnica-slvs-ec-ip-brings-sonys-new-imx742-sensor-to-single-use-endoscope-designs-302921311.html New Macnica SLVS-EC IP bridge chip, combined with Sony's new IMX742 sensor helps medical device makers carry high-resolution video over 5-meter cables. SOLANA BEACH, Calif., Oct. 27, 2026 -- Macnica Americas today announced that its SLVS-EC interface IP now supports the... ———————————————————————————————————————————————————————————— Octant Receives FDA Orphan Drug Designation for OCT-980 for the Treatment of Retinitis Pigmentosa 2026-10-27 · Business Wire · Healthcare, Food & drink, Biotech & pharma https://finance.yahoo.com/healthcare/articles/octant-receives-fda-orphan-drug-210900399.html EMERYVILLE, Calif., October 27, 2026--Octant, Inc. ("Octant"), a clinical-stage drug discovery company developing correctors for protein misfolding diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to OCT-980 for the treatment of retinitis pi ———————————————————————————————————————————————————————————— Prosperity Wellness Center Spotlights Co-Occurring Disorder Care During Depression Awareness Month 2026-10-27 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/952658473/prosperity-wellness-center-spotlights-co-occurring-disorder-care-during-depression-awareness-month Prosperity Wellness Center Logo TACOMA, WA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- In recognition of Depression Awareness Month, Prosperity Wellness Center is highlighting the importance of integrated support for individuals living with substance use disorders and co-occurring mental health conditions, including depression. The drug rehab center in Tacoma provides residential substance use disorder t ———————————————————————————————————————————————————————————— Artificial Intelligence (AI) for De Novo Drug Design Global Market Report 2026 | Secure 33.7% CAGR Through 2030 with Schrödinger, XtalPi, Owkin, Insilico Medicine and Recursion 2026-10-27 · GlobeNewswire · AI, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3389722/28124/en/artificial-intelligence-ai-for-de-novo-drug-design-global-market-report-2026-secure-33-7-cagr-through-2030-with-schr%C3%B6dinger-xtalpi-owkin-insilico-medicine-and-recursion.html Boost ROI with AI-native platforms, cloud deployment and automation to speed molecule design, improve candidate selection, cut R&D costs and scale pharma-biotech partnerships. Boost ROI with AI-native platforms, cloud deployment and automation to speed molecule design, improve candidate selection, cut R&D costs and scale pharma-biotech partnerships. ———————————————————————————————————————————————————————————— Covalon Showcases Contamination Protection Solution at ANCC Magnet & Pathway 2026 Conference 2026-10-27 · Business Wire · Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/covalon-showcases-contamination-protection-solution-210100118.html MISSISSAUGA, Ontario, October 27, 2026--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company today announced its upcoming participation in the 2026 American Nurses Credentialing Center (ANCC) National Magnet® & Pathway to Excellence ———————————————————————————————————————————————————————————— Eylsia Nicolas Returns to Live Studio Recording Following Medical Hiatus, Adds 35 Million Views and Receives Hundreds of Thousands of Messages of Support 2026-10-27 · ACCESS Newswire · Healthcare, Entertainment https://finance.yahoo.com/media-advertising/articles/eylsia-nicolas-returns-live-studio-205500330.html JUPITER, FL / October 27, 2026 / Award-winning singer-songwriter Eylsia Nicolas has returned to live studio recording following a medical hiatus that not only saw an outpouring of support from fans around the world, but also an extraordinary surge in audience engagement, adding more than 35 million views across her music platforms. For Eylsia, the warmth shown by listeners during her recovery was de ———————————————————————————————————————————————————————————— Marcus T. Brooks Addresses Unverified HIV Claims and Possible Misattribution of Email Account 2026-10-27 · EIN Presswire · Healthcare, Entertainment, Mining & metals https://www.einpresswire.com/article/952596746/marcus-t-brooks-addresses-unverified-hiv-claims-and-possible-misattribution-of-email-account MtB Entertainment's Marcus Christ The Brooks Brief Company Logo MtB Entertainment Company Logo Blue and White Marcus T. Brooks Calls for an End to Unsubstantiated HIV Claims, Citing Possible Misuse of a Longstanding Email Account If someone used my email address, that does not make their dating history, medical records, or test results mine. I have never tested positive for HIV...” — Marcus Todd Brooks HOLLYWOOD, CA, ———————————————————————————————————————————————————————————— Family of Leon Davis Sues City of Federal Way, Federal Way Police Department and Hospital Operators; Releases Body-Cam Footage, says Osborn Machler & Neff 2026-10-27 · Business Wire · Healthcare, Legal https://finance.yahoo.com/healthcare/articles/family-leon-davis-sues-city-203500531.html Attorneys say Leon Davis walked into the hospital for help and died on its hallway floor. SEATTLE, October 27, 2026--The family of Leon Davis filed a wrongful death lawsuit today in King County Superior Court against the City of Federal Way, the Federal Way Police Department, Virginia Mason Franciscan ———————————————————————————————————————————————————————————— Group Health Insurance in Dallas Faces Rising Employee Affordability Concerns 2026-10-27 · MarketersMEDIA · Healthcare, Insurance, Jobs & workplace https://news.marketersmedia.com/group-health-insurance-in-dallas-faces-rising-employee-affordability-concerns/89207572 Rising healthcare expenses are creating financial challenges for employees despite workplace insurance coverage. Employers are increasingly evaluating premium contributions, deductibles, and benefit structures to balance affordability, meaningful medical protection, and sustainable employee healthcare benefits. -- Group Health Insurance in Dallas continues to attract attention as employers and employees face increasi ———————————————————————————————————————————————————————————— Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placement 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Insurance https://www.globenewswire.com/news-release/2026/10/27/3389673/0/en/rapport-announces-proposed-public-offerings-of-common-stock-and-convertible-notes-as-well-as-concurrent-private-placement.html BOSTON and SAN DIEGO, Oct. 27, 2026 -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that it has commenced separate underwritten public offerings of $200.0 million of shares of its common stock (the “common stock offering”) and $150.0 million aggregate principal amount of convertible senior notes due 2032 (the “notes offering” and together with the common stock offering, the “underwritten offerings”). In addition, Rapport intends to grant the underwriters in the common stock offering a 30-day option to purchase up to an additional $30.0 million of shares of its common stock under the same terms and conditions and intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million aggregate principal amount of notes solely to cover over-allotments, if any. Concurrently with the underwritten offerings, Rapport intends to enter into a share purchase agreement with a certain investor named therein (the “Investor”), in a separately negotiated transaction (the “concurrent private placement” and together with the underwritten offerings, the “offerings”) pursuant to which Rapport intends to offer and sell, and the Investor intends to purchase shares of Rapport’s common stock at the price per share of common stock in the common stock offering. The sale of shares to the Investor in the proposed concurrent private placement will not be registered as part of the common stock offering. The proposed offerings are subject to market and other conditions, and there can be no assurance as to whether or when the offerings may be completed, or as to the actual size or terms of the offerings. ———————————————————————————————————————————————————————————— Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026 2026-10-27 · GlobeNewswire · Finance, AI, Healthcare, Medical devices https://www.globenewswire.com/news-release/2026/10/27/3389659/0/en/carlsmed-inc-to-report-third-quarter-2026-financial-results-on-november-10-2026.html CARLSBAD, Calif., Oct. 27, 2026 -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its third quarter 2026 financial results after market close on Tuesday, November 10, 2026. Management will also host a conference call and concurrent webcast starting at 1:30 PM Pacific Time. ———————————————————————————————————————————————————————————— Medical Component Specialists Appoints Pedro Moreira to Multisite Quality Manager III as Costa Rica Facility Begins Operation 2026-10-27 · Newswire.com · Healthcare https://www.newswire.com/news/medical-component-specialists-appoints-pedro-moreira-to-multisite-quality Medical Component Specialists (MCS), a leading provider of medical components, proudly announces the appointment of Pedro Moreira as Global Multisite Quality Manager III. ———————————————————————————————————————————————————————————— Universal Health Services, Inc. Announces Financial Results for the Three and Nine-Month Periods Ended September 30, 2026 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3389648/0/en/universal-health-services-inc-announces-financial-results-for-the-three-and-nine-month-periods-ended-september-30-2026.html Consolidated Results of Operations, As Reported and As Adjusted – Three-month periods ended September 30, 2026 and 2025: ———————————————————————————————————————————————————————————— Paragon Home Care Highlights Care Coordination for Arlington Seniors Returning Home 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951789436/paragon-home-care-highlights-care-coordination-for-arlington-seniors-returning-home Coming home from the hospital is a vulnerable moment for older adults. When families, caregivers, and care teams communicate well, the transition becomes safer and less stressful for all involved.” — Juan Tuason, Owner of Paragon Home Care ARLINGTON, VA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- When an older parent is preparing to return home after a hospital stay, family members often find themselves ———————————————————————————————————————————————————————————— 10x Genomics to Participate in the 2026 Jefferies Global Healthcare Conference 2026-10-27 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/10x-genomics-to-participate-in-the-2026-jefferies-global-healthcare-conference-302921150.html PLEASANTON, Calif., Oct. 27, 2026 -- 10x Genomics, Inc. (Nasdaq: TXG), the life science technology leader focused on accelerating science and advancing human health, announced today that members of its management team will participate in a fireside chat at the 2026 Jefferies... ———————————————————————————————————————————————————————————— Shoulder Innovations to Participate in Upcoming Investor Conferences 2026-10-27 · PR Newswire · Finance, Healthcare, Medical devices https://www.prnewswire.com/news-releases/shoulder-innovations-to-participate-in-upcoming-investor-conferences-302921195.html GRAND RAPIDS, Mich., Oct. 27, 2026 -- Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced that members of management... ———————————————————————————————————————————————————————————— Washington, DC Disability Parking Permits: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-27 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977311/washington-dc-disability-parking-permits-handicapmd-explains-online-medical-certification-and-eligibility Washington, DC handicap placard guidance explains Application for Disability Parking Placard or Tags, medical certification, and government application steps. Clear Washington, DC guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott WASHINGTON, DC, UNITED STATES, October 27, 2026 / EINPresswire.com / -- HandicapMD i ———————————————————————————————————————————————————————————— Heights Behavioral Health Opens Boutique Outpatient Practice Near 11th and Yale 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952660461/heights-behavioral-health-opens-boutique-outpatient-practice-near-11th-and-yale Heights Behavioral Health at 1009 Yale Street, just off 11th Street in the heart of the Houston Heights, offers private, individualized outpatient care for adults. The lounge at Heights Behavioral Health, where clients gather each program day for a chef-prepared lunch in a calm, residential setting. The outdoor patio at Heights Behavioral Health offers clients a quiet place to pause between sessions, steps from the t ———————————————————————————————————————————————————————————— NASA Invites Media to Crew Completion of Yearlong Mars Simulation 2026-10-27 · NASA · Healthcare, Aerospace & defense, Nonprofits https://www.nasa.gov/news-release/nasa-invites-media-to-crew-completion-of-yearlong-mars-simulation/ The four volunteers who lived and worked in a simulated NASA Mars mission for more than a year will exit their habitat on Saturday, Oct. 31, after 378 days of isolation in a facility at the agency’s Johnson Space Center in Houston. Health and performance data collected from the simulation can help NASA develop methods […] ———————————————————————————————————————————————————————————— P1 PRATIA ONCOLOGY EXPANDS INTO EUROPE WITH OC ESPAÑA'S MADRID RESEARCH SITE 2026-10-27 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/p1-pratia-oncology-expands-into-europe-with-oc-espanas-madrid-research-site-302921158.html SEATTLE, Oct. 27, 2026 -- P1 Pratia Oncology, a leading community-based oncology research network focused on early-phase clinical trials, announced the expansion of its network into Spain through the OC España clinical research site at Hospital Universitario Vithas Madrid La... ———————————————————————————————————————————————————————————— Harvard Street Neighborhood Health Center to Break Ground on New Building 2026-10-27 · EIN Presswire · Healthcare, Construction & engineering https://www.einpresswire.com/article/952654458/harvard-street-neighborhood-health-center-to-break-ground-on-new-building BOSTON, MA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- On Thursday, October 29 at 11am, Harvard Street Neighborhood Health Center (HSNHC) will celebrate the groundbreaking of a new and state-of-the-art health facility, continuing to expand its mission of providing health care and community to residents in a historically underserved neighborhood. Broadening its footprint on the Blue Hill Avenue corridor, ———————————————————————————————————————————————————————————— Did CVS Health Corporation Insiders Breach their Fiduciary Duties to Shareholders? 2026-10-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/did-cvs-health-corporation-insiders-breach-their-fiduciary-duties-to-shareholders-302921045.html Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses. Shareholders should contact the... ———————————————————————————————————————————————————————————— Deep Reasoning AI and Innolitics Achieve FDA 510(k) Clearance for NeuroDR, AI Software for Neurovascular CT Angiography 2026-10-27 · Business Wire · AI, Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/deep-reasoning-ai-innolitics-achieve-185200955.html Fully automated software turns head and neck CTA scans into 3D and curved planar views of the arteries that supply the brain, cleared 105 days after submission SARASOTA, Fla. & AUSTIN, Texas, October 27, 2026--Deep Reasoning AI Inc., a company founded by Cornell University artificial intelligence profe ———————————————————————————————————————————————————————————— Breast Cancer Canada and AstraZeneca Canada Advance Next-Generation Survivorship Research 2026-10-27 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/breast-cancer-canada-astrazeneca-canada-184000629.html Announced at ESMO 2026: $200,000 in matched funding to advance the future of Canadian breast cancer survivorship. TORONTO, October 27, 2026--Breast Cancer Canada and AstraZeneca Canada are investing $200,000 in matched research funding to address critical gaps in breast cancer survivorship and improve ———————————————————————————————————————————————————————————— Pathology's Future Is Connected, Hyland Is Bringing It Into Focus 2026-10-27 · Newswire.com · Healthcare, Medical devices https://www.newswire.com/news/pathology-s-future-is-connected-hyland-is-bringing-it-into-focus 85% of pathology labs still rely on glass slides as diagnostic workloads surge 42%, creating diagnosis delays that cost patients time and health systems millions FDA-cleared, Health Canada licensed, and CE-Marking digital pathology for primary diagnosis, eliminating the last major barrier to clinical adoption at scale A governed medical imaging architecture that connects pathology to radiology, cardiology, and multi-specialty care teams, without creating another information silo ———————————————————————————————————————————————————————————— NCHE Announces 20 New Fellows for its Culture of Health Leadership Institute for Racial Healing Program 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952639934/nche-announces-20-new-fellows-for-its-culture-of-health-leadership-institute-for-racial-healing-program Dr. Gail C. Christopher The Fourth cohort of the Culture of Health Leadership Institute for Racial Healing will focus on voting rights and immigration through the TRHT™ Law Pillar We are delighted to welcome 20 exceptional new leaders at a moment when the rights to vote and to belong are being tested in communities across the country,” — Dr. Gail C. Christopher WASHINGTON, DC, UNITED STATES, October 27, 2026 / EINPre ———————————————————————————————————————————————————————————— Vadzo Imaging Validates Onboard ISP on Falcon-521CRS: Onsemi AR0521 Color 5MP Low-Noise USB 3.2 Gen1 Camera for On Camera Image Processing 2026-10-27 · Newswire.com · Healthcare, Retail, Media, Medical devices https://www.newswire.com/news/vadzo-imaging-validates-onboard-isp-on-falcon-521crs-onsemi-ar0521-22879027 The Falcon-521CRS is an Onsemi AR0521 Color 5MP Low-Noise USB 3.2 Gen1 Camera, and Vadzo has validated its on-board ISP for on-camera image processing. A sensor produces raw data, and raw data is not a picture. Turning it into one takes demosaicing, color and contrast correction, gamma, noise reduction, lens correction, exposure control, and white balance, and where that work happens shapes cost, consistency, and effort. As an On-Camera Image Processing USB Camera and an Onboard Image Processing Camera, the Falcon-521CRS performs those steps inside the module with a high-performance ISP, and it exposes tuning controls through the standard UVC interface. It adds anti-flicker for 50Hz and 60Hz lighting, streams YUYV or MJPEG video, and captures BMP or JPEG stills. Large 2.2-micron pixels keep noise low before processing begins. Designed for security, retail, and medical device makers, it delivers a finished, consistent image from a single USB cable. ———————————————————————————————————————————————————————————— Pediatric Epilepsy & Neurology Specialists Earns Highest Patient Satisfaction 2026 in Tampa 2026-10-27 · EIN Presswire · Healthcare, Retail https://www.einpresswire.com/article/952634890/pediatric-epilepsy-neurology-specialists-earns-highest-patient-satisfaction-2026-in-tampa Tampa Bay's largest pediatric neurology group recognized by the Consumer Ratings Institute for a 4.6-star rating across 1,292 consumer reviews. TAMPA, FL, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Pediatric Epilepsy & Neurology Specialists (PENS), the largest group of pediatric neurologists in the Tampa Bay area, has been named Highest Patient Satisfaction 2026 — Tampa in the Brain Health Clinics catego ———————————————————————————————————————————————————————————— AlzeCure Pharma Announces Change of CEO Ahead of Next Phase of Development 2026-10-27 · ACCESS Newswire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/alzecure-pharma-announces-change-ceo-174500321.html STOCKHOLM, SE / October 27, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - AlzeCure Pharma AB (FN STO:ALZCUR), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's disease and pain, announces today that CEO Martin Jönsson is stepping down and is being replaced on an ———————————————————————————————————————————————————————————— Canouse Announces Unsatisfied Federal Judgment Against Protext Mobility, Inc. (OTC: TXTM) 2026-10-27 · ACCESS Newswire · Healthcare, Automotive, Biotech & pharma https://finance.yahoo.com/markets/stocks/articles/canouse-announces-unsatisfied-federal-judgment-173500664.html $563,396.72 judgment entered by the U.S. District Court for the Southern District of New York remains unpaid NEW YORK CITY, NY / October 27, 2026 / Joseph C. Canouse today announced that the judgment entered in his favor against Protext Mobility, Inc. (aka Protext Pharma, Inc.) (OTCID:TXTM) (the "Company ———————————————————————————————————————————————————————————— Glooko Recognized as Finalist for the Digital Health Hub Foundation Digital Health & AI Awards 2026 at HLTH 2026-10-27 · Business Wire · AI, Healthcare, Software & IT https://finance.yahoo.com/healthcare/articles/glooko-recognized-finalist-digital-health-172000348.html Best in Class finalist in Cardiometabolic, Obesity & Diabetes category PALO ALTO, Calif., October 27, 2026--Glooko, Inc., an enterprise software partner for diabetes and glycemic management from hospital to home, today announced its selection as a finalist in the Best in Class track for Cardiometabolic ———————————————————————————————————————————————————————————— Baystate Health and Health New England Remove Barriers to Streamline Access to Care 2026-10-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/baystate-health-and-health-new-england-remove-barriers-to-streamline-access-to-care-302921088.html Innovative one-year pilot initiative will reduce select prior authorization requirements while maintaining quality and safety SPRINGFIELD, Mass., Oct. 27, 2026 -- Baystate Health, with its health plan, Health New England, today announced the Clear Path Pilot Program, a... ———————————————————————————————————————————————————————————— Triple Victory Returns: DrSkin Sweeps 2026 Best of the Best East Valley Awards 2026-10-27 · ACCESS Newswire · Healthcare, Marketing & advertising https://finance.yahoo.com/healthcare/articles/triple-victory-returns-drskin-sweeps-171500599.html Gilbert, Arizona-based DrSkin earns first place honors in Best Med Spa, Best Plastic Surgery and Best Skin Care in the 2026 Best of the Best East Valley awards, marking its second consecutive year of recognition. GILBERT, AZ / October 27, 2026 / DrSkin Plastic Surgery, Regenerative & Medical Spa is proud ———————————————————————————————————————————————————————————— Social Media Victims Law Center and The Schenk Law Firm File Wrongful Death Lawsuit Against OpenAI Alleging ChatGPT’s Medical Advice Resulted in the Death of a Woman with Epilepsy 2026-10-27 · Business Wire · AI, Healthcare, Legal, Internet & apps https://finance.yahoo.com/healthcare/articles/social-media-victims-law-center-170100749.html Claims ChatGPT practiced medicine without a license advising Bowen Wan to reduce her anti-seizure medication to zero without telling her doctors, resulting in her death from a preventable seizure SAN FRANCISCO, October 27, 2026--The Social Media Victims Law Center , a legal advocacy organization repres ———————————————————————————————————————————————————————————— TGFb Inhibitors Clinical Trial Pipeline Accelerates as 25+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3389496/0/en/tgfb-inhibitors-clinical-trial-pipeline-accelerates-as-25-pharma-companies-rigorously-develop-drugs-for-market-entry-delveinsight.html The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial analysis. The TGFb inhibitor clinical trial analysis report delivers important insights into ongoing research on 30+ TGFb inhibitors in the pipeline, clinical strategies, upcoming therapeutics, and commercial analysis. ———————————————————————————————————————————————————————————— Walmart and Care Access Plan Three Additional Clinical Trial Centers to Expand Access to Medical Research 2026-10-27 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/walmart-care-access-plan-three-170000976.html Building on four initial locations in Texas, Georgia, and Florida, planned expansion into additional communities across three states aims to bring research opportunities closer to where people live and shop. HOUSTON, October 27, 2026--The Walmart Healthcare Research Institute (WHRI) and Care Access, a ———————————————————————————————————————————————————————————— Monebo and Innolitics Secure FDA 510(k) Clearance for a Cross-Platform ECG Arrhythmia Analysis Library 2026-10-27 · Business Wire · SaaS, Healthcare, Food & drink, Biotech & pharma, Software & IT, Medical devices https://finance.yahoo.com/healthcare/articles/monebo-innolitics-secure-fda-510-165400140.html Medical device makers can now build an FDA-cleared library for beat detection, heart rate and rhythm analysis into their own ECG products. AUSTIN, Texas, October 27, 2026--Monebo Technologies, Inc. and Innolitics today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Kinetic Software Library ( K260640 ), Monebo's ECG analysis library for medical device manu ———————————————————————————————————————————————————————————— Menopause and Heart Health: Expert Explains What Every Woman Should Know with YourUpdateTV 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3389486/0/en/menopause-and-heart-health-expert-explains-what-every-woman-should-know-with-yourupdatetv.html Cardiologist and Bayer® Aspirin Partner Dr. Jayne Morgan Discusses Why Midlife Is an Important Time for Women to Focus on Their Heart Health Cardiologist and Bayer® Aspirin Partner Dr. Jayne Morgan Discusses Why Midlife Is an Important Time for Women to Focus on Their Heart Health ———————————————————————————————————————————————————————————— San Diegan & U.S. Air Force Veteran Living with ALS Shares Support for Proposition 38 in New Advertisement 2026-10-27 · EIN Presswire · Finance, Healthcare, Media, Marketing & advertising https://www.einpresswire.com/article/952619333/san-diegan-u-s-air-force-veteran-living-with-als-shares-support-for-proposition-38-in-new-advertisement Jessy Ybarra hopes advances in medical research will help him live long enough to see his son and granddaughter graduate from college Prop 38 gives California a stable source of funding to keep that research moving at a pace our lives literally depend on.” — Jessy Ybarra, a San Diego-area U.S. Air Force veteran living with ALS SAN DIEGO, CA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- In a video advertise ———————————————————————————————————————————————————————————— PoolBar London Women’s Health Awards 2026 Winner 2026-10-27 · EIN Presswire · Healthcare, Consumer goods https://www.einpresswire.com/article/951565849/poolbar-london-women-s-health-awards-2026-winner PoolBar London Wins “Best Water Resistant Sunscreen” in the 2026 Women’s Health Skincare Awards. LONDON , GREATER LONDON, UNITED KINGDOM, October 27, 2026 / EINPresswire.com / -- PoolBar London has been named a winner in the 2026 Women’s Health Skincare Awards, with its Clear Sunscreen Spray SPF 50 taking home the title of “Best Water Resistant Sunscreen”. The annual awards, described by Women’s Health as its biggest ———————————————————————————————————————————————————————————— What If We Could Stop Aging? The Intriguing Premise of a New Medical Thriller, The Aging Code 2026-10-27 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/952624345/what-if-we-could-stop-aging-the-intriguing-premise-of-a-new-medical-thriller-the-aging-code Physician and author Robert J. McCunney, M.D. takes that question into the world of medical thrillers with The Aging Code, where cutting-edge genetics, life-extension research, terrorism and the war in Ukraine collide. Dr. McCunney treats us to a graduate course in international terrorist intrigue, geopolitics, environmental medicine, and the science of aging. Move over Sir Arthur Conan Doyle! Robert McLellan, MD, MP ———————————————————————————————————————————————————————————— Bionix Introduces ReadyHub™ Procedure Staging System, the Next Addition to OneLight® 2026-10-27 · Business Wire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/bionix-introduces-readyhub-procedure-staging-164000525.html New ecosystem connects one Rechargeable Light Source, lighted tools, procedure staging, preparation guidance and clinical education so care teams are ready before the procedure begins TOLEDO, Ohio, October 27, 2026--Bionix® today announced the launch of the ReadyHub™ Procedure Staging System , which j ———————————————————————————————————————————————————————————— Align Recovery Centers Calls Attention to Safe Prescription Drug Detox 2026-10-27 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/952618867/align-recovery-centers-calls-attention-to-safe-prescription-drug-detox Align Recovery Centers supports adults seeking prescription drug detox with supervised care that addresses substance use and co-occurring mental health needs. SONOMA, CA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Align Recovery Centers is raising awareness of the need for safe, compassionate prescription drug detox in California, encouraging individuals and families to seek professional support before d ———————————————————————————————————————————————————————————— UK health tech pioneer Patients Know Best launches global expansion at HLTH Las Vegas 2026-10-27 · GlobeNewswire · SaaS, Healthcare, Government & policy https://www.globenewswire.com/news-release/2026/10/27/3389453/0/en/uk-health-tech-pioneer-patients-know-best-launches-global-expansion-at-hlth-las-vegas.html Cambridge, UK, Oct. 27, 2026 -- Patients Know Best (PKB), the UK patient-controlled health record platform, will exhibit at HLTH Las Vegas (15–18 November, The Venetian Expo) as part of the UK Government pavilion hosted by the Department for Business, Innovation, Science and Trade (DBIST).  The event marks the launch of PKB’s next major growth phase outside the UK, accelerating its global footprint and engaging strategic partners to scale for its almost 9 million users. ———————————————————————————————————————————————————————————— DEADLINE ALERT for York Space Systems, Inc. (YSS), Hims & Hers Health, Inc. (HIMS), Unicycive Therapeutics, Inc. (UNCY), and Papa John's International, Inc. (PZZA): The Law Offices of Frank R. Cruz Reminds Investors of Lead Plaintiff Deadlines in Securities Fraud Class Actions 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma, Legal https://www.globenewswire.com/news-release/2026/10/27/3389451/0/en/deadline-alert-for-york-space-systems-inc-yss-hims-hers-health-inc-hims-unicycive-therapeutics-inc-uncy-and-papa-john-s-international-inc-pzza-the-law-offices-of-frank-r-cruz-remin.html Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions Investors in York Space Systems, Inc., Hims & Hers Health, Inc., Unicycive Therapeutics, Inc., and Papa John's International, Inc. have upcoming deadlines to seek lead plaintiff appointment in pending securities class actions ———————————————————————————————————————————————————————————— Global AI in Blood Pressure Monitoring Market Size, Share, Trends, and Forecast, 2026-2036 | 28.6% CAGR Drives a $15.20 Billion Opportunity in Cuffless Wearables and Remote Patient Monitoring 2026-10-27 · GlobeNewswire · AI, Healthcare, Consumer electronics https://www.globenewswire.com/news-release/2026/10/27/3389448/28124/en/global-ai-in-blood-pressure-monitoring-market-size-share-trends-and-forecast-2026-2036-28-6-cagr-drives-a-15-20-billion-opportunity-in-cuffless-wearables-and-remote-patient-monitor.html Dublin, Oct. 27, 2026 -- "AI in Blood Pressure Monitoring Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— Nestwell and Hardline Tie for Top Honors at PitchLive.LA 2026 2026-10-27 · EIN Presswire · AI, Healthcare, Construction & engineering https://www.einpresswire.com/article/952520830/nestwell-and-hardline-tie-for-top-honors-at-pitchlive-la-2026 Alena Tuttle, Co-Founder and CEO of Hardline (left), and Ben Parens, Founder and CEO of Nestwell (right), joint winners of PitchLive.LA 2026, at the October 13 event in Venice. Photo credit: Longest Title Creative Judges split the prize between an at-home environmental health startup and a construction voice AI company LOS ANGELES, CA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Judges at PitchLive.LA 202 ———————————————————————————————————————————————————————————— Washington State Disability Parking Permits: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-27 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977282/washington-state-disability-parking-permits-handicapmd-explains-online-medical-certification-and-eligibility Washington State handicap placard guidance explains TD-420-073, medical certification, and government application steps. Clear Washington State guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott OLYMPIA, WA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- HandicapMD is highlighting Washington State disable ———————————————————————————————————————————————————————————— Modular Medical Announces Positive Notified Body Decision on ISO 13485:2016 Certification 2026-10-27 · Newswire.com · Healthcare, Medical devices https://www.newswire.com/news/modular-medical-announces-positive-notified-body-decision-on-iso-13485-2016 Certification Represents Another Milestone Toward CE Mark Submission for Pivot ———————————————————————————————————————————————————————————— Blue Jay ABA Now Accepting New Families in the Charlotte Area, With Medicaid Accepted and No Waitlist 2026-10-27 · MarketersMEDIA · Healthcare, Insurance https://news.marketersmedia.com/blue-jay-aba-now-accepting-new-families-in-the-charlotte-area-with-medicaid-accepted-and-no-waitlist/89207496 Charlotte-area ABA provider highlights Medicaid acceptance, no waitlist, and help with insurance for families seeking autism therapy. -- Blue Jay ABA is accepting new families in the Charlotte area, offering parents a way to explore autism therapy services without facing a long waitlist. The organization accepts North Carolina Medicaid and multiple health plans, and its team helps families navigate insurance verifica ———————————————————————————————————————————————————————————— AcuraStem Receives Hoffman ALS Clinical Trial Award to Support Phase 1 Trial of AS-241, the Clinical Candidate of its UNC13A Program 2026-10-27 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/acurastem-receives-hoffman-als-clinical-trial-award-to-support-phase-1-trial-of-as-241-the-clinical-candidate-of-its-unc13a-program-302920910.html The ALS Association's $1 Million Award Will Fund Biomarker Development to Support First-in-Human Testing of AcuraStem's Lead ALS Therapy PASADENA, Calif., Oct. 27, 2026 -- ⎯ AcuraStem, a biotechnology company advancing treatments for amyotrophic lateral sclerosis (ALS),... ———————————————————————————————————————————————————————————— End Mills Market Worth US$ 2,828.77 Million by 2031, Growing at a CAGR of 5.2% 2026-10-27 · PR News Releaser · Healthcare, Automotive, Industrial, Aerospace & defense https://www.prnewsreleaser.com/news/479885 The global End Mills Market is poised for steady expansion over the current decade, accelerated by advancing industrial automation, rising adoption of Computer Numerical Control (CNC) machinery, and increasing demand for ultra-precise components across aerospace, automotive, medical, and electronics manufacturing. According to ... Read more ———————————————————————————————————————————————————————————— China Hospital Supplies - Market Size, Share, Trends, and Growth Forecasts (2026-2031) | Market to Reach USD 21.83 Billion as Hospital Expansion Drives 8.41% CAGR 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3389342/28124/en/china-hospital-supplies-market-size-share-trends-and-growth-forecasts-2026-2031-market-to-reach-usd-21-83-billion-as-hospital-expansion-drives-8-41-cagr.html ROI opportunities center on cost-efficient local supplies, rapid fulfillment, tender alignment, infection-control upgrades and IoT-enabled sterilization. ROI opportunities center on cost-efficient local supplies, rapid fulfillment, tender alignment, infection-control upgrades and IoT-enabled sterilization. ———————————————————————————————————————————————————————————— Vera Health Quietly Became One of the World's Most Used Clinical Tools. Now It Has Raised $32 Million to Give Every Clinician in the World the Best Medical Knowledge in Seconds 2026-10-27 · PR Newswire · Finance, AI, Healthcare https://www.prnewswire.com/news-releases/vera-health-quietly-became-one-of-the-worlds-most-used-clinical-tools-now-it-has-raised-32-million-to-give-every-clinician-in-the-world-the-best-medical-knowledge-in-seconds-302920905.html With a team of just 12 employees, the clinical AI company has grown largely through physician referrals, bringing total funding to $32 million More than 800,000 clinicians across 190 countries use Vera Health, including approximately 1 in 4 physicians in Spain and Italy, with most... ———————————————————————————————————————————————————————————— RX's Reed Sinopharm Leads the 94th CMEF Autumn Edition, Bringing Global Healthcare Leaders Together in Beijing 2026-10-27 · PR.com · Healthcare https://www.pr.com/press-release/982489 Reed Sinopharm, a global organizer of exhibitions and events, announced the opening of the 94th China International Medical Equipment Fair (CMEF) Autumn Edition at the Capital International Exhibition & Convention Center in Beijing. As one of Reed Sinopharm's flagship healthcare exhibitions, the event brings together healthcare leaders, manufacturers, buyers, innovators, and decision-makers from around the world to [PR.com] ———————————————————————————————————————————————————————————— IFF Identifies Ten Consumer Moments Reshaping Food and Beverage Innovation in the GLP-1 Era 2026-10-27 · Business Wire · Healthcare, Food & drink, Biotech & pharma https://finance.yahoo.com/healthcare/articles/iff-identifies-ten-consumer-moments-150000338.html New research reveals how smaller, more intentional eating occasions are creating new opportunities for nutrition, flavor and renewed enjoyment. NEW YORK, October 27, 2026--IFF (NYSE: IFF)—a global leader in flavors, fragrances and health and biosciences, today launched its latest report, "GLP-1 Consum ———————————————————————————————————————————————————————————— Pendral and PLEXIS Healthcare Systems Announce Strategic Partnership to Bring Governed AI to PLEXIS Payer Clients 2026-10-27 · Business Wire · AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/pendral-plexis-healthcare-systems-announce-145800777.html Pendral joins the PLEXIS Synergy Rewards Program, bringing its suite of governed AI tools to PLEXIS's network of health plan customers DALLAS & MEDFORD, Ore., October 27, 2026--Pendral , an enterprise AI platform born from the real-world, regulated healthcare operations of Evry Health , a health insur ———————————————————————————————————————————————————————————— DistillerSR Launches Smart Chat, an AI Chat Interface Built Into Its Evidence Platform 2026-10-27 · ACCESS Newswire · AI, SaaS, Healthcare https://finance.yahoo.com/technology/ai/articles/distillersr-launches-smart-chat-ai-145500994.html Talk to Your Evidence. Trust the Answer. OTTAWA, ON / October 27, 2026 / DistillerSR ® Inc. , the pioneer and market leader in AI-enabled literature review automation and evidence management, today announced the launch of Smart Chat. Smart Chat brings DistillerSR's Agentic AI capabilities in-platform. Si ———————————————————————————————————————————————————————————— AMA urges vaccination as respiratory virus season gets underway 2026-10-27 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=363395 With respiratory virus season getting underway and flu activity reported early in many parts of the country, the American Medical Association (AMA) is urging the public to stay up to date on recommended vaccinations to reduce the risk of severe illness from flu, CVID-19 and RSV. - - “As temperatures drop and people spend more time indoors with their loved ones and coworkers, respiratory viruses like flu spread,” said AMA President Willie Underwood III, MD, MSc, MPH. “Now is the time to get... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363395 ———————————————————————————————————————————————————————————— UNLOCKD (BFCH) Completes Acquisition of 1ENERGY, Expanding Consumer Wellness Portfolio to Three Brands 2026-10-27 · NewMediaWire · Finance, SaaS, Healthcare, Real estate, Energy, Retail, Industrial, Marketing & advertising, Consumer goods https://www.newmediawire.com/news/unlockd-bfch-completes-acquisition-of-1energy-expanding-consumer-wellness-portfolio-to-three-brands-7090877 Third Completed Acquisition Strengthens UNLOCKD's Growing Portfolio as Management Targets Additional Transactions and a Path Toward $1 Million in Annualized Revenue LANCASTER, PA - October 27, 2026 - BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD Inc. (“UNLOCKD” or the “Company”), today announced the completion of its acquisition of substantially all assets associated with 1ENERGY, a developed functional energy-shot brand and consumer product platform previously owned by XSBEV LLC. The acquisition marks UNLOCKD's third completed consumer wellness transaction, following its acquisitions of EVERMIND intellectual property and Ancient Extracts USA, an operating, revenue-generating wellness brand. With three brands now assembled under its growing platform, UNLOCKD continues executing its strategy of acquiring established consumer intellectual property, product formulations, brand assets and commercialization infrastructure that management believes can be developed and scaled more efficiently than building comparable platforms from inception. “We're demonstrating our ability to execute,” said John P. Gorst, Chief Executive Officer of UNLOCKD. “With Ancient Extracts generating revenue, EVERMIND positioned for commercialization and now 1ENERGY joining our portfolio, we're building a foundation of differentiated consumer brands at various stages of development. Each acquisition brings assets, intellectual property and opportunities that we believe can benefit from our broader operating platform.” Acquiring Established Assets. Unlocking New Potential The 1ENERGY acquisition includes brand intellectual property, existing formulations, product-development materials, packaging and creative assets, digital properties, manufacturing information, supplier relationships and other assets associated with the platform. Originally developed around the consumer proposition “Energy Without the Edge,” 1ENERGY represents an opportunity to build upon an existing brand identity and substantial product-development work. UNLOCKD intends to reposition the brand through targeted formulation enhancements, including the removal of CBD and other cannabinoid ingredients, while evaluating functional mushrooms, adaptogens, nootropics and other ingredients aligned with the Company's broader wellness strategy. “1ENERGY is an example of the opportunities we believe exist throughout the consumer products industry,” Gorst continued. “Significant resources can go into developing a brand, its formulations, packaging, creative identity and manufacturing infrastructure, yet the business may never reach its commercial potential. Our strategy is to identify those opportunities, acquire the underlying assets at attractive economics and provide a pathway toward commercialization.” The acquisition is structured as an asset purchase rather than an acquisition of XSBEV LLC, with historical liabilities remaining with the seller except for any obligations expressly assumed under the definitive agreement. Experienced Creative Leadership Joins the Opportunity Christian Struzan, the entrepreneur and brand strategist behind 1ENERGY, will remain involved in the brand's next phase in a strategic and creative capacity, contributing experience in branding, product positioning, packaging, marketing and commercialization. “A tremendous amount of work went into developing 1ENERGY, from the formulations and packaging to the brand identity and overall consumer experience,” said Christian Struzan. “What excites me about UNLOCKD is the opportunity to take that foundation and build upon it with a team focused on commercialization and growth. I'm looking forward to working with John, Jordan and the broader UNLOCKD team as we develop 1ENERGY's next chapter.” Building Momentum Toward the Next Revenue Milestone With three completed acquisitions, management believes UNLOCKD is establishing a repeatable model for identifying, acquiring and commercializing consumer wellness assets. The Company continues evaluating additional acquisition opportunities, including a prospective transaction that management believes could meaningfully accelerate its revenue base and advance its progress toward a $1 million annualized revenue milestone. “We've now successfully completed three acquisitions, bringing EVERMIND, Ancient Extracts USA and 1ENERGY into the UNLOCKD portfolio,” said Dr. Jordan P. Balencic, Chairman of UNLOCKD. “Each transaction strengthens our platform and demonstrates our ability to execute. We're building on that experience as we pursue our next acquisition, which we believe could bring us significantly closer to a $1 million annual revenue run rate sooner than many might expect. That milestone would be an important inflection point, but it's only the beginning. Our longer-term ambition is to build UNLOCKD into a company with $100 million or more in enterprise value. We're focused on assembling the assets, revenue and operating capabilities necessary to pursue that objective.” UNLOCKD intends to continue pursuing opportunities across functional wellness, nutritional health and consumer packaged goods, with an emphasis on acquiring established assets, advancing commercialization and expanding revenue-generating operations. About 1ENERGY 1ENERGY is a functional energy-shot brand developed around the “Energy Without the Edge” consumer proposition. The platform includes established branding, product formulations, packaging, creative assets, digital properties, manufacturing information and related intellectual property. UNLOCKD intends to develop a CBD-free formulation and evaluate opportunities for renewed commercialization. Website: https://www.1energyshot.com/ About UNLOCKD Inc. BitFrontier Capital Holdings, Inc. (OTCID: BFCH), doing business as UNLOCKD Inc., is building a diversified consumer health and wellness platform focused on acquiring, developing and commercializing differentiated brands, products and intellectual property. The Company's portfolio includes Ancient Extracts USA, a revenue-generating functional wellness brand; EVERMIND, a functional wellness platform with existing formulations and intellectual property; and 1ENERGY, a developed functional energy-shot brand. UNLOCKD's strategy emphasizes identifying undercapitalized or overlooked consumer assets with established brand equity, intellectual property and commercial potential, and seeking to create value through strategic acquisitions, product development, operational execution and expanded distribution. Website: https://unlockdinc.com/ Investor and Media Contact John P. Gorst Chief Executive Officer UNLOCKD Inc. John.gorst@unlockdinc.com https://unlockdinc.com/ OTCID: BFCH Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the future development, reformulation and commercialization of 1ENERGY; anticipated ingredients, manufacturing, distribution and product extensions; the commercialization of EVERMIND; the continued growth of Ancient Extracts USA; potential future acquisitions; the Company's anticipated progress toward a $1 million annualized revenue milestone; and UNLOCKD's broader acquisition, operating and growth strategy. Forward-looking statements are based on management's current expectations, estimates and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. There can be no assurance that UNLOCKD will successfully reformulate, manufacture or commercialize 1ENERGY; that EVERMIND will achieve commercial success; that Ancient Extracts USA will maintain or increase revenue; that any contemplated future acquisition will be completed; that the Company will achieve a $1 million annualized revenue run rate within any particular period or at all; or that its acquisition and commercialization strategy will produce the anticipated results. Future acquisitions may require additional financing, regulatory approvals, due diligence and definitive agreements, and may not be completed on acceptable terms. Readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to publicly update or revise such statements except as required by applicable law. ———————————————————————————————————————————————————————————— Inception Fertility Expands Donor Identity Programs, Offering Greater Transparency and Choice in Family Building 2026-10-27 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/inception-fertility-expands-donor-identity-143100685.html New donor identity options across MySpermBank, MyEggBank, and The Prelude Network give intended parents more transparency, choices in their donor-assisted family building journeys HOUSTON, TX / October 27, 2026 / Inception Fertility ™, a leading provider of comprehensive fertility services across North A ———————————————————————————————————————————————————————————— 2027 LITERARY / BROADCAST NEWS: Announcing Creative Management Partners (CMP) Agent Alan Morell Milestone 277th Book and Feature Film Milestone Sale of CMP Authors' Works to Publishers; Books Developed for TV/Film Optioned to Video Streamers, Networks 2026-10-27 · NewMediaWire · Finance, SaaS, Healthcare, Real estate, Retail, Automotive, Media, Education, Food & drink, Sports, Industrial, Aerospace & defense, Logistics, Insurance, Investing & markets, Legal, Government & policy, Marketing & advertising, Internet & apps, Consumer electronics, Entertainment https://www.newmediawire.com/news/2027-literary-broadcast-news-announcing-creative-management-partners-cmp-agent-alan-morell-milestone-277th-book-and-feature-film-milestone-sale-of-cmp-authors-works-to-publishers-books-developed-for-tv-film-optioned-to-video-streamers-networks-7090876 - Alan Morell Milestone of 277th book/book adaptation to TV/Film Options for 2027 BEVERLY HILLS, CA - October 27, 2026 - Announced today, Creative Management Partners (CMP) Agent Alan Morell Milestone 277th Book and Feature Film Milestone Sale of CMP authors' works to publishers (many Multilingual international country editions and series); Books developed for TV/Film optioned to video streamers, networks, studios, and audiobooks. eg. Macmillan, HarperCollins, William Morrow, Penguin Random House, Random House, Rodale, Blackstone, WhoopLNK, iBooks, Hay House Publishers, Crown, Harmony, Brick Tower Press, J. Boylston & Company, Milk and Cookies, St. Martins Press, Skyhorse, Island books,  Simon & Schuster, Grand Central, BenBella Books, Alcove et. al., positioned for Option Rights for TV DocuSeries/ Feature Films, Television Network and Cable, Digital, Development Adaptation of Original Content, Unscripted, Scripted, Documentary, Docudrama, Legitimate Theatre e.g. Netflix; Amazon Prime; DisneyABC; Hulu; PBS/BBC/ Focus Features; Disney Companies and Broadway. NY TIMES BEST SELLER LIST: “Lies I Taught In Medical School” by Dr. Robert Lufkin, Forward by Jason Fung MD to BenBella Books, Distributed by Random House and in Multilingual Editions; Former Supreme Allied Nato Commander, Four Star General Wesley K. Clark “ADVOCACY FOR PEACE” to iBooks; "Before the Knife”, A Regenerative Approach to Chronic Pain, Arthritis, and Injury by Dr. Adam Brockman, Host of Health Talk America to Blackstone Publishing; The Art of Chaos by Dr. Nicole Dolan to WhoopLNK;“THE WORK OF A NATION (Immigration, Identity, and Americas Future)” by Al Cardenas w/ Rod Thorn to WhoopLNK; “Rise and Climb” by Ben Barbic to Skyhorse Publishing;“Freedom For Pharmacy” by Dr. Patrick Ojo to Brick Tower Press; “Quantum Human”; Quantum Cuisine by Brian Clement Ph.D L.N to “iBooks”. “The Aztec Diet”, by NY Times Best Selling Author Dr. Bob Arnot to HarperCollins Publishers; “The Penis Book” by Dr. Aaron Spitz to Rodale Penguin Random House; “Is This Normal” by Dr. John Whyte, Chief Medical Officer of AMA to Rodale Penguin Random House; UNMASKED (Working Title) by Dr. Lee Newcomer (Publisher offer under negotiation); “The Fountain, 60 the new 30” by Dr. Rocco Monto to Penguin Random House Harmony Crown; “Escape from Plauen” by Renee Stoever to iBooks; BOOK SERIES OF HEADS OF STATE, by Dr. Frederic Teboul and Thierry Pastor to iBooks: “UNBREAKABLE” on President Donald J. Trump; “THE LION OF ISRAEL” on Prime Minister Benjamin Netanyahu; “EL LOCO”, The President of Argentina; President Xi Jinping (China) - Xi Jinping: “Leadership, Power, Peace, Road to Number One”; President Vladimir Putin (Russia) - The King’s Gambit: Understanding Vladimir Putin’ HRH King Hamad bin Isa Al Khalifa (Bahrain) - “The Bahraini Equation: Power, Reform, and Leadership” Under King Hamad; Prime Minister Narendra Modi (India); “The Ozempic Breakthrough” by Dr. Rudolph Eberwein to Brick Tower Press; “Encyclopedia of Longevity” 10 Book Series by Alan Morell and Dr. Robert Lufkin (Sale Pending);  “Greek Diet  PBS Series” by Chef Maria Loi to HarperCollins/ PBS/BBC; Of Course They Knew, Of Course They… Washington Square Entertainment (WSE) and NTD (Canada) Conspiracy Thriller Drama TV Series Based on John Moody’s Bestselling Hui Trilogy;  “Stars My Destination” by Alfred Bester to Beijing Laputta Media Technology Co., Ltd.; “Cubcoats" (Acquisition Vehicle LLC), multi Library Auction of Literary; “Supply Chain Ninja,-How to Grow Your Career in Purchasing, Procurement and Industrial Sales Management” by Henrik Bech Paulson to Brick Tower Press; “Coffee Lovers Diet” by Dr. Bob Arnot to HarperCollins; “Living Longer; The Forever Human; Living Better" by Dr. Eugene Antenucci to iBooks; “Grant Brace Story, True American Tragedy” by the Brace Family w/ Didi Gluck toJ. Boylston & Company Publishers; “Guide To Resilience And Success Longevity”, by Stephen Sideroff Ph.D, Forward by Peter Levine Ph.D to BenBella Books, Distributed by Random House; “The Secret Of Nitric Oxide - Bringing Nitric Oxide To Life” By Nathan Bryan PhD’to Brick Tower Press; "Surviving the 2020 Election Without Losing Your Mind: Dr. Calm’s Prescription for Electile Dysfunction"  And “Calming the Corona—Stay Calm, Think Rational, and Don’t Do Anything Stupid!”;”The Mantra of Peaceful Politics” By Dr. Kiran Dintyala to J. Boylston Publishers; Let’s Do Launch” Hollywood Talent Agent Icon Harry Abrams, Founder/Chairman of Abrams Artists Agency, with Rod Thorn to J. Boylston & Company; “Of Course they knew, of Cours they…; “Vindication” by John Moody to Brick Tower Press;"The Silent Epidemic” by Dr. Michel Baudry and Dr. Stella M. Sung to iBooks;“Arthur C. Clarke's Venus Prime Sci-Fi Book Series by Emmy Award Screenwriters Dwayne J. Hill and David Cormican, Washington Square Entertainment to Claxon Interactive; “The Perfect Entrepreneur” by Zef Vataj to Brick Tower Press; “Southern Inspired by Chef Jernard Wells to BenBella Books Distribution by Random House; ”Two Friends & a Stroke: From a Life-Threatening Stroke to a 66-Year-Old Model!” by Geri Rockstein to iBooks; “Frankie Avalon Italian Family Cookbook” by Frankie Avalon to MACMILLAN St. Martins Press; “How the Thinkpad Changed the World-And is Shaping the Future” (Lenovo) by Arimasa Naitoh and William J. Holstein to SkyHorse Publishing; “Bad Americans Feature Film by Jacques Hyzagi to Benaroya Pictures; “The New Art of War” by William J. Holstein, J. Boyston & Co.; “The Sicilian Diet” by Dr. Giovanni Campanile to Brick Tower Press; “Common Sense for Common Good” by Presidential Candidate Gary Johnson to Broadside;; “Ryde Studios Network Instagram World’s Largest Shopping Network Book” by Richard D’Alessio; “Coffee Lovers Diet” by Dr. Bob Arnot to HarperCollins; “The Sainted”( Trilogy) by Michael Medico to iBooks; “Global Immigration A-Z” by Lorraine D’Alessio Esq. to J. Boylston & Co.; “Osceola’s Revenge: The Phenomena of Indian Casinos” by Gary Green to iBooks; “Stop Pain” by Dr. Vijay Vad to Hay House Publishers; Dream Chronicles” Trilogy by David Rottenberg to iBooks; “The Greek Diet” by Chef Maria Loi to HarperCollins; “The Master” By Dr. Bob Arnot to J. Boylston & Company Publishers; “Just in Case: Lose Your Heart, Not Your Mind: The Smart Women’s Guide to Marriage” by Aliette H. Carolan, Esq. to Brick Tower Press; “Facing East” by Jingdaun Yang MD with Norma Kamali to William Morrow; “Silver Dollar” by Alan Susman to ibooks (Screenwriter for Thomas Crown Affair MGM); “Finding the SuperModel in Me” by Claudia Mason to Skyhorse Publishing; “U-Boats in Bahamas, Turks & Caicos” by Eric T. Wiberg to Brick Tower Press; “The Art of Managing Everyday Conflict: Understanding Emotions and Power Struggles” and“The Art of Empowered Parenting: The Manual You Wish Your Kids Came With” by Dr. Eric Fisher PhD; “U-Boats in Bermuda”; “U-Boats in New England” by Eric T. Wiberg to Brick Tower Press; “Seducing Celebrities One Meal At A Time” by Thaao Penghlis to iBooks; Judas, “His Brother Keeps Her” by Alan Susman to J. Boylston & Company Publishers; “God and Man on Wall Street” by CNBC Craig Columbus to Brick Tower Press; ““Hazel’s Masquerade” by Sarah Trautvetter to Milk and Cookies Publishers; “Salvage Chef” by Chef Michael Love to Skyhorse Publishing; “The Art of Empowered Parenting” by Eric Fisher, PhD, CNN; “Tower of Thieves: AIG” by Andrew Spencer, J. Boylston & Company Publishers; “Bear Trap: Fall of Bear Stearns” by Andrew Spencer, to J. Boylston & Company Publishers; “Eddie and The Emoticons” by Eric Fisher PhD to Milk and Cookies; “Being Uncle Charlie” by Bobby Deasy to Random House; “Ready…Set, Risk” by Danielle Levitt to J. Boyston & Company Publishers; “The Oxygen Plan” by Eric Lucas to iBooks; “The Real Man Plan” by Dr. John Shufeldt; “Exposing the Wall Street Boys Club” by James Goldberg with Danny Espinosa, Esq.; “Chefs Run Wild” by Tim Troke, Frogwater Media; “The Next American Economy: Blueprint for a Real Recovery” by William J. Holstein to Bloomsbury; “Cru Oyster Bar Cookbook” by Chef Erin Kircher, Jane Stoddard and Carlos Hidalgo, with Martha Murphy to St. Martins Press; “Frozen & Fabulous Cookbook” by Chef Gail Kurpgeweit to iBooks; “Conquering Cancer” by Dr. Yu to iBooks;  Audio book  of “Common Sense for Common Good” by Gary Johnson to HarperCollins Brilliance;  “The Peasant Chef” by Chef Sandy, FYI Network; “Secret of Blond Souk” by Robin Brouillette;  Audio Book of“The Penis Book”by Aaron Spitz MD to Brilliance Amazon; “Taking Away the Guilty Conscious Cookbook” by Chef Jernard Wells, Food Network Contributor; “Shift,The Power of Design to Create Longevity, Vitality and Productivity” by Fawn Chang to J. Boylston & Company Publishers; “Round the World in the Wrong Season”;  “Tanker Disasters”by Eric T. Wiberg to Island Books; “Venus Prime” (6 Volume Multi-Book Series) to Claxson Interactive. “Thank God for Sinners” by Eric Magun to iBooks; “The Space in My Heart” by Louise Strasenburgh with Illustrations by Rona Mor to Milk and Cookies; “Ryde Studios Network Instagram World’s Largest Shopping Network Book” by Richard D’Alessio; “The Sainted”( Trilogy) by Michael Medico to iBooks;; “Osceola’s Revenge: The Phenomena of Indian Casinos 2” by Gary Green to iBooks; “Dream Chronicles” Trilogy by David Rottenberg to iBooks; “The Greek Diet” by Chef Maria Loi to HarperCollins; “The Master” By Dr. Bob Arnot to J. Boylston & Company Publishers; “Just in Case: Lose Your Heart, Not Your Mind: The Smart Women’s Guide to Marriage” by Aliette H. Carolan, Esq. to Brick Tower Press; “Facing East” by Jingdaun Yang MD with Norma Kamali to William Morrow; “Silver Dollar” by Alan Susman to ibooks (Screenwriter for Thomas Crown Affair MGM); “Finding the SuperModel in Me” by Claudia Mason to Skyhorse Publishing;“Bear Trap: Fall of Bear Stearns” by Andrew Spencer, to J. Boylston & Company Publishers; “Eddie and The Emoticons” by Eric Fisher PhD to Milk and Cookies; “Being Uncle Charlie” by Bobby Deasy to Random House; “Ready…Set, Risk” by Danielle Levitt to J. Boyston & Company Publishers; “The Oxygen Plan” by Eric Lucas to iBooks; “The Real Man Plan” by Dr. John Shufeldt; “Exposing the Wall Street Boys Club” by James Goldberg with Danny Espinosa, Esq.; “Chefs Run Wild” by Tim Troke, Frogwater Media; “The Next American Economy: Blueprint for a Real Recovery” by William J. Holstein to Bloomsbury; “Cru Oyster Bar Cookbook” by Chef Erin Kircher, Jane Stoddard and Carlos Hidalgo, with Martha Murphy to St. Martins Press; “Frozen & Fabulous Cookbook” by Chef Gail Kurpgeweit to iBooks; “Conquering Cancer” The “Vitality Code” by Dr David Barczyk” to J. Boylston & Company. Media Links: Alan Morell - INTERNATIONAL BUSINESS LAW ATTORNEYS … https://gcvh.weebly.com/alan-morell.html https://www.newmediawire.com/news/heads-of-state-books-series-by-authors-dr-frederic-teboul-and-thierry-pastor-sold-to-brick-tower-press-represented-by-agent-alan-morell-of-creative-management-partners-llc-cmp-7089630 https://www.newmediawire.com/news/health-talk-america-america-s-premier-nationwide-radio-health-talk-show-and-co-host-dr-adam-brockman-sign-with-cmp-agent-alan-morell-for-commercial-rights-sponsorships-advertisers-and-talent-bookings-7087079 https://www.newmediawire.com/news/dr-lee-newcomer-author-of-unmasked-signs-with-creative-management-partners-cmp-agent-alan-morell-7088062 finance.yahoo.com › news › grant-brace-story-project The Grant Brace Story Project: A True Story American Tragedy ... https://www.newmediawire.com/news/creative-management-partners-chaingmai-book-manuscript-screen-writing-proposals-cut-authors-cost-70-7076038 https://www.newmediawire.com/news/washington-square-entertainment-wse-and-ntd-canada-to-develop-conspiracy-thriller-drama-series-based-on-john-moody-s-bestselling-hui-trilogy-of-course-they-knew-of-course-they-7086178 https://www.newmediawire.com/news/america-s-1-health-talk-radio-show-rebrands-as-health-talk-america-hta-7087538 About Creative Management Partners LLC (CMP) Alan Morell: Mr. Morell has over 40 years of global experience managing over 3,700 campaigns, (over 300 campaigns for Doctors; Advisory for C Suite in Health Wellness Sector Managing 277 Doctors, more than any Agency in the World) in the successful development and management of talent, literary, TV and film packaging, commercial rights, corporate consulting, media positioning, sponsorship of live events and intellectual property (IP) rights. Mr. Morell is one of the few in the sports, entertainment, medical, military, politics, corporate business and the arts industries who has represented and managed clients, that have won the prestigious awards: Grammy; Tony; Oscar; Emmy, ESPY, Victors, Telly, Clio, Gemini and NY Times Best Selling Authors. Media Contact Information: Creative Management Partners LLC (CMP) Beverly Hills Gardens Building 9440 Santa Monica Blvd., Suite 301 Beverly Hills, CA 90210 Direct Dial: 508-292-7900 www.creativemanagementpartners.com ———————————————————————————————————————————————————————————— Axora Medical Launches HERizon RD5(R) Resecting Device, the First 5Fr. Battery-Powered Device in the U.S. for Removing Uterine Polyps 2026-10-27 · ACCESS Newswire · Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/axora-medical-launches-herizon-rd5-143000494.html The single-use handheld device lets physicians move from diagnosis to treatment in the same visit, in the office or the OR. SUNNYVALE, CA / October 27, 2026 / Axora Medical, Inc. today announced the U.S. launch of the HER izon RD5 ® Resecting Device . It is a single-use, battery-powered, handheld device ———————————————————————————————————————————————————————————— New Research Finds Daily Peanut Consumption Benefits Brain's Response to Insulin in Memory Related Regions 2026-10-27 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/new-research-finds-daily-peanut-consumption-benefits-brains-response-to-insulin-in-memory-related-regions-302919924.html ALBANY, Ga., Oct. 27, 2026 -- A study from the Institute of Nutrition and Translational Research in Metabolism (NUTRIM) at Maastricht University Medical Center, Maastricht, Netherlands, has found that longer-term consumption of unsalted, skin-roasted peanuts can beneficially... ———————————————————————————————————————————————————————————— UNCY Investor Alert: Unicycive Therapeutics, Inc. Securities Class Action Notice - Contact SueWallSt 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma, Legal https://www.globenewswire.com/news-release/2026/10/27/3389248/0/en/uncy-investor-alert-unicycive-therapeutics-inc-securities-class-action-notice-contact-suewallst.html A securities class action alleges Unicycive Therapeutics assured the market that its third-party manufacturer had made "significant progress" toward FDA compliance without ever inspecting the facility, and UNCY shares lost 39.1% of their value in a single session when a second Complete Response Letter was announced A securities class action alleges Unicycive Therapeutics assured the market that its third-party manufacturer had made "significant progress" toward FDA compliance without ever inspecting the facility, and UNCY shares lost 39.1% of their value in a single session when a second Complete Response Letter was announced ———————————————————————————————————————————————————————————— Physicians Affiliated with 67 U.S. Healthcare Organizations Refer Patients to Evinature's Digital Patient Support Platform 2026-10-27 · PRWeb · SaaS, Healthcare https://www.prweb.com/releases/physicians-affiliated-with-67-us-healthcare-organizations-refer-patients-to-evinatures-digital-patient-support-platform-302919086.html Physicians affiliated with 67 U.S. healthcare organizations, including leading academic medical centers and children's hospitals, now refer patients to Evinature's digital patient support platform, bringing personalized supplement plans, dedicated guidance, and ongoing follow-up together... ———————————————————————————————————————————————————————————— BBNX Investor Alert: Beta Bionics, Inc. Securities Class Action Notice - Contact SueWallSt 2026-10-27 · GlobeNewswire · Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/27/3389236/0/en/bbnx-investor-alert-beta-bionics-inc-securities-class-action-notice-contact-suewallst.html A securities class action alleges Beta Bionics kept a June 2025 FDA Form 483 and more than 18,000 unreported iLet complaints out of public view for months, with the dates of each disclosure tracking a $23.09 per-share collapse in BBNX A securities class action alleges Beta Bionics kept a June 2025 FDA Form 483 and more than 18,000 unreported iLet complaints out of public view for months, with the dates of each disclosure tracking a $23.09 per-share collapse in BBNX ———————————————————————————————————————————————————————————— SynAct Pharma Signs First Commercial Partnership for Resomelagon with Leading Brazilian Pharmaceutical Company 2026-10-27 · ACCESS Newswire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/synact-pharma-signs-first-commercial-141200332.html LUND, SE / October 27, 2026 / SynAct Pharma AB (publ) ("SynAct") (Nasdaq Stockholm:SYNACT), a clinical-stage biotechnology company focused on treating inflammation through a novel therapeutic approach known as "pro-resolution", today announced that it has entered into a strategic co-development and comme ———————————————————————————————————————————————————————————— The Freedom 13 Advances Plans for Mental Health Healing Camps for Veterans and First Responders 2026-10-27 · MarketersMEDIA · Healthcare, Real estate, Nonprofits https://news.marketersmedia.com/the-freedom-13-advances-plans-for-mental-health-healing-camps-for-veterans-and-first-responders/89207532 The Freedom 13 is developing its first 171-acre healing camp in Bourbon, Missouri, as part of a vision to establish 50 retreats supporting veterans, law enforcement, and Gold Star families. -- The Freedom 13 is advancing plans for a network of recreational mental health healing camps, beginning with a 171-acre property in Bourbon, Missouri, where the nonprofit aims to create a place of respite, connection, and renewe ———————————————————————————————————————————————————————————— Alterome Therapeutics to Present First Clinical Data from Phase 1/1b Trial of ALTA3263 in KRAS-Mutant Advanced Solid Tumors in Late-Breaking Presentation at the 38th EORTC-NCI-AACR Symposium 2026-10-27 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/alterome-therapeutics-present-first-clinical-140100778.html Late-breaking oral presentation to showcase preliminary safety, tolerability, clinical activity, and pharmacokinetics data of ALTA3263 in monotherapy and in combination with cetuximab Additional presentation demonstrates potent monotherapy activity of ALTA3263 and synergistic activity in combination with cetuximab in KRAS ———————————————————————————————————————————————————————————— Inovaare and Sagility Partner to Deliver Audit-Ready Appeals and Grievances Operations for Medicare Advantage and Medicaid Health Plans 2026-10-27 · PRWeb · AI, SaaS, Healthcare https://www.prweb.com/releases/inovaare-and-sagility-partner-to-deliver-audit-ready-appeals-and-grievances-operations-for-medicare-advantage-and-medicaid-health-plans-302919089.html •The partnership combines Inovaare's AI-native HealthCloud platform for regulated payer workflows — including appeals and grievances, compliance reporting, and member and provider services — with Sagility's technology-led business operations model to provide health plans with a more... ———————————————————————————————————————————————————————————— Laxxon Medical Appoints Matthew Cascio as Vice President and Head of Business Development 2026-10-27 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/laxxon-medical-appoints-matthew-cascio-140000056.html Pharmaceutical business development leader to drive strategic partnerships and advance commercial opportunities for Laxxon's SPID® drug-delivery technology. NEW YORK, October 27, 2026--Laxxon Medical today announced the appointment of Matthew Cascio as Vice President and Head of Business Development. C ———————————————————————————————————————————————————————————— Guiding Stars: 3 Steps to Help You Evaluate AI Nutrition Information 2026-10-27 · ACCESS Newswire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/guiding-stars-3-steps-help-140000186.html SCARBOROUGH, ME / October 27, 2026 / by Kitty Broihier Originally published on Guiding Stars Health & Nutrition News Guiding Stars Licensing Company LLC Long gone are the days when "consulting Dr. Google" was the only online tool for quick information on health issues. These days there are many free, Art ———————————————————————————————————————————————————————————— Oncolytics Biotech® Reports Strong Durability and Survival Data in Anal Cancer, Positioning Pelareorep as Potential Backbone Immunotherapy Across HPV-Driven Cancers 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3389148/0/en/oncolytics-biotech-reports-strong-durability-and-survival-data-in-anal-cancer-positioning-pelareorep-as-potential-backbone-immunotherapy-across-hpv-driven-cancers.html Oncolytics announced durability and survival data in anal cancer from GOBLET study, with 100% of responding patients survived for longer than one year. ———————————————————————————————————————————————————————————— Addressing Critical Health Needs Through Innovation 2026-10-27 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/addressing-critical-health-needs-innovation-133000387.html NORTHAMPTON, MA / October 27, 2026 / Innovation in animal health is about more than developing something new; it's about understanding what animals need, identifying where current solutions fall short and finding stronger ways to help. At Elanco, that work begins with a simple belief: better solutions fo ———————————————————————————————————————————————————————————— As Ebola Spreads to Multiple Countries, the Importance of NV-387 Oral Gummies Treatment Cannot be Understated - Phase II Clinical Trial Advancing Towards the Second Part, Says NanoViricides 2026-10-27 · Newswire.com · Finance, Healthcare, Biotech & pharma https://www.newswire.com/news/as-ebola-spreads-to-multiple-countries-the-importance-of-nv-387-oral-gummies NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, explained today that the Phase IIA Ebola Treatment Clinical Trial of NV-387 Oral Gummies is progressing well, and the drug is expected to advance into the Phase IIB clinical trial part as soon as the Phase IIA part is completed. "The importance of the NV-387 Oral Gummies treatment ———————————————————————————————————————————————————————————— Natus Celebrates Grand Opening of Suzhou Facility - Advancing Innovation in China, for China 2026-10-27 · PR Newswire · Healthcare, Industrial https://www.prnewswire.com/news-releases/natus-celebrates-grand-opening-of-suzhou-facility--advancing-innovation-in-china-for-china-302919085.html Local development and manufacturing bring Natus neurodiagnostic expertise closer to clinicians and patients across China SUZHOU, China, Oct. 27, 2026 -- Natus Medical Incorporated, the world's largest pure-play neurodiagnostic company, today celebrated the grand opening of... ———————————————————————————————————————————————————————————— Egetis Therapeutics Announces U.S. Launch of EMCITATE® for Patients with MCT8 Deficiency 2026-10-27 · GlobeNewswire · Finance, Healthcare, Food & drink, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3389114/0/en/egetis-therapeutics-announces-u-s-launch-of-emcitate-for-patients-with-mct8-deficiency.html STOCKHOLM, SWEDEN, Sept. 27, 2026 – (GlobeNewswire) Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX), a commercial-stage pharmaceutical company focused on developing and delivering innovative therapies for patients with rare diseases, today announced the commercial availability of EMCITATE® (tiratricol), ahead of anticipated timelines following U.S. Food and Drug Administration (FDA) approval on September 28, 2026. ———————————————————————————————————————————————————————————— Take-Two Co-Founder Mark Seremet Turns Personal Health Scare Into New Longevity Book, 'More Tomorrows' 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950115234/take-two-co-founder-mark-seremet-turns-personal-health-scare-into-new-longevity-book-more-tomorrows After an unexpected diagnosis at 56, the entrepreneur rebuilt his health and now shares an evidence-based framework for staying strong, capable and independent. The same habits that help you feel better tomorrow are also the ones that can give you more tomorrows.” — Mark Seremet MIAMI, FL, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Five years ago, entrepreneur and Take-Two Interactive co-founder Mark Ser ———————————————————————————————————————————————————————————— aTyr Pharma Announces One-for-40 Reverse Stock Split 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3389032/0/en/atyr-pharma-announces-one-for-40-reverse-stock-split.html aTyr Pharma Announces One-for-40 Reverse Stock Split ———————————————————————————————————————————————————————————— Powerful Medical Granted CPT Code for AI ECG Heart Attack Detection, Weeks After FDA De Novo Authorization of Queen of Hearts™ 2026-10-27 · Business Wire · AI, Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/powerful-medical-granted-cpt-code-130000200.html Category III code 1139T becomes effective January 1, 2027, giving U.S. physicians and hospitals a dedicated procedure code to report AI ECG analysis for heart attacks NEW YORK, October 27, 2026--Powerful Medical, a leader in AI-driven cardiovascular diagnostics, today announced that the American Medic ———————————————————————————————————————————————————————————— Covenant HealthCare Joins Nomi Health's Direct Contracting Network for Michigan Employers 2026-10-27 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/covenant-healthcare-joins-nomi-healths-130000648.html Great Lakes Bay Region's most preferred health system extends Michigan's direct contracting movement, delivering $0 out-of-pocket care for employees and their families SAGINAW, Mich., October 27, 2026--Nomi Health today announced that Covenant HealthCare has joined its direct contracting network, givin ———————————————————————————————————————————————————————————— American College of Education and the Mississippi Hospital Association Partner to Grow Healthcare Leaders Statewide 2026-10-27 · Newswire.com · Healthcare, Education, Jobs & workplace https://www.newswire.com/news/american-college-of-education-and-the-mississippi-hospital-association-partner The agreement helps employees at member hospitals prepare for leadership roles while strengthening Mississippi's healthcare workforce. ———————————————————————————————————————————————————————————— Update - GeoVax Enters Into $1 Million Revolving Loan Agreement 2026-10-27 · NewMediaWire · Finance, Healthcare, Real estate, Industrial, Biotech & pharma, Banking https://www.newmediawire.com/news/update-geovax-enters-into-1-million-revolving-loan-agreement-7090873 ATLANTA, GA - October 27, 2026 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that it has entered into an unsecured $1,000,000 Revolving Loan Agreement dated October 23, 2026 (the “Revolving Loan Agreement”) with Bowery Consulting Group Inc. (the “Lender”). The revolving loan facility provides for advances of up to $1,000,000 (the “Revolving Loan”), with any advances subject to the Lender’s approval. The Revolving Loan bears interest at a rate of 12% per annum and matures 12 months from issuance. The Revolving Loan Agreement contains customary representations and warranties, indemnification provisions, and conditions precedent to borrowing. On October 23, 2026, Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan and John Spencer, Jr. resigned as directors of the Company, and Steven Brown, Tyler O’Brien and Manpreet Uppal were appointed as directors of the Company. Each of the newly appointed directors was nominated by the Lender pursuant to the Revolving Loan Agreement. Following these changes, the Company’s Board of Directors consists of five directors. The Board has determined that each of the newly appointed directors meet the independence standards of the Securities and Exchange Commission and Nasdaq. Following their appointment, Mr. O’Brien and Mr. Uppal will join the Audit Committee together with Dr. Robert McNally. David A. Dodd, Chairman and Chief Executive Officer of GeoVax, commented, “Securing this financing is an important achievement for GeoVax, reinforcing our balance sheet and providing the working capital needed to support our operations. I am pleased to welcome Steven, Tyler and Manpreet to our Board. Their diverse experience and strong leadership will bring fresh perspectives and valuable guidance as we continue to advance our GEO-MVA clinical program forward to what we believe will be an expedited pathway to commercialization. I would also like to express my deep appreciation to the departing Board members for their dedication and meaningful contributions to GeoVax’s journey. With strong leadership in place and a clear strategic path forward, we believe GeoVax is entering an exciting new chapter of growth and opportunity.” Further information concerning the Revolving Loan Agreement and the newly appointed directors of the Company will be contained in the Form 8-K to be filed with the Securities and Exchange Commission. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in late 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com. Forward-Looking Statements This release contains forward-looking statements regarding GeoVax’s business plans, the Revolving Loan Agreement and the availability of advances thereunder,. and the timing and outcome of its clinical development and regulatory activities. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, GeoVax is able to regain and maintain compliance with Nasdaq continued listing requirements, the timing of initiation and completion of the GEO-MVA Phase 3 trial and of any EMA marketing authorization, GeoVax's ability to continue as a going concern, the Lender permits GeoVax to draw down any portion of the loan commitment, which is subject to the Lender’s sole and absolute discretion, and whether the loan commitment is terminated, GeoVax is able to generate sufficient cash flow or raise additional capital to service, repay or refinance its indebtedness on acceptable terms or at all, GeoVax is able to comply with the covenants and other obligations in the Revolving Loan Agreement, including obtaining the Lender’s consent where required, an event of default occurs that results in the acceleration of GeoVax’s indebtedness or the exercise of other remedies by the Lender, GeoVax’s level of indebtedness limits its financial flexibility, operations or ability to pursue its business strategy or obtain additional financing, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: info@geovax.com 678-384-7220 Media Contact: Jessica Starman media@geovax.com ———————————————————————————————————————————————————————————— Global Sexual Wellness Market Thrives as Lifestyle and Wellness Trends Converge 2026-10-27 · PR News Releaser · Healthcare, Biotech & pharma https://www.prnewsreleaser.com/news/479649 The global Sexual Wellness Market is gaining momentum as awareness of sexual health, personal well-being, and preventive healthcare continues to increase. Sexual wellness products include condoms, contraceptive devices, pharmaceutical products, lubricants, and intimacy-related products designed to support sexual health, protection, ... Read more ———————————————————————————————————————————————————————————— Vincora Receives FDA Approval to Initiate U.S. Early Feasibility Study of Transcatheter Chordal Repair System 2026-10-27 · PR Newswire · Healthcare, Food & drink, Biotech & pharma, Medical devices https://www.prnewswire.com/news-releases/vincora-receives-fda-approval-to-initiate-us-early-feasibility-study-of-transcatheter-chordal-repair-system-302920271.html MAPLE GROVE, Minn., Oct. 27, 2026 -- Vincora (NeoChord, Inc. d/b/a Vincora), a medical technology company developing transcatheter therapies for mitral valve repair, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's Investigational... ———————————————————————————————————————————————————————————— Polyrizon Announces Successful Completion Enrollment of all 120 Patients in U.S. Clinical Study of NASARIX Allergy Blocker 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388975/0/en/polyrizon-announces-successful-completion-enrollment-of-all-120-patients-in-u-s-clinical-study-of-nasarix-allergy-blocker.html All 120 planned participants randomized across five clinical sites in the United States ———————————————————————————————————————————————————————————— Genomate and VivaMed to Rescue and Repurpose Oncology Drugs with AI and Clinical Data 2026-10-27 · ACCESS Newswire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/genomate-vivamed-rescue-repurpose-oncology-121200706.html The collaboration aims to identify and advance new oncology drug candidates. CAMBRIDGE, MA / October 27, 2026 / Genomate Health, a precision oncology company, today announced a strategic partnership with VivaMed BioPharma to advance existing drugs and promising compounds for new applications in cancer ba ———————————————————————————————————————————————————————————— VitroVivo Biotech LLC Highlights Tissue Microarray and Specialized Staining Resources for Biomedical Research 2026-10-27 · FinanceWire · Healthcare, Biotech & pharma https://financewire.com/2026/10/27/vitrovivo-biotech-llc-highlights-tissue-microarray-and-specialized-staining-resources-for-biomedical-research/ ROCKVILLE, United States, 27th October 2026, FinanceWire … Read More The post VitroVivo Biotech LLC Highlights Tissue Microarray and Specialized Staining Resources for Biomedical Research appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— New Self-Care Guide for Inner Transformation Chronicles Author's Journey from Skepticism to Spiritual Awakening 2026-10-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/new-self-care-guide-for-inner-transformation-chronicles-authors-journey-from-skepticism-to-spiritual-awakening-302920268.html Learn how author Emily Wells embraced spiritual synchronicities and dialogues with spirit beings SALEM, Ore., Oct. 27, 2026 -- When unexplainable things began to happen in her life, including a medical wake-up call, author Emily Wells had a choice: either deny them or go... ———————————————————————————————————————————————————————————— 60 Degrees Pharmaceuticals Announces Clinical Improvement and Negative PCR Results in All Completed Expanded Access Babesiosis Study Patients 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388968/0/en/60-degrees-pharmaceuticals-announces-clinical-improvement-and-negative-pcr-results-in-all-completed-expanded-access-babesiosis-study-patients.html 60 Degrees Pharma reports clinical improvement and negative conventional PCR results in all five completed expanded access babesiosis study patients. ———————————————————————————————————————————————————————————— Candel Therapeutics to Present at November Investor Conferences 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388965/0/en/candel-therapeutics-to-present-at-november-investor-conferences.html NEEDHAM, Mass., Oct. 27, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026. ———————————————————————————————————————————————————————————— Voyager’s Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer’s Disease to Be Featured in Poster Presentations at CTAD 2026 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388959/36461/en/voyager-s-tau-targeted-gene-therapy-vy1706-and-anti-tau-antibody-vy7523-for-alzheimer-s-disease-to-be-featured-in-poster-presentations-at-ctad-2026.html LEXINGTON, Mass., Oct. 27, 2026 -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to leveraging genetics to treat neurological diseases, today announced two poster presentations at the upcoming 19th Clinical Trials on Alzheimer's Disease (CTAD) Conference taking place in Boston, November 16-19, 2026. The poster presentations will highlight VY1706, Voyager’s investigational gene therapy designed to lower tau production in the brain, and VY7523, the Company’s clinical stage monoclonal antibody directed against the C-terminal region of tau. ———————————————————————————————————————————————————————————— Lumea Enhances Digital Diagnostic Ecosystem with Nonagen Bioscience’s Oncuria® Suite of Bladder Cancer Tests 2026-10-27 · EIN Presswire · SaaS, Healthcare, Medical devices https://www.einpresswire.com/article/951551255/lumea-enhances-digital-diagnostic-ecosystem-with-nonagen-bioscience-s-oncuria-suite-of-bladder-cancer-tests Lumea integrates Nonagen’s Oncuria® urine-based bladder cancer tests (Detect, Monitor, Predict) into its platform, right in urologists’ workflows. LEHI, UT, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Lumea, a U.S. leader in digital pathology and clinical diagnostic solutions, today announced the integration of Nonagen Bioscience’s Oncuria® suite of bladder cancer tests into Lumea’s comprehensive digital ———————————————————————————————————————————————————————————— THE REAL Summit NYC Unites Investors to Advance $10B Mental Health Mission 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951511162/the-real-summit-nyc-unites-investors-to-advance-10b-mental-health-mission The October Summit convened investors, family offices & leaders across healthcare, science and business to accelerate mental and brain health innovation by 2030 The right person to join THE REAL is simple: somebody who wants to be part of something bigger than themselves.” — Shawn Lesser NEW YORK CITY, NY, UNITED STATES, October 27, 2026 / EINPresswire.com / -- THE REAL Summit NYC convened investors, family office re ———————————————————————————————————————————————————————————— Ovadia Law Group Resolves Clawback Claims for Florida Medical Directors 2026-10-27 · EIN Presswire · Healthcare, Insurance, Legal https://www.einpresswire.com/article/949620305/ovadia-law-group-resolves-clawback-claims-for-florida-medical-directors Abe Ovadia resolves cases with medical directors across Florida Ovadia Law Group PA, Boca Raton Medical directors are vulnerable to claims by insurance companies Abraham Ovadia secures settlements across four federal lawsuits, resolving multi-million dollar insurer recovery claims with no admission of wrongdoing. BOCA RATON, FL, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Abraham Ovadia represented five m ———————————————————————————————————————————————————————————— Jennifer Woodward's New Book Debunks Peptide Myths for Women's Health 2026-10-27 · Newsworthy.ai · AI, SaaS, Healthcare, Energy, Education, Marketing & advertising https://newsworthy.ai/news/202610273109/jennifer-woodwards-new-book-debunks-peptide-myths-for-womens-health Los Angeles, CA Tuesday Oct 27, 2026 @ 5:00 AM Pacific — Jennifer Woodward introduces The Peptide Promise: How Smart Molecules Are Changing Everything We Know About Weight, Energy, and Aging, a new book intended to help women understand the science, questions and uncertainties surrounding peptides before deciding whether they belong in their health journey. Written for women who are curious about peptides, already using them or weighing the investment, the book explores GLP-1s, metabolism, hormones, inflammation, recovery, brain health and aging. Woodward aims to simplify complex information, helping readers discern between research-backed applications and experimental approaches. “I wrote The Peptide Promise because I was tired of watching women spend hundreds, sometimes thousands, of dollars on peptides without really understanding what they were putting into their bodies,” said Woodward. “There is so much excitement around peptides right now, and for good reason, but there’s also a LOT of misinformation, questionable protocols, and big promises that aren’t always backed by research.”  The book begins with a deeply personal experience. At forty-one, Woodward found herself confronting changes in her own body despite carefully managing her nutrition, exercise and daily health habits. In the opening passage, she describes looking in the mirror and recognizing the same confusion and frustration she had seen in women seeking her help. That experience provides the starting point for a broader conversation about what women want to understand before trying another intervention: what the evidence actually shows, what remains uncertain and whether an approach fits their individual needs. Central to the book is Woodward’s “Power Four”: protein, minerals, circadian rhythm and movement. She presents these as the foundation of her approach, whether a reader ultimately chooses to explore peptides or not. “I also teach my Power Four because I firmly believe that protein, minerals, circadian rhythm, and movement are the foundation of feeling good, whether you decide to use peptides or not,” Woodward said. The Peptide Promise provides midlife readers with an accessible foundation for informed discussions with healthcare professionals about body composition, muscle preservation, and energy. Its focus is education, with attention to both the interest surrounding peptides and the limits of available evidence. “This book is for the woman who’s curious about peptides, already using them, or wondering whether they’re worth the investment,” Woodward said. “I want you to understand what’s supported by research, what’s still experimental, and how to make informed decisions about your health without getting swept up in the latest wellness trend.” The Peptide Promise is available for pre-order and on Kindle now - releasing in paperback on November 10th, 2026. For book information and purchasing options, visit https://a.co/d/0gIiBkZB  About Jennifer Woodward Jennifer Woodward is the author of The Peptide Promise. Her work focuses on helping women understand midlife health, with an emphasis on nutrition, foundational habits and informed decisions about peptides. Learn more at www.JenniferWoodwardNutrition.com. ———————————————————————————————————————————————————————————— Actuate Therapeutics Announces Pricing of $11.0 Million Underwritten Public Offering 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388899/0/en/actuate-therapeutics-announces-pricing-of-11-0-million-underwritten-public-offering.html CHICAGO and FORT WORTH, Texas, Oct. 27, 2026 -- Actuate Therapeutics, Inc. (NASDAQ: ACTU) (“Actuate” or the “Company”), a clinical-stage biopharmaceutical company focused on developing novel therapies for difficult-to-treat cancers, today announced the pricing of an underwritten public offering of 30,985,900 shares of its common stock and warrants to purchase up to an aggregate of 15,492,950 shares of its common stock. The public offering price for each set of two shares of common stock and one accompanying warrant (each, a “Warrant” and collectively, the “Warrants”) to purchase one share of common stock is $0.71 per set of securities (the “Offering”). The Warrants are being sold at the rate of one Warrant for every two shares of common stock. The Warrants will have an exercise price of $0.45 per share, are exercisable immediately upon issuance and will expire five years following the date of issuance. The shares of common stock and Warrants will be issued separately but can only be purchased together in the Offering. ———————————————————————————————————————————————————————————— CareCloud Appoints Mitchell Brie as Chief Compliance Officer to Support Compliance Services Growth 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388898/16541/en/carecloud-appoints-mitchell-brie-as-chief-compliance-officer-to-support-compliance-services-growth.html Empower founder and frequent national health law and compliance speaker to scale CareCloud’s expanding compliance business across a base of more than 40,000 providers ———————————————————————————————————————————————————————————— CAMP4 Therapeutics Receives Clinical Trial Application Approval for Phase 1/2 Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder in the European Union 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388896/0/en/camp4-therapeutics-receives-clinical-trial-application-approval-for-phase-1-2-clinical-trial-of-cmp-002-in-patients-with-syngap1-related-disorder-in-the-european-union.html Approval under the EU Clinical Trials Regulation builds on CAMP4’s recent clearances in the United Kingdom, Australia, and Argentina to initiate the Company’s global Phase 1/2 trial of CMP-002 ———————————————————————————————————————————————————————————— Duly Health and Care Announces Acquisition of Fox Valley Imaging 2026-10-27 · ACCESS Newswire · Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/duly-health-care-announces-acquisition-120000409.html DOWNER'S GROVE, IL / October 27, 2026 / Duly Health and Care announced today the acquisition of Fox Valley Imaging, an independent diagnostic imaging center serving Naperville and surrounding communities for more than 30 years. The acquisition expands Duly's outpatient imaging network and advances its co ———————————————————————————————————————————————————————————— AbbVie Submits Biologics License Application (BLA) for Etentamig to U.S. FDA for Adults Living With Relapsed/Refractory Multiple Myeloma 2026-10-27 · AbbVie · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/abbvie-submits-biologics-license-application-bla-for-etentamig-to-us-fda-for-adults-living-with-relapsedrefractory-multiple-myeloma-302919984.html AbbVie (NYSE: ABBV) today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for... ———————————————————————————————————————————————————————————— CanSinoBIO Reports Growth in First Nine Months: Commercialization Accelerates Across Multiple Products as Platform Innovation Opens New Avenues for Growth 2026-10-27 · ACN Newswire · Finance, Healthcare, Biotech & pharma https://www.acnnewswire.com/press-release/english/111144/ Hong Kong, Oct 27, 2026 - On October 27, 2026, CanSino Biologics Inc. (HKEX: 06185; SSE: 688185) released its third-quarter financial report for 2026. For the nine months ended September 30, 2026, the company reported revenue of approximately RMB 882 million, an increase of 27.40% year-on-year. Net profit attributable to shareholders reached approximately RMB 16.29 million, an increase of 12.82% year-on-year. Net loss attributable to shareholders excluding non-recurring gains and losses narrowed by 45.72% year-on-year to approximately RMB 44.98 million. The growth reflects years of investment in R&D, portfolio development and commercial infrastructure. As innovative products reach the market and the product lineup continues to broaden, CanSinoBIO is gradually building a business driven by multiple complementary products. At the same time, its five core technology platforms continue to support innovative R&D and cross-field collaboration, laying the groundwork for long-term development. Successive Launches of Innovative Products: Commercialization Enters a Multi-Product Phase For an innovative vaccine developer, the ability to consistently translate R&D achievements into commercial products is an important measure of its capacity for growth. With several innovative products approved and entering the market, CanSinoBIO is moving from a focus on commercializing its core products toward a new phase of development across a broader, complementary portfolio. The third quarter of 2026 brought several important commercial milestones. In August, Tripecia(R) (DT3cP), the Company’s adsorbed diphtheria, tetanus and pertussis (acellular, three component) combined vaccine for infants, received the Certificate of Batch Release for its first batch, allowing market supply to begin. As China's first approved three-component acellular pertussis vaccine, Tripecia(R) further diversifies the Company’s innovative product portfolio and provides another product to support its expansion in the domestic vaccine market. CanSinoBIO is also continuing to build out its DTaP vaccine portfolio. Td5cp Adolescent and Adult, Tetanus, Reduced Diphtheria and Pertussis (Acellular, Five Components) Combined Vaccine, had previously been granted priority review,  and its New Drug Application (NDA) was accepted by China's NMPA in August. If approved, the vaccine could complement Tripecia(R) by serving different age groups, further extending the Company’s immunization portfolio across the life course. Also in August, Tetcia(R), the Company’s adsorbed tetanus vaccine, received marketing approval, broadening its portfolio for active immunization in adults. CanSinoBIO has granted Grand Life Sciences Group exclusive commercialization rights for the product in Greater China, drawing on its partner’s market network and promotional capabilities to expand coverage. This differentiated commercialization arrangement gives the Company additional options for bringing its R&D achievements to market more efficiently. Alongside new launches, the Company continues to develop the market potential of its established core products. Menhycia(R)(MCV4), Asia’s first quadrivalent meningococcal conjugate vaccine, is currently approved in China for children aged three months through six years. In July 2026, a supplemental application to extend the eligible age range to three months through 17 years was accepted for review, with the potential to reach a broader population. In pneumococcal vaccines, CanSinoBIO continues to advance domestic market access for iPneucia(R)(PCV13i), its 13-valent pneumococcal polysaccharide conjugate vaccine. Its 24-valent pneumococcal polysaccharide conjugate vaccine (PCV24) has entered Phase I/II clinical trials, with participant enrollment progressing across study cohorts. The marketed vaccine and follow-on candidates form a staggered product lineup that supports the Company's continued work in pneumococcal disease prevention. Together, new product approvals and the start of market supply, efforts to broaden the eligible populations for existing vaccines, and continued development of follow-on candidates are creating a more diversified portfolio with products progressing through successive stages of development. Together, new product approvals and the start of market supply, broader eligible populations for existing vaccines, and continued development of follow-on candidates are creating a more diversified and better-sequenced product portfolio. A broader portfolio offers the potential for additional revenue streams while extending market coverage and enabling commercial synergies among products. This is helping the Company build a more stable and sustainable commercial foundation. International Expansion Advances from Market Access to Multi-level Partnerships As domestic commercialization accelerates, international operations are also becoming an important avenue for CanSinoBIO to expand its growth opportunities. In recent years, the Company’s international strategy has gradually evolved from product exports to encompass overseas registrations, local manufacturing, technology transfer and joint development.  Internationalization is therefore no longer simply about bringing products to overseas markets; it is about combining technical, manufacturing and commercial resources to explore a more sustainable path to growth in global markets. In meningococcal vaccines, Menhycia(R) received registration approval in Argentina in June 2026, following approval in Indonesia in December 2024. These registrations provide a broader foundation for entry into different regional markets. Overseas partnerships for pneumococcal vaccines are also advancing. Drawing on its distinct advantages in manufacturing processes, product quality and clinical data, together with established local partnerships, CanSinoBIO supplied PCV13i products to its Indonesian partner in the first half of 2026. The supply supports subsequent local manufacturing and potential future supply to the national immunization program, helping to prevent pneumococcal disease in children locally. CanSinoBIO has also signed a letter of intent (LOI) with AGP Limited in Pakistan to explore opportunities for iPneucia(R) in the local market. Through overseas registrations, local partner networks, technology transfer and local manufacturing, CanSinoBIO is gradually establishing international business models tailored to the needs of different regional markets. These efforts could create broader opportunities for its long-term development. Five Core Technology Platforms Support Innovation and Future Expansion While commercialization across multiple products and international expansion demonstrate CanSinoBIO’s current business capabilities, its steadily built core technology platforms provide an important foundation for sustained innovation and future growth. The Company has established five core technology platforms covering adenovirus-based viral vectors technology, synthetic biotechnology, protein structure design and virus-like particle (VLP) assembly, mRNA and LNP technology, and formulation and drug delivery technology. Together, they form an R&D system spanning different technological approaches. For an innovative vaccine developer, technology platforms enable core technologies, research experience and manufacturing expertise to be accumulated and applied across programs. This supports ongoing product innovation and the exploration of new R&D directions in response to technological advances and market needs. As biopharmaceutical technologies evolve more rapidly and competition intensifies, the ability to sustain innovation and pursue new applications is becoming an important measure of long-term competitiveness. CanSinoBIO’s mRNA collaboration during the third quarter of 2026 offers a further indication of the potential applications of its technology platforms. On August 25, the Company announced that its subsidiary, CanSino (Shanghai) Biologics R&D Co., Ltd., had signed a strategic cooperation framework agreement with deepGeneAI (Hangzhou) Biotechnology Co., Ltd. for the joint development of personalized mRNA therapeutic cancer vaccines. The proposed collaboration targets global markets, focusing on gastrointestinal solid tumors and rare tumors. It would combine CanSinoBIO’s expertise in mRNA delivery, formulation, R&D and manufacturing with deepGeneAI’s AI-driven tumor neoantigen discovery and design capabilities to explore the development of personalized therapeutic cancer vaccines. The Company’s work in its established areas of technological expertise has also continued to receive professional recognition. In September 2026, CanSinoBIO announced that its project on key technologies for polysaccharide–protein conjugation and industrial-scale production had received a third prize in the Chinese Preventive Medicine Association’s 2025 Science and Technology Awards. The award reflects the Company’s sustained investment in core technology development and industrial applications. In international industry collaboration, CanSinoBIO also participated in the 27th Annual General Meeting of the Developing Countries Vaccine Manufacturers Network (DCVMN), where the Company discussed opportunities with international peers in joint R&D, technology transfer, local manufacturing and global vaccine access. From improvements to existing products and continued development of innovative R&D programs to collaboration across fields, the five core platforms are becoming an important source of support for CanSinoBIO’s continued innovation and future expansion. As More Innovations Reach the Market, the Path to Long-Term Growth Becomes Clearer CanSinoBIO’s operating and business progress in the first nine months of 2026 points to an increasingly clear development path. Continued approvals and market launches are broadening the product portfolio and building commercial capabilities. At the same time, international expansion and multi-level industry cooperation are advancing in parallel, creating further opportunities for business development. Behind these developments, the capacity for sustained innovation provided by the five core technology platforms creates a broader range of possibilities for future product development, technology partnerships and exploration of new fields. As commercialization advances across multiple products and international operations expand, the value of CanSinoBIO’s years of R&D investment is gradually being realized. By combining innovation across its technology platforms with product commercialization and international expansion, the Company is building a more diversified set of growth drivers and opening new opportunities for sustainable long-term development. ———————————————————————————————————————————————————————————— El Paso Group Health Insurance Responds to Evolving Healthcare Protections 2026-10-27 · MarketersMEDIA · Healthcare, Insurance https://news.marketersmedia.com/el-paso-group-health-insurance-responds-to-evolving-healthcare-protections/89204762 Evolving healthcare protections are prompting employers to review privacy standards, preventive care, prescription benefits, reproductive health services, and plan administration as expectations surrounding employee coverage continue to change. -- El Paso Group Health Insurance is gaining attention as broader healthcare policy discussions continue to influence how employers and benefit administrators evaluate privacy ———————————————————————————————————————————————————————————— Fort Worth Group Health Insurance Faces Rising Healthcare Cost Pressure 2026-10-27 · MarketersMEDIA · Healthcare, Insurance, Jobs & workplace https://news.marketersmedia.com/fort-worth-group-health-insurance-faces-rising-healthcare-cost-pressure/89204759 Employers are reviewing health plan costs, provider networks, employee contributions, and benefit structures as rising healthcare expenses place continued pressure on workplace coverage and long-term affordability. -- Fort Worth Group Health Insurance is receiving increased attention as rising healthcare expenses continue to place pressure on insurance premiums, employer benefit budgets, and household medical costs. ———————————————————————————————————————————————————————————— Arlington Group Health Insurance Faces Changes in Medical Practice Rules 2026-10-27 · MarketersMEDIA · Healthcare, Insurance https://news.marketersmedia.com/arlington-group-health-insurance-faces-changes-in-medical-practice-rules/89204761 Proposed changes to medical practice ownership and management could affect provider structures, administrative relationships, and clinical independence, with potential implications for health insurance networks and employer-sponsored coverage. -- Arlington Group Health Insurance is becoming increasingly relevant as federal policymakers consider broader restrictions on the corporate ownership and management of medical ———————————————————————————————————————————————————————————— Corpus Christi Group Health Insurance Gains Focus as Rural Hospitals Close 2026-10-27 · MarketersMEDIA · Healthcare, Insurance https://news.marketersmedia.com/corpus-christi-group-health-insurance-gains-focus-as-rural-hospitals-close/89204757 Rural hospital closures are raising concerns about emergency response, treatment delays, provider availability, and regional health care capacity, increasing attention on group health insurance networks and access to medical services across Texas communities. -- Corpus Christi Group Health Insurance is receiving increased attention as concerns grow around rural hospital closures and the effect reduced medical access ———————————————————————————————————————————————————————————— Irving Group Health Insurance Highlights Consumer Driven Plan Options 2026-10-27 · MarketersMEDIA · Healthcare, Retail, Banking, Insurance, Jobs & workplace https://news.marketersmedia.com/irving-group-health-insurance-highlights-consumer-driven-plan-options/89204755 Consumer-driven health plans are gaining attention as employers and employees consider lower premium structures, health savings accounts, flexible medical spending, and long-term financial planning when evaluating workplace health insurance options. -- Irving Group Health Insurance is receiving increased attention as employers and employees consider consumer-driven health plans as an alternative to more traditional c ———————————————————————————————————————————————————————————— Houston Group Health Insurance Gains Focus Amid Healthcare Funding Changes 2026-10-27 · MarketersMEDIA · Finance, Healthcare, Insurance https://news.marketersmedia.com/houston-group-health-insurance-gains-focus-amid-healthcare-funding-changes/89204619 Healthcare funding changes are placing greater emphasis on community clinics, preventive care, provider coordination, and coverage stability as employers and families navigate a changing healthcare environment. -- Houston Group Health Insurance is gaining attention as healthcare systems respond to rising financial pressure, changing public coverage structures, and growing demand for accessible primary care. Community ———————————————————————————————————————————————————————————— Austin Group Health Insurance Gains Focus as Coverage Rules Shift 2026-10-27 · MarketersMEDIA · Healthcare, Insurance https://news.marketersmedia.com/austin-group-health-insurance-gains-focus-as-coverage-rules-shift/89204624 Changes in public health coverage are increasing attention on employer-sponsored insurance, hospital finances, and access to care as businesses and workers consider coverage stability, provider networks, and long-term healthcare costs. -- Austin Group Health Insurance is receiving increased attention as changes to public health coverage and federal insurance rules create concern about continuity of care, affordabilit ———————————————————————————————————————————————————————————— Dallas Group Health Insurance Gains Focus as Healthcare Costs Rise 2026-10-27 · MarketersMEDIA · Healthcare, Sustainability, Insurance https://news.marketersmedia.com/dallas-group-health-insurance-gains-focus-as-healthcare-costs-rise/89204614 Employers are reassessing group health insurance options as increasing healthcare expenses affect affordability, employee participation, and long-term plan sustainability, encouraging greater attention to coverage design, administration, provider access, and cost management. -- Dallas Group Health Insurance is receiving increased attention as rising healthcare costs continue to place pressure on employers, organizati ———————————————————————————————————————————————————————————— Plastic Surgery Revenue Growth: OmniDominance Content System Explained 2026-10-27 · MarketersMEDIA · Finance, Healthcare, Media, Marketing & advertising, Chemicals & materials https://news.marketersmedia.com/plastic-surgery-revenue-growth-omnidominance-content-system-explained/89207365 MedFire Media outlines how its OmniDominance™ system uses multi-format content across 300+ platforms to build plastic surgeons' visibility, support patient acquisition and drive practice revenue growth without paid advertising. -- MedFire Media has detailed how its OmniDominance™ system operates for board-certified plastic surgeons seeking practice revenue growth. The company reports that the system is fully managed, ———————————————————————————————————————————————————————————— Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388854/29076/en/cellectar-biosciences-reports-case-study-highlighting-complete-response-lasting-more-than-eight-years-in-heavily-pretreated-dlbcl-patient-treated-with-iopofosine-i-131.html Durable Complete Response Achieved with Single Administration of Iopofosine I 131 ———————————————————————————————————————————————————————————— Mammogen and MammoLink Partner to Advance a New Model for Community-Based Breast Cancer Detection 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388846/0/en/mammogen-and-mammolink-partner-to-advance-a-new-model-for-community-based-breast-cancer-detection.html Today Mammogen announced a clinical research partnership with MammoLink, founded by breast imaging radiologist Dr. Ryan Polselli. ———————————————————————————————————————————————————————————— KFSH Uses Digital Twins to Let Surgeons Rehearse Patient-Specific Procedures Before Operating 2026-10-27 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952306876/kfsh-uses-digital-twins-to-let-surgeons-rehearse-patient-specific-procedures-before-operating A KFSH surgical team member preparing instruments beside a robotic surgical system in an operating room RIYADH, SAUDI ARABIA, October 27, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) is using digital-twin technology to let surgical teams rehearse patient-specific procedures before entering the operating room, so that complex operations can be planned in detail on a virtual m ———————————————————————————————————————————————————————————— Curative Introduces Zero First, Flipping the Traditional Health Insurance Deductible on Its Head 2026-10-27 · PR Newswire · Healthcare, Insurance https://www.prnewswire.com/news-releases/curative-introduces-zero-first-flipping-the-traditional-health-insurance-deductible-on-its-head-302920242.html New health plan innovation puts coverage first, keeps everyday care at $0 and gives employers a more affordable way to provide meaningful health benefits AUSTIN, Texas, Oct. 27, 2026 -- Curative, a health insurance company redefining the way employers and their employees... ———————————————————————————————————————————————————————————— CREATE Medicines to Host Pre-Congress Workshop and Present on In Vivo CAR-T for Autoimmune Disease at APLAR 2026 2026-10-27 · PR Newswire · Healthcare, Automotive, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/create-medicines-to-host-pre-congress-workshop-and-present-on-in-vivo-car-t-for-autoimmune-disease-at-aplar-2026-302920133.html CREATE will bring together leaders in cell therapy and rheumatology to discuss why in vivo CAR-T is poised to become the next standard of care for autoimmune disease. On October 31, Adam Raff, MD, PhD, SVP, Autoimmune Clinical Development, will present preclinical mouse and non-human... ———————————————————————————————————————————————————————————— Physician’s New Book Challenges the 'Pill for Every Problem' Approach to Chronic Health Conditions 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951522062/physician-s-new-book-challenges-the-pill-for-every-problem-approach-to-chronic-health-conditions Banji Awosika, MD releases “Drop Your Meds: A Physician’s Guide to Breaking Free from Medications and Other Dependencies” with Forbes Books. ISBN-13: 979-8887501710 “Drop Your Meds: A Physician’s Guide to Breaking Free from Medications and Other Dependencies” by Banji Awosika, MD is released with Forbes Books. NEW YORK, NY, UNITED STATES, October 27, 2026 / EINPresswire.com / -- “Drop Your Meds: A Physician’s Guide t ———————————————————————————————————————————————————————————— Beam Therapeutics Reports Initial Clinical Data from Phase 1/2 Trial of BEAM-301, Demonstrating Proof of Concept for Genetic Correction in Glycogen Storage Disease Type Ia (GSDIa) at ESGCT 33rd Annual Congress 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/27/3388826/0/en/beam-therapeutics-reports-initial-clinical-data-from-phase-1-2-trial-of-beam-301-demonstrating-proof-of-concept-for-genetic-correction-in-glycogen-storage-disease-type-ia-gsdia-at-.html In the 40 mg Cohort, Two Patients Achieved 15 Hours of Controlled Fasting, Improvements in Glucose Control and No Longer Required Starch Supplementation Following Treatment ———————————————————————————————————————————————————————————— Arvinas to Report Third Quarter 2026 Financial Results on November 3, 2026 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388821/0/en/arvinas-to-report-third-quarter-2026-financial-results-on-november-3-2026.html NEW HAVEN, Conn., Oct. 27, 2026 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that management will review third quarter 2026 financial results and provide a corporate update during a live webcast on Tuesday, November 3, 2026 at 8:00 a.m. ET. ———————————————————————————————————————————————————————————— Adagene to Participate in the Guggenheim Securities 3rd Annual Healthcare Innovation Conference 2026-10-27 · GlobeNewswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388810/0/en/adagene-to-participate-in-the-guggenheim-securities-3rd-annual-healthcare-innovation-conference.html SAN DIEGO and SUZHOU, China, Oct. 27, 2026 -- Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a platform-driven, clinical-stage biotechnology company transforming the discovery and development of novel antibody-based therapies, today announced that senior management will participate in a fireside chat and one-on-one meetings at the Guggenheim Securities 3rd Annual Healthcare Innovation Conference being held November 9-11, 2026 in Boston, MA. ———————————————————————————————————————————————————————————— Cullinan Therapeutics Advances Velinotamig into Global Clinical Development for Autoimmune Cytopenias Following IND Clearance by the U.S. FDA 2026-10-27 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/27/3388808/0/en/cullinan-therapeutics-advances-velinotamig-into-global-clinical-development-for-autoimmune-cytopenias-following-ind-clearance-by-the-u-s-fda.html Global regulatory clearances in the U.S. and Australia support initiation of a Phase 1b/2a study in relapsing and refractory ITP and wAIHA ———————————————————————————————————————————————————————————— 908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026 2026-10-27 · Business Wire · Finance, Healthcare, Chemicals & materials https://finance.yahoo.com/healthcare/articles/908-devices-report-third-quarter-110000504.html BURLINGTON, Mass., October 27, 2026--908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, announced it will report financial results for the third quarter 2026 before market ope ———————————————————————————————————————————————————————————— Stevanato Group and Aptar Pharma Collaborate to Help Accelerate Pre-Filled Syringe System Selection 2026-10-27 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/stevanato-group-aptar-pharma-collaborate-110000839.html Joint system-level testing combines Stevanato Group's glass syringes with Aptar Pharma's elastomer components to provide key data earlier in development and help inform packaging decisions for sensitive biologics and other injectable therapies PIOMBINO DESE, Italy, October 27, 2026--Stevanato Group S. ———————————————————————————————————————————————————————————— NationsBenefits Expands Member Access to Health Benefits Across Costco Stores Nationwide 2026-10-27 · Business Wire · SaaS, Healthcare, Retail, Payments & fintech https://finance.yahoo.com/healthcare/articles/nationsbenefits-expands-member-access-health-110000744.html New retail integration enables item-level verification, allowing eligible health plan members to use their benefit cards at more than 600 Costco locations. PLANTATION, Fla., October 27, 2026--NationsBenefits , the leading healthcare fintech and benefit outcomes company, today announced a nationwide retail integration with Costco Wholesale to roll out its proprietary Basket Adjudication Service ( ———————————————————————————————————————————————————————————— Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 26 10 2026] - (CGWL) 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388786/0/en/form-8-3-advanced-medical-solutions-group-plc-26-10-2026-cgwl.html FORM 8.3 ———————————————————————————————————————————————————————————— Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026 2026-10-27 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/anteris-announces-upcoming-data-release-for-medium-size-duravr-thv-from-embark-study-at-tct-2026 MINNEAPOLIS and BRISBANE, Australia, Oct. 27, 2026 — Anteris Technologies Global Corp. (“Anteris” or the “Company”) (NASDAQ: AVR, ASX: AVR) today announced that Azeem Latib, MD, will present the first 30-day clinical and hemodynamic outcomes for its medium-size DurAVR® Transcatheter Heart Valve (THV) at TCT® 2026 – The 38th Annual Transcatheter Cardiovascular Therapeutics … Continue reading "Anteris Announces Upcoming Data Release for Medium-Size DurAVR THV from EMBARK Study at TCT 2026" ———————————————————————————————————————————————————————————— Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium 2026-10-27 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/nautilus-to-measure-proteoforms-driving-alzheimers-disease-and-cancer-in-arpa-h-funded-seeds-consortium SEATTLE, Oct. 27, 2026 — Nautilus Biotechnology, Inc. (NASDAQ: NAUT), a company pioneering intact, single-molecule proteomics approaches, today announced its participation in SEEDS (Sequence-to-disease: Environment-aware Ensembles of Disordered proteins at Scale), a four-year, multi-center research consortium awarded up to $51.7 million by the Advanced Research Projects Agency for Health (ARPA-H). The consortium, which … Continue reading "Nautilus to Measure Proteoforms Driving Alzheimer’s Disease and Cancer in ARPA-H-Funded SEEDS Consortium" ———————————————————————————————————————————————————————————— Hengrui Pharma Reports Steady Growth in the First Nine Months of 2026 2026-10-27 · ScoopAsia · Healthcare, Biotech & pharma https://scoopasia.com/hengrui-pharma-reports-steady-growth-in-the-first-nine-months-of-2026/ Hengrui Pharma ("Hengrui" or "the Company") today announced its financial results for the first nine months of 2026. ———————————————————————————————————————————————————————————— Ovation Fertility ‘Embryo Glue’ Research Abstract Selected for Presentation at ASRM 2026 2026-10-27 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/952358971/ovation-fertility-embryo-glue-research-abstract-selected-for-presentation-at-asrm-2026 SAN ANTONIO, TX, UNITED STATES, October 27, 2026 / EINPresswire.com / -- Ovation® Fertility’s latest research analyzing the effectiveness of “embryo glue” as transfer media for frozen embryo transfer (FET) was presented at the 2026 American Society for Reproductive Medicine (ASRM) Scientific Congress & Expo, held Oct. 24-28 in Baltimore. The study, titled “High Cost Without Clinical Gain: Multicenter Evaluation of Hy ———————————————————————————————————————————————————————————— Healthgrades Names America's Top Hospitals for Outstanding Specialty Care, Outpatient Procedures, and State Rankings, 2027 2026-10-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/healthgrades-names-americas-top-hospitals-for-outstanding-specialty-care-outpatient-procedures-and-state-rankings-2027-302919545.html New research finds 80% of patients consider hospital quality when choosing a doctor, while 71% would switch doctors for access to a higher-rated hospital DENVER, Oct. 27, 2026 -- Healthgrades, the #1 site Americans use when searching for a doctor or hospital, today announced... ———————————————————————————————————————————————————————————— New research reveals reproductive history is associated with day 7 blastocyst pregnancy and live birth outcomes 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951288743/new-research-reveals-reproductive-history-is-associated-with-day-7-blastocyst-pregnancy-and-live-birth-outcomes The findings point to personalized day 7 transfer counseling: encouraging news for first-time patients & clearer expectations for those with a failed transfer. BALTIMORE, MD, UNITED STATES, October 27, 2026 / EINPresswire.com / -- A new study from US Fertility finds that the chance of live birth following a day 7 blastocyst embryo transfer are associated with a patient’s prior embryo transfer history. The findings we ———————————————————————————————————————————————————————————— Recent Release, "I Am the Helper," from Covenant Books Authors Roxanne Canfield, Sharon Walls, Kelly Kirk, Deborah Predmore, & Mary Stewart, Honors Nursing Professionals 2026-10-27 · PR.com · Healthcare https://www.pr.com/press-release/982329 Roxanne Canfield, Sharon Walls, Kelly Kirk, Deborah Predmore, & Mary Stewart have completed a new book, titled, "I Am the Helper": "The Nurse," a candid exploration of what it means to serve at the bedside. The work examines nursing through multiple perspectives—from the administrator who climbed institutional ranks to the devoted clinician who spent her entire career providing direct patient [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "THE ONE IMMIGRANT," from Covenant Books Author Amir A. Samardar, Ph.D., Explores How One Act of Compassion Can Illuminate a Child's Dreams 2026-10-27 · PR.com · Healthcare https://www.pr.com/press-release/982327 Amir A. Samardar, Ph.D. has completed a new book, "THE ONE IMMIGRANT" that opens with a harrowing childhood moment: a severe illness that forces a young boy to seek help at a Christian hospital. What begins as a desperate search for medical relief becomes something far more profound: an encounter with a nurse whose kindness and simple gesture of generosity plant seeds of hope that will shape his entire future. [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "The Cure," from Audiobook Network Author Michael Davis, Explores How Magic Mushroom Therapy Can Transform Mental Wellness on a National Scale 2026-10-27 · PR.com · Healthcare, Biotech & pharma https://www.pr.com/press-release/982295 Michael Davis has completed a groundbreaking audiobook that presents a revolutionary perspective on treating depression, anxiety, PTSD, and addiction through psilocybin-assisted therapy. With meticulous research and candid personal testimony, Davis argues that magic mushrooms represent the third most significant medical discovery in human history—comparable only to antibiotics and vaccines in their potential to heal [PR.com] ———————————————————————————————————————————————————————————— ORGANA Highlights Natural Wellness as Temperatures Begin to Drop 2026-10-27 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Education, Food & drink, Sports, Biotech & pharma, Marketing & advertising https://newsworthy.ai/news/202610273105/organa-highlights-natural-wellness-as-temperatures-begin-to-drop Springville, UT Tuesday Oct 27, 2026 @ 6:00 AM Eastern — As temperatures begin to drop across much of the United States, Americans are transitioning from summer activities to cooler-weather routines, bringing renewed attention to warm beverages, indoor activities, and everyday wellness habits. ORGANA International, a Utah-based natural wellness company founded in 1997, is highlighting how seasonal changes offer an opportunity to revisit familiar wellness traditions, including herbal teas, plant-derived ingredients, and simple daily practices that can be maintained throughout the colder months. "Every season brings changes to our daily routines, and cooler weather is no exception," said Larry Mills, CEO of ORGANA International. "As people spend more time indoors and prepare for winter, it's a good opportunity to think about the everyday habits and natural ingredients that are part of their wellness routines." The Return of Cold-Weather Wellness Traditions As fall transitions toward winter, many familiar seasonal traditions return. Warm beverages become more appealing, outdoor activities shift, and people often look for ways to maintain comfortable, consistent routines despite changing temperatures and shorter daylight hours. Herbal teas have long been part of seasonal traditions in cultures around the world, valued for their variety of botanical ingredients and their place in everyday routines. ORGANA's portfolio includes Essiac Tea, an herbal formulation that reflects the company's longstanding interest in traditional botanical ingredients and natural wellness products. "There's something about cooler weather that brings people back to familiar traditions, whether that's enjoying a warm cup of herbal tea or simply taking more time for themselves," Mills said. "We believe these everyday practices have an important place in a balanced approach to wellness." Natural Ingredients for Changing Seasons ORGANA's approach to wellness extends beyond any single product or season. The company's portfolio includes Fulvic Acid Trace Mineral Drink, Liquid Oxygen, Essiac Tea, magnesium creams, and its recently introduced Mineral Shots, offering a range of natural wellness products for different consumer preferences. As consumers evaluate their routines during the transition to colder weather, ORGANA encourages a thoughtful approach to ingredient selection, product quality, and consistency. Rather than viewing wellness as something that requires a complete seasonal overhaul, the company emphasizes the value of maintaining familiar habits while making practical adjustments to changing schedules and environments. "Wellness doesn't have to become more complicated when the seasons change," Mills said. "We believe in understanding the ingredients you choose, maintaining good daily habits, and finding routines that fit naturally into your lifestyle." Building Consistency Through the Winter Months Shorter days and colder temperatures can change how people approach exercise, meals, relaxation, and other everyday activities. Maintaining regular physical activity, eating a balanced diet, getting adequate sleep, and making time for relaxation remain important throughout the year. For ORGANA, the arrival of colder weather reinforces a broader philosophy that has guided the company for nearly three decades: wellness is built through everyday choices rather than seasonal trends or short-term solutions. "One of the things we've learned over the years is that people appreciate simplicity," Mills said. "Whether it's a familiar herbal tea, a favorite wellness product, or a daily routine, consistency is something people can carry with them from one season to the next." Continuing to Bring Natural Wellness to U.S. Consumers Founded in 1997, ORGANA International has developed a portfolio of natural wellness products that includes plant-derived minerals, herbal formulations, and topical products. The company continues expanding its presence in the U.S. marketplace, building on its availability through Amazon and OneLavi and its recent participation in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida. As the colder months approach, ORGANA remains focused on product education, ingredient transparency, and helping consumers better understand the natural wellness products they choose. About ORGANA International Founded in 1997, ORGANA International is a wellness company committed to delivering natural, bioavailable products that help people live healthier lives. From trace minerals and liquid oxygen to magnesium creams and detoxification teas, ORGANA’s product line is designed to restore vital elements often missing in modern lifestyles. Headquartered in Springville, Utah, ORGANA is a customer-first company with a 5-star BBB rating and nearly three decades of dedication to natural wellness. FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— RMA of New York Presents 22 Research Abstracts and Receives Two Awards at 2026 ASRM Scientific Congress 2026-10-27 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/947713191/rma-of-new-york-presents-22-research-abstracts-and-receives-two-awards-at-2026-asrm-scientific-congress An embryologist at Reproductive Medicine Associates of New York (RMANY) works in the laboratory, where specialized expertise and advanced reproductive technologies support the clinical care and research that drive advances in reproductive medicine. Research explores reproductive aging, ovarian reserve, embryo development, and evolving approaches to family building By compiling and analyzing data across so many areas, ———————————————————————————————————————————————————————————— Twin lighting fairs open with some 3,000 exhibitors showcasing global lighting solutions 2026-10-27 · ACN Newswire · AI, SaaS, Healthcare, Energy, Retail, Media, Education, Food & drink, Sports, Industrial, Sustainability, Entertainment https://www.acnnewswire.com/press-release/english/111142/ Hong Kong, Oct 27, 2026 - The 28th Hong Kong International Lighting Fair (Autumn Edition), organised by the Hong Kong Trade Development Council (HKTDC), opens today and runs for 4 days, from 27 October to 30 October, at the Hong Kong Convention and Exhibition Centre. The 11th Hong Kong International Outdoor and Tech Light Expo opened yesterday and runs until 29 October at AsiaWorld-Expo. HKTDC Associate Executive Director Silas Chu said: "As the lighting industry is evolving rapidly, the twin lighting fairs this year are held under the theme "Beyond Illumination", highlighting key industry trends related to smart connectivity, healthy living, immersive spatial experiences and sustainability, and showcasing cutting-edge lighting solutions to global buyers. The fairs attract some 3,000 exhibitors from more than 20 countries and regions, alongside international professional organisations and industry experts who share insights into the latest developments. By building an international trade and technology exchange platform, the fairs connect global buyers with industry players and foster the sustainable development of the lighting industry." The 28th Hong Kong International Lighting Fair (Autumn Edition) and the 11th Hong Kong International Outdoor and Tech Light Expo are open. Together they form a global lighting event showcasing the latest products from some 3,000 exhibitors representing more than 20 countries and regions. He added that the twin lighting fairs are international in scope. Besides exhibitors from Hong Kong, the Chinese Mainland and Taiwan, the fairs also welcome exhibitors from the Asia-Pacific region, including Australia, India, Korea and Singapore, as well as from Europe and America, including Denmark, Finland, Germany, the Netherlands, Mexico and the United Kingdom. The fairs gather exhibitors who have participated in landmark projects around the world and won international awards, as well as major industry alliances in global smart lighting and IoT such as the Connectivity Standards Alliance, the DALI Alliance, the SILA-EMN Alliance, the Zhaga Consortium and, making its debut at the fair, KNX, the global standard for smart building and home automation. Together with their member companies from around the globe, these alliances jointly demonstrate the smart lighting ecosystem. A highlight of the Autumn Lighting Fair, the Hall of Connected Lighting features some 70 leading local and international brands, including Dimon, a local company which has participated in the Hong Kong Palace Museum project, Inventronics and TUYA from the Chinese Mainland, Viso Systems from Denmark, Casambi from Finland, and Signify from the Netherlands. The zone also features immersive lighting installations and application-based displays. For example, Casambi brings an Artisan Cafe concept space to the fair, while Viliya creates an immersive mirrored art installation, Mirrorverse. The Hall of Connected Lighting features some 70 leading local and international brands, as well as immersive lighting installations and application-based displays. Signify collaborates with the Mercedes-AMG PETRONAS F1 Team to present a racing simulator experience and also displays Philips Skylight, which simulates natural light environments and adjusts light according to human circadian rhythms by integrating two major health-focused lighting technologies (VitaUp and BioUp) to create a healthier and more comfortable indoor lighting experience. Another signature zone, the Hall of Aurora, features some 500 renowned brands offering high-quality lighting products. Local exhibitors include Prosperity Lamps & Components whose products have been featured in the FIFA World Cup stadium and the Museum of the Future in Dubai, and Profiled Group which participated in Casa Batlló in Barcelona and the Guggenheim Museum in Bilbao, Spain. Chinese Mainland brands include General Lighting Electronic which participated in the Leaning Tower of Pisa in Italy, and Alpha Lighting which participated in the Madame Brasserie restaurant at the Eiffel Tower in Paris. Other international brands include Lival from Finland, Cupower from Germany, and Beghelli from Italy. The Hall of Aurora gathers some 500 renowned brands offering high-quality lighting products. The Autumn Lighting Fair always keeps pace with industry trends. This year it expands its product range and launches the new LED Display Solution Zone to build an LED commercial display ecosystem. This zone features the latest high-resolution LED screens, transparent displays, flexible panels and immersive visual systems, creating new visual experiences for retail spaces, event experiences, smart cities and architectural projects. Other featured zones include Commercial Lighting, Residential Lighting and LED Essentials. The Autumn Lighting Fair launches the new LED Display Solution Zone to build an LED commercial display ecosystem. This year, the Hong Kong International Outdoor and Tech Light Expo features three major zones, including Smart Pole and Solution; Outdoor, Industrial and Technical Lighting; and Landscape and Architectural Lighting. In addition to displaying lighting product applications in smart cities, industrial and professional scenarios, it has also added photovoltaic and energy storage solutions to help cities improve energy efficiency. The Outdoor and Tech Light Expo features multiple product zones displaying a variety of outdoor and professional technical lighting solutions for commercial and industrial applications.During the two fairs, numerous seminars and forums are being held, inviting industry leaders to analyse market and product trends. Two fairs showcase new trends in lighting - Various award-winning exhibitors and design products gather under one roof Local representatives include first-time exhibitor Ledman Hong Kong (Booth: 5B-D02), which introduces the LEDHUB Smart Conference Solution, integrating large-format display, video conferencing and collaboration functions into a single platform. This solution won the 2025 TITAN Innovation Awards Gold Award and has been adopted by leading institutions including the University of Hong Kong, the University of Warwick and Fudan University. Ledman Hong Kong also presents the QS Series IceScreen LED Display, which was deployed at the Milano Cortina 2026 Winter Olympic Games.   Another local exhibitor, Hongkong Sunricher Technology (Booth: 1D-C30), displays their Desktop Wizard. The product won the Red Dot Design Award, the iF Design Award and the German National Design Award. It replaces traditional lighting remote controls that often require complex operations and commands, as well as wall switches limited by fixed installations, to provide a more flexible and space-efficient home control solution.   - Finnish exhibitor Ledil Oy (Booth: GH-P21) showcases their LEDiL - STRADA reflector, the winner of the German Innovation Award 2025. This product offers precise beam control and excellent glare control with a glare rating of G6 and a threshold increment TI as low as 1%. Even when equipped with protective glass, its optical efficiency can reach about 90%, helping to create efficient, energy-saving and visually comfortable lighting solutions.   Chinese Mainland brand Zhongshan SUFN Lighting Technology Co Ltd (Booth: 1A-B24) presents REIZ II, which won the iF Design Award 2024 and Contemporary Good Design Award 2022. This product adopts an innovative convection cooling structure and concealed shift mechanism, improving heat dissipation efficiency by approximately 15%, and increasing light output by around 30%. Its dual anti-glare optical design with UGR≤6 supports a wide range of lighting applications, including downlighting, adjustable accent lighting and wall washing. - Green energy and energy-saving solutions support sustainable development According to GEP Research, it is expected that the global photovoltaic lighting market will reach US$18.5 billion in 2026, a year-on-year increase of 14.2% compared to US$16.2 billion in 2025. Outdoor and Tech Lighting Expo exhibitor Lansine Intelligent (Zhongshan) Energy Storage Technology Co Ltd (Booth: 8-F28) brings their LX-LC01 energy storage power station and foldable solar panel series, which are green power solutions specially designed for off-grid applications, outdoor camping, emergency backup power, as well as small-scale and residential energy storage. Auroras InnoTech Guangdong Co Ltd (Booth: 8-D21) showcases their Woodpecker Series & Architectural Pathway Light product which features a unique vertical architectural form, renewable solar energy and warm natural finishes, creating a modern outdoor space that blends with nature. The exhibitor also displays street lighting solutions applied at the Dubai Expo. Hishine Group Ltd (Booth: 8-E27) presents its Hi-Robot 1300W Stadium LED High Mast Light, which features a hexagonal anti-wind structure, a large cooling area, excellent heat dissipation performance and a service life exceeding 100,000 hours. These lights are waterproof, reduce power consumption by 70%, and have been installed in the Jaime Morón León Olympic Stadium in Colombia. - Smart lighting meets the needs of various scenarios According to a survey by Fortune Business Insights, the global lighting fixtures market size is projected to grow from US$142.52 billion in 2026 to US$221.39 billion by 2034, exhibiting a CAGR of 5.7% during the forecast period. Public demand for smart lighting systems is rising. Autumn Lighting Fair exhibitor Zhongshan Tauras Technologies Co Ltd (Booth: 1E-G35) displays a three-in-one integrated dimmable power supply designed for home bathroom applications, combining a high-efficiency switching power supply, a mirror defogging film and an intelligent touch dimming system in a single unit. It is suitable for humid and dusty environments and meets users' lighting and visual needs in different scenarios. Yndlux Lighting Co Ltd (Booth: 3B-B05), selected as a national high-tech enterprise, brings its independently developed 5272 linear module light. It can meet the lighting and design needs of different customers and places through an intelligent control system and the diverse selection of module styles. Multiple exchange and thematic events to discuss market trends The twin lighting fairs are hosting a series of thematic events with heavyweight international lighting organisations. For the Autumn Lighting Fair today at the Hong Kong Convention and Exhibition Centre, "Award-Winning Illumination - Highlights from the IES Illumination Awards", jointly organised with the Illuminating Engineering Society (IES) for the first time, invites winners of the prestigious "IES Illumination Awards" to share insights into the artistic and technical evolution of lighting design. On the same day, "Innovative Lighting Design Forum", under the theme "Treasures of Light: Artistic Brilliance Beyond Exhibitions", features three lighting design maestros who have participated in internationally renowned projects to share the latest trends. For the first time, the Autumn Lighting Fair will partner with Women in Lighting (WIL) to host "Circularity in Lighting Design" tomorrow (28 October), where several prominent female designers in the industry will discuss sustainable lighting design and how the circular economy concepts are being applied. Another key event "Connected Lighting Forum", co-organised with the Shanghai Pudong Intelligent Lighting Association, will be held on the same day on 28 October. Under the theme of "Healing Light for the Future: Illuminating Emotional Well-being", it will explore the development of intelligent and human-centric lighting technologies for emotional health and share case studies on the use of light to heal the body and mind. At AsiaWorld-Expo, the Outdoor and Tech Light Expo today is hosting "Smart Tech Integration in Outdoor Lighting", exploring how AI-driven outdoor lighting technology can be applied to today's smart cities. Running concurrently from 26 to 29 October, the Outdoor and Tech Light Expo and Eco Expo Asia at AsiaWorld-Expo, together with the Autumn Lighting Fair at the Hong Kong Convention and Exhibition Centre (HKCEC), provide a dynamic platform for cross-sector business opportunities. Free shuttle bus services will be provided between the HKCEC and AsiaWorld-Expo from 26 to 29 October. Under the EXHIBITION+ hybrid model, exhibitors and buyers can also meet online through the Click2Match business matching platform in addition to attending the physical fair. The online fairs run from 19 October to 6 November, facilitating business expansion both online and offline.    Hong Kong International Outdoor  and Tech Light Expo  Hong Kong International Lighting Fair  (Autumn Edition)  Date  26 - 29 October 2026 (Mon-Thu)  27- 30 October 2026 (Tue-Fri)  Opening hours  26 October 2026: 10:30 am - 6pm  27 - 28 October 2026: 10am - 6pm  29 October 2026:10am – 5pm  27 - 29 October 2026: 9:30am – 7pm  30 October 2026: 9:30am - 4pm  Venue  AsiaWorld-Expo  Hong Kong Convention and Exhibition Centre  Media registration  AsiaWorld-Expo East Lobby  Hall 1C Concourse, HKCEC, or at the HKTDC Media Centre (G/F, HKCEC, 1 Expo Drive, Wan Chai)  Media Centre  Room 108, Hall 8 Side Entrance,  AsiaWorld-Expo  HKTDC Media Centre  Website  hkotlexpo.hktdc.com  hklightingfairae.hktdc.com Photo Download: https://bit.ly/4zVvwDQ Media enquiries Please contact the HKTDC's Communications and Public Affairs Department: Christy Lee Tel: (852) 2584 4369 Email: christy.wn.lee@hktdc.org Dawn Yuen Tel: (852) 2584 4575 Email: dawn.nh.yuen@hktdc.org Jane Cheung Tel: (852) 2584 4137 Email: jane.mh.cheung@hktdc.org The HKTDC's Media Room:  http://mediaroom.hktdc.com/en About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. ———————————————————————————————————————————————————————————— Condom Market Forecast Reveals Emerging Industry Potential 2026-10-27 · Express Press Release · Healthcare, Retail, Industrial https://express-press-release.net/news/2026/10/27/1778803 The global Condom Market is expanding through a combination of established demand, regional manufacturing capabilities, public health initiatives, and changing consumer preferences. Valued at USD [read full press release...] ———————————————————————————————————————————————————————————— Single-Arm Medical Pendant Market Size, Growth Trends, and Global Forecast to 2034 2026-10-27 · PR News Releaser · Healthcare, Energy https://www.prnewsreleaser.com/news/479362 The global Single-Arm Medical Pendant market is experiencing steady growth, supported by the importance of organized medical equipment placement and efficient access to essential utilities in healthcare environments. Single-arm medical pendants are designed to support clinical workflows by providing convenient ... Read more ———————————————————————————————————————————————————————————— Intermountain Health Breaks Ground on a New Era of Children's Health in Nevada 2026-10-27 · PRUnderground · Healthcare, Construction & engineering https://prunderground.com/intermountain-health-breaks-ground-on-a-new-era-of-children-s-health-in-nevada/cmvq8scox000307i9l3yyd5ug Intermountain Health Felicia and Ben Horowitz Children's Hospital plans call for a 33-acre campus, an approximately 828,600-square-foot hospital with 228 beds. The post Intermountain Health Breaks Ground on a New Era of Children's Health in Nevada first appeared on ———————————————————————————————————————————————————————————— Image-guided Therapy Systems Market will Reach US$ 8.26 Billion by 2031 2026-10-27 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/479356 The Image-guided Therapy Systems Market is experiencing significant growth as healthcare providers increasingly adopt advanced imaging technologies to improve procedural accuracy, treatment outcomes, and patient safety. The rising prevalence of chronic diseases, growing demand for minimally invasive procedures, and continuous ... Read more ———————————————————————————————————————————————————————————— New Anglia University Examines How International Clinical Networks Are Expanding Opportunities for British Medical Students 2026-10-27 · GlobeNewswire · Healthcare, Education https://www.globenewswire.com/news-release/2026/10/27/3388752/0/en/new-anglia-university-examines-how-international-clinical-networks-are-expanding-opportunities-for-british-medical-students.html New Anglia University explores how international clinical networks expand medical training opportunities for British students through hospital partnerships ———————————————————————————————————————————————————————————— Hyasen Biotech Wraps Up a Successful Genética 2026 in Florianópolis 2026-10-27 · EIN Presswire · Healthcare, Biotech & pharma, Government & policy https://www.einpresswire.com/article/952542506/hyasen-biotech-wraps-up-a-successful-gen-tica-2026-in-florian-polis CHANGSHA, HUNAN, CHINA, October 27, 2026 / EINPresswire.com / -- Genética 2026 — the 71st Brazilian Congress of Genetics — concluded on October 2 in Florianópolis, Santa Catarina, and Hyasen Biotech is pleased to report a successful and productive showing at Booth 10, where the team met researchers, distributors, and industry partners from across Brazil and Latin America. Held under the theme “One Century of the Gene ———————————————————————————————————————————————————————————— Techno-Dent Clinic adds custom snoring and sleep apnoea appliances in Sandton 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952542451/techno-dent-clinic-adds-custom-snoring-and-sleep-apnoea-appliances-in-sandton A Techno-Dent Clinic dentist shows a patient how a two-piece snoring appliance sits on a model of the teeth, at the practice in Sandton, Johannesburg. The two-piece oral appliance is made from a digital scan, adjusted in half-millimetre steps and needs no power, so some CPAP users keep one for power cuts SANDTON, SOUTH AFRICA, October 27, 2026 / EINPresswire.com / -- Techno-Dent Clinic , the Sandton dental practice t ———————————————————————————————————————————————————————————— National Leader in Cancer Symptom Management, Ishwaria Subbiah, MD, Joins Perlmutter Cancer Center 2026-10-27 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/national-leader-in-cancer-symptom-management-ishwaria-subbiah-md-joins-perlmutter-cancer-center-302920035.html Dr. Subbiah will expand access to new treatment options while keeping quality of life at the center of care. NEW YORK, Oct. 27, 2026 -- NYU Langone Health announced the appointment of Ishwaria Subbiah, MD, as director of the Symptom Management Program for hematology and... ———————————————————————————————————————————————————————————— Leading U.S. Cannabis Brand Airo Launches AiroPro Inhalation System in the United Kingdom 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952373372/leading-u-s-cannabis-brand-airo-launches-airopro-inhalation-system-in-the-united-kingdom LISBON, PORTUGAL, October 27, 2026 / EINPresswire.com / -- AIRO BRANDS, Inc. (“Airo”), a U.S. company specializing in proprietary cannabis vaporization technology, together with SOMAÍ, a leading EU-GMP-certified vertically integrated Multi-Country Operator (MCO) specializing in cannabinoid-based medicines, today announced the launch of the AiroPro inhalation system in the United Kingdom, expanding patient access to a ———————————————————————————————————————————————————————————— Form 8.5 (EPT/RI)-Advanced Medical Solutions Group plc 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388742/0/en/form-8-5-ept-ri-advanced-medical-solutions-group-plc.html FORM 8.5 (EPT/RI) ———————————————————————————————————————————————————————————— Top Endoscope Manufacturer Zhejiang Jiacheng Advances Medical Instrument Solutions 2026-10-27 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952536413/top-endoscope-manufacturer-zhejiang-jiacheng-advances-medical-instrument-solutions Professional Arthroscope | 0° / 30° / 70° | 1.9mm / 2.7mm / 3.0mm / 4.0mm | CE | HD | OEM/ODM HANGZHOU, ZHEJIANG, CHINA, October 27, 2026 / EINPresswire.com / -- Zhejiang Jiacheng Medical Instrument Co., Ltd. is developing its presence in the international medical endoscopy market through a product portfolio that combines rigid endoscopes, surgical instruments, optical components, and medical accessories. Based in To ———————————————————————————————————————————————————————————— Breast Enlargement Falls 8% in BAAPS Audit: Dr Aykut Özpür Discusses Changing Patient Priorities 2026-10-27 · EIN Presswire · Healthcare, Medical devices, Chemicals & materials https://www.einpresswire.com/article/952428149/breast-enlargement-falls-8-in-baaps-audit-dr-aykut-zp-r-discusses-changing-patient-priorities dr aykut özpür dr aykut özpür reviews BAAPS figures show fewer breast enlargements and more implant removals. Dr Aykut Özpür discusses what changing priorities mean for individual surgical choices. ISTANBUL, TURKEY, October 27, 2026 / EINPresswire.com / -- Breast enlargement procedures fell 8% in the British Association of Aesthetic Plastic Surgeons’ audit of 2025 activity, bringing changing patient priorities into f ———————————————————————————————————————————————————————————— SNU Eye Clinic Emphasizes Precise Exams and Lens Selection for Cataract Surgery 2026-10-27 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952533466/snu-eye-clinic-emphasizes-precise-exams-and-lens-selection-for-cataract-surgery Dr. Chung Eui Sang of SNU Eye Clinic performing an ophthalmic examination as part of a comprehensive eye assessment. Dr. Chung Eui Sang, Chief Director of SNU Eye Clinic, speaking at a medical symposium on Clareon PanOptix Pro intraocular lens technology. Eye examination at SNU Eye Clinic using ophthalmic diagnostic equipment. SNU Eye Clinic explains the importance of precise examinations, lens selection, and postope ———————————————————————————————————————————————————————————— United Nations Day: seven regions of the Central African Republic to discover through a virtual exhibition 2026-10-27 · APO Group · Healthcare, Education https://www.africa-newsroom.com/press/united-nations-day-seven-regions-of-the-central-african-republic-to-discover-through-a-virtual-exhibition?lang=en On the occasion of United Nations Day, celebrated on October 24, a virtual photo exhibition titled "Investing in Peace" invites the public to explore the seven regions of the Central African Republic. Through images, stories, and faces, it highlights community initiatives, progress achieved with the support of the United Nations and its partners, and the remaining challenges to sustainably consolidate peace. The "Investing in Peace" exhibition presents the progress accomplished in the Central African Republic and the efforts required to preserve and strengthen it. Under the subtitle "Progress to preserve and consolidate in every region," the exhibition offers a photographic journey across the country's seven regions. It showcases initiatives by local communities, national authorities, MINUSCA, UN Agencies, Funds, and Programmes, and their partners. At the heart of daily life: concrete actions for peace and resilience A school where children learn, a water point that protects health, an economic activity that supports a family, local institutions close to residents, or communities reuniting through dialogue… the photographs illustrate the various forms that day-to-day investment in peace takes. Through these images and their stories, visitors discover how civilian protection, access to essential services, economic recovery, civic participation, and social cohesion contribute to establishing lasting peace. The exhibition also emphasizes the fragility of these advances. Consolidating them requires institutions that can meet the population's needs, sustainable support after disarmament, and ongoing protection in areas where threats persist, such as the country's Northeast and Southeast regions. Accessible online via an immersive virtual gallery, "Investing in Peace" offers a unique way to discover the Central African Republic and meet those working for its future. Distributed by APO Group on behalf of United Nations Multidimensional Integrated Stabilization Mission in the Central African Republic (MINUSCA). ———————————————————————————————————————————————————————————— Hospital Mobile Carts Market Expanding at 9.55% CAGR 2026-10-27 · PR News Releaser · Healthcare, Software & IT https://www.prnewsreleaser.com/news/479180 The Hospital Mobile Carts Market is witnessing remarkable growth as healthcare facilities increasingly focus on improving workflow efficiency, enhancing patient care delivery, and supporting digital transformation initiatives. The growing adoption of electronic health records (EHRs), rising demand for point-of-care technologies, ... Read more ———————————————————————————————————————————————————————————— From Sunlight to Cancer Prevention: World Vitamin D Day Will Honor Scientists Behind Decades of Groundbreaking Research 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952399853/from-sunlight-to-cancer-prevention-world-vitamin-d-day-will-honor-scientists-behind-decades-of-groundbreaking-research Dr. Edward D. Gorham Dr. William B. Grant Dr. Joan M. Lappe GrassrootsHealth honors pioneering scientists Nov. 2 as millions enter the “vitamin D winter,” when sunlight provides too little UVB for vitamin D production. From our earliest acquaintance, we realized how much cancer we could actually prevent, and that public health and vitamin D research was the best approach to doing so.” — Dr. Edward D. Gorham SAN DIEGO ———————————————————————————————————————————————————————————— KFSH Advances Patient-Centered Care Through ICHOM Accreditation 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952306778/kfsh-advances-patient-centered-care-through-ichom-accreditation ICHOM Accreditation RIYADH, SAUDI ARABIA, October 27, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) has earned Level 1 accreditation from the International Consortium for Health Outcomes Measurement (ICHOM) for its cataract surgery program, recognizing its implementation of internationally standardized measures that combine clinical outcomes with patients’ own assessments of ———————————————————————————————————————————————————————————— KFSH Strengthens Patient-Centered Care With ICHOM Accreditation 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388703/0/en/kfsh-strengthens-patient-centered-care-with-ichom-accreditation.html RIYADH, Saudi Arabia, Oct. 27, 2026 -- King Faisal Specialist Hospital and Research Centre (KFSH) has earned Level 1 accreditation from the International Consortium for Health Outcomes Measurement (ICHOM) for its cataract surgery program, recognizing its implementation of internationally standardized measures that combine clinical outcomes with patients’ own assessments of their vision and quality of life. ———————————————————————————————————————————————————————————— ONWARD Medical to Announce Third-Quarter 2026 Results on November 3, 2026 2026-10-27 · PressReach · Healthcare https://pressreach.com/onward-medical-to-announce-third-quarter-2026-results-on-november-3-2026 EINDHOVEN, The Netherlands, Oct. 27, 2026 — ONWARD Medical N.V. (Euronext: ONWD – US ADR: ONWRY), the leading neurotechnology company pioneering therapies to restore movement, function, and independence in people with spinal cord injury and other movement disabilities, today announced that it will release its third-quarter 2026 financial results and host a webcast … Continue reading "ONWARD Medical to Announce Third-Quarter 2026 Results on November 3, 2026" ———————————————————————————————————————————————————————————— Ebola survivor clinics strengthen the Ebola response in the Democratic Republic of the Congo 2026-10-27 · APO Group · Healthcare, Government & policy https://who-africa.africa-newsroom.com/press/ebola-survivor-clinics-strengthen-the-ebola-response-in-the-democratic-republic-of-the-congo?lang=en Leaving an Ebola treatment centre (ETC) does not mark the end of a patient’s care journey. In Bunia, the capital of Ituri Province, the survivor clinic takes over from treatment centres to support survivors through to the completion of their physical and psychological recovery. Beyond medical care, these clinics provide spaces for listening, support and assistance with social reintegration. “We cannot have a successful response without a survivor clinic,” says Dr Huguette Mbuyi Musadi, a member of the Ministry of Health’s survivor identification and follow-up pillar. For her, medical recovery alone is not enough. Since the beginning of the outbreak, more than 2700 people have been declared cured and require post-recovery medical follow-up. “When a survivor comes to the clinic, we examine them from head to toe to check whether they have any disorders or associated conditions, such as diabetes or hypertension. Above all, however, we must manage the aftereffects linked to Ebola,” she says. The effects of Ebola can take different forms, including joint pain, chronic fatigue, neurological disorders, particularly memory difficulties, as well as psychological manifestations such as stress and irritability. “As a survivor, I can say that forgetfulness is common. You may forget something today and only remember it two days later. Then there is irritability and a great deal of stress,” says Ganisikalé, an Ebola survivor. To manage Ebola-related conditions even after recovery, the Ministry of Health, in collaboration with the World Health Organization (WHO) and with support from UN’s Central Emergency Fund and the UK government, established its first survivor clinic in Bunia, the epicentre of the outbreak. Operational since 19 September 2026, the clinic had provided care to more than 400 Ebola survivors. A second survivor clinic was established in Beni, North Kivu Province and has been receiving survivors since 17 October 2026. Beyond health services, the clinics provide an environment where survivors can speak openly about their challenges and receive support to overcome stigma within their communities. These medical facilities are a natural continuation of the care provided by ETCs. “Once patients leave the ETC, they may experience physical as well as psychological complications and we are here to provide comprehensive care,” says Dr Roland Kasamaga, Coordinator of the Bunia Survivor Clinic. “Without these clinics, the consequences could be severe. The aftereffects can impact a person throughout their life. It is important for survivors to continue receiving care so that their health and well-being can be restored comprehensively and over the long term.” Another crucial role of the clinics is biological surveillance. The Ebola virus can persist in certain bodily fluids, particularly semen, for months after recovery. If survivors are not monitored, there could be a resurgence of the disease or a relapse. A survivor’s care at the clinic includes consultations in general medicine, psychology and nutrition, as well as laboratory tests. The process takes an average of two hours. At the pharmacy, the final stage of the care process, nurse Elisée Mbusi emphasizes the importance of taking medication correctly and adopting preventive measures. “We provide condoms to men because studies have shown that the virus can remain in semen for a long time. If a survivor continues to engage in unprotected sexual activity, they expose their partner to risk,” she says. For WHO, survivor clinics serve two key objectives. “First, they help prevent the resurgence of the disease within the community from people who have already recovered. Second, they address the physical, psychological and nutritional conditions experienced by survivors and provide holistic support that meets their needs,” explains Dr Brys Busanga, WHO focal person for survivor follow-up. “Without survivor follow-up, the response is incomplete. That is why WHO integrates this component into the response, so that the package of interventions is complete.” Beyond healthcare, survivor clinics also play a community mobilization role. Aimée, a survivor who has become a community mobilizer, explains how she encourages survivors to attend the clinic. “We have a list of survivors and we call them to inform them about the clinic and invite them to come for follow-up consultations. We also tell them that transport costs will be reimbursed,” she explains. The strategy is proving successful. More than 90% of the survivors who are contacted attend their follow-up appointments. Christian Buna, an Ebola survivor, was contacted by Aimée and visited the clinic two days later. “I was declared cured several months ago. I came for a follow-up check-up. I was told that everything is fine, but that I should continue with follow-up care,” he says. “I was listened to and reassured. I am truly satisfied with the work of the health workers. This clinic is extremely important.” Christian has committed himself to mobilizing other survivors to attend regular follow-up consultations. “I will encourage others to come for their check-ups because it is important to understand and monitor your physical and mental condition after such an ordeal,” he says. The Ebola response does not end at the doors of ETCs. Survivor follow-up clinics extend these efforts by ensuring biological surveillance, managing long-term health effects, combating stigma and strengthening community mobilization. They serve as a reminder that recovery is not only a medical victory, but also a process of human and social reconstruction. In these spaces, survivors become active participants in the response, bearers of hope and living proof that resilience is possible in the face of Ebola. The clinics embody a new dimension of the response. “When you go to another hospital, you feel ashamed to say that you are an Ebola survivor. Here, we are free to talk about anything and everything,” says Ganisikalé. “In our clinic, I feel comfortable. It really helps us.” Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— The Respiratory Biologics Market Is Projected to Grow at a 15.9% CAGR Through 2030 2026-10-27 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/951818611/the-respiratory-biologics-market-is-projected-to-grow-at-a-15-9-cagr-through-2030 Respiratory Biologics Market Respiratory Biologics Market Report Respiratory Biologics Market Analysis The Business Research Company’s The Respiratory Biologics Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 27, 2026 / EINPresswire.com / -- The respiratory biologics market is rapidly evolving, driven by advances in targeted therapies and increas ———————————————————————————————————————————————————————————— World News in Brief: Ethiopians flee to Kenya amidst renewed conflict, new head of UN’s food programme, United Nations' (UN) mission in Somalia concludes 2026-10-27 · APO Group · Healthcare, Food & drink, Government & policy, Agriculture https://www.africa-newsroom.com/press/world-news-in-brief-ethiopians-flee-to-kenya-amidst-renewed-conflict-new-head-of-uns-food-programme-un-mission-in-somalia-concludes?lang=en Around 36,600 people have fled into northern Kenya following an uptick in fighting on the Ethiopian side of the border.  That’s according to the UN migration agency, IOM.  Forces from the Somali and Oromia regions in Southern Ethiopia have been fighting for over two decades over boundary demarcations and resources, with recent escalations since last week sparking a new wave of displacement.  Amongst those who fled, nearly 11,000 have sought sanctuary within the large compound of the Oriental Mission Church (OMC), a prominent Korean-American Christian organisation based in Los Angeles, which does missionary and humanitarian work in Kenya, said IOM. Community support The remaining 25,600 people are being hosted by communities along the border.  IOM is working with the Kenyan government and the UN refugee agency, UNHCR, to collect and manage displacement data, as well as assess humanitarian needs.  So far it has identified needs for water and sanitation, shelter and essential household items, food assistance, health support and protection. It also stresses the need to pay special attention to the needs of host communities, who are accommodating most of the displaced, despite already limited resources. Lindberg takes helm at WFP with call to end famine Luke J. Lindberg took office as Executive Director of the UN World Food Programme (WFP) on Monday, calling on donors, partners and supporters worldwide to help sustain the agency’s life-saving work. “Conflict is driving people into hunger, and extreme weather and maritime choke points exacerbate this reality,” Mr. Lindberg said.  “We cannot do it alone. Governments, institutions, businesses, and individuals need to stand with us, fund the work, and help get food to people before it’s too late. No more famines.” Millions in need As many as 266 million people faced acute hunger worldwide last year, with conflict driving the most severe crises. WFP teams currently operate in 83 countries. Mr. Lindberg succeeds Cindy McCain, who led WFP from April 2023 to May 2026, and Carl Skau, who has served as Acting Executive Director since June. He previously served as Under Secretary for Trade and Foreign Agricultural Affairs at the US Department of Agriculture. Somalia takes the lead as UN mission bows out after three decades The UN’s political mission in Somalia will close on Saturday, ending more than three decades of UN missions in the country supporting peace, state-building and reconciliation.​ The UN Transitional Assistance Mission in Somalia (UNTMIS) completes its two-year mandate on 31 October.  The Security Council has decided not to renew it, at the request of the Somali Government, which wants to take greater ownership of its own peacebuilding and state-building. The mission’s work will pass to Somali institutions and to the UN agencies, funds and programmes already operating in the country. Tribute to those who served Secretary-General António Guterres praised the progress made over the decades and thanked those who made it possible, in particular his successive Special Representatives and the mission’s staff. He also paid tribute to UN personnel who lost their lives while serving in Somalia. Mr. Guterres acknowledged that Somalia still faces serious political, security, humanitarian and development challenges, and called on the international community to keep up its support so that the gains made are not lost. That means pushing forward with inclusive political dialogue and reconciliation, building stronger institutions, protecting human rights and confronting Al Shabaab, the Somalia-based terrorist group affiliated with al-Qaeda. Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— IX at IPVS 2026: Listening to Global Voices, Partnering to Advance HPV Prevention 2026-10-27 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/ix-at-ipvs-2026-listening-to-global-voices-partnering-to-advance-hpv-prevention-302920324.html ATHENS, Greece, Oct. 27, 2026 -- Xiamen Innovax Biotech Co., Ltd. (IX) participated in the 38th Annual Conference of the International Papillomavirus Society (IPVS 2026), held in Athens, Greece, from October 22 to 25, joining global experts and partners to exchange scientific... ———————————————————————————————————————————————————————————— Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories 2026-10-27 · PressReach · SaaS, Healthcare, Medical devices https://pressreach.com/roche-receives-ce-mark-for-cobas-smart-e-immunoanalyser-completing-a-portfolio-that-brings-central-lab-precision-to-healthcare-settings-ranging-from-small-clinics-to-large-hospital-laboratories The cobas smart e immunoanalyser – the newest addition to Roche’s industry-leading cobas immunoassay systems portfolio – is engineered to deliver central-lab performance in a footprint under one square metre.  With a planned menu of over 100 high-medical-value assays, and reaction times of 18 minutes or less for more than 90% of tests, the platform … Continue reading "Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories" ———————————————————————————————————————————————————————————— Ebola: United Nations (UN) officials condemn killing of nurse in Democratic Republic of the (DR) Congo 2026-10-27 · APO Group · Healthcare https://www.africa-newsroom.com/press/ebola-united-nations-un-officials-condemn-killing-of-nurse-in-democratic-republic-of-the-dr-congo?lang=en The nurse was killed by protesters in Bafwasende, a rural town in Tshopo province, on Saturday while responding to an Ebola alert.  A health worker was also severely injured in the attack and remains in hospital.  Call for probe  Julien Harneis, UN Senior Ebola Response Coordinator, issued a statement extending condolences to the nurse’s family and colleagues.  “I strongly condemn this attack and call for a thorough investigation,” he said. “I urge communities to protect health workers and allow them to carry out their work safely”.  The WHO Director-General, Tedros Adhanom Ghebreyesus, expressed his condolences in a post on social media.  He also wished a swift and full recovery to the injured health worker.  “Everyone working to protect communities from this deadly disease must be able to work in dignity and safety,” he wrote on X. “Healthcare must always be protected.”  Historic outbreak  The deadly incident occurred amid ongoing efforts to contain the spread of Ebola disease caused by Bundibugyo virus for which there currently is no approved vaccine.  More than 9,760 cases and some 4,727 deaths have been recorded in the DRC since the outbreak was declared on 15 May, according to recent WHO figures.  The outbreak is the deadliest in the country’s history.  It was first reported in the volatile eastern region and has now reached eight provinces: Bas-Uélé, Haut-Uélé, Ituri, North Kivu, South Kivu, Sud Ubangi, Tshopo and Nord-Ubangi.  Uganda also confronted a smaller Ebola outbreak which was declared defeated in August, while France, Kenya and Nigeria have reported cases.  ‘Remarkable achievement’ in Nigeria  Nigeria confirmed its first case last week – a woman who had travelled from Uganda.    She and a contact, who is her husband, were medically evacuated to Switzerland on Monday morning, WHO said, explaining that both are Swiss citizens and that the patient is clinically stable.   “The Nigerian medical team successfully managed her through the acute phase of the illness and stabilized her condition,” the WHO regional director for Africa, Dr. Mohamed Janabi, wrote on X.  ‘Vigilance remains critical’  He congratulated the Nigerian Government, health workers, clinicians, emergency responders and all those involved in the response.  “This is a remarkable achievement and a testament to what Africa can accomplish when we work together,” he said.  Dr. Janabi noted that the evacuation means Nigeria currently has no Ebola cases, “however, vigilance remains critical”.  Nigeria will continue to monitor 52 contacts, he said, while Switzerland will assume responsibility for the patient’s continued care and follow-up of her husband.  Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— Breast Cancer Awareness 2026: Office of the Economic Community of West African States (ECOWAS) Resident Representative and the ECOWAS Stabilisation Support Mission in Guinea-Bissau Champion Awareness Campaign 2026-10-27 · APO Group · Healthcare https://www.africa-newsroom.com/press/breast-cancer-awareness-2026-office-of-the-economic-community-of-west-african-states-ecowas-resident-representative-and-the-ecowas-stabilisation-support-mission-in-guineabissau-champion-awareness-campaign?lang=en The Office of the Resident Representative of President of ECOWAS Commission in collaboration with the troops of ECOWAS Stabilisation Support Mission in Guinea-Bissau (ESSMGB), on Thursday, 22nd October 2026, conducted a breast cancer awareness campaign at Kwame Nkrumah Secondary School Bissau, Guinea-Bissau, as part of activities marking the Breast Cancer Awareness Month 2026. The campaign, themed “Every Story Matters; Every Journey Is Unique,” was aimed at raising public awareness on breast cancer, promoting early detection and encouraging preventive health practices as part of efforts to strengthen civil-military relations and improve community health awareness. In her remarks, the Special Guest of Honour, the ECOWAS Resident Representative of the President and Head of Mission in Guinea-Bissau, Ambassador Ngozi Ukaeje, expressed delight at participating in the campaign and commended her Office and other  organisers for their commitment to promoting public health awareness. Ambassador Ukaeje noted that breast cancer remains a major public health concern worldwide but stressed that early detection significantly improves the chances of successful treatment. She urged women to seek prompt medical attention if they notice unusual lumps, changes in breast shape or skin, or abnormal nipple discharge. The Head of Mission further expressed appreciation to the dignitaries, the Force Commander, contingent commanders, staff officers, and other stakeholders for their contributions to the success of the campaign. She particularly commended GHANCOY 5 for taking the lead in organising the initiative and ensuring its successful execution. While delivering the opening remarks earlier, the Force Commander ECOWAS Stabilisation Support Mission in Guinea-Bissau, Brigadier General Danjuma Ribah Dantani, emphasised the importance of regular medical check-ups and early detection in the effective management of breast cancer. He encouraged women to visit healthcare facilities for routine examinations and highlighted the importance of awareness, healthy eating, regular physical exercise and limiting alcohol consumption in promoting overall health. Stating the purpose of the event, the Gender Advisor of the ECOWAS Representation Office, Dr Aisha Yanet, emphasised that the gathering underscored the importance of sustained awareness and community engagement in addressing breast cancer. This was followed by a sensitisation lecture delivered by the Senior Medical Officer of GHANCOY 5, Major Sylvester Alhassan. During the lecture, Major Alhassan provided an overview of breast cancer, including its nature, signs and symptoms, risk factors, prevention and available treatment options. He explained that breast cancer can affect both women and men and encouraged military personnel, students, and members of the public to prioritise breast health, regular medical examinations, and timely access to healthcare. Delivering brief remarks also, the representative of the Minister for Education, Helda Durate Batica, emphasised on the significance of the awareness, noting that Guinea-Bissau government was appreciative of the kind gesture by the Resident Representative of President of ECOWAS Commission and ECOWAS Stabilisation Support Mission in Guinea-Bissau. The campaign featured an interactive questions-and-answers session, the distribution of breast cancer awareness materials to female students and group photographs. The event was attended by members of the diplomatic corps, representative of the minister of education Guinea-Bissau, heads  of departments and agencies,  ESSMGB personnel, students and members of civil society organisations The initiative underscores the commitment of the ECOWAS Representation Office and ECOWAS Stabilisation Support Mission in Guinea-Bissau in promoting public health awareness, strengthening civil-military relations, and supporting community-centre engagement in Guinea-Bissau Distributed by APO Group on behalf of Economic Community of West African States (ECOWAS). ———————————————————————————————————————————————————————————— Intermountain Health Groundbreaking on a New Era of Children’s Health for Nevada 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388695/0/en/intermountain-health-groundbreaking-on-a-new-era-of-children-s-health-for-nevada.html Nevada’s first stand-alone children’s hospital groundbreaking marks the community-wide effort to build a stronger pediatric health system. Nevada’s first stand-alone children’s hospital groundbreaking marks the community-wide effort to build a stronger pediatric health system. ———————————————————————————————————————————————————————————— Innate Pharma: PACIFIC-9 Phase 3 Trial Readout Timing Updated to H1 2027 2026-10-27 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/innate-pharma-pacific-9-phase-060000335.html PACIFIC-9 Phase 3 trial led by AstraZeneca evaluates durvalumab in combination with monalizumab or oleclumab in unresectable Stage III NSCLC MARSEILLE, France, October 27, 2026--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced that AstraZ ———————————————————————————————————————————————————————————— ABIONYX Pharma Finalizes the Structuring of Its CER-001 Bioproduction Chain Through a Strategic Partnership with AXPLORA, Marking a Major Milestone Toward Its Potential Commercialization 2026-10-27 · Business Wire · Healthcare, Industrial, Biotech & pharma https://finance.yahoo.com/healthcare/articles/abionyx-pharma-finalizes-structuring-cer-060000740.html An end-to-end manufacturing process for the purification of recombinant human apoA-I has now been finalized with AXPLORA A decisive step toward potential first-in-class commercialization An infrastructure based on the production of a single natural protein, supporting two value creation pathways: regulatory support for ma ———————————————————————————————————————————————————————————— Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs 2026-10-27 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/27/3388690/0/en/basilea-raises-full-year-guidance-2026-and-financial-target-for-agenda-2030-and-provides-updates-on-late-stage-clinical-programs.html Ad hoc announcement pursuant to Art. 53 LR ———————————————————————————————————————————————————————————— New Documentary “The Long Way To Me” Explores Advances in Breast Cancer Reconstruction 2026-10-27 · EIN Presswire · Healthcare, Entertainment https://www.einpresswire.com/article/952499197/new-documentary-the-long-way-to-me-explores-advances-in-breast-cancer-reconstruction Documentary Cover Image Dr. Kamakshi Zeidler The Long Way To Me follows one woman’s breast cancer journey, highlighting advances in reconstruction, medical innovation, and renewed confidence. If I hadn’t gotten that first mammogram, I could have gone years without knowing I had cancer.” — Bethany, Documentary Participant SAN FRANCISCO, CA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- The Long Way To Me fol ———————————————————————————————————————————————————————————— Holi Health Massage Publishes Licence Details for All Branches as It Standardizes Traditional Thai Jap Kasai 2026-10-27 · PR Now · Healthcare, Government & policy https://pressreleasenews.org/pressroom/holi-health-massage-publishes-licence-details-for-all-branches-as-it-standardizes-traditional-thai-jap-kasai-2 On October 24, 2026, Holi Health Massage, a traditional Thai massage brand with branches in Bangkok, Pattaya and Chiang Mai and a franchise partner store in Phuket, published the government licence number, registered name, registered address and licensed floor area of each of its… ———————————————————————————————————————————————————————————— Singmed Wraps Up ALLPACK Indonesia 2026, Connecting Global Markets Through Device Innovation and Precision Engineering 2026-10-27 · PR Now · Healthcare, Industrial, Biotech & pharma, Consumer electronics, Medical devices https://pressreleasenews.org/pressroom/singmed-wraps-up-allpack-indonesia-2026-connecting-global-markets-through-device-innovation-and-precision-engineering-2 ALLPACK Indonesia 2026 has concluded. At the exhibition, Suzhou Singmed Medical Device Science and Technology Ltd. (Singmed) showcased its technical expertise and manufacturing capabilities in advanced pharmaceutical packaging, drug delivery systems, and wearable medical devices.… ———————————————————————————————————————————————————————————— Innovation Defender: GIHOMO Fortifies Hyperbaric Oxygen Chamber Brand Moat with IP & Compliance 2026-10-27 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952482995/innovation-defender-gihomo-fortifies-hyperbaric-oxygen-chamber-brand-moat-with-ip-compliance GUANGDONG GIHOMO MEDICAL TECHNOLOGY CO., LTD. Conveying a Professional, Stable and Sustainable Medical Equipment Brand Image to Global Clients CALIFORNIA, CA, UNITED STATES, October 27, 2026 / EINPresswire.com / -- China, October 27, 2026 — GUANGDONG GIHOMO MEDICAL TECHNOLOGY CO., LTD., a manufacturer of hard shell and portable hyperbaric oxygen chambers based in Shunde district, Foshan, Guangdong province, has set o ———————————————————————————————————————————————————————————— Grass-Fed Milk Market Analysis: Emerging Consumer Preferences and Industry Shifts 2026-10-27 · PR News Releaser · Healthcare, Retail https://www.prnewsreleaser.com/news/479011 The greens powder market is experiencing significant growth as consumers increasingly prioritize health, wellness, and preventive nutrition. Greens powder products, which typically include concentrated blends of vegetables, fruits, algae, grasses, herbs, and superfoods, have gained widespread popularity among health-conscious consumers ... Read more ———————————————————————————————————————————————————————————— Grass-Fed Milk Market Trends: Health, Sustainability, and Premiumization 2026-10-27 · PR News Releaser · Healthcare, Food & drink, Sustainability, Agriculture https://www.prnewsreleaser.com/news/479009 The grass-fed milk market is gaining significant momentum as consumers increasingly prioritize natural, nutritious, and sustainably produced dairy products. Growing awareness regarding the benefits associated with pasture-raised dairy cattle has encouraged consumers to shift toward premium milk alternatives that align ... Read more ———————————————————————————————————————————————————————————— Fortune India Exchange Features Guntur Neurosurgeon Dr. Mohana Rao Patibandla in October 2026 Profile 2026-10-27 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950738472/fortune-india-exchange-features-guntur-neurosurgeon-dr-mohana-rao-patibandla-in-october-2026-profile Dr. Mohana Rao Patibandla, Founder and Chief Neurosurgeon of Dr. Rao’s Hospital – International Institute of Neurosciences (IIN), Guntur, featured in Fortune India Exchange’s October 2026 “Trusted Brands & Leaders” section, in the profile “Building a Glob Dr. Mohana Rao Patibandla featured in Fortune India Exchange’s October 2026 “Trusted Brands & Leaders” section, with the profile “Building a Global Neuroscience Ins ———————————————————————————————————————————————————————————— Frost & Sullivan Released the 2026 Global Gene Therapy Industry Development Blue Book 2026-10-27 · MarketersMEDIA · Healthcare, Industrial, Biotech & pharma https://news.marketersmedia.com/frost-and-sullivan-released-the-2026-global-gene-therapy-industry-development-blue-book/89207470 -- Frost & Sullivan officially released the 2026 Global Gene Therapy Industry Development Blue Book in October 2026, in collaboration with industry partners. The report systematically examines the industry’s development history, core technology classifications, policy and capital market dynamics, upstream and downstream value chains, bottlenecks in viral vector manufacturing, clinical progress across key indications, ———————————————————————————————————————————————————————————— Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm 2026-10-27 · GlobeNewswire · Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/27/3388668/9788/en/bronstein-gewirtz-grossman-llc-urges-hims-hers-health-inc-investors-to-act-class-action-filed-alleging-investor-harm.html New class action for Hims & Hers (HIMS) urges investors to seek recovery for alleged securities fraud violations – lead plaintiff deadline of 11/1/2026 ———————————————————————————————————————————————————————————— MedTech Innovator Asia Pacific Names Ardens Lifescience 2026 Grand Prize Winner 2026-10-27 · Business Wire · Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/medtech-innovator-asia-pacific-names-021500154.html South Korea medical technology company developing a transbronchial RF ablation system with a conforming electrode for peripheral lung cancer awarded USD 175,000 Grand Prize at the 2026 MedTech Innovator Asia Pacific Showcase & Grand Finals in Singapore LOS ANGELES & SINGAPORE, October 27, 2026--MedTec ———————————————————————————————————————————————————————————— The 21st Eco Expo Asia Opens Today 2026-10-27 · NewMediaWire · SaaS, Healthcare, Energy, Automotive, Education, Travel, Food & drink, Fashion & luxury, Industrial, Aerospace & defense, Sustainability, Banking, Government & policy, Jobs & workplace, Marketing & advertising, Entertainment, Construction & engineering https://www.newmediawire.com/news/the-21st-eco-expo-asia-opens-today-7090871 More Than 340 Exhibitors Showcase Global Green Technologies With Over 80 Leaders From Government, Industry and Academia Exploring Business Opportunities HONG KONG - October 26, 2026 - The 21st Eco Expo Asia 2026, jointly organised by the Hong Kong Trade Development Council (HKTDC) and Messe Frankfurt (HK) Ltd and co-organised by the Environment and Ecology Bureau of the Government of the Hong Kong Special Administrative Region (HKSAR), opens today for a four-day run (26 to 29 October) at AsiaWorld-Expo. Held under the theme 'Connecting the World for a Sustainable Future', this year's Expo brings together over 340 exhibitors from 15 countries and regions. Some 200 senior officials and representatives of semi-official organisations from the Chinese Mainland, Hong Kong, Belt and Road and ASEAN countries will attend, further strengthening international exchange and ties. HKTDC Executive Director Sophia Chong said: "Hong Kong's first Five-Year Plan and the latest Policy Address both call for building a green and liveable city, to inject fresh momentum into the development of the green sector. As an important green trade platform in the region, Eco Expo Asia gathers innovative green technologies, products and solutions from around the world, fostering exchange and cooperation among governments, businesses, investors and research institutions. International participation has also grown this year, with Indonesia, Laos, the Philippines, Thailand and Vietnam joining for the first time. Through the Expo, we hope to harness Hong Kong's strengths as an international business centre and smart green technology hub, promoting cross-region collaboration and enabling enterprises to enter new markets and unlock fresh opportunities." Tse Chin-wan, Secretary for Environment and Ecology, said, "The nation embarks on its 15th Five-Year Plan, and the HKSAR's first Five-Year Plan proactively aligns with national development strategies, with green transformation and development of a green and liveable city as its key directions. Hong Kong will continue to leverage its roles of "super connector" and a "super value-adder" to foster regional and international green cooperation. In this year's Expo, the Environment and Ecology Bureau and the Ministry of Ecology and Environment jointly organise the Belt and Road Green Innovation Conference in Hong Kong on 26 October for the first time. Holding the two events concurrently fully harnesses the synergy. I am sure the Expo will inspire innovation and open up business collaboration opportunity, giving fresh impetus to a sustainable green future!” The Eco Expo Asia welcome ceremony will be held tomorrow (27 October). Tse Chin-wan, Secretary for Environment and Ecology, Sophia Chong, HKTDC Executive Director, and Jack Wong, Deputy General Manager of Messe Frankfurt (HK) Ltd, among other guests, will attend the ceremony. Pavilions gather participants from home and abroad, HKSAR Government booth debuts green living experiences The number of pavilions at this year's Expo has risen to 18. The new ASEAN Pavilion brings together seven ASEAN countries, namely Singapore, Laos, Malaysia, the Philippines, Indonesia, Thailand and Vietnam, with 12 green technology ventures presenting innovative solutions in water treatment, circular economy, green finance and ESG services, green building and environmental products. Several overseas pavilions also make a return, including Canada, Italy, Korea and the Netherlands. On the Chinese Mainland front, Qinghai Province makes its first appearance, while nine Greater Bay Area cities and Macau, Guangxi, Hunan, Shanghai and Nanjing of Jiangsu Province will also participate. On the Hong Kong front, the Hong Kong Science and Technology Parks Corporation leads 11 local start-ups to showcase various energy solutions. The Hong Kong Pavilion, supported by the Environmental Protection Department and coordinated by the Federation of Hong Kong Industries, gathers 19 local companies, while the Environmental Campaign Committee brings 22 start-ups together to demonstrate homegrown green innovations and drive their practical application. The HKSAR Government booth, formed by the Environment and Ecology Bureau, the Environmental Protection Department and nine other government departments, introduces a new comprehensive experience zone for green technology organised around four themes. "Green Flat" is built with sustainable building technologies and materials to illustrate sustainable living concepts, while "Green Match", "Green Cooperation" and "Green Innovation" foster collaboration among green enterprises and open up opportunities in the low-carbon economy. Leveraging Hong Kong’s professional services to support Chinese Mainland green enterprises in going global As a member of the "GoGlobal Task Force", the HKTDC has set up a GoGlobal Connect Zone for the first time at the Expo, to support Chinese Mainland environmental enterprises in reaching international markets through Hong Kong’s professional services. Today, the Expo hosts an "Experience Sharing Forum on Promoting Environmental Business in Overseas Markets". Sharing its story is Hunan exhibitor Lihe Technology, which signed a memorandum of understanding with a delegation from the Republic of Kazakhstan during the Expo last year. The session also features government officials from Belt and Road countries, together with representatives of InvestHK and several Chinese Mainland environmental enterprises, who explore how to tap Hong Kong’s advantages to go global. An ASEAN networking reception follows the session to connect green enterprises with the ASEAN region. Tomorrow (27 October), the organiser will stage a "GoGlobal Seminar", bringing together representatives of industrial parks in Malaysia and Thailand, the Bank of China (Hong Kong) and the Hong Kong Accreditation Service to discuss how Hong Kong can integrate international green finance, cross-border infrastructure expertise, global certification standards and strategic industrial park partnerships to build a comprehensive ecosystem that accelerates the expansion of Chinese Mainland green enterprises into the ASEAN market. Four thematic areas aligning with latest decarbonisation policies as frontier green technologies take the stage Green transformation is increasingly becoming a defining force in the market. The State Council of the People's Republic of China formally issued the action plan for carbon peaking during the 15th Five-Year Plan period this July, setting out comprehensive arrangements for the country's decarbonisation efforts over the next five years. On the Hong Kong front, the city's first Five-Year Plan also sets the green transformation direction for various industries, while the Policy Address 2026 goes further with concrete measures spanning zero-carbon energy, hydrogen energy, green transport, waste reduction and recycling. In line with these trends, this year's Expo centres on four areas: "Green Energy in Motion", "Frontier Green Tech", "Building for a Greener City" and "From Waste to Worth", keeping pace with the latest policy directions. Under "Green Energy in Motion", this year's Expo features green energy solutions spanning the maritime, land transport and aviation sectors. Making its debut, EcoCeres Limited (Booth: 3-F30), the world's second largest sustainable aviation fuel (SAF) producer, showcases SAF and hydrotreated vegetable oil (HVO) produced from waste feedstocks, in response to the HKSAR Government's call to build an SAF value chain. The Hong Kong Science and Technology Parks Pavilion (Booth: 3-E02) brings the slimmest wall-mounted DC Fast EV charger currently on the market, developed by TriTerra Technology Limited. The area of "Frontier Green Tech" features about 30 start-ups and university spin-offs. The Chinese University of Hong Kong (Booth: 3-G25) showcases high-strength bacterial cellulose films upcycled from tea waste. Being strong, flexible, and water-resistant, the material can serve as sustainable packaging or even a next-generation bio-based leather. Lingnan University (Booth: 3-F26) presents various newly developed technologies and products, among them a fleet management system combining AIoT with GeoAI technology to cut traffic delays and boost the overall operational efficiency of public and commercial transport fleets. Under "Building for a Greener City", Hyper-Tech Environmental Limited (Booth: 6-E28) showcases Oizom, the IoT-driven environmental monitoring system, whose patented active-sampling technology helps monitor pollutant and noise levels in support of smart city development. Umwelt Consulting Limited (Booth: 6-C19) brings its InvisQuiet Acoustic Window and Acoustic Balcony, which use the windowpane itself as a noise barrier to ease environmental noise while taking up less indoor space and consuming fewer materials. For "From Waste to Worth", Chongqing Sanfeng Environment Group Corp., Ltd. (Booth: 3-D30) brings its waste-to-energy projects, with technologies and equipment already deployed in the Chinese Mainland and 10 other countries. Baguio Green Technology Limited (Booth: 3-D29) demonstrates a Smart Waste Management Solution that integrates smart recycling equipment, IoT technology and a big data platform to track recycling data and streamline analysis, easing the burden of ESG reporting for businesses. Over 80 government, industry and academic leaders discuss policy, technology and green business opportunities This year's events are organised into four themed days aligned with the Expo's focus areas, featuring more than 30 forums and thematic sessions that bring together over 80 government officials and industry leaders from the Chinese Mainland, Australia, Malaysia, Thailand and other Belt and Road countries. The flagship event, the Eco Asia Conference, explores green development from multiple perspectives, spanning policy, technology, green finance, green building and industry applications. Various prominent industry leaders and experts will share their insights in person, including Ar Clarence Leung, Council Member and Chairperson of the Committee on Environment and Sustainability of the Construction Industry Council, Ir Kenny Wong, Director of Business Development & Projects - Hong Kong of ALBA Group Asia, and Henry Ho, Head of Sustainability of China State Construction Engineering (HK) Limited. One session of the Eco Asia Conference took place today, featuring Prof Su Hui, Department of Civil and Environmental Engineering of HKUST, who led the development of the Multi-Spectral Imaging Carbon Observatory (MUSICO). MUSICO was installed on China's Tiangong Space Station this year, and at the session she shared its practice and applications. Joined by Prof Kenneth Leung, Director of the State Key Laboratory of Marine Environmental Health at CityUHK, they also discussed extreme climate monitoring technologies. Tomorrow (27 October) will also feature multiple events, including the government session of the Eco Asia Conference. An official from the Chinese Mainland and a representative of United Nations Environment Programme will share their respective environmental policy updates. There is also a panel discussion with a number of officials and experts holding in-depth exchanges on the advancement of innovative technologies for the building of the Green Silk Road. The Government Department Forum will gather representatives from the Environmental Protection Department, the Civil Aviation Department, the Civil Engineering and Development Department, the Electrical & Mechanical Services Department and the Water Supplies Department to brief the industry on government procurement needs, thereby advancing the application of environmental solutions and driving green opportunities. On the same day, the Startup Edge Exhibitor Forum will invite start-ups from different environmental fields to share their experiences. Local university representatives will also explain how green technologies move from the laboratory to the market. Other highlights include the 7th Hydrogen Economy Forum on 28 October, at which Eddie Cheung, JP, Permanent Secretary for Environment and Ecology (Environment), will deliver a keynote speech. Experts including Ir Sammy Kong, General Manager of Commercial & Industrial Marketing & Sales at The Hong Kong and China Gas Company Limited, and Thomas Lui, Director of Decarbonisation and Integrated System Planning at CLP Power Hong Kong Limited, will then discuss the application of green fuels and energy storage technologies in Hong Kong. The final day of the Expo (29 October) will be Public Day, with free admission for the public, aiming to deepen public understanding of sustainability and to encourage the adoption of green lifestyles. A series of interactive environmental workshops and talks will be held that day. Speakers include representatives of the Hong Kong Observatory and the Asia Circular Economy Association, as well as Leung Wing Mo, former Assistant Director of the Hong Kong Observatory, who will discuss hot topics such as extreme heat and climate change with the public. Prof Karen Cheung, President of the UNESCO Hong Kong Association, together with representatives from Lingnan University and others, will host a Career Forum to share the prospects and trends of the green job market, encouraging talents to seize career opportunities in the green industry. In addition, Ways Out Hong Kong, a local social enterprise, will share its story of upcycling food waste into jewellery. Other concurrent fairs The Hong Kong International Outdoor and Tech Light Expo runs concurrently with Eco Expo Asia (26 to 29 October) at AsiaWorld-Expo, showcasing a wide range of outdoor and professional technical lighting solutions for commercial and industrial use. Meanwhile, the Hong Kong International Lighting Fair (Autumn Edition) will run for four days from tomorrow (27 to 30 October) at the Hong Kong Convention and Exhibition Centre. Free shuttle bus services are offered between these venues and other locations in the city throughout the fair period. Please refer to the following page for details: https://www.hktdc.com/event/ecoexpoasia/en/travel-to-fairground-awe Website: Eco Expo Asia – https://www.hktdc.com/event/ecoexpoasia/en Photo Download:  https://bit.ly/4kfc7ca Media enquiries: For enquiries, please contact: HKTDC Communication and Public Affairs Department: Christy Lee Tel: (852) 2584 4369 Email: christy.wn.lee@hktdc.org Dawn Yuen Tel: (852) 2584 4575 Email: dawn.nh.yuen@hktdc.org Jane Cheung Tel: (852) 2584 4137 Email: jane.mh.cheung@hktdc.org HKTDC Mediaroom: https://mediaroom.hktdc.com/ About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Follow us on @hktdc and LinkedIn About Messe Frankfurt The Messe Frankfurt Group is the world's largest trade fair, congress and event organiser with its own exhibition grounds. With a workforce of some 2,700 people at its headquarters in Frankfurt am Main and in 29 subsidiaries, it organises events around the world. Group sales in financial year 2025 were about EUR 766 million. We serve our customers' business interests efficiently within the framework of our Fairs & Events, Locations and Services business fields. One of Messe Frankfurt's key strengths is its powerful and closely knit global sales network, which covers around 180 countries in all regions of the world. Our comprehensive range of services - both onsite and online - ensures that customers worldwide enjoy consistently high quality and flexibility when planning, organising and running their events. Messe Frankfurt develops new business models based on its digital expertise. Its range of services encompasses venue rental as well as exhibition stand construction, marketing services, staffing services, and catering. Sustainability is a central pillar of our corporate strategy. Maintaining a balance between environmental and economic responsibility, social responsibility, and diversity lies at the heart of its approach. For more information, please visit our website at: www.messefrankfurt.com/sustainability With its headquarters in Frankfurt am Main, the company is owned by the City of Frankfurt (60 percent) and the State of Hesse (40 percent). For more information, please visit our website at: www.messefrankfurt.com ———————————————————————————————————————————————————————————— Elite365 Family of Brands Ranked No. 32 Among Largest Allied Healthcare Staffing Agencies in the U.S. 2026-10-27 · PRWeb · Healthcare, Travel, Jobs & workplace https://www.prweb.com/releases/elite365-family-of-brands-ranked-no-32-among-largest-allied-healthcare-staffing-agencies-in-the-us-302890080.html This recognition is a result of the organization's growth in allied health staffing led by Ashley Eagon, Senior Vice President of Elite365's travel division IRVING, Texas and TAMPA, Fla., Oct. 26, 2026 -- Elite365 Family of Brands ('Elite365'), a leading national... ———————————————————————————————————————————————————————————— Micot Pharma Showcases First-in-Class, Brain-Penetrant TrkB Agonist MT200605 at World Stroke Congress, Building the Case for Global Partnerships and Commercialization 2026-10-27 · ScoopAsia · Healthcare, Biotech & pharma, Government & policy https://scoopasia.com/micot-pharma-showcases-first-in-class-brain-penetrant-trkb-agonist-mt200605-at-world-stroke-congress-building-the-case-for-global-partnerships-and-commercialization/ Micot Pharma (HKEX: 2335) presented its in-house neuroprotective drug candidate MT200605 in an oral presentation at the 18th World Stroke Congress (WSC 2026), held in Seoul, South Korea, on October 21-23, 2026. The presentation covered the candidate's mechanism of action, preclinical findings and Phase I data from China and the United States. ———————————————————————————————————————————————————————————— The Adult Vaccines Market is projected to expand at a 9.5% CAGR, reaching a value of $62.74 billion by 2030. 2026-10-27 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/951771105/the-adult-vaccines-market-is-projected-to-expand-at-a-9-5-cagr-reaching-a-value-of-62-74-billion-by-2030 Adult Vaccines Market Adult Vaccines Market Report Adult Vaccines Market Analysis The Business Research Company’s The Adult Vaccines Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 27, 2026 / EINPresswire.com / -- The adult vaccines market is experiencing remarkable growth as global health priorities increasingly emphasize preventive care for mat ———————————————————————————————————————————————————————————— Cizzle Brands Accelerates U.S. National Exchange Listing Strategy to Drive Institutional Growth and Unlock Shareholder Value 2026-10-27 · Business Wire · Healthcare, Gaming, Sports, Investing & markets https://finance.yahoo.com/markets/stocks/articles/cizzle-brands-accelerates-u-national-003000571.html TORONTO, October 27, 2026--Cizzle Brands Corporation (Cboe Canada: CZZL; OTCQB: CZZLF; Frankfurt: 8YF) (" Cizzle Brands " or the " Company "), the vertically integrated sports nutrition company that is elevating the game in health and wellness, today announced a milestone in its capital markets expansi ———————————————————————————————————————————————————————————— Owl and Jest Releases -How to Deal With Your Disappointingly Small Penis,- a New Parody Self-Help Book 2026-10-27 · 1888 Press Release · Healthcare https://www.1888pressrelease.com/owl-and-jest-releases-how-to-deal-with-your-disappointingly-pr-773603.html The independent publisher's new adult humor book combines questionable medical advice and deadpan comedy, making it an unusual addition to the world of gag gifts and funny Christmas books. ———————————————————————————————————————————————————————————— AimedBio and Boehringer Ingelheim initiate Phase I study of antibody-drug conjugate BI 4060107 2026-10-27 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/aimedbio-boehringer-ingelheim-initiate-phase-000000351.html First patient dosed in first-in-human study evaluating BI 4060107 in people with advanced solid tumors Clinical development milestone triggers a payment to AimedBio under the companies' 2025 global licensing agreement SEOUL, South Korea, October 27, 2026--AimedBio today announced that the first patien ———————————————————————————————————————————————————————————— Florida Handicap Parking Placards: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-27 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977273/florida-handicap-parking-placards-handicapmd-explains-online-medical-certification-and-eligibility Florida handicap placard guidance explains HSMV 83039, medical certification, and government application steps. Clear Florida guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott TALLAHASSEE, FL, UNITED STATES, October 26, 2026 / EINPresswire.com / -- HandicapMD is highlighting Florida disabled parking permit guidan ———————————————————————————————————————————————————————————— Save the Date: HUTCHMED to Host Expert Insights Event on Recent Savolitinib Clinical Data in Non-Small Cell Lung Cancer 2026-10-27 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Banking, Government & policy https://www.globenewswire.com/news-release/2026/10/27/3388651/0/en/save-the-date-hutchmed-to-host-expert-insights-event-on-recent-savolitinib-clinical-data-in-non-small-cell-lung-cancer.html HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 26, 2026 -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces an expert webcast, co-hosted with Citigroup Global Markets Asia Limited (“Citigroup”) for analysts and investors, to discuss recent Phase III clinical data for savolitinib in MET-driven non-small cell lung cancer (“NSCLC”) recently presented at the European Society for Medical Oncology (ESMO) Congress 2026. This virtual webcast will take place on Thursday, November 5, 2026, at 4:30 pm HKT / 8:30 am GMT / 3:30 am EST. ———————————————————————————————————————————————————————————— Albany Dental Associates Helps Patients Compare Dental Implants, Implant Dentures and Bridges 2026-10-26 · PR Now · Healthcare, Medical devices https://pressreleasenews.org/pressroom/albany-dental-associates-helps-patients-compare-dental-implants-implant-dentures-and-bridges With 1,500+ dental implants placed yearly, Albany Dental Associates explains how a single tooth implant or implant denture fits each patient. ———————————————————————————————————————————————————————————— TMS Raleigh Opens Dedicated Clinic Offering FDA-Cleared TMS Therapy in Raleigh, NC. 2026-10-26 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/tms-raleigh-opens-dedicated-clinic-offering-fda-cleared-tms-therapy-in-raleigh-nc/89207371 New clinic opening gives patients access to new treatment options for depression, OCD, and other mental health conditions. -- TMS Raleigh has just announced the opening of its new clinic that specializes in FDA-cleared TMS therapy in Raleigh, NC . The clinic itself is open at 7780 Brier Creek Parkway, Suite 307, Raleigh, NC 27617 and is already accepting patients. It will provide services for a range of mental health ———————————————————————————————————————————————————————————— MNA: Berkshire VNA Nurses and Healthcare Professionals Deliver Petition Calling for a Fair Union Contract to Strengthen Patient Access to Home Care 2026-10-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/mna-berkshire-vna-nurses-and-healthcare-professionals-deliver-petition-calling-for-a-fair-union-contract-to-strengthen-patient-access-to-home-care-302919989.html While there has been bargaining progress on early-career wages, clinicians are urging BVNA to invest in experienced staff to support safe patient care PITTSFIELD, Mass., Oct. 26, 2026 -- Berkshire Visiting Nurse Association (BVNA) nurses and healthcare professionals,... ———————————————————————————————————————————————————————————— London West Aesthetics Introduces the Matrix® Skin Renewal Platform: A Revolutionary Approach to Skin Health 2026-10-26 · EIN Presswire · SaaS, Healthcare, Nonprofits https://www.einpresswire.com/article/952435386/london-west-aesthetics-introduces-the-matrix-skin-renewal-platform-a-revolutionary-approach-to-skin-health Houston day spa adds the Candela Matrix® platform, combining RF microneedling, fractional resurfacing and bulk heating in one treatment. The Candela Matrix RF lets us deliver precise collagen renewal for texture and fine lines, backed by medical oversight and a truly personalized plan.” — Shaunie Charity, Founder & Licensed Aesthetician HOUSTON, TX, UNITED STATES, October 26, 2026 / EINPresswire.com / -- London West ———————————————————————————————————————————————————————————— From the Lab to the Ballot: Leading Scientists Rally Behind Proposition 38 2026-10-26 · EIN Presswire · Finance, Healthcare, Government & policy https://www.einpresswire.com/article/952402660/from-the-lab-to-the-ballot-leading-scientists-rally-behind-proposition-38 With federal funding cuts putting medical research at universities at risk, CA scientists say Prop 38 will bring us closer to life-saving treatments and cures Prop 38 is a critical investment in the people who make life-saving and innovative research possible. It means we can keep California at the forefront of medical discoveries, treatments, and cures.” — Julia Falo-Sanjuan, Assistant Project Scientist at UC Berkel ———————————————————————————————————————————————————————————— Essential Oils Market Size to Reach $29.52 Bn by 2031 Amid Growing Demand for Aromatherapy and Pharmaceutical Applications, Says Mordor Intelligence 2026-10-26 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/essential-oils-market-size-to-reach-29-52-bn-by-2031-amid-growing-demand-for-aromatherapy-and-pharmaceutical-applications-says-mordor-intelligence-302919670.html HYDERABAD, India, Oct. 26, 2026 -- According to Mordor Intelligence, the essential oils market size is estimated to increase to $20.08 billion in 2026 before reaching $29.52 billion by 2031, registering a CAGR of 8.10% during 2026–2031. Growing awareness of mental health is... ———————————————————————————————————————————————————————————— GFM.News Publishes Judy Chu Profile on Policy, Public Service and Recovery 2026-10-26 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/952418535/gfm-news-publishes-judy-chu-profile-on-policy-public-service-and-recovery Official portrait of U.S. Representative Judy Chu, photographed May 2, 2019. In 2009, she became the first Chinese American woman elected to Congress. Photo: Eric Connolly, House Creative Services. The U.S. House Ways and Means Committee holds a hearing on health coverage for people with preexisting conditions on January 29, 2019. Archival photograph. Photo: U.S. House of Representatives, Office of David Schweikert. ———————————————————————————————————————————————————————————— Post University Announces New Academic Programs 2026-10-26 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/post-university-announces-new-academic-programs-302919971.html New undergraduate and graduate offerings expand academic options in technology, health sciences and behavioral sciences WATERBURY, Conn., Oct. 26, 2026 -- Post University launched seven new undergraduate and graduate degree programs, expanding opportunities for students to... ———————————————————————————————————————————————————————————— Kos Biotechnology Partners Announces Strategic Investment in Golden Age Health to Accelerate Global Access to Rare Disease Therapies 2026-10-26 · PR Newswire · Healthcare, Biotech & pharma, Investing & markets https://www.prnewswire.com/news-releases/kos-biotechnology-partners-announces-strategic-investment-in-golden-age-health-to-accelerate-global-access-to-rare-disease-therapies-302919963.html Golden Age Health is co-founded and chaired by Michel Vounatsos, former Biogen CEO and Merck President NEW YORK and ATHENS, Greece and SINGAPORE, Oct. 26, 2026 -- Kos Biotechnology Partners ("Kos"), a global life sciences investment firm bridging the U.S. and European... ———————————————————————————————————————————————————————————— Heath Insurance Agent in Dallas Addresses Coverage Gaps After Job Loss 2026-10-26 · MarketersMEDIA · Healthcare, Insurance https://news.marketersmedia.com/heath-insurance-agent-in-dallas-addresses-coverage-gaps-after-job-loss/89207451 Losing employer-sponsored coverage creates healthcare challenges for older workers. Exploring Dallas Health Insurance options, including employer continuation plans, marketplace policies, and alternative arrangements, can help unemployed individuals maintain essential medical protection while managing financial uncertainty. -- Heath Insurance Agent in Dallas can be a valuable resource for older workers seeking altern ———————————————————————————————————————————————————————————— GeoVax Enters Into $1 Million Revolving Loan Agreement 2026-10-26 · NewMediaWire · Finance, Healthcare, Real estate, Industrial, Biotech & pharma, Banking https://www.newmediawire.com/news/geovax-enters-into-1-million-revolving-loan-agreement-7090868 ATLANTA, GA - October 26, 2026 - GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing vaccines and immunotherapies for infectious diseases and cancer, today announced that it has entered into an unsecured $1,000,000 Revolving Loan Agreement dated October 23, 2026 (the “Revolving Loan Agreement”) with Bowery Consulting Group Inc. (the “Lender”). The revolving loan facility provides for advances of up to $1,000,000 (the “Revolving Loan”), with any advances subject to the Lender’s approval. The Revolving Loan bears interest at a rate of 12% per annum and matures 12 months from issuance. The Revolving Loan Agreement contains customary representations and warranties, indemnification provisions, and conditions precedent to borrowing. On October 23, 2026, Randal Chase, Dean Kollintzas, Nicole Lemerond, Jayne Morgan and John Spencer, Jr. resigned as directors of the Company, and Steven Brown, Tyler O’Brien and Manpreet Uppal were appointed as directors of the Company. Each of the newly appointed directors was nominated by the Lender pursuant to the Revolving Loan Agreement. Following these changes, the Company’s Board of Directors consists of five directors. The newly appointed directors will serve until the earlier of the repayment in full of the Revolving Loan and their resignation pursuant to the terms set forth in the Revolving Loan Agreement. The Board has determined that each of the newly appointed directors meet the independence standards of the Securities and Exchange Commission and Nasdaq. Following their appointment, Mr. O’Brien and Mr. Uppal will join the Audit Committee together with Dr. Robert McNally. David A. Dodd, Chairman and Chief Executive Officer of GeoVax, commented, “Securing this financing is an important achievement for GeoVax, reinforcing our balance sheet and providing the working capital needed to support our operations. I am pleased to welcome Steven, Tyler and Manpreet to our Board. Their diverse experience and strong leadership will bring fresh perspectives and valuable guidance as we continue to advance our GEO-MVA clinical program forward to what we believe will be an expedited pathway to commercialization. I would also like to express my deep appreciation to the departing Board members for their dedication and meaningful contributions to GeoVax’s journey. With strong leadership in place and a clear strategic path forward, we believe GeoVax is entering an exciting new chapter of growth and opportunity.” Further information concerning the Revolving Loan Agreement and the newly appointed directors of the Company will be contained in the Form 8-K to be filed with the Securities and Exchange Commission.  This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About GeoVax GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in late 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com. Forward-Looking Statements  This release contains forward-looking statements regarding GeoVax’s business plans, the Revolving Loan Agreement and the availability of advances thereunder,. and the timing and outcome of its clinical development and regulatory activities. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, GeoVax is able to regain and maintain compliance with Nasdaq continued listing requirements, the timing of initiation and completion of the GEO-MVA Phase 3 trial and of any EMA marketing authorization, GeoVax's ability to continue as a going concern, the Lender permits GeoVax to draw down any portion of the loan commitment, which is subject to the Lender’s sole and absolute discretion, and whether the loan commitment is terminated, GeoVax is able to generate sufficient cash flow or raise additional capital to service, repay or refinance its indebtedness on acceptable terms or at all, GeoVax is able to comply with the covenants and other obligations in the Revolving Loan Agreement, including obtaining the Lender’s consent where required, an event of default occurs that results in the acceleration of GeoVax’s indebtedness or the exercise of other remedies by the Lender, GeoVax’s level of indebtedness limits its financial flexibility, operations or ability to pursue its business strategy or obtain additional financing, and other factors, over which GeoVax has no control. Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Company Contact: info@geovax.com 678-384-7220 Media Contact: Jessica Starman media@geovax.com ———————————————————————————————————————————————————————————— CERo Therapeutics Announces Activation of the University of California, Davis as a Clinical Trial Site for the Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies 2026-10-26 · GlobeNewswire · Healthcare, Education, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388614/0/en/cero-therapeutics-announces-activation-of-the-university-of-california-davis-as-a-clinical-trial-site-for-the-ongoing-phase-1-certain-t-trial-of-cer-1236-in-hematologic-malignancie.html SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, today announced that the University of California, Davis (UC Davis), has been activated as a clinical trial site for CERTAIN-T, the Company's ongoing Phase 1 study evaluating CER-1236 in patients with hematologic malignancies. UC Davis also serves as the primary manufacturing site for CER-1236. ———————————————————————————————————————————————————————————— Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform 2026-10-26 · GlobeNewswire · SaaS, Healthcare, Automotive, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388603/0/en/octane-biotech-and-currus-biologics-automate-manufacturing-of-cur-001-car-t-cell-therapy-on-the-cocoon-platform.html Octane Biotech and Currus Biologics Automate Manufacturing of CUR-001 CAR T-Cell Therapy on the Cocoon® Platform ———————————————————————————————————————————————————————————— Onco360® Has Been Selected as a National Pharmacy Partner for ZEGFROVY® (sunvozertinib) 2026-10-26 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388600/0/en/onco360-has-been-selected-as-a-national-pharmacy-partner-for-zegfrovy-sunvozertinib.html LOUISVILLE, Ky., Oct. 26, 2026 -- Onco360®, the nation’s leading independent Specialty Pharmacy, has been selected as a national pharmacy partner by AstraZeneca Pharmaceuticals for Zegfrovy® (sunvozertinib), which is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose disease has progressed on or after platinum-based chemotherapy.1 ———————————————————————————————————————————————————————————— Aptar Pharma Acquires Pulmotree, Expanding Growth Opportunities in Next-Generation Pulmonary Drug Delivery 2026-10-26 · Business Wire · Finance, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/aptar-pharma-acquires-pulmotree-expanding-210000722.html Acquisition is expected to accelerate development and commercialization of Kolibri™ and expand Aptar Pharma's respiratory drug delivery platform CRYSTAL LAKE, Ill., October 26, 2026--Aptar Pharma, a global leader in drug delivery, dosing, protection technologies and services, today announced the strate ———————————————————————————————————————————————————————————— United Medical and Aesthetics Introduces the Matrix® Skin Renewal Platform: A Revolutionary Approach to Skin Health 2026-10-26 · EIN Presswire · SaaS, Healthcare, Energy, Education https://www.einpresswire.com/article/952423201/united-medical-and-aesthetics-introduces-the-matrix-skin-renewal-platform-a-revolutionary-approach-to-skin-health Wilmington, NC med spa adds the Candela Matrix® platform, combining RF microneedling, fractional resurfacing and bulk heating in one treatment. Safety, results and education guide how new technology is added to the practice. Matrix offers a way to treat texture, tone and laxity with energy delivery that is monitored in real time.” — Aleta Sloan WILMINGTON, NY, UNITED STATES, October 26, 2026 / EINPresswire.com / -- U ———————————————————————————————————————————————————————————— Bronwyn Brophy O'Connor to Become CEO of Carl Zeiss Meditec Group in December 2026 2026-10-26 · NewMediaWire · Finance, Healthcare, Energy, Retail, Education, Industrial, Semiconductors, Investing & markets, Marketing & advertising, Medical devices https://www.newmediawire.com/news/bronwyn-brophy-o-connor-to-become-ceo-of-carl-zeiss-meditec-group-in-december-2026-7090864 International Medtech Executive Brings Extensive Experience in Customer-focused Innovation and Business Transformation JENA and OBERKOCHEN, GERMANY - October 26, 2026 - Bronwyn Brophy O’Connor, currently CEO of the Vitrolife Group in Sweden, will take over as CEO of Carl Zeiss Meditec AG on December 1, 2026. On the same date, she will join the Executive Board of Carl Zeiss AG with responsibility for the Medical Technology segment. Her appointment as successor to current CEO Andreas Pecher had been first announced in May 2026. With the start date now confirmed, she will assume leadership of Carl Zeiss Meditec Group from Andreas Pecher, who has served as interim CEO since January 1, 2026. “I am delighted to join Carl Zeiss Meditec and the ZEISS Group. The company combines deep scientific expertise, close customer relationships and a strong commitment to improving patient care. I look forward to working with our teams and customers to build on these strengths, advance innovation and successfully shape the next stage of the company’s transformation,” said Bronwyn Brophy O’Connor. "With Bronwyn Brophy O’Connor, Carl Zeiss Meditec is gaining an internationally experienced medtech executive who will bring a strong customer and innovation perspective to the company. We wish her a great start,“ said Peter Kameritsch, Chairman of the Supervisory Board of Carl Zeiss Meditec AG. "We would like to thank Andreas Pecher, both for his temporary dual role as CEO of the ZEISS Group and interim CEO of Carl Zeiss Meditec AG, and for providing important momentum during this period. With her excellent skills, Bronwyn Brophy O’Connor will now be able to further advance the strategy and transformation of the Medical Technology segment forward and contribute to the success of the ZEISS Group,” said Dr. Michael Bolle, Chairman of the Supervisory Board of Carl Zeiss AG. Effective December 1, 2026, the Management Board of Carl Zeiss Meditec AG will comprise Bronwyn Brophy O’Connor as CEO and Justus Wehmer as CFO. The Executive Board of Carl Zeiss AG will comprise Andreas Pecher (President and CEO), Stefan Müller (CFO), Bronwyn Brophy O’Connor (Head of the ZEISS Medical Technology segment), Sven Hermann (Head of the ZEISS Consumer Markets segment), Dr. Frank Rohmund (Head of the ZEISS Semiconductor Manufacturing Technology segment), and Dr. Marc Wawerla (Head of the ZEISS Industrial Quality & Research segment). Short profiles: Bronwyn Brophy O’Connor studied at Dublin City University in Ireland. After earning a bachelor’s degree in International Marketing and Languages (Spanish and French), she completed her Master of Business Administration in 2002. She started her career at Johnson & Johnson in 1997, serving in roles of increasing seniority and ending her career there as General Manager of the Cardiovascular Care Group for the U.K. & Ireland in 2012. Bronwyn then joined Covidien, which was later acquired by Medtronic to form the largest medtech company globally. From 2013 until 2018, she first served as Vice President Early Technologies EMEA and later as President Women’s Health at Medtronic in Boston, USA. In 2019, Bronwyn joined Thermo Fisher Scientific as President for the EMEA region and one year later was promoted to Global President of the Immunodiagnostics Division in Uppsala, Sweden. She has worked internationally, including in Ireland, Spain, the U.K., Switzerland, Sweden and the U.S. Since 2023, Bronwyn Brophy O’Connor has been CEO of the Vitrolife Group, a global medtech company publicly listed on the NASDAQ Stockholm and headquartered in Gothenburg, Sweden. Andreas Pecher studied physics at the University of Würzburg, Germany, and the University of Texas at Austin, USA. He earned a Master of Business Administration (MBA) at the Kellogg School of Management as well as a Master of Engineering Management at the McCormick School of Engineering. He began his career at Motorola (today NXP) in Texas, USA, in 1998. After completing his MBA in 2005, Andreas Pecher worked as a project manager at McKinsey & Company in Germany. Starting in 2010, he headed the Strategy and Business Development department at the solar company Renewable Energy Corporation in Oslo, Norway, and Munich, Germany. In 2013, Andreas Pecher joined the ZEISS Semiconductor Manufacturing Technology (SMT) segment as Head of Strategic Business Development in Oberkochen, Germany. In 2015, he became Head of the Semiconductor Mask Solutions strategic business unit (SMS SBU) and, starting in 2017, headed the Semiconductor Manufacturing Optics strategic business unit. In 2022, Andreas Pecher became Head of the ZEISS SMT segment and was simultaneously appointed a Member of the Executive Board of Carl Zeiss AG. He was named President and CEO of Carl Zeiss AG effective April 1, 2025. In this role, he also took on the interim position as CEO of the publicly listed Carl Zeiss Meditec AG on January 1, 2026, becoming Head of the Medical Technology segment. Contact for investors and the press Sebastian Frericks Head of Group Finance & Investor Relations Carl Zeiss Meditec AG Phone: +49 3641 220-116 Email: investors.med@zeiss.com www.zeiss.com/newsroom About Carl Zeiss Meditec AG Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the TecDAX and SDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With 5,784 employees worldwide, the Group generated revenue of EUR 2,228m in fiscal year 2024/25 (to 30 September). The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 39 percent of Carl Zeiss Meditec AG’s shares are in free float. Approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. For more information visit our website at www.zeiss.com/med ———————————————————————————————————————————————————————————— Expanding Urgent Care in Southeastern San Diego 2026-10-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/expanding-urgent-care-in-southeastern-san-diego-302919901.html New San Ysidro Health Urgent Care Center will expand access to timely, high-quality care closer to home and work SAN DIEGO, Oct. 26, 2026 -- Blue Shield of California Promise Health Plan announced a $1 million community investment to support the new San Ysidro Health... ———————————————————————————————————————————————————————————— Marvin Smoot Named Chief Executive Officer of Missouri Valley Regional Medical Center 2026-10-26 · Newswire.com · Healthcare https://www.newswire.com/news/marvin-smoot-named-chief-executive-officer-of-missouri-valley-regional-medical Experienced healthcare executive to lead continued growth, operational excellence, and expanded access to care across the region. ———————————————————————————————————————————————————————————— Viromed Medical AG: Successful Completion of Capital Increase 2026-10-26 · NewMediaWire · Finance, Healthcare, Investing & markets https://www.newmediawire.com/news/viromed-medical-ag-successful-completion-of-capital-increase-7090862 RELLINGEN, GERMANY - October 26, 2026 - Viromed Medical AG ("Viromed"; ISIN: DE000A40ZVN7) has successfully completed the capital increase announced today. A total of 450,000 new registered no-par value shares were placed at a placement price of EUR 4.50 per share. The gross proceeds amount to approximately EUR 2 million and will be used to finance the company's working capital. Subject to the registration of the implementation of the capital increase in the commercial register, the share capital will increase from EUR 21,250,000 by EUR 450,000 to EUR 21,700,000. The capital increase was carried out by partially utilizing the Authorized Capital 2025 and with the exclusion of the shareholders' subscription rights.  About Viromed Medical AG Viromed Medical AG specializes in the development, manufacture and distribution of medical products. The operating business of the company, which has been listed on the stock exchange since October 2022, focuses on the distribution of innovative cold plasma technology for medical applications via its wholly owned subsidiary Viromed Medical GmbH. Viromed can draw on a broad customer base in the DACH region and beyond. Viromed is pursuing the goal of further advancing the use of cold plasma technology in medicine in the coming years and realizing the corresponding growth potential. www.viromed-medical-ag.de Contact Viromed E-Mail: kontakt@viromed-medical.de Press contact E-mail: viromed@kirchhoff.de ———————————————————————————————————————————————————————————— PolyPeptide Announces Results of the Extraordinary General Meeting of Shareholders 2026-10-26 · NewMediaWire · Healthcare, Industrial, Biotech & pharma, Marketing & advertising https://www.newmediawire.com/news/polypeptide-announces-results-of-the-extraordinary-general-meeting-of-shareholders-7090861 BAAR, SWITZERLAND - October 26, 2026 - PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, announced that the shareholders approved all proposals by its board of directors (the "Board") at today's extraordinary general meeting of shareholders. In particular, the shareholders elected John Chongbo Rim, Seungho Ryu, Cheol Woo Ryu, Mihyun Yang and Joonkyung Seong as members of the Board for a term of office ending at the conclusion of the next annual general meeting. John Chongbo Rim was elected as chair of the Board, and Cheol Woo Ryu and Seungho Ryu were elected as members of the Remuneration and Nomination Committee, in each case for a term of office ending at the conclusion of the next annual general meeting. All elections are subject to and effective as of the settlement of the public tender offer by Samsung Peptide AG, a wholly owned subsidiary of Samsung Biologics Co., Ltd., for all publicly held registered shares of PolyPeptide. The shareholders also resolved, subject to the satisfaction or waiver of all of the offer conditions set forth in the offer prospectus of Samsung Peptide AG dated 31 August 2026 (the "Offer Prospectus"), other than the offer condition set forth in section B.7.1(e) of the Offer Prospectus, to remove from the articles of association of PolyPeptide the transfer restrictions (Vinkulierung) and the voting limitations (Stimmrechtsbeschränkungen). Contact PolyPeptide Group AG    Strategic Marketing and Corporate Communications Laura Rosso     mediateam@polypeptide.com T: +41 43 502 0580 PolyPeptide Group AG  Finance / Investor Relations Tim Brandl investorrelations@polypeptide.com  T: +41 43 502 0580  About PolyPeptide PolyPeptide Group AG and its consolidated subsidiaries ("PolyPeptide") is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide's shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com. @PolyPeptide - follow us on LinkedIn Forward-looking Information and Statements This media release has been prepared by PolyPeptide Group AG and contains certain forward-looking statements that reflect the current views of management. Such statements are subject to known and unknown risks, uncertainties and other factors that may cause actual developments to differ materially from those expressed or implied in this release. PolyPeptide Group AG is providing the information in this release as of this date and, except as required by applicable laws or regulations, does not undertake any obligation to update any statements contained in it as a result of new information, future events or otherwise. File: PolyPeptide_EGM Results 2026_ENG ———————————————————————————————————————————————————————————— Arcus Biosciences Announces New Employment Inducement Grants 2026-10-26 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/arcus-biosciences-announces-employment-inducement-203500538.html HAYWARD, Calif., October 26, 2026--Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for the treatment of cancer and immune diseases, today announced that the Compensation Committee of the Com ———————————————————————————————————————————————————————————— Lycia Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares 2026-10-26 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Insurance https://www.globenewswire.com/news-release/2026/10/26/3388557/0/en/lycia-therapeutics-announces-closing-of-upsized-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares.html SOUTH SAN FRANCISCO, Calif., Oct. 26, 2026 -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the closing of its upsized initial public offering of 20,286,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 2,646,000 additional shares, at the initial public offering price of $18.00 per share. The aggregate gross proceeds to Lycia from the initial public offering, before deducting underwriting discounts and commissions and other offering expenses, were approximately $365.1 million. All of the shares of common stock were offered by Lycia. Lycia’s common stock began trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol “LYCA.” ———————————————————————————————————————————————————————————— Franklin County Office of Justice Policy and Programs (OJPP), the Franklin County Sheriff's Office and Armor Health highlight early Jail Population Review initiative results. 2026-10-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/franklin-county-office-of-justice-policy-and-programs-ojpp-the-franklin-county-sheriffs-office-and-armor-health-highlight-early-jail-population-review-initiative-results-302919842.html COLUMBUS, Ohio, Oct. 26, 2026 -- Armor Health (Armorhealthcare.com), a leading provider of integrated correctional healthcare, in partnership with Franklin County, Ohio, the Franklin County Sheriff's Office, and the Franklin County Office of Justice Policy and Programs,... ———————————————————————————————————————————————————————————— Clover Health to Participate in Upcoming UBS Global Healthcare Conference 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3388535/0/en/clover-health-to-participate-in-upcoming-ubs-global-healthcare-conference.html Clover Health to Participate in Upcoming UBS Global Healthcare Conference ———————————————————————————————————————————————————————————— Wisconsin Handicap Parking Placards: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-26 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977258/wisconsin-handicap-parking-placards-handicapmd-explains-online-medical-certification-and-eligibility Wisconsin handicap placard guidance explains MV2548 or MV2933, medical certification, and government application steps. Clear Wisconsin guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott MADISON, WI, UNITED STATES, October 26, 2026 / EINPresswire.com / -- HandicapMD is highlighting Wisconsin disability parking per ———————————————————————————————————————————————————————————— Western Slope Health Center Expands Rehabilitation Options With Smart Therapy™ 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/948253941/western-slope-health-center-expands-rehabilitation-options-with-smart-therapy Skilled nursing and rehabilitation team brings immersive therapy into treatment with an emphasis on patient engagement and flexible seated participation WESTERN SLOPE HEALTH CENTER, CA, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Western Slope Health Center , a PACS-supported skilled nursing and rehabilitation facility in Placerville, California, has introduced Smart Therapy ™ as an additional tool for it ———————————————————————————————————————————————————————————— Rippon Capital and Monzo Bank Founder Paul Rippon Backs Laser On Tour 2026-10-26 · Pressat · Finance, AI, SaaS, Healthcare, Energy, Retail, Banking, Payments & fintech, Marketing & advertising, Mining & metals https://pressat.co.uk/releases/rippon-capital-and-monzo-bank-founder-paul-rippon-backs-laser-on-tour-703a1626af02750dc4ce3c85cdb03d40/ Monday 26 October, 2026 Paul Rippon has backed Laser On Tour after being impressed by its founders, technology-enabled business model and ambition to create hundreds of successful female entrepreneurs across the UK. HERTFORDSHIRE, UK, Laser On Tour, the home-visiting laser clinic platform, has secured backing from Paul and Debbie Rippon as the company expands across the UK with plans to create more than 400 female-owned businesses over the next three years. Paul Rippon, founder of Rippon Capital and Monzo Bank, has spent much of his career building and backing high-growth technology businesses. While most of his investment experience has been in fintech, Laser On Tour stood out for a different reason: its founders. Having met founder Neda Namin and co-founder Sacha Bright several times, Paul was particularly struck by Neda's energy, ambition and determination to build the business at scale. After discussing the opportunity with Debbie, the Rippons decided to back Laser On Tour and its ambition to help hundreds of women establish successful businesses of their own. Founded by Neda Namin, Laser On Tour is changing the traditional laser clinic model by bringing professional laser treatments directly into clients' homes. Its platform combines specialist practitioner training, portable laser technology, AI-powered client acquisition, clinical governance, marketing, payments and ongoing business support. This enables practitioners to establish and grow their own businesses without the cost and risk associated with opening a traditional clinic. Paul Rippon, founder of Rippon Capital and Monzo Bank, said: "Neda blew me away. "I've spent quite a bit of time with Neda and Sacha now, and you occasionally meet a founder where the energy, ambition and absolute determination to make something happen are immediately obvious. Neda is one of those people. "I came away from our early meetings incredibly impressed by what they are trying to build. I talked it through with Debbie, who was very supportive of us backing them. "Most of my investing experience has been in fintech, but ultimately I back people. Great founders spot opportunities that other people don't see and then have the drive to make them happen. "Laser On Tour is much more interesting than simply putting laser equipment into people's homes. They are using technology, AI, training and infrastructure to create a platform that can help other people build successful businesses. "If they get this right, they can create hundreds, perhaps eventually thousands, of female entrepreneurs. That's a big commercial opportunity, but it can also have a genuinely positive impact on people's lives. That's exactly the sort of combination Debbie and I like backing." The investment sits outside Rippon Capital, but Paul sees a clear connection with what he is building there, backing exceptional founders with the ambition to create category-defining businesses. "Rippon Capital will remain heavily focused on fintech, but I've never believed great entrepreneurs only exist in one sector," Paul added. "Neda is a great example of that. When you meet exceptional founders doing something genuinely different, you pay attention. Laser On Tour certainly got mine." Laser On Tour's model also reflects a wider change in consumer behaviour, with more professional services increasingly being delivered conveniently in people's homes. Rather than simply supplying equipment, Laser On Tour provides much of the infrastructure needed to establish and operate a business, including training, technology, customer acquisition, compliance, clinical governance and ongoing support. Neda Namin, Founder of Laser On Tour, said: "Having Paul and Debbie believe in what we're building means a huge amount to me. "From the beginning, our ambition has been much bigger than laser hair removal. We want to create an opportunity for women to build successful, independent businesses with the technology, training and support behind them to succeed. "Paul has built and backed businesses at enormous scale, so having his experience and support around us as we grow is incredibly valuable." Sacha Bright, Co-founder of Laser On Tour, added: "Paul immediately understood that Laser On Tour is both a commercial opportunity and a platform for creating entrepreneurs. "We're already exploring how fintech innovation could make it easier for future entrepreneurs to access the funding they need to start and grow a Laser On Tour business. "Removing that barrier could enable many more women to become successful business owners, and having Paul's experience, network and strategic thinking alongside us as we explore that opportunity is hugely valuable." About Laser On Tour Laser On Tour is a home-visiting laser clinic platform specialising in laser hair removal utilising portable laser technology, AI-powered client acquisition, specialist practitioner training, clinical governance and an integrated business platform. The company enables entrepreneurs to establish and grow their own laser clinic businesses while delivering professional treatments directly in clients' homes. Laser On Tour is expanding across the UK and plans to help create more than 400 female-owned businesses over the next three years. ———————————————————————————————————————————————————————————— R3 Stem Cell Research Team Publishes Review of Umbilical Cord-Derived Stem Cells for Arthritis 2026-10-26 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/952412298/r3-stem-cell-research-team-publishes-review-of-umbilical-cord-derived-stem-cells-for-arthritis Researchers from R3 Medical Research and R3 Stem Cell have published a peer-reviewed narrative review on Arthritis in the journal titled Regenerative Therapy. Data from emerging preclinical and clinical trials on stem cell therapy for arthritis have shown significant improvements in pain relief and function improvements with minimal adverse effects” — David Greene, MD, PhD, MBA SCOTTSDALE, AZ, UNITED STATES, October ———————————————————————————————————————————————————————————— Certified Sewer & Drain of North Jersey Proves Sewer Video Inspections Show Damage in Old Pipes Over 50% of the Time 2026-10-26 · EIN Presswire · Healthcare, Media https://www.einpresswire.com/article/947787578/certified-sewer-drain-of-north-jersey-proves-sewer-video-inspections-show-damage-in-old-pipes-over-50-of-the-time Certified Sewer & Drain Clifton NJ Over half of all sewer video camera inspections reveal roots or pipe damage, turning the process into a tool for evaluating overall pipe health. Even if a sewer line is still carrying wastewater, underground deterioration can occur unnoticed; video inspections reveal the underlying condition before it leads to major, costly repairs.” — Certified Sewer & Drain Spokesperson CLIFTON, N ———————————————————————————————————————————————————————————— Ethiopia: H.E. Ambassador Eshete Tilahun meets with Mr. Francesco Di Lillo, Director of European Union and International Office of The Church of Jesus Christ of Latter-day Saints 2026-10-26 · APO Group · Healthcare, Food & drink, Agriculture https://www.africa-newsroom.com/press/ethiopia-he-ambassador-eshete-tilahun-meets-with-mr-francesco-di-lillo-director-of-european-union-and-international-office-of-the-church-of-jesus-christ-of-latterday-saints?lang=en H.E. Ambassador Eshete Tilahun meets with Mr. Francesco Di Lillo, Director of European Union and International Office of The Church of Jesus Christ of Latter-day Saints Ambassador Eshete Tilahun and his team received Mr. Francesco Di Lillo of The Church of Jesus Christ of Latter-day Saints together with accompanying representatives at the Embassy to discuss humanitarian and development activities in Ethiopia. The Church representatives briefed the Ambassador on their ongoing projects, as partner organization involved in irrigation, maternal and newborn health care, vaccination, food security and emergency relief. Ambassador Eshete commended the Church’s contribution to community level development works focusing on the most vulnerable. Looking ahead, the two sides exchanged views on future priorities in the areas of humanitarian assistances, afforestation, irrigation and agriculture. The meeting closed with a shared commitment to deepen cooperation and regular exchanges. Distributed by APO Group on behalf of Embassy of Ethiopia in Brussels. ———————————————————————————————————————————————————————————— U.S. FDA Drops TB Testing Requirement for Skyrizi®, Following NPF Medical Board Guidance 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952407758/u-s-fda-drops-tb-testing-requirement-for-skyrizi-following-npf-medical-board-guidance People no longer need a TB test before starting risankizumab (Skyrizi®), unless their healthcare professional decides one is needed. ALEXANDRIA, VA, UNITED STATES, October 26, 2026 / EINPresswire.com / -- There is one less barrier to care for people living with a range of immune-mediated and autoimmune diseases, thanks to the leadership of the National Psoriasis Foundation (NPF) Medical Board. Last week, the U.S. Foo ———————————————————————————————————————————————————————————— Ethiopia stakeholders chart path forward for stronger hand hygiene systems 2026-10-26 · APO Group · Healthcare, Government & policy, Nonprofits https://who-africa.africa-newsroom.com/press/ethiopia-stakeholders-chart-path-forward-for-stronger-hand-hygiene-systems?lang=en As the world marks Global Handwashing Day, stakeholders in Ethiopia are renewing efforts to strengthen hand hygiene systems as a cornerstone of public health, disease prevention, and emergency preparedness. Government institutions, development partners, civil society organizations, and media representatives gathered in Addis Ababa to review findings from Ethiopia's Hand Hygiene for All (HH4A) Enabling Environment Assessment and identify actions to advance hand hygiene systems across community settings. The national stakeholders' workshop brought together representatives from the Ministry of Health, Ministry of Water and Energy, Ministry of Transport, the World Health Organization (WHO), UNICEF, WaterAid, CARE, World Vision, IRC-WASH, iDE, Water For Good, PSI, media organizations, and other partners. The workshop reviewed progress and challenges in creating an enabling environment for sustainable hand hygiene interventions in households, schools, workplaces, public institutions, and communities. Participants examined findings from the HH4A Enabling Environment Assessment, which evaluates governance, financing, human capacity, and monitoring systems that support hand hygiene implementation. Hand hygiene remains one of the most cost-effective public health interventions, helping prevent infectious diseases and strengthen community resilience. Observed annually on 15 October, Global Handwashing Day serves as a reminder that handwashing with soap is a simple yet powerful practice that can save lives, reduce disease transmission, and improve health outcomes. The workshop highlighted the importance of translating global guidance, including the WHO and UNICEF Guidelines on Hand Hygiene in Community Settings, into practical actions that improve access to handwashing facilities, promote behaviour change, and strengthen national systems. “Hand hygiene is a highly cost-effective way to protect health, and COVID-19 demonstrated that it is a frontline defence in emergency and pandemic response. Yet attention too often fades once the emergency passes. We need sustained political commitment, dedicated financing, and clear accountability to make hand hygiene part of routine planning in every sector.” Waltaji Terfa Kutane, Health and Environment Officer, WHO Ethiopia Through group discussions, participants identified several priority challenges affecting HH4A implementation in Ethiopia. These included inadequate political commitment and prioritization of hand hygiene, weak accountability and leadership ownership, fragmented financing, limited human and institutional capacity, and weak monitoring and information systems. Participants noted that although hand hygiene often receives heightened attention during public health emergencies, sustained investments and routine implementation remain limited. Stakeholders also highlighted the need for stronger multisectoral coordination, improved data systems, dedicated financing mechanisms, clearer accountability arrangements, and setting-specific standards and targets. Poor integration of hand hygiene indicators into monitoring systems, insufficient advocacy, inadequate resource mobilization, and limited technical capacity were identified as key barriers to sustainable progress. To address these challenges, participants recommended a set of priority actions, including high-level advocacy to secure stronger political commitment; integration of hand hygiene into sector plans, budgets, and performance reviews; establishment of clear accountability mechanisms; strengthened domestic resource mobilization; development of dedicated financing and expenditure-tracking systems; enhanced technical and institutional capacity; and improved data collection, analysis, and use for decision-making. The workshop also called for revitalizing existing multisectoral coordination platforms, strengthening collaboration among the health, water, education, and other sectors, and expanding engagement with media and professional associations to sustain awareness and behaviour change efforts. Participants emphasized the importance of developing and disseminating setting-specific standards and targets to ensure consistent implementation across community settings. As a way forward, stakeholders agreed on the need to maintain momentum through continued dialogue, stronger partnerships, and joint resource mobilization efforts. Recommendations from the assessment and workshop discussions will be shared with relevant ministries and decision-makers to support high-level action and implementation of the HH4A roadmap. As Ethiopia commemorates Global Handwashing Day, the workshop underscores the country's commitment to ensuring that hand hygiene remains a national public health priority. Strengthening hand hygiene systems will not only help prevent the spread of infectious diseases but also contribute to healthier communities, improved preparedness for future health emergencies, and progress toward universal access to safe hygiene services for all. Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Twenty contacts of Kenya’s first Ebola case released from quarantine 2026-10-26 · APO Group · Healthcare, Government & policy https://who-africa.africa-newsroom.com/press/twenty-contacts-of-kenyas-first-ebola-case-released-from-quarantine?lang=en Today 20 contacts associated with Kenya’s first imported case of Bundibugyo virus disease were released from quarantine and reunited with their families after completing the mandatory 21-day monitoring period. A total of 98 contacts now remain in quarantine. The contacts discharged today remained asymptomatic during quarantine. They underwent standard protocols, including a final health assessment, counselling on post-discharge precautions and follow-up where required before being released. “We ask communities to welcome them home warmly,” said Dr Patrick Amoth, Director General for Health in Kenya. “Having completed 21 days without symptoms, they pose no risk of infection to anyone.” Following confirmation of the first Ebola case on 6 October 2026, the Ministry of Health conducted robust contact tracing of anyone who may have been exposed. By 22 October, all contacts were traced, both in Kenya and internationally, and placed in quarantine.   As of 26 October 2026, eight contacts had developed symptoms and were confirmed positive for Ebola through laboratory testing. All eight cases were already in quarantine at the time and were immediately transferred to the country’s Ebola treatment centre in Nairobi. In total, Kenya has reported nine confirmed cases and two deaths. All nine cases are part of one connected group and there is no evidence that the virus has spread to the community.   World Health Organization (WHO) continues to support health authorities in Kenya on all aspects of the response, including response coordination, disease surveillance, contact tracing, laboratory testing, case management, infection prevention and control, health screening at points of entry and risk communication and community engagement. “People who complete quarantine have helped protect their families, their communities and the whole country,” said Dr Neema Rusibamayila Kimambo, WHO Representative to Kenya. “WHO commends the Ministry of Health, the Kenya National Public Health Institute, national and county health teams for their work in responding quickly to every new case.” While there is no licensed vaccine or specific treatment for Bundibugyo virus disease, detecting cases early and providing supportive care improves chances of recovery.  WHO advises against travel restrictions and recommends evidence-based public health measures, including entry and exit screening at points of entry, surveillance and contact tracing.   Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Northwell Health’s Constellation Forum 2026 Unites Global Leaders to Accelerate Innovation in Women’s Health 2026-10-26 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/northwell-health-constellation-forum-2026-193200629.html Leaders from Anthropic, Google, WHOOP, National Institutes of Health and U.S. House of Representatives joined scientists, clinicians, investors and policymakers in New York City for a two-day summit dedicated to transforming women's health care NEW HYDE PARK, N.Y., October 26, 2026--Northwell Health's ———————————————————————————————————————————————————————————— SS Innovations International (SSII) Showcases Robotic Telesurgery Capabilities at International Medical Conferences 2026-10-26 · NewMediaWire · Finance, AI, Healthcare, Gaming, Media, Legal, Medical devices https://www.newmediawire.com/news/ss-innovations-international-ssii-showcases-robotic-telesurgery-capabilities-at-international-medical-conferences-7090859 LOS ANGELES, CA - October 26, 2026 - SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced that its SSi Mantra surgical robotic system and SSi MantrAsana tele-surgeon console were featured in successful telesurgeries during two international medical conferences in October 2026. At the European Association for Cardio-Thoracic Surgery (“EACTS”) Annual Meeting in Barcelona, Spain, Chairman and CEO Dr. Sudhir Srivastava performed a robotic-assisted cardiac procedure remotely on a patient in Bengaluru, India, approximately 7,500 miles away. At the Society of Robotic Surgery India (“SRS India”) Conference in New Delhi, four surgeons completed four separate robotic-assisted telesurgeries involving kidney, colorectal, pediatric urological and gynecological procedures. The SSi MantrAsana console is designed to enable real-time remote surgery through ultra-low latency connectivity, high-definition visualization and precise instrument control. As of Oct. 23, 2026, a total of 205 telesurgeries, including complex cardiac procedures, had been performed using the SSi Mantra system. To view the full press release, visit https://ibn.fm/Ujtlm About SS Innovations SS Innovations International, Inc. develops innovative surgical robotic technologies with a vision to make the benefits of robotic surgery affordable and accessible to a larger segment of the global population. The Company’s product range includes its proprietary “SSi Mantra” surgical robotic system and its comprehensive suite of “SSi Mudra” surgical instruments, which support a variety of surgical robotic procedures including cardiac surgery.  Headquartered in India, SS Innovations is a U.S. company focused on expanding the global presence of its technologically advanced, user-friendly, and cost-effective surgical robotic solutions.  Visit the Company’s website at ssinnovations.com or LinkedIn for more information and updates. About the SSi Mantra The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including: 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, a touch panel monitor for all patient related information display, a virtual real-time image of the robotic patient side arm carts, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative to the SSi Mantra’s standard surgeon command center that is intended to provide equivalent control functionality while enabling enhanced portability, ergonomic flexibility, and telesurgery capability. The SSi Mantra utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. A vision cart is designed to provide the table-side team with the same magnified 3D 4K view as the surgeon to provide better safety and efficiency. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures. Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— Beyond Defence: Kenya Defence Forces (KDF) Mobilises Specialised Rescue Teams to Save Lives in Eastleigh 2026-10-26 · APO Group · Healthcare, Aerospace & defense, Government & policy, Nonprofits https://www.africa-newsroom.com/press/beyond-defence-kenya-defence-forces-kdf-mobilises-specialised-rescue-teams-to-save-lives-in-eastleigh?lang=en Saving lives in times of crisis is a critical dimension of national service. Beyond safeguarding Kenya’s sovereignty and territorial integrity, the Kenya Defence Forces (KDF) remains committed to supporting civil authorities in humanitarian emergencies and disaster response, bringing specialised capabilities, operational expertise and rapid response capacity to communities in distress. This commitment is evident in the ongoing multi-agency search and rescue operation following the collapse of a building along 9th Street in Eastleigh, Nairobi, where KDF personnel have joined emergency responders in a coordinated effort to locate survivors and save lives. The KDF deployed specialised Urban Search and Rescue (USAR) teams, a Rapid Response Unit (RRU) from the Kenya Air Force and canine units, supported by specialised vehicles and equipment to facilitate search operations, debris clearance and access to areas affected by the collapse. Working alongside the National Police Service, Kenya Red Cross Society, Nairobi County Fire Brigade, National Disaster Management Unit, National Disaster Operations Centre, Ministry of Health, St John Ambulance and other emergency responders, KDF personnel are contributing to a coordinated operation focused on saving lives and supporting affected families. The joint rescue efforts have so far resulted in the recovery of six survivors, including two rescued during subsequent operations. The two were reported to be in stable condition and referred to Kenyatta National Hospital for further medical attention and monitoring. As the search continues, rescue teams are carefully clearing debris and examining the collapsed structure for possible survivors. Excavators and specialised equipment provided by the KDF, National Youth Service and Nairobi City County are supporting access to the rubble and facilitating the rescue operation. The General Officer Commanding Central Command (CENTCOM), Major General William Kamoiro, visited the scene to assess the progress of the operation, engage emergency responders and express solidarity with affected families. His visit reaffirmed the KDF’s commitment to supporting civilian authorities and sustaining coordinated efforts to save lives. The Eastleigh rescue operation underscores the importance of inter-agency coordination, rapid mobilisation and specialised response capabilities in managing emergencies and mitigating the impact of disasters. Through its continued involvement in humanitarian assistance and disaster response, the KDF demonstrates that service to the nation extends beyond the battlefield to protecting lives, restoring hope and standing with Kenyans in their moments of greatest need. Distributed by APO Group on behalf of Ministry of Defence - Kenya. ———————————————————————————————————————————————————————————— Clinique Orâme Launches in Downtown Montréal with Nordlys® Laser Treatments by Candela 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952399841/clinique-or-me-launches-in-downtown-montr-al-with-nordlys-laser-treatments-by-candela Dr. Valérie Smadar Tourjman, MD, CM, PhD, FRCP(C), Owner and Medical Director of Clinique Orâme in Montréal, Quebec, where Nordlys® laser and IPL treatments by Candela are now available. MONTRéAL, QUEBEC, CANADA, October 26, 2026 / EINPresswire.com / -- The award-winning Nordlys ® system provides advanced laser and IPL treatments for skin rejuvenation, pigmentation correction , vascular lesions, and more. Clinique Or ———————————————————————————————————————————————————————————— Hawkeye Bio and HealthQuest Esoterics Announce LEAP Blood Test Availability to Support Early Lung Cancer Detection 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951099751/hawkeye-bio-and-healthquest-esoterics-announce-leap-blood-test-availability-to-support-early-lung-cancer-detection Collaboration pairs patented biosensor technology with HealthQuest’s clinical laboratory expertise and established delivery infrastructure Our goal is to help physicians engage more eligible patients for recommended lung cancer screening and eliminate tens of thousands of preventable deaths each year.” — André de Fusco IRVINE, CA, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Hawkeye Bio, Inc., a developer ———————————————————————————————————————————————————————————— UNCY Deadline Alert: Levi & Korsinsky Reminds Unicycive Therapeutics, Inc. (UNCY) Investors of Securities Class Action Deadline on November 2, 2026 2026-10-26 · GlobeNewswire · Healthcare, Biotech & pharma, Legal https://www.globenewswire.com/news-release/2026/10/26/3388501/3080/en/uncy-deadline-alert-levi-korsinsky-reminds-unicycive-therapeutics-inc-uncy-investors-of-securities-class-action-deadline-on-november-2-2026.html A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility A securities class action alleges Unicycive Therapeutics told investors its third-party manufacturer had made "significant progress" toward regaining FDA compliance, while the Company had never verified that claim through its own inspection of the facility ———————————————————————————————————————————————————————————— NRC Health Launches nQuire Pro, Extending the Reach of Patient-Experience Teams 2026-10-26 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/nrc-health-launches-nquire-pro-190000078.html Co-designed with healthcare leaders, new conversational analytics gives healthcare leaders on-demand analytical expertise, connecting patient-experience feedback, performance data, and benchmarks in seconds LINCOLN, Neb., October 26, 2026--NRC Health, a recognized leader in healthcare experience manage ———————————————————————————————————————————————————————————— Global Hospital Command Center Software Market Expected to Reach $3.59 Billion by 2030 2026-10-26 · EIN Presswire · Healthcare, Software & IT https://www.einpresswire.com/article/951497566/global-hospital-command-center-software-market-expected-to-reach-3-59-billion-by-2030 Hospital Command Center Software Market Hospital Command Center Software Market growth Hospital Command Center Software Market segments The Business Research Company’s Hospital Command Center Software Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 26, 2026 / EINPresswire.com / -- The Hospital Command Center Software market is rapidly evolving as ———————————————————————————————————————————————————————————— BayCare to Become First Health System in Florida to Pilot Robotic Blood-Draw Technology 2026-10-26 · GlobeNewswire · Healthcare, Nonprofits https://www.globenewswire.com/news-release/2026/10/26/3388477/0/en/baycare-to-become-first-health-system-in-florida-to-pilot-robotic-blood-draw-technology.html CLEARWATER, Fla., Oct. 26, 2026 -- BayCare, the largest not-for-profit academic health care system in West Central Florida, is developing plans to become the first health system in Florida to pilot Aletta®, an FDA-approved, image-guided robotic blood-draw device from Vitestro.     Expected to launch in the fourth quarter of 2027, the 18- to 24-month pilot will include two Aletta devices at BayCare's Suncoast Medical Office Building and BayCare HealthHub® (Bardmoor) locations.    Aletta uses real-time imaging to guide blood collection. According to Vitestro, the device has achieved a 94.5% first-stick success rate, and the needle remains out of the patient’s view during the robotic procedure. Patients age 21 and older can select the robotic option when scheduling an appointment or, if available, during a walk-in visit. Those who prefer a traditional blood draw can choose to have a phlebotomist perform the procedure.    A phlebotomist will remain in the room to oversee the process, with one BayCare team member supervising two devices. Laboratory team members would also prepare the devices and handle required cleaning and disposal procedures between patients. The technology is intended to supplement BayCare’s existing laboratory services and support phlebotomists at two of BayCare's busiest laboratory patient service centers.   “We’re excited for BayCare to help pioneer this technology in Florida and explore how it can enhance the blood-draw experience,” said Donna Lynch, BayCare vice president of Laboratory. “Aletta will give patients another option and our laboratory teams another tool, complementing the expertise of our phlebotomists as they care for patients.”    During the pilot, BayCare will evaluate blood-draw accuracy, patient and team member satisfaction, and operational performance to help inform future decisions about the technology.     Learn more: BayCare’s laboratory services ———————————————————————————————————————————————————————————— Fortune Media and Great Place To Work Name CityVet to 2026 Best Workplaces in Health Care List 2026-10-26 · Business Wire · Healthcare, Jobs & workplace https://finance.yahoo.com/healthcare/articles/fortune-media-great-place-name-180500536.html Veterinarian-owned practice network earns national recognition for its people-first culture, commitment to professional growth, and empowering approach to veterinary medicine DALLAS, October 26, 2026--CityVet , a community of veterinarian-owned practices, has been named to the 2026 Fortune Best Workpl ———————————————————————————————————————————————————————————— More Than $1 Million Awarded to Six North Carolina Community Health Centers to Combat Maternity Deserts 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950726553/more-than-1-million-awarded-to-six-north-carolina-community-health-centers-to-combat-maternity-deserts A Commitment to Investing in Women and Children in Rural Communities Every mother deserves access to quality prenatal care close to home, and this initiative is an important step toward making that a reality for our community.” — Suzanne Freeman, CEO, Kinston Health RALEIGH, NC, UNITED STATES, October 26, 2026 / EINPresswire.com / -- North Carolina Community Health Center Association (NCCHCA)--in partnership with Nur ———————————————————————————————————————————————————————————— MGMA Elects Audrey Fisher and Melanie Stohl as Directors-at-Large; Gena Graves as Vice Chair; Jeffrey Smith as Board Chair 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3388473/0/en/mgma-elects-audrey-fisher-and-melanie-stohl-as-directors-at-large-gena-graves-as-vice-chair-jeffrey-smith-as-board-chair.html New board leaders bring expertise spanning physician practice management, healthcare operations, clinical leadership and advocacy as MGMA begins its second century. New board leaders bring expertise spanning physician practice management, healthcare operations, clinical leadership and advocacy as MGMA begins its second century. ———————————————————————————————————————————————————————————— MOPE Clinic Issues Hair Health Education Tips for South Louisiana Adults 2026-10-26 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/952385039/mope-clinic-issues-hair-health-education-tips-for-south-louisiana-adults MOPE Clinic highlights practical hair-health awareness, including monitoring excessive shedding, nutritional changes, and knowing when to seek professional medical evaluation. Metairie clinic explains temporary hair shedding, nutritional concerns, practical care tips, and signs that may warrant medical evaluation. Hair shedding can have several causes. Understanding recent health changes, nutrition, and the pattern o ———————————————————————————————————————————————————————————— Pfizer’s TALZENNA Plus XTANDI FDA-Approved for an Earlier Metastatic Prostate Cancer Treatment Setting 2026-10-26 · Business Wire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/pfizer-talzenna-plus-xtandi-fda-174100422.html TALZENNA plus XTANDI is now approved for HRR gene-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, offering a potential new standard of care earlier in the course of disease Approval based on pivotal Phase 3 TALAPRO-3 data, which showed an estimated 52% reduction in the risk of radiograp ———————————————————————————————————————————————————————————— Keep Kids Safe From Lead: Puerto Rico Families and Communities Urged to Take Action During National Lead Poisoning Prevention Week 2026-10-26 · WebWire · Healthcare, Real estate https://www.webwire.com/ViewPressRel.asp?aId=363346 As National Lead Poisoning Prevention Week (NLPPW) is observed October 25–31, Zimmetry Environmental is encouraging families, property owners, contractors, schools, businesses, and community organizations throughout Puerto Rico to take practical steps to prevent lead exposure and protect children's health. - - The 2026 NLPPW theme, “Keep Kids Safe From Lead,” emphasizes three actions: Get the Facts, Get Your Child Tested, and Get Your Home Tested. The U.S. Environmental Protection Agency (E... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363346 ———————————————————————————————————————————————————————————— Pharmacist urges public to turn to pharmacies as NHS winter pressures mount 2026-10-26 · Pressat · Healthcare, Biotech & pharma https://pressat.co.uk/releases/pharmacist-urges-public-to-turn-to-pharmacies-as-nhs-winter-pressures-mount-b000dfce4ef35b5457fcf725e277cf0f/ Monday 26 October, 2026 Ahsan Bhatti, Superintendent Pharmacist at licensed online pharmacy Quick Meds and owner of Frankley Pharmacy in Birmingham, explains why your local pharmacy could be your first port of call for common health concerns this winter. As winter approaches, the familiar NHS winter pressures are starting to make headlines again. Seasonal viruses, respiratory infections and other cold-weather illnesses can put extra strain on GP surgeries, urgent care services and A&E departments. For patients, that can mean another winter of trying to get an appointment when they need medical advice or treatment, but there’s another option that many people still overlook: their local pharmacy. Many people still think of pharmacists as simply the people who dispense GP-issued prescriptions, but our role has grown considerably over the years. Today, qualified pharmacists can offer advice, assess a range of common conditions and, where appropriately trained and authorised, prescribe treatment. That’s especially useful when getting seen quickly by your local GP proves difficult. Last winter, it was reported that an additional 300,000 patients waited for a month to see a GP compared with the previous year - so knowing when your pharmacist can help could help you get treated much sooner. Part of the problem is the lack of awareness of the types of issues a pharmacist can help with. We typically see and treat patients with common problems such as colds, sore throats, sinus problems, migraines, cystitis, thrush, bacterial vaginosis (BV), urinary tract infections (UTIs), acne, rosacea and impetigo, as well as lifestyle issues like hair loss, erectile dysfunction (ED) and weight management. If you’re suffering with any of these issues, you might typically head straight to your GP. But depending on your symptoms, medical history and the treatment needed, Pharmacist Independent Prescribers can prescribe any licensed medicine within their scope of clinical competence, including antibiotics. You don’t necessarily have to visit a pharmacy in person, either. Licensed online pharmacies in the UK who are registered with the General Pharmaceutical Council can offer consultations with qualified clinicians, including senior prescribing pharmacists, allowing patients to seek advice and treatment remotely through an established clinical process. These services are especially important for people juggling work, caring responsibilities or difficulties getting out of the house. Winter is one of the toughest times of year for the NHS, but by turning to pharmacies for non-urgent conditions, patients may be able to access the advice and treatment they need while helping to ensure GP appointments are available for those who need them most. For more information, visit www.quickmeds.co.uk ———————————————————————————————————————————————————————————— Sober Sidekick Members Exchanged More Than 1 Million Peer Engagements of Support in the Past Year 2026-10-26 · EIN Presswire · SaaS, Healthcare https://www.einpresswire.com/article/952379897/sober-sidekick-members-exchanged-more-than-1-million-peer-engagements-of-support-in-the-past-year Sober Sidekick is establishing a new standard in substance use disorder care. Every member who asked the community for help got an answer from a peer in recovery. Onboarding was rebuilt and tracking now covers nicotine, gambling and more. BENTONVILLE, AR, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Sober Sidekick, the digital recovery support platform by Empathy Health Technologies, today reported that it ———————————————————————————————————————————————————————————— Citius Oncology Reports Continued Institutional Demand and 120% Growth in Shipments of LYMPHIR® Units to U.S. Wholesalers During the Fiscal Fourth Quarter of 2026 2026-10-26 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/citius-oncology-reports-continued-institutional-demand-and-120-growth-in-shipments-of-lymphir-units-to-us-wholesalers-during-the-fiscal-fourth-quarter-of-2026-302919586.html CRANFORD, N.J., Oct. 26, 2026 -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nasdaq: CTXR), today announced... ———————————————————————————————————————————————————————————— KFSH Opened Blocked Arteries in a Median 79 Minutes for Heart Attack Patients in 2025 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952306694/kfsh-opened-blocked-arteries-in-a-median-79-minutes-for-heart-attack-patients-in-2025 KFSH Heart Center staff caring for a patient in a hospital lounge RIYADH, SAUDI ARABIA, October 26, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) achieved a median door-to-balloon time of 79 minutes for STEMI patients in 2025, below the 90-minute target and down from 96 minutes in 2010, through an integrated program that makes it Saudi Arabia’s only accredited Chest Pain Cent ———————————————————————————————————————————————————————————— Colorectal Cancer Market Set for Significant Growth During the Forecast Period (2026–2036), Due to the Emergence of Emerging Targets such as KRAS G12C, NTRK Fusions, and PIK3CA Mutations | DelveInsight 2026-10-26 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388434/0/en/colorectal-cancer-market-set-for-significant-growth-during-the-forecast-period-2026-2036-due-to-the-emergence-of-emerging-targets-such-as-kras-g12c-ntrk-fusions-and-pik3ca-mutation.html The colorectal cancer market is expected to grow steadily, driven by the rising incidence of colorectal cancer worldwide and increasing disease awareness. The adoption of targeted therapies, immunotherapies, and biomarker-driven treatment approaches is further reshaping the treatment landscape. Additionally, the launch of emerging therapies such as RYBREVANT (amivantamab) + Chemotherapy (Johnson & Johnson Innovative Medicine), Serplulimab (HLX10) + HLX04 + Chemotherapy (Shanghai Henlius Biotech), Zanzalintinib (XL092; Exelixis), and others will further propel the market growth. The colorectal cancer market is expected to grow steadily, driven by the rising incidence of colorectal cancer worldwide and increasing disease awareness. The adoption of targeted therapies, immunotherapies, and biomarker-driven treatment approaches is further reshaping the treatment landscape. Additionally, the launch of emerging therapies such as RYBREVANT (amivantamab) + Chemotherapy (Johnson & Johnson Innovative Medicine), Serplulimab (HLX10) + HLX04 + Chemotherapy (Shanghai Henlius Biotech), Zanzalintinib (XL092; Exelixis), and others will further propel the market growth. ———————————————————————————————————————————————————————————— Meta Cell Technology Brings Together International Medical Educators for First MCT Academy – Train the Trainers 2026-10-26 · Business Wire · Healthcare, Education https://finance.yahoo.com/healthcare/articles/meta-cell-technology-brings-together-165200908.html Physicians and scientific experts from MCT's international network met in Crete for advanced medical education, scientific exchange and the formal recognition of MCT Trainers. BARCELONA, Spain, October 26, 2026--Meta Cell Technology has held the first edition of MCT Academy – Train the Trainers in Hers ———————————————————————————————————————————————————————————— The Hollywood Wellness Trend Putting NAD+ and Peptides in the Spotlight at California Trim Clinic 2026-10-26 · PRUnderground · Healthcare, Entertainment https://prunderground.com/the-hollywood-wellness-trend-putting-nad-and-peptides-in-the-spotlight-at-califo/cmvonumrj000308l2swajnxqo As Hollywood explores longevity and beauty trends, California Trim Clinic examines the science, medical evidence and growing interest surrounding NAD+ and peptides. The post The Hollywood Wellness Trend Putting NAD+ and Peptides in the Spotlight at California Trim Clinic first appeared on ———————————————————————————————————————————————————————————— EaseUS Software Releases Disk Health Insights Report 2026 H1 from 440K Disk Samples, Finding HDDs Show a 20x Higher Share of Caution/Bad Ratings Than SSDs 2026-10-26 · PR Newswire · Healthcare, Software & IT https://www.prnewswire.com/news-releases/easeus-software-releases-disk-health-insights-report-2026-h1-from-440k-disk-samples-finding-hdds-show-a-20x-higher-share-of-cautionbad-ratings-than-ssds-302919108.html NEW YORK, Oct. 26, 2026 -- EaseUS Software released the Disk Health Insights Report 2026 H1 from 444,282 disk samples, highlighting differences in HDD and SSD health ratings, key warning indicators, and storage characteristics that may warrant closer monitoring. According to... ———————————————————————————————————————————————————————————— HiringThing and Nationwide Screening Services Partner to Simplify Background Screening 2026-10-26 · PRWeb · SaaS, Healthcare, Biotech & pharma, Jobs & workplace https://www.prweb.com/releases/hiringthing-and-nationwide-screening-services-partner-to-simplify-background-screening-302919079.html Integration Brings PBSA-Accredited Background Checks, Drug Testing, and Occupational Health Screening Into HiringThing's White-Label ATS NOKOMIS, Fla., Oct. 26, 2026 -- HiringThing, the leader in white-label recruiting, today announced a new integration with Nationwide... ———————————————————————————————————————————————————————————— Dr. Justin Anyokwu Encourages Georgians to Seek Support for Holiday Stress, Grief, Anxiety and Depression at Avant 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952368891/dr-justin-anyokwu-encourages-georgians-to-seek-support-for-holiday-stress-grief-anxiety-and-depression-at-avant You can be grateful and still be struggling. Avant Interventional Psychiatry offers in-person and telehealth mental health care to help individuals navigate the holiday season. Avant Interventional Psychiatry reminds individuals and families they don’t have to face holiday stress alone, with therapy and psychiatric care available. You do not have to carry everything alone. If you need someone to talk to, we are here ———————————————————————————————————————————————————————————— UCSF Center for Reproductive Health and Conceivable Life Sciences Announce Collaboration and Plans for UCSF Fertility Excellence Center 2026-10-26 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/ucsf-center-reproductive-health-conceivable-161200205.html Planned research hub will explore automation-assisted IVF laboratory technology to improve outcomes and expand access to fertility care SAN FRANCISCO & NEW YORK, October 26, 2026--UCSF Center for Reproductive Health and Conceivable Life Sciences today announced a collaboration and plans to establish th ———————————————————————————————————————————————————————————— ProclaimRx Launches The Next Generation Marketing Mix Modeling (MMM) Product for Commercial-Stage Biopharma Companies 2026-10-26 · PR Newswire · AI, Healthcare, Biotech & pharma, Marketing & advertising https://www.prnewswire.com/news-releases/proclaimrx-launches-the-next-generation-marketing-mix-modeling-mmm-product-for-commercial-stage-biopharma-companies-302919546.html Pharma-trained AI turns your MMM into a living operating model, giving commercial teams transparent, on-demand answers on how to maximize their investments. TIBURON, Calif., Oct. 26, 2026 -- ProclaimRx, the award-winning pharma commercial intelligence and decision workflows... ———————————————————————————————————————————————————————————— SS Innovations International (NASDAQ: SSII) Showcases Robotic Telesurgery Capabilities at International Medical Conferences 2026-10-26 · FinanceWire · Finance, Healthcare https://financewire.com/2026/10/26/ss-innovations-international-nasdaq-ssii-showcases-robotic-telesurgery-capabilities-at-international-medical-conferences/ Austin, Texas, United States, 26th October 2026, FinanceWire … Read More The post SS Innovations International (NASDAQ: SSII) Showcases Robotic Telesurgery Capabilities at International Medical Conferences appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Pennsylvania Trauma Systems Foundation announces the voluntary withdrawal of Allegheny Health Network Grove City Hospital's Level IV Trauma Center Accreditation 2026-10-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/pennsylvania-trauma-systems-foundation-announces-the-voluntary-withdrawal-of-allegheny-health-network-grove-city-hospitals-level-iv-trauma-center-accreditation-302919457.html MECHANICSBURG, Pa., Oct. 26, 2026 -- The Pennsylvania Trauma Systems Foundation (PTSF) is announcing the voluntary withdrawal of AHN Grove City – Allegheny Health Network's Level IV Trauma Center Accreditation effective Sunday, November 1, 2026. AHN Grove City is located in... ———————————————————————————————————————————————————————————— Vadzo Imaging Introduces Innowave-2020CRS: Onsemi AR2020 20MP Color GigE WiFi Camera with Onboard Dewarping Engine for Embedded Vision Engineers and System Integrators 2026-10-26 · Newswire.com · Healthcare, Retail https://www.newswire.com/news/vadzo-imaging-introduces-innowave-2020crs-onsemi-ar2020-20mp-color-22878020 The Innowave-2020CRS is a 20MP Color GigE WiFi Camera built on the Onsemi AR2020 sensor, and Vadzo Imaging is introducing it for embedded vision engineers and system integrators. Real installations rarely suit a single connection type. A camera on a pole may have a cable, a camera on a moving cart may not, and a temporary setup may need to run before any cable is pulled. The Innowave-2020CRS carries both Gigabit Ethernet and WiFi in one camera, so the same unit can be commissioned wirelessly and then run on a cable, or fall back to wireless if the cable fails. It complies with ONVIF, synchronizes clocks with IEEE 1588 PTP, records to onboard storage, and streams unicast or multicast. An onboard dewarping engine corrects lenses up to 200 DFOV, and an M12 lens mount with an electromechanical IR cut filter handles day and night. Designed for smart city, telematics, kiosk, medical, security, robotics, and retail systems, this 20MP ONVIF GigE WiFi Camera and 20MP Onboard Dewarping Engine Camera bring 20MP detail to flexible networks. ———————————————————————————————————————————————————————————— Many Americans Live With Chronic Pain, and Manhattan's Craniosacral Therapy NY Practice Offers a Hands-On, Non-Invasive Path Forward 2026-10-26 · MarketersMEDIA · Healthcare, Biotech & pharma https://news.marketersmedia.com/many-americans-live-with-chronic-pain-and-manhattans-craniosacral-therapy-ny-practice-offers-a-hands-on-non-invasive-path-forward/89207388 As chronic pain reshapes daily life for millions of Americans, patients increasingly seek drug-free relief. Craniosacral Therapy NY, led by Dr. Alex Kaminsky in Manhattan, now welcomes patients of all ages, offering hands-on, multi-modal care designed for lasting comfort. -- Chronic pain is one of the most inadequately addressed health conditions in the United States. According to the CDC, 24.3% of U.S. adults live w ———————————————————————————————————————————————————————————— African Energy Chamber (AEC) Applauds Afreximbank President George Elombi as Billions in Financing Drive Africa’s Industrial Growth 2026-10-26 · APO Group · SaaS, Healthcare, Energy, Industrial, Banking, Insurance, Jobs & workplace, Construction & engineering, Chemicals & materials, Mining & metals, Oil & gas https://africanenergychamber.africa-newsroom.com/press/african-energy-chamber-aec-applauds-afreximbank-president-george-elombi-as-billions-in-financing-drive-africas-industrial-growth?lang=en The African Energy Chamber (AEC) (https://EnergyChamber.org/) has commended Dr. George Elombi, President and Chairman of the Board of Directors of the African Export-Import Bank (Afreximbank), for his decisive leadership in advancing African industrialization, energy security and economic integration. Since succeeding Professor Benedict Oramah in October 2025, Dr. Elombi has overseen a series of landmark financing commitments spanning oil and gas, critical minerals, infrastructure and manufacturing, demonstrating the growing capacity of African financial institutions to mobilize capital for the continent’s development. “I was privileged to attend the inauguration of Dr. George Elombi in October 2025 as Afreximbank President and Chairman, succeeding Professor Benedict Oramah. Since that day, I have watched a man of few words keep the promises he made not with grand speeches, but with practical action. At this crossroads in our history, Dr. Elombi understands that leadership is not about occupying the moment. It is about shaping the future,” states NJ Ayuk, Executive Chairman, AEC. A cornerstone of Dr. Elombi’s commitment to Africa’s energy sector is the establishment of the Africa Energy Bank (AEB) alongside the African Petroleum Producers Organization. Designed to finance large-scale energy and infrastructure projects across the continent, the AEB will use a corridor approach, prioritizing projects that deliver regional economic development across four pillars: export infrastructure, domestic infrastructure, clean cooking and power. The bank is expected to become operational within weeks and begin financing projects at the start of 2027. Dr. Elombi’s work is reflected in a series of milestones reached by Afreximbank in recent months as the bank moves to advance intra-African trade, mobilize capital and bring new countries into its mission. In April 2026, South Africa acceded to the Establishment Agreement of the bank, marking the entry of one of the continent’s biggest economies into the bank’s membership. With the move, Afreximbank launched major financial interventions in the country, including a $8 billion Country Program designed to deepen economic growth. According to Dr. Elombi, South Africa’s membership builds on a strong pipeline of Afreximbank-led projects in the country, exceeding $6 billion and spanning healthcare, energy, manufacturing, financial services and mining. Beyond South Africa, Afreximbank continues to advance financing for strategic projects across a myriad of sectors. Notable transactions include a $3.8 billion agreement with Gabon to support manganese and gold trading as well as energy development and rail infrastructure; a $25 million facility for Lilium Gold to support operations at the Boungou and Wahgnion mines in Burkino Faso; and a $1.75 billion syndicated receivables-purchase facility for Angola’s national oil company Sonangol. In Nigeria, the bank announced a $2.5 billion underwriting commitment – part of a $4 billion syndicated facility – for Dangote Petroleum and Petrochemicals as well as a $750 million reserve-based lending facility for Heirs Energies, supporting indigenous African energy capacity. The bank was also responsible for the first-recorded Southern African energy sector transaction through the Africa Trade Gateway – a one-stop digital trade ecosystem developed by Afreximbank and the African Continental Free Trade Area. The transaction features a $5.3 million cross-border gasoil trade involving Zimbabwe. One of the most significant developments Afreximbank’s mandate transcends energy. The bank continues to mobilize capital for infrastructure that can connect African markets, supporting continent-wide industrialization and job creation. In healthcare, the African Medical Center of Excellence in Ajuba, a landmark 170-bed specialty healthcare center developed by Afreximbank, has set a new standard in healthcare in the country. The facility treats more than 5,000 patients from over 20 countries, with plans to expand to 500 beds in the near-term.   “This is more than a list of transactions; it is a practical expression of economic sovereignty, financing African businesses, moving African commodities, developing African infrastructure and keeping more value on the continent,” Ayuk said. “Dr. Elombi is running his race. He is not chasing applause; he is building momentum. He knows that Africa’s future will be secured by institutions that are bold enough to invest, disciplined enough to deliver, and confident enough to believe in Africa’s own capacity.” Distributed by APO Group on behalf of African Energy Chamber. ———————————————————————————————————————————————————————————— RTI Researchers Introduce New Measure to Track Adverse Events Among Patients Starting Care at Opioid Treatment Programs 2026-10-26 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/rti-researchers-introduce-new-measure-to-track-adverse-events-among-patients-starting-care-at-opioid-treatment-programs-302919547.html Highlights: New measure tracks substance use-related hospital visits after opioid treatment begins. Study found median 90-day acute care rate was 5%, though rates varied considerably across programs. Research team examined data from 1,226 treatment programs across the U.S. RESEARCH... ———————————————————————————————————————————————————————————— From Medevac to Mental Wealth: Army Veteran Builds NootriMind After Loss and Brain Fog 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952355828/from-medevac-to-mental-wealth-army-veteran-builds-nootrimind-after-loss-and-brain-fog Joe Mousa, U.S. Army veteran, Integrative Health Coach and founder of NootriMind®, a veteran-owned wellness brand built around the Mental Wealth philosophy. Indianapolis veteran Joe Mousa turned personal loss and post-service struggle into NootriMind, a wellness brand built around his Mental Wealth philosophy. We spend our lives trying to build wealth, but your mind is the asset behind everything you are trying to bu ———————————————————————————————————————————————————————————— MVM Health Opens New Powell, Ohio Location to Expand Access to Minimally Invasive Vein Care 2026-10-26 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/mvm-health-opens-new-powell-ohio-location-to-expand-access-to-minimally-invasive-vein-care/89207368 Demand for vein treatment in Powell, Ohio, continues to grow as patients seek treatment options that can address varicose veins and related symptoms without traditional surgery. MVM Health has opened its new Powell, Ohio, location to provide specialized vein care. -- Varicose veins can be more than a cosmetic concern. For some patients, visible veins come with swelling, heaviness, aching, or other symptoms that can d ———————————————————————————————————————————————————————————— AGFA HealthCare Selected by Infirmary Health to Modernize Imaging Across Its Health System 2026-10-26 · ACCESS Newswire · SaaS, Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/agfa-healthcare-selected-infirmary-health-150000522.html Enterprise Imaging Cloud investment advances Infirmary Health's strategy to modernize imaging, simplify radiology workflows and create a scalable foundation for continued growth. CARLSTADT, NJ / October 26, 2026 / Infirmary Health has selected AGFA HealthCare Enterprise Imaging Cloud (SaaS) to modernize ———————————————————————————————————————————————————————————— Fukuda Denshi USA Introduces the BDS-2100: Designed to Simplify Bedside Monitoring 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951841433/fukuda-denshi-usa-introduces-the-bds-2100-designed-to-simplify-bedside-monitoring BDS-2100 Bedside Monitor A compact 12.1-inch touchscreen monitor for acute care setting, built for easy operation, clear viewing, and patient comfort. Hospitals keep telling us they need monitoring that’s simple to learn, simple to use, and fits where space is tight. The BDS-2100 delivers exactly that.” — Justin Criddle, Vice President of Sales at Fukuda Denshi USA REDMOND, WA, UNITED STATES, October 26, 2026 / EINPr ———————————————————————————————————————————————————————————— Medcor Keeps Its Nurses at the Center of a New Approach to Triage Quality 2026-10-26 · Business Wire · AI, Healthcare, Jobs & workplace https://finance.yahoo.com/healthcare/articles/medcor-keeps-nurses-center-approach-150000357.html Every injury triage call is now reviewed against Medcor's AFKAM® QAi and what it finds becomes coaching for the nurse who took the call MCHENRY, Ill., October 26, 2026--Medcor, a national leader in occupational health and workplace injury triage, today announced it has implemented an AI-assisted triage ———————————————————————————————————————————————————————————— Gilead’s Latest Deal Shows Big Pharma’s Appetite for Oral Peptides. Which Stocks Are Worth Watching? 2026-10-26 · FinanceWire · Healthcare, Biotech & pharma https://financewire.com/2026/10/26/gileads-latest-deal-shows-big-pharmas-appetite-for-oral-peptides-which-stocks-are-worth-watching/ WSW, NY, 26th October 2026, FinanceWire … Read More The post Gilead’s Latest Deal Shows Big Pharma’s Appetite for Oral Peptides. Which Stocks Are Worth Watching? appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Safety Training Seminars Offer Daily CPR, BLS, ACLS & PALS Classes for Sacramento Healthcare Workers 2026-10-26 · PR Now · Healthcare https://pressreleasenews.org/pressroom/safety-training-seminars-offer-daily-cpr-bls-acls-pals-classes-for-sacramento-healthcare-workers For nurses, physicians, medical assistants, and allied health professionals across the Sacramento region, keeping life-support certifications current can be challenging. Rotating shifts, on-call responsibilities, and demanding patient-care schedules often make it difficult to fin… ———————————————————————————————————————————————————————————— Form 8.3 - Advanced Medical Solutions Group plc - Octopus Investments 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3388243/0/en/form-8-3-advanced-medical-solutions-group-plc-octopus-investments.html FORM 8.3 ———————————————————————————————————————————————————————————— Dragonfleye Therapeutics Corp. Takes Flight, Raising US$37.5 Million in Private Placement Offerings to Advance Novel Ocular Platform-Based Treatments 2026-10-26 · ACCESS Newswire · SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/dragonfleye-therapeutics-corp-takes-flight-140000934.html TORONTO, ON / October 26, 2026 / Dragonfleye Therapeutics Corp. ("Dragonfleye" or the "Company"), a patient-centered, innovation-focused company developing minimally invasive treatments for pathologic conditions in ophthalmology using its platform technology, today announced that it completed two non-bro ———————————————————————————————————————————————————————————— Together Women’s Health Earns 2026 Great Place To Work Certification™ 2026-10-26 · Business Wire · Healthcare, Jobs & workplace https://finance.yahoo.com/healthcare/articles/together-women-health-earns-2026-140000394.html DETROIT, October 26, 2026--Together Women's Health (TWH) is proud to earn Great Place to Work Certification™ for 2026. The prestigious award is based entirely on what current employees say about their experience working at TWH and our affiliate practices. Together Women's Health is a women's health-foc ———————————————————————————————————————————————————————————— Twenty contacts of Kenya’s first Bundibugyo virus disease case released from quarantine 2026-10-26 · APO Group · Healthcare, Travel, Biotech & pharma, Government & policy https://who-africa.africa-newsroom.com/press/twenty-contacts-of-kenyas-first-bundibugyo-virus-disease-case-released-from-quarantine-1?lang=en Today 20 contacts associated with Kenya’s first imported case of Bundibugyo virus disease were released from quarantine and reunited with their families after completing the mandatory 21-day monitoring period. A total of 98 contacts now remain in quarantine. The contacts discharged today remained asymptomatic during quarantine. They underwent standard protocols, including a final health assessment, counselling on post-discharge precautions and follow-up where required before being released. “We ask communities to welcome them home warmly,” said Dr Patrick Amoth, Director General for Health in Kenya. “Having completed 21 days without symptoms, they pose no risk of infection to anyone.” Following confirmation of the first Ebola case on 6 October 2026, the Ministry of Health conducted robust contact tracing of anyone who may have been exposed. By 22 October, all 135 contacts were traced, both in Kenya and internationally, and placed in quarantine.   As of 26 October 2026, eight contacts had developed symptoms and were confirmed positive for Ebola through laboratory testing. All eight cases were already in quarantine at the time and were immediately transferred to the country’s Ebola treatment centre in Nairobi. In total, Kenya has reported nine confirmed cases and two deaths. All nine cases are part of one connected group and there is no evidence that the virus has spread to the community.   World Health Organization (WHO) continues to support health authorities in Kenya on all aspects of the response, including response coordination, disease surveillance, contact tracing, laboratory testing, case management, infection prevention and control, health screening at points of entry and risk communication and community engagement. “People who complete quarantine have helped protect their families, their communities and the whole country,” said Dr Neema Rusibamayila Kimambo, WHO Representative to Kenya. “WHO commends the Ministry of Health, the Kenya National Public Health Institute, national and county health teams for their work in responding quickly to every new case.” While there is no licensed vaccine or specific treatment for Bundibugyo virus disease, detecting cases early and providing supportive care improves chances of recovery.  WHO advises against travel restrictions and recommends evidence-based public health measures, including entry and exit screening at points of entry, surveillance and contact tracing.   Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Humanetics Corporation Announces FDA Acceptance of Investigational New Drug (IND) Application for BIO 300 Injectable Suspension 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/humanetics-corporation-announces-fda-acceptance-135500779.html The Company will initiate its planned clinical study of BIO 300 Injectable Suspension, subject to Institutional Review Board approval and other applicable requirements MINNEAPOLIS, October 26, 2026--Humanetics Corporation, an advanced clinical-stage specialty pharmaceutical company pioneering novel med ———————————————————————————————————————————————————————————— Democratic Republic of the Congo - Ebola response: Disinformation kills, care saves lives 2026-10-26 · APO Group · Healthcare, Media, Government & policy, Marketing & advertising, Internet & apps https://who-africa.africa-newsroom.com/press/democratic-republic-of-the-congo-ebola-response-disinformation-kills-care-saves-lives?lang=en “They said that at the hospital, they would give my child bad injections and he would die,” says Jeanne*, her voice trembling. These words deeply marked this mother whose six year old child showed suspected symptoms of Ebola. Out of fear of treatment centres, she first sought solutions elsewhere. When her child was finally taken to a health facility, his condition was already critical. Forty eight hours later, he died. Today, Jeanne shares her testimony to prevent other families from experiencing the same tragedy. It all began with a fever and vomiting. Thinking it was malaria, she opted for self medication. But her child’s condition did not improve. Around her, disinformation portrayed Ebola as a commercial scheme and claimed that patients received lethal injections in treatment centres. These falsehoods fueled her mistrust. She then consulted a traditional healer her family had relied on before. “I took my son to our healer. I had hope because he had treated our family for a long time,” Jeanne explains. The child gradually weakened. As his condition worsened, the healer recommended transfer to a health facility. “It was truly painful to lose my child. I deeply regret not going quickly to the health centre,” says the grieving mother. Her testimony reveals how disinformation can influence decisions about seeking appropriate care. For Salif Diarra, social listening analyst at the World Health Organization (WHO), this story should not be seen as an individual fault. “This mother wanted to protect her child. But rumours fueled fear that influenced her decision. When a family sees the treatment centre as a threat, they may hesitate to seek help, even as their loved one’s condition deteriorates,” he says. Such accounts are not isolated. Social listening teams regularly identify claims about supposed lethal injections and rumours that undermine trust in public health interventions. To address this, WHO supports health authorities in analysing community concerns through media, social networks and the toll free number 151. Between May and September 2026, more than 34 650 items of online content were analysed, including rumours and concerns. Three times a week, Ministry of Health and WHO teams review information gathered from communities to identify mis- and disinformation that could delay care seeking. According to Diarra, these exchanges help adapt messages and interventions to community concerns, strengthening trust in the Ebola response. In Rwampara health zone, demystification sessions were organized to address fears about treatment centres. WHO, with partner support, also helped train 100 traditional healers, 20 social media influencers and 150 hotline operators to improve access to reliable information. In Ituri, these efforts include community dialogues and public forums. Frédérick Mungobijira, head of infodemic management in Ituri, recalls a situation in Katogu health area where rumours had sparked strong resistance to response teams. “We organized community dialogues with local leaders to explain the disease and fight misinformation. After these exchanges, response teams were able to access communities that had previously been hostile.” Since the start of the outbreak, more than 1000 rumours have been addressed in Ituri. These interventions help reduce resistance and encourage early care seeking. For Jeanne, healing also requires psychological support. After her child’s death, she attends sessions with a WHO psychologist who helps her express her grief and gradually regain emotional balance. “The psychologist helps me a lot. He listens, advises and supports me. Today, I feel better,” she says. Jeanne’s sister denounces the influence of rumours, disinformation and misinformation. “Some people said it was dangerous to take a sick person to the hospital, that they might never return alive. Today, we stay close to our sister, listen to her and encourage her to overcome this ordeal. We are all deeply affected. The little one was full of life,” she says. For Diarra, restoring trust requires listening to communities and responding concretely to their concerns. “Reliable information must be accessible, understandable and delivered by people communities trust. We must listen to families’ fears and respond with respect,” he says. Despite her grief, Jeanne has chosen to testify to encourage other parents to seek care quickly. “I ask all parents not to believe mis- and disinformation. As soon as a child is sick, you must go quickly to a health centre to receive appropriate care. I would not want another mother to live what I have lived,” she says. Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Incyte Highlights New Data Advancing its Gastrointestinal Cancer Portfolio at ESMO 2026 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/incyte-highlights-data-advancing-gastrointestinal-134500958.html INCB161734 (KRAS G12D inhibitor) and INCA33890 1 (TGFβR2×PD-1 bispecific antibody) data reinforce ongoing and planned registrational trials, including DAWN-303 in pancreatic ductal adenocarcinoma (PDAC) and NEXERA-303 in colorectal cancer (CRC), respectively New data evaluating INCB161734 in CRC highlight its clinical act ———————————————————————————————————————————————————————————— Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT) 2026-10-26 · FinanceWire · Finance, Healthcare, Biotech & pharma https://financewire.com/2026/10/26/nuvectis-reports-complete-brain-tumor-responses-as-big-pharma-pays-billions-for-cancer-drugs-nasdaq-nvct/ WSW, NY, 26th October 2026, FinanceWire … Read More The post Nuvectis Reports Complete Brain Tumor Responses as Big Pharma Pays Billions for Cancer Drugs (NASDAQ: NVCT) appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— HIMS Deadline in 7 Days: Hims & Hers Health, Inc. (NYSE: HIMS) Class Action Lawsuit Seeks Recovery for Investors; November 2, 2026 Deadline- Contact Kessler Topaz Meltzer & Check, LLP 2026-10-26 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/26/3388175/0/en/hims-deadline-in-7-days-hims-hers-health-inc-nyse-hims-class-action-lawsuit-seeks-recovery-for-investors-november-2-2026-deadline-contact-kessler-topaz-meltzer-check-llp.html Did you buy HIMS securities between August 4, 2025 and July 29, 2026? ———————————————————————————————————————————————————————————— Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS) 2026-10-26 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388178/0/en/longeveron-announces-updated-results-from-elpis-ii-phase-2b-clinical-trial-evaluating-laromestrocel-as-a-potential-treatment-for-hypoplastic-left-heart-syndrome-hlhs.html Longeveron announces updated results of ELPIS II, the Company's trial evaluating its stem cell therapy in HLHS. ———————————————————————————————————————————————————————————— Niki BioSolutions Announces New York State Approval for Its APOE Genotyping Test Using Dried Blood Spots, Plasma, and Urine 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3388176/0/en/niki-biosolutions-announces-new-york-state-approval-for-its-apoe-genotyping-test-using-dried-blood-spots-plasma-and-urine.html NYSDOH CLEP approval extends validated APOE genotyping beyond blood, buccal swab, saliva, and tissue for clinical and research use ———————————————————————————————————————————————————————————— X9 Receives FDA Breakthrough Device Designation for Investigational Dialysis Cannulation System and Completes Second Clinical Study 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3388171/0/en/x9-receives-fda-breakthrough-device-designation-for-investigational-dialysis-cannulation-system-and-completes-second-clinical-study.html ACCESS-2 study provides additional clinical experience with X9's investigational technology for vascular access in hemodialysis ACCESS-2 study provides additional clinical experience with X9's investigational technology for vascular access in hemodialysis ———————————————————————————————————————————————————————————— SRX Global Announces Activation of the University of California, Davis as a Clinical Trial Site for CERo Therapeutics’ Ongoing Phase 1 CERTAIN-T Trial of CER-1236 in Hematologic Malignancies 2026-10-26 · GlobeNewswire · Healthcare, Education, Industrial, Logistics, Biotech & pharma, Jobs & workplace https://www.globenewswire.com/news-release/2026/10/26/3388166/0/en/srx-global-announces-activation-of-the-university-of-california-davis-as-a-clinical-trial-site-for-cero-therapeutics-ongoing-phase-1-certain-t-trial-of-cer-1236-in-hematologic-mali.html UC Davis is the primary manufacturing site for CER-1236, site activation is expected to expand patient recruitment capacity and streamline treatment logistics ———————————————————————————————————————————————————————————— Panchmukhi Air Ambulance in Raipur Helps from Emergency Pickup to Hospital Admission 2026-10-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/10/26/1776395 Raipur, India, 2026-10-26 — Some medical journeys are too long or too complicated for critical patients to cover by ordinary transport; in [read full press release...] ———————————————————————————————————————————————————————————— Paradromics Receives FDA Approval to Expand Connexus® Brain-Computer Interface Clinical Study Recruitment Nationwide 2026-10-26 · Business Wire · Healthcare, Biotech & pharma, Jobs & workplace https://finance.yahoo.com/healthcare/articles/paradromics-receives-fda-approval-expand-130300473.html Updated protocol removes four-hour geographic restriction and opens a path to broader participation through three U.S. academic medical centers AUSTIN, Texas, October 26, 2026--Paradromics Inc., a neurotechnology company developing high-data-rate brain-computer interfaces to restore and enhance human c ———————————————————————————————————————————————————————————— Rising Stress Levels Highlight the Need for Accessible Anxiety Support in Australia 2026-10-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/10/26/1776408 Melbourne, Australia, 2026-10-26 — Growing awareness of mental health and the impact of ongoing stress is encouraging Australians to consider a wider [read full press release...] ———————————————————————————————————————————————————————————— TIFFANY HADDISH AND ELLIOTT CONNIE LAUNCH THE ELLIOTT CONNIE SHOW ON YOUTUBE 2026-10-26 · EIN Presswire · Healthcare, Media, Internet & apps, Entertainment https://www.einpresswire.com/article/951619053/tiffany-haddish-and-elliott-connie-launch-the-elliott-connie-show-on-youtube Tiffany Haddish executive produces new podcast on mental health & wellness. Executive Produced by She Ready Productions, New Series Brings Together Leading Trailblazers for Conversations About Mental Health & Personal Growth LOS ANGELES, CA, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Emmy, Grammy, and NAACP Image Award winning actress, comedian, producer and bestselling author Tiffany Haddish has teamed ———————————————————————————————————————————————————————————— The Digital Therapeutics Market Is Projected to Grow to $37.61 Billion by 2030 Due to Increasing Industry Demand 2026-10-26 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/951504466/the-digital-therapeutics-market-is-projected-to-grow-to-37-61-billion-by-2030-due-to-increasing-industry-demand Digital Therapeutics Digital Therapeutics Market Report 2026 Digital Therapeutics Market Size The Business Research Company’s Digital Therapeutics Market Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 26, 2026 / EINPresswire.com / -- "The digital therapeutics market is carving out a significant niche within the broader digital health landscape, ———————————————————————————————————————————————————————————— CERo Therapeutics Announces Activation of Additional Clinical Trial Site for the CERTAIN-T Trial, its Ongoing Phase 1 Clinical Trial of CER-1236 in Hematological Cancers 2026-10-26 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388129/0/en/cero-therapeutics-announces-activation-of-additional-clinical-trial-site-for-the-certain-t-trial-its-ongoing-phase-1-clinical-trial-of-cer-1236-in-hematological-cancers.html SOUTH SAN FRANCISCO, Calif, Oct. 26, 2026 -- CERo Therapeutics Holdings, Inc., (OTCQB: CERO) (“CERo” or the “Company”), an innovative cellular immunotherapy company advancing engineered T cell therapeutics designed to engage phagocytic mechanisms, announces that Fred Hutch Cancer Center (“Fred Hutch”) in Seattle, Wash., has been activated as a clinical trial site for the Company’s Phase 1 clinical trial of CER-1236, CERTAIN-T. ———————————————————————————————————————————————————————————— Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment 2026-10-26 · Abbott · Healthcare, Biotech & pharma, Medical devices https://abbott.mediaroom.com/2026-10-26-Abbott-launches-whole-genome-sequencing-Oncodetect-R-molecular-residual-disease-MRD-test-to-detect-traces-of-cancer-during-and-after-treatment Abbott launches whole-genome sequencing Oncodetect® molecular residual disease (MRD) test to detect traces of cancer during and after treatment Powered by whole-genome sequencing and MAESTRO * technology, the next-generation Oncodetect test takes a distinct approach to MRD, tracking up to 5,000 patient-specific variants with a limit of detection below one part per million under high-end inputs 1, 2, 3 The next-genera ———————————————————————————————————————————————————————————— Francisco Partners Completes Acquisition of Weave 2026-10-26 · Business Wire · Finance, AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/francisco-partners-completes-acquisition-weave-125800424.html Transaction positions Weave to accelerate investment in its AI-powered platform for healthcare practices LEHI, Utah & SAN FRANCISCO, October 26, 2026--Weave Communications, Inc. ("Weave"), a leading AI-powered patient engagement and payments platform purpose-built for healthcare practices, today announ ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Subsidiary Real Game Used Maintains Steady Authentication Backlog 2026-10-26 · ACCESS Newswire · Finance, Healthcare, Gaming https://finance.yahoo.com/technology/articles/medical-care-technologies-inc-otcid-125700874.html Automated Submission System Supports Continuous Customer and Auction Brand Work as Company Operates Multiple Revenue Streams MESA, AZ / October 26, 2026 / Medical Care Technologies Inc. (OTCID:MDCE) today announced that its subsidiary Real Game Used continues to operate with a steady backlog of customer- ———————————————————————————————————————————————————————————— Chiropractic Health Geelong Emphasises Personalised Approaches to Managing Back and Neck Pain 2026-10-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/10/26/1776381 Geelong, Victoria, Australia, 2026-10-26 — Back and neck discomfort can affect people across different occupations, age groups and lifestyles, influencing their ability to [read full press release...] ———————————————————————————————————————————————————————————— CMS Direct Supervision Requirements For Medical Facilities: Guide Released 2026-10-26 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/cms-direct-supervision-requirements-for-medical-facilities-guide-released/89207356 ContrastConnect has released a guide on the CMS’ definition of direct supervision and when virtual direct supervision is allowed. -- ContrastConnect has published a guide outlining the Centers for Medicare & Medicaid Services’ (CMS) current definition of direct supervision. Administrators can refer to the resource to learn about revisions to federal guidelines, when virtual direct supervision is allowed, and how to e ———————————————————————————————————————————————————————————— Alpha Rehabilitation Medical Centers Now Offers Hormone Replacement Therapy in Berwyn 2026-10-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/10/26/1776325 Berwyn, IL, 2026-10-26 — Alpha Rehabilitation Medical Centers, a Berwyn medical center known for pain management and rehabilitation, is helping local men and [read full press release...] ———————————————————————————————————————————————————————————— H.E. Ambassador Eshete Tilahun meets with Mr. Francesco Di Lillo, Director of European Union and International Office of The Church of Jesus Christ of Latter-day Saints 2026-10-26 · APO Group · Healthcare, Food & drink, Agriculture https://www.africa-newsroom.com/press/he-ambassador-eshete-tilahun-meets-with-mr-francesco-di-lillo-director-of-european-union-and-international-office-of-the-church-of-jesus-christ-of-latterday-saints?lang=en H.E. Ambassador Eshete Tilahun meets with Mr. Francesco Di Lillo, Director of European Union and International Office of The Church of Jesus Christ of Latter-day SaintsAmbassador Eshete Tilahun and his team received Mr. Francesco Di Lillo of The Church of Jesus Christ of Latter-day Saints together with accompanying representatives at the Embassy to discuss humanitarian and development activities in Ethiopia. The Church representatives briefed the Ambassador on their ongoing projects, as partner organization involved in irrigation, maternal and newborn health care, vaccination, food security and emergency relief. Ambassador Eshete commended the Church’s contribution to community level development works focusing on the most vulnerable. Looking ahead, the two sides exchanged views on future priorities in the areas of humanitarian assistances, afforestation, irrigation and agriculture. The meeting closed with a shared commitment to deepen cooperation and regular exchanges Distributed by APO Group on behalf of Embassy of Ethiopia in Brussels. ———————————————————————————————————————————————————————————— HeartBeam’s Heart Attack Assessment Technology Accepted into FDA’s Total Product Life Cycle Advisory Program (TAP) 2026-10-26 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/heartbeam-heart-attack-assessment-technology-123100934.html Acceptance into FDA's TAP Pilot follows Breakthrough Device Designation granted earlier this month for HeartBeam's heart attack assessment technology TAP Pilot provides dedicated FDA advisors and early engagement with payers, including CMS, as well as patient and provider organizations, to help accelerate future reimburse ———————————————————————————————————————————————————————————— Contract Sterilization Services Market to Reach US$ 2.45 Billion by 2033 2026-10-26 · PR News Releaser · Healthcare, Medical devices https://www.prnewsreleaser.com/news/478842 The Contract Sterilization Services Market was valued at US$ 1.72 billion in 2025 and is projected to reach US$ 2.45 billion by 2033, registering a CAGR of 4.52% during 2026–2033. Market growth is supported by increasing outsourcing among medical device ... Read more ———————————————————————————————————————————————————————————— Medical Devices Market to Reach US$ 1.09 Trillion by 2033 2026-10-26 · PR News Releaser · Healthcare, Medical devices https://www.prnewsreleaser.com/news/478833 The Medical Devices Market was valued at US$ 600.93 billion in 2025 and is projected to reach US$ 1,091.64 billion by 2033, registering a CAGR of 7.75% during 2026–2033. Market growth is driven by aging populations, increasing chronic disease prevalence, ... Read more ———————————————————————————————————————————————————————————— Get a Trusted Medical Journey by Train with King Train Ambulance in Patna 2026-10-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/10/26/1776296 Patna, India, 2026-10-26 — A medical transfer becomes easier when transportation, medical assistance, and destination coordination are managed professionally, ensuring patient safety at [read full press release...] ———————————————————————————————————————————————————————————— ConstructAfrica Summit & Awards 2026: Programme Update 2026-10-26 · APO Group · SaaS, Healthcare, Travel, Sustainability, Software & IT, Construction & engineering https://www.africa-newsroom.com/press/constructafrica-summit-and-awards-2026-programme-update?lang=en ConstructAfrica (https://ConstructAfrica.com) announces that the ConstructAfrica Summit & Awards (CSA) 2026, originally scheduled to take place in person in Nairobi, Kenya, from 26–28 November 2026, will now be held entirely online on 27–28 November 2026. The decision follows enquiries and concerns raised by registered delegates and speakers regarding the evolving public health situation in Kenya, alongside careful consideration of health concerns relating to Ebola and the need to prioritise the wellbeing of delegates, speakers, partners, sponsors, and team members. In response to these concerns, ConstructAfrica has decided that transitioning to an online format is the most appropriate way to safeguard participants while ensuring that the summit proceeds and its important conversations remain accessible. As part of this transition, participation in the online summit will be free. This decision is a goodwill gesture to registered delegates and speakers who had already made travel arrangements and whose plans have been disrupted by the change. It also reflects ConstructAfrica’s commitment to expanding global access to the summit, particularly for participants outside Africa interested in engaging with the continent’s construction and infrastructure opportunities. ConstructAfrica will contact delegates who have already paid registration fees to facilitate refunds and communicate the relevant arrangements. The 2026 edition, themed “Creating a Sustainable Future for Africa’s Built Environment,” will focus on critical issues shaping the continent’s construction and infrastructure sectors, including infrastructure development, sustainable construction, digital transformation, smart cities, and project delivery excellence. The online format will give participants across Africa and around the world a platform to exchange insights, explore business opportunities, build meaningful connections, and contribute to conversations shaping the future of Africa’s built environment, without the need for international travel. Despite the change in format, ConstructAfrica remains committed to delivering the summit’s planned programme in an adapted online format. Further information regarding participation, access, programme arrangements, and refunds will be communicated through official channels. ConstructAfrica appreciates the understanding and continued support of its delegates, speakers, sponsors, partners, and the wider construction and infrastructure community. The organisation looks forward to welcoming participants from across the globe for two days of knowledge exchange, collaboration, and actionable conversations focused on advancing Africa’s built environment. Distributed by APO Group on behalf of ConstructAfrica. ConstructAfrica Summit & Awards Team : https://Summit.ConstructAfrica.com/ ———————————————————————————————————————————————————————————— Aptevo Reports Mipletamig Combination Therapy Enabled 21% of Frontline AML Patients to Advance to Potentially Curative Stem Cell Transplant 2026-10-26 · Newswire.com · Healthcare, Biotech & pharma https://www.newswire.com/news/aptevo-reports-mipletamig-combination-therapy-enabled-21-of-frontline-aml Ten patients initially deemed unfit for intensive chemotherapy proceeded to stem cell transplant Transplant rate compares favorably with historical standard-of-care experience, adding to growing clinical evidence supporting mipletamig's potential to improve outcomes in frontline AML Aptevo expects the RAINIER dose optimization trial to conclude by year-end, with FDA interaction and initiation of a Phase 2 clinical trial anticipated in the first half of 2027 ———————————————————————————————————————————————————————————— Hepion Pharmaceuticals Receives FDA Feedback Supporting a Path to Demonstrating Prophylactic Protection for GV104 Against Fentanyl-Induced Cardiac Arrest 2026-10-26 · ACCESS Newswire · Healthcare, Biotech & pharma, Entertainment https://finance.yahoo.com/healthcare/articles/hepion-pharmaceuticals-receives-fda-feedback-120100307.html - In a simulation of 200 virtual subjects, a single dose of GV104 (16 mg nalmefene buccal film) taken at least 15 minutes before exposure prevented every potential fentanyl-induced cardiac arrest, at intravenous fentanyl doses known to be lethal in humans - - FDA re-affirmed the overall approach and provided comments that ———————————————————————————————————————————————————————————— Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks; Weighs Strategic Options 2026-10-26 · ACCESS Newswire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/valion-bio-receives-unsolicited-acquisition-120000142.html Unsolicited Interest Reinforces Velocity's Strategic Value as Valion Bio Evaluates Opportunities to Advance Entolimod SAN ANTONIO, TX / October 26, 2026 / Valion Bio, Inc. (NASDAQ:VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immun ———————————————————————————————————————————————————————————— BioAgilytix Expands Global Bioanalytical Capabilities Through New 360biolabs Sydney Laboratory 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951595343/bioagilytix-expands-global-bioanalytical-capabilities-through-new-360biolabs-sydney-laboratory Expansion strengthens 360biolabs' Australian laboratories and supports early-phase clinical development with continuity into global programs. DURHAM, NC, UNITED STATES, October 26, 2026 / EINPresswire.com / -- BioAgilytix , a global bioanalytical Contract Research Organization (CRO), announces the expansion of its Australian laboratories through the opening of a new purpose-designed facility for 360biolabs , a BioAgi ———————————————————————————————————————————————————————————— Ideal Option Releases 2025 Patient Outcomes Annual Report, Highlighting Life-Saving Treatment Amid Alaska's Ongoing Overdose Crisis 2026-10-26 · PRWeb · Healthcare https://www.prweb.com/releases/ideal-option-releases-2025-patient-outcomes-annual-report-highlighting-life-saving-treatment-amid-alaskas-ongoing-overdose-crisis-302917790.html New data show 97% opioid abstinence rates among long-term patients in Alaska as state faces high overdose death rates and persistent polysubstance use. ANCHORAGE, Alaska, Oct. 26, 2026 -- Ideal Option, a national leader in outpatient medication-assisted treatment (MAT)... ———————————————————————————————————————————————————————————— Optiqueye Named 2026 Best of Texas Award Winner 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/947962568/optiqueye-named-2026-best-of-texas-award-winner MISSOURI CITY , TX, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Optiqueye, a Missouri City eye care practice offering comprehensive vision care and curated eyewear, has been named a recipient of the 2026 Best of Texas Award. The recognition honors the practice’s commitment to personalized care and clinical excellence. It also celebrates the welcoming environment the team has built for patients of all ages ———————————————————————————————————————————————————————————— New Financial Wellness Advisory Board to Guide 2027 Research and Industry Insights 2026-10-26 · Newsworthy.ai · AI, SaaS, Healthcare, Banking, Jobs & workplace, Marketing & advertising https://newsworthy.ai/news/202610263099/new-financial-wellness-advisory-board-to-guide-2027-research-and-industry-insights Jacksons Point, Ontario, Canada Monday Oct 26, 2026 @ 8:00 AM Eastern — HR.com’s HR Research Institute has announced its State of Financial Wellness Advisory Board for 2027, bringing together experienced HR, benefits, and financial professionals to help shape upcoming research and industry insights on employee financial literacy and well-being. The advisory board will guide research into employees’ financial challenges, workplace financial wellness programs and their effectiveness, best practices, and the benefits of financial literacy initiatives, including the role of tools, metrics, and emerging technologies such as AI in improving employee financial well-being.  “Financial stress can have a significant impact on employees’ overall well-being and their ability to thrive at work,” said Debbie McGrath, CEO of HR.com. “This research will help HR leaders better understand employees’ needs and identify practical, effective ways to build financial wellness strategies that make a meaningful difference.” The findings and insights will be explored at a follow-up virtual event in the new year, offered free to the HR community. The research and event aim to equip HR professionals with actionable insights to strengthen financial wellness initiatives and better support employees’ financial health. State of Financial Wellness 2027 Virtual Event  March 10, 2027  [Register for free] The newly formed 2027 State of Financial Wellness Advisory Board features these distinguished experts: Heather Coleman, Financial Wellness Queen, Enriched Academy Dan Comisar, Strategy and Growth Officer, BrightDime Shatrina Cosby, VP of Account Management & Development, Purchasing Power Kim Duffy-Wylam, Managing Partner, Baker Tilly Damond Fauconier, CHRO, Transportation Federal Credit Union Marite Marlow, Chief Financial Officer, Center for Employment Training Lilah Raynor, CEO, Logica Research Cassandra Rose, SPHR, Fractional CPO, Fringe Rahkim Sabree, AFC®, Financial Wellness Consultant, Keynote Speaker, and Author of Overcoming Financial Trauma The HR Research Institute releases annual “State of the Industry” reports across a variety of HR topic areas, including the most recent report on this topic, HR.com’s State of Employee Financial Wellness 2026.  This and other free research reports and infographics can be downloaded at hr.com/researchinstitute.     About HR.com and the HR Research Institute The #1 source for HR research - read by more HR professionals than any other! The HR Research Institute (HRRI), powered by HR.com, identifies key trends and best practices to help more than 2 million HR professionals and their organizations make strategic decisions with informed and insightful research findings. The HRRI has published hundreds of high-quality reports across a wide array of HR topics. HR.com’s free membership offers many benefits, including access to over 300 exclusive primary research, state-of-the-industry reports, and infographics. These resources are published based on surveys developed with the assistance of a panel of thought leaders and industry experts on the advisory boards. Visit  hr.com/hrresearchinstitute to maximize your HR potential. #hrresearchinstitute Become a part of HR.com’s HR research influencer panel today! Participate in surveys, share your insights, and earn rewards! HR.com Newsroom ———————————————————————————————————————————————————————————— GT Biopharma Selected for Oral Presentation at the SITC 2026 Annual Meeting 2026-10-26 · GlobeNewswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3388025/0/en/gt-biopharma-selected-for-oral-presentation-at-the-sitc-2026-annual-meeting.html SAN FRANCISCO, CALIFORNIA, Oct. 26, 2026 -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary TriKE® natural killer (NK) cell engager platform, today announced that it has been selected for an oral presentation at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting taking place from November 4-8, 2026 in Phoenix, AZ. ———————————————————————————————————————————————————————————— Stryker completes acquisition of ZuriMED to enhance its shoulder offering 2026-10-26 · GlobeNewswire · Finance, Healthcare, Medical devices https://www.globenewswire.com/news-release/2026/10/26/3388024/0/en/stryker-completes-acquisition-of-zurimed-to-enhance-its-shoulder-offering.html Portage, Michigan, Oct. 26, 2026 -- Stryker (NYSE:SYK), a global leader in medical technologies, announced it has completed the acquisition of ZuriMED, a privately held company and developer of the FiberLocker® System. ———————————————————————————————————————————————————————————— Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3388017/0/en/senseonics-initiates-first-in-human-study-of-freedom-designed-to-be-the-world-s-first-cgm-system-with-no-on-body-component.html First clinical evaluation of investigational, transmitter-free one-year CGM marks an important milestone on Senseonics’ innovation roadmap, with potential launch in 2028 ———————————————————————————————————————————————————————————— Sumitomo Pharma America Announces Enzomenib (DSP-5336) Receives FDA Breakthrough Therapy Designation for Treatment of R/R KMT2A-Rearranged Acute Leukemia 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sumitomo-pharma-america-announces-enzomenib-120000332.html – Enzomenib is being evaluated as monotherapy in the registrational Phase 2 Horizen-1 study in relapsed/refractory (R/R) acute leukemia with KMT2A rearrangement or NPM1 mutation – Enzomenib is also being evaluated in combination with standard of care regimens for patients with newly diagnosed and R/R acute myeloid leukemi ———————————————————————————————————————————————————————————— Vyome Co-Founder Dr. Shiladitya Sengupta Promoted to Professor at Harvard Medical School 2026-10-26 · Business Wire · Healthcare, Education, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vyome-co-founder-dr-shiladitya-120000929.html Promotion to full Professor recognizes Dr. Sengupta's longstanding contributions to biomedical research and translational medicine Scientific leadership and expertise in drug discovery, bioengineering and therapeutic innovation have helped shape Vyome's research-driven approach to addressing unmet medical needs CAMBRIDGE, ———————————————————————————————————————————————————————————— Estrella Immunopharma Appoints Cynthia Pussinen as Chief Executive Officer and Chairperson of the Board of Directors 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/estrella-immunopharma-appoints-cynthia-pussinen-120000022.html An accomplished biotechnology executive, Ms. Pussinen brings more than 30 years of global leadership experience spanning advanced therapies, clinical development, commercialization, strategic partnerships and capital formation Appointment comes at a pivotal stage as Estrella advances its differentiated ARTEMIS ® T-cell th ———————————————————————————————————————————————————————————— Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers 2026-10-26 · Business Wire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/iambic-presents-updated-iam1363-clinical-120000618.html IAM1363, now in a Phase 1/1b study, was designed using Iambic's molecular superintelligence platform and brought to clinical development in approximately two years Data presented at ESMO 2026 demonstrates IAM1363 was well tolerated with low rates of Grade 3 or higher treatment-related adverse events, serious adverse event ———————————————————————————————————————————————————————————— Automated Patient Follow-Up for Healthcare Practices 2026-10-26 · Express Press Release · AI, SaaS, Healthcare https://express-press-release.net/news/2026/10/26/1776228 NEW YORK, NY, 2026-10-26 — Novareach Digital, a New York-based AI growth platform, today announced automated patient follow-up for healthcare practices, built on [read full press release...] ———————————————————————————————————————————————————————————— Atlantis Medical Marks Five Years With Focus On Beard, Eyebrow And Scar Restoration 2026-10-26 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/atlantis-medical-marks-five-years-with-focus-on-beard-eyebrow-and-scar-restoration/89207345 Atlantis Medical marks its fifth year of operation in 2026 by highlighting specialised hair restoration procedures for beards, eyebrows and scar tissue, alongside its established treatments for men and women experiencing hair loss. -- Atlantis Medical is marking five years of operation in 2026, having been founded in 2021, and is highlighting its range of specialised restoration procedures that extend beyond standard ———————————————————————————————————————————————————————————— Monarch Mental Health Group Expands Comprehensive ADHD Assessments for Undiagnosed Adults 2026-10-26 · MarketersMEDIA · Healthcare, Medical devices https://news.marketersmedia.com/monarch-mental-health-group-expands-comprehensive-adhd-assessments-for-undiagnosed-adults/89207343 Monarch Mental Health Group has expanded its adult ADHD assessment service to combine psychological testing with formal psychiatric consultation and a structured post-diagnostic support programme for previously undiagnosed adults across Australia. -- Monarch Mental Health Group has expanded its adult ADHD assessment pathway for undiagnosed adults, pairing psychological testing and clinical interviews with a formal ps ———————————————————————————————————————————————————————————— ENvue Medical Issues Letter to Shareholders 2026-10-26 · ACCESS Newswire · Healthcare, Biotech & pharma, Medical devices https://finance.yahoo.com/healthcare/articles/envue-medical-issues-letter-shareholders-113000047.html Letter Highlights Inova Clinical Data, Hospital Customer Base and Leaner Operating Structure ARLINGTON HEIGHTS, IL / October 26, 2026 / ENvue Medical, Inc. (OTC PINK:FEED) ("ENvue," "ENvue Medical" or the "Company"), a medical technology company focused on enteral feeding and therapeutic ultrasound, toda ———————————————————————————————————————————————————————————— Transcatheter Aortic Valve Replacement Market: The Impact of Medical Imaging 2026-10-26 · Express Press Release · Healthcare https://express-press-release.net/news/2026/10/26/1778531 The global transcatheter aortic valve replacement market was valued at USD 6.8 billion in 2024 and is projected to grow from USD 7.9 billion in [read full press release...] ———————————————————————————————————————————————————————————— Boao Lecheng Opens Its Doors to Medical Tourists 2026-10-26 · MarketersMEDIA · Healthcare, Travel, Medical devices https://news.marketersmedia.com/boao-lecheng-opens-its-doors-to-medical-tourists/89207329 -- The "Tianya Teahouse" session of the "Let's Hainan" Media Salon kicked off on Oct. 23 in the atrium of the "Never-Ending" International Innovative Medical Devices Exhibition in Boao Lecheng. Guests sat among display cases of the latest approved medicines and devices, and between panels, tried singing-bowl healing and TCM diagnosis — the kind of wellness experience people now fly to Hainan for. This time, the talk ———————————————————————————————————————————————————————————— MacroGenics Announces Positive Interim Phase 2 LINNET Results for Lorigerlimab in Advanced Clear Cell Gynecologic Cancer 2026-10-26 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/26/3387988/0/en/macrogenics-announces-positive-interim-phase-2-linnet-results-for-lorigerlimab-in-advanced-clear-cell-gynecologic-cancer.html ROCKVILLE, MD, Oct. 26, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its ongoing Phase 2 LINNET study evaluating lorigerlimab, a bispecific DART® molecule that targets PD-1 and CTLA-4, in patients with CCGC. These Phase 2 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. ———————————————————————————————————————————————————————————— Serapha Bio Announces Positive Interim Safety and Efficacy Data from the SERP-01 Investigator-Initiated Trial Presented at the ERS Alpha-1 Antitrypsin Conference 2026 2026-10-26 · GlobeNewswire · Healthcare, Education, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3387986/0/en/serapha-bio-announces-positive-interim-safety-and-efficacy-data-from-the-serp-01-investigator-initiated-trial-presented-at-the-ers-alpha-1-antitrypsin-conference-2026.html NEW YORK, Oct. 26, 2026 -- Serapha Bio, Inc. (Serapha), a clinical-stage genetic medicines company committed to transforming the treatment of alpha-1 antitrypsin deficiency (AATD), today announced early clinical data for YOLT-202 (SERP-01), an investigational one-time in vivo base editing therapy, from the ongoing investigator-initiated trial (IIT) evaluating its safety and efficacy in four participants with the PiZZ genotype. Simon Krooss, M.D., Ph.D. of Hannover Medical School presented the data at the European Respiratory Society Alpha-1 Antitrypsin Conference 2026, held on October 23-24 in Barcelona, Spain. The IIT is being conducted through a collaboration between Renji Hospital in Shanghai, China and Hannover Medical School in Germany. ———————————————————————————————————————————————————————————— Medical Device Security Market to Reach USD 22234.52 Million by 2035, Driven by Connected Healthcare and Rising Cybersecurity Demand 2026-10-26 · MarketersMEDIA · Healthcare, Cybersecurity, Medical devices https://news.marketersmedia.com/medical-device-security-market-to-reach-usd-2223452-million-by-2035-driven-by-connected-healthcare-and-rising-cybersecurity-demand/89207319 The global Medical Device Security Market is projected to grow from USD 9046.21 million in 2026 to USD 22234.52 million by 2035, at a CAGR of 10.51%. -- Precision Reports projects that the global Medical Device Security Market is estimated at USD 9046.21 million in 2026 and is projected to reach USD 22234.52 million by 2035, growing at a CAGR of 10.51%. Market growth is supported by increasing cybersecurity threats, ———————————————————————————————————————————————————————————— RMTG's ISSCA Division Announces Successful Santa Cruz, Bolivia Conference, October 23-24 2026-10-26 · ACCESS Newswire · Healthcare, Education, Medical devices https://finance.yahoo.com/healthcare/articles/rmtgs-issca-division-announces-successful-110100934.html A new country on ISSCA's calendar extends the division's market-by-market Latin American education cadence. MIAMI, FL / October 26, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a regenerative medicine company operating through its wholly owned subsidiary Glob ———————————————————————————————————————————————————————————— Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 23 10 2026] - (CGWL) 2026-10-26 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/26/3387984/0/en/form-8-3-advanced-medical-solutions-group-plc-23-10-2026-cgwl.html FORM 8.3 ———————————————————————————————————————————————————————————— KFSH Showcases Nursing Leadership in Collaborative Clinical Care and Patient Safety 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952306446/kfsh-showcases-nursing-leadership-in-collaborative-clinical-care-and-patient-safety A KFSH nurse documenting patient care at the bedside in a hospital room RIYADH, SAUDI ARABIA, October 26, 2026 / EINPresswire.com / -- At King Faisal Specialist Hospital and Research Centre (KFSH), nurses play an integral role in patient safety and continuous improvement and take part in clinical decision-making. As essential members of multidisciplinary care teams, nursing professionals contribute their clinical exp ———————————————————————————————————————————————————————————— Pluri and ZEO ScientifiX Partner to Expand U.S. Manufacturing and Commercial Platform for Regenerative Medicine 2026-10-26 · EIN Presswire · SaaS, Healthcare, Industrial, Biotech & pharma https://www.einpresswire.com/article/951876113/pluri-and-zeo-scientifix-partner-to-expand-u-s-manufacturing-and-commercial-platform-for-regenerative-medicine Left to Right: Ian Bothwell-CEO of ZEO Scientifix, Bob Smoley- Founder of ZEO Scientifix, Yaky Yanay, President and Chief Executive Officer of Pluri Partnership combines Pluri’s proprietary cell technology and clinical-development experience with ZEO’s biologics manufacturing expertise FORT LAUDERDALE, FL, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Pluri and ZEO ScientifiX Partner to Expand U.S. Manufact ———————————————————————————————————————————————————————————— Trillium Wellness Brings Nature Therapy Approach to Mental Health Treatment in Tennessee 2026-10-26 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950803056/trillium-wellness-brings-nature-therapy-approach-to-mental-health-treatment-in-tennessee Trillium Wellness Center Logo KNOXVILLE, TN, UNITED STATES, October 26, 2026 / EINPresswire.com / -- Trillium Wellness is bringing a nature-centered approach to residential mental health treatment in Tennessee , integrating structured, therapist-led outdoor experiences with clinical care to support individuals on their journey toward healing and well-being. Located in the Knoxville area, Trillium Wellness incorporate ———————————————————————————————————————————————————————————— NVEC INVESTOR ALERT: Investigation of NVE Corporation Announced by Holzer & Holzer, LLC 2026-10-26 · GlobeNewswire · Finance, Healthcare, Legal, Medical devices https://www.globenewswire.com/news-release/2026/10/26/3387942/0/en/nvec-investor-alert-investigation-of-nve-corporation-announced-by-holzer-holzer-llc.html ATLANTA, Oct. 26, 2026 -- Holzer & Holzer, LLC is investigating whether NVE Corporation (“NVE” or the “Company”) (NASDAQ: NVEC) complied with federal securities laws. On October 21, 2026, NVE announced financial results for the second quarter of fiscal 2027 revealing a significant decrease in revenue, product sales, gross profit, and diluted earnings per share compared to the prior quarter. On the accompanying earnings call NVE disclosed that, “The decrease in product sales was due to a short-term inventory adjustment at one of our large medical device customers and a 95% decrease in defense product sales.” On this news, the price of the Company’s stock dropped. ———————————————————————————————————————————————————————————— Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 2026-10-26 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/immunome-presents-additional-clinical-data-110000030.html Rapid oral presentation highlights improvements in patient-reported symptom burden and physical function through week 48 Four presentations build on the previously reported Phase 3 RINGSIDE results BOTHELL, Wash., October 26, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology comp ———————————————————————————————————————————————————————————— RyCarma Announces First Patient Dosed in Phase 2 Clinical Trial of Surlorian for the Treatment of RYR1-Related Myopathy 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/rycarma-announces-first-patient-dosed-110000198.html RYR1-RM is one of the most common congenital skeletal muscle disorders and has no approved therapeutics Surlorian (ARM210) is a novel small molecule therapeutic designed to restore skeletal muscle function by targeting ryanodine receptors and calcium leak Phase 2 topline data are anticipated in the second half of 2027 BOS ———————————————————————————————————————————————————————————— Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV) 2026-10-26 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/enanta-pharmaceuticals-announces-first-patient-110000613.html Global Phase 2b/3 Study Will Evaluate Symptom Duration and Hospitalization Rates in Adult Outpatients at High Risk of Severe Outcomes from RSV Topline Phase 2b Data Expected in 2027 WATERTOWN, Mass., October 26, 2026--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company d ———————————————————————————————————————————————————————————— FDA Registration Assistance Opens U.S. Markets 2026-10-26 · MarketersMEDIA · Healthcare, Industrial https://news.marketersmedia.com/fda-registration-assistance-opens-us-markets/89207302 A global compliance partner helps exporters enter the United States with clarity, speed, and confidence. -- A shipment is ready to leave the factory. Labels are printed, pallets are wrapped, buyers are waiting, and a new opportunity in the United States seems within reach. Then a question stops the momentum: has every FDA requirement been handled before the product reaches the border? For many international companies ———————————————————————————————————————————————————————————— Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress 2026-10-26 · PressReach · Healthcare, Biotech & pharma, Government & policy https://pressreach.com/eikon-therapeutics-presents-updated-eik1001-data-from-teluride-005-at-the-european-society-for-medical-oncology-congress TLR7/8 dual-agonist EIK1001 plus pembrolizumab and chemotherapy in first-line, stage 4 non-small cell lung cancer (NSCLC) demonstrates durable effect in combination with standard-of-care, and a tolerability profile supportive of systemic administration in an outpatient setting With median follow-up of 12.7 months, objective response rate (ORR) for the squamous cohort was 72% and disease control rate … Continue reading "Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress" ———————————————————————————————————————————————————————————— Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company 2026-10-26 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/corxel-us-and-amanat-acquisition-corp-announce-definitive-business-combination-agreement-to-create-publicly-listed-obesity-focused-biopharmaceutical-company Combined company expected to advance differentiated oral obesity franchise led by CX11, a clinical-stage, once-daily oral small-molecule GLP-1 receptor agonist (“RA”), and CX12, a preclinical oral small-molecule amylin receptor agonist. CX11 has demonstrated clinically meaningful weight loss and a generally favorable tolerability profile across Phase 2 obesity studies in the United States. Following an End-of-Phase … Continue reading "Corxel US and Amanat Acquisition Corp Announce Definitive Business Combination Agreement to Create Publicly Listed Obesity-Focused Biopharmaceutical Company" ———————————————————————————————————————————————————————————— New Framework Aims to Identify Antibiotic Resistance Risks Before Clinical Trials 2026-10-26 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/951732798/new-framework-aims-to-identify-antibiotic-resistance-risks-before-clinical-trials The framework guides antibiotic development through screening, resistance risk assessment and classification to prioritise, optimise or deprioritise compounds. Predicting antibiotic resistance early in drug development could help researchers identify promising candidates before clinical trials. Drug candidates are assessed for efficacy and safety early in development, but how readily bacteria can evolve resistance is ———————————————————————————————————————————————————————————— Former FDA Head Dr. Stephen Hahn Joins BreakBio, a Personalized Cancer Drug Company, as Advisor 2026-10-26 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951874106/former-fda-head-dr-stephen-hahn-joins-breakbio-a-personalized-cancer-drug-company-as-advisor Dr. Stephen Hahn, Former FDA Commissioner BreakBio, which uses AI to design cancer drugs tailored to each patient’s own tumor, taps former FDA chief Dr. Stephen Hahn to help shape a new era of medicine. I believe we are entering a new era of medicine in which therapies designed for each patient become an important new class of pharmaceuticals.” — Dr. Stephen Hahn MIAMI, FL, UNITED STATES, October 26, 2026 / EINPressw ———————————————————————————————————————————————————————————— Recent Release, "Fabulous Food Life Cookbook," from Fulton Books Author Gail Du Fossé, Offers a Guide to Home Cooking, Wellness, and Sophisticated Entertaining 2026-10-26 · PR.com · Healthcare, Travel, Food & drink https://www.pr.com/press-release/982204 Gail du Fossé has completed a new book, titled, "Fabulous Food Life Cookbook": Volume 1, a comprehensive cookbook, diet, and lifestyle guide that celebrates the art of home cooking and gracious hospitality as the foundation for excellent health. This beautifully curated collection features unprocessed ingredients designed to be low in fat and carbs without artificial substitutes, allowing readers to enjoy [PR.com] ———————————————————————————————————————————————————————————— Recent Release, "Killer Schools," from Christian Faith Publishing Author Jennifer Kindred, Exposes Hidden Environmental Dangers Destroying Health in America's Classrooms 2026-10-26 · PR.com · Healthcare, Education https://www.pr.com/press-release/982174 Jennifer Kindred has completed a new book, "Killer Schools," a unflinching account of how toxic mold in school buildings systematically dismantled her career, marriage, and physical health. For over two decades, she dedicated herself to nurturing children with special needs, pouring her passion into their educational journeys. Then, gradually and relentlessly, water damage and mold infiltration transformed her [PR.com] ———————————————————————————————————————————————————————————— President Herminie Discharged from Seychelles Hospital 2026-10-26 · APO Group · Healthcare https://www.africa-newsroom.com/press/president-herminie-discharged-from-seychelles-hospital?lang=en The President of the Republic, Dr Patrick Herminie, has been discharged from the Seychelles Hospital following a full recovery. The President will resume his official duties at State House on Wednesday 28 October 2026. The President extends his sincere gratitude to the doctors, nurses, medical professionals and all staff of the Seychelles Hospital for their dedication, professionalism and the excellent care he received during his stay. The President also thanks the people of Seychelles for their thoughts, prayers and expressions of concern during his illness. Distributed by APO Group on behalf of State House Seychelles. ———————————————————————————————————————————————————————————— $LULU Stock Losses: BFA Law Reminds Lululemon Investors with Losses of the Ongoing Securities Fraud Investigation into Potential Growth Misrepresentations 2026-10-26 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/26/3387888/0/en/lulu-stock-losses-bfa-law-reminds-lululemon-investors-with-losses-of-the-ongoing-securities-fraud-investigation-into-potential-growth-misrepresentations.html BFA Law is investigating whether Lululemon committed securities fraud by making false and misleading statements to investors regarding the strength of its growth and overall business health. BFA Law is investigating whether Lululemon committed securities fraud by making false and misleading statements to investors regarding the strength of its growth and overall business health. ———————————————————————————————————————————————————————————— Atom Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Lingdolinurad (ABP-671) for Chronic Kidney Disease with Hyperuricemia 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/atom-therapeutics-announces-first-patient-093000982.html HANGZHOU, China & NEWARK, Calif., October 26, 2026--Atom Therapeutics, an innovative clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases, today announced that the first patient has been successfully do ———————————————————————————————————————————————————————————— BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer 2026-10-26 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/biontech-and-dualitybio-announce-topline-results-of-the-dynasty-breast02-global-phase-3-clinical-trial-evaluating-trastuzumab-pamirtecan-in-hr-her2-low-metastatic-breast-cancer MAINZ, Germany and SHANGHAI, China, October 26, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and DualityBiologics (Suzhou) Co., Ltd. (“DualityBio”, HKEX: 9606.HK) announced today that the DYNASTY-Breast02 global Phase 3 clinical trial (NCT06018337) met its primary endpoint demonstrating a statistically significant, yet modest improvement in progression-free survival (“PFS”) with trastuzumab pamirtecan (BNT323/DB-1303) compared to investigator’s choice of chemotherapy in chemotherapy-naïve patients … Continue reading "BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer" ———————————————————————————————————————————————————————————— Sodium Chlorite Market to Hit US$ 416.37 Million by 2034 at 3.98% CAGR 2026-10-26 · PR News Releaser · Healthcare, Industrial https://www.prnewsreleaser.com/news/478540 The Sodium Chlorite Market is set for steady growth as water, health and industrial users look for dependable disinfection and bleaching tools. It was valued at US$ 293.03 million in 2025. It is expected to reach US$ 416.37 million by ... Read more ———————————————————————————————————————————————————————————— Why Every Stage of Life Matters for a Woman's Heart Health 2026-10-26 · NewMediaWire · Healthcare, Media, Education, Food & drink, Nonprofits, Internet & apps, Medical devices https://www.newmediawire.com/news/why-every-stage-of-life-matters-for-a-woman-s-heart-health-7090853 What to know about women’s heart health: A new approach to women’s heart health looks at risk and opportunity across every stage of their life. Hormonal health, mental health and well-being, heart health and brain health are closely connected. Periods, pregnancy and the time around and during menopause can offer important opportunities to better protect heart health. DALLAS - October 26, 2026 - A new approach to women’s heart health may offer them a lifetime of opportunities. A trio of scientific papers, published today in the journal Circulation, spells out how fluctuating hormones, mental health and well-being, the heart and the brain are linked and how those connections need to be a routine part of care from a young age. “Women experience their healthcare across clinical specialties, but it often is fragmented or disconnected. Specifically, these reports connect the dots for clinicians, for patients, and across health domains so that care is holistic and begins in adolescence,” Dr. Sadiya Khan, chair of the writing group, said in a news release. Khan is the Magerstadt Professor of Cardiovascular Epidemiology at Northwestern University’s Feinberg School of Medicine in Chicago. “Heart disease and other forms of cardiovascular disease don’t suddenly become relevant when we become older women,” said Dr. Stacey E. Rosen, immediate past volunteer president of the American Heart Association, who helped write the reports. They view a woman’s life in distinct stages – each of which offers chances for early detection, risk factor identification and treatment, she said. The publications are a joint effort among the Heart Association, the American Academy of Pediatrics, the American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine. They represent “a paradigm shift in how we look at women’s cardiovascular and brain health,” Rosen said. For pediatricians, primary care clinicians, endocrinologists, obstetricians, gynecologists and cardiologists, the documents offer a unified approach to cardiovascular concerns specifically for women, said Dr. Esther S.H. Kim, director of the Center for Women’s Cardiovascular Health at Atrium Health in Charlotte, North Carolina. She also helped write the publications. Each stage of a woman’s life offers “windows of opportunity” to prevent heart disease, she said.“We can go all the way back to adolescence and even childhood and figure out, ‘This person is at risk; we need to keep a closer eye on them," said Kim, who is also a professor and chair of cardiovascular medicine at the Wake Forest University School of Medicine in Charlotte. For women themselves, it comes down to a simple point, said Dr. Natalie A. Cameron, an internal medicine specialist who is an assistant professor at Northwestern. She led the writing team for one of the documents and contributed to the other two.“We don’t want heart attacks and strokes to happen,” she said. By being proactive, women have opportunities to lower their risks. Here are some of the key points from the new publications that women may want to discuss with their healthcare team to ensure their hearts are as healthy as possible. How does heart disease differ in men and women? The reports emphasize how hormonal health affects cardiovascular health across a woman’s life. For years, scientists ignored the importance of hormones in women’s heart health, Rosen said, because the monthly fluctuations made research more complicated. But estrogen, estradiol and progesterone “impact cells in blood vessels, in the brain, in heart muscle,” Rosen said. They affect cholesterol levels, the stickiness of blood cells, inflammation, blood pressure and the body’s stress response. “If you appreciate the understanding that these hormones are not just affecting the uterus, ovaries and fallopian tubes but affecting in a rhythmic way every part of the cardiovascular system and brain, you can appreciate why these fluctuations or issues related to these hormones in women have an enormous impact” on heart and brain health, she said.   And while the most common cardiovascular issue in women is the same as in men - plaque buildup that narrows arteries - Kim said that women are more likely to have other serious problems. The classic image of heart disease, Kim said, is a “Homer Simpson-type of person - a middle-aged or older man with very obvious cardiovascular risk factors. But you know, Marge Simpson can also have heart disease.” “And the heart disease that Marge could have may look different than Homer’s; things like microvascular coronary disease, which affects small blood vessels in the heart; or heart failure with preserved ejection fraction, in which the heart contracts normally but fails to relax properly between beats; or spontaneous coronary artery dissection, where a heart artery suddenly tears,” Kim said.   Doctors need to think about such conditions in women, Kim said, because they require specific diagnostic tests, “and if you don’t think of the disease processes, you won’t order the right tests, and these diseases will be missed.” And women should not be afraid to speak up, Kim said. “Know the symptoms of cardiovascular disease, and if you’re having them, talk about them,” Kim said. “And if your doctor is ignoring you, you should be persistent.” Why the teen years matter in women’s heart health “Heart health for women doesn’t start at menopause,” said Dr. Amanda M. Perak, an associate professor of pediatrics and preventive medicine at Northwestern. “Puberty is a big turning point.” For example, details about menstrual cycles, or periods, offer a look at future heart health, said Perak, who is also a pediatric cardiologist at Ann & Robert H. Lurie Children's Hospital of Chicago who worked on all three publications. She said: A first period before age 10 is linked to a higher risk of heart disease later in life. “That’s not automatically a reason for alarm or medication,” Perak said. “It’s a reason to pay a little closer attention to healthy habits and routine checkups.” Irregular periods, especially along with stubborn, deep acne or unusually extra facial or body hair growth, can be a sign of polyendocrine metabolic ovarian syndrome (previously known as polycystic ovary syndrome, or PCOS), which has been linked to problems regulating blood sugar, diabetes and heart disease later on. “Some irregularity is expected in the first one to three years after a girl’s first period,” Perak said, “so what matters is a pattern that persists.” By knowing their period history, older teens can be ready to talk with their adult doctor or healthcare professional after they leave a pediatrician’s care. “The goal isn't to worry teens about the chance of a heart attack, which are decades away for nearly all of them,” Perak said. “It’s that the teen years are when patterns get set, and it’s much easier to keep good heart health than to get it back.” Early adulthood: What women may want to discuss with their doctors “Women should just be aware that they can be at risk for cardiovascular disease,” Kim said. She has worked with older women who were referred to her for testing that measures plaque buildup in the heart’s arteries and were “shocked out of their minds” to see abnormal scores. If those women had been aware of cholesterol problems, family history issues or the need for healthy habits at an earlier age, their abnormal scores might have been prevented, she said. “At every phase of life, women can ask their clinicians, ‘How can I optimize my heart health?’” Cameron said. And at every phase, the basics known as Life’s Essential 8 will be part of the answer.  That means maintaining healthy weight, blood pressure, blood sugar and cholesterol levels; eating a healthy diet; getting enough physical activity and quality sleep; and avoiding tobacco. Other important questions Cameron suggested include: What is a normal period? Abnormalities at this age can signal higher cardiovascular risk.   How do contraceptive options affect heart health? Some are better for women with heart disease or cardiovascular disease risk factors.   If a woman is planning pregnancy, does she need any specific tests related to her history or medication adjustments? The reports emphasize the importance of having good cardiovascular health before pregnancy. But 9 out of 10 women ages 20 to 44 have less-than-ideal heart health when they become pregnant. After pregnancy: Why heart health still matters postpartum   Pregnancy is often seen as a stress test for the heart. High blood pressure in pregnancy, gestational diabetes, or having a preterm birth, are linked to higher risk of heart disease later in life, Cameron said. The first year after a pregnancy is also “a very critical time” for controlling and monitoring those risks, she said. But many women face challenges that prevent them from getting follow-up care. The links between a woman’s mental health and their heart For women, mental health and well-being, hormonal health and heart health are connected in many ways at every life stage. Mood changes, which may include symptoms of anxiety and depression, can be related to hormonal fluctuations.  Anxiety or depression may influence lifestyle choices. “You may exercise less or eat less healthy foods if you’re feeling very depressed,” Cameron said. Starting around age 12, eating disorders, which can affect future cardiovascular health, become more common in girls, Perak said. By age 17, girls are twice as likely as boys to be diagnosed with depression. Teens with depression are more likely to develop obesity later, Perak said, and teens with obesity are more likely to develop depression. Women with established cardiovascular disease are more likely to have depression and anxiety, Rosen said, while depression and anxiety can harm their cardiovascular health.  The new series of papers call for making mental health and well-being screening a routine part of a woman’s care.  What happens to heart health before and after menopause? Hormones fluctuate in the years before menopause, Cameron said. “In general, as those changes are happening, women may experience increases in their low-density lipoprotein (“bad cholesterol”) levels, weight gain and potentially rising blood pressure.” It’s also a time when years of unhealthy lifestyle choices may start to catch up, and overt heart disease may emerge. Does that mean it’s time to throw in the towel and surrender to something inevitable? “The answer is an absolute, positive, emphatic no,” Rosen said. It's never too late to make healthy changes.  But the years around menopause are a good time for a woman and her healthcare team to discuss questions such as:   Am I at risk for heart disease? What can I do about it?  What tests should I have? “It's really important to know your numbers and monitor those numbers with a clinician at your annual visits, or more often” if you're actively managing blood pressure or cholesterol levels, Cameron said. What should women know about menopause and heart health? Menopause marks the end of a woman’s periods. But if she lives an average life span, 40% of her life is still ahead of her. Key things a woman may want to discuss with her healthcare team, Rosen said, include: How do I predict my risk? A doctor may use a risk calculator, such as the American Heart Association’s PREVENT equations, to guide care. What can I do to address those essential risk factors?   Sleep, for example, is often a concern during menopause, Rosen said. Anyone having problems may want to ask, “Is this something to be concerned about and how should I be evaluated? What are treatment options?” What else can I do to make sure the next 40 years are as healthy as possible? It’s never too late to do something, Rosen emphasized, noting that her mother, 87, was just put on cholesterol-lowering medications – a decision she heartily endorsed. “It’s always about opportunities,” she said. How coordinated care can support women’s heart health Women’s healthcare is fragmented, Cameron said. Over the course of her life, she may see a pediatrician, primary care doctor, obstetrician/gynecologist, cardiologist and psychologist. Communication is not a given, and health records do not always transfer. The new publications spell out the need for unified care, but women can find ways to own and organize their own health journey as well, Rosen said. “I joke with new patients, ‘You would never go to your accountant before tax season without your paperwork,’” expecting them to know your salary and what taxes you’ve paid in the past. So whether it’s in a notepad or a digital folder, Rosen encourages tracking that medical history as a way of taking an active role in care. Cameron suggested asking anyone who sees multiple doctors if their clinicians can see each other’s medical notes and whether they’ve talked. Some of her patients have provided phone numbers to help her connect with clinicians outside of her healthcare system. Some women are better taking such steps on behalf of others, Rosen said. A woman caring for a sick parent or child can be “a lioness” about preventive care. “Remind yourself that you’re worthy of doing that work for yourself.” Cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in women, claiming more than 400,000 lives in the U.S. each year. That’s more than breast cancer, lung cancer and chronic lung disease combined. Yet only about 4 in 10 women recognize it as their greatest health threat. The American Heart Association, through its Go Red for Women initiative, aims to empower women to take charge of their heart health. Resources are available to help protect and strengthen your heart at every stage of life. Additional Resources: Multimedia, including survivor/patient video interview clips, is on the right column of the release link. Infographic (PDF) - A Woman’s Heart Through Every Stage of Life - A guide to protecting your heart from your first period through menopause and beyond What Women Need to Know - Adolescence Infographic (PDF). Learn more about supporting good heart health in adolescence. What Women Need to Know - Young Adulthood Infographic (PDF). Learn more about supporting good heart health in pregnancy and postpartum. What Women Need to Know - Perimenopause Infographic (PDF). Learn more about supporting good heart health in midlife. What Women Need to Know - Postmenopause Infographic (PDF). Learn more about supporting good heart health during menopause and beyond. Infographic (PDF) - My Heart & Health Checklist - Questions to think about before your next visit American Heart Association news release: Leading health groups redefine heart health for girls and women - Spanish news release (Oct. 26, 2026) American Heart Association News story: Why every stage of life matters for a woman's heart health (Oct. 26, 2026) American Heart Association news release: New cardiology-OB-GYN continuing education to launch with $1 million gift from leading media voice on health Dr. Jennifer Ashton and husband Tom Werner American Heart Association news release: This is Our Lane - Too: Joint Statement on the Maternal Health Crisis from the Association of Black Cardiologists, American College of Cardiology and American Heart Association Follow AHA/ASA news on X @HeartNews. Follow news from the American Heart Association's flagship journal Circulation @CircAHA. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Maggie Francis; Maggie.Francis@heart.org For Public Inquiries: 1-800-AHA-USA1 (242-8721) heart.org and stroke.org ———————————————————————————————————————————————————————————— Leading Health Groups Redefine Heart Health for Girls and Women 2026-10-26 · NewMediaWire · Finance, Healthcare, Media, Education, Biotech & pharma, Nonprofits, Internet & apps https://www.newmediawire.com/news/leading-health-groups-redefine-heart-health-for-girls-and-women-7090852 Highlights: For the first time, the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine have come together to release shared guidance to help clinicians identify cardiovascular risk early and take action. The landmark three-part publication highlights how female-specific biology affects girls’ and women’s hearts and creates a “Female Life Stage” framework to help protect heart health from puberty through menopause and beyond. The societies also call for a national network of Comprehensive Centers of Excellence for Women's Cardiovascular Care, built on four pillars: interdisciplinary clinical care, professional education and training, research and community engagement. DALLAS - October 26, 2026 - Today, the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists and the Society for Maternal-Fetal Medicine released a landmark publication that redefines heart health in girls and women. The organizations together outline four distinct “Female Life Stages” offering women and healthcare professionals a chance to have heart health conversations from puberty through menopause and beyond. Three manuscripts published today in the American Heart Association’s flagship journal, Circulation, are the first coordinated, multi-society framework to prevent, detect and manage cardiovascular disease among girls and women. The publications outline a path to connect care across the clinical specialties that see women throughout their lives. “Women experience their healthcare across clinical specialties, but it often is fragmented or disconnected,” said Sadiya S. Khan, M.D., M.Sc., FAHA, chair of the collaborative writing group and Magerstadt Professor of Cardiovascular Epidemiology at Northwestern University Feinberg School of Medicine in Chicago. “Specifically, these reports connect the dots for clinicians, for patients and across health domains so that care is holistic and begins in adolescence, recognizing that women’s heart health is uniquely shaped by biological transitions not experienced by men – periods, pregnancy, perimenopause and menopause.” According to the American Heart Association, cardiovascular disease, which includes heart disease and stroke, is the leading cause of death in women, claiming more than 400,000 lives in the U.S. each year - more than breast cancer, lung cancer and chronic lung disease combined. Yet only about 4 in 10 (41%) women recognize it as their greatest health threat. “Women make up more than half the population, and their heart health must be a part of everyday care across medicine,” said Mariell Jessup, M.D., FAHA, chief science and medical officer of the American Heart Association. “These publications give clinicians and health systems a shared foundation for recognizing risk throughout a woman’s life.” Why a new approach is needed Progress has stalled in preventing cardiovascular deaths among women over the past two decades. To get ahead of risk, the new approach to women’s cardiovascular health views it as a lifelong process. A 2026 American Heart Association scientific statement that forecasted women’s health and risk factors concluded that if trends continue through 2050, the proportion of U.S. women ages 20 and older living with high blood pressure will increase from approximately 49% in 2020 to 59% in 2050. At the same time, maternal mortality has increased and cardiovascular disease is now the leading cause of medical-related deaths during pregnancy. The American Heart Association notes that cardiovascular conditions account for more than one-third of maternal mortality in the U.S. "These projections underscore the urgency of making cardiovascular health a priority at every stage of a woman’s life,” said Khan. “This new approach gives clinicians across specialties shared guidance to recognize risk earlier, personalize prevention, and act before a heart attack, stroke or heart failure event." A first-of-its-kind Female Life Stage framework The Female Life Stage framework is based on female biology and offers windows of opportunity to prevent heart disease and stroke. Each life stage is defined by a change in hormones that is uniquely experienced by girls and women, with pregnancy identified as an event affecting cardiovascular health that may occur at any or multiple life stages: Stage 1 perimenarche - This stage represents the transition around the first menstrual period. Approximate age range is 8 - 15 years. Stage 2 ovarian cycling - Regular ovulatory and hormone cycles are established and when pregnancy typically occurs. Approximate age range is 15 - 44 years. Stage 3 perimenopause - This stage represents the transition to variable cycle length, skipped cycles and hormone changes. Approximate age range is 45-51 years. Stage 4 postmenopause - This stage represents the years that begin after menopause or 12 months after the final menstrual period. Approximate age is 51 years and older. Pregnancy, in any life stage - the time before, during and after pregnancy is highlighted as a biological “stress test” that can identify cardiovascular risks that may have been previously unrecognized. Within each life stage, the framework takes a holistic approach to women’s heart health by considering cardiovascular, hormonal and emotional health together, Khan said. “For clinicians, this approach underscores that heart health cannot be understood by looking at the heart alone. We need to recognize that women’s heart health is deeply interconnected with hormonal and emotional health.” The framework also allows for earlier recognition of risk, earlier prevention, and better continuity of care beginning in childhood. “Heart health begins long before adulthood,” said Amanda Marma Perak, M.D., M.Sc., FAHA, vice-chair of the collaborative writing group and a pediatric cardiologist at Lurie Children’s Hospital in Chicago. “As pediatric clinicians, we have the opportunity to help every girl start strong and to ensure that what we learn about her health follows her as she grows.” Heart, hormonal and psychosocial health connections Periods can be a marker of heart health. The new publications recognize menstrual cycle patterns as a female-specific vital sign. Specifically, heavy or irregular menstrual bleeding can serve as early markers of cardiovascular risk, such as polyendocrine metabolic ovarian syndrome (PMOS, formerly known as polycystic ovary syndrome, or PCOS). Perimenopause is a cardiovascular inflection point. Changes in cholesterol and metabolic health during the perimenopause stage can be early signs of cardiovascular risk. Identifying risk early and acting on it may reduce risk of cardiovascular disease. Postmenopause is an important time for cardiovascular disease prevention. The years after menopause can represent up to 40% of a woman’s lifetime. Most heart attacks, strokes and heart-failure events occur in this stage, and they are more than 80% preventable if action is taken early. Psychosocial health is important for heart health. Women are more likely to experience anxiety, depression and eating disorders, each of which can contribute to poor heart health. Pregnancy history is heart history. Changes in pregnancy can unmask cardiovascular disease risk. Pregnancy complications such as high blood pressure, preeclampsia, gestational diabetes, preterm birth, small-for-gestational-age infants and stillbirth, are recognized as female-specific risk enhancers. The 2026 American Heart Association/American College of Cardiology cholesterol guideline now includes pregnancy-related factors in cardiovascular risk assessment for women. Postpartum care is often a missed opportunity. Only about 60% of U.S. women with high blood pressure-related complications during pregnancy receive follow-up care for their high blood pressure within six months of delivery. The American Heart Association and the collaborating societies call for immediate action on this prevention gap. “Pregnancy and the postpartum period are important windows into cardiovascular health throughout the life course. An adverse pregnancy outcome can unmask increased cardiovascular risk and that information should guide care well beyond pregnancy,” said William A. Grobman, M.D., MBA, vice-chair of the writing group and professor of obstetrics & gynecology at The Warren Alpert Medical School of Brown University in Providence, Rhode Island. “This multi-society guidance gives clinicians who provide obstetric, gynecologic, and cardiovascular care a shared framework for recognizing and acting on that risk.” Grobman is also a former president of the Society for Maternal‑Fetal Medicine and associate dean of clinical research at Brown. Translating evidence into coordinated interdisciplinary care The societies call for a national infrastructure of Comprehensive Centers of Excellence for Women's Cardiovascular Care, built on four pillars: interdisciplinary clinical care, professional education and training, research and community engagement. Existing tools and therapies offer opportunities to improve cardiovascular health now, while research is needed to continue to address gaps in evidence specific to women by prioritizing inclusion of women in research, expansion of funding of women’s health, and translation of evidence into action. “Over the last several decades, research has led to substantive advances in the understanding of female-specific risk of cardiovascular disease,” Khan said. “Today, cardiovascular risk can be identified earlier in women with 10- and 30-year sex-specific risk estimation using the American Heart Association PREVENT equations. The goal is to assess health comprehensively and longitudinally across life stages, identify earlier opportunities for prevention, and close implementation gaps for women.” “All girls and women deserve more healthy years to live their fullest lives,” Khan said. “Advancing women’s health is a responsibility we all share. This investment improves not only women’s health, but also the health of their families and their communities.” Editor's Notes Joint guidance on the management of women’s cardiovascular disease across the life course is made up of three papers. Links will be live when the manuscripts publish online: Presidential Advisory: A Female-Specific Life Course Approach to the Prevention and Management of Cardiovascular Disease – establishes the female life stage construct and life course framework Scientific Statement: Consensus Guidance for the Female-Specific Prevention and Management of Cardiovascular Disease – provides clinical guidance, including a multi-society guideline crosswalk Science Advisory: Comprehensive Centers of Excellence for Women's Cardiovascular Care – maps the current landscape of women’s cardiovascular centers and proposes a national infrastructure The papers were all prepared by the volunteer writing group on behalf of the American Heart Association, American Academy of Pediatrics, American College of Obstetricians and Gynecologists, and the Society for Maternal-Fetal Medicine. American Heart Association scientific statements and advisories promote greater awareness about cardiovascular diseases and stroke issues and help facilitate informed health care decisions. Scientific statements outline what is currently known about a topic and what areas need additional research. While scientific statements inform the development of guidelines, they do not make treatment recommendations. American Heart Association guidelines provide the Association’s official clinical practice recommendations. Co-authors, disclosures and funding sources are listed in the manuscripts. The Association receives more than 85% of its revenue from sources other than corporations. These sources include contributions from individuals, foundations and estates, as well as investment earnings and revenue from the sale of our educational materials. Corporations (including pharmaceutical, device manufacturers and other companies) also make donations to the Association. The Association has strict policies to prevent any donations from influencing its science content and policy positions. Overall financial information is available here. Additional Resources: Multimedia, including video interviews with Sadiya S. Khan, M.D., M.Sc., FAHA, chair of the collaborative writing group and patients, are on the right column of the release link. Spanish news release Infographic (PDF) - A Woman’s Heart Through Every Stage of Life - A guide to protecting your heart from your first period through menopause and beyond What Women Need to Know - Adolescence Infographic (PDF). Learn more about supporting good heart health in adolescence. What Women Need to Know - Young Adulthood Infographic (PDF). Learn more about supporting good heart health in pregnancy and postpartum. What Women Need to Know - Perimenopause Infographic (PDF). Learn more about supporting good heart health in midlife. What Women Need to Know - Postmenopause Infographic (PDF). Learn more about supporting good heart health during menopause and beyond. Infographic (PDF) - My Heart & Health Checklist - Questions to think about before your next visit American Heart Association news release: Why every stage of life matters for a woman’s heart health American Heart Association News story: Why every stage of life matters for a woman's heart health American Heart Association news release: New cardiology-OB-GYN continuing education to launch with $1 million gift from leading media voice on health Dr. Jennifer Ashton and husband Tom Werner American Heart Association news release: This is Our Lane - Too: Joint Statement on the Maternal Health Crisis from the Association of Black Cardiologists, American College of Cardiology and American Heart Association Follow Association news on X @HeartNews. Follow news from the American Heart Association's flagship journal Circulation @CircAHA. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1. For Media Inquiries: 214-706-1173 Maggie Francis; Maggie.Francis@heart.org For Public Inquiries: 1-800-AHA-USA1 (242-8721) heart.org and stroke.org ———————————————————————————————————————————————————————————— HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026 2026-10-26 · PressReach · Healthcare, Biotech & pharma, Government & policy https://pressreach.com/hutchmed-highlights-sanovo-phase-iii-data-for-orpathys-plus-tagrisso-in-first-line-egfr-mutated-lung-cancer-presented-at-esmo-congress-2026 — ORPATHYS® plus TAGRISSO® reduced the risk of disease progression or death by 44% in the overall population and 55% in the high MET overexpression population in the first-line setting —  — Robust PFS gains alongside very encouraging OS clinical benefit in this treatment-naïve biomarker-selected patient population —  — Offers a potential new standard of care through … Continue reading "HUTCHMED Highlights SANOVO Phase III Data for ORPATHYS® plus TAGRISSO® in First-Line EGFR-Mutated Lung Cancer Presented at ESMO Congress 2026" ———————————————————————————————————————————————————————————— Cantargia Appoints Dr. Monic Stuart as Chief Medical Officer 2026-10-26 · ACCESS Newswire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/cantargia-appoints-dr-monic-stuart-084500867.html LUND, SE / October 26, 2026 / Cantargia AB (publ)(STO:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced the appointment of Monic Stuart, MD, PhD, MBA as Chief Medical Officer, effective immediately. Dr. Stuart will lead the clinical de ———————————————————————————————————————————————————————————— CStone Announces Major Clinical Validation Milestone for CS2009 at ESMO 2026: Data from More Than 300 Patients Support Mechanism, Safety and Broad Antitumor Activity 2026-10-26 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cstone-announces-major-clinical-validation-milestone-for-cs2009-at-esmo-2026-data-from-more-than-300-patients-support-mechanism-safety-and-broad-antitumor-activity-302919153.html CS2009, an Innovative PD-1/VEGF/CTLA-4 trispecific antibody, demonstrates a differentiated profile through synergistic triple-pathway targeting, favorable tolerability and encouraging efficacy across multiple solid tumors Highlights Three pillars of clinical validation: Clinical data from... ———————————————————————————————————————————————————————————— Phathom Pharmaceuticals Provides Update on FDA Litigation 2026-10-26 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma, Legal https://pressreach.com/phathom-pharmaceuticals-provides-update-on-fda-litigation FLORHAM PARK, N.J., Oct. 26, 2026 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, today announced the U.S. Food and Drug Administration’s (FDA’s) establishment of a public docket (Docket No. FDA-2026-N-13038) to solicit comment on legal and regulatory questions regarding certain … Continue reading "Phathom Pharmaceuticals Provides Update on FDA Litigation" ———————————————————————————————————————————————————————————— Asundexian first Factor XIa inhibitor approved in China for stroke risk reduction after priority review 2026-10-26 · Bayer · Healthcare, Biotech & pharma https://www.bayer.com/media/en-us/asundexian-first-factor-xia-inhibitor-approved-in-china-for-stroke-risk-reduction-after-priority-review/ Berlin, October 26, 2026 – Bayer announced today that China’s National Medical Products Administration (NMPA) has granted marketing authorization for asundexian, under the brand name Sunharbo®. Asundexian, 50 mg, a selective, once-daily oral Factor XIa inhibitor (FXIa), is indicated to reduce the risk of stroke in adults after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). Sunharbo® (asundexian) is the first FXIa inhibitor approved worldwide. In China, stroke is the leading cause of death and disability. Between 2010 and 2021, the prevalence of ischemic stroke increased by 10% to more than 20 million ischemic stroke cases in China. Globally, approximately 1 in 10 non-cardioembolic ischemic stroke survivors experience another stroke within one year, even with available secondary stroke prevention strategies. “With the approval of asundexian, we have reached an important milestone and are proud soon to be able to offer physicians in China a new treatment option for stroke survivors after a non-cardioembolic ischemic stroke or high‑risk transient ischemic attack. This enables us to address an unmet need with limited therapeutic advances over the past two decades," said Christian Rommel, Ph.D., Global Head of Research and Development at Bayer`s Pharmaceuticals Division. "We are working with stakeholders and medical communities to support equitable and timely access for eligible patients in China."  Asundexian has been submitted for marketing authorization in additional markets around the world. These applications are currently under review, while Bayer continues to work with health authorities worldwide to bring asundexian to patients in other regions. Key Clinical Trial Findings Supporting Approval The approval by China’s National Medical Products Administration (NMPA) is based on positive data from the pivotal, global Phase III OCEANIC-STROKE study, the first successfully completed Phase III study of a Factor XIa inhibitor in combination with dual antiplatelet therapy (DAPT) / single antiplatelet therapy (SAPT) demonstrating superiority in reducing ischemic stroke, compared to DAPT/SAPT alone. The incidence of all bleeding events was similar between the two treatment groups, in patients after a non-cardioembolic stroke or high-risk TIA. Key findings demonstrated: Asundexian 50 mg in combination with DAPT/SAPT, significantly reduced ischemic stroke by 26% in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA), compared to DAPT/SAPT alone. The incidence of all bleeding events was similar between the two treatment groups. Treatment effect for the primary endpoint was consistent across key subgroups (including age, sex, type of index event, non-cardioembolic stroke subtypes, stroke severity, and planned antiplatelet therapy) supporting its potential use across a broad patient population. The full results from OCEANIC-STROKE have been published in The New England Journal of Medicine About OCEANIC-STROKE The Phase III OCEANIC-STROKE study investigated the efficacy and safety of the selective, once-daily oral Factor XIa inhibitor asundexian 50 mg in combination with DAPT/SAPT, compared to DAPT/SAPT alone, for risk reduction of ischemic stroke in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack (TIA). OCEANIC-STROKE is a multicenter, international, randomized, placebo-controlled, double-blind, parallel group and event-driven study, that randomized 12,327 participants worldwide. The primary efficacy endpoint was time to ischemic stroke; the primary safety endpoint was ISTH (International Society on Thrombosis and Hemostasis) major bleeding. About FXIa Inhibitors and Asundexian Factor XIa (FXIa) is a protein in the blood coagulation pathway with different roles in hemostasis and thrombosis. FXIa is thought to contribute to the formation of pathological thrombus growth and vessel blockage. However, FXIa has a minor role in the formation of a hemostatic plug that seals the leak at the site of vessel injury. Asundexian is the first approved FXIa inhibitor worldwide. It selectively inhibits FXIa, allowing to reduce pathological clot formation, with similar incidence of all bleeding events between the two treatment groups, by uncoupling hemostasis from pathological thrombosis. About Bayer’s Commitment in Cardiovascular and Cerebrovascular Medicine Bayer is a leader in cardiology and is advancing a portfolio of innovative treatments in cardiovascular (CV) and cerebrovascular diseases of high unmet medical need. The company has set a clear focus on developing therapies to treat such diseases (e.g. stroke, heart failure, cardiomyopathies, and chronic kidney disease) and it is our ambition to take a leading role in the care of patients with these diseases. Bayer is actively shaping the future of cardiology and neurology with a robust and diversified pipeline, strategically positioned to address critical unmet needs and drive significant long-term value. Bayer’s portfolio already includes several innovative products and compounds in various stages of preclinical and clinical development. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com Follow us on Facebook: http://www.facebook.com/bayer Follow us on LinkedIn: Bayer | Pharmaceuticals Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Basil Extracts Market to Register a 2.27% CAGR During 2026–2034 2026-10-26 · PR News Releaser · Healthcare, Energy, Consumer goods https://www.prnewsreleaser.com/news/478511 The global Basil Extracts Market is gaining attention as manufacturers explore plant-based ingredients for health, personal care, and wellness products. Basil extracts are derived from basil plants and are available in different forms, including powder, capsules, and oil. Their versatility ... Read more ———————————————————————————————————————————————————————————— BioAgeDiagnostics Welcomes Dr. Charles Randquist to Its Medical Advisory Board 2026-10-26 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952286846/bioagediagnostics-welcomes-dr-charles-randquist-to-its-medical-advisory-board About BioAgeDiagnostics Strengthening clinical expertise at the intersection of longevity medicine and precision diagnostics. I am delighted to join the Medical Advisory Board of BioAgeDiagnostics and contribute my clinical experience to advancing a more evidence-informed, practical and patient-centred approach.” — Dr. Charles Randquist, Medical Advisory Board, BioAgeDiagnostics CHARLOTTENLUND, DENMARK, October 26, 2 ———————————————————————————————————————————————————————————— Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/izalontamab-brengitecan-iza-bren-doubles-073000087.html Late-breaking results to be presented in an oral presentation at ESMO 2026 PANKU-Lung01 is the first Phase 3 trial to evaluate a dual-targeting EGFRxHER3 bispecific antibody-drug conjugate in this patient population Iza-bren, a potentially first-in-class dual-targeting EGFRxHER3 bispecific antibody-drug conjugate, has now ———————————————————————————————————————————————————————————— Hospital-Acquired Infection Control Market Size to Reach US$ 31.98 Billion by 2031 2026-10-26 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/478436 According to The Insight Partners, The Hospital Acquired Infection Control Market size is expected to reach US$ 31.98 Billion by 2031. The market is anticipated to register a CAGR of 4.6% during 2025-2031. The global Hospital-Acquired Infection Control Market is experiencing ... Read more ———————————————————————————————————————————————————————————— Health practices can now send eScripts directly from the patient record in Zanda 2026-10-26 · EIN Presswire · SaaS, Healthcare, Software & IT https://www.einpresswire.com/article/951546835/health-practices-can-now-send-escripts-directly-from-the-patient-record-in-zanda e-Prescribing Software for Australian Practices New integration lets authorised prescribers create, send and manage electronic prescriptions from Zanda, with patient details synced automatically. This has been a great product. It has made prescribing so much easier for myself and more reliable for clients” — Dr Yolandie Goodyear BALLARAT, VICTORIA, AUSTRALIA, October 26, 2026 / EINPresswire.com / -- Zanda, the global ———————————————————————————————————————————————————————————— Disposable Medical Gloves Market Trends, Size & Growth by 2034 2026-10-26 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/478426 The global Disposable Medical Gloves Market was valued at US$ 8.4 billion in 2025 and is expected to reach US$ 12.81 billion by 2034, registering an estimated CAGR of 4.8% during 2026–2034. The market is supported by rising health awareness, ... Read more ———————————————————————————————————————————————————————————— TME Pharma extends financial visibility by lengthening debt maturity to June 2028 2026-10-26 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/26/3387829/0/en/tme-pharma-extends-financial-visibility-by-lengthening-debt-maturity-to-june-2028.html TME Pharma extends debt maturity to June 2028 and secures new bond financing to minimize shareholder dilution while advancing NOX-A12 licensing discussions ———————————————————————————————————————————————————————————— Merz Therapeutics Presents New Phase 2 PaiNT Data in Peripheral Neuropathic Pain at IASP 2026 2026-10-26 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/merz-therapeutics-presents-phase-2-070000888.html Clinical and preclinical presentations reflect the company's ongoing exploration of peripheral neuropathic pain FRANKFURT, Germany, October 26, 2026--Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced the presentation of new clinical and translational research in ———————————————————————————————————————————————————————————— Contact Lens Manufacturers: A Buyer's Guide to Vetting Top 10 Suppliers 2026-10-26 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/952283981/contact-lens-manufacturers-a-buyer-s-guide-to-vetting-top-10-suppliers BAIYIN, GANSU, CHINA, October 26, 2026 / EINPresswire.com / -- Contact lens sourcing rarely fails on price. It fails on what a quotation does not show: whether the supplier owns the line, whether the certificate covers the product you are buying, and whether the fifth batch will match the first. Contact lenses are regulated as medical devices in every major market, and decorative lenses with no corrective power are t ———————————————————————————————————————————————————————————— Architectural Spaces Gain Fluidity as China Top Professional Solid Surface Fabricator Koris Explains Material Versatilit 2026-10-26 · EIN Presswire · Healthcare, Travel https://www.einpresswire.com/article/952283942/architectural-spaces-gain-fluidity-as-china-top-professional-solid-surface-fabricator-koris-explains-material-versatilit JIANGMEN, GUANGDONG, CHINA, October 26, 2026 / EINPresswire.com / -- A visitor walking into a modern hotel lobby or a specialized medical center often stops to admire a sleek, seamlessly curved reception desk that looks as though it was carved from a single piece of stone. Achieving these flowing geometries without visible seams or structural weak points can be surprisingly difficult with traditional building materia ———————————————————————————————————————————————————————————— NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development 2026-10-26 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/novabridge-biosciences-reports-mature-phase-1b-data-at-esmo-2026-positioning-givastomig-for-registrational-development Updated Phase 1b dataset provides nearly 18 months of median follow-up and shows the durability of clinical benefit observed with givastomig Clinical activity observed across CLDN18.2 expression levels, including in patients with lower-expression tumors not eligible for currently approved CLDN18.2-targeted therapies Totality of efficacy, safety and long-term follow-up data supports selection of the 8 mg/kg … Continue reading "NovaBridge Biosciences Reports Mature Phase 1b Data at ESMO 2026 Positioning Givastomig for Registrational Development" ———————————————————————————————————————————————————————————— ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026 2026-10-26 · PressReach · Finance, Healthcare, Biotech & pharma, Government & policy https://pressreach.com/arrivent-announces-initial-phase-1-data-for-cdh17-targeted-adc-arr-217-in-patients-with-gastrointestinal-cancers-at-esmo-congress-2026 44.8% ORR at 6mg/kg dose in late-line CRC patients   ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa., Oct. 25, 2026 — ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company … Continue reading "ArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026" ———————————————————————————————————————————————————————————— Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026 2026-10-26 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/oruka-therapeutics-to-host-conference-call-to-report-week-16-data-for-orka-001-from-the-ongoing-everlast-b-trial-on-october-26-2026 MENLO PARK, Calif., Oct. 25, 2026 — Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical-stage biotechnology company developing novel biologics designed to set a new standard for the treatment of chronic skin diseases including plaque psoriasis (PsO) and hidradenitis suppurativa (HS), today announced it will report Week 16 data for ORKA-001 from the … Continue reading "Oruka Therapeutics to Host Conference Call to Report Week 16 Data for ORKA-001 from the Ongoing EVERLAST-B Trial on October 26, 2026" ———————————————————————————————————————————————————————————— Allenby Cosmetic Dermatology Partners with Aviva Aesthetics, Bringing the Platform to Florida 2026-10-26 · PRWeb · SaaS, Healthcare https://www.prweb.com/releases/allenby-cosmetic-dermatology-partners-with-aviva-aesthetics-bringing-the-platform-to-florida-302919043.html Internationally recognized cosmetic dermatologist Dr. Janet Allenby joins Aviva's growing national network of founder-led aesthetic practices CHICAGO, Oct. 25, 2026 -- Aviva Aesthetics, the only entrepreneur-owned national platform built for medical aesthetics practice... ———————————————————————————————————————————————————————————— American Hospital Dubai and HEI Global Health Announce Strategic Partnership to Collaboratively Build an Advanced AI-Powered Revenue Cycle Innovation 2026-10-26 · Business Wire · Finance, AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/american-hospital-dubai-hei-global-050000773.html American Hospital Dubai Named Inaugural Alpha Partner for RevOptix™, HEI Global Health's Next-Generation Revenue Cycle and Patient Accounting Intelligence Platform DUBAI, United Arab Emirates, October 26, 2026--American Hospital Dubai ("AHD"), one of the Middle East's premier private healthcare provide ———————————————————————————————————————————————————————————— Fermented Non-Alcoholic Drinks Market Trends Influencing Global Beverage Preferences 2026-10-26 · PR News Releaser · Healthcare, Retail, Food & drink https://www.prnewsreleaser.com/news/478264 The global Fermented Non-Alcoholic Drinks Market is witnessing steady expansion, driven by rising consumer awareness of gut health, probiotic-rich beverages, natural ingredients, and functional nutrition. Fermented beverages such as kefir, kombucha, fermented juices, and probiotic drinks are gaining popularity among ... Read more ———————————————————————————————————————————————————————————— Flea and Tick Products Market Size, Share, and Future Industry Insights 2026-10-26 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/478241 The Flea and Tick Products Market is witnessing strong growth as pet owners worldwide increasingly prioritize animal health, preventive care, and parasite protection. Fleas and ticks remain among the most common external parasites affecting companion animals, creating a sustained need ... Read more ———————————————————————————————————————————————————————————— Honnas Veterinary in Austin Explains How Client Feedback Shapes Staff Training 2026-10-26 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/honnas-veterinary-austin-explains-client-000000220.html Austin's Honnas Veterinary details the internal process it uses to turn client feedback, both good and bad, into staff training and better care. AUSTIN, TX / October 25, 2026 / A Method Built Around Listening Honnas Veterinary, the Fear Free certified, female-owned practice in Austin, Texas, is sharing the internal method it uses to respond to client feedback. Rather than treating complaints or conc ———————————————————————————————————————————————————————————— Indiana Handicap Parking Placards: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-26 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977209/indiana-handicap-parking-placards-handicapmd-explains-online-medical-certification-and-eligibility Indiana handicap placard guidance explains State Form 42070, medical certification, and government application steps. Clear Indiana guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott INDIANAPOLIS, IN, UNITED STATES, October 25, 2026 / EINPresswire.com / -- HandicapMD is highlighting Indiana disability parking perm ———————————————————————————————————————————————————————————— Wellness Tourism &Mental Health Retreat Market Trends &Forecast Analysis Indicate Significant Long-Term Growth Potential 2026-10-26 · EIN Presswire · Healthcare, Travel https://www.einpresswire.com/article/950055405/wellness-tourism-mental-health-retreat-market-trends-forecast-analysis-indicate-significant-long-term-growth-potential Wellness Tourism And Mental Health Retreat Market The Business Research Company The Business Research Company's Wellness Tourism And Mental Health Retreat Market Report 2026 – Market Size, Trends, And Global Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 26, 2026 / EINPresswire.com / -- "The wellness tourism and mental health retreat sector has experienced significant expansion lately, driven by a ———————————————————————————————————————————————————————————— HIMS FINAL DEADLINE: ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important November 2 Deadline in Securities Class Action - HIMS 2026-10-25 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/25/3387776/673/en/hims-final-deadline-rosen-a-globally-respected-law-firm-encourages-hims-hers-health-inc-investors-to-secure-counsel-before-important-november-2-deadline-in-securities-class-action-.html NEW YORK, Oct. 25, 2026 -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Hims & Hers Health, Inc. (NYSE: HIMS) between August 4, 2025 and July 29, 2026, both dates inclusive (the “Class Period”), of the important November 2, 2026 lead plaintiff deadline. ———————————————————————————————————————————————————————————— Fibroid Institute Opens New Fibroid Clinic in the Heights area of Houston, TX 2026-10-25 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/fibroid-institute-opens-new-fibroid-clinic-in-the-heights-area-of-houston-tx/89207069 Fibroid Institute opens its newest fibroid clinic to serve the Greater Heights and Memorial Heights areas of Houston, Texas. With additional locations, this specialized concierge medical practice provides local access to care for thousands of women seeking non-surgical relief from fibroids. -- HOUSTON, TEXAS, USA (October 2026): The Fibroid Institute , a revolutionary medical practice providing non-surgical fibroid t ———————————————————————————————————————————————————————————— Tennessee Oncology Researchers Help Lead Global Trial of Next-Generation Lung Cancer Therapy 2026-10-25 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/tennessee-oncology-researchers-help-lead-global-trial-of-next-generation-lung-cancer-therapy-302918831.html Research Conducted at Tennessee Oncology's Greco-Hainsworth Centers for Research Contributes to Study Showing Longer Overall Survival with Next-Generation KRAS G12C Therapy NASHVILLE, Tenn., Oct. 25, 2026 -- Researchers at Tennessee Oncology served as investigators in a... ———————————————————————————————————————————————————————————— Handicap Placard Qualifying Conditions: HandicapMD Launches Eligibility Resource Center 2026-10-25 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977178/handicap-placard-qualifying-conditions-handicapmd-launches-eligibility-resource-center New educational resource connects condition-specific guides, medical evaluation questions, and state-by-state handicap parking eligibility information. A condition guide should help people ask better questions. Medical certification depends on an individual assessment, and the government decides whether to issue a parking credential.” — Dr. Eric Jackson-Scott LOS ANGELES, CA, UNITED STATES, October 25, 2026 / EINPres ———————————————————————————————————————————————————————————— Hims & Hers Health (HIMS) Alert: Securities Class Action Pending, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline 2026-10-25 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/25/3387767/32716/en/hims-hers-health-hims-alert-securities-class-action-pending-investors-with-losses-encouraged-to-contact-hagens-berman-before-november-2-2026-lead-plaintiff-deadline.html Investors who lost money in HIMS after its stock plunged due to allegedly misleading financial statements are urged to contact Hagens Berman. ———————————————————————————————————————————————————————————— EverNear Develops AI Voice Companion to Support Older Adults Living With Alzheimer's Disease 2026-10-25 · EIN Presswire · AI, Healthcare https://www.einpresswire.com/article/952101050/evernear-develops-ai-voice-companion-to-support-older-adults-living-with-alzheimer-s-disease Jaswanth Chintala, Founder of EverNear Founded by 17-year-old Jaswanth Chintala, EverNear offers AI voice companionship for older adults with Alzheimer's disease. HYDERABAD, INDIA, October 25, 2026 / EINPresswire.com / -- EverNear , an artificial intelligence (AI) voice companion developed by 17-year-old entrepreneur and self-taught engineer Jaswanth Chintala, aims to address loneliness among older adults living with ———————————————————————————————————————————————————————————— Singapore Cervicogenic Dizziness: Drug-Free Upper Cervical Care Announced 2026-10-25 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/singapore-cervicogenic-dizziness-drug-free-upper-cervical-care-announced/89207286 With dizziness affecting roughly 40% of neck pain patients, Singapore’s Dr Neck Pain has announced an X-ray-guided program that targets cervicogenic dizziness at its structural source in the upper cervical spine. -- Dr Neck Pain, a structural correction chiropractic clinic in Singapore, has announced a drug-free, X-ray-guided approach to resolving cervicogenic dizziness, characterized by chronic unsteadiness and pers ———————————————————————————————————————————————————————————— Dr. Don and Brandi MacDonald Redefine Chiropractic Education Through Polyvagal-Informed Care and Precision Adjusting 2026-10-25 · MarketersMEDIA · Healthcare, Education https://news.marketersmedia.com/dr-don-and-brandi-macdonald-redefine-chiropractic-education-through-polyvagal-informed-care-and-precision-adjusting/89207282 Two educators are helping chiropractors connect precise adjusting with safer, clearer communication. -- The question did not arrive suddenly for Dr. Don MacDonald. It followed him through decades of practice in Edmonton, through thousands of clinical conversations, and through the quiet moments after an adjustment when a chiropractor wonders what else a person’s body may be communicating. After nearly 30 years in pra ———————————————————————————————————————————————————————————— Beyond the Fairways: Kenya Defence Forces (KDF) Drives Wellness, Unity and Esprit de Corps Through Golf 2026-10-25 · APO Group · Healthcare, Sports https://www.africa-newsroom.com/press/beyond-the-fairways-kenya-defence-forces-kdf-drives-wellness-unity-and-esprit-de-corps-through-golf?lang=en Sport remains a powerful pillar in strengthening physical fitness, mental resilience and esprit de corps within the Kenya Defence Forces (KDF). Beyond competition, golf provides a platform for promoting discipline, teamwork, social interaction and lasting relationships, reinforcing the importance of holistic wellness in sustaining a healthy, motivated and mission-ready force. The 2026 Commander Kenya Army Trophy Golf Tournament, held at Thika Greens Golf Resort, brought together over 260 military and civilian golfers in a spirited display of sportsmanship, camaraderie and friendly competition. Organised by the Kenya Defence Forces Golf Association (KDFGA) under the KDF wellness programme, the tournament underscored the role of sport in strengthening cohesion within the military fraternity and fostering civil-military relations. The Deputy Army Commander, Major General John Nkoimo, who represented the Commander Kenya Army, emphasised the importance of balancing physical fitness, mental well-being and social engagement in sustaining operational effectiveness. He noted that golf cultivates patience, discipline, concentration and integrity, qualities that are equally fundamental to military professionalism and leadership. Maj Gen Nkoimo commended the participants for their competitive spirit and sportsmanship, while appreciating the sponsors for supporting initiatives that advance personnel welfare and institutional cohesion. KDFGA Chairperson, Major General Eric Kinuthia, hailed the impressive turnout, noting that sporting engagements provide valuable opportunities to strengthen bonds among service personnel, veterans and the civilian golfing community. The tournament produced outstanding performances, with Corporal Christine Mwirigi emerging as the overall KDFGA champion with 48 points. Colonel Benjamin Kiprop claimed the Men’s Division A title with 43 points, while Major Douglas Omaore won Division B with 44 points. In the ladies’ category, Major Lucia Mwaniki secured the Division A title with 43 points, while Sergeant Lucy Talam emerged victorious in Division B with 42 points. Lieutenant Colonel (Rtd) Mike Talam won the veterans’ category, while Major (Rtd) Dennis Owino and Warrant Officer Class Two Priscillah Mutash claimed the men’s and ladies’ Longest Drive honours, respectively. Beyond the trophies and individual achievements, the tournament reinforced the KDF’s commitment to promoting a culture of wellness, strengthening civil-military bonds and nurturing a cohesive military community. Through sport, the KDF continues to invest in the physical and mental well-being of its personnel, recognising that a healthy, resilient and united force is fundamental to operational readiness and mission success. Distributed by APO Group on behalf of Ministry of Defence - Kenya. ———————————————————————————————————————————————————————————— Veneers vs. Teeth Whitening: Cebu Clinic Compares Cost and Longevity 2026-10-25 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/veneers-vs-teeth-whitening-cebu-clinic-compares-cost-and-longevity/89207283 Aratea Dental Clinic in Lahug, Cebu City, compares veneers and teeth whitening, outlining cost, longevity, and suitability differences to help patients choose confidently after a proper dental assessment with Dr. Ma. Chona Aratea-Fajardo. -- Aratea Dental Clinic and Laboratory is presenting Cebu-area patients with a patient-focused comparison of veneers and teeth whitening, outlining differences in cost, longevity, a ———————————————————————————————————————————————————————————— Ohio Disability Parking Permits: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-25 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977152/ohio-disability-parking-permits-handicapmd-explains-online-medical-certification-and-eligibility Ohio handicap placard guidance explains BMV 4826, medical certification, and government application steps. Clear Ohio guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott COLUMBUS, OH, UNITED STATES, October 25, 2026 / EINPresswire.com / -- HandicapMD is highlighting Ohio handicap placard guidance centered on a deta ———————————————————————————————————————————————————————————— South Africa: Deputy President Mashatile to visit Bronkhorstspruit following water crisis 2026-10-25 · APO Group · Healthcare, Government & policy https://www.africa-newsroom.com/press/south-africa-deputy-president-mashatile-to-visit-bronkhorstspruit-following-water-crisis?lang=en Deputy President Shipokosa Paulus Mashatile will on Monday, 26 October 2026, visit Bronkhorstspruit in the City of Tshwane Metropolitan Municipality, Gauteng Province, following reports of gastrointestinal illness linked to the consumption of contaminated water in the area. The visit forms part of the work of the Inter-Ministerial Committee (IMC) on Water and Sanitation chaired by Deputy President Mashatile, which is coordinating government interventions to address water and sanitation challenges, strengthen accountability and accelerate responses to service delivery concerns affecting communities. During the visit, the Deputy President will visit the Bronkhorstspruit Water Treatment Works (BWTW) to assess the situation, receive an update on the condition of the water treatment infrastructure and engage with relevant authorities on the measures being implemented to restore the safety and reliability of the water supply. The Deputy President will also visit hospitalised patients following reports of gastrointestinal illness associated with the consumption of contaminated water. The engagement will provide an opportunity to receive updates on the condition of affected residents and the healthcare response. Approximately 408 cases of gastrointestinal illness were reported in the Bronkhorstspruit area following the consumption of water suspected to have been contaminated and linked to the Bronkhorstspruit Water Treatment Works. The incident has raised serious concerns about the safety of the water supply and the potential health risks to communities. The City of Tshwane Metropolitan Municipality has been leading response efforts, including interventions to address water quality concerns, assess the affected infrastructure and implement measures aimed at safeguarding public health and restoring the provision of safe water to affected residents. Through this visit, the Deputy President will assess progress made in addressing the crisis and engage with the City of Tshwane and relevant government departments to reinforce the importance of coordinated action, effective oversight and accountability in ensuring access to safe and reliable water. Deputy President Mashatile will be accompanied by the Minister of Water and Sanitation, Ms Pemmy Majodina; Deputy Minister of Water and Sanitation, Mr David Mahlobo; Gauteng Premier, Mr Panyaza Lesufi; Gauteng MEC for Roads and Transport, Mr Jacob Mamabolo; and the Executive Mayor of the City of Tshwane Metropolitan Municipality, Dr Nasiphi Moya, alongside other relevant government officials. Distributed by APO Group on behalf of The Presidency of the Republic of South Africa. ———————————————————————————————————————————————————————————— Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China 2026-10-25 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ivonescimab-plus-chemotherapy-demonstrates-overall-155200749.html First Regimen to Achieve a Statistically Significant and Clinically Meaningful Overall Survival Benefit over an Anti-PD-(L)1 Antibody Combined with Chemotherapy in a Phase III Clinical Trial in BTC Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 25% Compared to Durvalumab Plus Chemotherapy; OS Hazard Ratio 0.75 ———————————————————————————————————————————————————————————— Sonesitatug vedotin reduced the risk of death by 42% in 2nd and later-line CLDN18.2-positive advanced gastric/GEJ cancers in CLARITY-Gastric01 2026-10-25 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sonesitatug-vedotin-reduced-risk-death-153500833.html Sone-Ve reduced the risk of death by 53% in 3rd and later-line setting in primary endpoint Consistent data across CLDN18.2 expression levels supports potential for expanded use in up to 60% of patients in this setting WILMINGTON, Del., October 25, 2026--Positive results from the CLARITY-Gastric01 globa ———————————————————————————————————————————————————————————— Roche’s divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer 2026-10-25 · Roche · Healthcare, Education, Food & drink, Biotech & pharma, Government & policy, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-25 Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the phase III Krascendo 1 study1,2 At the time of primary analysis, divarasib achieved a median overall survival of approximately 18 months, compared to 12 months for sotorasib or adagrasib1,2 No new safety signals were observed with divarasib; the most common treatment-related adverse events were mainly low grade and manageable1,2 Data presented as a late-breaking abstract during a Presidential Symposium at the 2026 ESMO Congress and simultaneously published in The New England Journal of Medicine1,2 Basel, 25 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today pivotal results from the phase III Krascendo 1 study, which demonstrated the superior efficacy of investigational divarasib, a next-generation KRAS G12C inhibitor, compared with current standard of care KRAS G12C inhibitors in people with previously treated KRAS G12C-mutated non-small cell lung cancer (NSCLC).1,2 Participants treated with divarasib monotherapy lived significantly longer, lowering the risk of death by 44% compared with sotorasib or adagrasib (overall survival, OS, HR 0.56, [95% CI: 0.41-0.78], p=0.0005).1,2 Median OS for divarasib is currently approximately 18 months, compared to 12 months for the control arm (see table below).1,2 No new safety findings were observed with divarasib and the most common treatment-related adverse events (TRAEs) were mainly low grade and manageable.1,2 These data were presented as a late-breaking abstract during a Presidential Symposium at the 2026 European Society for Medical Oncology (ESMO) Congress and simultaneously published in The New England Journal of Medicine.1,2 “The phase III Krascendo 1 results demonstrate the potential for divarasib to become a new standard of care for people with previously treated KRAS G12C-mutated lung cancer,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. "The superior efficacy against the current standard of care demonstrated in this head-to-head trial reinforces divarasib's best-in-class profile. We are working closely with health authorities to bring this new treatment option to the people who need it.” The G12C mutation is one of the most common KRAS mutations, found in approximately one in eight people with NSCLC.3,4 Accumulating evidence suggests that people with NSCLC who have the KRAS G12C mutation may have poorer outcomes than those who have the unmutated KRAS gene (wild-type disease).5,6 Despite the approval of current, first-generation KRAS G12C-targeted treatments, there remains a significant unmet need for more effective therapy options. “New life-extending treatments are greatly needed, as most patients with this type of cancer will eventually relapse after initial therapy, and there are limited effective treatments for recurrent disease,” said study lead author Ferdinandos Skoulidis, MD, PhD, Professor of Thoracic/Head and Neck Medical Oncology at The University of Texas MD Anderson Cancer Center. “The Krascendo 1 results highlight divarasib’s practice-changing potential, as the first KRAS inhibitor to meaningfully improve overall survival for people with previously treated KRAS G12C-mutated lung cancer, compared with current treatment options.” The Krascendo 1 study is the only global head-to-head study to evaluate a next-generation KRAS G12C inhibitor versus approved first-generation KRAS G12C inhibitors.1,2 The study met primary and key secondary endpoints, and divarasib demonstrated statistically significant and clinically meaningful improvements in OS and progression-free survival (PFS) over sotorasib or adagrasib.1,2 In addition to the OS benefit, divarasib reduced the risk of disease progression or death by 42% (PFS HR 0.58, [95% CI: 0.44-0.76], p<0.0001).1,2 The OS and PFS benefit was consistent across clinically relevant subgroups, and was observed regardless of PD-L1 expression or KEAP1 mutation status.1,2 The objective response rate (ORR) with divarasib was nearly double that of sotorasib or adagrasib.1,2 Key efficacy results from the phase III Krascendo 1 study:1,2 Primary and key secondary endpointsDivarasib arm (n=167)*Control arm (adagrasib, sotorasib) (n=171)*Hazard Ratio / (95% CI)p-value Median OS (months) 17.712.0HR 0.56 (0.41-0.78)p=0.0005 Median PFS (months) 9.8 5.7 HR 0.58 (0.44-0.76)p<0.0001 12-month PFS rate (%)44% 24%-- Confirmed ORR (%)*58%32%-- Median DOR (months)* 11.96.9-- *Assessed in response-evaluable population (n=328; ten patients [divarasib arm, n=6; control arm, n=4] did not have measurable disease at baseline and were excluded from the response-evaluable set). Duration of Response (DOR) evaluated in those who responded to treatment (divarasib arm, n=94; control arm, n=54). The safety profile of divarasib monotherapy was consistent with the known class effects of KRAS G12C inhibitors.1,2 The most common TRAEs comprised GI toxicity (most commonly, diarrhoea, nausea, and vomiting) and hepatotoxicity.1,2 Fewer participants discontinued treatment due to TRAEs with divarasib (4.8% versus 11.7%) and the rate of serious TRAEs was approximately half that of sotorasib or adagrasib (7.8% versus 15.2% respectively), despite patients remaining on treatment for more than twice as long (11.3 months compared with 5.0 months).1,2 Roche is advancing a comprehensive phase III clinical development programme in NSCLC, investigating divarasib as both a monotherapy and as a chemotherapy-free combination, across different disease settings and lines of therapy. The US Food and Drug Administration granted Breakthrough Therapy Designation to divarasib in 2022, and in 2026, Orphan Drug Designation for KRAS G12C-mutated NSCLC. About Krascendo 11,2 The Krascendo 1 study [NCT06497556] is the only global head-to-head study evaluating a Kirsten rat sarcoma virus (KRAS) G12C inhibitor in direct comparison with first-generation approved KRAS G12C inhibitors. This phase III, randomised, open-label, multicentre study evaluates the efficacy and safety of divarasib monotherapy versus sotorasib or adagrasib in people with previously treated KRAS G12C-mutated advanced or metastatic non-small cell lung cancer. The study includes 338 adults, randomised to receive either divarasib once daily (n=167) or, either sotorasib once daily or adagrasib twice daily (n=171). The primary endpoint is blinded independent central review (BICR)-assessed progression-free survival. Secondary endpoint measures include overall survival, confirmed objective response, duration of response, as well as other efficacy and safety measures. About divarasib Divarasib is an investigational, best-in-class, next-generation, oral, KRAS G12C inhibitor, discovered and developed by researchers within Roche and Genentech. It has shown greater potency and selectivity in preclinical studies compared with first-generation KRAS G12C-targeting treatments, sotorasib or adagrasib, with superior efficacy demonstrated in people with previously treated KRAS G12C-mutated NSCLC.1,2,7 Divarasib is designed to selectively bind to the KRAS G12C protein, locking the protein in an inactive (off) state, thereby turning off its tumour-driving signalling.7,8,9 Divarasib’s comprehensive clinical development programme is anchored by three phase III studies: StudyInterventionPatient population Krascendo 1 [NCT06497556]Divarasib monotherapy vs sotorasib or adagrasib Previously treated KRAS G12C-mutated  advanced or metastatic NSCLC (second-line) Krascendo 2 [NCT06793215]Divarasib plus pembrolizumab (chemotherapy-free combination) vs chemotherapy plus pembrolizumabPreviously untreated KRAS G12C-mutated advanced NSCLC (first-line) Krascendo 3 [NCT07541170]Adjuvant divarasib monotherapy vs immunotherapy or observationResected stage II–IIIB KRAS G12C-mutated NSCLC after standard of care chemoimmunotherapy (early-stage) Divarasib underpins Roche’s diversified pipeline targeting the RAS signalling pathway, including other mutant-selective inhibitors and a pan-RAS inhibitor, designed to extend the benefits of RAS inhibition strategies to more patients. About KRAS G12C-mutated non-small cell lung cancer Despite advances in treatment, lung cancer remains the leading cause of cancer-related deaths worldwide, surpassing the combined mortality rates of breast, prostate, and stomach cancers.10,11 Each year, it claims the lives of 1.8 million people, with non-small cell lung cancer (NSCLC) accounting for approximately 85% of cases.10,12 KRAS is one of the most frequently mutated genes in lung cancer, occurring in approximately 25% of newly diagnosed lung cancers, and is associated with poor prognosis for patients.9 The G12C mutation is one of the most common KRAS mutations, found in approximately 12-14% of NSCLC cases.3,4 The KRAS gene produces the KRAS protein, which acts as a cellular control switch, cycling between an active (on) and inactive (off) state to regulate cell growth and proliferation, making it a critical target for new therapeutic strategies.9 G12C mutation locks the KRAS protein in its active (on) state, leading to continuous, unregulated signalling for cell growth, driving tumour proliferation.8,9 About Roche in lung cancer Roche is committed to advancing the field of lung cancer treatments, leveraging more than 20 years of deep scientific expertise to improve patient outcomes and their overall experience. Roche’s strong commitment to investment in research and development has built a robust portfolio of approved medicines and companion diagnostics, which empowers physicians to better understand a patient's disease and optimise care. Roche’s broad portfolio includes approved medicines such as Alecensa® (alectinib), Tecentriq® (atezolizumab), and Rozlytrek® (entrectinib). Its extensive pipeline includes investigational treatments across three key focus areas: small cell lung cancer, non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGA), and NSCLC without AGA. Utilising diverse approaches, ranging from cancer-cell-killing ‘cytotoxics’ and immunotherapies to treatments targeting specific characteristics of cancer cells, we aim to translate scientific discoveries into meaningful progress in patient care. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] Skoulidis F, et al. Krascendo 1: efficacy and safety of divarasib vs sotorasib or adagrasib in previously treated locally advanced or metastatic KRAS G12C-mutated NSCLC. Presented at: ESMO Congress; 2026 October 23-27; Madrid, Spain. #LBA5. [2] Skoulidis F, et al. Divarasib as compared with sotorasib or adagrasib in KRAS G12C–mutated NSCLC. N Engl J Med 2026; DOI: 10.1056/NEJMoa2605703 [3] Nassar AH, et al. Distribution of KRAS (G12C) Somatic Mutations across Race, Sex, and Cancer Type. N Engl J Med. 2021; 384 (2): 185-187. [4] Lee JK, et al. Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ Precis Oncol. 2022;9;6(1):91. [5] Wankhede D, et al. Prognostic role of KRAS G12C mutation in non-small cell lung cancer: a systematic review and meta-analysis. Diagnostics. 2023: 25;13(19): 3043. [6] Isaksson J, et al. KRAS G12C Mutant Non-Small Cell Lung Cancer Linked to Female Sex and High Risk of CNS Metastasis: Population-based Demographics and Survival Data From the National Swedish Lung Cancer Registry. Clin Lung Cancer. 2023: 24(6):507-518. [7] Endres NF, et al. Discovery and Characterization of Divarasib (GDC-6036), a Potent Covalent Inhibitor of KRAS G12C. J Med Chem. 2026; 69 (5): 5147-5165. [8] Friedlaender A, et al. KRAS as a druggable target in NSCLC: rising like a phoenix after decades of development failures. Cancer Treat Rev. 2020;85:101978. [9] Pakkala S, et al. Personalized therapy for lung cancer: striking a moving target. JCI Insight. 2018; 3 (15). [10] World Health Organization. Global cancer burden growing, amidst mounting need for services [Internet; cited 2026 September]. Available from: https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services. [11] American Lung Association. Lung Cancer Statistics [Internet; cited 2026 September]. Available from: https://www.lung.org/lung-health-diseases/lung-disease-lookup/lung-cancer/resource-library/lung-cancer-fact-sheet. [12] World Health Organization. Lung cancer [Internet; cited 2026 September]. Available from: https://www.who.int/news-room/fact-sheets/detail/lung-cancer. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83Kirti Pandey Phone: +41 79 398 38 53 Yvette Petillon Phone: +41 79 961 92 50Irène Stephan Phone:  +41 79 377 83 75 Albert Thottiyil Phone: +41 79 775 66 12  Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media&Investor Release divarasib in KRAS G12C lung cancer English ———————————————————————————————————————————————————————————— Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer 2026-10-25 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/genentech-divarasib-demonstrated-best-class-153000115.html Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved a median overall survival of approximately 1 ———————————————————————————————————————————————————————————— INVESTOR DEADLINE: Hims & Hers Health, Inc. (HIMS) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline 2026-10-25 · PR Newswire · Finance, Healthcare, Legal https://www.prnewswire.com/news-releases/investor-deadline-hims--hers-health-inc-hims-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-before-november-2-2026-deadline-302917704.html SAN DIEGO, Oct. 25, 2026 -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, all dates inclusive (the "Class Period"), have until Monday, November 2, 2026 to... ———————————————————————————————————————————————————————————— Leads Biolabs' LBL-034 Shows 21.8-Month Median PFS in First-in-Human RRMM Data at ESMO 2026, Validating Its Proprietary TCE Platform 2026-10-25 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/25/3387749/0/en/leads-biolabs-lbl-034-shows-21-8-month-median-pfs-in-first-in-human-rrmm-data-at-esmo-2026-validating-its-proprietary-tce-platform.html Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline Updated Results Show Deep and Durable Responses in High-Risk, Heavily Pretreated Multiple Myeloma, Supporting Further Development of the Company’s TCE Pipeline ———————————————————————————————————————————————————————————— Subcutaneous RYBREVANT®▼ (amivantamab) demonstrates 77% overall response rate in first-line treatment of patients with certain types of advanced head and neck cancer 2026-10-25 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/25/3387748/0/en/subcutaneous-rybrevant-amivantamab-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-certain-types-of-advanced-head-and-neck-cancer.html BEERSE, BELGIUM, Oct. 25, 2026 -- Johnson & Johnson today announced new results from Cohort 5 of the Phase 1b/2 OrigAMI-4 study with first-line subcutaneous RYBREVANT®▼ (amivantamab) plus a PD-1 inhibitor and fixed-duration carboplatin chemotherapy in patients with advanced recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) other than human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma (OPSCC).1 These findings support the ongoing pivotal Phase 3 OrigAMI-5 study and further expand the clinical development programme for subcutaneous amivantamab for patients with head and neck cancer. ———————————————————————————————————————————————————————————— RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer 2026-10-25 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/rybrevant-faspro-amivantamab-and-hyaluronidase-lpuj-combination-demonstrates-77-overall-response-rate-in-first-line-treatment-of-patients-with-advanced-head-and-neck-cancer-302918746.html Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO regimen in the ongoing first-line Phase 3 study Data highlight the role of dual-targeting EGFR and MET, key drivers of tumor growth and... ———————————————————————————————————————————————————————————— Early Detection, Stronger Hope: Kenya Defence Forces (KDF) Steps Up Fight Against Breast Cancer 2026-10-25 · APO Group · Healthcare, Government & policy https://www.africa-newsroom.com/press/early-detection-stronger-hope-kenya-defence-forces-kdf-steps-up-fight-against-breast-cancer?lang=en Early detection saves lives. As the world marks Breast Cancer Awareness Month, the Kenya Defence Forces (KDF) continues to strengthen preventive healthcare, medical professionalism and patient-centred care through initiatives aimed at improving cancer awareness, timely diagnosis and treatment outcomes. Lanet Regional Hospital (LRH) marked the annual awareness campaign by conducting a Continuing Medical Education (CME) session focused on strengthening healthcare professionals’ knowledge and clinical capacity in breast cancer prevention, early detection, diagnosis, treatment and patient support. The session provided a platform for medical personnel to exchange professional knowledge, examine evolving clinical practices and explore effective approaches to breast cancer management, reinforcing the importance of continuous professional development in delivering quality healthcare. Addressing participants, the hospital leadership, led by Chief Medical Officer Colonel (Dr) Muithya, emphasised that early detection, timely medical intervention and access to appropriate treatment remain critical in improving survival rates and quality of life for individuals affected by breast cancer. The leadership encouraged healthcare professionals to intensify public awareness on breast cancer risk factors, warning signs and recommended screening practices, while promoting prompt medical assessment of suspicious breast changes. Beyond clinical interventions, the session highlighted the importance of compassionate, patient-centred care, psychosocial support and sustained engagement with patients and their families throughout the cancer care journey. Participants were challenged to translate the knowledge gained into improved clinical practice, strengthen preventive healthcare initiatives and remain responsive to advances in cancer diagnosis and treatment. The initiative underscores the KDF’s commitment to strengthening military healthcare services through professional capacity development, preventive medicine and accessible, quality healthcare. Through sustained awareness, early detection and compassionate care, Lanet Regional Hospital continues to advance the fight against breast cancer, reaffirming that protecting lives begins with knowledge, timely action and collective responsibility. Distributed by APO Group on behalf of Ministry of Defence - Kenya. ———————————————————————————————————————————————————————————— Filling a Surgeon's Surgical Calendar: Patient Flow Content Strategy Explained 2026-10-25 · MarketersMEDIA · SaaS, Healthcare, Media, Chemicals & materials https://news.marketersmedia.com/filling-a-surgeonandx27s-surgical-calendar-patient-flow-content-strategy-explained/89207279 MedFire Media outlines a done-for-you, multi-platform content strategy helping board-certified plastic surgeons build sustained visibility and convert more inquiries into booked consultations and surgical procedures. -- MedFire Media provides a fully managed, multi-platform content strategy built for board-certified plastic surgeons who are generating plastic surgery patient inquiries but struggling to turn them into ———————————————————————————————————————————————————————————— Economic Community of West African States (ECOWAS), Centre for Research and Information on Substance Abuse (CRISA) Convene Regional Conference on Substance Use Research and Data Systems 2026-10-25 · APO Group · Healthcare, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/economic-community-of-west-african-states-ecowas-centre-for-research-and-information-on-substance-abuse-crisa-convene-regional-conference-on-substance-use-research-and-data-systems?lang=en The Economic Community of West African States (ECOWAS) Commission, in collaboration with the Centre for Research and Information on Substance Abuse (CRISA), has convened the 16th Biennial International Conference on Drugs, Alcohol and Society in Africa to strengthen evidence-based responses to substance use across West Africa. Held from the 21st to 22nd of October 2026 in Abuja, Nigeria, the conference is themed “Substance Use Research and Data Systems in Africa: Advances, Relevance and Challenges.” It brings together researchers, policymakers, public health professionals and development partners to examine emerging drug trends, strengthen data systems and develop practical recommendations for prevention, treatment and rehabilitation. Delivering a statement on behalf of the ECOWAS Commissioner for Human Development and Social Affairs, Prof. Nassirou Bako-Arifari, Dr. Daniel Amankwaah, Head of the ECOWAS Drug Prevention and Control Division, highlighted the growing public health and security challenges associated with substance use and illicit drug trafficking. He disclosed that, as of September 2026, 12 drug treatment and rehabilitation centres in 10 Member States had received renovation and equipment upgrades, while more than 300 health and allied professionals had been trained in evidence-based prevention and treatment. He also highlighted ECOWAS efforts to advance Alternatives to Incarceration, promoting treatment, rehabilitation and social reintegration for eligible people who use drugs and come into contact with the criminal justice system. He reaffirmed the Commission’s commitment to strengthening regional data through the West African Epidemiology Network on Drug Use (WENDU). Representing CRISA, Prof. Gboyega Abikoye expressed satisfaction with the Centre’s achievements after more than 30 years, highlighting its work in substance use research, information sharing on alcohol use and abuse, and the organisation of workshops and conferences to advance knowledge and inform responses to drug-related challenges. In remarks delivered on behalf of the UNODC Country Representative in Nigeria, Cheikh Touré, by Dr. Akanidomo Ibanga, Project Management Support Specialist at UNODC, participants were urged to bridge the gap between research and policymaking. He emphasised that evidence must inform government decisions, resource allocation, prevention programmes and access to quality treatment and care. The conference features country-level drug situation reports, panel discussions and research presentations, including a study on alternatives to incarceration for people who use drugs in Nigeria. Through its partnership with CRISA and other stakeholders, ECOWAS continues to promote regional cooperation and evidence-informed policies for more effective and humane responses to substance use across West Africa. Distributed by APO Group on behalf of Economic Community of West African States (ECOWAS). ———————————————————————————————————————————————————————————— Beyond Live Streaming: Tango Gives Back by Supporting Cancer Detection in Ukraine 2026-10-25 · GlobeNewswire · SaaS, Healthcare, Media https://www.globenewswire.com/news-release/2026/10/25/3387721/0/en/beyond-live-streaming-tango-gives-back-by-supporting-cancer-detection-in-ukraine.html MOUNTAIN VIEW, Calif., Oct. 25, 2026 -- Through its Tango for Good initiative, the global live-streaming platform supports FRIDA Ukraine's mobile cancer screening program, bringing essential medical services to local communities. ———————————————————————————————————————————————————————————— KFSH Expands Virtual Care Pathways to Bring Specialized Follow-Up Closer to Patients 2026-10-25 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/25/3387718/0/en/kfsh-expands-virtual-care-pathways-to-bring-specialized-follow-up-closer-to-patients.html RIYADH, Saudi Arabia, Oct. 25, 2026 -- King Faisal Specialist Hospital and Research Centre (KFSH) is expanding virtual and alternative care pathways at its Jeddah hospital, giving patients greater flexibility in how they access specialized services while reducing the need for unnecessary hospital visits. ———————————————————————————————————————————————————————————— Xencor Presents Phase 1 Dose Selection Data for XmAb819, a Potential First-in-Class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Patients With Advanced Clear Cell Renal Cell Carcinoma and ENPP3+ Tumors 2026-10-25 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/xencor-presents-phase-1-dose-083500804.html -- 400 mcg/kg chosen as proposed IV RP3D based on 45.5% cORR, 55% uORR and 82% 6-month PFS Kaplan-Meier estimate -- -- Xencor plans to discuss a potential accelerated approval pathway with the FDA in key ccRCC patient subgroups in 1H2027 -- -- Xencor plans global randomized study of monotherapy XmAb819 compared to tivozan ———————————————————————————————————————————————————————————— Bronwen Sciortino Wins 'Author of the Year' at Influencer Magazine Awards 2026 2026-10-25 · EIN Presswire · Healthcare, Marketing & advertising https://www.einpresswire.com/article/950188262/bronwen-sciortino-wins-author-of-the-year-at-influencer-magazine-awards-2026 LONDON, UNITED KINGDOM, October 25, 2026 / EINPresswire.com / -- Bronwen Sciortino , internationally recognised author, speaker and thought leader on health, wellbeing and sustainable success, has been awarded Author of the Year at the Influencer Magazine Awards (E3) on October 25, 2026, honouring her writing and thought leadership that challenges the belief that success must come at the expense of our health, happin ———————————————————————————————————————————————————————————— BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy 2026-10-25 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/25/3387717/0/en/biontech-and-bristol-myers-squibb-report-encouraging-global-phase-2-data-for-pumitamig-in-advanced-nsclc-after-progression-on-immunotherapy-plus-chemotherapy.html MAINZ, Germany, and PRINCETON, USA, October 25, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Bristol Myers Squibb Company (NYSE: BMY, “BMS”) today announced first data from the global Phase 2 ROSETTA Lung-107 clinical trial (NCT06841055) evaluating pumitamig, an investigational PD-L1xVEGF-A bispecific immunomodulator (BNT327/BMS986545), in combination with docetaxel in patients with metastatic non-small cell lung cancer (“NSCLC”) whose disease progressed on or after first-line immunotherapy plus chemotherapy. ———————————————————————————————————————————————————————————— Frontier Medicines Presents Promising Anti-Tumor Activity from Phase 1/2 PROSPER Trial of FMC-376 in a Highly Resistant Patient Population of KRAS G12C-Mutant NSCLC at ESMO 2026 2026-10-25 · Business Wire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/frontier-medicines-presents-promising-anti-073000845.html FMC-376 is an equipotent ON+OFF KRAS G12C inhibitor designed with the Frontier™ Platform to address limitations of current KRAS G12C inhibitors, including resistance and tolerability Treatment with FMC-376 in the Phase 1A portion of the trial led to confirmed overall objective response rate of 56% in NSCLC patients, inclu ———————————————————————————————————————————————————————————— Lubbock Plastic Surgeon Dr. Thanapoom Boonipat Leads Suturing Workshop for Texas Tech Women in STEM Premed Students 2026-10-25 · 24-7 Press Release · Healthcare, Education https://www.24-7pressrelease.com/press-release/539893/lubbock-plastic-surgeon-dr-thanapoom-boonipat-leads-suturing-workshop-for-texas-tech-women-in-stem-premed-students Suturing workshop ———————————————————————————————————————————————————————————— Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer 2026-10-25 · PressReach · Finance, Healthcare, Biotech & pharma https://pressreach.com/genmab-and-incyte-announce-clinical-trial-collaboration-in-metastatic-colorectal-cancer Media Release COPENHAGEN, Denmark and WILMINGTON, Del.; October 24, 2026 Phase 1/2 study will evaluate petosemtamab plus INCB161734 and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) Genmab A/S (Nasdaq: GMAB) and Incyte (Nasdaq: INCY) today announced a clinical trial collaboration to evaluate petosemtamab, Genmab’s investigational IgG1-bispecific antibody targeting the epidermal growth factor … Continue reading "Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer" ———————————————————————————————————————————————————————————— Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors 2026-10-25 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/parabilis-medicines-presents-updated-phase-1-2-data-for-zolucatetide-demonstrating-compelling-efficacy-and-favorable-safety-and-tolerability-profile-in-patients-with-desmoid-tumors Objective response rate of 72.2% among response-evaluable patients receiving a starting dose of ≥450 mg at 32-week landmark Disease control rate of 100% across all response-evaluable patients receiving a starting dose of ≥450 mg, with no disease progression and no treatment discontinuations due to TRAEs Data informed FDA-aligned dose and regimen selection for upcoming PEDESTAL … Continue reading "Parabilis Medicines Presents Updated Phase 1/2 Data for Zolucatetide Demonstrating Compelling Efficacy and Favorable Safety and Tolerability Profile in Patients with Desmoid Tumors" ———————————————————————————————————————————————————————————— Easy Fitness Routines You Can Do at Home 2026-10-25 · Newswire.com · Healthcare, Energy https://www.newswire.com/news/easy-fitness-routines-you-can-do-at-home Exercise helps you build your strength, boost your mood and increase your energy levels. But many people may feel put off by the cost, especially if they have a lot of other financial obligations weighing on them. Fitness doesn't have to be expensive, however. There are many ways to work out at home that can make a significant difference in your health. Just as a debt consolidation loan helps make it easier to tackle ———————————————————————————————————————————————————————————— Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting 2026-10-25 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/zhejiang-wenda-pharma-announces-positive-results-from-phase-ii-trial-of-oral-bet-inhibitor-nhwd-870-hcl-at-the-2026-esmo-annual-meeting-302918672.html SHAOXING, China, Oct. 25, 2026 -- At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data for NHWD-870 HCl, an oral BET inhibitor, in Chinese patients with advanced NUT carcinoma (NC).... ———————————————————————————————————————————————————————————— Dr. Agravat Dental Clinic Implant Wellness Center Integrates 10-Minute Blinkit Delivery 2026-10-25 · freePRnow · Healthcare, Retail, Medical devices http://www.freePRnow.com/pr/dr-agravat-dental-clinic-implant-wellness-center-integrates-10-minute-blinkit-delivery This clinical-to-quick-commerce bridge eliminates traditional 3- to 7-day e-commerce shipping delays, allowing patient ———————————————————————————————————————————————————————————— HotelKey Announces Strategic Leadership Updates to Expand Global Footprint and Drive Operational Excellence 2026-10-25 · ACN Newswire · Finance, SaaS, Healthcare, Real estate, Travel, Marketing & advertising, Software & IT https://www.acnnewswire.com/press-release/english/111062/ CARROLLTON, TX, Oct 25, 2026 - HotelKey, the leading cloud-based property management platform for the hospitality industry, today announced strategic updates to its leadership bench. Driving the company's vision and global scaling efforts are Julie Arrowsmith, Executive Vice President and Chief Financial Officer (EVP & CFO); Craig Chait, Vice President, Asia-Pacific (VP, APAC); Adnan Malik, Vice President, Europe, Middle East, and Africa (VP, EMEA); and Laura Atallah, Head of Marketing. These leadership roles underscore HotelKey's commitment to optimizing financial performance, elevating its brand presence, and accelerating its footprint across highly competitive international hospitality markets. "We are thrilled to formally introduce these accomplished leaders who are helping drive HotelKey's operations forward," said Aditya Thyagarajan, Co-Founder & President of HotelKey. "With Julie and Laura anchoring our financial and marketing strategies, and Craig and Adnan spearheading our vital APAC and EMEA markets, we have significantly strengthened our already exceptional leadership team to execute our vision and deliver unparalleled value to our partners worldwide." Strengthening the Executive Bench Julie Arrowsmith, Executive Vice President & Chief Financial Officer (EVP & CFO) Julie oversees HotelKey's financial strategy, planning, and reporting, actively positioning the company for sustained profitability and scale. She brings over 25 years of financial expertise in the hospitality industry, including executive leadership as both CFO and CEO at G6 Hospitality, the corporate headquarters of the Motel 6 and Studio 6 brands. Prior to G6, Julie worked in public accounting with Deloitte. Working closely with the leadership team, she supports key growth initiatives, drives operational efficiency, and ensures the organization's long-term financial health, playing a pivotal role in guiding strategic decision-making. Expanding Global Reach: APAC and EMEA Craig Chait, Vice President, Asia-Pacific (VP, APAC) Driving HotelKey's rapid expansion across the Asia-Pacific region, Craig steers the company's go-to-market strategy, regional sales, and strategic partnerships. As a commercial-led B2B SaaS executive, he brings 30 years of hospitality technology experience, with prior senior leadership roles at Oracle Hospitality, Xn protel, and Planet. With a career rooted in hotel operations at Accor and Marriott, Craig leverages deep domain expertise to guide major enterprise chains through complex transitions to the cloud. Adnan Malik, Vice President, Europe, Middle East, and Africa (VP, EMEA) Adnan takes the helm of the EMEA region, where he is responsible for accelerating market penetration, building regional teams, and nurturing localized client relationships. He brings over 20 years of experience spanning London's luxury hotel segment, large-scale property operations, and enterprise SaaS. Having previously served as Managing Director of a global hospitality tech firm and CEO of an international hotel brand, Adnan offers a deep, ground-up understanding of how to align technology with enterprise growth and owner profitability. Elevating the Brand Laura Atallah, Head of Marketing Laura leads HotelKey's comprehensive marketing strategy, focusing on worldwide brand positioning, demand generation, and go-to-market initiatives. She brings over 20 years of experience in B2B SaaS and technology marketing, having previously built the marketing function for an early-stage technology company and directed high-impact campaigns at Yardi, where she led a product launch that acquired over 1,000 owner/operator clients in its first year. Known for pairing strategy with hands-on execution, Laura leverages creativity and data-driven precision to accelerate HotelKey's commercial growth. For more information about HotelKey and its leadership team, please visit https://www.hotelkeyapp.com. About HotelKey The HotelKey suite of products is a cutting-edge, cloud-based property management platform built on proven industry innovations. These advancements enable HotelKey to deliver a true plug-and-play solution that enhances revenue growth, streamlines operations, and simplifies guest interactions, empowering hotels and enterprise groups to succeed at scale. Today, HotelKey supports more than 25,000 contracted hotels, with over 15,000 live on its Hospitality Management Platform. HotelKey's customer base includes 10 enterprise hotel chains and more than 800 independent properties worldwide. Media Contact: Laura Atallah Head of Marketing, HotelKey laura.atallah@hotelkeyapp.com https://www.hotelkeyapp.com SOURCE: HotelKey ———————————————————————————————————————————————————————————— Universal AAP: HandicapMD Highlights Medical Documentation and Attraction Access Planning 2026-10-24 · EIN Presswire · Healthcare, Travel https://www.einpresswire.com/article/952073099/universal-aap-handicapmd-highlights-medical-documentation-and-attraction-access-planning Universal access guidance connects IAC preregistration, the resort conversation, appropriate clinical support, and practical park-day arrangements. Useful preparation identifies the actual access need and the next responsible organization. Clinical documentation and a park accommodation serve different purposes.” — Dr. Eric Jackson-Scott LOS ANGELES, CA, UNITED STATES, October 24, 2026 / EINPresswire.com / -- Handica ———————————————————————————————————————————————————————————— IBCCES Accessibility Card Doctor Letter: HandicapMD Highlights Clinical Evaluation Guidance 2026-10-24 · EIN Presswire · Healthcare https://www.einpresswire.com/article/952072990/ibcces-accessibility-card-doctor-letter-handicapmd-highlights-clinical-evaluation-guidance Existing guidance explains optional $159 Doctor's Note Evaluations, accepted documents, clinical availability, and free IBCCES registration. A useful documentation request starts with the actual requirement, relevant information, and an honest clinical assessment. A letter cannot promise a park's decision.” — Dr. Eric Jackson-Scott LOS ANGELES, CA, UNITED STATES, October 24, 2026 / EINPresswire.com / -- HandicapMD is ———————————————————————————————————————————————————————————— Multiple Sclerosis Handicap Placards: HandicapMD Highlights Medical Evaluation and Certification Guidance 2026-10-24 · EIN Presswire · Healthcare, Automotive https://www.einpresswire.com/article/952072830/multiple-sclerosis-handicap-placards-handicapmd-highlights-medical-evaluation-and-certification-guidance Existing guide helps people with MS explain walking limitations, prepare relevant records and understand state-specific medical certification. An MS parking evaluation should connect the person's actual mobility limitations with the state's criteria. A diagnosis starts the discussion; it does not decide the application.” — Dr. Eric Jackson-Scott LOS ANGELES, CA, UNITED STATES, October 24, 2026 / EINPresswire.com / -- ———————————————————————————————————————————————————————————— Handicap Placard Costs: HandicapMD Highlights Medical Evaluation Fees and Government Charges Guide 2026-10-24 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/952072395/handicap-placard-costs-handicapmd-highlights-medical-evaluation-fees-and-government-charges-guide National cost guidance separates clinical evaluation charges, government application fees, plate costs, and everyday parking expenses. A useful cost comparison identifies the service, the payment recipient, and the next step. Clear terms help people ask better questions before booking.” — Dr. Eric Jackson-Scott LOS ANGELES, CA, UNITED STATES, October 24, 2026 / EINPresswire.com / -- HandicapMD is highlighting its nat ———————————————————————————————————————————————————————————— Uniting for Shared Growth, Linking the World: 2026 FHC Future Health Industry Conference Successfully Held in Hangzhou 2026-10-24 · PR Now · Healthcare https://pressreleasenews.org/pressroom/uniting-for-shared-growth-linking-the-world-2026-fhc-future-health-industry-conference-successfully-held-in-hangzhou From October 16 to 18, the 2026 FHC Future Health Industry Conference was successfully held at the Hangzhou International Expo Center. With the theme “Connecting Global Health Resources · Facilitating Collaborative Industry Progress,” the conference was initiated and hosted by Ha… ———————————————————————————————————————————————————————————— Martial Arts History Museum, A Cultural Gem in Glendale 2026-10-24 · NewMediaWire · Finance, Healthcare, Education, Travel, Nonprofits, Marketing & advertising https://www.newmediawire.com/news/martial-arts-history-museum-a-cultural-gem-in-glendale-7090850 GLENDALE, CA - October 25, 2026 - Known throughout Southern California as the "Jewel City," Glendale boasts iconic cultural treasures, from the historic Alex Theatre and the Museum of Neon Art to the Americana at Brand and the upcoming Armenian Museum. Yet, tucked right along Brand Boulevard lies a destination unlike any other on the planet: The Martial Arts History Museum. Now celebrating its 27th year, the Martial Arts History Museum is the only institution of its kind in the world - a distinction that puts Glendale on the global map for cultural tourism, history, and education. Since relocating from Burbank to its spacious 8,000-square-foot facility on Brand and Wilson, the museum has drawn thousands of visitors from across the country and around the globe. In fact, the majority of all its visitors are from out of country. A Bridge Between Cultures and Communities Thanks to the visionary leadership of Museum President Michael Matsuda, alongside key support from local champions like Mayor Ardy Kassakhian and Eric Fleishman who spearheaded the move from Burbank to Glendale, the expanded location has allowed the museum to grow into a vibrant multi-cultural hub. Beyond honoring traditional Asian martial arts, history, and art, the museum features special exhibits celebrating Armenian heritage, Native American history, Celtic traditions, and the powerful legacy of Warrior Women. "We are honored to call Glendale our home," says Museum President Michael Matsuda. "It took tremendous vision and hard work to build this cultural gem in the heart of the city, and our goal is to ensure it remains a cornerstone of Glendale’s artistic and educational identity for decades to come." Looking Toward the Future: Expanding Community Impact The clock is ticking on their current lease, and with less than two years, the Martial Arts History Museum is gearing up to hopefully relocate to another facility within Glendale. A fundraising effort is being launched to help them raise enough funds for the move. Beyond historical preservation, the non-profit institution acts as a vital community resource, hosting specialized outreach programs for local senior centers, individuals living with dementia, and those with special needs. Their plans for the upcoming new facility include dedicated spaces for health and wellness lectures, senior Tai Chi classes, and expanded community workshops. "We offer so much more to Glendale than people realize," Matsuda adds. "We bring global tourism to Brand Boulevard, preserve living history, and provide compassionate outreach to our local seniors and special-needs residents.” Museum Visitor Information & Support Hours: Wednesday - Sunday, 11:00 AM - 6:00 PM Admission: $12 Adults | $5 Children Location: 201 N. Brand Blvd., B100, at Wilson Ave., Glendale, CA Support: As a 501(c)(3) non-profit organization, the museum relies on community donations, sponsorships, and support to fuel its expansion and community outreach programs. To learn more, donate, or plan your visit, please go to MAmuseum.com. ———————————————————————————————————————————————————————————— North Carolina Handicap Parking Placards: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-24 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951977121/north-carolina-handicap-parking-placards-handicapmd-explains-online-medical-certification-and-eligibility North Carolina handicap placard guidance explains MVR-37A, medical certification, and government application steps. Clear North Carolina guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott, MD, MPH RALEIGH, NC, UNITED STATES, October 24, 2026 / EINPresswire.com / -- HandicapMD is highlighting North Carolina disabil ———————————————————————————————————————————————————————————— Maine Handicap Parking Placards: HandicapMD Explains Online Medical Certification and Eligibility 2026-10-24 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951976894/maine-handicap-parking-placards-handicapmd-explains-online-medical-certification-and-eligibility Maine handicap placard guidance explains PS-18, medical certification, and government application steps. Clear Maine guidance helps residents prepare medical documentation and understand the separate government application for disability parking.” — Dr. Eric Jackson-Scott AUGUSTA, ME, UNITED STATES, October 24, 2026 / EINPresswire.com / -- For a Maine resident, a disability parking question can begin with a familiar ———————————————————————————————————————————————————————————— Good Dentist Altrincham Makes Preventive Oral Care a Priority for Local Families 2026-10-24 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951509476/good-dentist-altrincham-makes-preventive-oral-care-a-priority-for-local-families Dedicated to advancing quality dental care Professional cleaning to help maintain healthy gums Maintaining oral health through regular dental care Personalised dental care for individual needs How do routine check-ups support oral health? Explore the role of dental hygiene, early intervention and personalised care for families. Our focus is on helping patients understand their oral health needs and make informed deci ———————————————————————————————————————————————————————————— Good Dentist Oldham Looks at Why Gum Health Deserves More Attention 2026-10-24 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951786313/good-dentist-oldham-looks-at-why-gum-health-deserves-more-attention Supporting patient-focused dentistry in Oldham Individualised dental care based on patient needs Professional dental hygiene for healthier gums Restorative dental care for healthy, confident smiles Healthy gums are important for long-term oral health. Find out why gum assessments matter before restorative and orthodontic dental treatment. Our approach is to help patients understand the factors affecting their gum hea ———————————————————————————————————————————————————————————— Dev Hospital Focuses on Patient-Centred Care Through Minimally Invasive Procedures 2026-10-24 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951787295/dev-hospital-focuses-on-patient-centred-care-through-minimally-invasive-procedures Clinical expertise in vascular and interventional radiology Dedicated care in vascular and interventional radiology Addressing uterine fibroids through individualized care Assessment and treatment options for varicose veins An overview of how image-guided procedures and individual clinical assessments provide non-surgical alternatives for fibroids and vascular care. Our priority is to help patients understand their t ———————————————————————————————————————————————————————————— Alabama Disability Parking Permits: HandicapMD Highlights Online Medical Certification for Alabama Residents 2026-10-24 · EIN Presswire · Healthcare, Government & policy https://www.einpresswire.com/article/951972647/alabama-disability-parking-permits-handicapmd-highlights-online-medical-certification-for-alabama-residents Alabama and Montgomery resources explain medical certification, Form MVR 32-6-230, and government application steps for disability parking permits. Clear guidance helps Alabama residents understand medical certification, prepare their application, and know which government office issues their disability parking credential.” — Dr. Eric MONTGOMERY, AL, UNITED STATES, October 24, 2026 / EINPresswire.com / -- HandicapMD ———————————————————————————————————————————————————————————— Why Vinyl Flooring Is the Preferred Choice for Hospitals, Schools, and Commercial Projects 2026-10-24 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/951990731/why-vinyl-flooring-is-the-preferred-choice-for-hospitals-schools-and-commercial-projects BAODING, HEBEI, CHINA, October 25, 2026 / EINPresswire.com / -- When walking down a bustling hospital hallway on a busy morning, the floor underfoot encounters a steady mix of foot traffic, medical carts, and rolling equipment. By afternoon, maintenance crews quietly clean those same surfaces with everyday disinfectants to prepare for evening appointments. Similar daily patterns play out across school corridors and c ———————————————————————————————————————————————————————————— 2-stage Screw Compressor Factory: AIRERA Secures TUV Class 0 Certification to Lead Pharma and Food-Grade Air 2026-10-24 · EIN Presswire · Healthcare, Food & drink, Industrial, Biotech & pharma https://www.einpresswire.com/article/951924085/2-stage-screw-compressor-factory-airera-secures-tuv-class-0-certification-to-lead-pharma-and-food-grade-air SHANGHAI, SHANGHAI, CHINA, October 25, 2026 / EINPresswire.com / -- Pharma and Food-Grade Air Solutions In highly sensitive industrial manufacturing, particularly within the pharmaceutical and food and beverage sectors, the procurement logic for compressed air systems differs fundamentally from standard manufacturing applications. Compressed air in these environments acts as a direct or indirect contact medium during ———————————————————————————————————————————————————————————— Cleveland Clinic Abu Dhabi LLC Shares Overview of Breast Screening Technologies and Access Across Asia 2026-10-24 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/cleveland-clinic-abu-dhabi-llc-shares-overview-of-breast-screening-technologies-and-access-across-asia/89207256 -- Cleveland Clinic Abu Dhabi LLC has presented an informational overview of breast screening technologies, service coordination, and access challenges across Asia. The overview brings together developments in imaging, remote interpretation, community-based screening, and multidisciplinary care, with an emphasis on how these elements connect within breast health programs. The material examines screening as a service- ———————————————————————————————————————————————————————————— THE RAIMONDO LAW FIRM SECURES $325,000 MEDIATION SETTLEMENT FOR HARDWARE STORE CUSTOMER INJURED BY FALLING TOOLBOXES 2026-10-24 · EIN Presswire · Healthcare, Legal, Medical devices https://www.einpresswire.com/article/951843365/the-raimondo-law-firm-secures-325-000-mediation-settlement-for-hardware-store-customer-injured-by-falling-toolboxes Attorney MICHAEL RAIMONDO Attorney DAVID J. RAIMONDO Attorney JON L. RAIMONDO THE CUSTOMER’S NECK INJURIES REQUIRED SURGERY AND PERMANENT MEDICAL IMPLANTS AFTER RETAILER FAILED TO KEEP OVERHEAD MERCHANDISE SECURE When choices and negligence result in a severe injury, surgery, and permanent hardware, we fight for the compensation that the victim is owed.” — Michael A. Raimondo, Esq. LAKE GROVE, NY, UNITED STATES, Octo ———————————————————————————————————————————————————————————— In HelloNation, Behavioral Health Experts Cody Luke and David Spencer Explain What to Expect During Your First Therapy Session 2026-10-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/in-hellonation-behavioral-health-experts-cody-luke-and-david-spencer-explain-what-to-expect-during-your-first-therapy-session-302918284.html The article outlines how first sessions build understanding, set goals, and support a comfortable start to therapy. IDAHO FALLS, Idaho, Oct. 24, 2026 -- What should you expect during your first therapy session? HelloNation published an article that answers this question,... ———————————————————————————————————————————————————————————— Growing a Plastic Surgery Practice: Full Growth System Outlined by MedFire Media 2026-10-24 · MarketersMEDIA · Healthcare, Media, Marketing & advertising, Chemicals & materials https://news.marketersmedia.com/growing-a-plastic-surgery-practice-full-growth-system-outlined-by-medfire-media/89207255 MedFire Media outlines a system-based approach to plastic surgery practice growth, covering visibility, trust, inquiry conversion and patient experience, and offers its OmniDominance™ content marketing system to help surgeons attract more qualified consultations. -- MedFire Media has outlined a system-based approach to growing a plastic surgery practice, addressing visibility, trust-building, inquiry conversion, pati ———————————————————————————————————————————————————————————— Swanson Vitamins Launches Swanson Vitamins Nexus Pro to Champion Registered Dietitians and Licensed Nutritionists at Every Stage of Their Careers 2026-10-24 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/swanson-vitamins-launches-swanson-vitamins-nexus-pro-to-champion-registered-dietitians-and-licensed-nutritionists-at-every-stage-of-their-careers-302918428.html New network for health and nutrition professionals offers CPEU-accredited continuing education, profession-wide promotion, practicum support and exam scholarships FARGO, N.D., Oct. 24, 2026 -- Swanson Vitamins today launched Swanson Vitamins Nexus Pro, a network for health... ———————————————————————————————————————————————————————————— Quanta Presents Positive Clinical Combination Data in KRAS G12D-Mutant CRC at ESMO and Highlights Pan-KRAS Progress 2026-10-24 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/24/3387679/0/en/quanta-presents-positive-clinical-combination-data-in-kras-g12d-mutant-crc-at-esmo-and-highlights-pan-kras-progress.html Quanta presents positive clinical combination data in KRAS G12D-mutant CRC at ESMO and highlights pan-KRAS progress with advancement of QTX6255 ———————————————————————————————————————————————————————————— VOKA 3D Anatomy & Pathology App Surpasses 1 Million Registrations Worldwide 2026-10-24 · ACCESS Newswire · Healthcare, Media https://finance.yahoo.com/healthcare/articles/voka-3d-anatomy-pathology-app-114500698.html VOKA 3D Anatomy & Pathology app surpasses 1 million registrations worldwide, offering 1,100+ interactive 3D models of human anatomy and pathology. BOSTON, MA / October 24, 2026 / VOKA, a medical visualization company specializing in 3D medical content and interactive technologies, announced that its VOKA 3D Anatomy & Pathology app has reached 1 million registrations worldwide. The app provides acces ———————————————————————————————————————————————————————————— Likang Life Sciences Showcases Personalized Cancer Immunotherapy and Global Ambitions at Abu Dhabi Future Health Summit 2026 2026-10-24 · PR Newswire · AI, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/likang-life-sciences-showcases-personalized-cancer-immunotherapy-and-global-ambitions-at-abu-dhabi-future-health-summit-2026-302918646.html BEIJING, Oct. 24, 2026 -- Likang Life Sciences ("Likang"), a biotechnology company advancing AI-enabled personalized cancer immunotherapies, sponsored and exhibited at the Abu Dhabi Future Health Summit 2026, held from 20 to 22 October at ADNEC Centre Abu Dhabi. The summit... ———————————————————————————————————————————————————————————— Incyte and Genmab Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer 2026-10-24 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/incyte-genmab-announce-clinical-trial-110000998.html Phase 1/2 study will evaluate INCB161734 plus petosemtamab and standard-of-care chemotherapy in first-line KRAS G12D-mutated metastatic colorectal cancer (mCRC) WILMINGTON, Del. & COPENHAGEN, Denmark, October 24, 2026--Incyte (Nasdaq:INCY) and Genmab A/S (Nasdaq:GMAB) today announced a clinical trial c ———————————————————————————————————————————————————————————— Bio-Thera Announces Promising Clinical Data for BAT8008 in Combination with BAT1308 in First-Line Non-Small Cell Lung Cancer at ESMO 2026 2026-10-24 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/bio-thera-announces-promising-clinical-data-for-bat8008-in-combination-with-bat1308-in-first-line-non-small-cell-lung-cancer-at-esmo-2026-302918492.html GUANGZHOU, China, Oct. 24, 2026 -- Bio-Thera Solutions, Ltd. (688177.SH), a commercial-stage biopharmaceutical company developing innovative therapies and biosimilars, today announced the presentation of clinical data for BAT8008, a TROP2-targeted antibody-drug conjugate... ———————————————————————————————————————————————————————————— NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma 2026-10-24 · GlobeNewswire · Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/24/3387671/0/en/nanobiotix-announces-final-data-from-phase-1-study-evaluating-jnj-1900-nbtxr3-with-immune-checkpoint-inhibitors-as-a-2l-therapy-in-anti-pd-1-resistant-primary-cutaneous-melanoma.html Data presented at the 2026 Congress of the European Society for Medical Oncology ———————————————————————————————————————————————————————————— United Nations (UN), partners support cholera response in south-eastern Democratic Republic of the Congo (DRC) 2026-10-24 · APO Group · Healthcare https://www.africa-newsroom.com/press/united-nations-un-partners-support-cholera-response-in-southeastern-democratic-republic-of-the-congo-drc?lang=en OCHA says that the UN and its partners are supporting response efforts as cholera spreads in the east of the Democratic Republic of the Congo, with more than 55,000 suspected cases reported between January and October, according to national authorities. The situation is especially concerning in Tanganyika Province, in south-eastern DRC, where provincial authorities say that the outbreak has affected all health zones. More than 6,300 cases have been reported there since January, nearly 1,000 more than during the same period last year. Tanganyika has also recorded one of the highest numbers of deaths due to cholera. In the provincial capital Kalemie, the treatment centre for diarrheal disease is overwhelmed, putting further pressure on health services already strained by limited access to safe water and sanitation. Some households have resorted to using untreated water from Lake Tanganyika and nearby rivers, increasing the potential for further transmission. Displacement sites hosting more than 6,500 people have also been affected, while over 12,000 displaced people are at risk of infection. The UN and its partners – including UNICEF and WHO – are providing treatment, medical supplies and water chlorination. However, they remain deeply concerned by the trajectory of the outbreak and call for additional support to expand treatment capacity and meet urgent needs. Beyond the immediate response, sustained investment in water and sanitation infrastructure is essential to prevent future outbreaks and ensure that vulnerable communities have lasting access to safe water. Distributed by APO Group on behalf of Office for Coordination of Humanitarian Affairs (OCHA). ———————————————————————————————————————————————————————————— KFSH Extends Emergency Access Through Virtual Care and Specialist Coordination 2026-10-24 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/24/3387666/0/en/kfsh-extends-emergency-access-through-virtual-care-and-specialist-coordination.html RIYADH, Saudi Arabia, Oct. 24, 2026 -- King Faisal Specialist Hospital and Research Centre (KFSH) is widening patients’ access to emergency expertise beyond its physical departments. Its virtual Emergency Department access and specialist coordination allow patients to be assessed early and directed to the most appropriate level of care. ———————————————————————————————————————————————————————————— Seraphis Group Sets Aside $3 Billion for AI Startups, Betting on Patient Capital Over Hype 2026-10-24 · FinanceWire · AI, Healthcare https://financewire.com/2026/10/24/seraphis-group-sets-aside-3-billion-for-ai-startups-betting-on-patient-capital-over-hype/ NEW YORK, USA, 24th October 2026, FinanceWire … Read More The post Seraphis Group Sets Aside $3 Billion for AI Startups, Betting on Patient Capital Over Hype appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026 2026-10-24 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/compass-therapeutics-announces-publication-of-phase-2-3-companion-002-results-for-tovecimig-in-the-journal-of-clinical-oncology-and-oral-presentation-at-esmo-2026 As published in the Journal of Clinical Oncology (JCO) and presented at ESMO, COMPANION-002 met its primary endpoint of ORR and key secondary endpoint of PFS, with a 56% reduction in the risk of disease progression or death. Responses were durable, with a median duration of response (DOR) of 4.9 months, and disease control rate … Continue reading "Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026" ———————————————————————————————————————————————————————————— BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026 2026-10-24 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/beone-presents-compelling-data-hard-081500952.html Potential first-in-class GPC3 x 4-1BB bispecific achieves a 36% confirmed response rate at Phase 3 dose and favorable safety profile in heavily pretreated liver cancer Brain-penetrant PRMT5 inhibitor shows promising antitumor and CNS activity in the largest publicly shared MTAP-deficient dataset First clinical data of CEA ———————————————————————————————————————————————————————————— CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026 2026-10-24 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/catalym-presents-phase-2-data-081500844.html Visugromab combined with PD-1 inhibitor nivolumab demonstrated higher response rates versus nivolumab alone across primary and secondary endpoints: pathologic Complete Response (pCR; 33% vs. 8%), radiographic Objective Response Rate (ORR; 60% vs. 15%) and Major Pathologic Response (MPR; 60% vs. 23%) Enhanced responses wer ———————————————————————————————————————————————————————————— David Ferrera Spotlights RC Medical's Venture Studio Model for Interventional Radiology 2026-10-24 · 24-7 Press Release · Healthcare https://www.24-7pressrelease.com/press-release/539873/david-ferrera-spotlights-rc-medicals-venture-studio-model-for-interventional-radiology David Ferrera, CEO of RC Medical, explains how the venture studio turns physician ideas into standalone device companies, and why that structure fits interventional radiology better than a traditional consulting shop. ———————————————————————————————————————————————————————————— Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting 2026-10-24 · PressReach · Healthcare, Biotech & pharma https://pressreach.com/immatics-presents-clinical-activity-of-ima402-prame-bispecific-and-ima203cd8-prame-cell-therapy-across-advanced-solid-tumors-in-two-oral-presentations-at-2026-esmo-annual-meeting IMA402 PRAME bispecific continues to demonstrate encouraging anti-tumor activity in multiple indications, alongside a favorable safety profile IMA402 achieved a cORR of 32%, 12.5 months median DOR and a 1-year OS rate of 91% in advanced melanoma patients with high PRAME expression Clinical profile of IMA402 reinforces development path across multiple solid tumor indications, including … Continue reading "Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual Meeting" ———————————————————————————————————————————————————————————— Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence 2026-10-24 · Bayer · Finance, Healthcare, Education, Biotech & pharma, Government & policy, Internet & apps, Chemicals & materials https://www.bayer.com/media/en-us/darolutamide-plus-adt-and-radiation-therapy-reduces-risk-of-metastasis-or-death-by-58-in-prostate-cancer-patients-at-high-risk-of-recurrence/ Berlin, October 24, 2026 – New late-breaking data to be presented today at the European Society for Medical Oncology (ESMO) Congress 2026 will show that adding Bayer’s androgen receptor inhibitor (ARi), darolutamide, to standard-of-care androgen deprivation therapy (ADT) and locoregional radiation therapy (RT), significantly improves metastasis-free survival based on conventional imaging (MFS-CI) in prostate cancer patients with high risk of recurrence compared to placebo. Darolutamide is currently not approved for this treatment setting. These data will be presented at Presidential Symposium I at the ESMO Congress 2026 (LBA4, Saturday 24 October, 16:30 CET). At a median follow-up of 3.8 years, the interim analysis demonstrated a 58% reduction in the risk of metastasis or death with darolutamide plus ADT and RT compared with placebo plus ADT and RT (hazard ratio [HR] 0.42; 95% CI: 0.27–0.66; p=0.0001). The 4-year metastasis-free survival rate was 95% for patients receiving darolutamide compared with 88% for those receiving placebo. “Prostate cancer patients at a high risk of relapse face a considerable risk of recurrence and metastatic spread, making early, highly effective intervention vital,” said Dr. Tamim Niazi, Associate Professor of Oncology at McGill University, Radiation Oncologist at the Jewish General Hospital in Montreal, Canada. and Co-Lead Investigator of the study. “The clear improvement in metastasis-free survival seen in interim results from the DASL-HiCaP trial highlights the potential of adding darolutamide to standard androgen deprivation therapy and radiation therapy to help prevent or delay disease progression in patients who are at high risk of progression despite receiving primary curative therapy.” Secondary endpoints also showed consistent positive trends with darolutamide, with a 53% reduction in the risk of prostate-specific antigen progression free survival (PSA-PFS; HR 0.47; 95% CI: 0.33–0.67), and a 4-year PSA-PFS rate of 91% versus 83% with placebo. Prostate cancer-specific survival (PCSS) and overall survival (OS) hazard ratios were 0.58 (95% CI: 0.17–1.97; 99% vs 99% at 4 years) and 0.88 (95% CI: 0.49–1.59; 97% vs 95% at 4 years), respectively, with follow-up ongoing. The safety profile of darolutamide was consistent with its known tolerability, with adverse events being similar to the placebo group. Proportions of patients experiencing Grade ≥2 adverse events of special interest for darolutamide versus placebo were: fatigue/asthenia (14% vs 10%), hypertension (7% vs 9%), fractures (2% vs 3%), and cardiac events (3% vs 3%). Any Grade ≥3 adverse event occurred in 43% of patients in the darolutamide group versus 36% in the placebo group. "These new data highlight the potential of darolutamide to make a meaningful difference for patients earlier in the course of their prostate cancer,” said Christine Roth, Executive Vice President, Global Product Strategy and Commercialization at Bayer’s Pharmaceuticals Division. “By advancing darolutamide into earlier disease settings, we aim to reach more patients across the prostate cancer care continuum. We are proud to support ANZUP, the Sydney Clinical Trials Centre, CCTG and international partners in research as we work together with the potential to improve outcomes for men living with prostate cancer.” Follow-up of participants is continuing to provide further information on longer-term outcomes, including overall survival. About the DASL-HiCaP trial (ANZUP1801)  The DASL-HiCaP trial is an investigator-initiated, randomized, placebo-controlled, Phase III trial (NCT04136353) evaluating darolutamide added to standard-of-care ADT and locoregional radiation therapy in prostate cancer patients at high risk of recurrence. DASL-HiCaP was conducted in collaboration with the University of Sydney and ANZUP Clinical Trials Group and is the fourth Phase III trial for darolutamide. Following ARAMIS, ARASENS, and ARANOTE, which demonstrated darolutamide’s efficacy and safety in advanced prostate cancer, DASL-HiCaP represents the first Phase III study of darolutamide in early prostate cancer. A total of 1,106 participants across Australia, New Zealand, Canada, the United States, Ireland and the United Kingdom were randomized 1:1 to receive darolutamide (600 mg twice daily) or matching placebo for 96 weeks, combined with an LHRH analog for 96 weeks and RT to the prostate/prostate bed and pelvic lymph nodes. The primary endpoint was metastasis-free survival based on conventional imaging (MFS-CI). Secondary endpoints included prostate-specific antigen progression free survival (PSA-PFS), prostate cancer-specific survival (PCSS), and overall survival (OS). The protocol specified an interim analysis after 87 MFS-CI events; follow-up is ongoing to evaluate long-term overall survival. About the Sydney Clinical Trials Centre The Sydney Clinical Trials Centre is a flagship research centre of the Faculty of Medicine and Health at the University of Sydney that designs and manages clinical trials. This includes responsibility for study coordination, monitoring, data acquisition and management and statistical analysis. The Sydney Clinical Trials Centre has health economics, biostatistics, systematic reviews and biomarker teams that work with trial data and inform healthcare providers about best practice. For further details, please visit its website at https://www.ctc.usyd.edu.au About ANZUP Clinical Trials Group  ANZUP (https://www.anzup.org.au) is the leading cancer-cooperative trials group bringing together all of the professional disciplines and groups involved in researching and treating urogenital cancers to conduct high-quality cancer research. ANZUP’s mission is to improve the lives of people affected by bladder, kidney, testicular, penile, and prostate cancers, towards our vision of living life without fear of cancer. ANZUP identifies gaps in evidence and areas of clinical need, collaborates with the best clinicians and researchers in genitourinary cancer and communicates frequently and effectively with the broader community along the way. ANZUP receives valuable infrastructure support from the Australian Government through Cancer Australia and research funding from Prostate Cancer Foundation of Australia. About Prostate Cancer Prostate cancer is the second most common cancer and the fourth most common cause of cancer death in men worldwide. Over 1.5 million men are diagnosed with prostate cancer each year and almost 420,000 die from the disease worldwide. By 2040, prostate cancer diagnoses are projected to increase to 2.9 million. Standard therapy for prostate cancer patients at high risk of recurrence combines radiation therapy with androgen deprivation therapy (ADT). However, despite this approach, a significant proportion of patients experience treatment failure, local recurrence, or distant metastases. Intensifying therapy early with an advanced androgen receptor inhibitor aims to improve long-term disease control and delay metastatic progression. About darolutamide (Nubeqa™) Darolutamide is an oral ARi with a distinct chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration and low potential for clinically relevant drug-drug interactions. Darolutamide, under the brand name Nubeqa™ plus androgen deprivation therapy (ADT), is already approved in more than 85 markets around the world, including the US, EU and China. It is approved for the treatment of adult patients with mHSPC without docetaxel in 75 markets and with docetaxel in more than 85 countries, and for adult patients with nmCRPC at high risk of developing metastatic disease in more than 85 countries. Darolutamide is developed jointly by Bayer and Orion Corporation, a globally operating Finnish pharmaceutical company. Darolutamide demonstrated efficacy and tolerability in pivotal Phase 3 studies, supporting its indications in nmCRPC and mHSPC with and without chemotherapy, with a favorable safety profile that offers an advancement in treatment management for physicians and patients. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. Current ongoing trials include the Phase III ARASTEP trial evaluating the efficacy of darolutamide plus ADT compared to ADT alone in hormone-sensitive prostate cancer (HSPC), in patients with high-risk biochemical recurrence (BCR) who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. About Prostate Cancer at Bayer Bayer is committed to delivering science for a better life by advancing a portfolio of innovative treatments. The company has the passion and determination to develop new medicines that help improve and extend the lives of people living with cancer. Prostate cancer is the second most commonly diagnosed cancer in men and a key area of focus for Bayer. The company’s franchise includes two products on the market (Nubeqa™ and Xofigo™) and several compounds in development. Bayer is focused on addressing the unique needs of patients with prostate cancer, providing treatments that extend their lives throughout the different stages of the disease and allowing them to continue with their everyday activities, so that patients can live longer, better lives. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to support efforts to master major challenges presented by a growing and aging global population and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com. Find more information at www.bayer.com/en/portfolio/pharmaceuticals Follow us on Facebook: http://www.facebook.com/bayer Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires. ———————————————————————————————————————————————————————————— Lilly presents first clinical data in platinum-sensitive ovarian cancer for its investigational, next-generation, FRα-targeting ADC at ESMO 2026 2026-10-24 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/lilly-presents-first-clinical-data-in-platinum-sensitive-ovarian-cancer-for-its-investigational-next-generation-fr-targeting-adc-at-esmo-2026-302918153.html Sofetabart mipitecan (Sofe-M) in combination with bevacizumab demonstrated a 79% confirmed objective response rate and 100% disease control rate, with similar activity observed across FRα expression levels Clinical activity with Sofe-M was maintained even in patients with prior PARP... ———————————————————————————————————————————————————————————— Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026 2026-10-24 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/24/3387658/0/en/zymeworks-presents-new-phase-1-data-for-folate-receptor-alpha-targeting-antibody-drug-conjugate-zw191-at-esmo-congress-2026.html VANCOUVER, British Columbia, Oct. 24, 2026 -- Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, today presented new clinical data from the randomized dose-optimization portion of its ongoing Phase 1 study evaluating ZW191, a FRα-targeting antibody-drug conjugate (ADC), at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. ———————————————————————————————————————————————————————————— Knee Cartilage Stem Cell Therapy Korea: Non-Surgical Options and Costs Explained 2026-10-24 · MarketersMEDIA · Healthcare, Biotech & pharma https://news.marketersmedia.com/knee-cartilage-stem-cell-therapy-korea-non-surgical-options-and-costs-explained/89207234 Lydian Cosmetic Surgery Clinic in Seoul details non-surgical stem cell injections for knee osteoarthritis, covering candidacy, process, costs and realistic limits on cartilage regeneration for international patients weighing treatment in Korea. -- Lydian Cosmetic Surgery Clinic in Seoul offers non-surgical stem cell injections for knee osteoarthritis, using cells collected from a patient's own fat tissue or bone marr ———————————————————————————————————————————————————————————— How to Build an Emergency Fund for Your Furry Best Friend 2026-10-24 · Newswire.com · Healthcare https://www.newswire.com/news/how-to-build-an-emergency-fund-for-your-furry-best-friend Pets bring joy, comfort and a whole lot of love into your home. But they also come with costs, and some of those costs show up when you least expect them. A sudden illness or accident can turn into an urgent trip to the vet and a major expense. With an emergency fund for your pet, you can handle those surprises and focus on your pet's health instead of worrying about how to pay for their care. If a large bill ever do ———————————————————————————————————————————————————————————— 5 Ways to Prepare Financially for Parenthood 2026-10-24 · Newswire.com · Healthcare https://www.newswire.com/news/5-ways-to-prepare-financially-for-parenthood Becoming a parent is one of the biggest changes you can experience, and it comes with plenty of new expenses. From medical bills to baby gear, the costs of raising a child add up quickly. Getting your finances in order ahead of time can help you when your little one arrives. Some paths to parenthood come with added costs. Family-building expenses like fertility treatments can be significant, and they aren't always co ———————————————————————————————————————————————————————————— Vadzo Imaging Positions Bolt-521CRS: Onsemi AR0521 Color 5MP Low-Noise MIPI Camera with NVIDIA Jetson AGX Orin for Medical and Life Science Imaging 2026-10-24 · Newswire.com · SaaS, Healthcare https://www.newswire.com/news/vadzo-imaging-positions-bolt-521crs-onsemi-ar0521-color-5mp-low-noise-22878021 The Bolt-521CRS is a 5MP Low-Noise MIPI Camera built on the Onsemi AR0521 sensor, and Vadzo is positioning it with NVIDIA Jetson AGX Orin for medical and life science imaging. Medical and laboratory instruments image small, dim, and often strobe lit subjects, and they depend on clean color and consistent exposure. The Bolt-521CRS pairs large 2.2 micron pixels with an on board ISP, so the frame arrives with low noise and finished color. Its sensor also supports Global Reset Release, a mode that starts exposure on every row at the same moment, which lets a rolling shutter sensor work with a flash or a controlled light source and avoids much of the usual skew. The module supports NVIDIA Jetson Orin Nano, Orin NX, and AGX Orin through 2 lane and 4 lane adapter boards. Designed for instrument makers building microscopes, ophthalmic and intraoral devices, and laboratory systems, this 5MP Jetson AGX Orin MIPI Camera and 5MP GRR MIPI Camera supplies clean, correctly colored images to the Jetson platform of their choice. ———————————————————————————————————————————————————————————— Junshi Biosciences Announces Completion of First Patient Dosing in the Phase 3 Clinical Trial of JS203 in Combination with Chemotherapy for the Treatment of Diffuse Large B-cell Lymphoma 2026-10-24 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/24/3387653/0/en/junshi-biosciences-announces-completion-of-first-patient-dosing-in-the-phase-3-clinical-trial-of-js203-in-combination-with-chemotherapy-for-the-treatment-of-diffuse-large-b-cell-ly.html The first patient dosing has been completed in phase 3 clinical study of JS203 (CD20/CD3 bsAb), in combination with chemotherapy in patients with R/R DLBCL ———————————————————————————————————————————————————————————— PatientGain Launches ReputeMD: A HIPAA-Compliant Online Reputation Management Service for Doctors and Dentists 2026-10-24 · MarketersMEDIA · Healthcare, Marketing & advertising https://news.marketersmedia.com/patientgain-launches-reputemd-a-hipaa-compliant-online-reputation-management-service-for-doctors-and-dentists/89207148 The HIPAA-compliant full-service reputation management app is designed for doctors, dentists, and healthcare clinics wanting to streamline patient reviews. -- PatientGain, a leading provider of HIPAA-compliant healthcare marketing solutions, has officially launched ReputeMD. This automated digital application is engineered specifically for doctors, dentists, and healthcare clinics to streamline and maximize their onl ———————————————————————————————————————————————————————————— Pathalys Pharma Presents Positive Data from Pivotal Phase 3 Studies of Upacicalcet in Featured Oral Presentation at ASN Kidney Week 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/pathalys-pharma-presents-positive-data-from-pivotal-phase-3-studies-of-upacicalcet-in-featured-oral-presentation-at-asn-kidney-week-2026-302918517.html ~ In PATH-1 and PATH-2 upacicalcet met primary and key secondary endpoints of reducing parathyroid hormone (PTH) in patients with end-stage kidney disease and Secondary Hyperparathyroidism (SHPT) on hemodialysis ~ Upacicalcet also reduced FGF23 and markers of bone turnover in the trial... ———————————————————————————————————————————————————————————— International Medical Aid Brings Global Health Education to the 2026 UC Davis Pre-Health Conference 2026-10-23 · EIN Presswire · Healthcare, Education, Jobs & workplace https://www.einpresswire.com/article/951901104/international-medical-aid-brings-global-health-education-to-the-2026-uc-davis-pre-health-conference International Medical Aid representatives and alumni at the IMA booth during the 2026 UC Davis Pre-Health Conference on October 17. IMA’s Founder and Managing Director leads the “Ethics, Culture, and Care: Responsible Approaches to International Clinical Internships” workshop at the UC Davis Pre-Health Conference. Conference attendees review information about International Medical Aid's healthcare internship and educ ———————————————————————————————————————————————————————————— Ryan Watkins DDS Inc. Built Dreamtime Dentistry Around a Rare Dual Credential in Dental Anesthesiology 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951880515/ryan-watkins-dds-inc-built-dreamtime-dentistry-around-a-rare-dual-credential-in-dental-anesthesiology Ryan Watkins DDS Inc. in Vista, CA Dr. Ryan Watkins and two team members standing together in the office at Dreamtime Dentistry Patient positioned for a panoramic X-ray scan with treatment area visible in background at Dreamtime Dentistry Dental staff member assisting a patient in a treatment chair with imaging displayed on monitor RYAN WATKINS DDS INC. — Dental.me Verified, Score 98 Since 2011, Dr. Ryan Watkins has ———————————————————————————————————————————————————————————— The Inner Circle acknowledges Joshua L. Davenport, RN, as a 3rd Year Pinnacle Member 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-joshua-l-davenport-rn-as-a-3rd-year-pinnacle-member-302918469.html LOUISVILLE, K.y., Oct. 23, 2026 -- Prominently featured in The Inner Circle, Joshua L. Davenport, RN is honored as a 3rd Year Pinnacle Member for his contributions to 25 Years of Dedication to Emergency Nursing and Occupational Health. Joshua L. Davenport, RN, has built a... ———————————————————————————————————————————————————————————— The Galien Foundation Presents Senator John Kerry with 2026 Roy Vagelos Pro Bono Humanum Award for Global Health Equity 2026-10-23 · PR Newswire · Healthcare, Sustainability, Government & policy https://www.prnewswire.com/news-releases/the-galien-foundation-presents-senator-john-kerry-with-2026-roy-vagelos-pro-bono-humanum-award-for-global-health-equity-302918473.html Honoring the former U.S. Secretary of State and Special Presidential Envoy for Climate for pioneering efforts to address climate change and public health initiatives Award to be presented on October 29, 2026, at the Prix Galien USA Awards Ceremony in New York City NEW YORK, Oct. 23, 2026... ———————————————————————————————————————————————————————————— Senior Market Advisors and Agent Review Launch National Insurance Agent Verification Initiative at Protectors Las Vegas 2026-10-23 · EIN Presswire · AI, Healthcare, Media, Insurance https://www.einpresswire.com/article/951886738/senior-market-advisors-and-agent-review-launch-national-insurance-agent-verification-initiative-at-protectors-las-vegas Agent Review Logo Corp Senior Market Advisors Agent Verification With Agent Review Agent Review Video Ai Verification - Verified Agent Program AmeriLife affiliate has tapped licensed agents from every state to verify credentials across life insurance, health insurance, and retirement solutions. Our goal is to provide verification services to all our agents. Consumers deserve access to qualified professionals and a pr ———————————————————————————————————————————————————————————— Robotic Dental Implant Surgery Comes to Wallingford 2026-10-23 · EIN Presswire · Healthcare, Travel, Medical devices https://www.einpresswire.com/article/951884873/robotic-dental-implant-surgery-comes-to-wallingford Wolfy Dental Group is the first Wallingford dental practice to offer robot-guided implant placement with the FDA-cleared Yomi system. WALLINGFORD, CT, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Patients in Wallingford and the greater New Haven area no longer need to travel to a hospital or a specialty surgical center for robot-assisted dental implants. Wolfy Dental Group, led by Dr. Sandra Vukovic, DDS, ———————————————————————————————————————————————————————————— Peptide Sciences Closed: California Trim Clinic Offers Physician-Prescribed Peptide Therapy Options 2026-10-23 · PRUnderground · Healthcare https://prunderground.com/peptide-sciences-closed-california-trim-clinic-offers-physician-prescribed-pepti/cmvletmwu000008i6hplwiys9 Peptide Sciences closed? California Trim Clinic explains peptide therapy, personalized options, medical guidance, and supervised care for patients seeking alternatives. The post Peptide Sciences Closed: California Trim Clinic Offers Physician-Prescribed Peptide Therapy Options first appeared on ———————————————————————————————————————————————————————————— Intermountain Health Receives One of the Nation's Largest Gifts in Pediatric Care 2026-10-23 · PRUnderground · Healthcare https://prunderground.com/intermountain-health-receives-one-of-the-nation-s-largest-gifts-in-pediatric-car/cmvlfgq0a003207kza0ke61e2 Felicia and Ben Horowitz's gift will help Intermountain Health bring leading pediatric specialists and expertise to the Nevada's first stand-alone children's hospital. The post Intermountain Health Receives One of the Nation's Largest Gifts in Pediatric Care first appeared on ———————————————————————————————————————————————————————————— Inspired Health Opens Waitlist for Integrative Cognitive Care in Columbia, SC 2026-10-23 · PR Now · Healthcare https://pressreleasenews.org/pressroom/inspired-health-opens-waitlist-for-integrative-cognitive-care-in-columbia-sc The practice is accepting waitlist registrations from adults whose cognitive symptoms persist despite normal-range lab results, offering a root-cause evaluation model that investigates the system's standard workups. COLUMBIA, SC, September 7, 2026 - Inspired Health, the integrati… ———————————————————————————————————————————————————————————— Quest Diagnostics Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Unauthorized Access to Patient Records 2026-10-23 · PR Newswire · Healthcare, Cybersecurity, Legal, Medical devices https://www.prnewswire.com/news-releases/quest-diagnostics-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-unauthorized-access-to-patient-records-302918491.html National class action law firm offers free, confidential case evaluations to Quest Diagnostics patients and others whose information may have been exposed. SECAUCUS, N.J., Oct. 23, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is investigating data privacy... ———————————————————————————————————————————————————————————— AN2 Therapeutics, Inc. Reports Inducement Grants Under Listing Rule 5635(c)(4) 2026-10-23 · Business Wire · Finance, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/an2-therapeutics-inc-reports-inducement-210000048.html MENLO PARK, Calif., October 23, 2026--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform, today announced it granted inducement equity awards to two newly-hired employees. On October 19 ———————————————————————————————————————————————————————————— New Report Examines Chinese Communist Party Influence Over China's Organ Transplant System 2026-10-23 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/950868663/new-report-examines-chinese-communist-party-influence-over-china-s-organ-transplant-system Chinese Communist Party–Affiliated Transplant Leaders by Province (2020–2025) Oath For a Medical Student (China State Education Commission) New Investigation Identifies Transplant Surgeons Holding Senior Party Positions and Questions Whether China's Claims of Reform Can Be Believed Every entity that Chinese officials present to international audiences as ostensibly independent or as a ‘third party’ is in fact a node ———————————————————————————————————————————————————————————— Millennial Medical Reports Record Growth, Launches Crutches.com to Transform the Consumer Crutch Market 2026-10-23 · PRWeb · Healthcare, Retail, Automotive, Consumer goods https://www.prweb.com/releases/millennial-medical-reports-record-growth-launches-crutchescom-to-transform-the-consumer-crutch-market-302917760.html St. George, Utah-based medical mobility company reports strong sales growth as expanded digital strategy drives launch of dedicated consumer brand ST. GEORGE, Utah, Oct. 23, 2026 -- Millennial Medical, a family-owned medical mobility company based in St. George, Utah,... ———————————————————————————————————————————————————————————— Leading Pediatric Therapy Software Provider Ambiki Secures Additional Investment to Accelerate Growth 2026-10-23 · ACCESS Newswire · Finance, Healthcare, Software & IT https://finance.yahoo.com/healthcare/articles/leading-pediatric-therapy-software-provider-205500625.html Funding will expand practice management technology, managed billing and data migration services, and innovative clinical tools for pediatric therapy practices. NASHVILLE, TN / October 23, 2026 / Ambiki today announced an additional equity investment from existing investor Green Hills Partners. The invest ———————————————————————————————————————————————————————————— "Health Is Wealth": Unicoin Foundation Launches Crypto for Good Breast Cancer Campaign 2026-10-23 · PR Newswire · Crypto, Healthcare, Education https://www.prnewswire.com/news-releases/health-is-wealth-unicoin-foundation-launches-crypto-for-good-breast-cancer-campaign-302918389.html RISE IN PINK aims to turn Breast Cancer Awareness Month into action, mobilizing communities to fund early detection, breast health education and patient support while recognizing donors' generosity with digital tokens MIAMI, Oct. 23, 2026 -- With the message "Health Is... ———————————————————————————————————————————————————————————— Documentary ‘NURSE: Empathy Heals’ highlights nurses’ stories 2026-10-23 · GlobeNewswire · Healthcare, Entertainment https://www.globenewswire.com/news-release/2026/10/23/3387617/0/en/documentary-nurse-empathy-heals-highlights-nurses-stories.html Nashville, Tenn., Oct. 23, 2026 -- The experiences of nurses and the essential role of empathy in healthcare took center stage Oct. 21 at Nashville’s Belcourt Theatre during a special screening of “NURSE: Empathy Heals.” The documentary shares nurses’ personal stories, offering a closer look at the emotional demands of caregiving and the people behind patient care. ———————————————————————————————————————————————————————————— Healthcare Business Intelligence Software Must Model FQHC Payments 2026-10-23 · MarketersMEDIA · Finance, SaaS, Healthcare, Software & IT https://news.marketersmedia.com/healthcare-business-intelligence-software-must-model-fqhc-payments/89207211 Healthcare business intelligence software often misreports revenue at community health centers because it cannot model PPS rates, wraparound payments, or sliding-scale determinations. A Visualutions guide outlines six capabilities FQHC finance leaders should test before choosing a platform. -- Healthcare business intelligence software often fails at community health centers for one main reason. It does not understand ———————————————————————————————————————————————————————————— Cumberland Pharmaceuticals Announces ASSIST-SSc Trial Top-Line Results 2026-10-23 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-announces-assist-ssc-trial-top-line-results-302918449.html Ifetroban was well tolerated in patients with systemic sclerosis NASHVILLE, Tenn., Oct. 23, 2026 -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, announces... ———————————————————————————————————————————————————————————— Strata Critical Medical Schedules Third Quarter 2026 Earnings Conference Call 2026-10-23 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/10/23/3387605/0/en/strata-critical-medical-schedules-third-quarter-2026-earnings-conference-call.html NEW YORK, Oct. 23, 2026 -- Strata Critical Medical. (Nasdaq: SRTA, “Strata” or the “Company”), will release financial results for the third quarter ended September 30, 2026 on Tuesday, November 3, 2026 before the market opens. The company will hold a conference call on the same day at 8:00 am Eastern Time to discuss the results. The call will be hosted by Melissa Tomkiel, Strata’s Co-Chief Executive Officer and General Counsel, and Will Heyburn, Strata’s Co-Chief Executive Officer and Chief Financial Officer, and will include a question-and-answer session for call participants. ———————————————————————————————————————————————————————————— GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026 2026-10-23 · Business Wire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/genedx-report-third-quarter-2026-200500743.html GAITHERSBURG, Md., October 23, 2026--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will ho ———————————————————————————————————————————————————————————— ABARTA COCA-COLA TEAMSTERS LAUNCH ULP STRIKE 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/abarta-coca-cola-teamsters-launch-ulp-strike-302918453.html Members of Local 110 Demand Fair Contract, Affordable Health Care EBENSBURG, Pa., Oct. 23, 2026 -- Members of Teamsters Local 110 at two Abarta Coca-Cola facilities in Dubois and Ebensburg, Pa., have been forced to the picket line after months of negotiations. The 85... ———————————————————————————————————————————————————————————— Mission MSA to Host Externally Led Patient-Focused Drug Development Session on Multiple System Atrophy 2026-10-23 · PRWeb · Healthcare, Biotech & pharma, Nonprofits https://www.prweb.com/releases/mission-msa-to-host-externally-led-patient-focused-drug-development-session-on-multiple-system-atrophy-302917749.html Free, virtual meeting on March 16, 2027 will gather patient and care partner testimony on life with MSA to inform future treatments. CHICAGO, Oct. 23, 2026 -- Mission MSA, a nonprofit supporting people affected by multiple system atrophy (MSA), will host a virtual... ———————————————————————————————————————————————————————————— ArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387598/0/en/arrivent-to-present-initial-phase-1-data-for-cdh17-targeted-adc-arr-217-in-patients-with-gastrointestinal-cancers-at-the-esmo-congress-2026.html NEWTOWN SQUARE, Pa., Oct. 23, 2026 -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that initial safety and efficacy data from the Phase 1 (NCT07066657) study of CDH17-targeted ADC ARR-217 (MRG007) in patients with gastrointestinal cancers, will be presented in a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place in Madrid, Spain, on October 23-27, 2026. ArriVent plans to host a virtual webinar on October 26, 2026 at 8 am ET to discuss the data and ARR-217 program. To register for the event, click here. ———————————————————————————————————————————————————————————— GondolaBio and Children’s Tumor Foundation Announce Partnership to Advance GondolaBio’s Neurofibromatosis Type 1 Program 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/gondolabio-children-tumor-foundation-announce-200000022.html Collaboration brings Children's Tumor Foundation's deep NF1 expertise and patient and family perspectives into development of GondolaBio's neurofibromatosis type 1 (NF1) program PALO ALTO, Calif. & NEW YORK, October 23, 2026--GondolaBio, a clinical-stage biopharmaceutical company developing novel medic ———————————————————————————————————————————————————————————— Orthofix to Report Third Quarter 2026 Financial Results 2026-10-23 · Business Wire · Finance, Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/orthofix-report-third-quarter-2026-200000888.html Company to Host Conference Call on Monday, November 9, 2026, at 8:30 am Eastern Time LEWISVILLE, Texas, October 23, 2026--Orthofix Medical Inc . (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its third quarter 2026 financial results on Monday, November ———————————————————————————————————————————————————————————— Is Teen Obesity a Medical Condition? California Trim Clinic Explains Why Willpower Isn't Enough 2026-10-23 · PRUnderground · Healthcare https://prunderground.com/is-teen-obesity-a-medical-condition-california-trim-clinic-explains-why-willpowe/cmvl7rj6m001j08l2uduhoqp1 California Trim Clinic highlights TeenHealthRx, a physician-guided approach to teen obesity that goes beyond willpower to support healthier, long-term weight management. The post Is Teen Obesity a Medical Condition? California Trim Clinic Explains Why Willpower Isn't Enough first appeared on ———————————————————————————————————————————————————————————— Seychelles: First Lady Outlines Four-Year Plan to Strengthen and Expand Community Initiatives 2026-10-23 · APO Group · Finance, Healthcare, Energy, Automotive, Education, Sustainability, Government & policy https://www.africa-newsroom.com/press/seychelles-first-lady-outlines-fouryear-plan-to-strengthen-and-expand-community-initiatives?lang=en First Lady Mrs Veronique Herminie has outlined an ambitious four-year plan aimed at strengthening support for women, children and vulnerable groups, while expanding initiatives that promote education, empowerment, health and community well-being. The plan builds on initiatives such as Welcome to Puberty, Boys Connect and Build Your Dream, which will continue to form part of the Office of the First Lady's efforts to equip young people with knowledge, confidence and opportunities for personal development. To translate this commitment into action, the First Lady presented a Strategic Framework to Vice-President Mr Sebastien Pillay and Principal Secretary for Administration Mrs Doreen Zelia at State House on Friday. The framework sets out the priorities that will guide the Office of the First Lady over the next four years. "It will also serve as a foundation for mobilising resources, securing funding and establishing partnerships to support the implementation of its initiatives," said Mrs Herminie. She added "a key feature of the framework is a commitment to ensuring continuity in programmes that have made a positive difference in people's lives." Under the theme Empowering Seychelles Together, the framework places particular emphasis on health and wellness, support for vulnerable groups, education, empowerment, gender equality and environmental stewardship. The Office's main initiatives will be implemented annually, with each one targeting specific vulnerable groups and addressing their particular needs. Through Welcome to Puberty, the Office will continue promoting awareness and education among young people navigating adolescence, while Boys Connect will focus on engaging boys in discussions and activities that encourage positive development and responsible decision-making. Build Your Dream will seek to inspire young people to pursue their ambitions and explore opportunities for personal growth. As part of its commitment to continuity, Mrs Herminie also intends to carry forward the Hug in a Mug initiative introduced by former First Lady Mrs Linda Ramkalawan, recognising the importance of maintaining meaningful programmes that support vulnerable members of society. The framework also outlines environmental actions specific to the Office's operations over the four years, including the introduction of green energy in 2026, waste recycling and sorting in 2027, and the adoption of a green vehicle in 2028. These measures aim to make the Office's daily operations more environmentally sustainable. Several initiatives will be organised around relevant United Nations International Days and other international observances, providing opportunities to raise awareness and encourage public participation in issues relating to women, children, health, environmental protection and vulnerable groups. An important component of the framework is the strengthening of partnerships with government institutions, civil society organisations, the private sector and international development partners. These collaborations are expected to broaden the reach of the Office's programmes while ensuring the effective use of available resources. Aligned with national development priorities and the United Nations Sustainable Development Goals, the framework also introduces monitoring and evaluation measures to assess progress and ensure accountability throughout its implementation. Through this four-year strategic direction, the Office of the First Lady seeks to build on existing programmes, expand its community outreach and ensure that its initiatives deliver meaningful and lasting benefits to the people of Seychelles.  Distributed by APO Group on behalf of State House Seychelles. ———————————————————————————————————————————————————————————— New Film Series Turns the Spotlight on Arrow Electronics’ SAM Car Project 2026-10-23 · 3BL Media · Finance, AI, SaaS, Healthcare, Energy, Retail, Automotive, Media, Logistics, Consumer goods, Entertainment, Agriculture https://www.3blmedia.com/news/new-film-series-turns-spotlight-arrow-electronics-sam-car-project New Film Series Turns the Spotlight on Arrow Electronics’ SAM Car Project Mon, 10/26/2026 - 09:15 Body Centennial, Colo., October 23, 2026 – When former IndyCar driver Sam Schmidt was left paralyzed after a crash in 2000, he assumed his racing career was over.  “I crashed, backed into the wall and just disintegrated my C3, C4, and C5 vertebrae,” said Schmidt. “I was paralyzed from the neck down. You know, that was that.” But Schmidt’s story shifted when Arrow Electronics reached out in 2013, asking if he would consider getting back behind the wheel in a vehicle powered by semi-autonomous technology.  The collaboration between Arrow and Schmidt resulted in the Arrow SAM (semi-autonomous motorcar) Car Project, which modifies performance cars with electronic interfaces to allow Schmidt to drive at racetrack speeds using head movements and breath and voice commands. Schmidt’s return to racing is chronicled in a new film produced for Arrow by BBC StoryWorks. The film, “Getting back on the racetrack,” is part of the original content series All In, which highlights how technology is helping improve accessibility for disabled people.  Since the SAM Car Project launched, Schmidt has driven these uniquely equipped race cars in dozens of high-speed demonstrations, including at the Indy 500, the Pikes Peak International Hill Climb in Colorado, and the Goodwood Festival of Speed in England. “This guy is not afraid of anything, said Arrow Principal Field Applications Engineer Stephen Harper of Schmidt. “Like, you get in the car and he's six inches from the wall at 200 miles an hour.” Schmidt drives the car – currently a 2021 McLaren 720S Spyder – using head motions for steering, sip-and-puff assistive technology for acceleration and braking and additional voice controls.  Image Arrow has evolved the car as Schmidt’s skills and technology have improved. The most recent advancements include a new AI steering system (built on the NVIDIA Jetson Orin platform) and a redesign of the sip-and-puff controller that operates the throttle and brakes. Powered by Edge AI, which integrates artificial intelligence with edge computing, the new steering system can process Schmidt’s head movements in real time and adjust the steering angle automatically and incredibly quickly – within a few thousandths of a second. This enables a faster and more responsive driving experience.  “I'm controlling the brakes, I'm controlling the gas, and it's all on me, and it's completely changed my life. It's amazing,” said Schmidt.  The integration of edge AI shows how Arrow has turned the SAM Car Project into an engineering platform for new technology, with applicability far beyond the racetrack. “If we can do this in a race car, we can do this in just about anything - wheelchairs, autonomous machines, tractors and farming, trucking,” said Harper.  Image About Arrow Electronics Arrow Electronics (NYSE:ARW) sources and engineers technology solutions for thousands of leading manufacturers and service providers. With 2025 sales of $31 billion, Arrow’s portfolio enables technology across major industries and markets. Learn more at www.arrow.com/company. About All In All In is an original content series presented by The Valuable 500 and produced by BBC StoryWorks. The series brings together stories from across industries, including health, technology, arts and culture, and consumer goods, to explore more inclusive innovation, accessibility by design and productive partnerships in business. The series is hosted at www.allinthevaluable500.com  and distributed across BBC.com and BBC StoryWorks’ social platforms. Featured Image Type of Content Press Release ———————————————————————————————————————————————————————————— PsychPlus Expands World's Largest Technology-Enabled Mental Health Platform with Major California Acquisition 2026-10-23 · EIN Presswire · Finance, SaaS, Healthcare https://www.einpresswire.com/article/951508774/psychplus-expands-world-s-largest-technology-enabled-mental-health-platform-with-major-california-acquisition Acquisition adds 100+ psychiatrists to PsychPlus's growing network, expanding clinical capacity and strengthening hospital partnerships across California. BAKERSFIELD, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- PsychPlus , the world's largest technology-enabled mental health company, today announced the acquisition of Precision Psychiatric Services, Inc., an established California-based psychiatric o ———————————————————————————————————————————————————————————— Texas Involuntary Drug & Alcohol Rehab For Teenagers: Guide For Parents Released 2026-10-23 · MarketersMEDIA · Healthcare, Biotech & pharma https://news.marketersmedia.com/texas-involuntary-drug-andamp-alcohol-rehab-for-teenagers-guide-for-parents-released/89207201 Clearfork Academy, a youth mental health and rehab center in Texas, has released a guide on involuntary drug and alcohol rehab for teenagers in the state. -- Clearfork Academy has released a guide on involuntary drug and alcohol addiction treatment for teens struggling with substance use disorders in Texas. The guide acknowledges that addicted teens may resist treatment and offers insight into what parents should do ———————————————————————————————————————————————————————————— U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease 2026-10-23 · AbbVie · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-for-adults-with-moderately-to-severely-active-crohns-disease-302918434.html Now with a new route of induction administration, subcutaneous SKYRIZI supports early symptomatic and endoscopic control with an on-body injector... ———————————————————————————————————————————————————————————— Premier Nursing and Rehab Center of Far Rockaway Named One of America's Best Nursing Homes for Third Straight Year 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/943377333/premier-nursing-and-rehab-center-of-far-rockaway-named-one-of-america-s-best-nursing-homes-for-third-straight-year Premier Nursing and Rehab Center of Far Rockaway named one of Newsweek's America's Best Nursing Homes 2026 - No. 61 in the nation and third consecutive year on the list. Premier Nursing and Rehab Center of Far Rockaway, a 183-bed skilled nursing and subacute rehabilitation center in Queens, NY, part of Northern Care Group. Patient being helped by family to return home after successful rehab stay Newsweek's 2026 list, ———————————————————————————————————————————————————————————— UCB Establishes the Emmanuel Janssen Endowed Chair for the Evaluation of Medicines at Brigham and Women's Hospital 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ucb-establishes-the-emmanuel-janssen-endowed-chair-for-the-evaluation-of-medicines-at-brigham-and-womens-hospital-302918406.html Permanent endowment advances pharmacoepidemiology and real-world evidence research Sebastian Schneeweiss, MD, ScD, an internationally recognized pharmacoepidemiologist whose research focuses on improving medication safety, effectiveness, and value through real-world evidence, has been... ———————————————————————————————————————————————————————————— GLOW Oncology and Mount Sinai Medical Center’s to Host FREE GI & GU Patient Journey Symposium on November 6 2026-10-23 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951804309/glow-oncology-and-mount-sinai-medical-center-s-to-host-free-gi-gu-patient-journey-symposium-on-november-6 GLOW Oncology to Host FREE LIVE and Virtual GI and GU Patient Journey Symposium MIAMI BEACH, FL, FL, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Free educational event in Miami Beach will bring patients, caregivers, and healthcare professionals together to explore clinical trials, medical advances, AI in cancer care, nurse navigation, nutrition, and survivorship. Global Leadership in Oncology & Wellness ( ———————————————————————————————————————————————————————————— Citizens Commission on Human Rights International Urges the FDA to Follow UK Warnings on Antidepressant Suicide Risk and Persistent Sexual Dysfunction 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387583/0/en/citizens-commission-on-human-rights-international-urges-the-fda-to-follow-uk-warnings-on-antidepressant-suicide-risk-and-persistent-sexual-dysfunction.html The UK’s drug regulatory agency has expanded suicide-risk information to all ages and formally recognizes antidepressant-induced sexual dysfunction The UK’s drug regulatory agency has expanded suicide-risk information to all ages and formally recognizes antidepressant-induced sexual dysfunction ———————————————————————————————————————————————————————————— Stanton Optical breaks new ground in Conway, SC 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950814434/stanton-optical-breaks-new-ground-in-conway-sc Stanton Optical Conway (SC) Staff Celebrating Grand Opening Ceremony Stanton Optical: We Make Eye Care Easy, Accessible, and Affordable for All With over 1,000 frames to choose from, Stanton Optical is the one-stop shop for all your eye care needs. Expanded clinical services include Dry Eye Screenings and Dry Eye Therapy Affordable, same-day eye care and glasses now available at 2676-A Church St, Conway, SC 29526 We’ ———————————————————————————————————————————————————————————— Frederick Flying Cows and Maryland Farm Bureau Announce Cowfest 2026! 2026-10-23 · PR Newswire · Healthcare, Entertainment, Agriculture https://www.prnewswire.com/news-releases/frederick-flying-cows-and-maryland-farm-bureau-announce-cowfest-2026-302918288.html Frederick's signature fall festival returns October 25 with a world record attempt, family entertainment, a presenting sponsor and a new partnership benefiting the Mental Health Association of Frederick County. FREDERICK, Md., Oct. 23, 2026 -- This weekend, the Frederick... ———————————————————————————————————————————————————————————— DEA Burden of Proof, Missing Rulebooks, and Expert Witness Admissions Threaten Marijuana Rescheduling 2026-10-23 · Newswire.com · Healthcare, Government & policy https://www.newswire.com/news/dea-burden-of-proof-missing-rulebooks-and-expert-witness-admissions-threaten "The marijuana rescheduling burden of proof is on the government. Its own DEA and FDA scientist said marijuana would not have passed the test, and its own watchdog found no written rulebook." - Duane Boise, CEO, MMJ International Holdings ———————————————————————————————————————————————————————————— Teen Obesity Is a Medical Issue, Not a Willpower Problem, Says California Trim Clinic 2026-10-23 · PRUnderground · Healthcare https://prunderground.com/teen-obesity-is-a-medical-issue-not-a-willpower-problem-says-california-trim-cli/cmvl3f2vo000308l4fmmufqxa TeenHealthRx offers exclusive, physician-led concierge obesity care for California teens, with tailored treatment plans, dedicated support, and a family-centered approach The post Teen Obesity Is a Medical Issue, Not a Willpower Problem, Says California Trim Clinic first appeared on ———————————————————————————————————————————————————————————— The Full Cost of Hospital RCM: Black Book Examines Outsourcing, AI Savings Claims and Vendor Consolidation in New 2027 Accountability Report 2026-10-23 · Newswire.com · Finance, AI, Healthcare https://www.newswire.com/news/the-full-cost-of-hospital-rcm-black-book-examines-outsourcing-ai-22877041 Seven connected reviews help hospital boards assess costs beyond vendor fees, work remaining after automation, cash continuity and patient billing-with practical guidance for rural hospitals and defined accountability for CFOs, CIOs and revenue cycle executives. ———————————————————————————————————————————————————————————— Novo's Awiqli® receives FDA approval as the first and only once-weekly insulin for children 10 years of age and older with type 2 diabetes 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/novos-awiqli-receives-fda-approval-as-the-first-and-only-once-weekly-insulin-for-children-10-years-of-age-and-older-with-type-2-diabetes-302918384.html Awiqli® offers children 10 years and older a once-weekly basal insulin alternative, reducing basal injection frequency from seven times per week to one1 As type 2 diabetes incidence rates among youth continue to rise,² Awiqli® may help reduce administration barriers associated with daily... ———————————————————————————————————————————————————————————— Is There a Best Age for a Facelift? Palm Beach Plastic Surgeon Dr. Thomas Pane Discusses Changing Patient Trends 2026-10-23 · ACCESS Newswire · Healthcare, Chemicals & materials https://finance.yahoo.com/healthcare/articles/best-age-facelift-palm-beach-180000569.html Double board-certified plastic surgeon explains how facelift candidacy is shifting, including younger patients with facial changes after GLP-1 weight loss. PALM BEACH GARDENS, FL / October 23, 2026 / Dr. Thomas Pane , a double board-certified plastic surgeon practicing in Palm Beach Gardens, is addressing a question about facelift timing: Is there a right age for the procedure? His evaluation focuse ———————————————————————————————————————————————————————————— Hansa Biopharma announces positive Idefirix PAES results presented in the High-Impact Clinical Trials session at ASN Kidney Week 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/hansa-biopharma-announces-positive-idefirix-paes-results-presented-in-the-high-impact-clinical-trials-session-at-asn-kidney-week-302918373.html The 1-year graft failure-free survival at 12 months post-transplant was 90%, which is clinically meaningful Graft and patient survival were 92% and 98%, respectively Idefirix was generally well tolerated with a safety profile consistent with previous clinical trial experience LUND,... ———————————————————————————————————————————————————————————— Dimora Medical Supports Empower HS 2026, Advancing Everyday Wound Care for the HS Community 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/dimora-medical-supports-empower-hs-2026-advancing-everyday-wound-care-for-the-hs-community-302917667.html - Silicone foam dressings featuring MegaSorb™ technology were included in attendee gift bags to support at-home management of exuding wounds NEW YORK, Oct. 23, 2026 -- Dimora Medical, a pioneer in professional wound care, supported the HS Connect Empower Conference 2026.... ———————————————————————————————————————————————————————————— 10 Italian Startups Take on Drug-Resistant Cancer, Healthcare AI and Sustainable Biotech in San Diego and Boston 2026-10-23 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951832809/10-italian-startups-take-on-drug-resistant-cancer-healthcare-ai-and-sustainable-biotech-in-san-diego-and-boston The Italian Startups with Consul General Raffaella Valentini The Italian Trade Agency brings a delegation of biotech and life sciences innovators to two of America's leading industry hubs for a 4-week acceleration program SAN DIEGO, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- New approaches to overcoming drug resistance in cancer, technologies that accelerate drug discovery, and innovative uses of bio ———————————————————————————————————————————————————————————— TikaMobile Announces TikaMedInfo, Medical Information Request Management Built for the AI Era 2026-10-23 · Newswire.com · AI, Healthcare https://www.newswire.com/news/tikamobile-announces-tikamedinfo-medical-information-request-management-built Every HCP Inquiry Moves Through One Queue to an Approved Answer, With AI Assisting the Team and a Complete Audit Trail Behind Every Response ———————————————————————————————————————————————————————————— Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/phase-3-rainier-results-supporting-174200652.html - Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept – - Data published in NEJM and presented at ASN highlight povetacicept's unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with ———————————————————————————————————————————————————————————— TikaMobile Launches TikaInsights, AI-Powered Medical Insights Management Software for Medical Affairs 2026-10-23 · Newswire.com · AI, Healthcare, Software & IT https://www.newswire.com/news/tikamobile-launches-tikainsights-ai-powered-medical-insights-management Available on Its Own or Alongside Veeva CRM, TikaInsights Helps Medical Affairs Teams Capture Stronger Insights and See Each One Through to Action ———————————————————————————————————————————————————————————— Ionis partner Roche announces new Phase 3 data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ionis-partner-roche-announces-phase-173700964.html – Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups – – Sefaxersen inhibits complement factor B production and has the potential to reduce kidney infla ———————————————————————————————————————————————————————————— Staffing firm Medical Virtual Assistants (medicalvirtualassistants.com) launches online hiring platform MedicalVirtual 2026-10-23 · EIN Presswire · SaaS, Healthcare, Jobs & workplace, Internet & apps https://www.einpresswire.com/article/951829027/staffing-firm-medical-virtual-assistants-medicalvirtualassistants-com-launches-online-hiring-platform-medicalvirtual MedicalVirtual Homepage Medical Virtual Assistants matches US practices and providers with experienced healthcare support from Latin America, working your US clinic hours. LOS ANGELES, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- • Medical Virtual Assistants matches US practices and providers with experienced healthcare support from Latin America, working your US clinic hours. • The new online platform ———————————————————————————————————————————————————————————— Olena Medical Sets the Standard for Anesthesia Services at Ambulatory Surgery Centers 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950974433/olena-medical-sets-the-standard-for-anesthesia-services-at-ambulatory-surgery-centers HACKENSACK, NJ, UNITED STATES, October 23, 2026 / EINPresswire.com / -- As ambulatory surgery centers (ASCs) continue to play an increasingly important role in delivering efficient, high-quality outpatient care, the need for dependable, experienced anesthesia providers has never been greater. Olena Medical is addressing that need through a physician-led approach that emphasizes clinical excellence, operational effici ———————————————————————————————————————————————————————————— Roche presents interim phase III data showing sefaxersen significantly reduced proteinuria in people with IgA nephropathy (IgAN) 2026-10-23 · Roche · Healthcare, Biotech & pharma, Nonprofits, Internet & apps, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-23 Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups1 As the first antisense oligonucleotide (ASO) evaluated in IgAN, sefaxersen inhibits complement factor B production and has the potential to slow IgAN disease progression by reducing kidney inflammation2 Investigational sefaxersen is intended to be a once-monthly subcutaneous injection and designed to enable convenient self-administration at home3 Despite recent advances, many people with IgAN remain at risk of disease progression and kidney failure, highlighting the need for additional targeted treatment options for those who do not respond to initial therapy4,5 Basel, 23 October 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today late-breaking oral presentation data from the ongoing phase III IMAgINATION study in adults with primary IgA nephropathy (IgAN) receiving optimised standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1% reduction in proteinuria (95% confidence interval [CI]: 32.5 - 52.0, P<0.0001), relative to placebo at 37 weeks, as measured by 24-hour urine protein-to-creatinine ratio (UPCR).1 Proteinuria is a key indicator of kidney damage and a reduction in UPCR is strongly associated with the preservation of long-term kidney function.6,7 Results presented at the American Society of Nephrology (ASN) Kidney Week 2026 also showed that, among patients with baseline haematuria (blood in urine), a greater proportion of patients achieved haematuria resolution at Week 37 with sefaxersen versus placebo.1 “These phase III results demonstrate the potential for sefaxersen to meaningfully reduce protein in the urine, a key indicator of kidney damage, in people with IgA nephropathy,” said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. “By inhibiting complement factor B in the liver, sefaxersen may offer a novel approach to slow disease progression in IgAN, potentially helping patients delay or avoid long-term dialysis or kidney transplantation.” The treatment effect in all prespecified subgroups was consistent with the clinically meaningful reductions in proteinuria shown in the primary endpoint results.1 Sefaxersen was well tolerated with a safety profile consistent with the previously reported phase II study, exhibiting no new safety signals.1,2 Sefaxersen is an investigational once-monthly subcutaneous injection designed to enable convenient self-administration for people with IgAN.3 The IMAgINATION study will continue as a blinded study to evaluate the change in kidney function over two years, as measured by estimated glomerular filtration rate (eGFR) at week 105. Data will be shared with health authorities, with the goal of bringing this treatment to patients as soon as possible. Typically diagnosed before the age of 40, IgAN affects at least 25 adults per million worldwide each year.8,9 IgAN, also known as Berger’s disease, is a chronic and progressive autoimmune disease that leads to end-stage kidney disease in up to 50% of patients within 20 years of diagnosis.5,10 It is the most common form of primary glomerulonephritis (inflammation of the tiny filters, glomeruli, in the kidneys) and is a major cause of chronic kidney disease as well as kidney failure.8 About sefaxersen Investigational sefaxersen is the first highly specific liver-directed antisense oligonucleotide (ASO) inhibitor of factor B production being evaluated in IgA nephropathy (IgAN).2 Serum complement factor B levels are elevated in people with IgAN. When we reduce these levels, it in turn reduces the level of protein in urine, which is a key indicator of improved kidney function.11,12 Sefaxersen is designed to provide sustained control of the alternative complement pathway, an important pathway in IgAN, enabling once-monthly subcutaneous dosing and is intended for self-administration in people with IgAN.3 In phase I and II trials, sefaxersen was shown to be generally well tolerated in healthy volunteers and people with IgAN who were at high risk of progression, and reduced proteinuria and plasma complement factor B.2,13 Roche licensed sefaxersen from Ionis Pharmaceuticals for the treatment of complement mediated diseases. About the IMAgINATION study IMAgINATION [NCT05797610] is a phase III, multicentre, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of subcutaneous sefaxersen, an investigational antisense inhibitor of complement factor B, in patients with primary IgA nephropathy at high risk of progression.1,14 The study enrolled 459 people, who are randomised 1:1 to receive sefaxersen or placebo for 105 weeks.1,14 Participants may switch to open-label treatment after week 105 at the investigator's discretion or after the common-close timepoint, whichever occurs first.1,14 The primary endpoint of the study is the change from baseline in the urine protein-to-creatinine ratio at 37 weeks.1,14 About primary immunoglobulin A nephropathy (IgAN) IgAN, also known as Berger’s disease, is a serious, chronic and progressive autoimmune kidney disease affecting at least 25 adults per million worldwide each year and is typically diagnosed before the age of 40 years.8-10 In IgAN, immune complexes deposit in the kidneys, which activates the complement system’s alternative pathway, leading to inflammation and subsequent kidney damage.15 It is the most common form of primary glomerulonephritis (inflammation of kidney glomeruli) and remains a leading cause of kidney failure, with up to 50% of patients experiencing end-stage kidney disease within 20 years of diagnosis.5,8 Many current therapies aim to reduce protein levels in the urine and control blood pressure to slow progression of the disease.16 Updated KDIGO 2025 guidelines* highlight the need to address both the underlying immune-mediated causes of IgAN and the downstream consequences of kidney damage.4 While new therapies have expanded treatment options, important unmet needs remain, including improved long-term preservation of kidney function and more targeted approaches that address key drivers of disease progression.4,16 About Roche in Immunology For over two decades, Roche has advanced immune system research, creating groundbreaking targeted treatments that have transformed care for people with blood disorders, neurological conditions and autoimmune diseases. With a development pipeline exploring more than 20 medical approaches, we are targeting widespread, complex conditions like chronic lung disease (COPD) and inflammatory bowel disease (IBD), alongside lupus and autoimmune kidney diseases. Our ultimate goal is to lessen the burden of chronic immune disorders on patients, healthcare systems, and society. About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceutical divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. *KDIGO guidelines serve as the foundational framework for healthcare organisations, policymakers, and clinicians worldwide to standardise kidney disease diagnosis, staging, and treatment. References [1] Barratt J., et al. Sefaxersen, a Novel mRNA-Targeted Therapy for IgA Nephropathy: Interim Analysis of the Phase 3 IMAgINATION Trial. Presented at: ASN Kidney Week; 2026 Oct 20-26; Denver, CO, USA. Abstract #FR-OR104. [2] Barbour SJ, et al. A single-arm phase 2 trial of an investigational RNA therapeutic to complement factor B sefaxersen for treatment of IgA nephropathy. Kidney Int. 2026;109:592-601. [3] Barratt J, et al. IMAGINATION: a global phase 3 trial of RO7434656, an antisense oligonucleotide inhibitor of complement factor B, in IgA nephropathy. Kidney Int Rep. 2024;9 Suppl. WCN24-912. [4] Kidney Disease: Improving Global Outcomes (KDIGO) IgAN and IgAV Work Group. KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV). Kidney Int. 2025;108(4S):S1–S71. [5] Caster DJ, et al. Clinicopathological characteristics of adult IgA nephropathy in the United States. Kidney Int Rep. 2023;8:1792-1800. [6] Longhitano E, et al. Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach. Medicina (Kaunas). 2024 Nov 6;60(11):1821. [7] Qin X, et al. Association Between Urinary Protein-to-Creatinine Ratio and Chronic Kidney Disease Progression: A Secondary Analysis of a Prospective Cohort Study. Front. Med. 2022; 9:854300. [8] Pitcher D, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18:727-738. [9] McGrogan A, Franssen CF and de Vries CS. The incidence of primary glomerulonephritis worldwide: a systematic review of the literature. Nephrol Dial Transplant 2011; 26: 414-430. [10] Cleveland Clinic. IgA Nephropathy [Internet; cited 2026 October 15]. Available from: https://my.clevelandclinic.org/health/diseases/5990-iga-nephropathy. [11] Chiu YL, et al. Alternative complement pathway is activated and associated with galactose-deficient IgA. Front Immunol 2021; 12: 638309. [12] Marques F, et al. Impact of early proteinuria reduction in glomerular disease and decline of kidney function: a retrospective cohort. J Clin Med. 2022;11(19):5968. [13] McCaleb ML, et al. Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen. Immunobiology. 2025 Mar;230(2):152876. [14] ClinicalTrials.gov. A Study to Evaluate RO7434656 in Participants With Immunoglobulin A Nephropathy (IgAN) (IMAGINATION) (NCT05797610) [Internet; cited 2026 Oct 15]. Available from: https://clinicaltrials.gov/study/NCT05797610. [15] Wu MY, et al. The emerging role of pathogenesis of IgA nephropathy. J Clin Med. 2018;7:225. [16] Floege J, et al. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43:717-728. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 68-88027 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com  Attachment Media Investor Release Sefaxersen IMAgINATION ASN ———————————————————————————————————————————————————————————— Genentech Presents Interim Phase III Data Showing Sefaxersen Significantly Reduced Proteinuria in People With IgA Nephropathy (IgAN) 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/genentech-presents-interim-phase-iii-173000615.html - Sefaxersen achieved a statistically significant 43.1% reduction in proteinuria, a key indicator of kidney damage, relative to placebo at 37 weeks with consistent treatment effects across all prespecified patient subgroups - - As the first antisense oligonucleotide (ASO) evaluated in IgAN, sefaxersen inhibits complement ———————————————————————————————————————————————————————————— Tampa General Hospital and Health Care District of Palm Beach County to Open Lakeside Cancer Center in September 2027, Expanding Access to Academic-Based Cancer Care in Florida's Rural Communities 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/tampa-general-hospital-and-health-care-district-of-palm-beach-county-to-open-lakeside-cancer-center-in-september-2027-expanding-access-to-academic-based-cancer-care-in-floridas-rural-communities-302918344.html Lakeside Cancer Center will connect cancer patients in the Glades with world-class treatment, complex care coordination and access to oncology specialists. BELLE GLADE, Fla., Oct. 23, 2026 -- Tampa General Hospital (TGH) and the Health Care District of Palm Beach County... ———————————————————————————————————————————————————————————— Palleon Pharmaceuticals Presents Phase 2 Results for HLX79/E-602 in Primary Membranous Nephropathy at ASN Kidney Week 2026 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/palleon-pharmaceuticals-presents-phase-2-170000284.html HLX79/E-602 plus rituximab produced faster responses and a higher response rate than rituximab alone, with a safety profile suited to outpatient administration WATERTOWN, Mass., October 23, 2026--Palleon Pharmaceuticals , a clinical-stage biotechnology company developing glycan editing therapeutics fo ———————————————————————————————————————————————————————————— Bringing preventive health screenings closer to Arizona communities 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/bringing-preventive-health-screenings-closer-to-arizona-communities-302918328.html AZ Blue Health Choice and Zeihan ProHealth train community health workers to help identify health concerns early and connect people to care. PHOENIX, Oct. 22, 2026 -- A simple health screening can uncover a concern before it becomes a crisis. But for many Arizonans,... ———————————————————————————————————————————————————————————— La Opinión Endorses YES on Proposition 38 to Advance Life-Saving Medical Research 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951812947/la-opini-n-endorses-yes-on-proposition-38-to-advance-life-saving-medical-research ...The breakthroughs in disease prevention and treatment–made possible by research funded in this way–are a priority for resuming research that had been stalled by the Trump administration.” — La Opinión’s editorial board LOS ANGELES, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- La Opinión endorsed Proposition 38 in an October 10 editorial, saying the measure would provide a stable source of support fo ———————————————————————————————————————————————————————————— DEPH Labs Appoints Lisa Loud as CEO to Accelerate Privacy-Centric Precision Health and Biological Age Testing 2026-10-23 · FinanceWire · Healthcare https://financewire.com/2026/10/23/deph-labs-appoints-lisa-loud-as-ceo-to-accelerate-privacy-centric-precision-health-and-biological-age-testing/ London, UK, 23rd October 2026, FinanceWire … Read More The post DEPH Labs Appoints Lisa Loud as CEO to Accelerate Privacy-Centric Precision Health and Biological Age Testing appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Alloop Officially Launches Trio: A Modular 3-in-1 Wearable Built Around Its Personal AI Agent 2026-10-23 · ACCESS Newswire · AI, SaaS, Healthcare, Consumer electronics https://finance.yahoo.com/healthcare/articles/alloop-officially-launches-trio-modular-164000743.html One sensing core, interchangeable wearable forms, and voice-powered AI bring personal health data and everyday context together in one open platform. NEW YORK CITY, NY / October 23, 2026 / Alloop , an AI-native personal health technology company, officially unveiled Alloop Trio at its New York City launc ———————————————————————————————————————————————————————————— HIMS 10-DAY DEADLINE ALERT: Hims & Hers Health Facing Securities Class Action Lawsuit, Investors with Losses Encouraged to Contact Hagens Berman 2026-10-23 · PR Newswire · Finance, Healthcare, Legal https://www.prnewswire.com/news-releases/hims-10-day-deadline-alert-hims--hers-health-facing-securities-class-action-lawsuit-investors-with-losses-encouraged-to-contact-hagens-berman-302918171.html SAN FRANCISCO, Oct. 23, 2026 -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business... ———————————————————————————————————————————————————————————— Circumcision LA Physician Dr. Padra Nourparvar Highlights 2026 Clinical Guidelines on Adult Circumcision for Phimosis 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/circumcision-la-physician-dr-padra-nourparvar-highlights-2026-clinical-guidelines-on-adult-circumcision-for-phimosis-302912538.html New evidence-based guidance addresses the role of adult circumcision when chronic inflammatory skin disease causes persistent foreskin tightening that does not respond to medical treatment. LOS ANGELES, Oct. 23, 2026 -- Updated clinical guidelines published in 2026 are... ———————————————————————————————————————————————————————————— Pentara to Present Rare Disease Statistical Innovations at NORD Summit Aligning with FDA’s New Framework Initiative 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951283537/pentara-to-present-rare-disease-statistical-innovations-at-nord-summit-aligning-with-fda-s-new-framework-initiative Posters on Global Statistical Tests, Basket Trials and Natural History Controls address clinical evidence gaps at the center of the FDA’s new regulatory effort. Standard evidentiary standards severely penalize rare disease patients by passing up treatments that work in order to guard tightly against approving an ineffective treatment.” — Suzanne Hendrix, PhD, CEO SALT LAKE CITY, UT, UNITED STATES, October 23, 2026 / ———————————————————————————————————————————————————————————— Blende Dental Group Discusses Authorized Decision-Making and Patient Autonomy in Special Needs Dentistry 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951225430/blende-dental-group-discusses-authorized-decision-making-and-patient-autonomy-in-special-needs-dentistry Specialized dental practice highlights the importance of clarifying consent for dental treatment while preserving patient autonomy. SAN FRANCISCO, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- For adults with disabilities, dementia, and other conditions that may affect decision-making capacity, accessing dental care can involve challenges beyond transportation, accessibility, or finding an experienced p ———————————————————————————————————————————————————————————— More Than 30 Caregivers Coordinate Rare Procedure to Help Baby Breathe Before Birth Is Complete 2026-10-23 · PR Newswire · Healthcare, Entertainment https://www.prnewswire.com/news-releases/more-than-30-caregivers-coordinate-rare-procedure-to-help-baby-breathe-before-birth-is-complete-302918276.html Memorial Healthcare System and Joe DiMaggio Children's Hospital team performs highly complex delivery for baby with life-threatening neck mass; one year later, the family reunites with the caregivers who helped bring him safely into the world. HOLLYWOOD, Fla., Oct. 20, 2026... ———————————————————————————————————————————————————————————— AM Best Revises Outlooks to Stable for Members of Coverys Companies 2026-10-23 · Business Wire · Healthcare, Insurance https://finance.yahoo.com/healthcare/articles/am-best-revises-outlooks-stable-154700194.html OLDWICK, N.J., October 23, 2026--AM Best has revised the outlooks to stable from negative and affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICR) of "a" (Excellent) of Medical Professional Mutual Insurance Company (Boston, MA) and its r ———————————————————————————————————————————————————————————— NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 2026-10-23 · ScoopAsia · Healthcare, Biotech & pharma https://scoopasia.com/nec-presents-phase-i-ii-results-for-individualized-oral-neoantigen-therapy-necvax-neo1-at-esmo-2026/ NEC Bio will be presenting results from the Phase I/II TNBC clinical trial of its orally administered individualized neoantigen therapy, NECVAX-NEO1, used in combination with checkpoint inhibitors (CPIs) and chemotherapy for patients with triple-negative breast cancer (TNBC). ———————————————————————————————————————————————————————————— Will Artificial Intelligence Replace the Doctor—or Set the Doctor Free? 2026-10-23 · Presswire · AI, Healthcare https://presswire.com/release/will-artificial-intelligence-replace-the-doctor-or-set-the-doctor-free/ Yale medical alumni presentation challenges a central assumption of healthcare AI: recording a physician’s words is not the same as understanding the physician’s clinical reasoning. NEW HAVEN, Conn. — October 2026 — As artificial intelligence rapidly enters medical practice, a fundamental distinction is emerging between recording what physicians say and understanding what physicians actually […] ———————————————————————————————————————————————————————————— SAPPE Showcases Product Innovations at SIAL Paris 2026 2026-10-23 · NewMediaWire · Finance, Healthcare, Retail, Food & drink, Sustainability, Investing & markets, Internet & apps https://www.newmediawire.com/news/sappe-showcases-product-innovations-at-sial-paris-2026-7090834 Mogu Mogu Leads a Diverse New Product Lineup on the Global Stage BANGKOK - October 23, 2026 - Sappe Public Company Limited (SAPPE PCL.) is showcasing its innovative product portfolio at SIAL Paris 2026, a global food and beverage trade exhibition held from 17-21 October 2026 at Paris Nord Villepinte Exhibition Centre in Paris, France. The company is presenting new products and flavours that combine fun and creativity while welcoming trade partners, importers and distributors from around the world to exchange ideas and explore business opportunities. Leading SAPPE’s showcase is its flagship brand, Mogu Mogu, with a wide range of new offerings, including Zero Sugar drinks, Jelly, Gummy, Candy and Iced Tea, alongside new flavours in its original drink range. The lineup extends the brand’s signature fun and creativity across diverse product formats, giving trade partners and visitors the opportunity to discover and taste the products firsthand. SAPPE is also presenting products from Sappe Aloe Vera, Sappe Beauti and All Coco, adding variety to its booth and offering new choices for international markets. Trade partners, importers, distributors and other interested visitors can meet the team to discuss the products and explore opportunities for international business development. SIAL Paris is one of the world’s largest food and beverage trade exhibitions, taking place every two years. For its 2026 edition, organisers expect 8,000 exhibitors and approximately 400,000 products across 10 industry sectors, covering 280,000 square metres of exhibition space. Bringing together manufacturers, buyers and distributors from around the world, the event provides SAPPE with another opportunity to showcase the capabilities of Thai brands and its diverse portfolio of innovative products to international trade partners. Visitors can discover and sample SAPPE’s products at Booth 5C F035, Hall 5C, throughout SIAL Paris 2026, from 17-21 October 2026. About SAPPE Sappe PCL (SAPPE) is a leading Thai beverage innovator and the creator of the "Snack Drink" category through its iconic global brand, Mogu Mogu, now exported to over 100 countries across Asia, Europe, the Middle East, and beyond. The company specializes in fruit juice and functional health beverages designed to serve the evolving lifestyle needs of modern consumers around the world. SAPPE's diverse portfolio includes globally recognized brands such as Mogu Mogu, the world's first snackable drink; Sappe Aloe Vera, known for its refreshing taste and natural ingredients; and Sappe Beauti, a functional drink line focused on health, wellness, and women empowerment. Headquartered in Bangkok, Thailand, SAPPE is listed on the Stock Exchange of Thailand (SET) under the symbol SAPPE. Driven by innovation, deep consumer insights, and a strong commitment to sustainability, SAPPE operates with a balanced focus on product innovation, economic performance, social responsibility, and environmental impact. The company believes that building a sustainable future begins with valuing people, embracing diversity, and leading with authenticity, creativity, and the courage to drive positive change. SAPPE's mission is to inspire lives worldwide one meaningful beverage at a time. Sappe official: https://www.sappe.com/en/ Facebook: https://www.facebook.com/sappeplayground Instagram: https://www.instagram.com/mogumogu_global/ Line: https://shop.line.me/@sappeonline Shopee: https://shopee.co.th/sappe.official Email: corpcom@sappe.com Sappe PCL [SET: SAPPE, SAPPE/F, SAPPE-R] https://www.sappe.com/en/ ———————————————————————————————————————————————————————————— Novomins puts women’s health in the driver’s seat with first-ever OOH campaign 2026-10-23 · Pressat · SaaS, Healthcare, Automotive, Education, Marketing & advertising https://pressat.co.uk/releases/novomins-puts-womens-health-in-the-drivers-seat-with-first-ever-ooh-campaign-587cacfda36f337ebbc7f8f8d6179591/ Friday 23 October, 2026 The nutrition brand has taken its women’s health message onto the streets of London with a taxi activation featuring ambassador Vicky Pattison, creating space for conversations about issues women too often feel go unheard. Novomins has made its first move into out-of-home (OOH) advertising with Put Women’s Health in the Driver’s Seat, a London taxi activation designed to put women’s health in the spotlight. On Wednesday 21 October, North-East personality and Novomins women’s health ambassador Vicky Pattison took to central London in a fully branded Novomins taxi, offering women free rides and opening up conversations about the health concerns that affect them. The activation focused on issues women may find difficult to discuss, or feel have been dismissed as ‘normal’. By taking these conversations into everyday public spaces, Novomins aimed to give women the opportunity to speak openly about their experiences and feel heard. The taxi featured Novomins’ distinctive pink branding, product imagery and the message, “Whatever your health goals, we have a gummy for it!”. While the creative brought the brand into view across London, the campaign’s central purpose was to encourage more open conversations about women’s health. Valerie Stark McQuillan, Formulator, Neuroscientist and Chief Marketing Officer at Novomins, said: “Too many women are still being told their symptoms are ‘normal’, or waiting years for a diagnosis, simply because no one stopped to really listen. ‘Put Women’s Health in the Driver’s Seat’ is about changing that. Vicky brings honesty and warmth to every conversation, and by giving women a lift across London, we’re giving them space to talk about the things that bother them, the things that get brushed aside, and the things they’ve never felt able to say out loud. At Novomins, women’s health isn’t a side project; it’s a serious focus. As a formulator and neuroscientist, I know how much daily nutrition can matter, which is why together with our in-house team of experts I created a dedicated range of gummy vitamins for women. Whether a woman is looking after her urinary health, supporting herself through her monthly cycle, or caring for her intimate balance, we want to be part of that everyday support. But this campaign is about more than products. We’re here to educate, to listen and to give women a voice.” The campaign marks Novomins’ first-ever OOH brief, with Loud! OOH appointed to bring the activation to life. It shows how outdoor advertising can create a physical platform for conversations that deserve greater attention, rather than simply putting a brand in front of an audience. The release follows the news that Loud! OOH has been shortlisted for ‘New Agency to Watch’ at the Prolific North Marketing Awards 2026, a milestone for the independent advertising agency as it continues to build its presence in the UK out-of-home market. Through the activation, Novomins has used its OOH debut to take its women’s health message directly to the streets, with a clear commitment to listening, education and giving women a voice. For brands looking to explore taxi advertising as part of their own campaigns, Loud! OOH has put together a guide to taxi advertising in the UK, covering formats, costs and opportunities. ———————————————————————————————————————————————————————————— LifeSecure Launches Starscape Insurance Agency 2026-10-23 · PR Newswire · Healthcare, Insurance https://www.prnewswire.com/news-releases/lifesecure-launches-starscape-insurance-agency-302918228.html BRIGHTON, Mich., Oct. 23, 2026 -- LifeSecure Holdings Corporation has expanded its insurance industry footprint with the founding of Starscape Insurance Agency, a new agency focused on providing health insurance solutions to individuals, families, and organizations.... ———————————————————————————————————————————————————————————— WHO and ENHYPEN join efforts to inspire young blood donors globally 2026-10-23 · WebWire · Healthcare, Internet & apps, Entertainment https://www.webwire.com/ViewPressRel.asp?aId=363260 World Health Organization (WHO) Director-General Dr Tedros Adhanom Ghebreyesus met with global K-pop powerhouse ENHYPEN in Seoul on 22 October to celebrate the success of their collaboration for World Blood Donor Day 2026 and recognize the group's role in inspiring young people around the world to donate blood and save lives. - - The collaboration between WHO and ENHYPEN started on World Blood Donor Day on 14 June 2026, bringing together the power of music, social media and the group's glob... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363260 ———————————————————————————————————————————————————————————— PFP Senior Home Care Named People's Choice — Bensalem Township 2026-10-23 · EIN Presswire · Healthcare, Retail https://www.einpresswire.com/article/951800228/pfp-senior-home-care-named-people-s-choice-bensalem-township Bensalem agency providing in-home care for seniors and adults with disabilities earned a 4.8-star rating across overall reviews. BENSALEM TOWNSHIP, PA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- The Consumer Ratings Institute named PFP Senior Home Care , a home care agency in Bensalem, Pennsylvania, serving seniors and people with disabilities, People's Choice — Bensalem Township in the Home Health Care ———————————————————————————————————————————————————————————— KFSH Advances Gene Therapy for Sickle Cell Disease Using Patients’ Own Modified Stem Cells 2026-10-23 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/951516847/kfsh-advances-gene-therapy-for-sickle-cell-disease-using-patients-own-modified-stem-cells A KFSH scientist working in the research laboratory in Riyadh RIYADH, SAUDI ARABIA, October 23, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) is advancing gene therapy for sickle cell disease through a 2026 clinical trial that uses the patient’s own hematopoietic stem cells, genetically modified to address the underlying defect and offer a potential path beyond repeated suppo ———————————————————————————————————————————————————————————— Autonoma Health Launches Virtual Coaching to Support Users Transitioning off GLP-1 for Long-Term Weight Management 2026-10-23 · EIN Presswire · AI, Healthcare, Education, Travel https://www.einpresswire.com/article/944962494/autonoma-health-launches-virtual-coaching-to-support-users-transitioning-off-glp-1-for-long-term-weight-management A new kind of virtual health-coaching for transitioning off GLP-1 Programs offer education, coaching and AI-supported accountability for adults using GLP-1 meds or navigating treatment changes with their prescribing clinician. I see how physical limitations can make people pull back from the things they enjoy, whether that’s traveling, spending time with family, or returning to a favorite hobby” — Rich Planzo LOS ANG ———————————————————————————————————————————————————————————— Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/congruence-therapeutics-announces-oral-presentation-on-cgx-195-a-novel-small-molecule-aat-corrector-at-the-ers-alpha-1-antitrypsin-aat-conference-2026-302918168.html – CGX-195 increased functional, secreted Z-A1AT and reduced polymerized Z-A1AT in cellular assays and in the PiZ mouse model – MONTREAL, Oct. 23, 2026 -- Congruence Therapeutics ("Congruence"), a clinical-stage, computationally driven biotechnology company building a pipeline... ———————————————————————————————————————————————————————————— TG Therapeutics Announces Phase 1 Data Evaluating Azer-cel in Progressive Multiple Sclerosis in a Late-Breaking Oral Presentation at MSToronto2026 2026-10-23 · Business Wire · Healthcare, Automotive, Biotech & pharma https://finance.yahoo.com/healthcare/articles/tg-therapeutics-announces-phase-1-145500267.html First reported clinical evaluation of an allogeneic CD19-directed CAR T-cell therapy in progressive MS demonstrated an encouraging preliminary safety profile with no high-grade CAR-T associated toxicities observed 89% of evaluable participants (16/19) had stable or improved disability scores at Day 90, despite documented ———————————————————————————————————————————————————————————— Perspective’s [212Pb]Bamzireotide Navoxetan (VMT-α-NET) Demonstrates Encouraging Safety, Durable Disease Control, and Robust Tumor Response Across Multiple Dose Cohorts in Phase 1/2a Trial in Advanced SSTR2-Expressing NETs 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387456/0/en/perspective-s-212pb-bamzireotide-navoxetan-vmt-%CE%B1-net-demonstrates-encouraging-safety-durable-disease-control-and-robust-tumor-response-across-multiple-dose-cohorts-in-phase-1-2a-tr.html SEATTLE, Oct. 23, 2026 -- Perspective Therapeutics, Inc. (“Perspective,” the “Company,” “we,” “us,” and “our”) (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced systemic treatments for cancers, today announced new interim results from its ongoing Phase 1/2a clinical trial of [212Pb]VMT-α-NET in patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing neuroendocrine tumors (NETs). These data are being presented as a rapid oral presentation at the European Society for Medical Oncology (ESMO) Congress 2026 taking place October 23-27, 2026 in Madrid, Spain. ———————————————————————————————————————————————————————————— Study Finds Lower Rates of Overweight Among Vegan-Fed Cats 2026-10-23 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/study-finds-lower-rates-overweight-144500867.html LONDON, UK / October 23, 2026 / A large-scale survey published in Frontiers in Animal Science has found cats fed vegan diets had lower rates of obesity and related health problems, than those fed conventional meat-based diets. An online survey analysed carer-reported veterinary assessments of 1,305 cats ———————————————————————————————————————————————————————————— Amid Rising Costs and Surgical Disruptions in ASCs, NorthStar Anesthesia Strengthens Focus on ASC Partnerships 2026-10-23 · PR Newswire · Healthcare, Jobs & workplace https://www.prnewswire.com/news-releases/amid-rising-costs-and-surgical-disruptions-in-ascs-northstar-anesthesia-strengthens-focus-on-asc-partnerships-302918226.html With 17 new ASC partnerships nationwide to date in 2026, NorthStar Anesthesia emphasizes proactive patient assessment, reliable staffing, and clinical consistency to help surgery centers reduce preventable cancellations and maximize surgical capacity. IRVING, Texas, Oct. 23, 2026... ———————————————————————————————————————————————————————————— Kyverna Therapeutics Highlights Promising Updated Clinical Data with Miv-cel in Progressive Multiple Sclerosis at MS Toronto 2026 2026-10-23 · GlobeNewswire · Healthcare, Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387428/0/en/kyverna-therapeutics-highlights-promising-updated-clinical-data-with-miv-cel-in-progressive-multiple-sclerosis-at-ms-toronto-2026.html Single-dose miv-cel continues to demonstrate promising clinical benefit in progressive multiple sclerosis, achieving robust CAR T-cell penetration in the central nervous system (CNS) and improving disability scores while removing the need for chronic immunotherapies ———————————————————————————————————————————————————————————— eClinicalWorks and healow Announce Record Revenues Exceeding $1.3 Billion for 2026, Driven by Accelerating AI Adoption 2026-10-23 · Business Wire · AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/eclinicalworks-healow-announce-record-revenues-143000688.html At the 2026 National Conference, eClinicalWorks announces a redesigned platform, turnkey agents, clinical intelligence tools, and autonomous operational capabilities among expansion in pharmacy and inpatient care NASHVILLE, Tenn., October 23, 2026--At the 2026 eClinicalWorks and healow National Confere ———————————————————————————————————————————————————————————— Pinnacle Building Services Expands Medical Cleaning Services in Phoenix 2026-10-23 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/pinnacle-building-services-expands-medical-cleaning-services-in-phoenix/89207152 Pinnacle Building Services brings decades of commercial cleaning experience to Phoenix’s growing healthcare sector, serving medical offices, clinics, and other healthcare facilities across the city. -- Pinnacle Building Services, an Arizona commercial cleaning company serving businesses since 1994, has expanded its medical office and healthcare facility cleaning services in Phoenix . The expansion comes as Greater Ph ———————————————————————————————————————————————————————————— TikaMobile Introduces TikaConference, AI-Powered Congress Management Software for Medical Affairs 2026-10-23 · Newswire.com · AI, Healthcare, Government & policy, Software & IT https://www.newswire.com/news/tikamobile-introduces-tikaconference-ai-powered-congress-management-software From Session Planning to an AI-Drafted Readout, TikaConference Turns Every Medical Congress Into Insights Leadership Can Use ———————————————————————————————————————————————————————————— Summers Plumbing Heating & Cooling Joins K99.1FM Cares for Kids Radiothon as Phone Bank Sponsor 2026-10-23 · PRWeb · Healthcare, Banking https://www.prweb.com/releases/summers-plumbing-heating--cooling-joins-k99-1fm-cares-for-kids-radiothon-as-phone-bank-sponsor-302917730.html Summers team members will answer calls this Friday, Oct. 23, as the K99.1FM Cares for Kids Radiothon celebrates its 29th year supporting Dayton Children's Hospital. DAYTON, Ohio, Oct. 23, 2026 -- Summers Plumbing Heating & Cooling is excited to participate for the first... ———————————————————————————————————————————————————————————— Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387398/0/en/zentalis-pharmaceuticals-announces-meaningful-median-overall-survival-data-in-cyclin-e1-positive-platinum-resistant-ovarian-cancer-from-denali-part-1b-to-be-presented-at-the-esmo-c.html SAN DIEGO, Oct. 23, 2026 -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today presented results from an interim analysis of the DENALI Part 1b study (GOG-3066) as of a May 22, 2026 data cutoff, including the first overall survival analysis for azenosertib, at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain. ———————————————————————————————————————————————————————————— East African Community Partner States Sign Mental Health Declaration 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951594111/east-african-community-partner-states-sign-mental-health-declaration Declaration and Proposed Regional Policy Emphasize Community-based Approach These developments demonstrate and reinforce the political will to treat mental health as a development priority, a key ingredient to economic and human progress and to peace.” — Vincent Mujune, StrongMinds Uganda KAMPALA, UGANDA, October 23, 2026 / EINPresswire.com / -- At the conclusion of the 2nd annual East African Mental Health Summit on ———————————————————————————————————————————————————————————— Sustainable Innovation & Health Dividend Fund Distributions 2026-10-23 · GlobeNewswire · Healthcare, Investing & markets https://www.globenewswire.com/news-release/2026/10/23/3387399/0/en/sustainable-innovation-health-dividend-fund-distributions.html TORONTO, Oct. 23, 2026 -- Sustainable Innovation & Health Dividend Fund (TSX: SIH.UN) (the “Fund”) is pleased to announce that distributions for the fourth quarter of 2026 will be payable to unitholders of Sustainable Innovation & Health Dividend Fund as follows: ———————————————————————————————————————————————————————————— Clinical Laboratory Molecular Diagnostics for Infectious Diseases Market, 2025-2029: Forecast by Application, Place, and Country | Multiplex and Rapid Testing Unlock Growth 2026-10-23 · GlobeNewswire · Healthcare, Medical devices https://www.globenewswire.com/news-release/2026/10/23/3387386/28124/en/clinical-laboratory-molecular-diagnostics-for-infectious-diseases-market-2025-2029-forecast-by-application-place-and-country-multiplex-and-rapid-testing-unlock-growth.html A 354-page report profiles 36 companies, including Abbott, bioMérieux, Roche and Thermo Fisher, across respiratory, gastrointestinal and meningitis testing in 15 countries — though costs and shifting disease prevalence complicate the outlook A 354-page report profiles 36 companies, including Abbott, bioMérieux, Roche and Thermo Fisher, across respiratory, gastrointestinal and meningitis testing in 15 countries — though costs and shifting disease prevalence complicate the outlook ———————————————————————————————————————————————————————————— Frisco Spinal Rehab Highlights Non-Surgical Treatment Options for Herniated Disc 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951481277/frisco-spinal-rehab-highlights-non-surgical-treatment-options-for-herniated-disc Herniated Disc Treatment i DRX9000 computerized spinal decompression chiropractic and spinal rehabilitation clinic; Our Staff Frisco Spinal Rehab, Texas Frisco Spinal Rehab educates patients on herniated disc symptoms, evaluation, conservative treatment options, and when further medical assessment may be needed FRISCO, TX, UNITED STATES, October 23, 2026 / EINPresswire.com / -- FRISCO, Texas — Frisco Spinal Rehab is ———————————————————————————————————————————————————————————— City of Hope Cancer Center Chicago Unites Industry Leaders for Health Technology Innovation Roundtable 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/city-of-hope-cancer-center-chicago-unites-industry-leaders-for-health-technology-innovation-roundtable-302917568.html CHICAGO, Oct. 23, 2026 -- Faster access to care, more affordable treatment and policies that support innovation were central themes of a Health Technology Innovation Roundtable convened by City of Hope® Cancer Center Chicago on Thursday, October 15, at its hospital in Zion.... ———————————————————————————————————————————————————————————— Employers Health selects Archimedes to reduce costs 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/employers-health-selects-archimedes-reduce-140000790.html More than 500 plan sponsors can access proven specialty-drug management solutions BRENTWOOD, Tenn., October 23, 2026--Archimedes, the nationwide leader in specialty drug management solutions, announced today that it will offer proven strategies for addressing rising specialty-drug costs to the more tha ———————————————————————————————————————————————————————————— Gerstenberg.clinic Brings Medical-Grade Body Composition Analysis to Port Neches Primary Care 2026-10-23 · PR Now · Healthcare https://pressreleasenews.org/pressroom/gerstenberg-clinic-brings-medical-grade-body-composition-analysis-to-port-neches-primary-care Patients on weight loss, hormone therapy, and fatigue protocols can now track fat mass, lean muscle, and cellular health, not just weight, at the same practice managing their care. PORT NECHES, TX, September 7, 2026 - Gerstenberg.clinic today announced the addition of the Seca Me… ———————————————————————————————————————————————————————————— GeneMetrics Brings White-Label DNA Testing to Medical Offices 2026-10-23 · PR Now · SaaS, Healthcare https://pressreleasenews.org/pressroom/genemetrics-brings-white-label-dna-testing-to-medical-offices Austin, Texas - September 3, 2026 - GeneMetrics, a white-label genetic testing platform built for health professionals, is offering medical offices and clinics full access to its branded DNA testing services, enabling practitioners to launch a fully operational genetic testing pr… ———————————————————————————————————————————————————————————— Global Clinical Trials Market Size, Share, Growth Trends, and Forecast, 2026-2035 | Clinical Trials Market set to more than Double to $144.4bn as Drugmakers Lean on Outside Researchers 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma, Insurance https://www.globenewswire.com/news-release/2026/10/23/3387296/28124/en/global-clinical-trials-market-size-share-growth-trends-and-forecast-2026-2035-clinical-trials-market-set-to-more-than-double-to-144-4bn-as-drugmakers-lean-on-outside-researchers.html New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn obstacles for IQVIA, ICON, Medpace and Charles River Laboratories New Report puts the market at $66.3bn in 2025, with oncology accounting for 38.3% and North America just over half, though patchy insurer coverage and infrastructural barriers remain stubborn obstacles for IQVIA, ICON, Medpace and Charles River Laboratories ———————————————————————————————————————————————————————————— Health Information Alliance, Inc. Names Michelle Puhlick as Interim Executive Director 2026-10-23 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/health-information-alliance-inc-names-131500784.html Longtime COO to lead Health Information Alliance, Inc. and guide Connecticut's Health Information Exchange, Connie, as it shifts from building statewide infrastructure to making health data more actionable WEST HARTFORD, Conn., October 23, 2026--Health Information Alliance, Inc. (HIA) — the operating e ———————————————————————————————————————————————————————————— Eikon Therapeutics Presents Data from PARP1-Selective and WRN Helicase Programs at the European Society for Medical Oncology Congress 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387290/0/en/eikon-therapeutics-presents-data-from-parp1-selective-and-wrn-helicase-programs-at-the-european-society-for-medical-oncology-congress.html MILLBRAE, Calif., Oct. 23, 2026 -- Eikon Therapeutics, Inc. (Nasdaq: EIKN) (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing innovative medicines to address serious unmet medical needs, today announced the presentation of initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 European Society for Medical Oncology (ESMO) Congress in Madrid, Spain. ———————————————————————————————————————————————————————————— Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387289/0/en/pasithea-therapeutics-announces-positive-pas-004-clinical-data-from-phase-1-advanced-cancer-study-presented-at-esmo-congress-2026.html Pasithea Therapeutics Announces Positive PAS-004 Clinical Data from Phase 1 Advanced Cancer Study Presented at ESMO Congress 2026 ———————————————————————————————————————————————————————————— MacroGenics Announces Positive Interim Phase 1 Results for MGC026 and Highlights Plans to Initiate Front-Line Combination Study in SCCHN 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387288/0/en/macrogenics-announces-positive-interim-phase-1-results-for-mgc026-and-highlights-plans-to-initiate-front-line-combination-study-in-scchn.html ROCKVILLE, MD, Oct. 23, 2026 -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on developing innovative antibody-based therapeutics for the treatment of cancer, today announced positive interim data from its Phase 1 study evaluating MGC026, a B7-H3-directed antibody-drug conjugate (ADC), in patients with advanced solid tumors. These Phase 1 data were presented today at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain. These results demonstrated durable activity across a broad range of solid tumors, which the Company believes supports expanded development of MGC026 in front-line metastatic squamous cell carcinoma of the head and neck (SCCHN) in combination with pembrolizumab. ———————————————————————————————————————————————————————————— Oral Cavity (Mouth) Cancer - Global Clinical Trials Review, 2026 | Sponsor, Pipeline, and Enrollment Trends Highlight Strategic R&D Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387294/28124/en/oral-cavity-mouth-cancer-global-clinical-trials-review-2026-sponsor-pipeline-and-enrollment-trends-highlight-strategic-r-d-opportunities.html Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors. Identify cost-saving trial locations, guide investment strategies, uncover business opportunities, and benchmark trial success, enrollment trends and competitors. ———————————————————————————————————————————————————————————— Multiple Myeloma (Kahler Disease) - Global Clinical Trials Landscape and Strategic Review, 2026 | Pipeline, Enrollment, and Sponsor Trends Reveal R&D and Partnership Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387287/28124/en/multiple-myeloma-kahler-disease-global-clinical-trials-landscape-and-strategic-review-2026-pipeline-enrollment-and-sponsor-trends-reveal-r-d-and-partnership-opportunities.html Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge. Optimize trial ROI by identifying cost efficient locations, enrollment trends, success rates and key opportunities to sharpen investment strategies and gain a competitive edge. ———————————————————————————————————————————————————————————— Membranous Glomerulonephritis - Global Clinical Trials Landscape and Competitive Review, 2026 | Pipeline, Enrollment, and Regional Trends Guide Strategic Investment 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387285/28124/en/membranous-glomerulonephritis-global-clinical-trials-landscape-and-competitive-review-2026-pipeline-enrollment-and-regional-trends-guide-strategic-investment.html Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights. Identify efficient trial locations, investment opportunities and competitive strategies using global trial, enrollment, sponsor and success rate insights. ———————————————————————————————————————————————————————————— Asthma - Global Clinical Trials and Therapeutics Market Review, 2026 | Novel Biologics and Oral Therapies Drive Pipeline Investment and Partnership Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387284/28124/en/asthma-global-clinical-trials-and-therapeutics-market-review-2026-novel-biologics-and-oral-therapies-drive-pipeline-investment-and-partnership-opportunities.html Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors. Identify strategic trial locations to save time and cost, uncover business opportunities, guide investments and benchmark enrollment trends, success rates and competitors. ———————————————————————————————————————————————————————————— Dermatomyositis - Global Clinical Trials Landscape and Competitive Intelligence, 2026 | Pipeline Activity and Enrollment Trends Reveal Strategic R&D Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387282/28124/en/dermatomyositis-global-clinical-trials-landscape-and-competitive-intelligence-2026-pipeline-activity-and-enrollment-trends-reveal-strategic-r-d-opportunities.html Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage. Identify cost-saving trial locations, investment opportunities, enrollment trends and success rates to sharpen strategy and gain competitive advantage. ———————————————————————————————————————————————————————————— Florida Cancer Specialists & Research Institute Drug Development Research Featured at ESMO Congress 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/florida-cancer-specialists--research-institute-drug-development-research-featured-at-esmo-congress-2026-302918109.html ESMO 2026 abstracts featuring FCS research: 52P, 1017P, 1076TiP, 1021P, 1134eTiP, 1146eTiP, 1594P, 1846P, 3151P, 2216O FORT MYERS, Fla., Oct. 23, 2026 -- Findings from early-phase clinical research conducted with participation from Florida Cancer Specialists & Research... ———————————————————————————————————————————————————————————— Rheumatic Disorders - Global Clinical Trials Landscape Review, 2026 | Trial Hotspots, Enrollment Trends, and Sponsor Activity Reveal Strategic Investment Opportunities 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387281/28124/en/rheumatic-disorders-global-clinical-trials-landscape-review-2026-trial-hotspots-enrollment-trends-and-sponsor-activity-reveal-strategic-investment-opportunities.html Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage. Identify high-potential trial locations, reduce time and costs, guide investment strategies, uncover business opportunities and strengthen competitive advantage. ———————————————————————————————————————————————————————————— Bolt Biotherapeutics Announces Acquisition of Prana Therapies and $120 Million Concurrent Private Placement to Advance PRA-216 in Multiple High-Value Inflammatory Indications 2026-10-23 · GlobeNewswire · Finance, SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387280/0/en/bolt-biotherapeutics-announces-acquisition-of-prana-therapies-and-120-million-concurrent-private-placement-to-advance-pra-216-in-multiple-high-value-inflammatory-indications.html REDWOOD CITY, Calif., Oct. 23, 2026 -- Bolt Biotherapeutics, Inc. (Nasdaq: BOLT) (“Bolt” or the “Company”) today announced the acquisition of Prana Therapies, Inc. (“Prana”), a clinical-stage biotechnology company pioneering next-generation half-life-extended multispecific antibodies designed to deliver best-in-disease therapies. Following the acquisition, the Company will focus on advancing Prana’s pipeline of half-life-extended multispecific antibodies generated from its proprietary INSPIRE platform, led by PRA-216, a novel IL-4Rα/TSLP bispecific antibody currently in Phase 2 development in asthma, chronic obstructive pulmonary disease (COPD) and atopic dermatitis, with a Phase 2 study in eosinophilic esophagitis (EoE) planned. ———————————————————————————————————————————————————————————— CUMBERLAND PHARMACEUTICALS PROVIDES UPDATED WEBCAST REGISTRATION LINK FOR IFETROBAN DMD PROGRAM CALL 2026-10-23 · PR Newswire · Finance, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/cumberland-pharmaceuticals-provides-updated-webcast-registration-link-for-ifetroban-dmd-program-call-302917759.html NASHVILLE, Tenn., Oct. 23, 2026 -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), an innovation-driven biopharmaceutical company advancing new therapies that address significant unmet medical needs, confirmed that it will provide an update on its ifetroban product candidate... ———————————————————————————————————————————————————————————— FC Mother Releases MASS™, the First Standard for Mobilizing Fan Teams for Health 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951615203/fc-mother-releases-mass-the-first-standard-for-mobilizing-fan-teams-for-health MASS: Mobilizing Assists at Societal Scale Fans form teams around new mothers, every act of support is verified, and every team is measured on whether loneliness goes down. Every new mother needs a team. Fans already know how to be one. MASS gives fandom a standard: who showed up, for whom, and whether it made a difference.” — Morad Fareed, Founder & CEO, FC Mother LISBON, PORTUGAL, October 23, 2026 / EINPresswire.co ———————————————————————————————————————————————————————————— Michigan Workers Can Compare COBRA with Private Health Plans 2026-10-23 · Newswire.com · Healthcare https://www.newswire.com/news/michigan-workers-can-compare-cobra-with-private-health-plans Brokerage helps laid-off and transitioning employees evaluate cost, network and timing. ———————————————————————————————————————————————————————————— Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387264/0/en/elicio-therapeutics-presents-late-breaking-phase-2-amplify-7p-results-at-esmo-congress-2026-and-announces-simultaneous-publication-in-nature-medicine.html BOSTON, Oct. 23, 2026 -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced results from the randomized Phase 2 AMPLIFY-7P study of camupepimut (ELI-002 7P), presented in a late-breaking Proffered Paper oral session at the European Society for Medical Oncology (“ESMO”) Congress 2026 in Madrid, Spain, and simultaneously published in Nature Medicine: "Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial". ———————————————————————————————————————————————————————————— Tempus Expands Strategic Collaboration with Bristol Myers Squibb 2026-10-23 · Business Wire · Finance, AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/tempus-expands-strategic-collaboration-bristol-130000904.html CHICAGO, October 23, 2026--Tempus AI, Inc. (NASDAQ: TEM, "Tempus") today announced a multi-year agreement with Bristol Myers Squibb (NYSE: BMY, "BMS"), under which BMS will license multimodal oncology data from Tempus through 2031 to support biological and clinical insight identification, novel drug ta ———————————————————————————————————————————————————————————— Pathos AI Secures $237 Million in Series E Financing to Scale Agentic AI Drug Development Platform and Advance Oncology Pipeline 2026-10-23 · Business Wire · Finance, AI, SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/pathos-ai-secures-237-million-130000823.html Funding follows rapid portfolio expansion and will power the initiation of a registrational study for AI-identified asset JSKN016 NEW YORK, October 23, 2026--Pathos AI, Inc., a clinical-stage AI and technology company advancing its own therapeutic pipeline of drugs, today announced the closing of a $23 ———————————————————————————————————————————————————————————— Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova’s VNS Therapy for Drug-Resistant Epilepsy 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/neuromodulation-publishes-full-36-month-130000394.html – CORE-VNS is the largest prospective, multinational observational study evaluating contemporary VNS Therapy devices in people with Drug-Resistant Epilepsy – Demonstrated 76% median reduction in seizure frequency and a durable clinical benefit – Data also showed improvements in rescue medication use, healthcare resource u ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Engages Task-Based Software Technicians and External Platforms to Accelerate Technology and Enterprise Expansion 2026-10-23 · Newswire.com · AI, Healthcare, Software & IT https://www.newswire.com/news/medical-care-technologies-inc-otcid-mdce-engages-task-based-software Company Adds Specialized Technical Capacity to Speed Development Across AI Platforms, Software Offerings, and Consulting Services ———————————————————————————————————————————————————————————— Fifth UK–West and Central Francophone Africa Trade and Investment Forum (WCAF V): African Development Bank Group and UK Export Finance sign Memorandum of Understanding (MOU) to mobilise financing for Africa 2026-10-23 · APO Group · Healthcare, Energy, Logistics, Sustainability, Banking, Insurance, Mining & metals, Agriculture https://afdb.africa-newsroom.com/press/fifth-ukwest-and-central-francophone-africa-trade-and-investment-forum-wcaf-v-african-development-bank-group-and-uk-export-finance-sign-memorandum-of-understanding-mou-to-mobilise-financing-for-africa?lang=en The African Development Bank Group (AfDB) (www.AfDB.org) and UK Export Finance (UKEF), the United Kingdom’s export credit agency, have signed a Memorandum of Understanding to strengthen cooperation on co-financing projects across Africa and mobilise additional resources for the continent’s sustainable development. Abdul Kamara, Officer in Charge, Vice President of the African Development Bank Group, and Tim Reid, Chief Executive of UK Export Finance, signed the agreement on 21 October in Conakry, Guinea, on the sidelines of the fifth UK–West and Central Francophone Africa Trade and Investment Forum (WCAF V). It is the first framework agreement between the two institutions. “Africa’s financing needs call for partnerships that bring additional capital to the continent at scale. This agreement with UK Export Finance gives our cooperation a structured framework and opens new opportunities to finance the infrastructure and investments that will drive Africa’s growth,” said Abdul Kamara, OIC Vice President of the African Development Bank Group. The Memorandum of Understanding provides a framework for the two institutions to identify, assess and develop co-financing opportunities for sovereign and non-sovereign operations in the Bank’s regional member countries, drawing on each institution’s financial instruments. The partnership will bring together development finance and export credit to crowd in additional capital for Africa’s strategic investments. Priority areas include energy, infrastructure, water and sanitation, health, digital infrastructure, critical minerals, supply chain resilience, alongside agriculture and trade finance. “This agreement deepens the relationship between UK Export Finance and the African Development Bank Group. By combining our financial instruments and expertise, we can unlock greater co-financing for the infrastructure, energy and trade priorities that matter most to Africa's growth. UKEF is committed to supporting that ambition, and this partnership will help us do so at greater scale”, said Tim Reid, Chief Executive, UK Export Finance. The partnership supports the Bank Group’s efforts to mobilise capital at scale, in line with its Four Cardinal Points (https://apo-opa.co/4jHBqUh) strategic priorities. The agreement also reflects the long-standing partnership between the Bank Group and the United Kingdom. The United Kingdom joined the African Development Fund (ADF) in 1973 and became a member of the African Development Bank in 1983. He remains a major contributor to the African Development Fund, which is the Bank Group’s concessional financing window. The UK Export Finance, established in 1919 as the world’s first export credit agency, provides finance and insurance to support UK businesses and is increasingly active across Africa. Distributed by APO Group on behalf of African Development Bank Group (AfDB). Media contact: media@afdb.org ———————————————————————————————————————————————————————————— Allotex Five-Year Clinical Results on Its TransForm Human Tissue Platform 2026-10-23 · Business Wire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/allotex-five-clinical-results-transform-125000640.html Long-term observations presented at ESCRS describe the performance of precision-defined sterile human corneal tissue profiles over five years BOSTON, October 23, 2026--Allotex today announced five-year clinical observations presented in an ESCRS Free Paper by Cafer Tanrıverdi, MD, and collaborators fr ———————————————————————————————————————————————————————————— Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses. 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/brenus-pharmas-novel-vivo-immunotherapy-125000466.html Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics MADRID, October 23, 2026--Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nin ———————————————————————————————————————————————————————————— CVS Health: Thank You! Phoenix Residential Grand Opening in Milwaukee, Wisconsin 2026-10-23 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/cvs-health-thank-phoenix-residential-124500168.html WOONSOCKET, RI / October 23, 2026 / CVS Health Recently, the Grand Opening of Phoenix Residential in Milwaukee marked a milestone for the residents, local leaders, community and development organizations, who helped bring the community to life. Phoenix Residential offers 21 affordable homes for families ———————————————————————————————————————————————————————————— FluoGuide A/S Invites Investors to Q3 Webcast - Clinical Progress and the Road Ahead 2026-10-23 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/fluoguide-invites-investors-q3-webcast-124500031.html KØBENHAVN, DK / October 23, 2026 / FluoGuide A/S (STO:FLUO) - FluoGuide A/S will publish its interim report for Q3 2026 on Thursday, 26 November 2026, followed by a live investor webcast later the same day at 14:00 CET. CEO Morten Albrechtsen and CFO Ole Larsen will present the company's operational and ———————————————————————————————————————————————————————————— Lesotho Government Heeded the Qacha’s Nek Community’s Long-Standing Plea for Improved Mobility as Tebellong Bridge Will Soon Be Constructed 2026-10-23 · APO Group · Healthcare, Real estate, Automotive, Education, Travel, Sports, Government & policy, Jobs & workplace, Construction & engineering https://www.africa-newsroom.com/press/lesotho-government-heeded-the-qachas-nek-communitys-longstanding-plea-for-improved-mobility-as-tebellong-bridge-will-soon-be-constructed?lang=en Public Works and Transport Minister, Honourable Matjato Moteane  introduced Unik Construction as the contractor for the Tebellong Bridge project and turned the sod to mark the start of construction. The project, expected to take 24 months, will include a tarred road linking the Senqu River to Tebellong Hospital, this was announced by Moteane adding that many people lost their lives while crossing the Senqu River. He said the government was continuing efforts to make the river safer through bridge construction, adding that when the current administration took office, it found plans for projects that had been drawn up more than a decade earlier. Hon. Moteane said delays in the bridge project had, among other factors, been caused by its politicisation and changes in government. He urged Unik Construction to work closely with the relevant authorities and maintain the quality demonstrated in its previous projects.The minister also called on the contractor to source materials, including cement and sand, from local businesses where possible. He revealed that the government had spent more than M3 billion on service delivery across the three constituencies in Qacha’sNek during its four years in office, saying it was committed to providing services to the public without political discrimination. Recalling his own experience of crossing the river by boat, Hon. Moteane expressed hope that the project would eventually bring an end to such risky crossings for the public. Minister of Tourism, Sports, Arts and Culture, Honourable Mputi Mputi said the development presented an opportunity to promote tourism and create jobs in the area. He challenged community leaders to identify ways of using local tourism attractions to stimulate economic activity, urging all stakeholders to contribute to job creation and the promotion of Lesotho. Hon. Mputi said tourism and sports development were everyone’s responsibility and called on communities to take advantage of development initiatives to improve livelihoods. Chairperson of the Portfolio Committee on Natural Resources, Tourism and Land Cluster Lebohang Phohleli expressed gratitude on behalf of the public, saying they would return to monitor progress and ensure the project was implemented successfully. Qacha’s Nek Member of Parliament (MP) Mohlahlobi Busa said the bridge was a long-awaited development that would help protect communities from the dangers of crossing the Senqu River.“We have long been waiting for this, as it is a long-time plan, and now that a contractor has been introduced, we have to be thankful,” he said. Hon. Busa said the bridge would benefit not only residents of Tebellong and Whitehill but also the wider community, particularly people travelling to access services at Tebellong Hospital. He expressed hope that construction would begin soon, given the risks faced by residents, and called for local people to be prioritised for employment. “Only skilled labourers should be sourced from outside. We need transparency,” he said. Busa further urged the contractor to maintain good relations with the community and avoid any form of abuse.“Preserve the dignity and peace in this area,” he said. Lebakeng MP Letsekang Moloi described the occasion as historic, saying bridge construction had been among the public’s expectations when he was elected. “We are thankful for this big gift, and I am glad I took on the assignment and my plea was heard for this project to eventually be happening,” he said. Moloi said the bridge would stimulate economic growth by improving business opportunities for local shops and transport operators while making access to the hospital easier. He raised concerns about the limited availability of boats for crossing the river, saying residents depended on three existing boats, some of which had been washed away by the river. He appealed to residents whose property, including fields, might be affected by construction to cooperate with the project team to ensure smooth implementation. Moloi also called on the community to embrace and protect the development.“May this bridge unite us and not cause any divisions. Let’s accept the project and protect it,” he said. Tebellong Area Chief Makhaola Makhaola thanked the government for responding to the community’s longstanding calls for a bridge.“I have been asking for this multiple times for the people of Tebellong, and we are grateful for this big day,” he said. Makhaola also highlighted the challenges faced by Tebellong Hospital, saying patients had lost their lives while seeking care and the transportation of medication to the facility had been difficult. Speaking on behalf of the Principal Chief, he welcomed the development and pledged the community’s support in protecting the infrastructure.Nts’upe Community Council Chairperson Tefo Lehakoe thanked all those who had contributed to making the project possible, including residents who had raised concerns, community leaders and the government. He recalled seeing structural steel in the river and believing they signalled the beginning of construction, only for them to disappear later. Lehakoe said major projects such as the bridge should create opportunities for local businesses and residents. However, he raised concerns about access to quarry materials and sand, calling for clear guidelines to ensure businesses from Qacha’s Nek could benefit. He also warned against political interference in recruitment and called for transparent employment procedures that would allow Basotho living in the project area to benefit. “Unskilled labourers should be sourced locally,” he said. Lehakoe expressed hope that the completion of the bridge would bring an end to the deaths associated with crossing the river. Speaking on behalf of Qanya Community Council Chairperson, Whitehill Councillor Rorisang Marotholi commended the government for taking up the bridge project rather than abandoning it because it had been planned by a previous administration. He also called for transparency in recruitment, urging that councillors and chiefs from affected areas be involved in the process. “Developments are neither political nor campaigning, but need to happen, though some stakeholders treat them like that, and it is wrong according to me,” he said. Marotholi urged everyone involved to focus on the project’s successful implementation and protect the development for the benefit of the community. The event also featured songs by Tebellong Primary School and a mohobelo dance performance by Matseka Primary School. Distributed by APO Group on behalf of Government of Lesotho. ———————————————————————————————————————————————————————————— RX K Fairs and ASLS to Present Latest Medical Aesthetic Technologies and Regenerative Treatments at ASLS Korea 2026 Autumn 2026-10-23 · PR.com · Healthcare https://www.pr.com/press-release/982131 More than 5,000 healthcare professionals, researchers and industry stakeholders are expected to gather at ASLS Korea 2026 Autumn on Nov. 7-8, 2026, at COEX in Seoul, where 170 companies and more than 350 exhibition booths will showcase emerging technologies, clinical developments and innovations shaping the future of aesthetic medicine. The event will highlight the latest developments in aesthetic medicine, with [PR.com] ———————————————————————————————————————————————————————————— Pacific Dermatology & Cosmetic Laser Center Named People's Choice in San Diego 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951762917/pacific-dermatology-cosmetic-laser-center-named-people-s-choice-in-san-diego Dermatology practice led by Douglas Keel, D.O., recognized for personalized patient care after earning a 4.9-star rating across 249 Google reviews. SAN DIEGO, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Pacific Dermatology & Cosmetic Laser Center , a medical and cosmetic dermatology practice in San Diego led by board-certified dermatologist Douglas Keel, D.O., has been named 2026 People's Choice — San ———————————————————————————————————————————————————————————— Aimwell Partners Successfully Renegotiates Fixed-Price Debt Provision, Clearing the Path to Scale Verified Healthcare Intelligence Through Biotech Acquisitions 2026-10-23 · ACCESS Newswire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/aimwell-partners-successfully-renegotiates-fixed-120000789.html At current market prices, restructured terms would require approximately 98.6% fewer shares to convert the same debt; Company advances acquisition discussions as AimwellBio expands its network of featured healthcare companies and professionals MIAMI, FL / October 23, 2026 / Aimwell Partners Inc. (OTC PIN ———————————————————————————————————————————————————————————— Hub71 Startup, Vivan Therapeutics to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu Dhabi 2026-10-23 · EIN Presswire · AI, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951734819/hub71-startup-vivan-therapeutics-to-begin-tumatch-clinical-registration-study-at-burjeel-cancer-institute-abu-dhabi Hub71 Startup, Vivan Therapeutics set to Begin TuMatch™ Clinical Registration Study at Burjeel Cancer Institute, Abu Dhabi Prospective study of AI-enabled clinical decision support in colorectal cancer will generate the first UAE outcomes and health-economics evidence for TuMatch™ NEW YORK CITY , NY, UNITED STATES, October 23, 2026 / EINPresswire.com / -- Vivan Therapeutics , a precision oncology company developing A ———————————————————————————————————————————————————————————— Empirical Health launches support for iPhone Duo, including a custom 3D simulator 2026-10-23 · PRWeb · Healthcare, Consumer electronics https://www.prweb.com/releases/empirical-health-launches-support-for-iphone-duo-including-a-custom-3d-simulator-302917673.html Unfolding your health for iPhone Duo required more than just enlarging an existing app. It required re-thinking major screens and building a custom 3D simulator. NEW YORK, Oct. 23, 2026 -- Empirical Health today launched support for iPhone Duo, with an experience... ———————————————————————————————————————————————————————————— Intensity Therapeutics, Inc. to Present INVINCIBLE-4 Neoadjuvant Triple-Negative Breast Cancer Study Data for the First Seven (7) Patients After INT230-6 Treatment (Cohort A) in an ePoster Presentation at the European Society of Medical Oncology (ESMO) Meeting 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/intensity-therapeutics-inc-to-present-invincible-4-neoadjuvant-triple-negative-breast-cancer-study-data-for-the-first-seven-7-patients-after-int230-6-treatment-cohort-a-in-an-eposter-presentation-at-the-european-society-of-m-302917587.html Pathological complete response (pCR) achieved in the breast (ypT0/Tis) and affected lymph nodes (ypN0) in 5 out of 7 patients (71%; 95% CI 29-96%) in the INT230-6 plus standard-of-care cohort No invasive breast cancer cells were detected in the axillary lymph nodes in 6 of the 7 INT230-6... ———————————————————————————————————————————————————————————— Waters and Labcorp to Expand Access to Cervical Cancer Screening with the Most Comprehensive FDA-Approved HPV Testing Option Beginning in Late 2026 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/waters-and-labcorp-to-expand-access-to-cervical-cancer-screening-with-the-most-comprehensive-fda-approved-hpv-testing-option-beginning-in-late-2026-302918049.html Labcorp intends to be the first commercial laboratory to offer FDA-approved HPV testing with the BD Onclarity™ HPV Assay across clinician-collected and self-collected screening options in clinic, patient service center, and at-home settings Through a network serving more than 850,000... ———————————————————————————————————————————————————————————— Avanos CHRO Camille Chang Gilmore Receives Inaugural Seramount Ted Childs Award 2026-10-23 · PR Newswire · Healthcare, Jobs & workplace, Medical devices https://www.prnewswire.com/news-releases/avanos-chro-camille-chang-gilmore-receives-inaugural-seramount-ted-childs-award-302917541.html Recognition honors courageous leadership and workforce strategies that advance opportunity and performance ALPHARETTA, Ga., Oct. 23, 2026 -- Avanos Medical, Inc., a leading medical technology company, today announced that Camille Chang Gilmore, senior vice president and chief... ———————————————————————————————————————————————————————————— Coreline Soft Receives U.S. FDA 510(k) Clearance for AVIEW Aorta Metrics, Expanding Its Chest CT AI Portfolio in the U.S. 2026-10-23 · PR Newswire · AI, Healthcare, Medical devices https://www.prnewswire.com/news-releases/coreline-soft-receives-us-fda-510k-clearance-for-aview-aorta-metrics-expanding-its-chest-ct-ai-portfolio-in-the-us-302916220.html Secures its 13th FDA 510(k) clearance, expanding its U.S. portfolio from lung nodule detection and coronary artery calcium (CAC) analysis to quantitative aortic assessment Enables automated aortic segmentation and diameter measurements across anatomical regions, broadening the... ———————————————————————————————————————————————————————————— Niki BioSolutions Signs Agreement to Supply APOE Genotyping to Charter Research 2026-10-23 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/23/3387217/0/en/niki-biosolutions-signs-agreement-to-supply-apoe-genotyping-to-charter-research.html Agreement brings CAP and NYS CLEP-approved genotyping test to a multi-site Alzheimer’s clinical research network ———————————————————————————————————————————————————————————— Tokyo Lifestyle Co., Ltd. Opens Third Australian Store at Westfield Chatswood, Advancing Its Retail Expansion 2026-10-23 · GlobeNewswire · Finance, Healthcare, Retail, Consumer goods https://www.globenewswire.com/news-release/2026/10/23/3387216/0/en/tokyo-lifestyle-co-ltd-opens-third-australian-store-at-westfield-chatswood-advancing-its-retail-expansion.html Tokyo, Japan, Oct. 23, 2026 -- Tokyo Lifestyle Co., Ltd. (“Tokyo Lifestyle” or the “Company”) (Nasdaq: TKLF), a retailer and wholesaler of Japanese beauty and health products, sundry products, luxury products, electronic products, collectible cards, trendy toys as well as other products in Hong Kong, Japan, North America, Thailand, Vietnam, the United Kingdom and Australia, today announced the grand opening of its third directly operated retail store (the “Store”) in Australia under its proprietary “Tokyo Lifestyle” brand on October 17, 2026. Located at Westfield Chatswood in Sydney’s Lower North Shore, the new store marks another milestone in the Company’s physical retail footprint and strengthens its presence in the Australian market. ———————————————————————————————————————————————————————————— ImPact Biotech Reports Encouraging Early Clinical Results From Phase 1 Study of Padeliporfin VTP in Pancreatic Cancer, with Seven Previously Unresectable Patients Undergoing Surgical Resection Following Treatment 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387201/0/en/impact-biotech-reports-encouraging-early-clinical-results-from-phase-1-study-of-padeliporfin-vtp-in-pancreatic-cancer-with-seven-previously-unresectable-patients-undergoing-surgica.html TEL AVIV, Israel, Oct. 23, 2026 -- ImPact Biotech, a clinical-stage biotechnology company developing Padeliporfin vascular targeted photodynamic (VTP) therapy for the treatment of solid tumors, today announced the successful completion of treatment in Part A of its Phase 1 clinical trial in patients with Stage III, locally advanced, unresectable pancreatic ductal adenocarcinoma (PDAC). ———————————————————————————————————————————————————————————— Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner 2026-10-23 · GlobeNewswire · Healthcare, Biotech & pharma, Medical devices https://www.globenewswire.com/news-release/2026/10/23/3387207/0/en/humacyte-at-asn-kidney-week-phase-3-trial-built-for-women-shows-atev-advantage-over-fistula-getting-patients-off-catheters-months-sooner.html - The presenter, Dr. Roy-Chaudhury said, “These results give the nephrology community a strong reason to rethink our approach to access decisions for women and, once approved by the FDA, to consider the ATEV as a meaningful new option.” ———————————————————————————————————————————————————————————— Salubris Biotherapeutics Announces Updated Phase 1b/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the European Society for Medical Oncology Congress 2026 2026-10-23 · Business Wire · Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/salubris-biotherapeutics-announces-updated-phase-120000997.html JK06 continued to demonstrate a highly differentiated safety profile for an MMAE ADC among 230 patients in the target dose range; predominantly low-grade, manageable treatment-related adverse events (TRAEs) were observed with low rates of dose reduction and discontinuation Among response-evaluable squamous non-small cell ———————————————————————————————————————————————————————————— Harvest Declares Big Pharma Split Corp. October 2026 Distributions 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/markets/stocks/articles/harvest-declares-big-pharma-split-113000757.html OAKVILLE, Ontario, October 23, 2026--Harvest Portfolios Group Inc. ("Harvest") declares the monthly cash distribution payable for Big Pharma Split Corp. of $0.1031 for each class A share (PRM:TSX) for the month ending October 31, 2026. The distribution is payable November 6, 2026 to class A shareholder ———————————————————————————————————————————————————————————— Hong Kong International Optical Fair Opens in November 2026-10-23 · NewMediaWire · AI, SaaS, Healthcare, Education, Fashion & luxury, Sports, Industrial, Biotech & pharma, Sustainability, Consumer electronics https://www.newmediawire.com/news/hong-kong-international-optical-fair-opens-in-november-7090830 - Showcasing Innovation, Technology and Trendsetting Designs to Capture New Opportunities in the Eyewear Industry HONG KONG - October 23, 2026 - Organised by the Hong Kong Trade Development Council (HKTDC) and co-organised by the Hong Kong Optical Manufacturers Association (HKMOA), the 34th Hong Kong International Optical Fair will be held from 4 to 6 November at the Hong Kong Convention and Exhibition Centre (HKCEC). Under the theme "Bright Eyes • New Horizons", the fair will bring together more than 600 exhibitors from 14 countries and regions, featuring a wide range of products and solutions covering smart eyewear, eye care, sports and specialist eyewear, frames, lenses and more, providing buyers with a comprehensive one-stop sourcing platform. HKTDC Associate Executive Director Smilely Lam said: "The eyewear industry is entering a new era driven by technological innovation, sustainability and changing lifestyles. AI-powered smart glasses, for example, recorded global shipments of 8.7 million units last year, representing a remarkable year-on-year increase of 322%, underscoring the sector’s strong growth momentum. The Hong Kong International Optical Fair showcases the latest products and technologies, and also inspires the industry to explore emerging market opportunities from fresh perspectives and foster cross-industry collaboration. From smart eyewear and green solutions to innovative fashion-forward designs, we look forward to providing a platform for exchanges and partnerships within and beyond the industry while reinforcing Hong Kong's position as an international business hub and regional sourcing centre." Global brands unveil the next wave of eyewear innovation This year, the fair brings together exhibitors from Hong Kong, the Chinese Mainland, Taiwan, and across Asia, Europe and the United States. Industry associations and enterprises from various regions will also be featured, including the HKOMA, Danyang in Jiangsu Province, Zhejiang, Yingtan in Jiangxi Province, Taiwan, ASEAN, Korea and the Fukui Optical Association, as well as the Visionaries of Style zone dedicated to creative designer brands. Making its debut at the fair, Daegu Health College of Korea will bring a number of local eyewear companies and showcase their innovative products. The spotlighted "Brand Name Gallery" will showcase some 200 renowned brands from around the world, highlighting the latest designs and technological innovations. The 34th Hong Kong International Optical Fair has already attracted pre-registered buyers from leading retailers and distributors worldwide, including Capitol Optical (Singapore), Eyespace Eyewear (UK), Grand Optik (Indonesia), Kaundi GmbH (Austria), Optica Halperin Ltd (Israel), Optical London Drugs (Canada), Parasite Design (France), The Optical Company (Australia) and Vision Plus (US), demonstrating the event’s strong international sourcing appeal. Capturing growth in smart eyewear and the silver economy Rapid advances in artificial intelligence and wearable technology are driving strong growth in the smart eyewear sector. According to IDC, global smart glasses shipments reached 3.566 million units in the first quarter of 2026, up 130.1% year-on-year. Meanwhile, market research firm Omdia reported that global AI eyewear shipments reached 8.7 million units in 2025, representing annual growth of 322%, highlighting the transition of smart eyewear from a niche category to mainstream adoption. This year's fair will feature a wide array of smart eyewear equipped with augmented reality (AR), AI voice assistants, real-time translation, 4K recording and navigation functions. At the same time, growing demand from the silver economy is fuelling interest in vision care and eye-health products. Exhibitors will showcase progressive lenses, smart reading glasses, bone-conduction audio glasses and eye-care devices designed for older consumers, helping to enhance quality of life and visual wellbeing. Sports eyewear, performance eyewear, sustainability-focused products and green manufacturing technologies will also be among the highlights. Industry events spotlight emerging trends and future opportunities A series of forums and seminars will be held during the fair, covering topics such as smart eyewear, performance eyewear, testing and certification, enabling industry professionals to keep abreast of the latest market developments. The 24th Hong Kong International Optometric Symposium, organised by the HKTDC and co-organised by the Hong Kong Optometric Association and The Hong Kong Polytechnic University, will take place on 5 November. Under the theme "Primary Eye Care in Action: Elevating Clinical Scope and Community Impact", experts from Chinese Mainland, Hong Kong, Australia, the United Kingdom, and the United States will share the latest research findings and clinical experiences on a wide range of topics, including paediatric eye care, digital eye strain, driving vision assessment, dry eye management, inherited retinal diseases, and collaborative management between optometrists and ophthalmologists. In addition, the 26th Hong Kong Eyewear Design Competition will hold its award presentation ceremony on the opening day of the fair. This year's theme, "Mix & Match", encourages designers to showcase eyewear as an expression of fashion and personal style through innovative designs. A new Technology Concept Award has been introduced for student participants to encourage the integration of creativity and technology. The fair will continue to adopt the EXHIBITION+ hybrid model which seamlessly integrates online and offline elements to extend business opportunities. Exhibitors and buyers can connect and arrange meetings through the Click2Match online smart business-matching platform until 13 November. During the physical event, buyers can also use the Scan2Match function on the HKTDC Marketplace App to scan exhibitors’ QR codes to bookmark favourite suppliers, access product details and interactive floor plans, and make product enquiries - enabling engagement with exhibitors before and after the fair to continue their sourcing journey. Featured Products Driven by technological innovation, demographic shifts and increasing health awareness, the eyewear industry is entering a new era of growth and transformation. This year's fair spotlights five major trends: smart technology, the silver economy, fashion and design, active lifestyles, and sustainability. Showcasing innovative products and solutions that combine technology, wellness, design and environmental responsibility, the fair offers a glimpse into the future of the industry while opening up fresh business opportunities. Highlights include: Photo Download: https://bit.ly/4iuIl1Q Websites The Hong Kong International Optical Fair: https://www.hktdc.com/event/hkopticalfair/en Event details of the Hong Kong International Optical Fair: https://www.hktdc.com/event/hkopticalfair/en/programme The 24th Hong Kong International Optometric Symposium:  https://www.hktdc.com/event/hkopticalfair/en/the-24th-hong-kong-international-optometric-symposium The HKTDC's Media Room: http://mediaroom.hktdc.com/en Fair Details Date: 4 – 6 November 2026 (Wednesday to Friday) Time: (4 to 5 November) 9:30am – 6:30pm (6 November)      9:30am – 5:00pm Venue: Hong Kong Convention and Exhibition Centre Admission: For trade visitors aged 18 or above only. Onsite Registration Fee: HK$100 per person (free for e-Badge registration and pre-registered buyers) Click2Match – Smart Business Matching Platform: Date: 28 October – 13 November Media enquiries: For enquiries, please contact: HKTDC Communication and Public Affairs Department: Navin Law Tel: (852) 2584 4525 Email: navin.cm.law@hktdc.org Winnie Kan Tel: (852) 2584 4055 Email: winnie.wy.kan@hktdc.org About HKTDC The Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. ———————————————————————————————————————————————————————————— Biotech Ingredients Market Trends, Size & Growth by 2034 2026-10-23 · PR News Releaser · Healthcare, Food & drink, Fashion & luxury, Biotech & pharma, Sustainability, Consumer goods https://www.prnewsreleaser.com/news/477958 The Biotech Ingredients Market is gaining importance as biotechnology, pharmaceutical, food, cosmetics, and personal care companies increasingly adopt biologically derived ingredients to develop innovative and sustainable products. Market Overview The Biotech Ingredients Market size is expected to reach US$ 5.09 ... Read more ———————————————————————————————————————————————————————————— Super Vision Technology: World’s first i-NYS implant for congenital nystagmus in a Chinese boy 2026-10-23 · GlobeNewswire · Healthcare, Education, Medical devices https://www.globenewswire.com/news-release/2026/10/23/3387168/0/en/super-vision-technology-world-s-first-i-nys-implant-for-congenital-nystagmus-in-a-chinese-boy.html BEIJING, Oct. 23, 2026 -- A 9-year-old boy has become the world's first patient to receive a newly approved implant to treat congenital nystagmus, in a procedure performed at Peking University People's Hospital. This marks that the technology has moved from regulatory clearance to clinical practice. ———————————————————————————————————————————————————————————— Treace to Report Third Quarter 2026 Financial Results on November 6, 2026 2026-10-23 · GlobeNewswire · Healthcare, Medical devices https://www.globenewswire.com/news-release/2026/10/23/3387164/0/en/treace-to-report-third-quarter-2026-financial-results-on-november-6-2026.html PONTE VEDRA, Fla., Oct. 23, 2026 -- Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities, today announced that it will release financial results for the third quarter 2026 before the start of trading on Friday, November 6, 2026. Company management will host a conference call to discuss financial results beginning at 8:00 am ET. ———————————————————————————————————————————————————————————— KFSH Marks Four Decades of Cardiac Innovation, from One Cath Lab to an Integrated Heart Center 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951516550/kfsh-marks-four-decades-of-cardiac-innovation-from-one-cath-lab-to-an-integrated-heart-center A surgical team at work in a KFSH operating room in Riyadh RIYADH, SAUDI ARABIA, October 23, 2026 / EINPresswire.com / -- What began with a single cardiac catheterization laboratory four decades ago has evolved into an advanced cardiovascular program at King Faisal Specialist Hospital and Research Centre (KFSH), reflecting the institution’s continued investment in specialized expertise, technology, and increasingly i ———————————————————————————————————————————————————————————— Alebund Pharmaceuticals Announces Poster Presentation by Partner R1 Therapeutics of Global Phase IIb Multi-Regional Clinical Trial Design for AP306 at ASN Kidney Week 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/alebund-pharmaceuticals-announces-poster-presentation-by-partner-r1-therapeutics-of-global-phase-iib-multi-regional-clinical-trial-design-for-ap306-at-asn-kidney-week-2026-302917966.html SHANGHAI, Oct. 23, 2026 -- Alebund Pharmaceuticals (Jiangsu) Limited ("Alebund" or the "Company"; HKEX: 09637), a renal-focused biopharmaceutical company, today announced that its partner, R1 Therapeutics, Inc. ("R1"), presented a trial-in-progress poster outlining the design... ———————————————————————————————————————————————————————————— CHICAGO NURSES FILE FOR ELECTION TO JOIN TEAMSTERS 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/chicago-nurses-file-for-election-to-join-teamsters-302917344.html Endeavor Health Nurses, Teamsters to Hold Press Conference CHICAGO, Oct. 22, 2026 -- Nurses at Endeavor Health will hold a press conference on Friday, Oct. 23, at 10:30 a.m. to announce they have filed for their union election to join Teamsters Local 743. The group of over... ———————————————————————————————————————————————————————————— Marengo Therapeutics Announces Landmark Nature Medicine Publication Establishing First-in-Human Proof of Vβ-Directed T-Cell Biology and Antitumor Activity 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/marengo-therapeutics-announces-landmark-nature-medicine-publication-establishing-first-in-human-proof-of-v-directed-t-cell-biology-and-antitumor-activity-302917323.html First-in-human results from the STARt-001 Phase 1/2 clinical trial demonstrate selective activation of Vβ6/Vβ10 T cells expands functional effector and memory populations, generating single-agent antitumor activity in heavily pretreated, checkpoint-resistant solid tumors Peer-reviewed... ———————————————————————————————————————————————————————————— BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/biolinerx-and-hemispherian-present-preclinical-data-demonstrating-synergy-of-glix1-with-parp-inhibitors-in-hr-proficient-ovarian-cancer-at-esmo-2026-302917934.html GLIX1 demonstrated reproducible synergy across different PARP inhibitors and multiple HR-proficient ovarian cancer cell lines, with high ZIP synergy scores, highlighting GLIX1's potential to expand the efficacy of PARP inhibitors In an HR-proficient ovarian cancer patient-derived... ———————————————————————————————————————————————————————————— Aardvark Therapeutics Reports Exploratory Data from the Terminated HERO and Open-Label Extension Trials 2026-10-23 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/23/3387158/0/en/aardvark-therapeutics-reports-exploratory-data-from-the-terminated-hero-and-open-label-extension-trials.html SAN DIEGO, Oct. 23, 2026 -- Aardvark Therapeutics, Inc. (Aardvark or the Company) (Nasdaq: AARD), a clinical-stage biopharmaceutical company developing novel, small-molecule therapeutics designed to suppress hunger for the treatment of Prader-Willi syndrome (PWS) and metabolic diseases, today reported exploratory efficacy data from its previously terminated Phase 3 Hunger Elimination or Reduction Objective (HERO) trial and open-label extension (OLE) trial. As previously announced, Aardvark unblinded the data accumulated across both the HERO trial and OLE trial to assess the totality of available efficacy and safety data to inform the path forward for ARD-101. ———————————————————————————————————————————————————————————— Foundation Medicine’s FoundationOne®MRD Named a 2026 Top Innovation Winner by The Scientist 2026-10-23 · Business Wire · Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/foundation-medicine-foundationone-mrd-named-110000378.html First-of-its-kind molecular residual disease test combining structural variants and digital PCR recognized for enabling ultra-sensitive molecular disease detection, with high specificity, in the Healthcare and Diagnostics category BOSTON, October 23, 2026--Foundation Medicine, Inc ., a global, patient ———————————————————————————————————————————————————————————— DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network 2026-10-23 · Newswire.com · AI, Healthcare, Retail, Education, Food & drink, Biotech & pharma, Internet & apps https://www.newswire.com/news/datameds-ai-establishes-health-lives-here-community-respiratory-program-for Being marketed to 6,500+ Corexa Health Pharmacy Network of independent pharmacies To be launched first at Corexa Pharmacy in Lakeland, FL retail location in Q4/2026 Program will aim to bring best practices for respiratory season to community pharmacies Nuvaxovid COVID vaccine (protein-based / non-mRNA) prioritized for campaign rollout Improve telehealth availability in the pharmacy through Health Lives Here mobile app Tests to include COVID neutralizing antibodies, antibodies & acute respiratory infections Long COVID-related biomarkers (cardiovascular, incl microclots; immune; metabolic; etc) Immune profiling for other circulating respiratory diseases (influence, RSV, strep, others) Improve access to FDA-approved antivirals Pharmacist education on Tollo Health medical foods and dietary supplements ———————————————————————————————————————————————————————————— Political Consultations between Burkina Faso and The Republic 0f Turkey: Wide-Ranging Consultations to Strengthen Cooperation 2026-10-23 · APO Group · Healthcare, Energy, Education, Food & drink, Logistics, Biotech & pharma, Banking, Government & policy, Entertainment, Mining & metals https://www.africa-newsroom.com/press/political-consultations-between-burkina-faso-and-the-republic-0f-turkey-wideranging-consultations-to-strengthen-cooperation?lang=en During their stay in Ankara for the first session of political consultations between Burkina Faso and the Republic, the Burkinabe delegation led by the Comrade Secretary General of the Ministry of Foreign Affairs, Ambassador Hermann Yirigouin TOE, conducted wide-ranging consultations on October 20 and 21, 2026 with numerous figures within various Turkish state structures. Thus, the delegation visited in turn the Maarif Foundation, the Cooperation and Coordination Agency (TIKA), the Higher Education Information Council, the Ministry of Health, the Council for External Economic Relations (DEIK), and the Ministry of National Education. At the MAARIF Foundation, Ambassador Hermann Yirigouin TOE and his delegation held discussions with Anet BEY, Head of Africa at the MAARIF Foundation, assisted by colleagues. He welcomed the signing of an establishment and management agreement with the foundation, which already owns schools in Ouagadougou and Bobo-Dioulasso, and the awarding of scholarships for Burkinabe students. She also requested the foundation's support for increasing the number of these scholarships and for support in the areas of education and vocational and technical training. MAARIF agreed to all of these requests. The two parties also discussed opportunities for expanding the foundation's activities in Burkina Faso. At the Cooperation and Coordination Agency (TIKA), the Turkish development agency founded in 1992, the Secretary General of the Ministry of Foreign Affairs was received by Dr. Yahya Coskun, Vice President of the institution. TIKA has numerous achievements in Burkina Faso. Among other things, she supported the development of emergency medicine with the SAMU (Emergency Medical Service). The Agency expressed its support for a review of the project for its implementation. For 2027, it committed to providing support to Burkina Faso in the area of ​​vocational and technical training, in line with the country's endogenous development objective. The Burkinabe delegation also expressed the wish that a TIKA office could be opened soon in Ouagadougou. At the Higher Education Council, discussions between Burkinabe and Turkish representatives focused primarily on the issue of renewing the 2024 memorandum of understanding, which sets out the conditions for cooperation in academic and university matters and which has now expired. From the outset, Burkina Faso expressed its commitment to preserving the existing agreements, maintaining this cooperation, and strengthening it. The Turkish Council for Higher Education also supports this renewal and promises to increase the number of scholarships for Master's and Doctoral programs for Burkinabe students. The Turkish side stated that it was open to any proposals for improving our cooperation within the framework of the new agreement. A prioritized list of Burkina Faso's needs will be sent to Turkey immediately. Researchers from Burkina Faso will also be able to access and apply to the project bank of Turkish research centers. At the Ministry of Health, the Burkinabe delegation was received by the Vice-Minister, Professor Nurullah OKUMUS. Ambassador Hermann Yirigouin TOE praised the dynamism of cooperation between our two countries in the field of health, with the success of the first kidney transplant in Burkina Faso as a concrete achievement. The Turkish Deputy Minister expressed his country's commitment to continuing its support for Burkina Faso in organ transplantation. This support will take the form of training and skills development for trainers, keeping pace with evolving knowledge in the field. He also expressed support for facilitating agreements between Turkish public hospitals and the Burkinabe Ministry of Health as part of deepening health cooperation. Professor Nurullah OKUMUS expressed interest in the Kokologho pharmaceutical technopole project, which could offer investment opportunities to Turkish companies. At the Foreign Economic Relations Board (DEIK), which represents 4,000 Turkish companies, discussions led to a proposal to hold a business and investment forum between Burkina Faso and Turkey in Burkina Faso. Turkish exports to Burkina Faso are projected to increase from US$122.24 million in 2023 to US$177.84 million in 2025. This growth testifies to the dynamism of our trade relations, and Ambassador TOE commended the important role played by DEIK in bringing Turkish and Burkinabe businesses closer together. He urged the institution to be more actively involved in resolving disputes between Turkey and Burkinabe to prevent Burkinabe companies from continually suffering losses. DEIK, through Ms. Vahit Oguz Cetin, one of its leaders for West Africa, advocated for the facilitation of banking transactions and an agreement on the elimination of double taxation. The Burkinabe delegation explained that this issue of double taxation is addressed at the confederal level within the Confederation of Sahel States (AES). It encouraged joint ventures and the establishment of sustainable partnerships, particularly in agri-food, cold chain logistics, textiles, solar energy, mining, technical training, etc., to boost national economic development. At the Turkish Ministry of National Education, discussions focused primarily on the issue of improving the quality of education desired and sought by Burkina Faso to support its project for the economic and social transformation of the country within the framework of the Popular Progressive Revolution. The Turkish Department of Education has stated its readiness to examine all options regarding the training of teachers and administrators of the education system, the sharing of experience in vocational and technical training, the sharing of school programs and training curricula, and the implementation of new programs. He also proposed twinning projects between Turkish and Burkinabe schools for a mixing of peoples, the ambition being to leave future generations a legacy of relations based on friendship and cooperation. Between two consultations, Ambassador Hermann Yirigouin TOE and his delegation visited the Atatürk Mausoleum named after Mustafa Kemal ATATÜRK, the Founder of the Republic of Türkiye. A return to the roots of modern Türkiye, rich in lessons about the determination of a man and the nationalism of a people who knew how to take charge of their destiny and establish themselves in the concert of nations. Distributed by APO Group on behalf of Ministère des Affaires étrangères, Burkina Faso. ———————————————————————————————————————————————————————————— Bioprocess Validation Market Analysis, Development, and Competitive Landscape by 2031 2026-10-23 · PR News Releaser · Healthcare, Industrial, Biotech & pharma https://www.prnewsreleaser.com/news/477952 The Bioprocess Validation Market is gaining importance as pharmaceutical, biotechnology, and biopharmaceutical companies increasingly focus on manufacturing consistency, product quality, patient safety, and regulatory compliance. Bioprocess validation involves documented procedures used to demonstrate that manufacturing processes consistently produce products meeting ... Read more ———————————————————————————————————————————————————————————— Cresco Labs Celebrates Sunnyside Prestonsburg Grand Opening, Marking Major Milestone for Kentucky Medical Cannabis 2026-10-23 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/cresco-labs-celebrates-sunnyside-prestonsburg-103000647.html CHICAGO, October 23, 2026--Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF) (FSE: 6CQ) ("Cresco Labs" or the "Company"), today announced the grand opening of Sunnyside Prestonsburg in Kentucky, the Company's 83rd dispensary nationwide. Sunnyside's opening marks a major milestone for Kentucky's emerging medica ———————————————————————————————————————————————————————————— Merck Foundation Chief Executive Officer (CEO), Senator Dr. Rasha Kelej and Kenya First Lady H.E. Mrs. Rachel Ruto, E.G.H. Officially Launched their Joint Programs at the Kenya State House 2026-10-23 · APO Group · Finance, Healthcare, Media, Education, Food & drink, Fashion & luxury, Biotech & pharma, Government & policy, Nonprofits, Internet & apps, Entertainment https://merckfoundation.africa-newsroom.com/press/merck-foundation-chief-executive-officer-ceo-senator-dr-rasha-kelej-and-kenya-first-lady-he-mrs-rachel-ruto-egh-officially-launched-their-joint-programs-at-the-kenya-state-house?lang=en Merck Foundation (www.Merck-Foundation.com), the philanthropic arm of Merck KGaA Germany, launched their Educating Linda Program to support girl education at Kenya State House, in partnership with H.E. Mrs. RACHEL RUTO E.G.H, The First Lady of the Republic of Kenya and Ambassador of “Merck Foundation More Than a Mother”. During the visit, the Merck Foundation Kenya Alumni Summit 2026 was also conducted to highlight the impact of their scholarships program with the aim to build healthcare capacity and transform patient care landscape across Kenya nationwide. The program was attended by The First Lady of the Republic of Kenya H.E. Mrs. RACHEL RUTO E.G.H, Chairman of Merck Foundation Board of Trustees, Prof. Dr. Frank Stangenberg-Haverkamp, and CEO of Merck Foundation and President of “More Than a Mother” Campaign, Dr. Rasha Kelej and Kenya Minister of Health, Hon. Aden Duale. Senator Dr. Rasha Kelej (Ret.), CEO of Merck Foundation and President of “More Than a Mother” Campaign emphasized, “It is a great pleasure to meet my dear sister, H.E. Mrs. RACHEL RUTO E.G.H. First Lady of the Republic of Kenya and to recognize her for her tremendous efforts as the Ambassador of “Merck Foundation More Than a Mother”. I am proud that through our long-term partnership we have provided 328 scholarships for young Kenyan healthcare providers in 44 critical and underserved specialties. I am also happy to share that nearly 50% of these scholarships have been awarded to women healthcare providers, reinforcing our commitment to women empowerment. It was also great meeting Kenya Minister of Health, Hon. Aden Duale and our Alumni, who are the future healthcare experts of Kenya.” “We are looking forward to extending our scholarship program to more healthcare providers in partnership with First Lady of Kenya and in collaboration with Medical Societies and Ministry of Health when possible.” She added. H.E. Mrs. Rachel Ruto E.G.H., The First Lady of the Republic of Kenya expressed, “Through our impactful partnership with Merck Foundation, we are not just implementing programs, we are transforming lives. Together, we are strengthening our healthcare capacity, empowering girls through education, breaking infertility stigma, and addressing other critical social and health challenges across Kenya. We are immensely proud that, through our strong partnership, we have been able to provide 328 scholarships for our healthcare providers, not only in the capital city, but across the country. It represents a powerful investment in the future of our healthcare system, a commitment to building expertise where it is needed most, and a significant step towards ensuring equitable access to quality care for all our people. At the same time, we are equally proud to support the education of 47 high-performing yet underprivileged Kenyan schoolgirls, providing them with annual scholarships till they graduate. By empowering these young girls through education, we are not only transforming individual lives, but also shaping stronger families, communities, and a brighter future for our nation.” Prof. Dr. Frank Stangenberg-Haverkamp Chairman of Merck Foundation Board of Trustees added, “Our aim is to improve the overall health and wellbeing of people by building healthcare capacity in Kenya and across developing countries. We are strongly committed to transforming patient care through our scholarships program.” Hon. Aden Duale, Cabinet Secretary, Ministry of Health, Kenya shared, “We sincerely appreciate the Merck Foundation Scholarships Program through which 328 scholarships have been provided till today for our local healthcare providers in many critical underserved specialties, helping us to build and strengthen our healthcare capacity, across the country.” One of the important specialties that Merck Foundation is focusing on in 2025 and 2026 in Kenya is the scholarship of One Year Diploma in Nutrition, to support the program of Feeding and Food Security of Kenya First Lady. More than 90 scholarships are dedicated to this specialty across the 47 provinces of Kenya. This will create a culture shift in leading a healthy lifestyle for the whole population which will contribute to healthier communities and hence social and economic development of the whole country nationwide. The program was also attended by the Kenyan winners of Merck Foundation Media Awards 2024 and 2025. “It was a pleasure meeting and celebrating our Winners, the health and social champions, who are the voice of the voiceless”, added Dr. Rasha Kelej. Out of the total 328 scholarships, Merck Foundation has provided: 121 scholarships for one-year postgraduate diplomas and two-year master’s degrees in Diabetes, Preventative Cardiovascular Medicine, Cardiology, and Endocrinology. These programs enable doctors to establish specialized diabetes clinics across the country. 10 scholarships for Oncology, which is a critical specialty to strengthen cancer care capacity. 49 scholarships for Fertility, Embryology, and Reproductive Medicine under the “More Than a Mother” campaign, bringing hope and support to couples facing infertility challenges. 148 scholarships for other important specialties such as Internal Medicine, Psychiatry, Neurology, Emergency Medicine, Dermatology, and many more, contributing significantly to strengthening Kenya’s healthcare system. Merck Foundation has overall provided more than 2,600 scholarships for healthcare providers in 44 critical and undeserved specialties from over 52 countries. During the Summit, Merck Foundation alumni shared inspiring testimonies on how these scholarships have transformed their professional journeys and improved patient care in their communities. Merck Foundation, in partnership with the First Lady of Kenya, is also launching children’s storybooks — “More Than a Mother”, “Educating Linda”, “Jackline’s Rescue”, “Not Who You Are”, “Ride into the Future”, “Sugar Free Jude” and “Mark’s Pressure” in English and Swahili to raise awareness about critical social and health issues among young children. Thousands of copies will be distributed across schools in Kenya. These storybooks have also been adapted into animated films to further enhance their impact. Moreover, Merck Foundation has conducted 4 Editions of their Online Health Media Training for Kenyan journalists to empower them to raise awareness about sensitive social and health issues such as breaking infertility stigma, supporting girl education, ending child marriage and GBV, and promoting healthy lifestyle practices. Merck Foundation, together with the First Lady of Kenya, also organizes annual awards for media, musicians, filmmakers, and fashion designers to encourage creative talents to raise awareness about important social issues. Merck Foundation in partnership with the First Lady of the Republic of Kenya has also announced the Call for Application for their important annual Awards for Media, Musicians, Fashion Designers, Filmmakers, students, and new potential talents in these fields. Details of the Awards: 1. Merck Foundation Media Recognition Awards 2026 “Diabetes & Hypertension”: Media representatives are invited to showcase their work through strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 2. Merck Foundation Film Awards 2026 “Diabetes & Hypertension”: All Filmmakers, Students of Film Making Training Institutions, or Young Talents are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to promote a healthy lifestyle raise awareness about prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 3. Merck Foundation Fashion Awards 2026 “Diabetes & Hypertension”: All Students and Designers are invited to create and share designs to deliver strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. 4. Merck Foundation Song Awards 2025 “Diabetes & Hypertension”: All Singers and Musical Artists are invited to create and share a SONG with the aim to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension. Submission deadline: 30th October 2026. Apply here: https://apo-opa.co/4siT2b4 Entries for all the awards are to be submitted via email to: submit@merck-foundation.com Distributed by APO Group on behalf of Merck Foundation. Contact: mehak.handa@external.merckgroup.com Join the conversation on our social media platforms below and let your voice be heard! https://apo-opa.co/4siApEp https://apo-opa.co/4sjDsw3 https://apo-opa.co/48grr0V https://apo-opa.co/4k9Cq3t https://apo-opa.co/4stVHij https://apo-opa.co/4i0xWef www.Merck-Foundation.com https://apo-opa.co/4yD9HHU About Merck Foundation: Merck Foundation works across more than 50 countries with First Ladies, their Foundations, Ministries, and other key stakeholders. Through complementary roles in advocacy, local government coordination, healthcare & media capacity building, girls’ education, and community awareness initiatives. It is this coordinated ecosystem of partnerships—with distinct responsibilities and a shared vision—that enables Merck Foundation to build local capacity, create sustainable impact, and contribute to long-term transformation in healthcare and society. Through their various programs and initiatives, Merck Foundation has provided 2,750+ scholarships for healthcare providers from 52 countries in 44 critical and underserved specialties, awarded 1,570+ scholarships to underprivileged African schoolgirls across 21 countries, trained 4,000+ media professionals, recognized 980 award winners, and reached 9+ million followers across 15 social media channels, driving lasting impact in healthcare, education, and awareness across Africa and Asia. The Merck Foundation is dedicated to improving social and health outcomes for communities in need. While it collaborates with various partners, including governments to achieve its humanitarian goals, the foundation remains strictly neutral in political matters. It does not engage in or support any political activities, elections, or regimes, focusing solely on its mission to elevate humanity and enhance well-being while maintaining a strict non-political stance in all of its endeavors. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website.  Please visit www.Merck-Foundation.com to read more. Follow the social media of Merck Foundation: Facebook (https://apo-opa.co/4siApEp), X (https://apo-opa.co/4sjDsw3),Instagram (https://apo-opa.co/4k9Cq3t), YouTube (https://apo-opa.co/48grr0V), Threads (https://apo-opa.co/4stVHij) and Flickr (https://apo-opa.co/4i0xWef). This content is not intended for US/ Canadian audiences. ———————————————————————————————————————————————————————————— Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 22 10 2026] - (CGWL) 2026-10-23 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/23/3387125/0/en/form-8-3-advanced-medical-solutions-group-plc-22-10-2026-cgwl.html FORM 8.3 ———————————————————————————————————————————————————————————— Angel Yeast Marks 40th Anniversary, Setting Its Sights on Becoming a Global Biotech Powerhouse 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/angel-yeast-marks-40th-anniversary-setting-its-sights-on-becoming-a-global-biotech-powerhouse-302917975.html YICHANG, China, Oct. 23, 2026 -- Angel Yeast (SSE: 600298), one of the world's leading yeast manufacturers, has hosted the 2026 International Synthetic Biology Symposium and the Angel Group High-Quality Development Conference in Yichang, its headquarters city, on October... ———————————————————————————————————————————————————————————— ReGen Medical's Focused Energy Wave Technology Sets New Benchmark in Shockwave Therapy Precision 2026-10-23 · EIN Presswire · Healthcare, Energy, Biotech & pharma https://www.einpresswire.com/article/950744904/regen-medical-s-focused-energy-wave-technology-sets-new-benchmark-in-shockwave-therapy-precision RCT's focused-energy approach delivers therapeutic results in 3-5 sessions, now available at the Center for New Medicine in Irvine, California IRVINE, CA, UNITED STATES, October 23, 2026 / EINPresswire.com / -- ReGen Medical Network Teams with Center for New Medicine to Bring Advanced Regenerative Technology to Leading Integrative Medicine Practice Strategic Alliance Expands Access to Cutting-Edge Cellular and Aesthe ———————————————————————————————————————————————————————————— Recent Release, "PIP's Prayers," from Christian Faith Publishing Author Jeri Le, Explores How Unwavering Faith Transforms Lives Through Constant Prayer 2026-10-23 · PR.com · Healthcare, Education https://www.pr.com/press-release/982018 Jeri Le has completed a new book, "PIP'S Prayers," which follows Pippi Jean Lisle, a young woman abandoned at birth who refuses to let her circumstances define her destiny. Raised as a ward of the court in the deep South, Pippi demonstrates remarkable resilience as she pursues her dream of becoming a healer, graduating at the top of her medical school class and securing acceptance at the prestigious Phoenix [PR.com] ———————————————————————————————————————————————————————————— Massachusetts Health Connector Kicks Off 2027 Open Enrollment 2026-10-23 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/massachusetts-health-connector-kicks-off-100000889.html Residents encouraged to line up their health coverage for 2027 and take advantage of free enrollment assistance Public officials and health leaders to host event Friday urging Commonwealth residents to Get Covered BOSTON, October 23, 2026--Today, the Massachusetts Health Connector kicked off the start ———————————————————————————————————————————————————————————— M42 and Inocras Announce Strategic Collaboration to Advance Earlier Detection of Cancer Recurrence in the UAE Using Whole Genome Powered MRD Technology 2026-10-23 · Business Wire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/m42-inocras-announce-strategic-collaboration-100000963.html Collaboration will bring tumor-informed MRD monitoring to Abu Dhabi, starting with a breast cancer pilot at Cleveland Clinic Abu Dhabi ABU DHABI, United Arab Emirates, October 23, 2026--M42, a global health leader powered by artificial intelligence (AI), technology and genomics, and San Diego-based bio ———————————————————————————————————————————————————————————— SmileCrafters Dental Celebrates 10 Years of Trusted Dental Care Across Ontario 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951743581/smilecrafters-dental-celebrates-10-years-of-trusted-dental-care-across-ontario Dr. Rami El Sebai- SmileCrafters SmileCrafters Team SmileCrafters Dental marks 10 years of patient-centred care in Ontario, growing clinics in Ancaster, Hamilton, Brantford, and Toronto under Dr. Rami El Sebai. TORONTO, ONTARIO, CANADA, October 23, 2026 / EINPresswire.com / -- SmileCrafters Dental is celebrating its 10th anniversary, marking a decade of comprehensive, judgment-free dental care for individuals and fam ———————————————————————————————————————————————————————————— In Kinshasa, Congolese National Police (PNC), MONUSCO Police (UNPOL) and U-Report raise youth awareness on security and health 2026-10-23 · APO Group · Finance, SaaS, Healthcare, Education, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/in-kinshasa-congolese-national-police-pnc-monusco-police-unpol-and-ureport-raise-youth-awareness-on-security-and-health?lang=en The MONUSCO Police (UNPOL) supported a forum held in Kinshasa on Wednesday, 21 October, organized by the Congolese National Police (PNC) in collaboration with the U-Report platform. The forum focused on youth, peace, health and community safety. Participants included young people, health-sector stakeholders, civil society representatives and residents of Mont-Ngafula, where the local U-Report section initiated the event. The initiative aims to draw public attention to drug use and violence among young people. According to the mayor of Mont-Ngafula, the municipality is particularly affected by the use of psychoactive substances among young people, a practice that often leads to violence. “Our young people face many challenges, particularly drug use,” said Séverin Lumbu. Andréa Amisi, who coordinates U-Report in the municipality, shares the mayor’s concerns. His youth and involvement in U-Report bring him into contact with many young people. He regrets that, in the absence of opportunities and proper guidance, many young people turn to hard liquor and psychoactive substances. He also points out that most of those selling these products are young people themselves. This trade provides them with a source of income while endangering the health of other young people and undermining community safety. “This reality calls on all of us to act,” said the mayor of Mont-Ngafula. “It requires collective awareness, but above all, concrete and lasting action.” This is precisely the purpose of the forum: to bring together young people, health professionals, local authorities and the police to discuss effective ways of steering young people away from drugs and preventing urban violence. “We need responsible young people who are engaged and aware of their rights, but also of their duties towards their community and their nation,” Séverin Lumbu stressed. To combat drug use, he called for substantial efforts in education and prevention. A shared commitment to fighting drug use The police share this view. The Deputy Executive Secretary of the Committee for Monitoring Police Reform in the Democratic Republic of the Congo, which co-organized the forum, also highlighted the harmful effects of hard liquor and drug use among young people. “Drug addiction is a real scourge that destroys human lives in our society,” said Deputy Divisional Commissioner Jean-Rémy Nkanga, calling for coordinated action by all stakeholders in the sector. His appeal echoed UNPOL’s advocacy. Edmond Tapsoba, who spoke on behalf of the MONUSCO Police at the forum, reminded participants that “security is a shared responsibility,” emphasizing the important role young people play in ensuring security in a vast municipality such as Mont-Ngafula. There is indeed a link between the use of psychoactive substances and security. Dr. Patrice Milambo, coordinator of the National Programme for Combating Drug Addiction and Toxic Substances, explained that, according to African Union figures, 6% of people who commit acts of violence do so under the influence of these substances. He described the connection as “clear.” For Amisi of U-Report, the same pattern is evident. The more idle young people are, the more likely they are to turn to drugs, increasing the risk of their involvement in criminal activities. He recalled a campaign he conducted in 2024 after noticing an increase in burglaries in his municipality on evenings when Africa Cup of Nations matches were being played. The campaign revealed that many young people involved in the burglaries were using psychoactive substances. Like all the other forum participants, Andréa Amisi is calling for greater awareness-raising and educational efforts among young people to address drug addiction. U-Report is a community-based youth engagement platform that enables young people to express their views on issues that affect them. In Mont-Ngafula, the platform reports having approximately 200 active young members, with just over 5,000 others following and participating in its activities across the municipality. Distributed by APO Group on behalf of Mission de l'Organisation des Nations unies en République démocratique du Congo (MONUSCO). ———————————————————————————————————————————————————————————— Stephanie Mills to Headline 2026 Pennsylvania Maternal Health Summit, Bringing National Attention to Maternal and Infant Health 2026-10-23 · GlobeNewswire · Healthcare, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387113/0/en/stephanie-mills-to-headline-2026-pennsylvania-maternal-health-summit-bringing-national-attention-to-maternal-and-infant-health.html The November 9 event in Pittsburgh will unite government leaders, healthcare experts and community advocates to advance maternal health and family wellness. The November 9 event in Pittsburgh will unite government leaders, healthcare experts and community advocates to advance maternal health and family wellness. ———————————————————————————————————————————————————————————— Preventative healthcare venture Ohas launches in London with £1.5million clinic in Westbourne Grove opening January 2027 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/preventative-healthcare-venture-ohas-launches-in-london-with-1-5million-clinic-in-westbourne-grove-opening-january-2027--302917946.html Founded by health tech entrepreneur Richard Chambers with Dr Luke Pratsides Ohas will combine health screening, medical assessment, treatment and ongoing monitoring under one roof The Ohas Health Scan can identify potential health risks in need of early intervention Ohas seeks to simplify... ———————————————————————————————————————————————————————————— Nanotechnology In Medical Devices Market: 6.17% CAGR Signals Steady Growth Through 2033 2026-10-23 · PR News Releaser · Healthcare, Medical devices https://www.prnewsreleaser.com/news/477703 The Nanotechnology In Medical Devices Market size is expected to reach US$ 6.57 Billion by 2033 from US$ 4.07 Billion in 2025. The market is estimated to record a CAGR of 6.17% from 2026 to 2033. Market growth is best ... Read more ———————————————————————————————————————————————————————————— E Health Market: Growth Drivers Behind the US$1,185.1 Billion Forecast 2026-10-23 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/477691 The E Health Market size is expected to reach US$ 1185.1 Billion by 2033 from US$ 291.7 Billion in 2025. The market is estimated to record a CAGR of 19.15% from 2026 to 2033. Market growth is best read through ... Read more ———————————————————————————————————————————————————————————— American Heart Association Encourages Nationwide Participation in Nation of Lifesavers CPR Initiative 2026-10-23 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/950991356/american-heart-association-encourages-nationwide-participation-in-nation-of-lifesavers-cpr-initiative Hands-Only CPR Doubles or Triples Chance of Survival from Sudden Cardiac Arrest DALLAS, TX, UNITED STATES, October 23, 2026 / EINPresswire.com / -- The American Heart Association is encouraging people nationwide to join the Nation of Lifesavers by learning CPR, challenging the misconception that only individuals with medical training should perform the lifesaving technique. According to the American Heart Association ———————————————————————————————————————————————————————————— Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA 2026-10-23 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma, Legal https://pressreach.com/phathom-pharmaceuticals-provides-update-on-litigation-filed-by-bdr-pharmaceuticals-against-fda FLORHAM PARK, N.J., Oct. 23, 2026 — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) diseases, announced today that BDR Pharmaceuticals International Pvt. Ltd. (BDR) has filed suit against the U.S. Food and Drug Administration (FDA) and related Federal Defendants in the United … Continue reading "Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA" ———————————————————————————————————————————————————————————— Brisbane Dentist Outlines When a Referral to an Orthodontist May Be Needed 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951722889/brisbane-dentist-outlines-when-a-referral-to-an-orthodontist-may-be-needed Logo - Aspley Elite Dental Orthodontic Treatment at Aspley Elite Dental Aligner Treatment Orthodontic care is about understanding how the teeth and jaws work together. Every patient has different needs, and a proper assessment helps determine which treatment options may be appropriate.” — Dr Dev BRISBANE, QLD, AUSTRALIA, October 23, 2026 / EINPresswire.com / -- Aspley Elite Dental Care , a dental practice in Aspley, ———————————————————————————————————————————————————————————— ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026 2026-10-23 · PressReach · Healthcare, Biotech & pharma, Government & policy https://pressreach.com/oric-pharmaceuticals-presents-preclinical-and-translational-data-to-support-the-potential-of-rinzimetostat-to-enhance-sensitivity-to-androgen-receptor-inhibition-in-prostate-cancer-at-esmo-congr Preclinical data highlight potential advantages of targeting PRC2 via EED over EZH2, including the emergence of resistance mutations to EZH2 inhibitors like mevrometostat and against which the EED inhibitor rinzimetostat maintained effectiveness Preclinical results, supported by translational data in mCRPC patient samples, show rinzimetostat reinforces a luminal, AR-dependent state, restricts lineage plasticity and enhances sensitivity … Continue reading "ORIC® Pharmaceuticals Presents Preclinical and Translational Data to Support the Potential of Rinzimetostat to Enhance Sensitivity to Androgen Receptor Inhibition in Prostate Cancer at ESMO Congress 2026" ———————————————————————————————————————————————————————————— Texas Counseling Center Outlines Mental Health Service Options for Communities Across Texas 2026-10-23 · FinanceWire · Healthcare https://financewire.com/2026/10/23/texas-counseling-center-outlines-mental-health-service-options-for-communities-across-texas/ HOUSTON, Texas, USA, 23rd October 2026, FinanceWire … Read More The post Texas Counseling Center Outlines Mental Health Service Options for Communities Across Texas appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Robotimize Presents FES Cycling Solution in Hands-On Session with Hospital Rehabilitation Team 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950008516/robotimize-presents-fes-cycling-solution-in-hands-on-session-with-hospital-rehabilitation-team Robotimize team member guides the rehabilitation team on RevitaVivante™ ProMax. Hands-on trial of the RevitaVivante™ ProMax upper limb setup by the hospital rehabilitation team. RevitaVivante™ ProMax, an upper and lower limb FES cycling device. The RevitaVivante™ FES Cycling Series, including the ProMax. Robotimize: Tech For Care. Advancing intelligent neurorehabilitation robotics and digital neurotechnologies across ———————————————————————————————————————————————————————————— Magnetic Particle Imaging Market to Reach US$ 612 Million by 2034, Growing at 20.11% CAGR 2026-10-23 · PR News Releaser · Healthcare, Medical devices https://www.prnewsreleaser.com/news/477280 The global Magnetic Particle Imaging market is expected to experience significant expansion through 2034, reflecting its growing potential in medical imaging, diagnostic research, and emerging healthcare technologies. The Magnetic Particle Imaging market size is projected to increase from US$ 117.60 ... Read more ———————————————————————————————————————————————————————————— How Uganda is bringing malaria care closer to every family 2026-10-23 · APO Group · Healthcare, Travel, Government & policy, Medical devices https://who-africa.africa-newsroom.com/press/how-uganda-is-bringing-malaria-care-closer-to-every-family?lang=en Whenever fever strikes nine-year-old Joshua Ekimwere in his rural Ogaramio village, getting help has not always been easy. For his grandmother, Akurut Dinah Loy, a suspected malaria infection often meant difficult choices. Either finding money for transport and medicine, missing a day's work, or waiting anxiously while his condition worsens. For years, this was the reality for many families in rural Uganda. Community-based malaria services helped protect children under five, but older children and adults often had to travel long distances to a health facility just to find out whether they had malaria and begin treatment. Today, that is changing. Through a Ministry of Health-led initiative, Village Health Teams (VHTs) and Community Health Extension Workers (CHEWs) are being trained and equipped to test people of all ages using rapid diagnostic tests and provide free lifesaving treatment within their communities. For Akurut Dinah Loy and her family, the difference has been significant. “It is frightening to watch a child become sick and not know how quickly you can get help. Having services nearby has changed a lot for our family,” she said. “Now, when Joshua gets sick, I no longer think first about the journey to the health facility. I think about getting him help quickly.” Improving access to timely care Uganda has made remarkable progress in the fight against malaria. Since 2000, malaria-related deaths have fallen by more than 50%, reflecting sustained investments in prevention, diagnosis and treatment. Yet malaria remains one of the country's most significant public health challenges. In 2025, an estimated 13.2 million malaria cases were reported, meaning roughly one in every 20 malaria cases worldwide occurred in Uganda. WHO estimates that between 16,000 and 20,000 people died from malaria during the same year. Many challenges affecting the fight against malaria include people reaching health services too late, waiting more than 24 hours after symptoms begin before seeking care and relying on poor-quality medicines or fail to complete treatment. These delays increase the risk of severe illness and place additional pressure on families and the health system. The expansion of community-based malaria services is helping address these challenges by making diagnosis and treatment available where people live, particularly in areas where access to health facilities remains difficult. For Dr Cathrine Maiteki Sebuguzi, Deputy Programme Manager at the National Malaria Elimination Department, timely access to care is critical to sustaining Uganda's progress. “Reaching communities where transmission occurs is the foundation of our efforts towards malaria elimination. Through this initiative, we are ensuring timely diagnosis, prompt treatment and protection of those most at risk,” said Dr Cathrine. Strengthening primary health care and advancing equity The initiative does more than improve access to malaria services. It strengthens primary health care by expanding the role of community health workers and ensuring that essential services reach people who might otherwise be left behind. Today, approximately 85,000 VHT members provide community-based health services across Uganda. Extending malaria diagnosis and treatment to all age groups helps address a larger reservoir of infection while improving equity in access to essential health services. The expansion of VHTs and CHEWs is part of Uganda's 24-2 Hours Initiative, which aims to ensure malaria diagnosis and treatment within 24 hours of symptom onset and lifesaving pre-referral treatment for severe malaria within two hours. By reaching rural, peri-urban and underserved communities, the initiative is helping accelerate progress towards Universal Health Coverage. “When health services are available closer to home, people can get help earlier. That is especially important for malaria, where timely diagnosis and treatment can save lives,” said Dr Christine Chiedza Musanhu, Team Lead for Disease Prevention and Control, WHO Uganda. “Community-based care also helps us reach people who might otherwise be left behind.” The programme is supported through a broad partnership involving the Global Fund, the United States Government and UNICEF. For Akurut Dinah Loy, the success of this initiative means knowing that when Joshua develops a fever, help is no longer a distant journey away. “As a grandmother, nothing is more important than seeing my grandchildren healthy. Knowing they can be tested and treated quickly gives our family comfort and hope,” added Loy. For families across Uganda, timely access to malaria services means fewer delays, less uncertainty and a better chance of receiving treatment when it matters most. And for Uganda, it is another step towards a future where no family's health is determined by how far they live from care. Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— CCHR Urges the FDA to Follow UK Warnings on Antidepressant Suicide Risk and Persistent Sexual Dysfunction 2026-10-23 · 24-7 Press Release · Healthcare, Biotech & pharma https://www.24-7pressrelease.com/press-release/539872/cchr-urges-the-fda-to-follow-uk-warnings-on-antidepressant-suicide-risk-and-persistent-sexual-dysfunction The UK's drug regulatory agency has expanded suicide-risk information to all ages and formally recognizes antidepressant-induced sexual dysfunction ———————————————————————————————————————————————————————————— Victor Care Network Puts People at the Heart of Mental Health on All Access hosted by Andy Garcia 2026-10-23 · PR Newswire · Healthcare, Nonprofits https://www.prnewswire.com/news-releases/victor-care-network-puts-people-at-the-heart-of-mental-health-on-all-access-hosted-by-andy-garcia-302917098.html The California nonprofit's upcoming feature explores the relationships that help people take the next step when life feels difficult. LOS ANGELES, Oct. 23, 2026 -- A parent may know their child is struggling without knowing why or where to turn. In an upcoming feature of "All... ———————————————————————————————————————————————————————————— Laur Zimmardi Honored on Times Square Billboards by P.O.W.E.R. (Professional Organization of Women of Excellence Recognized) 2026-10-23 · PR.com · Healthcare, Education https://www.pr.com/press-release/982584 Laur Zimmardi of Tucson, Arizona, was showcased on the iconic Times Square billboards in New York City on September 23, 2026. P.O.W.E.R. (Professional Organization of Women of Excellence Recognized) recognized Zimmardi for her contributions and achievements in phlebotomy, education, entrepreneurship, and patient safety. She was featured on “The Cube,” six giant screens located on 47th Street between 7th Avenue [PR.com] ———————————————————————————————————————————————————————————— KFSH Cuts the Wait for an Echocardiography Appointment from 126 Days to One 2026-10-23 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/23/3387073/0/en/kfsh-cuts-the-wait-for-an-echocardiography-appointment-from-126-days-to-one.html RIYADH, Saudi Arabia, Oct. 23, 2026 -- King Faisal Specialist Hospital and Research Centre (KFSH) has reduced the wait for the first available echocardiography appointment at its Heart Center of Excellence from 126 days in June 2023 to one day in 2026, removing one of the main delays between a cardiac referral and a treatment decision. ———————————————————————————————————————————————————————————— Institute for Science, Entrepreneurship and Investments Announces Precision Longevity™ Framework 2026-10-23 · 24-7 Press Release · Healthcare, Sustainability https://www.24-7pressrelease.com/press-release/539867/institute-for-science-entrepreneurship-and-investments-announces-precision-longevity-framework An integrated strategic architecture designed to advance the convergence of precision medicine, longevity science, regenerative health care, and planetary sustainability. ———————————————————————————————————————————————————————————— BlackFox Media Spotlights Clinical Apps 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951077914/blackfox-media-spotlights-clinical-apps BlackFox Media's 15 offline medical study and clinical reference apps Two offline clinical reference tools lead a lineup of 14 medical study and reference apps with no ads, accounts or tracking. CORPUS CHRISTI, TX, UNITED STATES, October 23, 2026 / EINPresswire.com / -- BlackFox Media LLC is highlighting two clinical reference apps, Infusion Ready and Patient Advocate Pro, from its lineup of 14 offline medical apps f ———————————————————————————————————————————————————————————— Democratic Republic of the (DR) Congo: Ebola responders under pressure as outbreak expands 2026-10-23 · APO Group · Healthcare, Travel, Biotech & pharma, Government & policy https://www.africa-newsroom.com/press/democratic-republic-of-the-dr-congo-ebola-responders-under-pressure-as-outbreak-expands?lang=en Authorities in Abuja confirmed their first case of infection in an individual arriving from Uganda, which borders the worst-hit provinces in DRC. “The source of exposure is still not known and the travel history of the patient is being pieced together now in terms of her movement from Uganda up to Nigeria,” said Dr Patrick Otim, from the UN World Health Organization (WHO)’s Emergency Response programme, in an online update.  “This is rapidly evolving. As we get more information, we’ll try to determine where she was exposed. And then it’s at that point where we can say whether there is any transmission happening.” Nigeria is the fifth country this year after DRC, France, Uganda and Kenya to confirm the presence of Ebola disease caused by Bundibugyo virus.  The original DRC outbreak was declared in mid-May where it has led to more than 4,600 deaths and a total of 9,552 confirmed infections. Around six in 10 of these deaths have occurred outside health centres, indicating the continuing difficulty of halting community transmission.  The latest DRC province to confirm infections is Nord Ubangi, which borders Central African Republic, where ongoing armed violence continues to uproot thousands of people, increasing the difficulty of halting transmission. Nairobi controls The Kenyan authorities have reported a total of nine cases of infection including one death earlier this month, of a Kenyan national who had been working in DRC before flying back to Nairobi via Entebbe, Uganda. Uganda previously recorded two deaths and 20 confirmed cases of infection, before officially declaring the Ebola threat over at the end of August. “Immediately after [the death of the Kenyan patient], we commenced on contact tracing,” said Dr Patrick Amoth, Director General of Kenya’s Ministry of Health, adding that 135 contacts with the deceased patient have been traced “and we have been able to account for them, 100 per cent”. According to the Nigerian authorities, the patient developed symptoms on 7 October and sought care at a clinic before being hospitalised 48 hours later.  Genetic sequencing of the infection is underway to confirm that it is the same Ebola Bundibugyo disease circulating inside DRC. More than 40 close contacts have been identified to date, WHO has said.  “All the Infection Prevention and Control measures have been put in place to try to ensure that the risk of amplification of transmission within the health facilities is limited,” said WHO’s Dr Otim.  “The message is being passed to all the private facilities within [Abuja] and also all the other health facilities within the country to step up.” Vaccine research ongoing Inside DRC, in addition to the essential work of contact tracing, vaccination research is ongoing using Ervebo vaccine, which was originally designed for and is effective against Ebola disease caused by Zaire virus, in a bid to find out if it provides protection against Ebola Bundibugyo. “We still do not have preliminary data yet as to whether there is…sufficient cross-protection between the Ervebo vaccine – which is for the Zaire species – and the Bundibugyo species. As soon as we get it, we'll be able to share that information,” Dr Otim told journalists. Remote communities hardest-hit Responding to questions about the Ebola response inside DRC, the UN health agency highlighted ongoing transmission of infection and reports last week of 15 deaths per day in the rural commune of Mangina in Beni territory, North Kivu province.  After negotiating access, an emergency response team from WHO arrived there two weeks ago and started working with impacted communities. “There was a lot of community preoccupation and community resistance in the beginning to receive help, it’s a very highly insecure area,” said Dr Anne Ancia, WHO Country Representative in DRC.  “Ebola does not wait. It follows movement, exploits gaps and tests the strength of our health systems,” said Dr Mohamed Janabi, Regional Director for WHO Africa, underscoring that the virus is “no longer confined to one place, it is a regional concern”. He added: “We must reach people earlier, bring safe care closer and strengthen trust before fear becomes a barrier to survival. We also know that success is possible where surveillance is strong, where contacts are found and followed.” Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— Democratic Republic of Congo - Ebola response: Strengthening treatment and preserving essential care 2026-10-23 · APO Group · Finance, Healthcare, Biotech & pharma, Government & policy https://who-africa.africa-newsroom.com/press/democratic-republic-of-congo-ebola-response-strengthening-treatment-and-preserving-essential-care?lang=en “We were separated only by ropes.” When Dr Prince Afandia Alafu, 33, returns to the place where he was treated for Ebola, memories of his hospitalization resurface. In Isiro, in Haut Uélé province in northeastern of the Democratic Republic of the Congo, this general practitioner discovers, just weeks after his recovery, an expanded and better equipped treatment centre. Progress has been made to improve care for Ebola patients while allowing the hospital to gradually resume its usual activities. A few days before his admission, Dr Prince experienced persistent fever and headaches, which he initially attributed to malaria or typhoid. A test confirmed his infection with the Bundibugyo virus, responsible for the current Ebola outbreak. Accustomed to treating others, he suddenly became a patient himself. After several days of care, he managed to overcome the disease. On August 24, when he was admitted to the Isiro Ebola Treatment Centre (ETC), the facilities were still rudimentary. Spaces were cramped and care conditions difficult. Today, the centre has 50 beds and appropriate equipment. “There has really been a big improvement. Now there is electricity and water. The rooms are maintained regularly, and the conditions of care have changed,” he notes. Behind these changes lie the story of a hospital deeply shaken by the epidemic. Before Ebola arrived, the Isiro General Reference Hospital (GRH) had 130 beds and provided internal medicine, surgery, pediatrics, and obstetrics gynecology care, with an occupancy rate above 90%. When the first cases appeared in July 2026, the facility had to reorganize its services. “We had to move the pediatric ward. The pediatric pavilion became the first nucleus of the ETC within the hospital. With the increase in cases, we had to mobilize a second pavilion,” explains Dr David Kamalu, director of the GRH. The presence of Ebola patients in hospital buildings and fear of contamination gradually drove other patients away. According to Dr Kamalu, bed occupancy dropped to 30% in August. For medical teams, the challenge was immense: treating Ebola patients without interrupting care for pregnant women, children, and patients with other illnesses. As of 19 October 2026, 7 of the 13 health zones in Haut Uélé were affected by the Ebola outbreak. The province had recorded 421 confirmed cases, including 180 deaths. Isiro health zone was among the hardest hit. Under the leadership of the Ministry of Health, with support from WHO and partners, the ETC — initially with 40 beds — was expanded to 50 beds in collaboration with Médecins Sans Frontières (MSF). “This extension allows us to strengthen reception capacity and improve care for Ebola patients. It helps secure care circuits and reduce transmission risks,” emphasizes Dr Catherine Smallwood, WHO incident manager. “By having an adapted treatment centre, we also help the hospital gradually resume its usual activities.” The effects are already visible. Patients who had deserted the hospital out of fear are gradually returning. Today, we have about 55 patients hospitalized. Now that the centre is secure and circuits are better organized, patients are starting to come back for their usual care,” notes Dr Kamalu. Improved treatment capacity is accompanied by other interventions to preserve health services. WHO has delivered more than a ton of medicines, supplies, and medical equipment to the GRH, including oxygen therapy materials, personal protective equipment, beds, and mattresses, to support continuity of essential care. In Haut Uélé, health authorities also launched vaccination of frontline personnel for research purposes with the ERVEBO vaccine. Nationally, more than 9,000 agents have been vaccinated as part of this study. The effectiveness of this vaccine against the Bundibugyo Ebola virus, responsible for the current outbreak, is still under investigation. For Dr Steve Ahuka, incident manager of the Presidential Task Force dedicated to the Ebola response, complementarity of interventions is essential. “When we prevent through vaccination, when we treat the disease, when we raise awareness through survivors — these packages of activities are what make the disease recede,” he explains. For Dr Prince, the improvements are deeply meaningful. Having faced the challenges of the epidemic’s early weeks, he now sees how better care and stronger prevention are giving patients hope and helping rebuild community trust. His experience shows that Ebola does not have to be fatal: timely, appropriate care can save lives. “With the progress made in the response and the improvement of care conditions, I have hope that more patients will overcome Ebola, reunite with their families, and resume their normal lives.” Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Kenya Steps Up Global Drive to Feed Children in Schools 2026-10-23 · APO Group · Healthcare, Education, Food & drink, Government & policy https://www.africa-newsroom.com/press/kenya-steps-up-global-drive-to-feed-children-in-schools?lang=en Kenya has been named the fourth Co-Chair of the School Meals Coalition, joining Brazil, Finland and France in providing global leadership to an initiative aimed at ensuring children have access to healthy and nutritious meals at school. The announcement was made during the Third Ministerial Session of the Global School Meals Coalition held at the World Food Programme (WFP) headquarters in Rome on Wednesday, October 14th. Kenya was represented at the meeting by Cabinet Secretary for Education Julius Migos Ogamba, who said the country’s new leadership role builds on its previous contribution to the Coalition’s agenda. “Kenya is deeply honoured to officially join Brazil, Finland and France as the fourth Co-Chair of the School Meals Coalition,” said Mr. Ogamba, describing the appointment as a responsibility the country takes with a strong sense of commitment. Kenya previously hosted the Second Ministerial Meeting of the Coalition’s Task Force in Nairobi in 2024, where member states reviewed progress and identified priorities for accelerating collective action on school meals. Among the priorities identified in Nairobi were sustaining political commitment, expanding access to predictable and sustainable financing, improving the quality and reach of national school meals programmes, strengthening evidence and measurement, and increasing advocacy at all levels. According to World Food Programme, 466 million children currently receive school meals globally and while this is an enormous achievement, there remains numerous school age children that have not been reached. Coverage has grown by about 80 million children since 2020, showing that governments are increasingly treating school meals as a national development priority, as documented by School Meals Coalition. The Coalition has continued to gain momentum, with more governments investing in national school meals programmes and increasing recognition of school feeding as a strategic public investment. Mr. Ogamba highlighted the wider benefits of school meals, noting that their impact extends beyond education to social protection, health and nutrition. He cited studies showing that every dollar invested in feeding a child can generate up to nine dollars in social and economic returns. However, he cautioned that significant challenges remain, with millions of children still unreached and countries facing financing and implementation constraints in delivering nutritious school meals. Kenya is exploring innovative approaches to financing its own School Meals Programme. These include a clean cooking programme aimed at exploring carbon financing opportunities, as well as a proposed debt-for-food conversion being developed with the WFP. The initiative could redirect savings from debt servicing towards long term investment in food security and resilience. As Co-Chair, Kenya says it will work with Brazil, Finland, France, Coalition members and partners to promote national ownership and sustainable financing, strengthen cooperation and ensure that African experiences and leadership remain central to the global school meals agenda. The Coalition’s overarching ambition is to see every child access a healthy and nutritious meal at school while enabling countries to develop strong, nationally owned school meals programmes. Distributed by APO Group on behalf of Ministry of Education, Kenya. ———————————————————————————————————————————————————————————— Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01 2026-10-23 · PressReach · Healthcare, Biotech & pharma, Government & policy https://pressreach.com/evaxion-announces-89-vaccine-target-precision-and-sustained-t-cell-and-clinical-responses-at-three-year-follow-up-in-phase-2-trial-with-personalized-cancer-vaccine-evx-01 EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses  Three-year data from the EVX-01 phase 2 trial in patients with advanced melanoma to be presented at the ESMO 2026 Congress supplementing very convincing two-year data from the trial The data will be … Continue reading "Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01" ———————————————————————————————————————————————————————————— Fermented Dairy Products Market: Trends Driving Growth in Functional Nutrition 2026-10-23 · PR News Releaser · Healthcare, Retail, Food & drink https://www.prnewsreleaser.com/news/477102 The fermented dairy products market is expected to witness significant growth through 2034, driven by rising consumer interest in health-focused food products, increasing awareness of digestive wellness, and growing demand for functional nutrition. Fermented dairy products, including yogurt, kefir, cultured ... Read more ———————————————————————————————————————————————————————————— From Small Clinical Trials to a Single Patient, Genialis Demonstrates the Power of Biology-First AI in Cancer Research 2026-10-23 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/small-clinical-trials-single-patient-060000346.html New ESMO data from three trial-sized cohorts, and a 25-month analysis of GitLab co-founder Sid Sijbrandij's osteosarcoma highlight the potential to extract meaningful insights from limited patient data MADRID, October 23, 2026--Genialis, the therapeutic intelligence company, will present data at the Eu ———————————————————————————————————————————————————————————— Rakuten Medical Presents Long-Term Follow-up Results of ASP-1929 Photoimmunotherapy in Combination with Pembrolizumab for R/M HNSCC at ESMO 2026 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/rakuten-medical-presents-long-term-follow-up-results-of-asp-1929-photoimmunotherapy-in-combination-with-pembrolizumab-for-rm-hnscc-at-esmo-2026-302917714.html Median DOR of 44.3 months supports durability of response 4-year overall survival rate of 35.3% and median OS of 28.2 months suggest meaningful long-term survival Long-term survival of 42+ - 60+ months observed among complete responders SAN DIEGO, Oct. 23, 2026 -- Rakuten... ———————————————————————————————————————————————————————————— STEMart Introduces Gel Imaging System Solutions to Support Molecular Biology and Laboratory Research 2026-10-23 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/951699412/stemart-introduces-gel-imaging-system-solutions-to-support-molecular-biology-and-laboratory-research STEMart launches a range of Gel Imaging System solutions to support molecular biology research, electrophoresis analysis, and laboratory documentation. NEW YORK, NY, UNITED STATES, October 23, 2026 / EINPresswire.com / -- STEMart , a US-based provider of comprehensive services and technical solutions for all phases of medical device development, has launched a range of Gel Imaging System solutions to support molecula ———————————————————————————————————————————————————————————— AI and Oncologists Team Up to Prevent Cancer Misdiagnosis 2026-10-23 · ACCESS Newswire · AI, SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/ai-oncologists-team-prevent-cancer-053000565.html DOVER, DE / October 23, 2026 / Healz (healz.ai) is a platform for getting a cancer second opinion online . It brings strong AI tools and experienced oncologists into one chat. People can get answers without waiting as long as they would with usual steps. The service is meant to help reduce health mistakes. It focuses on where those errors matter most, in cancer care. When a Single Diagnosis Isn't En ———————————————————————————————————————————————————————————— Santhera’s Licensing Partner, Nxera Pharma, Submits Marketing Authorization Application for AGAMREE® (Vamorolone) in South Korea 2026-10-23 · GlobeNewswire · Healthcare, Food & drink, Biotech & pharma, Government & policy https://www.globenewswire.com/news-release/2026/10/23/3387042/0/en/santhera-s-licensing-partner-nxera-pharma-submits-marketing-authorization-application-for-agamree-vamorolone-in-south-korea.html Pratteln, Switzerland, October 23, 2026 – Santhera Pharmaceuticals (SIX: SANN) today notes that its licensing partner Nxera Pharma Co., Ltd. (“Nxera”) has submitted a Marketing Authorization Application (MAA) to South Korea’s Ministry of Food and Drug Safety (MFDS) for AGAMREE (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD). ———————————————————————————————————————————————————————————— Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines 2026-10-23 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/galderma-relfydess-relabotulinumtoxina-receives-approval-050000597.html The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the temporary improvement of moderate-to-severe glabellar lines (frown lines) in adults1,2 The approval is based on phase III results from a local ———————————————————————————————————————————————————————————— Minding Dementia Addresses Alzheimer's Care Challenges 2026-10-23 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/minding-dementia-addresses-alzheimers-care-challenges/89207085 Minding Dementia, LLC shares expert insight into why Alzheimer's disease presents unique challenges for families and care partners. -- Minding Dementia, LLC has released new guidance aimed at helping families understand why Alzheimer's disease is often more difficult to manage than many other medical conditions. Drawing on more than three decades of experience, the organization continues its mission to support care p ———————————————————————————————————————————————————————————— Lotus Endometriosis Institute Expands Robotic Excision Surgery As Demand Grows 2026-10-23 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/lotus-endometriosis-institute-expands-robotic-excision-surgery-as-demand-grows/89207088 Lotus Endometriosis Institute announces expanded capacity for robotic excision surgery to remove diseased lesions at the root, reduce pain, and ease organ irritation. With offices in Arroyo Grande and Santa Monica, the institute serves patients both from California and out of state. -- Endometriosis diagnoses are on the rise, with a 32% increase between 2017 and 2024, according to Becker's Hospital Review. More and m ———————————————————————————————————————————————————————————— ImmunoForge to Showcase Proprietary Platform Technologies and Next-Generation Oncology & Phase 2 Clinical Pipelines at BIO-Europe 2026 2026-10-23 · PR Newswire · SaaS, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/immunoforge-to-showcase-proprietary-platform-technologies-and-next-generation-oncology--phase-2-clinical-pipelines-at-bio-europe-2026-302917622.html SEOUL, South Korea and COLOGNE, Germany, Oct. 22, 2026 -- ImmunoForge Co., Ltd., a clinical-stage biopharmaceutical company dedicated to developing transformative therapies for rare and intractable diseases, today announced that its executive management team will participate... ———————————————————————————————————————————————————————————— My MMJ Doctor Launches Partner Program to Help Dispensaries Earn Commissions & Reward Customers 2026-10-23 · Newsworthy.ai · Finance, AI, SaaS, Healthcare, Retail, Marketing & advertising, Software & IT, Consumer electronics https://newsworthy.ai/news/202610233090/my-mmj-doctor-launches-partner-program-to-help-dispensaries-earn-commissions-and-reward-customers California Thursday Oct 22, 2026 @ 8:00 PM Central — My MMJ Doctor, a leading telehealth platform in the US connecting patients with state-licensed medical cannabis physicians, announced the launch of its Dispensary Partner Program. The program is designed to empower licensed cannabis retailers to earn affiliate commissions on every patient evaluation while offering exclusive discounts and rewards. As cannabis dispensaries face falling product prices and tighter profit margins, many are looking for new ways to generate revenue without adding high costs. My MMJ Doctor’s Partner Program offers dispensaries another potential income source through recurring referral commissions on qualifying medical marijuana card evaluations and renewals, without requiring upfront program fees.  Under the new program, participating dispensaries receive customized promotional portals, QR code displays, and co-branded digital collateral. When dispensary customers sign up to obtain or renew their medical marijuana card, the dispensary earns a competitive affiliate commission for every completed evaluation. Simultaneously, customers benefit from discounted evaluation rates and gain access to the financial advantages of holding a state medical card-including state excise tax exemptions, higher daily possession limits, and access for qualifying young adults. This way, both dispensaries and customers benefit from this alliance. Program Highlights for Dispensary Partners: Recurring Affiliate Commissions: Every patient who evaluates or renews their medical marijuana card via the dispensary's dedicated portal earns direct commissions. With MyMMJDoctor, participating dispensaries can earn 10-15 % for each qualifying referral. Customer Loyalty & VIP Perks: Store Customers get rewarded with discounted online evaluations, creating immediate goodwill and trust. It positions the dispensary as a trusted patient advocate. Increased Customer Lifetime Value: Anyone who holds a medical marijuana card has benefits like tax savings, higher purchase limits, etc. This leads to high visit frequency and comparatively larger purchases from dispensaries  No Upfront Program Fee: Requires no upfront fees, software integration costs, or inventory risk, maintaining complete clinical independence and healthcare compliance. Full-Circle Patient Shopping Journey: Bridges online medical evaluations directly with physical and online dispensary retail, turning health-conscious consumers into active buyers. Patients complete their online physician evaluation via smartphone or desktop and return directly to the partner dispensary to purchase products tailored to their qualifying conditions.  “Dispensary operators today are working harder than ever to protect their margins while providing exceptional care to their communities, " said the Director of Partnerships at My MMJ Doctor.. Our Affiliate Program is built to solve that exact equation. By removing financial friction and automating the medical certification journey, we give dispensaries a turnkey strategy to increase patient foot traffic, elevate customer lifetime value, and build a sustainable healthcare bridge in their local markets." The My MMJ Doctor Affiliate Partnership Program is now open to licensed medical and dual-use dispensaries across all active medical cannabis states. ———————————————————————————————————————————————————————————— The Smart Shoes Market is projected to grow at a CAGR of 20.8%, reaching a value of $2.12 billion by 2030. 2026-10-23 · EIN Presswire · Healthcare https://www.einpresswire.com/article/950509270/the-smart-shoes-market-is-projected-to-grow-at-a-cagr-of-20-8-reaching-a-value-of-2-12-billion-by-2030 Smart Shoes Market Trends The Business Research Company The Business Research Company’s Smart Shoes Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 23, 2026 / EINPresswire.com / -- The smart shoes sector has witnessed remarkable growth recently, driven by technological advancements and a growing focus on health and fitness. As consumers increasin ———————————————————————————————————————————————————————————— Uncovering the Shadows of Childhood Trauma: A Journey of Survival and Resilience 2026-10-23 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/uncovering-the-shadows-of-childhood-trauma-a-journey-of-survival-and-resilience-302917574.html Palmetto Publishing presents a powerful autobiography detailing a journey from childhood trauma to becoming a Secret Service Special Agent, highlighting resilience and the impact of mental health. CHARLESTON, S.C., Oct. 22, 2026 -- In From paperboy to Secret Service Special... ———————————————————————————————————————————————————————————— Important work from our team in Science Magazine today, showing how our diagnostic orchestrator can reason through complex medical cases, achieving greater diagnostic accuracy while reducing testing costs. 2026-10-23 · Microsoft · Healthcare, Medical devices https://www.linkedin.com/feed/update/urn:li:activity:7519138392542953472/ The post Important work from our team in Science Magazine today, showing how our diagnostic orchestrator can reason through complex medical cases, achieving greater diagnostic accuracy while reducing testing costs. appeared first on Source. ———————————————————————————————————————————————————————————— ASN 2026: HighTide Therapeutics Presents New HTD1801 Data Highlighting Therapeutic Potential in Chronic Kidney Disease 2026-10-23 · ACN Newswire · Healthcare, Biotech & pharma https://www.acnnewswire.com/press-release/english/111020/ Hong Kong, Oct 23, 2026 - HighTide Therapeutics, Inc. (02511.HK), an innovative biopharmaceutical company specializing in the development of multifunctional, multi-targeted therapies for cardiovascular–kidney–metabolic (CKM) diseases, today presented new preclinical findings for HTD1801 in autosomal dominant polycystic kidney disease (ADPKD) at Kidney Week 2026, the 59th Annual Meeting of the American Society of Nephrology (ASN), in Denver, US. The findings demonstrate potent inhibitory activity of HTD1801 against cyst expansion in ADPKD. ADPKD is the most common inherited kidney disorder, characterized by progressive cyst formation and kidney failure by age 60 in approximately 50% of patients. Although existing treatments are available to slow disease progression in certain patients, safety risks and eligibility limitations leave substantial unmet medical needs in ADPKD. HTD1801 targets the AMPK–NLRP3 axis by activating AMPK, suppressing cAMP-driven epithelial cyst proliferation while inhibiting NLRP3 to mitigate renal inflammation and fibrotic remodeling, thereby potentially targeting key pathological processes in ADPKD. In this study, the effect of HTD1801 on forskolin (FSK)-induced cyst expansion was evaluated in PKD1−/− human iPSC-derived nephron organoids, with metformin and tolvaptan as reference comparators. The results showed that HTD1801 significantly reduced the median cystic area fraction to 10.70%, compared with 20.40% in the FSK model control group. Meanwhile, organoids with a low cystic burden (<20%) increased from 46.9% in the model control group to 97.3%, while organoids with a high cystic burden (≥30%) decreased from 8.2% to 0%. By comparison, metformin reduced the median cystic area fraction to 13.12%, while tolvaptan did not alter cyst burden, as this model does not respond to tolvaptan. These findings further expand the potential multidimensional renal benefits of HTD1801. Previous studies have demonstrated the potential of HTD1801 to improve metabolic abnormality-associated renal impairment. HTD1801 effectively suppresses cyst expansion in PKD1-mutant human nephron organoids, validating its dual effects of AMPK activation and NLRP3 inhibition in ADPKD pathogenesis. These preclinical findings provide a strong rationale for further clinical investigation of HTD1801 to explore its potential as a disease-modifying therapy for ADPKD. They further highlight the therapeutic potential of HTD1801 for patients with ADPKD and other chronic kidney diseases (CKD), particularly those currently underserved by existing treatment options. Presentation Title: HTD1801 Suppresses Cyst Expansion in PKD1-Mutant Nephron Organoids: Evidence for AMPK-NLRP3 Axis Efficacy in ADPKD Presentation Number: TH-PO0204 Date and Time: October 22, 2026, 10:00 AM–12:00 PM MDT Format: Poster Presentation Session: ADPKD and Cystic Kidney Disease – 1 [PO1201-1] Presenter: Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics “ADPKD continues to pose a substantial unmet medical need, as progressive cyst growth can lead to deterioration of kidney function and ultimately kidney failure, underscoring the need for effective therapies that can inhibit cyst growth,” said Dr. Filip Surmont, Chief Medical Officer of HighTide Therapeutics. “The significant suppression of cyst expansion observed with HTD1801 in this study provides new scientific evidence to support its further development in ADPKD and highlights its potential as a disease-modifying therapy. We will continue to advance research on HTD1801 to further validate these findings and explore its potential therapeutic value in kidney diseases.” ———————————————————————————————————————————————————————————— Harbour BioMed Receives China NMPA Approval of Batoclimab Injection (Subcutaneous Injection) for the Treatment of Generalized Myasthenia Gravis 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/harbour-biomed-receives-china-nmpa-approval-of-batoclimab-injection-subcutaneous-injection-for-the-treatment-of-generalized-myasthenia-gravis-302917545.html The first NMPA-approved anti-FcRn therapy to complete its full clinical development for gMG patients in China CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Oct. 22, 2026 -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to... ———————————————————————————————————————————————————————————— MLC Dharmendra Bhardwaj launches seven-point programme for the Women of Meerut 2026-10-23 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/951459129/mlc-dharmendra-bhardwaj-launches-seven-point-programme-for-the-women-of-meerut MLC Dharmendra Bhardwaj launches seven-point programme for the Women of Meerut MLC Dharmendra Bhardwaj sets seven commitments for Meerut’s women: safe streets, self-help groups, credit, health cover, girls in school & women in leadership When a woman in Meerut is safe on her street, secure in her health and has credit in her hand, the whole family moves forward” — MLC Dharmendra Bhardwaj MEERUT, UTTAR PRADESH, INDIA, ———————————————————————————————————————————————————————————— Excellence Medical & Skin Care Clinic Announces Fall Skin Renewal Offers 2026-10-23 · EIN Presswire · Healthcare, Consumer goods https://www.einpresswire.com/article/951428710/excellence-medical-skin-care-clinic-announces-fall-skin-renewal-offers Exclusive Fall Skin Renewal Celebration. Embrace the Season. Rediscover Your Radiance. Every patient's skin is unique. Our approach combines personalized assessment, appropriate technology, and evidence-based care to support individual skin goals” — Dr. Sharmeen Shaikh SHERWOOD PARK, CA-AB, CANADA, October 22, 2026 / EINPresswire.com / -- As the leaves turn golden and the season of renewal begins, Excellence Medical ———————————————————————————————————————————————————————————— ImmVira Presents Clinical Data from Three Bladder Cancer Studies at ESMO 2026 2026-10-23 · PR Newswire · Healthcare, Biotech & pharma, Government & policy https://www.prnewswire.com/news-releases/immvira-presents-clinical-data-from-three-bladder-cancer-studies-at-esmo-2026-302915052.html SUZHOU, China, Oct. 22, 2026 -- ImmVira Group ("ImmVira") today announced that updated clinical data from three bladder cancer studies of its lead oncolytic immunotherapy candidate, MVR-T3011, will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress.... ———————————————————————————————————————————————————————————— Lycia Therapeutics Announces Pricing of Upsized Initial Public Offering 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Insurance https://www.globenewswire.com/news-release/2026/10/22/3387000/0/en/lycia-therapeutics-announces-pricing-of-upsized-initial-public-offering.html SOUTH SAN FRANCISCO, Calif., Oct. 22, 2026 -- Lycia Therapeutics, Inc. (“Lycia”) (Nasdaq: LYCA), a clinical-stage biotechnology company focused on the discovery and development of novel therapeutics designed to degrade disease-causing extracellular proteins, with an initial focus on addressing autoimmune, inflammatory and allergic diseases, today announced the pricing of its upsized initial public offering of 17,640,000 shares of its common stock at an initial public offering price of $18.00 per share. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $317.5 million. All shares of common stock to be sold in the offering will be sold by Lycia. In addition, Lycia has granted the underwriters a 30-day option to purchase up to an additional 2,646,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. Lycia’s common stock is expected to begin trading on the Nasdaq Global Select Market on October 23, 2026, under the symbol “LYCA.” The offering is expected to close on October 26, 2026, subject to the satisfaction of customary closing conditions. ———————————————————————————————————————————————————————————— Warhound Launches with $200 Million to Rebuild America's Military Working Dog Supply, Using Advanced Genetics and Defense Technology 2026-10-22 · PR Newswire · Healthcare, Aerospace & defense https://www.prnewswire.com/news-releases/warhound-launches-with-200-million-to-rebuild-americas-military-working-dog-supply-using-advanced-genetics-and-defense-technology-302917498.html Company will produce genetically enhanced working dogs that leverage cybernetics technology to improve health and performance while ending reliance on foreign suppliers DALLAS and COSTA MESA, Calif., Oct. 22, 2026 -- Warhound, a new defense technology company conceived by... ———————————————————————————————————————————————————————————— Hazlet NJ Medicare Diabetic Shoe Coverage & Eligibility: Guide Released 2026-10-22 · MarketersMEDIA · Healthcare, Fashion & luxury, Biotech & pharma https://news.marketersmedia.com/hazlet-nj-medicare-diabetic-shoe-coverage-andamp-eligibility-guide-released/89207072 Hazlet Medical Supplies has released a guide covering Medicare Part B benefits for diabetic shoes, including eligibility criteria, annual limits, and 2026 out-of-pocket costs for NJ patients. -- New Jersey residents with diabetes who are uncertain about their footwear coverage options now have a dedicated resource from Hazlet Medical Supplies. The newly released guide addresses how Medicare Part B handles therapeutic ———————————————————————————————————————————————————————————— Sharpen Your Memory in a Minute a Day: Resona Health Launches Memory Room, a Free Daily Memory Game 2026-10-22 · ACCESS Newswire · Healthcare, Retail, Gaming https://finance.yahoo.com/healthcare/articles/sharpen-memory-minute-day-resona-223500990.html From the author of #1 Amazon bestseller The Memory Room comes a new room to explore every day - free, in any browser, no download required. COCOA BEACH, FL / October 22, 2026 / Resona Health today announced the launch of Memory Room, a free daily game designed to help players sharpen their memory and att ———————————————————————————————————————————————————————————— Tampa General Hospital Recognized Among World's Best Smart Hospitals for 2027 by Newsweek 2026-10-22 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/tampa-general-hospital-recognized-among-worlds-best-smart-hospitals-for-2027-by-newsweek-302917494.html Tampa General ranks as the No. 1 academic health system in Tampa Bay and is among only eight hospitals in Florida recognized for its use of advanced technologies to improve patient care, clinical outcomes and operational efficiency. TAMPA, Fla., Oct. 22, 2026 -- Tampa General... ———————————————————————————————————————————————————————————— The Family Behind Indonesia's Wardah Support Research Into Faith and Mental Health at Stanford Medicine 2026-10-22 · PR Newswire · Healthcare, Fashion & luxury, Consumer goods https://www.prnewswire.com/news-releases/the-family-behind-indonesias-wardah-support-research-into-faith-and-mental-health-at-stanford-medicine-302917484.html A new fund from the family behind ParagonCorp, maker of the Wardah brand, will support the Stanford Muslim Mental Health & Islamic Psychology Lab LOS ANGELES, Oct. 22, 2026 -- The founding family of ParagonCorp, Indonesia's largest domestic cosmetics and personal care... ———————————————————————————————————————————————————————————— California Waste Solutions Leads Youth Education, Worker Programs & Government Delegations As Founder David Duong Says He Will Continue "Reinvesting" In Vietnam 2026-10-22 · PR Newswire · Healthcare, Education, Government & policy https://www.prnewswire.com/news-releases/california-waste-solutions-leads-youth-education-worker-programs--government-delegations-as-founder-david-duong-says-he-will-continue-reinvesting-in-vietnam-302917487.html David Duong supports environmental education for young people in Vietnam while workers at Vietnam Waste Solutions get a free health check-up, in keeping with the company's long-running commitment to its employees' wellbeing. Separately, a delegation of Hưng Long commune officials on... ———————————————————————————————————————————————————————————— Gulf of America Alliance Releases Governors’ Action Plan V for Healthy and Resilient Coasts 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951312984/gulf-of-america-alliance-releases-governors-action-plan-v-for-healthy-and-resilient-coasts Governors Action Plan V Cover This collaborative work plan identifies priority issues, focus areas, and actions to enhance the environmental and economic health of the Gulf of America Working across the region on issues of shared importance, we’ve made an incredible impact on one of the nation’s most vital and beautiful natural resources.” — Laura Bowie, Executive Director, Gulf of America Alliance OCEAN SPRINGS, MS, ———————————————————————————————————————————————————————————— Neovii Advances FDA Fast Track-Designated ATLG Program in Type 1 Diabetes With Pivotal Phase 2 Study - Company Appoints Physician-scientist Salvatore Alesci as Chief Medical Officer 2026-10-22 · NewMediaWire · Healthcare, Food & drink, Industrial, Biotech & pharma, Medical devices https://www.newmediawire.com/news/neovii-advances-fda-fast-track-designated-atlg-program-in-type-1-diabetes-with-pivotal-phase-2-study-company-appoints-physician-scientist-salvatore-alesci-as-chief-medical-officer-7090826 BOSTON, MA and RAPPERSWIL-JONA, SWITZERLAND - October 22, 2026 - Neovii Pharmaceuticals AG, a Swiss-headquartered, commercial-stage biopharmaceutical company with more than four decades of experience in antibody-based immunotherapies, today announced that it is advancing its Type 1 Diabetes (T1D) clinical program through a company-sponsored pivotal Phase 2 study in the United States and European Union. The international expansion builds on the ongoing investigator-initiated European GIRO (Grafalon in early onset) T1D study and is supported by U.S. Food and Drug Administration (FDA) Fast Track designation for anti-T-lymphocyte globulin (ATLG) for the prevention of declining C-peptide production in patients with recent-onset T1D. Patients have already been treated in GIRO, and clinical data are being generated. The expected 12-month efficacy and safety interim analysis will provide an important near-term milestone and inform the pivotal study program. This next stage marks an important expansion beyond transplantation and reflects Neovii’s strategy to apply its expertise in immune modulation to autoimmune and immune-mediated diseases with strong biological rationale and significant unmet medical need. In connection with this expansion, Neovii has appointed Salvatore “Salvo” Alesci, M.D., Ph.D., as Chief Medical Officer, effective October 15, 2026. Dr. Alesci will lead the company’s medical and clinical development activities, including translational medicine and regulatory strategy. He will oversee the Type 1 Diabetes program and help shape the company’s broader clinical development strategy, including the evaluation of future development opportunities. Scientific Rationale for ATLG in Type 1 Diabetes Type 1 Diabetes is a chronic autoimmune disease characterized by T-cell-mediated destruction of insulin-producing pancreatic beta cells. Many patients retain residual beta-cell function following diagnosis, and preserving this endogenous function remains an important therapeutic objective. ATLG is a polyclonal anti-T-lymphocyte globulin with preferential activity against activated T cells and broader effects across T-cell populations and immune pathways involved in autoimmune responses. Published clinical proof of concept in recent-onset Type 1 Diabetes was reported by Saudek et al. in a placebo-controlled study of ATLG. Together with other clinical evidence that modulation of pathogenic T-cell responses can preserve residual beta-cell function, these findings provide a clinical and mechanistic rationale for evaluating ATLG in the ongoing GIRO T1D study and company-sponsored pivotal Phase 2 study. ATLG has been used in transplantation medicine for more than four decades. Building on this extensive manufacturing, preclinical, and clinical experience, Neovii is now evaluating its potential role in autoimmune disease. The investigator-initiated European GIRO T1D study and the company-sponsored pivotal Phase 2 study in the United States and the European Union are complementary components of the ATLG clinical development program. Neovii is using emerging efficacy and safety data from GIRO to inform the pivotal study and support ongoing discussions with the FDA, European regulatory authorities, and other health authorities on a potential registration pathway. Executive Commentary Frederic Prince, Ph.D., Chief Executive Officer of Neovii Pharmaceuticals AG, commented: “Despite major advances in glucose monitoring and insulin delivery, Type 1 Diabetes continues to impose a substantial burden on patients. ATLG’s well-characterized activity against activated T cells, clinical proof of concept in recent-onset disease, and extensive clinical experience provide a strong foundation for its further evaluation. Building on the investigator-initiated GIRO T1D study, we are advancing a company-sponsored pivotal Phase 2 study to assess whether ATLG can preserve endogenous beta-cell function and reduce treatment burden. "As we take this important step in expanding Neovii’s clinical development activities, I am also delighted to welcome Salvo to Neovii as our Chief Medical Officer. His expertise in endocrinology, translational medicine, and clinical development will be highly valuable as we advance our Type 1 Diabetes program and evaluate future opportunities in immune-mediated diseases.” Salvatore Alesci, M.D., Ph.D., Chief Medical Officer of Neovii Pharmaceuticals AG, said: “I am excited to join Neovii at this important stage in the company’s evolution and help drive its expansion into Type 1 Diabetes and other immune-mediated diseases. Despite significant advances in disease management, preservation of endogenous beta-cell function remains an important therapeutic objective in Type 1 Diabetes. ATLG provides an opportunity to rigorously evaluate a differentiated immunomodulatory approach in a randomized clinical setting. I look forward to working with the Neovii team, investigators, patients, advocacy groups, and regulatory authorities to execute a scientifically rigorous Type 1 Diabetes development program and shape the company’s broader clinical strategy in immune-mediated diseases.” About Salvatore Alesci, M.D., Ph.D. Dr. Alesci is a physician-scientist and biopharmaceutical executive with combined expertise in endocrinology and immunology and more than 25 years of experience spanning translational medicine, clinical development, regulatory strategy and scientific and patient affairs. Throughout his career, he has held senior leadership roles in biotechnology and pharmaceutical organizations, leading multidisciplinary global programs from early research through late-stage clinical development. About Neovii Pharmaceuticals AG Neovii Pharmaceuticals AG is a Swiss-headquartered, fully integrated biopharmaceutical company focused on developing, manufacturing, and commercializing antibody-based therapy for immune-mediated diseases. The company markets Grafalon® (ATLG, formerly named as ATG-F), an anti-human T-lymphocyte immunoglobulin approved in multiple countries for transplantation-related indications; approved uses vary by country. Grafalon is manufactured at Neovii’s dedicated biotechnology manufacturing facility in the Munich area and is commercialized in more than 50 countries. Building on decades of expertise in immune modulation, Neovii is expanding its research and development activities into selected autoimmune and immune-mediated diseases with significant unmet medical need. ATLG is investigational in Type 1 Diabetes and has not been approved for this use. Nothing in this release should be interpreted as promoting ATLG for an unapproved indication. Forward-Looking Statement This press release contains forward-looking statements regarding Neovii’s planned clinical development activities, regulatory interactions, clinical-study design and execution, business strategy, and potential future registration pathways. These statements are based on current beliefs, expectations, and assumptions and involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Clinical development outcomes, regulatory decisions, trial initiation and enrollment, safety and efficacy findings, development timelines, manufacturing readiness, and business objectives are subject to factors beyond Neovii’s control. Fast Track designation does not guarantee that ATLG will qualify for Accelerated Approval or Priority Review, that regulatory review will be completed within any particular timeframe, or that ATLG will receive marketing approval for Type 1 Diabetes. Neovii undertakes no obligation to update these forward-looking statements except as required by applicable law. Reference: Saudek, F., et al. The Review of Diabetic Studies, Vol. 1, No. 2, 2004. Media contact Neovii Pharmaceuticals AG, info@neovii.com, www.neovii.com ———————————————————————————————————————————————————————————— Aptar Taps Pharma Packaging Veteran Virginie Maes as President of its Pharma Business 2026-10-22 · Business Wire · Finance, Healthcare, Retail, Biotech & pharma https://finance.yahoo.com/healthcare/articles/aptar-taps-pharma-packaging-veteran-213000960.html CRYSTAL LAKE, Ill., October 22, 2026--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced the appointment of Virginie Maes as President of Aptar Pharma, effective January 1, 2027. Maes joins Aptar from Amco ———————————————————————————————————————————————————————————— Pediatric Expert Meredith A. Byington, MD, FAAP, Discusses When a Child's Fever Requires Medical Attention in HelloNation 2026-10-22 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/pediatric-expert-meredith-a-byington-md-faap-discusses-when-a-childs-fever-requires-medical-attention-in-hellonation-302917462.html The article explains how age, temperature, hydration, and accompanying symptoms help parents determine when to seek medical attention for a fever. KAUFMAN, Texas, Oct. 22, 2026 -- When should parents call a pediatrician about their child's fever? That question is answered in... ———————————————————————————————————————————————————————————— 42 Mercy Medical Center Physicians Named Among Region's "TOP DOCTORS" in November 2026 Issue of BALTIMORE Magazine 2026-10-22 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/42-mercy-medical-center-physicians-named-among-regions-top-doctors-in-november-2026-issue-of-baltimore-magazine-302917439.html BALTIMORE, Oct. 22, 2026 -- A total of 42 Mercy Medical Center physicians were recognized in Baltimore magazine's November 2026 "Top Doctors" issue, representing 30 separate specialties, ranging from neurosurgery to gynecologic oncology, specifically: 2026 – MERCY MEDICAL... ———————————————————————————————————————————————————————————— Delta Dental Foundation of North Carolina Commits $1 Million to Expand Oral Health Access Statewide 2026-10-22 · GlobeNewswire · Healthcare, Jobs & workplace https://www.globenewswire.com/news-release/2026/10/22/3386955/0/en/delta-dental-foundation-of-north-carolina-commits-1-million-to-expand-oral-health-access-statewide.html The Delta Dental Foundation of North Carolina launches with a $1M pledge to expand access to oral health care and strengthen the state's dental workforce. ———————————————————————————————————————————————————————————— AM Best Withdraws Credit Ratings of Individual Assurance Company, Life, Health & Accident 2026-10-22 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/am-best-withdraws-credit-ratings-203800929.html OLDWICK, N.J., October 22, 2026--AM Best has withdrawn the Financial Strength Rating of B++ (Good) and the Long-Term Issuer Credit Rating of "bbb" (Good) of Individual Assurance Company, Life, Health & Accident (IAC) (Oklahoma City, OK). At the time of withdrawal, the outlook of these Credit Ratings ( ———————————————————————————————————————————————————————————— Historic win for PSWs everywhere as Arbitrator denies Durham region's HSCPOA policy 2026-10-22 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/historic-win-psws-everywhere-arbitrator-203700825.html Ajax, ON, October 22, 2026--For months, Personal Support Workers (PSWs) employed by the Region of Durham have been fighting to protect their seniority rights and their ability to transfer into PSW positions at the Region's new Seaton Village Long-Term Care home. Although registration with the Health an ———————————————————————————————————————————————————————————— CVRx to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call on November 5, 2026 2026-10-22 · GlobeNewswire · Finance, Healthcare, Industrial, Medical devices https://www.globenewswire.com/news-release/2026/10/22/3386926/0/en/cvrx-to-report-third-quarter-2026-financial-and-operating-results-and-host-conference-call-on-november-5-2026.html MINNEAPOLIS, Oct. 22, 2026 -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that it plans to release third quarter 2026 financial and operating results after market close on Thursday, Nov. 5, 2026. The Company will host a conference call to review its results at 4:30 p.m. Eastern Time the same day. ———————————————————————————————————————————————————————————— Emmy-Award Winning Television Host Montel Williams to Join Next ‘Let’s Huddle’ Webinar 2026-10-22 · GlobeNewswire · Healthcare, Consumer electronics, Entertainment https://www.globenewswire.com/news-release/2026/10/22/3386918/33471/en/emmy-award-winning-television-host-montel-williams-to-join-next-let-s-huddle-webinar.html Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisions Patient advocacy initiative expands its reach with a nationally recognized voice on health, resilience and informed treatment decisions ———————————————————————————————————————————————————————————— Lana Kerr Launches HERgevity™, New Book Exploring Women's Longevity Through Skin, Sex and Strength 2026-10-22 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/951556926/lana-kerr-launches-hergevity-new-book-exploring-women-s-longevity-through-skin-sex-and-strength Lana Kerr, Founder of CO2Lift® and Author of HERgevity™ Copy of the HERgevity™ Printed Book Released October 22, 2026, the book examines women's aging, intimate wellness and the importance of education in understanding lifelong health. HERgevity™ is about changing the conversation around women’s health, aging, and longevity. It’s time we stop accepting silence and start demanding answers.” — Lana Kerr, Author of HERg ———————————————————————————————————————————————————————————— Vadzo Imaging Positions Innova-234CGE: Onsemi AR0234 2MP Color Global Shutter GigE Camera for Reliable Day and Night Video Recording 2026-10-22 · Newswire.com · Healthcare, Media https://www.newswire.com/news/vadzo-imaging-positions-innova-234cge-onsemi-ar0234-2mp-color-global-22876289 The Innova-234CGE is a 2MP Color GigE Camera built on the Onsemi AR0234 sensor, and Vadzo is positioning it for reliable day and night video recording. Recording that never stops asks more of a camera than a good picture. The stream must stay up for months, the bitrate must fit the network and the storage, the image must stay usable as daylight fades, and installation must be simple enough to repeat across many positions. As a 2MP Day Night GigE Camera and a 2MP Color Day Night GigE Camera, the Innova-234CGE answers those needs with a global shutter, an on-board ISP, ONVIF compliance, and PTP synchronization. It streams 1080p, 720p, and VGA at up to 60 frames per second, and it carries video, control, and power over a single Ethernet cable. Designed for smart surveillance, patient monitoring, and mobile robot systems, it gives integrators a color GigE camera that is built to keep recording. ———————————————————————————————————————————————————————————— Cosmos Health Expands E-Commerce and Subscription Business to Australia, New Zealand and the Broader Oceania Region, With Sales Already Underway 2026-10-22 · ACCESS Newswire · Healthcare, Retail https://finance.yahoo.com/healthcare/articles/cosmos-health-expands-e-commerce-195500735.html Now live in Oceania: e-commerce subscription business operating across Australia, New Zealand and the broader Oceania region, with sales already underway Attractive markets: together, Australia and New Zealand represent multibillion-dollar, well-established health and wellness markets with strong consumer demand and high ———————————————————————————————————————————————————————————— Nano-X Imaging (NNOX) Advances Its Mission to Expand Access to Medical Imaging 2026-10-22 · NewMediaWire · Finance, AI, SaaS, Healthcare, Media, Legal, Jobs & workplace, Medical devices https://www.newmediawire.com/news/nano-x-imaging-nnox-advances-its-mission-to-expand-access-to-medical-imaging-7090818 Nanox is working to make advanced medical imaging more accessible through digital 3D tomosynthesis technology designed to enhance visualization beyond conventional X-rays. Its Nanox.ARC platform combines imaging hardware with cloud-based infrastructure, while the company’s broader services support image interpretation and clinical workflows. By connecting image acquisition with remote radiology expertise and AI-powered analysis, Nanox aims to support healthcare providers’ imaging and interpretation workflows more efficiently. LOS ANGELES, CA - October 22, 2026 - Access to medical imaging remains an important consideration for healthcare systems, particularly in underserved regions where equipment, infrastructure and trained personnel may be limited. While conventional X-rays play an essential role in diagnostic care, their two-dimensional images can make certain anatomical details more difficult to distinguish when structures overlap. In some healthcare settings, rising imaging volumes and radiologist workforce constraints can also place pressure on diagnostic services. These challenges underscore the importance of developing imaging technologies that can complement existing diagnostic approaches while integrating into established clinical environments and workflows. Nano-X Imaging (NASDAQ: NNOX) is approaching that problem from a different direction. Nanox is assembling an integrated platform intended to extend medical imaging into outpatient facilities, clinics and other settings where conventional advanced… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to NNOX are available in the company’s newsroom at https://ibn.fm/NNOX Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— World Health Organization (WHO) Ethiopia and Plan International Ethiopia champion girls’ leadership through Girls Takeover 2026 campaign 2026-10-22 · APO Group · AI, Healthcare, Education, Sustainability https://who-africa.africa-newsroom.com/press/world-health-organization-who-ethiopia-and-plan-international-ethiopia-champion-girls-leadership-through-girls-takeover-2026-campaign?lang=en The World Health Organization (WHO) Ethiopia Country Office, in partnership with Plan International Ethiopia, hosted Ms. Timrhabiruk Mulugeta as the symbolic WHO Representative for a Day as part of the global Girls Takeover 2026 (#ChangeHerForecast) campaign. The initiative marked the International Day of the Girl and supported this year’s theme, “End Child Marriage and Invest in Girls’ Rights.” The Girls Takeover initiative empowers adolescent girls and young women by providing opportunities to assume leadership roles, amplify their voices, challenge gender stereotypes, and participate in decision-making processes. This year’s global campaign, #ChangeHerForecast, highlights the disproportionate impact of climate change and humanitarian crises on girls, particularly in relation to their health, education, protection, and future opportunities. During her symbolic leadership role, Ms. Timrhabiruk participated in high-level meetings and engagements, gaining firsthand insight into WHO’s work in Ethiopia. She accompanied the WHO Representative on a visit to the Ethiopian Artificial Intelligence Institute and contributed to discussions on innovation, health, youth leadership, and development. She also participated in a coordination meeting to prepare for the 7th Emergency Medical Teams Global Meeting. Throughout the day, Ms. Timrhabiruk advocated for girls’ rights, gender equality, youth participation, and stronger action to address the challenges that climate change and humanitarian crises pose to girls and young women. Her participation underscored the importance of creating meaningful opportunities for young women to engage directly with leaders and contribute to shaping policies that affect their communities. A 2026 graduate of the School of Social Work at Addis Ababa University, Ms. Timrhabiruk has been actively engaged in community support, youth participation, and social justice advocacy. Through her work with the Ethiopia ACT Project, she has supported vulnerable individuals and families through psychosocial services, counselling, livelihood assistance, and conflict resolution initiatives. Speaking at the conclusion of the event, Professor Francis Chisaka Kasolo, WHO Representative to Ethiopia, the African Union, and the United Nations Economic Commission for Africa (UNECA), commended Ms. Timrhabiruk’s leadership and engagement. “We commend her commitment and enthusiasm and extend our best wishes for her continued success as a future leader and advocate for positive change,” Professor Kasolo said. The event reaffirmed the shared commitment of WHO Ethiopia and Plan International Ethiopia to promoting girls’ leadership, empowerment, and meaningful participation in decision-making. By investing in girls and creating opportunities for them to lead, the Girls Takeover initiative contributes to building a more equitable and inclusive future. Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— October Half-Term Adventures Put Family Travel Insurance Exclusions in Focus 2026-10-22 · Travel PR News · Healthcare, Travel, Insurance https://travelprnews.com/article/october-half-term-adventures-put-family-travel-insurance-exclusions-in-focus/?utm_source=rss&utm_medium=rss&utm_campaign=october-half-term-adventures-put-family-travel-insurance-exclusions-in-focus MoneySuperMarket advises UK parents to check activity limits, children's eligibility and medical cover before booking holiday excursions. KEY TAKEAWAYS MoneySuperMarket warns that quad biking, horse riding and some excursions may require added insurance cover or carry restrictions. Parents should confirm emergency medical and repatriation benefits, as well as liability for damaged hired equipment. Family-policy eligibility... Read the full news article ———————————————————————————————————————————————————————————— The Washington Home Invests $328K to Reduce Barriers to Hospice Care Access for Older Adults Across Washington, DC 2026-10-22 · EIN Presswire · Healthcare, Real estate, Jobs & workplace https://www.einpresswire.com/article/951566718/the-washington-home-invests-328k-to-reduce-barriers-to-hospice-care-access-for-older-adults-across-washington-dc New citywide collaboration unites four partners to expand access to hospice and medical respite care and strengthen workforce capacity This initiative will help more DC residents access quality end-of-life care by reducing financial, housing, and caregiver-support barriers, and by expanding the healthcare workforce’s expertise.” — Crystal Townsend, MPA, Chief Executive Officer, The Washington Home WASHINGTON, DC, UNI ———————————————————————————————————————————————————————————— National Kidney Foundation Highlights New Blood Pressure Guidance Putting Kidney Health at the Forefront 2026-10-22 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/national-kidney-foundation-highlights-new-blood-pressure-guidance-putting-kidney-health-at-the-forefront-302917378.html New KDOQI commentary emphasizes early kidney testing, accurate blood pressure measurement, and individualized care NEW YORK, Oct. 22, 2026 -- The National Kidney Foundation (NKF) is highlighting a new Kidney Disease Outcomes Quality Initiative (KDOQI) commentary on the 2025... ———————————————————————————————————————————————————————————— Congo: Continuity of care in Lita: A hospital transformed by the Ebola response 2026-10-22 · APO Group · Healthcare, Travel, Government & policy https://who-africa.africa-newsroom.com/press/congo-continuity-of-care-in-lita-a-hospital-transformed-by-the-ebola-response?lang=en When the Ebola outbreak struck Ituri province, the Lita General Reference Hospital (HGR) found itself on the front line, facing unprecedented pressure. Dilapidated infrastructure, a shortage of beds, and the absence of a functional laboratory made patient care extremely difficult, both for Ebola patients and for others not affected by the Bundibugyo virus. “From the very beginning, internal medicine unit was urgently targeted to receive Ebola patients, and it was not easy. We had to put two patients together on the same bed,” recalls Dr Alphonse Abekani Jawotho, the hospital’s medical director. This situation had a considerable impact on attendance at this referral health facility. The maternity ward, which averaged 80 deliveries per month, saw that number cut in half in the first weeks after the outbreak was declared. In June, only 42 deliveries were performed, reflecting the community’s mistrust of a hospital that had become an Ebola treatment centre. To expand capacity and provide facilities that met safety standards in the context of the outbreak, the World Health Organization (WHO) installed three tents and supplied 29 beds and mattresses for maternity and pediatrics. Beyond beds, support included essential equipment such as oxygen concentrators, monitoring devices, personal protective equipment (PPE), and medicines. “The PPE we received was sufficient to cover our needs for three to four months,” notes Dr Jawotho. The hospital also received two new ambulances dedicated to the Ebola response, while the old ambulance continues to serve other patients. These investments enabled the hospital not only to respond immediately to Ebola but also to ensure continuity of care for the wider population, improving patient comfort and reducing exposure risks. With these reinforcements and measures that reassure the community, Lita Hospital is gradually regaining its clientele. When four year old Dieuveille* was injured in a traffic accident, his mother did not hesitate to travel 12 kilometers from Limani, in the Nizi health zone, to Lita. Suffering from trauma, the boy has been treated in pediatrics for 10 days. “We are no longer afraid to come to the hospital here. Moreover, the staff are doing their job well. Since we arrived, my son is getting better, and I hope we can go home soon,” says Aimerance, Dieuveille’s mother. The quality care praised by Aimerance stems from an intensive training conducted for more than 600 health workers across all categories, from internal medicine to maternity to hygiene staff. Additionally, a borehole was also installed to strengthen infection prevention and control (IPC) measures. These improvements transformed the way pregnant women and newborns are cared for, while guaranteeing free pediatric services. The Lita experience illustrates a holistic approach to epidemic response while ensuring continuity of primary health care. “The Lita health zone will play a central role in managing not only Ebola virus disease but also in strengthening the health system,” says Dr Célestin Kambale Ndaliko, WHO field coordinator in the Lita health zone. WHO, alongside other partners, helped reinforce basic services within the hospital. Coordination under the leadership of the Ministry of Health, in collaboration with community committees, integrated these gains into a sustainable dynamic. “The Ebola response served as a lever to profoundly transform the overall quality of our local health system. We moved from a one off emergency response to a dynamic of sustainable consolidation of our infrastructure,” emphasizes Dr Patience Pacifique Lokengama, chief medical officer of the zone. Investments improved biosafety, hygiene, access to safe water, and medical waste management, strengthening community trust in the facility. Key services were particularly consolidated. Pediatrics and neonatology now welcome children in safer conditions, with reorganized care pathways. Maternity benefits from access to water and sanitation, ensuring more dignified and secure deliveries. Finally, the establishment of triage and IPC circuits allows suspected cases to be isolated quickly without interrupting general care. Lita is no longer just an Ebola response centre: it has become a health hub attracting patients beyond its zone, a model of resilience and solidarity for the entire region. In maternity, services are gradually returning to normal. In September, 56 deliveries were performed. Miriam, 39, a resident of Linji in the Nizi health zone, has just given birth at Lita’s maternity ward. Rocking her newborn gently, she expresses satisfaction with the care she received. “I can see that the service has improved. As soon as you arrive, you go through triage, and if you don’t show signs of Ebola, you are quickly redirected. And everything goes very well,” says Miriam. “The beds are very comfortable,” she adds with a hearty laugh. Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Hims & Hers Health, Inc. - HIMS 2026-10-22 · GlobeNewswire · Finance, Healthcare, Legal https://www.globenewswire.com/news-release/2026/10/22/3386839/35454/en/hims-hers-health-shareholder-alert-claimsfiler-reminds-investors-with-losses-in-excess-of-100-000-of-lead-plaintiff-deadline-in-class-action-lawsuit-against-hims-hers-health-inc-hi.html NEW ORLEANS, Oct. 22, 2026 -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until November 2, 2026 to file lead plaintiff applications in a securities class action lawsuit against Hims & Hers Health, Inc. (“Hims” or the “Company”) (NYSE: HIMS), if they purchased or otherwise acquired the Company’s securities between August 4, 2025 and July 29, 2026, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of California. ———————————————————————————————————————————————————————————— BioStack Raises $9.5M to Turn Global Hospital Data into Multimodal Training Datasets for Medical AI 2026-10-22 · PR Newswire · AI, Healthcare, Education https://www.prnewswire.com/news-releases/biostack-raises-9-5m-to-turn-global-hospital-data-into-multimodal-training-datasets-for-medical-ai-302916123.html Y Combinator startup transforms 100 million fragmented patient records into multimodal training data and reinforcement learning environments for medical AI agents. SAN FRANCISCO, Oct. 22, 2026 -- BioStack, a healthcare technology company, announced today that it's launching a... ———————————————————————————————————————————————————————————— MOBI Helps Families Create More Personal Health and Wellness Gifts This Holiday Season 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951569459/mobi-helps-families-create-more-personal-health-and-wellness-gifts-this-holiday-season Families can combine connected and standalone MOBI products to create practical gifts around the everyday needs of the people they care about. LOS ANGELES, CA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Holiday shopping often starts with one question: What would this person actually use? As families prepare their gift lists for parents, grandparents, partners, caregivers, and other loved ones, MOBI Techn ———————————————————————————————————————————————————————————— VIOVOC Issued U.S. Patent for Ambient Sensing Technology That Decodes Gut Microbiome Signals 2026-10-22 · Business Wire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/viovoc-issued-u-patent-ambient-184800202.html New Patent Covers the Passive Measurement of Volatile Organic Compounds and Delivery of Personalized Fiber Guidance CHICAGO, October 22, 2026--VIOVOC, the wellness platform that helps users master their gut health by working with their own biology, today announced that the U.S. Patent and Trademark Off ———————————————————————————————————————————————————————————— AHN Cancer Center Expands Successful Screening Initiative with New Workplace Program for Regional Employers 2026-10-22 · PR Newswire · Healthcare, Banking, Jobs & workplace https://www.prnewswire.com/news-releases/ahn-cancer-center-expands-successful-screening-initiative-with-new-workplace-program-for-regional-employers-302917237.html Dollar Bank becomes first participating employer as AHN brings life-saving cancer screenings directly to the workplace PITTSBURGH, Oct. 22, 2026 -- Building on the success of its longstanding cancer screening program, Allegheny Health Network (AHN) Cancer Center is launching... ———————————————————————————————————————————————————————————— Nivia Fontanez Highlights the Importance of Bone Density Screening in Preventive Healthcare 2026-10-22 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/nivia-fontanez-highlights-importance-bone-184500366.html Bronx-based radiology technologist Nivia Fontanez discusses how bone density examinations help healthcare providers assess bone health, identify potential fracture risks, and support informed decisions about preventive care. THE BRONX, NY / October 22, 2026 / Bone health is an important part of long-term ———————————————————————————————————————————————————————————— Dr. Megan Appleby of Keith Family Medicine Earns 2026 GA Top Docs Recognition 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951569174/dr-megan-appleby-of-keith-family-medicine-earns-2026-ga-top-docs-recognition Dr. Megan Appleby Megan Appleby, M.D. has been reviewed and approved by GA Top Docs based on merit for 2026. DAWSONVILLE, GA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Megan Appleby, M.D., of Keith Family Medicine, has been reviewed and approved based on merit by GA Top Docs for 2026. Patients searching for a family physician often want more than just medical expertise, they want someone who listens, un ———————————————————————————————————————————————————————————— National Conference Highlights Growth of Mobile Healthcare Programs 2026-10-22 · PRWeb · Healthcare https://www.prweb.com/releases/national-conference-highlights-growth-of-mobile-healthcare-programs-302917074.html Recent news coverage features mobile medical vehicles as healthcare organizations explore new ways to deliver care. COLUMBUS, Ohio, Oct. 22, 2026 -- LifeLine Mobile and other mobile healthcare programs were in the spotlight at the Mobile Healthcare Association's... ———————————————————————————————————————————————————————————— Ionis ranked #1 on Science’s Top Employers list 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma, Jobs & workplace https://finance.yahoo.com/healthcare/articles/ionis-ranked-1-science-top-182500186.html CARLSBAD, Calif., October 22, 2026--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical industries. Rising from #2 last year to #1, Ionis was recognized for it ———————————————————————————————————————————————————————————— Cal Orey Wins 2026 Hollywood Book Awards Best Health & Wellness Honor for The Healing Powers of Honey 2026-10-22 · FinanceWire · Healthcare, Entertainment https://financewire.com/2026/10/22/cal-orey-wins-2026-hollywood-book-awards-best-health-wellness-honor-for-the-healing-powers-of-honey/ SOUTH LAKE TAHOE, Calif., 22nd October 2026, FinanceWire … Read More The post Cal Orey Wins 2026 Hollywood Book Awards Best Health & Wellness Honor for The Healing Powers of Honey appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Vitek IP Announces the Availability of the Medical Simulation Intelligence Patent Portfolio 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951558783/vitek-ip-announces-the-availability-of-the-medical-simulation-intelligence-patent-portfolio PORTLAND, OR, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Vitek IP , LLC announced that they are the exclusive representative to sell the Medical Simulation Intelligence patent portfolio originally developed by CodeScribe, a developer of augmented reality clinical simulation technologies. The Medical Simulation Intelligence patent portfolio includes three U.S. patents covering technologies for immersive h ———————————————————————————————————————————————————————————— Eyemart Express Offers First Responders 20% Off Glasses for National First Responders Day 2026-10-22 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/eyemart-express-offers-first-responders-20-off-glasses-for-national-first-responders-day-302917325.html Police officers, firefighters, paramedics, emergency medical technicians, nurses, and doctors can save on prescription glasses and sunglasses at 277 stores nationwide, with many pairs made on-site and ready the same day DALLAS, Oct. 22, 2026 -- First responders can take 20%... ———————————————————————————————————————————————————————————— BODYWELLE's Dr. Alonso Martin Explains the Benefits of Botox for Facial Rejuvenation 2026-10-22 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/bodywelles-dr-alonso-martin-explains-180000648.html The Miami Beach physician describes how neuromodulators soften expression lines, where treatment can be applied, and why dosing and placement are individualized for each patient. MIAMI BEACH, FL / October 22, 2026 / BODYWELLE , a physician-led longevity and functional medicine practice founded by Alonso Martin, MD, offers Botox as part of its approach to facial rejuvenation. Botox is an FDA-approved ———————————————————————————————————————————————————————————— FDA grants 510(k) clearance for BoneEnhance, the first machine learning layer on RIVANNA's Accuro XV platform 2026-10-22 · PR Newswire · AI, SaaS, Healthcare, Education, Biotech & pharma, Medical devices https://www.prnewswire.com/news-releases/fda-grants-510k-clearance-for-boneenhance-the-first-machine-learning-layer-on-rivannas-accuro-xv-platform-302917179.html Anatomy segmentation and three-dimensional skeletal visualization arrive with this clearance; an injury detection module for clinical decision support is in development on the platform roadmap CHARLOTTESVILLE, Va., Oct. 22, 2026 -- RIVANNA®, developer of AI-enabled clinical... ———————————————————————————————————————————————————————————— Warp Sciences Emerges From Stealth With $215 Million to Build U.S. Chemistry Services for Drug Research 2026-10-22 · Business Wire · AI, Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/warp-sciences-emerges-stealth-215-180000040.html Founded by leaders from OpenAI, Terremoto Biosciences, Meta, Devoted Health, and the White House, Warp is using AI and robotics to help biotech and pharma discover new medicines faster in the U.S. The company is backed by Lightspeed, IVP, Mayfield, Lux, Premji Invest, and Menlo Ventures, among others SAN FRANCISCO, Octobe ———————————————————————————————————————————————————————————— New Grid Therapeutics GT103 Data to be Presented at ESMO 2026 2026-10-22 · Business Wire · Healthcare, Energy, Biotech & pharma https://finance.yahoo.com/healthcare/articles/grid-therapeutics-gt103-data-presented-175400994.html DURHAM, N.C., October 22, 2026--Grid Therapeutics , a clinical-stage biotechnology company committed to developing better and safer human-derived therapeutic antibodies for cancer, today announced that new data on its lead clinical asset, GT103, will be presented at the 2026 European Society for Medic ———————————————————————————————————————————————————————————— reVolver Podcasts’ Erazno y La Chokolata and Código Vital Win Silver at The 2026 Signal Awards 2026-10-22 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/22/3386801/0/en/revolver-podcasts-erazno-y-la-chokolata-and-c%C3%B3digo-vital-win-silver-at-the-2026-signal-awards.html Two Spanish-language programs earn Silver honors in Comedy and Health & Wellness at the 5th Annual Signal Awards, recognizing excellence in podcasting Two Spanish-language programs earn Silver honors in Comedy and Health & Wellness at the 5th Annual Signal Awards, recognizing excellence in podcasting ———————————————————————————————————————————————————————————— St. Louis Personal Injury Firm Reports Higher Initial Offers and 87% Faster Medical Record Review Using EvenUp 2026-10-22 · Business Wire · AI, SaaS, Healthcare, Insurance, Legal https://finance.yahoo.com/technology/ai/articles/st-louis-personal-injury-firm-172100854.html Holland Injury Law says EvenUp's AI platform cut up to 30 hours from complex demands and put stronger cases in front of insurers ST. LOUIS, Mo., October 22, 2026--A medical review that once took Holland Injury Law's attorneys a couple of hours now takes about 15 minutes. The St. Louis trial firm credits EvenUp's AI platform, and says the gains extend to the negotiating table: higher initial offers ———————————————————————————————————————————————————————————— CorWave Completes Enrollment in Feasibility Study and Presents First Clinical Data on Adaptive Support with its Wave Membrane LVAD 2026-10-22 · Business Wire · Healthcare, Biotech & pharma, Medical devices https://finance.yahoo.com/healthcare/articles/corwave-completes-enrollment-feasibility-study-171700231.html CLICHY, France, October 22, 2026--CorWave SA, a clinical-stage medical technology company pioneering innovative cardiac assist devices, announces the completion of enrollment in its feasibility study of the CorWave Left Ventricular Assist System (LVAS). The company also presented the first clinical da ———————————————————————————————————————————————————————————— Vadzo Imaging Positions Bolt-1335CRA: Onsemi AR1335 Color Autofocus MIPI CSI-2 Camera with RK3588 Rockchip Processor for Pathology Imaging in Medical and Life Science Applications 2026-10-22 · Newswire.com · Healthcare https://www.newswire.com/news/vadzo-imaging-positions-bolt-1335cra-onsemi-ar1335-color-autofocus-22877061 The Bolt-1335CRA is an AR1335 Color Autofocus MIPI CSI-2 Camera built on the Onsemi AR1335 sensor, and Vadzo is positioning it with the RK3588 Rockchip processor for pathology imaging in medical and life science applications. Pathology devices judge tissue by color and detail, and they photograph specimens, slides, and labels that sit at different heights and distances. A fixed lens must be refocused by hand each time, and a camera with weak color processing changes what a reviewer sees. As a 13MP Autofocus MIPI CSI-2 Camera, the Bolt-1335CRA focuses automatically from 100mm to infinity with a voice coil motor, finishes the image in an on-board ISP, and connects through 2-lane or 4-lane adapter boards. It supports the RK3588 and the NVIDIA Jetson Orin Nano, Orin NX, and AGX Orin platforms, so an instrument maker can choose compute separately from the camera. Designed for device makers building pathology and life science instruments, it supplies sharp, consistently colored images without manual focus. ———————————————————————————————————————————————————————————— Fresno Medical Waste Disposal Company Deals with Escalating Needlestick Injuries Through Essential Guide 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/937094489/fresno-medical-waste-disposal-company-deals-with-escalating-needlestick-injuries-through-essential-guide According to the CDC, healthcare workers in the United States face an estimated 385,000 needlestick and sharps injuries each year. The increasing rate of needlestick injuries and their serious repercussions on healthcare workers and the community are of great concern. ” — JP Richards FRESNO, CA, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Responding to the growing concern over needlestick injuries, BioMed ———————————————————————————————————————————————————————————— AI Med Consult Joins ModMed SynapSYS Marketplace as an Integration Partner for Plastic Surgery and Cosmetic Surgery Practices 2026-10-22 · Business Wire · AI, SaaS, Healthcare, Chemicals & materials https://finance.yahoo.com/healthcare/articles/ai-med-consult-joins-modmed-171000163.html Bidirectional integration reduces staff effort while enhancing patient experience. TAMPA, Fla., October 22, 2026--AI Med Consult , a HIPAA-compliant patient engagement platform for aesthetic surgery practices, today announced that it went live on the ModMed SynapSYS Marketplace as an integration partn ———————————————————————————————————————————————————————————— Array Skin Therapy Celebrates 15 Years of Expert Light Therapy With "15 Years of Light" Anniversary Campaign 2026-10-22 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/array-skin-therapy-celebrates-15-years-of-expert-light-therapy-with-15-years-of-light-anniversary-campaign-302916780.html Marking 15 years of specialized phototherapy, patient-centered care, and expanding access to drug-free treatment for psoriasis, vitiligo, eczema, and other chronic skin conditions. LOS ANGELES and ORANGE COUNTY, Calif., Oct. 22, 2026 -- Array Skin Therapy, a provider of... ———————————————————————————————————————————————————————————— OPM Announces Its 2026 Half-Year Financial Results and Provides an Update on Its Clinical Developments and Financial Position 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/opm-announces-2026-half-financial-170800273.html OPM-201: secured funding from the Michael J. Fox Foundation to support the development of the LARKIN program in Parkinson's disease OPM-101: continued preparation for the REVERT Phase 1b/2a clinical trial in advanced melanoma and partnership discussions regarding chronic inflammatory bowel diseases Significant reduction i ———————————————————————————————————————————————————————————— Vicore's Phase 2b ASPIRE Trial of Buloxibutid in IPF Passes Pre-Planned Futility Analysis and Remains on Track for Mid-2027 Topline Results 2026-10-22 · ACCESS Newswire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vicores-phase-2b-aspire-trial-170500979.html Independent Data Monitoring Committee recommends ASPIRE continue without modification; no safety concerns identified Fully enrolled 378-patient trial advances toward 52-week readout STOCKHOLM, SE AND CAMBRIDGE, MA / October 22, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a bi ———————————————————————————————————————————————————————————— MICHIGAN HEALTH CARE WORKERS BECOME TEAMSTERS 2026-10-22 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/michigan-health-care-workers-become-teamsters-302917270.html Nurses, Aides, and Other Employees Join Teamsters Local 406 CEDAR SPRINGS, Mich., Oct. 22, 2026 -- Two groups of health care workers at Intersect Healthcare of Cedar Springs in Cedar Springs, Mich., overwhelmingly voted to join Teamsters Local 406. The groups include 19... ———————————————————————————————————————————————————————————— Mundipharma Announces Further Phase III ReSPECT Results Presented as a Late-Breaking Oral Presentation at IDWeek 2026 2026-10-22 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/mundipharma-announces-further-phase-iii-170300644.html For Trade and Medical Media Only CAMBRIDGE, England, October 22, 2026--Today Mundipharma announced additional results from the global Phase III ReSPECT clinical trial evaluating REZZAYO ® (rezafungin acetate) for prophylaxis of invasive fungal diseases (IFDs) in adult patients undergoing allogeneic hae ———————————————————————————————————————————————————————————— Alzheimer's Disease Clinical Trial and Competitive Landscape Enters a New Phase as 200+ Companies Advance Clinical Programs | DelveInsight 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386781/0/en/alzheimer-s-disease-clinical-trial-and-competitive-landscape-enters-a-new-phase-as-200-companies-advance-clinical-programs-delveinsight.html The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis. The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming therapeutics, and commercial analysis. ———————————————————————————————————————————————————————————— A Turning Point: A Kidney Diagnosis Leads to a Path Toward Healing 2026-10-22 · 3BL Media · Healthcare, Media, Education, Travel, Biotech & pharma https://www.3blmedia.com/news/turning-point-kidney-diagnosis-leads-path-toward-healing A Turning Point: A Kidney Diagnosis Leads to a Path Toward Healing Fri, 10/23/2026 - 08:05 Body “Learning I had kidney disease was a big turning point,” Nobert Mike remembers. Nobert shares that he had a hard life growing up: “I lost a lot of good people, lost a lot of good things in my life.” He, like many other people he knows living on Navajo Nation, struggled with alcohol addiction. Eventually, his experience with addiction led to health complications. He was in the hospital for a week when test results confirmed his diagnosis, stage 3 kidney disease that had developed from undiagnosed IgA nephropathy. IgA nephropathy, also called Berger disease, is the third leading cause of chronic kidney disease (CKD). It involves a buildup of antibodies that inflames the kidneys and leads to blood and protein in the urine, high blood pressure and other symptoms of CKD. The diagnosis offered Nobert clarity: He wanted to get clean. He wanted to live a healthier life. He wanted to be able to take care of his daughter. After quitting alcohol and drugs, Nobert also focused on his physical health, shedding nearly 100 pounds in a few months. Still, Nobert’s kidney disease progressed, and ultimately, he and his nephrologist determined that he would need to start dialysis. While Nobert was familiar with hemodialysis, his doctor offered another option, peritoneal dialysis (PD). As a home modality, PD offers Nobert the ability to perform treatments at home while he sleeps without the need to travel a far distance from his home on Navajo Nation. Learning how to do PD at home Transitioning to home dialysis initially felt daunting. “It seemed difficult,” Nobert says. “It seemed like I was going to have trouble, but DaVita helped me a lot with the way they ran the procedure. And they gave me a bunch of booklets. It painted a very good picture of what you had to do. So, they were pretty thorough with the information.” Nobert has also leaned on his home nurse, Caitlin, and the rest of the DaVita care team to manage his care. “Caitlin’s been like my guardian angel,” Nobert says. “I’ve been through a lot, and she’s helped me through a lot of painful things — mentally, physically. It hasn’t been an easy ride…but the way she’s been taking care of me… I trust her with my life.” Benefits of PD & the path to transplant Performing PD overnight has given Mike back his independence and eliminated the burden of long-distance medical travel. “I can stay at home. I can fall asleep while I do my treatments,” he said. “I grew up being self-sufficient even when I was a lot younger, so I’m used to taking care of myself.” Today, stable home treatments have positioned Mike to pursue his ultimate goal: a kidney transplant. “Back when I was diagnosed, it felt like it was the end of the road,” Mike said. “I’m working toward it. With what kidney care provides now, five years later, I’m optimistic about my transplant. I’ve surprised myself with how far I’ve come.” Learn More Watch Healing in Our Own Way: Native Stories of Life and Dialysis to hear more from Nobert as well as other people navigating kidney health in rural America. Video Video Featured Image Type of Content Blog ———————————————————————————————————————————————————————————— NFL Biosciences Reports Its 2026 Half-Year Results and Progress With Its Two Immunotherapies for Smoking and Nicotine Cessation 2026-10-22 · Business Wire · Healthcare, Sports, Industrial https://finance.yahoo.com/healthcare/articles/nfl-biosciences-reports-2026-half-164400862.html NFL-101 – immunotherapy aimed at reducing neuroinflammation: Biomarker results supporting a personalized medicine approach Next step: discussions with the FDA and EMA to confirm the Phase 3 clinical development plan NFL-102 – immunotherapy aimed at restoring neuroplasticity Successful manufacturing of a GMP-compliant clin ———————————————————————————————————————————————————————————— Blue Sky Laser & Tox Introduces XERF Skin Tightening and becoming the first provider in Arlington, Virginia 2026-10-22 · MarketersMEDIA · SaaS, Healthcare, Energy https://news.marketersmedia.com/blue-sky-laser-and-tox-introduces-xerf-skin-tightening-and-becoming-the-first-provider-in-arlington-virginia/89205936 Blue Sky Laser & Tox has become Arlington, Virginia's first provider of XERF, a Korean-developed dual-frequency radiofrequency platform for nonsurgical skin tightening. The launch expands the practice's energy-based treatment menu and reflects growing patient demand for collagen remodeling without surgery. -- The market for nonsurgical aesthetic procedures continues to expand as patients prioritize visible improvemen ———————————————————————————————————————————————————————————— Lux Strands Highlights EverStrands Hair Preservation Program During Breast Cancer Awareness Month 2026-10-22 · EIN Presswire · Healthcare, Consumer goods https://www.einpresswire.com/article/951065677/lux-strands-highlights-everstrands-hair-preservation-program-during-breast-cancer-awareness-month The New York City and Nashville luxury salon highlights options for preserving natural hair before and after medical treatment For many people, hair carries memories, identity, and years of personal care” — Sandy Cannon NEW YORK, NY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Lux Strands, a luxury hair extension and restoration salon with locations in Manhattan and Nashville, is highlighting EverStrands, ———————————————————————————————————————————————————————————— Connected Nation study highlights broadband adoption and population health outcomes in the U.S. 2026-10-22 · PR Newswire · Healthcare, Telecom, Internet & apps https://www.prnewswire.com/news-releases/connected-nation-study-highlights-broadband-adoption-and-population-health-outcomes-in-the-us-302917211.html BOWLING GREEN, Ky., Oct. 22, 2026 -- Connected Nation (CN) has released a new report examining the relationship between household computer ownership and internet adoption and health outcomes at the county level across the United States. The report, titled "Broadband Adoption... ———————————————————————————————————————————————————————————— GTC Consulting Announces Publication of AI-Enabled Hybrid Healthcare Patent Application 2026-10-22 · EIN Presswire · AI, Healthcare https://www.einpresswire.com/article/951534934/gtc-consulting-announces-publication-of-ai-enabled-hybrid-healthcare-patent-application AI-enabled hybrid healthcare connects patients, clinicians, hospitals, and health plans through remote patient monitoring, artificial intelligence, and coordinated care delivery. New patent application expands telehealth innovation through AI, remote monitoring, and coordinated care. Ultimately, we started with the question, how do we create a healthcare delivery system where everyone wins?” — Benjamin Mink, Co-Inven ———————————————————————————————————————————————————————————— Nano-X Imaging (NASDAQ: NNOX) Advances Its Mission to Expand Access to Medical Imaging 2026-10-22 · FinanceWire · Finance, Healthcare https://financewire.com/2026/10/22/nano-x-imaging-nasdaq-nnox-advances-its-mission-to-expand-access-to-medical-imaging/ Austin, Texas, United States, 22nd October 2026, FinanceWire … Read More The post Nano-X Imaging (NASDAQ: NNOX) Advances Its Mission to Expand Access to Medical Imaging appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— BOXABL (NASDAQ: BXBL) Announces Workforce Housing Project at Sage Memorial Hospital in Arizona 2026-10-22 · FinanceWire · Finance, Healthcare, Real estate, Jobs & workplace https://financewire.com/2026/10/22/boxabl-nasdaq-bxbl-announces-workforce-housing-project-at-sage-memorial-hospital-in-arizona/ Austin, Texas, United States, 22nd October 2026, FinanceWire … Read More The post BOXABL (NASDAQ: BXBL) Announces Workforce Housing Project at Sage Memorial Hospital in Arizona appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— SeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKI 2026-10-22 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/22/3386723/0/en/seastar-medical-reports-statistically-significant-survival-findings-from-post-approval-quelimmune-save-registry-analysis-in-pediatric-sepsis-associated-aki.html New late-breaking data presented today at ASN Kidney Week 2026 ———————————————————————————————————————————————————————————— KFSH Governs Clinical AI with Safeguards Against Bias, Hallucinations and Performance Drift 2026-10-22 · EIN Presswire · AI, Healthcare https://www.einpresswire.com/article/951448372/kfsh-governs-clinical-ai-with-safeguards-against-bias-hallucinations-and-performance-drift A clinical training session for KFSH staff in Riyadh RIYADH, SAUDI ARABIA, October 22, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) governs the artificial intelligence applications it develops through safeguards against bias, inaccurate outputs, and performance drift, testing tools before deployment and monitoring them afterward to keep AI safe for clinical use. An AI model ———————————————————————————————————————————————————————————— The Risk-Based Monitoring System Market Is Expected to Grow at a Steady CAGR of 11.4% Through 2030 2026-10-22 · EIN Presswire · Healthcare, Biotech & pharma https://www.einpresswire.com/article/950142997/the-risk-based-monitoring-system-market-is-expected-to-grow-at-a-steady-cagr-of-11-4-through-2030 Risk-Based Monitoring System Market Report The Business Research Company The Business Research Company’s Risk-Based Monitoring System Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035 LONDON, GREATER LONDON, UNITED KINGDOM, October 22, 2026 / EINPresswire.com / -- The risk-based monitoring system market is seeing rapid development driven by the evolving needs of clinical trials and regulatory de ———————————————————————————————————————————————————————————— InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386711/0/en/inflarx-highlights-izicopan-s-therapeutic-potential-at-kidney-week-2026.html Jena, Germany, Oct. 22, 2026 -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced the presentation of new pre-clinical data on izicopan in renal disease models at the American Society of Nephrology’s Kidney Week 2026, taking place in Denver, Colorado, October 21 - 25. The in vivo and in vitro data demonstrated that izicopan robustly inhibited C5aR-mediated inflammatory responses and provided renal protection, supporting its potential as a therapeutic candidate for complement-driven kidney diseases. ———————————————————————————————————————————————————————————— The Fibroid Foundation Outlines Priorities Following Women's Health Executive Order 2026-10-22 · Newswire.com · Finance, Healthcare, Education https://www.newswire.com/news/the-fibroid-foundation-outlines-priorities-following-womens-health-22877046 Calls for research funding, stronger medical education, and patient input ———————————————————————————————————————————————————————————— Nexus Medical Enterprises, LLC Announces Renewed Partnership with Kids’ Chance of Texas 2026-10-22 · Business Wire · Healthcare, Nonprofits, Jobs & workplace https://finance.yahoo.com/healthcare/articles/nexus-medical-enterprises-llc-announces-152600453.html Focusing Support on Educational Opportunities for Students Impacted by Workplace Injuries SCHERTZ, Texas, October 22, 2026--Nexus Medical Enterprises, LLC is proud to announce our renewed partnership with Kids' Chance of Texas (KCTX), a nonprofit organization dedicated to providing scholarships to Texas students whose parents have been seriously injured or killed on the job. Through this partnersh ———————————————————————————————————————————————————————————— PLEOPHARMA TO PRESENT SURVEY DATA ON CANNABIS WITHDRAWAL IN WOMEN SEEKING CANNABIS CESSATION PleoPharma, Inc. October 22 2026-10-22 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/pleopharma-to-present-survey-data-on-cannabis-withdrawal-in-women-seeking-cannabis-cessation-pleopharma-inc-october-22-302917149.html PleoPharma presents research survey findings characterizing women's experiences with frequent cannabis use, cessation efforts, and cannabis withdrawal symptoms. PHOENIXVILLE, Pa., Oct. 22, 2026 -- PleoPharma, Inc., a clinical-stage development company focused on... ———————————————————————————————————————————————————————————— Intermountain Health Lutheran Breast Center Reaccredited by American College of Surgeons 2026-10-22 · PRUnderground · Healthcare, Agriculture https://prunderground.com/intermountain-health-lutheran-breast-center-reaccredited-by-american-college-of-/cmvjmkz0g000307l5hnnlp4s6 Intermountain Health Lutheran Hospital Breast Care Center in Wheat Ridge receives renewed NAPBC accreditation. The post Intermountain Health Lutheran Breast Center Reaccredited by American College of Surgeons first appeared on ———————————————————————————————————————————————————————————— Avel eCare Awarded Grant to Expand EMS Telemedicine 2026-10-22 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/avel-ecare-awarded-grant-expand-151000876.html $1.36 million Investment will bring next-generation telehealth technology to more South Dakota ambulances SIOUX FALLS, SD / October 22, 2026 / Avel eCare, the nation's leading virtual health system, has received a $1.36 million Rural Health Transformation Program award from the South Dakota Department of ———————————————————————————————————————————————————————————— New Global Initiative Seeks to Modernize Health Workforce Mobility 2026-10-22 · ScoopAsia · Healthcare, Automotive, Jobs & workplace https://scoopasia.com/new-global-initiative-seeks-to-modernize-health-workforce-mobility/ TruMerit and Centennial College, with support of the Groningen Declaration Network (GDN Network), have unveiled a new vision for the future of global health workforce mobility, introducing a framework designed to help health professionals carry trusted, verifiable records of their qualifications and competencies across borders. ———————————————————————————————————————————————————————————— Allstar Opens Elite Soccer Training for Players 12 to 19 2026-10-22 · ACCESS Newswire · Healthcare, Gaming, Sports https://finance.yahoo.com/media-advertising/articles/allstar-opens-elite-soccer-training-150000365.html The Allstar coaching team will run every camp in person, in a one-week series built for the years that decide whether a young player has a future in the game MIAMI, FL / October 22, 2026 / Allstar Health Brands today opened registration for Allstar Elite Training, a series of one-week performance camps f ———————————————————————————————————————————————————————————— Las Vegas Dentist on Psychological Impact of Tooth Loss 2026-10-22 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/951043039/las-vegas-dentist-on-psychological-impact-of-tooth-loss Dr. Jim Willardsen details how missing teeth can affect self-esteem, and what patients should know about dental implants and other treatment options. LAS VEGAS, NV, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Tooth loss is often discussed in terms of chewing, speech, and bone health, but its emotional and psychological effects can be just as significant. At True Dentistry, Las Vegas implant dentist Jim Wi ———————————————————————————————————————————————————————————— Alignment Health Adds New Medicare Advantage Plan in Pima County, Increasing Access and Choice for Arizona Seniors 2026-10-22 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/22/3386654/0/en/alignment-health-adds-new-medicare-advantage-plan-in-pima-county-increasing-access-and-choice-for-arizona-seniors.html New plan strengthens Alignment’s Arizona portfolio available to nearly 1.1 million Medicare beneficiaries across Maricopa, Pima and Santa Cruz counties New plan strengthens Alignment’s Arizona portfolio available to nearly 1.1 million Medicare beneficiaries across Maricopa, Pima and Santa Cruz counties ———————————————————————————————————————————————————————————— Eco-Friendly Water Bottle Market Analysis: Consumer Demand and Industry Innovations 2026-10-22 · PR News Releaser · Healthcare, Retail, Sustainability, Chemicals & materials https://www.prnewsreleaser.com/news/477065 The eco-friendly water bottle market is expected to witness substantial growth through 2034 as consumers increasingly prioritize sustainability, convenience, and health-conscious living. The growing movement toward reducing single-use plastics has accelerated demand for reusable water bottles made from stainless steel, ... Read more ———————————————————————————————————————————————————————————— DEA's Marijuana Rescheduling Defense Under Fire: The Fallout From GAO's Procedural Findings 2026-10-22 · Newswire.com · Healthcare, Government & policy https://www.newswire.com/news/deas-marijuana-rescheduling-defense-under-fire-the-fallout-from-gaos-procedural Duane Boise CEO of MMJ International Holdings: "The government restricted its own witness's testimony, then argued the other side already had its chance while a Federal watchdog findings expose serious weaknesses in DEA and FDA decision making as the government fights to prevent further scrutiny of marijuana rescheduling". ———————————————————————————————————————————————————————————— Sofusa® Holdings Relaunches as Independent Company to Advance Lymphatic Drug Delivery 2026-10-22 · Business Wire · SaaS, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/sofusa-holdings-relaunches-independent-company-143700103.html Precision lymphatic targeting platform validated with clinical data in both Rheumatoid Arthritis and in Cancer; Class II Device FDA submission planned in Q2 2027. NEW YORK, October 22, 2026--Sofusa Holdings today announced its launch as an independent, clinical-stage company pioneering the development ———————————————————————————————————————————————————————————— The Quantra® System from HemoSonics Earns Best Instrument Honors at 85th Annual AAST Meeting 2026-10-22 · Business Wire · Healthcare, Government & policy https://finance.yahoo.com/healthcare/articles/quantra-system-hemosonics-earns-best-143200671.html Attendee-voted recognition highlights the Quantra System's relevance to trauma care. DURHAM, N.C., October 22, 2026--HemoSonics, LLC announced that its Quantra® System was named Best Instrument at the 85th Annual Meeting of the American Association for the Surgery of Trauma (AAST) and Clinical Congress of Acute Care Surgery, held September 16–19 in Dallas, TX. The award was voted on by meeting at ———————————————————————————————————————————————————————————— Charcot Marie Tooth Disease - Drug Pipeline Insights and Competitive Landscape, 2026 | 15+ Drugs Signal Gene Therapy and Neuromuscular Innovation Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386596/28124/en/charcot-marie-tooth-disease-drug-pipeline-insights-and-competitive-landscape-2026-15-drugs-signal-gene-therapy-and-neuromuscular-innovation-opportunities.html Track Charcot-Marie-Tooth pipeline innovation, from first-in-class therapies to gene therapy, with clinical progress, unmet needs, collaborations, licensing and M&A insights Track Charcot-Marie-Tooth pipeline innovation, from first-in-class therapies to gene therapy, with clinical progress, unmet needs, collaborations, licensing and M&A insights ———————————————————————————————————————————————————————————— AI in Clinical Trials Market Size, Share, Trends, and Forecast 2026-2035 | 14% CAGR to USD 8.67 Billion as Predictive Analytics Accelerates Drug Development 2026-10-22 · GlobeNewswire · AI, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386588/28124/en/ai-in-clinical-trials-market-size-share-trends-and-forecast-2026-2035-14-cagr-to-usd-8-67-billion-as-predictive-analytics-accelerates-drug-development.html Dublin, Oct. 22, 2026 -- "AI in Clinical Trials Market Size, Share and Forecast Trends - Growth Analysis and Outlook Report (2026-2035)" has been added to ResearchAndMarkets.com's offering. ———————————————————————————————————————————————————————————— AI in Remote Patient Monitoring Market Size and Forecast to 2040 by Component, Application, End-User, and Region | Predictive Care Drives 23.1% CAGR to $61.40 Billion 2026-10-22 · GlobeNewswire · AI, SaaS, Healthcare, Consumer electronics https://www.globenewswire.com/news-release/2026/10/22/3386587/28124/en/ai-in-remote-patient-monitoring-market-size-and-forecast-to-2040-by-component-application-end-user-and-region-predictive-care-drives-23-1-cagr-to-61-40-billion.html AI-driven predictive monitoring, adherence tools and wearable integration enable earlier interventions, fewer readmissions, lower costs and scalable value-based care. AI-driven predictive monitoring, adherence tools and wearable integration enable earlier interventions, fewer readmissions, lower costs and scalable value-based care. ———————————————————————————————————————————————————————————— Lyric Releases Framework for Measuring Healthcare Decision Intelligence Maturity in Payment Accuracy 2026-10-22 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/lyric-releases-framework-measuring-healthcare-134200159.html New framework assesses how far core payment accuracy functions have advanced as health plans set priorities for 2027 NASHVILLE, Tenn., October 22, 2026--Lyric, a healthcare decision intelligence company helping health plans make faster, more accurate, and more transparent payment decisions, today rele ———————————————————————————————————————————————————————————— VSee Health Shareholder Letter 2026-10-22 · Newswire.com · Healthcare https://www.newswire.com/news/vsee-health-shareholder-letter-22876981 VSee Health Projects a Transformative 2027 ———————————————————————————————————————————————————————————— DP World Supports Community Health Recovery in Chile Following Devastating Wildfires 2026-10-22 · ACCESS Newswire · Healthcare, Construction & engineering https://finance.yahoo.com/healthcare/articles/dp-world-supports-community-health-133000059.html Through a land-use agreement, DP World is helping enable the construction of a new community health center in Lirquén, restoring access to essential healthcare services for more than 3,000 residents affected by the January 2026 wildfires. LIRQUÉN, CL / October 22, 2026 / DP World is supporting the recove ———————————————————————————————————————————————————————————— NeOnc Heads to Fox Business as Brain Cancer Milestones Put Its Mission in the Spotlight 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386506/0/en/neonc-heads-to-fox-business-as-brain-cancer-milestones-put-its-mission-in-the-spotlight.html NeOnc (NASDAQ: NTHI) is taking its brain cancer story to Fox Business Network when several developments put the clinical-stage biotech in the spotlight ———————————————————————————————————————————————————————————— Psoriatic Arthritis - Global Clinical Trials Review and Competitive Landscape, 2026 | Pipeline Innovation and Trial Expansion Drive Strategic Growth 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386477/28124/en/psoriatic-arthritis-global-clinical-trials-review-and-competitive-landscape-2026-pipeline-innovation-and-trial-expansion-drive-strategic-growth.html Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy. Identify cost-efficient trial locations, investment priorities and business opportunities while benchmarking enrollment trends and trial success to sharpen competitive strategy. ———————————————————————————————————————————————————————————— Diffuse Large B-Cell Lymphoma (DLBCL) - Global Clinical Trials Review, 2026 | CAR-T and Phase III Pipelines Fuel Investment and Partnership Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Automotive, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386476/28124/en/diffuse-large-b-cell-lymphoma-dlbcl-global-clinical-trials-review-2026-car-t-and-phase-iii-pipelines-fuel-investment-and-partnership-opportunities.html Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage. Identify cost-efficient trial locations, investment opportunities and enrollment trends to sharpen strategy and gain a competitive advantage. ———————————————————————————————————————————————————————————— MIMOSA Diagnostics Wins Ontario Centre of Innovation’s 2026 Mind2Market Award for MIMOSA Pro 2026-10-22 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/951340015/mimosa-diagnostics-wins-ontario-centre-of-innovation-s-2026-mind2market-award-for-mimosa-pro MIMOSA Diagnostics, maker of the MIMOSA Pro wound and tissue-health imaging device, receives the Ontario Centre of Innovation’s 2026 Mind2Market Award, sponsored by GeoMate. The MIMOSA Pro Device MIMOSA Pro helps clinicians identify early signs of pressure injuries and deep tissue injuries and manage chronic wounds from admission to discharge TORONTO, ON, CANADA, October 22, 2026 / EINPresswire.com / -- Key facts Who ———————————————————————————————————————————————————————————— Frozen Shoulder Syndrome - Global Clinical Trials Landscape and Competitive Intelligence Report, 2026 | Enrollment Trends and Sponsor Activity Reveal R&D Investment Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386465/28124/en/frozen-shoulder-syndrome-global-clinical-trials-landscape-and-competitive-intelligence-report-2026-enrollment-trends-and-sponsor-activity-reveal-r-d-investment-opportunities.html Optimize trial investment by identifying cost-efficient locations, key business opportunities, enrollment trends and competitive strategies across global markets. Optimize trial investment by identifying cost-efficient locations, key business opportunities, enrollment trends and competitive strategies across global markets. ———————————————————————————————————————————————————————————— Mycosis Fungoides - Global Clinical Trials Landscape Review, 2026 | Pipeline, Enrollment, Sponsor, and Regional Trends Reveal R&D Investment Opportunities 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386464/28124/en/mycosis-fungoides-global-clinical-trials-landscape-review-2026-pipeline-enrollment-sponsor-and-regional-trends-reveal-r-d-investment-opportunities.html Identify trial locations that save time and cost, uncover investment opportunities, and shape competitive strategies with global trial, enrollment and success rate insights. Identify trial locations that save time and cost, uncover investment opportunities, and shape competitive strategies with global trial, enrollment and success rate insights. ———————————————————————————————————————————————————————————— Sagility Accelerates Provider Growth Strategy Through Acquisition of Chirok Health 2026-10-22 · PRWeb · Finance, Healthcare https://www.prweb.com/releases/sagility-accelerates-provider-growth-strategy-through-acquisition-of-chirok-health-302916692.html Transaction expands provider - focused capabilities in Clinical Documentation Improvement, Coding Audit and Quality Assurance, Revenue Integrity, Value-Based Care Solutions, HCC Coding and Risk Adjustment ATLANTA, Oct. 22, 2026 -- Sagility, a leading technology and... ———————————————————————————————————————————————————————————— NeuroThera Labs Reports Positive Progress in FDA-Approved Phase IIb Clinical Trial for Tourette Syndrome 2026-10-22 · NewMediaWire · Healthcare, Education, Food & drink, Industrial, Biotech & pharma, Government & policy https://www.newmediawire.com/news/neurothera-labs-reports-positive-progress-in-fda-approved-phase-iib-clinical-trial-for-tourette-syndrome-7090795 TORONTO, ONTARIO - October 22, 2026 - NeuroThera Labs Inc. (TSXV: NTLX) (the "Company" or "NeuroThera"), a clinical-stage pharmaceutical company and a subsidiary of SciSparc Ltd., today announced further progress in its U.S. Food and Drug Administration (“FDA”) approved clinical trial program evaluating SCI-110 for the treatment of Tourette Syndrome (“TS”) in adults. The Company has successfully completed the manufacturing of the investigational product and obtained the required batch release certification from a European Qualified Person (“QP”), a key regulatory milestone authorizing shipment of clinical trial material to participating study sites. The release enables site activation activities and supports the initiation of patient enrollment in the FDA-approved Phase IIb clinical trial for TS. The Phase IIb clinical trial is being conducted at three clinical sites: Yale Child Study Center at Yale School of Medicine in New Haven, Connecticut, USA; Hannover Medical School in Hanover, Germany; and Tel Aviv Sourasky Medical Center in Tel Aviv, Israel. All participating sites have successfully completed their site initiation activities and are prepared to receive clinical trial drug supplies following QP batch release. Completion of site initiation activities across all participating clinical centers, together with the successful European QP release of clinical trial supplies, marks a significant operational milestone for NeuroThera. The Company is now advancing toward patient enrollment in its Phase IIb clinical trial for TS, with investigational product shipments to study sites expected in the near term. SCI-110 is NeuroThera’s proprietary, patent-protected cannabinoid-based drug candidate, combining dronabinol and palmitoylethanolamide (PEA) in a single oral dosage form. The Phase IIb study is evaluating SCI-110's efficacy, safety and tolerability in adults with TS, a condition with substantial unmet treatment needs. About NeuroThera Labs Inc. NeuroTheraLabsInc. (TSXV:NTLX) is a clinical-stage pharmaceutical company focused on developing novel therapeutics for central nervous system disorders and other underserved health conditions through collaborations and innovative combinations. For further information, please contact: Michal Efraty IR Manager NeuroThera Labs Inc. Telephone: +972-3-7617108 Email: michal@efraty.com Neither the TSXV nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this release. Cautionary Notice on Forward-Looking Statements This news release contains statements that constitute "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking information and are based on expectations, estimates and projections as at the date of this news release. Forward-looking information in this news release includes statements regarding: the initiation of patient enrollment in the Phase IIb clinical trial for TS; the expected timing for investigational product shipments to study sites; and the potential efficacy, safety and tolerability of SCI-110. These statements are not guarantees of future performance and undue reliance should not be placed on them. Such forward-looking information necessarily involves known and unknown risks and uncertainties, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking information. Such factors include, without limitation: the ability of the Company to progress toward patient enrollment for its Phase IIb clinical trial for TS; and the other risks described in the Company's continuous disclosure documents filed on SEDAR+ (www.sedarplus.ca). The Company does not undertake any obligation to update or revise any forward-looking information, except as required by applicable securities laws. ———————————————————————————————————————————————————————————— Everleap Fertility to Present Industry-Leading Scientific Research at ASRM 2026 2026-10-22 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/everleap-fertility-present-industry-leading-130000148.html Research Advances in Embryo Genetics, Male-Factor Infertility and More to Improve Clinical Processes and Outcomes Across the Fertility Industry BASKING RIDGE, N.J., October 22, 2026--Everleap Fertility , a leader in fertility care and assisted reproduction, will deliver 19 scientific presentations at ———————————————————————————————————————————————————————————— UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2026 2026-10-22 · ACCESS Newswire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/utmd-reports-financial-performance-third-130000827.html SALT LAKE CITY, UT / October 22, 2026 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2026 financial results that include changes from the prior year's same period results. Currencies in this release are denoted as $ or USD = U.S. Dollars ———————————————————————————————————————————————————————————— AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa 2026-10-22 · AbbVie · Healthcare https://www.prnewswire.com/news-releases/abbvie-announces-topline-results-from-the-phase-3-intrepid-trial-showing-lutikizumab-significantly-improved-signs-and-symptoms-of-disease-in-patients-with-hidradenitis-suppurativa-302915895.html In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16... ———————————————————————————————————————————————————————————— Champ's Pet Kitchen Expands California Grocery Footprint with Stater Bros. Markets Launch 2026-10-22 · EIN Presswire · Healthcare, Food & drink https://www.einpresswire.com/article/935405431/champ-s-pet-kitchen-expands-california-grocery-footprint-with-stater-bros-markets-launch Champ’s Pet Kitchen announces its launch of dog treats at Stater Bros. Markets in Southern California. Communities throughout Southern California can now find Champ's Pet Kitchen dog treats at Stater Bros. Markets. Made in the USA with clean ingredients, Champ’s Pet Kitchen dog treats deliver a minimum of 26% real protein with functional ingredients to support canine health. High-protein, functional dog treats now on ———————————————————————————————————————————————————————————— Biograph Completes First U.S. Study with Caristo Diagnostics’ AI-Powered Coronary Inflammation Detection, Finding Risk in Over 42% of Asymptomatic Patients 2026-10-22 · Business Wire · AI, Healthcare, Medical devices https://finance.yahoo.com/healthcare/articles/biograph-completes-first-u-study-130000817.html The study evaluated whether AI analysis of coronary inflammation in cardiac CT scans can help identify early cardiovascular risk before symptoms or obstructive plaque appear SAN MATEO, Calif. & NEW YORK, October 22, 2026--Biograph , the world's most advanced preventive health and diagnostics clinic, t ———————————————————————————————————————————————————————————— IHI and Bristol Myers Squibb Launch National Collaborative to Expand Access to Cancer Clinical Trials 2026-10-22 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ihi-bristol-myers-squibb-launch-125500423.html Three-year initiative will bring clinical research closer to patients and address barriers to trial participation BOSTON, October 22, 2026--The Institute for Healthcare Improvement (IHI), in partnership with Bristol Myers Squibb (BMS), is launching a new Cancer Collective Action Collaborative. This thr ———————————————————————————————————————————————————————————— The Evolution of Pregnancy Test Kits: From Traditional Methods to Digital Solutions 2026-10-22 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/476746 The global Pregnancy Test Kits Market is witnessing steady growth as awareness of reproductive health, early pregnancy detection, and convenient home-based testing continues to increase. Pregnancy test kits provide a quick and accessible method for detecting pregnancy, enabling individuals to ... Read more ———————————————————————————————————————————————————————————— Perimeter Medical Imaging AI to Participate in the Planet MicroCap Showcase in Toronto 2026-10-22 · PR Newswire · AI, Healthcare, Medical devices https://www.prnewswire.com/news-releases/perimeter-medical-imaging-ai-to-participate-in-the-planet-microcap-showcase-in-toronto-302916356.html TORONTO and DALLAS, Oct. 22, 2026 -- Perimeter Medical Imaging AI, Inc. (TSX-V: PINK) (OTCQX: PYNKF) ("Perimeter" or the "Company"), a commercial-stage medical technology company, is pleased to announce that its CEO, Adrian Mendes, will present a Company update regarding... ———————————————————————————————————————————————————————————— Uwill's Expanded Mental Health Offering Provides Unlimited Counseling and Crisis Support for University of Michigan Students 2026-10-22 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/uwills-expanded-mental-health-offering-provides-unlimited-counseling-and-crisis-support-for-university-of-michigan-students-302916137.html In partnership with Uwill, U-M students will receive unlimited access to licensed therapists around the clock, wherever in the world they are studying NATICK, Mass., Oct. 22, 2026 -- Uwill, the leading mental health and wellness solution for colleges and students, is... ———————————————————————————————————————————————————————————— Medical Mask Market Expansion at 7.03% CAGR Through 2033 Amid Rising Infection Prevention Awareness 2026-10-22 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/476729 The Medical Mask Market size was valued at US$ 3.75 Billion in 2025 and is projected to reach US$ 6.46 Billion by 2033, growing at a CAGR of 7.03% during 2026–2033. The retrieved public source material for this batch did ... Read more ———————————————————————————————————————————————————————————— Influential Women Spotlights Carolyn Vicenzino: Strengthening Cardiovascular Care Through Leadership And Partnership 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951491186/influential-women-spotlights-carolyn-vicenzino-strengthening-cardiovascular-care-through-leadership-and-partnership MORRIS TOWN, NJ, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Vice President of Operations for the Heart and Vascular Service Line at RWJBarnabas Health Drives Program Development, Physician Alignment, and Performance Improvement Morristown, New Jersey – Carolyn Vicenzino is the Vice President of Operations for the Heart and Vascular Service Line at RWJBarnabas Health, where she leads strategic and operati ———————————————————————————————————————————————————————————— Candel Therapeutics Appoints Maria Ostrovsky as General Counsel 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386313/0/en/candel-therapeutics-appoints-maria-ostrovsky-as-general-counsel.html NEEDHAM, Mass., Oct. 22, 2026 -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Maria Ostrovsky as General Counsel, effective November 3, 2026. Ms. Ostrovsky has 20 years of legal experience, most of it in the life sciences industry. She will oversee Candel’s legal and compliance functions, including corporate governance, and report to Candel’s President and Chief Executive Officer. ———————————————————————————————————————————————————————————— SCIENTURE Issues Shareholder Letter Highlighting Sequential Revenue Growth, Two FDA-Approved Commercial Products, and Continued Progress Toward Profitability in 2027 2026-10-22 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/10/22/3386312/0/en/scienture-issues-shareholder-letter-highlighting-sequential-revenue-growth-two-fda-approved-commercial-products-and-continued-progress-toward-profitability-in-2027.html Preliminary Unaudited Third Quarter Revenue Increased 256% Sequentially to Approximately $1.22 Million, Supported by Continued Arbli™ Growth and the Commercial Launch of REZENOPY™ ———————————————————————————————————————————————————————————— Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia 2026-10-22 · GlobeNewswire · Finance, Healthcare, Education, Medical devices https://www.globenewswire.com/news-release/2026/10/22/3386309/21634/en/stereotaxis-announces-first-robotic-magnetic-navigation-system-in-latvia.html ST. LOUIS, Oct. 22, 2026 -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigation System. ———————————————————————————————————————————————————————————— Dr. LaReesa Ferdinand Addresses Midlife Health for World Menopause Day on TipsOnTV 2026-10-22 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/dr-lareesa-ferdinand-addresses-midlife-120000624.html A More Informed Approach to Aging ATLANTA, GA / October 22, 2026 / Women's hormone expert Dr. LaReesa Ferdinand shares why menopause deserves a broader conversation about the changes women may experience throughout midlife. In recognition of World Menopause Day, she offers practical guidance to help wome ———————————————————————————————————————————————————————————— 4Tissue raises €7 million in Series A financing and appoints Stéphanie Dupont as CEO 2026-10-22 · GlobeNewswire · Finance, Healthcare, Chemicals & materials https://www.globenewswire.com/news-release/2026/10/22/3386239/0/en/4tissue-raises-7-million-in-series-a-financing-and-appoints-st%C3%A9phanie-dupont-as-ceo.html 4Tissue raises €7 million in Series A funding and appoints Stéphanie Dupont as CEO to advance its regenerative medicine technology and clinical development ———————————————————————————————————————————————————————————— SCYNEXIS Completes Phase 1 Study of Intravenous SCY-247, a Novel, Triterpenoid Antifungal in Development for Treatment and Prevention of Invasive Fungal Diseases 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386244/0/en/scynexis-completes-phase-1-study-of-intravenous-scy-247-a-novel-triterpenoid-antifungal-in-development-for-treatment-and-prevention-of-invasive-fungal-diseases.html JERSEY CITY, N.J., Oct. 22, 2026 -- SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS”, or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced topline results from its Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) trial of the intravenous (IV) formulation of SCY-247, its second-generation triterpenoid (fungerp) antifungal candidate. SCY-247 is under development in both oral and intravenous (IV) formulations for the treatment and prevention of invasive fungal infections with the potential to provide therapeutic advantages by having activity against drug-resistant fungi. ———————————————————————————————————————————————————————————— CareView Communications Announces New Business Agreement with San Juan Regional Medical Center 2026-10-22 · Business Wire · AI, Healthcare, Nonprofits https://finance.yahoo.com/healthcare/articles/careview-communications-announces-business-agreement-120000657.html LEWISVILLE, Texas, October 22, 2026--CareView Communications, Inc. ("CareView" or the "Company") (OTCQB: CRVW), a leader in virtual patient observation and AI-powered safety solutions, today announced a new business agreement with San Juan Regional Medical Center, a community-owned, nonprofit healthcar ———————————————————————————————————————————————————————————— RiboX Therapeutics Announces Publication in The New England Journal of Medicine Highlighting First-in-Human Circular RNA Therapy for Radiation-Induced Xerostomia 2026-10-22 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/ribox-therapeutics-announces-publication-england-120000249.html Research Letter Reports First-in-Human Use of Circular RNA Therapy, with RXRG001 Demonstrating Durable Improvements in Salivary Flow and Patient-Reported Xerostomia Symptoms Single-Dose Treatment Was Well Tolerated with No Dose-Limiting Toxicities Observed in the First Six Patients Across Two Dose Cohorts RXRG001 Recently ———————————————————————————————————————————————————————————— UnitedHealthcare to Support Northeast Missouri Health Council Efforts to Sustain and Expand Rural Maternal Healthcare 2026-10-22 · Business Wire · Healthcare, Jobs & workplace https://finance.yahoo.com/healthcare/articles/unitedhealthcare-support-northeast-missouri-health-120000604.html Investment will help strengthen OB-GYN coverage, recruit maternal health providers and advance a rural family medicine with obstetrics workforce pipeline October 22, 2026--UnitedHealthcare today announced a $540,000 investment to support Northeast Missouri Health Council (NMHC), a federally qualified h ———————————————————————————————————————————————————————————— DiaMedica Therapeutics Announces Enrollment of 200th Patient in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/diamedica-therapeutics-announces-enrollment-200th-120000870.html Independent Data Safety Monitoring Board to Conduct a Pre-Specified Interim Analysis to Assess Need for Sample Size Re-Estimation Interim Analysis Results Expected in Q1 2027 MINNEAPOLIS, October 22, 2026--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on ———————————————————————————————————————————————————————————— At the Border, Democratic Republic of Congo (DRC) and South Sudan Strengthen Ebola Surveillance 2026-10-22 · APO Group · Healthcare, Travel, Government & policy https://who-africa.africa-newsroom.com/press/at-the-border-democratic-republic-of-congo-drc-and-south-sudan-strengthen-ebola-surveillance?lang=en “Information is important. Being informed is part of prevention,” says Cosmas Sandani Lasuba, a South Sudanese refugee living in the Méri camp in the Aba health zone, about 18 kilometers from the border between the Democratic Republic of the Congo (DRC) and South Sudan. As President of the South Sudanese refugees settled at this site, Cosmas closely follows an awareness session on Bundibugyo virus disease. He is tasked with raising awareness among his peers about preventive measures. “People must wash their hands and respect distancing. I think this is very important to avoid being infected with Ebola,” he explains. Like Cosmas, more than 26,000 South Sudanese refugees live in the Aba health zone. Located about 436 km from Isiro, the capital of Haut-Uélé province, Aba is a strategic surveillance point along the border with South Sudan. The proximity of communities, cross-border movements, and refugee flows require constant vigilance on both sides. These population movements are a major concern as the Ebola outbreak has already affected several health zones in Haut-Uélé. As of 17 October 2026, the province had recorded 408 confirmed cases and 176 deaths, with 7 of its 13 health zones impacted. Aba has not reported any cases, but its geographical position and regular cross-border movements make it a high-risk area. To reduce this risk, health authorities in the DRC and South Sudan, with support from the World Health Organization (WHO), are strengthening cross-border surveillance and coordination to quickly detect alerts and prevent the virus from spreading beyond the border. For Dr Simon Sebit Yatoma, Medical Director of Yei River County in South Sudan, the challenge is anticipation: “Ebola is in the DRC, and the DRC is close to Yei. That is why we are working together so that, if a case occurs, we are able to respond jointly and rapidly. As you know, viruses have no borders, and only our solidarity can help us defeat them.” Health officials from both countries met in Aba to define common mechanisms for surveillance and response. The meeting resulted in a roadmap covering information sharing, disease surveillance, joint investigations, and risk communication. “Since there are many movements between Aba and the Yei health zone, this was an opportunity for us to exchange and set up joint mechanisms to effectively fight the spread of this epidemic,” explains Dr Patrick Banza Piongo, Head of the Haut-Uélé Provincial Health Division. “We have established a schedule where each week we will share information on communication and disease surveillance. We will work together in coordination to carry out this fight jointly.” At points of entry, the system relies on handwashing, temperature checks, and information collection to quickly identify travelers with suspicious symptoms. A temporary isolation space allows suspected cases to be held until a rapid response team intervenes for investigations, sample collection, and patient care. In Aba, five of the eleven proposed entry and control points are already operational. However, challenges remain: the health zone faces shortages of personal protective equipment, inadequate isolation capacity, and the absence of an ambulance for transferring suspected cases. Assessments are underway by the Ministry of Health with partner support to fill these gaps as quickly as possible. For WHO, this local cooperation must ensure that communities living on both sides of the border benefit from a coordinated response. “Our priority is to strengthen the capacities of neighboring countries so they can quickly detect alerts, confirm suspected cases, and ensure patient care. This is essential to reduce the risk of Ebola spreading beyond borders,” emphasizes Dr Marie Roseline Bélizaire, Regional Director for Emergencies at WHO Africa. WHO is also supporting capacity building in South Sudan and other neighboring countries at risk of importing the virus. This support includes assessing existing capacities, strengthening disease surveillance, training in contact tracing and investigations, enhancing laboratory detection and confirmation capacities, preparing treatment facilities, and training health professionals involved in all these activities. In Aba and Yei alike, this cooperation also foresees joint investigations, contact tracing, and harmonized awareness messages for communities. In Méri, strengthened surveillance and prevention directly concern the thousands of refugees living near the border. In this context of an Ebola outbreak, Cosmas welcomes the attention given to them: “We appreciate the commitment of the authorities and partners who think of our health and act to protect our community against Ebola,” he concludes. Distributed by APO Group on behalf of WHO Regional Office for Africa. ———————————————————————————————————————————————————————————— DataMEDS AI Enters Into Amended and Restated LOI to License and Acquire IP that Enables Goal-Driven Prescription Drug Telehealth, Medical Drones and Healthcare Blockchain Technologies 2026-10-22 · Newswire.com · Finance, Crypto, AI, Healthcare, Sports, Aerospace & defense, Biotech & pharma, Software & IT https://www.newswire.com/news/datameds-ai-enters-into-amended-and-restated-loi-to-license-and-acquire-ip-that Proprietary IP Position Until At Least 2042 to Enable Consolidation of Infrastructure targeting market expected to grow from $9.6 billion in 2025 to $93.4 billion in 2035 Customer Acquisition Plan Leverages Existing Relationship with NFL Alumni Health Final Guidance issued by FDA Provides Roadmap for Prescription Drug Proprietary Health Lives Here™ App and DelivMeds® Software Network of 6,500 Pharmacies to Provide Nationwide Physical Healthcare Outlet ———————————————————————————————————————————————————————————— Patient Lift Slings Market to Grow from US$ 4.88 Billion by 2034, at a CAGR of 8.61% 2026-10-22 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/476563 According to the latest market analysis published by The Insight Partners, the Patient Lift Slings Market was valued at approximately US$ 2.32 Billion in 2025 and is projected to reach US$ 4.88 Billion by 2034, registering a CAGR of 8.61% ... Read more ———————————————————————————————————————————————————————————— CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026 2026-10-22 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/caredx-announces-koar-data-linking-110500282.html In an independent randomized trial, AlloSure-based monitoring demonstrates a significant reduction in kidney transplant biopsies while maintaining similar clinical outcomes A multinational study shows AlloSure Kidney & AlloSure Plus maintained strong rejection prediction under updated Banff 2024 pathology criteria BRISBAN ———————————————————————————————————————————————————————————— RMTG's ISSCA Division Returns to São Paulo for a Second Brazil Congress, November 20-21 2026-10-22 · ACCESS Newswire · Healthcare, Government & policy, Medical devices https://finance.yahoo.com/healthcare/articles/rmtgs-issca-division-returns-o-110100459.html A second Brazil event in a single year - a frequency ISSCA has not previously applied - underscores Brazil's priority alongside Cellgenic's permanent operations there. MIAMI, FL / October 22, 2026 / Regenerative Medical Technology Group, Inc. (the "Company" or "RMTG") (OTCID:RMTG), a Regenerative Medicine Company. operating through its wholly owned subsidiary Global Stem Cells Group, today announced ———————————————————————————————————————————————————————————— Vital Pet Life's Donie Yamamoto to Showcase Science-Backed Pet Wellness Solutions at NAVC’s HiVE West 2026-10-22 · EIN Presswire · Healthcare, Energy, Sustainability https://www.einpresswire.com/article/951337719/vital-pet-life-s-donie-yamamoto-to-showcase-science-backed-pet-wellness-solutions-at-navc-s-hive-west Vital Pet Life logo Donie Yamamoto, Founder and CEO of Vital Pet Life Vital Pet Life's Advanced Gut Health For Dogs & Only Salmon Oil Pet Brand Is Highlighting Ingredient Transparency & Sustainability With Products Only Salmon Oil & Advanced Gut Health For Dogs Veterinary professionals play an important role in helping pet parents make informed decisions about their animals’ health. HiVE is a great opportunity to con ———————————————————————————————————————————————————————————— BlossomHill Therapeutics Announces Collaboration with Foundation Medicine to Develop First Companion Diagnostic for BH-30643 in EGFR C797S Mutated Non-Small Cell Lung Cancer 2026-10-22 · GlobeNewswire · Finance, Healthcare, Biotech & pharma, Medical devices https://www.globenewswire.com/news-release/2026/10/22/3386178/0/en/blossomhill-therapeutics-announces-collaboration-with-foundation-medicine-to-develop-first-companion-diagnostic-for-bh-30643-in-egfr-c797s-mutated-non-small-cell-lung-cancer.html SAN DIEGO, Oct. 22, 2026 -- BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines for the treatment of cancer, today announced a collaboration with Foundation Medicine, Inc. to develop a companion diagnostic assay (CDx) for the EGFR C797S resistance mutation. The collaboration will leverage the ongoing Phase 1/2 SOLARA clinical trial evaluating BH-30643 in the targeted treatment of epidermal growth factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) patients to validate the assay. ———————————————————————————————————————————————————————————— Foundation Medicine Appoints Chadi Nabhan, M.D., MBA, as Chief Medical Officer 2026-10-22 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/foundation-medicine-appoints-chadi-nabhan-110000601.html BOSTON, October 22, 2026--Foundation Medicine, Inc ., a global, patient-focused precision medicine company, today announced the appointment of Chadi Nabhan, M.D., MBA, as chief medical officer, effective November 16, 2026. In this role, Dr. Nabhan will lead the company's global medical affairs and cli ———————————————————————————————————————————————————————————— Swim Across America-Funded Cancer Research Leads to Landmark FDA Approval of Immunotherapy for Rectal Cancer 2026-10-22 · EIN Presswire · Finance, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951380757/swim-across-america-funded-cancer-research-leads-to-landmark-fda-approval-of-immunotherapy-for-rectal-cancer Dr. Luis Diaz, gastrointestinal oncologist and head of the Division of Solid Tumor Oncology at MSK, speaks at a recent Swim Across America - Long Island Sound open water swim. Drs. Andrea Cercek and Luis Diaz, along with a patient who is alive 10 years after participating in the initial clinical trial for Jemperli (dostarlimab), celebrate the funding from Swim Across America that made this clinical trial possible. Gr ———————————————————————————————————————————————————————————— Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies 2026-10-22 · PressReach · Finance, Healthcare, Food & drink, Biotech & pharma https://pressreach.com/cognition-therapeutics-announces-alignment-with-fda-on-pivotal-phase-3-trial-of-zervimesine-ct1812-in-dementia-with-lewy-bodies PURCHASE, N.Y., Oct. 22, 2026 — Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing product candidates that treat neurodegenerative disorders, has aligned with the U.S. Food and Drug Administration (FDA) on key elements of a Phase 3 study in dementia with Lewy bodies (DLB) including patient selection, dose, … Continue reading "Cognition Therapeutics Announces Alignment with FDA on Pivotal Phase 3 Trial of Zervimesine (CT1812) in Dementia with Lewy Bodies" ———————————————————————————————————————————————————————————— Two-Year FDA Award of up to $2.2 Million to Develop Wearable Digital Measures for CMT1A 2026-10-22 · EIN Presswire · Healthcare, Food & drink, Biotech & pharma, Consumer electronics https://www.einpresswire.com/article/947714593/two-year-fda-award-of-up-to-2-2-million-to-develop-wearable-digital-measures-for-cmt1a CureCMT Wearable sensors will track real-world changes in foot drop, walking, and hand function across four sites, a major step toward the first approved CMT treatment NEW YORK, NY, UNITED STATES, October 22, 2026 / EINPresswire.com / -- BioSensics LLC and CureCMT (Hereditary Neuropathy Foundation) today announced a two-year cooperative agreement award of up to $2.2 million from the U.S. Food and Drug Administration, ———————————————————————————————————————————————————————————— Ping An Unveils China's First Brain Health Service Management Program, Focused on Alzheimer's Prevention and Care 2026-10-22 · PR Newswire · Healthcare, Insurance https://www.prnewswire.com/news-releases/ping-an-unveils-chinas-first-brain-health-service-management-program-focused-on-alzheimers-prevention-and-care-302916779.html HONG KONG and SHANGHAI, Oct. 22, 2026 -- On 21 October, Ping An Insurance (Group) Company of China ("Ping An") unveiled China's first Brain Health Service Management Program at a seminar in Beijing on proactive Alzheimer's management and brain health services. At the event,... ———————————————————————————————————————————————————————————— Aspley Elite Dental Care Publishes Patient Guide to Professional and Over-the-Counter Teeth Whitening in Brisbane 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951468096/aspley-elite-dental-care-publishes-patient-guide-to-professional-and-over-the-counter-teeth-whitening-in-brisbane Logo of Aspley Elite Dental Care dental clinic affordable Brisbane teeth whitening Before-after Teeth Whitening Results We encourage patients to understand their whitening options and seek professional advice to ensure treatment is suitable for their dental health and goals.” — Dr Dev ASPLEY, BRISBANE, AUSTRALIA, October 22, 2026 / EINPresswire.com / -- Brisbane dental practice outlines the factors patients may wish ———————————————————————————————————————————————————————————— Year Two Marks a Turning Point in Sierra Leone’s Cataract Outreach, and Opens the Door to a Bigger, Faster, More Connected Year Three 2026-10-22 · APO Group · Healthcare, Automotive, Media, Education, Travel, Biotech & pharma, Sustainability, Government & policy, Jobs & workplace, Agriculture https://www.africa-newsroom.com/press/year-two-marks-a-turning-point-in-sierra-leones-cataract-outreach-and-opens-the-door-to-a-bigger-faster-more-connected-year-three?lang=en October marks a global moment for eye‑health advocacy, and Sierra Leone’s most anticipated cataract outreach campaign is entering a new phase of acceleration in the fight against avoidable blindness. The influential campaign is delivered by Choithram International Foundation (https://www.Choithrams.com/) in association with Noor Dubai Foundation, led by CEO Dr. Manal Taryam as part of Mohammed bin Rashid Al Maktoum Global Initiatives (MBRGI), and the Ministry of Health, Sierra Leone alongside Choithram Memorial Hospital, reflecting a shared commitment to world‑class eye care and the elimination of preventable blindness. Download Document: https://apo-opa.co/4ihCOKT Download Infographic: https://apo-opa.co/4z72uky Conceived in 2024, the multi‑year initiative has restored sight to thousands of Sierra Leoneans through free cataract surgeries, community screenings, and long‑term capacity building. Cataracts remain the leading cause of blindness in the country, where the 2021 RAAB study found that 5.4% of adults over 50 are blind, with cataracts responsible for nearly 60% of cases. A newly published peer-reviewed study in BMJ Open provides important evidence from the programme's first implementation cycle, demonstrating improvements in patients' vision-related quality of life while highlighting the operational challenges and adaptations necessary to deliver cataract services in resource-constrained settings. A Year of Acceleration The second surgical cycle, conducted between March and August 2026, marked a turning point. More than 5,768 adults were screened or consulted, 2,460 received medical treatment, and 1,522 cataract surgeries were performed, all this while also managing additional surgical interventions and referrals. It makes Year Two one of the largest eye‑care outreach efforts in Sierra Leone’s history, with patients travelling from across the country and neighbouring Guinea and Liberia, underscoring the programme’s growing regional reach and influence. Capacity building, a core goal of the campaign, has also seen a clear uptick. Seventeen ophthalmic professionals were trained across clinical and surgical roles, including cataract surgeons, ophthalmology nurses, OT nurses, and registrars, further strengthening the country’s long‑term eye‑care workforce. WHO (World Health Organization) notes that more than 80% of global vision impairment is preventable or treatable, underscoring the importance of programmes that combine service delivery with long‑term capacity building. This aligns with WHO’s 2030 global eye‑care targets, which call for major increases in effective cataract surgical coverage and sustained investment in national eye‑health systems. Two operating theatres ran simultaneously at Choithram Memorial Hospital, supported by Sierra Leonean staff trained through monthly exchanges with Choithram Netralaya (India). Every patient received surgery, medication, transport, accommodation, and follow‑up care at no cost, establishing a model that continues to set a benchmark for accessible eye care in the region. To help ensure that the programme delivers lasting impact, researchers Dr Gabriel Osei-Anokye and Dr Ving Fai Chan from Queen’s University Belfast (QUB) and Dr M Mansur Rabiu from Noor Dubai Foundation are leading a comprehensive evaluation. The evaluation examines programme efficiency, patient satisfaction, quality of care, and changes in patients’ quality of life following cataract surgery. Aligned with WHO standards, the research assesses not only improvements in vision and clinical outcomes, but also the wider psychosocial and socioeconomic benefits of restoring sight among people who have limited access to cataract services. Drawing on expertise in global health and eye care, the team is generating evidence to identify what works, where improvements can be made, and how lessons from the programme can inform future outreach. These findings will support the continued strengthening and sustainability of cataract services in Sierra Leone and provide learning that may be relevant to similar programmes elsewhere. Human Impact at the Centre For many beneficiaries, restored sight means restored independence. One patient, Isatu Kamara, shared: “My right eye is now very bright. I am happy with the result and I look forward to coming back next year for the left eye.” Such stories reflect the programme’s broader social impact, enabling farmers to return to work, caregivers to regain mobility, and older adults to reconnect with their families. Quality of life improves immediately, restoring dignity and participation in socio‑economic life. Independent Evaluation Published in BMJ Open Strengthens the Evidence Base A peer-reviewed study published in BMJ Open on 9 October 2026 evaluated the programme's first implementation cycle (February–August 2025), examining its achievements, operational challenges and adaptations during implementation. Led by researchers from Queen's University Belfast and programme partners Noor Dubai Foundation, the study reported that 9,117 individuals were screened and 1,433 cataract surgeries performed in Year One of the cycle. Among 271 patients with complete follow-up assessments, vision-related quality of life improved significantly by an average of 17 points, particularly in mental health, near-vision and distance-vision activities. Beyond these achievements, the evaluation highlighted important challenges, including workforce limitations, transportation barriers, incomplete clinical records and low postoperative follow-up attendance, with only 19% returning at one month. The findings emphasise that successful cataract outreach requires more than delivering surgeries; it also depends on effective referral pathways, continuity of care and responsive programme management. Lessons from the first cycle have helped identify opportunities to strengthen subsequent implementation cycles and offer valuable insights for similar programmes in resource-constrained settings. Voices from the Partnership Mr. L.T. Pagarani, Chairman, Choithrams Group “Goodness inspires more goodness, and this second year of our cataract outreach shows exactly that. After restoring sight for hundreds of people in our first cycle, we returned with even greater resolve to deepen our collaborative action. We are grateful to the Government of Sierra Leone, especially the Ministry of Health, for their partnership, and to Noor Dubai Foundation for their leadership and guidance. Above all, we honour the dedication of our doctors and staff whose work makes this impact possible. The celebration of restored vision belongs as much to the beneficiaries as it does to all of us who believe in the power of service to society.” Drs. Gabriel Osei-Anokye and Ving Fai Chan, Queen’s University Belfast “The progress we see in this second year is the careful reflection, rigorous evaluation, and a shared commitment to learning from the first cycle. Our research shows that when cataract programmes use evidence to continually improve how services are delivered, the benefits extend far beyond better vision. People regain mobility, confidence, independence, and the ability to participate more fully in their families and communities. Sierra Leone’s experience shows how strong leadership, continuous learning, and cross-sector collaboration can deliver high-quality outcomes even in challenging settings. Restoring sight is therefore more than a medical intervention; it is about enabling people to regain independence, opportunity, and their place in community life.” Looking Ahead: A Bigger, Faster, More Connected Year Three The programme now moves into its third cycle, scheduled from January to April 2027, marking another step in Sierra Leone’s long‑term journey toward eliminating avoidable blindness. With approximately 80 working days earmarked for clinical interventions, partners aim to perform 2,500 to 3,000 cataract surgeries, the most ambitious target yet, reflecting rising demand and growing national capacity. Preparations are already underway. Level 1 screenings began on 1 September, with a deliberate focus on rural provinces where access to eye care remains limited. Strengthening collaboration with district health authorities is central to this next phase, ensuring increased referrals and earlier identification of at‑risk patients. Operationally, Year Three will rely on the expanded cadre of Sierra Leonean ophthalmic staff trained during the first two cycles, supported by ongoing mentorship from Choithram Netralaya (India). With an average of 40 surgeries per day, the programme is moving steadily toward domestic clinical self‑sufficiency while maintaining world‑class standards of care. Distributed by APO Group on behalf of Choithram International Foundation. Links to additional content: Testimonials of beneficiaries in links below: Link 1: https://apo-opa.co/4z9MeiU https://apo-opa.co/4sms9mL Please refer to the following study for implementation lessons from a high‑-volume cataract screening and surgical programme in Sierra Leone: Full paper available at: https://apo-opa.co/4z5wX2z Detailed Year 1 Report Link: https://apo-opa.co/4yXEnEM Detailed Year 1 Ophthalmic Training Report Link: https://apo-opa.co/47udPiv The Infographic Shows Effective Management for Sustainable Outcomes: How Sierra Leone’s Cataract Outreach Model Restores Sight Through Coordinated Planning, Collaboration, and Data‑-Driven Impact. About Noor Dubai Foundation, Dubai, UAE:  Noor Dubai was launched with the vision of a world free from avoidable causes of blindness.  therapeutic, preventative and educational programmes to treat and prevent blindness and visual impairment in developing countries on a regional and international scale. Following the success achieved of reaching out to over 5.8 million individuals worldwide in its first year, a decree was passed by His Highness Sheikh Mohammed Bin Rashid Al Maktoum, launching the Noor Dubai Foundation as a non-governmental, non-for-profit organization, aiming to eliminate all forms of preventable blindness globally. About Queen’s University Belfast, UK: About Choithram Netralaya – Indore, India:  Choithram Netralaya is a one-stop solution for all eye problems, and provides comprehensive eye care services covering Cataracts, glaucoma, Orbit & Oculoplasty, Cornea & Retina, Paediatric Ophthalmology, Community Ophthalmology, Ocular Oncology, Corneal Transplant, Squint, Ocular Trauma, Neuro-Ophthalmology, Uveitis, Low vision aids & visual rehabilitation, Ocular Prosthesis, and Ophthalmic Anaesthesia, among other services. About Choithram Memorial Hospital, Freetown, Sierra Leone: Choithram Memorial Hospital (CMH) is a leading multispecialty healthcare provider in Freetown, Sierra Leone, committed to delivering high-quality, accessible medical care. Established in 1993, CMH has grown into one of the country’s most trusted hospitals, offering a wide range of services, including cardiology, neurology, ophthalmology, and emergency care. Situated on a five-acre campus, the hospital is equipped with modern facilities and a dedicated team of medical professionals. CMH plays a vital role in Sierra Leone’s healthcare ecosystem, providing comprehensive treatment while ensuring affordability and accessibility for all patients ———————————————————————————————————————————————————————————— KFSH Expands Capacity for Complex Care by Redesigning the Emergency Patient Journey 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951448031/kfsh-expands-capacity-for-complex-care-by-redesigning-the-emergency-patient-journey An emergency patient transfer inside KFSH in Riyadh RIYADH, SAUDI ARABIA, October 22, 2026 / EINPresswire.com / -- King Faisal Specialist Hospital and Research Centre (KFSH) has expanded capacity for complex care by redesigning the emergency patient journey, meeting rising demand without compromising timely access for patients requiring highly specialized treatment. KFSH operates more than 1,500 beds dedicated to hig ———————————————————————————————————————————————————————————— The Tech Festival Canada Puts a Number on Business Connections With a 70% Buyer-Meeting Guarantee 2026-10-22 · EIN Presswire · Healthcare, Cybersecurity, Banking https://www.einpresswire.com/article/951415715/the-tech-festival-canada-puts-a-number-on-business-connections-with-a-70-buyer-meeting-guarantee A physician can meet a health-tech expert, a bank executive can meet a quantum founder, and a utility leader can meet a cybersecurity specialist Conferences like TTFC create the opportunity for those conversations to happen early, with the people who understand both the technology and the stakes.” — Christian Weedbrook, CEO & Founder of Xanadu TORONTO, ONTARIO, CANADA, October 22, 2026 / EINPresswire.com / -- Most te ———————————————————————————————————————————————————————————— CoachCare Launches AI-Powered CarePredict to Prioritize At-Risk Patients and Guide Clinical Interventions 2026-10-22 · EIN Presswire · AI, SaaS, Healthcare https://www.einpresswire.com/article/950830611/coachcare-launches-ai-powered-carepredict-to-prioritize-at-risk-patients-and-guide-clinical-interventions CarePredict AI-powered platform for remote monitoring turns longitudinal connected-care data into a prioritized workflow with actionable health intelligence for care teams Remote care depends on more than devices, dashboards and technology. We built CarePredict to make people more effective by bringing the right information, priorities and workflows together.” — Teresa Sieck, Chief Medical Officer NEW YORK, NY, UNITE ———————————————————————————————————————————————————————————— We Built a Sick-Care System. It's Time to Build a Healthcare System 2026-10-22 · PR Newswire · Healthcare, Education https://www.prnewswire.com/news-releases/we-built-a-sick-care-system-its-time-to-build-a-healthcare-system-302916173.html Dr. Russell H. Greenfield urges changes to payment models, professional education, and measures of success to help Americans achieve lasting health WHITTIER, Calif., Oct. 22, 2026 -- Russell H. Greenfield, MD, Founding Executive Director of The Institute for the Advancement... ———————————————————————————————————————————————————————————— Sage Memorial Hospital breaks ground on workforce housing featuring BOXABL Studio Casitas 2026-10-22 · PR Newswire · Finance, Healthcare, Real estate, Jobs & workplace, Construction & engineering https://www.prnewswire.com/news-releases/sage-memorial-hospital-breaks-ground-on-workforce-housing-featuring-boxabl-studio-casitas-302916564.html LAS VEGAS, Oct. 22, 2026 -- BOXABL Inc. (Nasdaq: BXBL), an innovative technology company transforming the housing market with its modular building systems, today announced that Sage Memorial Hospital in Ganado, Arizona, held a groundbreaking ceremony Oct. 14, 2026, for its... ———————————————————————————————————————————————————————————— Istios Health Expands Clinical Research Network into Texas Through Kidney Care Associates Partnership 2026-10-22 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/22/3386123/0/en/istios-health-expands-clinical-research-network-into-texas-through-kidney-care-associates-partnership.html Istios Health Expands Clinical Research Network into Texas Through Kidney Care Associates Partnership ———————————————————————————————————————————————————————————— Vitaquest International Appoints Martin Gargiule as Chief Financial Officer 2026-10-22 · GlobeNewswire · Healthcare, Retail, Industrial, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386118/0/en/vitaquest-international-appoints-martin-gargiule-as-chief-financial-officer.html Vitaquest names Martin Gargiule CFO, adding 25+ years of consumer health, pharma, and manufacturing finance expertise to its growing leadership team. ———————————————————————————————————————————————————————————— Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma, Government & policy https://finance.yahoo.com/healthcare/articles/ivonescimab-data-sets-across-multiple-100000492.html Highlights Include Phase II Data Supporting Clinical Development Expansion for Ivonescimab MIAMI, October 22, 2026--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2 ———————————————————————————————————————————————————————————— Jason Diebold to Appear on Legacy Makers TV 2026-10-22 · EIN Presswire · Healthcare, Sports https://www.einpresswire.com/article/951467693/jason-diebold-to-appear-on-legacy-makers-tv FL, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Jason Diebold, a health and fitness entrepreneur, is set to appear on Legacy Makers TV, where he will share insights on accessible health testing, nutrition, resilience, and building sustainable business opportunities. Legacy Makers is a cinematic docu-series showcasing actors, athletes, entrepreneurs, and other iconic figures by capturing their personal and ———————————————————————————————————————————————————————————— Madrid Wins Global and European Incentive Destination Honours at 2026 World MICE Awards 2026-10-22 · Travel PR News · Healthcare, Travel, Government & policy https://travelprnews.com/article/madrid-wins-global-and-european-incentive-destination-honours-at-2026-world-mice-awards/?utm_source=rss&utm_medium=rss&utm_campaign=madrid-wins-global-and-european-incentive-destination-honours-at-2026-world-mice-awards The Spanish capital’s two awards spotlight its corporate travel experiences and cross-sector events industry ahead of a major medical congress. KEY TAKEAWAYS Madrid won both the world and European best incentive destination titles at the 2026 World MICE Awards held in Jamaica on 12 October. Madrid Convention Bureau works with 225 member companies to support... Read the full news article ———————————————————————————————————————————————————————————— Cortisone Shots Market Value Projected to Grow at 4.65% CAGR Through 2034 2026-10-22 · PR News Releaser · Healthcare, Sports https://www.prnewsreleaser.com/news/476175 The Cortisone Shots Market is experiencing steady growth due to the increasing prevalence of musculoskeletal disorders, arthritis, joint inflammation, and sports-related injuries. Cortisone injections are widely used in clinical practice to help reduce inflammation and relieve pain associated with various ... Read more ———————————————————————————————————————————————————————————— Courtesy Call on State Minister NAKASONE by His Excellency (H.E.) Mr. Ragui Eletreby, Ambassador Extraordinary and Plenipotentiary of the Arab Republic of Egypt to Japan 2026-10-22 · APO Group · Healthcare, Education, Government & policy, Agriculture https://www.africa-newsroom.com/press/courtesy-call-on-state-minister-nakasone-by-his-excellency-he-mr-ragui-eletreby-ambassador-extraordinary-and-plenipotentiary-of-the-arab-republic-of-egypt-to-japan?lang=en On October 22, from 3:45 p.m. for approximately 30 minutes, Mr. NAKASONE Yasutaka, State Minister for Foreign Affairs of Japan, received a courtesy call by H.E. Mr. Ragui Eletreby, Ambassador Extraordinary and Plenipotentiary of the Arab Republic of Egypt to Japan. At the outset, State Minister NAKASONE touched upon the recent active exchange of high-level officials and the cooperation between Japan and Egypt in various fields such as agriculture, health, education, and transportation, and stated his intention to work together to further strengthen the traditional friendly relations and strategic partnership between the two countries. Ambassador Eletreby congratulated State Minister NAKASONE on his appointment and expressed his wish to further develop cooperation in a wide range of areas, including the field of education, such as the Egypt-Japan University of Science and Technology (E-JUST) and Egypt-Japan School (EJS). Both sides also exchanged views on regional situations in the Middle East and concurred on working toward further deepening bilateral relations. Distributed by APO Group on behalf of Ministry of Foreign Affairs of Japan. ———————————————————————————————————————————————————————————— UAE fast-tracking advanced diagnostics as global market heads for US$152 billion 2026-10-22 · EIN Presswire · Healthcare, Medical devices https://www.einpresswire.com/article/951458175/uae-fast-tracking-advanced-diagnostics-as-global-market-heads-for-us-152-billion Mohini Mehta, Senior Consultant, Healthcare & Life Sciences, Frost & Sullivan Solenne Singer, Senior Vice President - Healthcare, inD WHX 2026 Labs Zone at WHX 2027 will connect global suppliers to the Middle East’s growing US$5.4 billion diagnostics market The next frontier in diagnostics will not be defined by who adopts the most advanced technology first, but by who can integrate it into clinical practice at scale ———————————————————————————————————————————————————————————— Wolfson Group Brings Men's Wellness Brand TestoPrime to OneLavi 2026-10-22 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Education, Sports, Marketing & advertising https://newsworthy.ai/news/202610223072/wolfson-group-brings-mens-wellness-brand-testoprime-to-onelavi Boca Raton, Florida Thursday Oct 22, 2026 @ 5:00 AM Eastern — Wolfson Group, a Scotland-based international consumer wellness company, today announced that TestoPrime, its established men's wellness brand, is now available to U.S. consumers through OneLavi.com, expanding the brand's online retail presence beyond Amazon. The addition of TestoPrime to One Lavi represents another step in Wolfson Group's ongoing U.S. expansion strategy, which focuses on increasing consumer access to its portfolio through additional online retailers and brick-and-mortar distribution opportunities. TestoPrime serves the men's wellbeing category, with a focus on vitality, everyday performance and healthy ageing. The brand is part of Wolfson Group's broader portfolio of wellness products designed around different consumer lifestyles and priorities. "Men's wellness is an important part of our portfolio, and we're pleased to expand access to TestoPrime through another U.S. retail channel," said the founder and CEO of Wolfson Group. "Our focus is on building a stronger retail presence while making our established brands easier for consumers to find." The expansion comes as conversations around men's wellness increasingly encompass a broader range of lifestyle priorities, including physical activity, nutrition, maintaining vitality and healthy ageing. Wolfson Group believes this broader approach reflects changing consumer interests, with more men considering everyday wellbeing as part of their long-term lifestyle goals rather than focusing on a single aspect of health. TestoPrime is already available to U.S. consumers through Amazon. Its new availability on OneLavi provides another online purchasing option while supporting Wolfson Group's strategy of expanding its distribution network across multiple retail channels. The company recently participated in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where it presented its portfolio during scheduled meetings with U.S. retail industry participants. TestoPrime is part of Wolfson Group's multi-category portfolio, which also spans weight management, cognitive wellness and gut health. The company continues to develop its U.S. retail presence while investing in consumer education and science-led brand development. "Expanding into additional online retail channels is an important part of our long-term strategy," the founder said. "We want to create more opportunities for consumers to discover our brands while continuing to build relationships across the U.S. retail marketplace." Wolfson Group said it plans to continue broadening its U.S. distribution footprint as it develops additional retail relationships and supports growth across its consumer wellness portfolio. About Wolfson Group Wolfson Group is an international consumer wellness company focused on building science-led brands that help people live healthier lives. Its portfolio spans weight management, cognitive health, gut health, men's wellness, beauty and healthy ageing, serving millions of consumers worldwide through direct-to-consumer, marketplace and retail channels. Wolfson Group's portfolio includes the established wellness brands PhenQ, TestoPrime, NooCube and YourBiology, spanning categories such as weight management, cognitive wellness, gut health and men's wellbeing. The brands are currently available to U.S. consumers through Amazon while the company pursues broader retail opportunities nationwide. ———————————————————————————————————————————————————————————— AgeReverse RESURGE Now Available on OneLavi.com 2026-10-22 · Newsworthy.ai · AI, SaaS, Healthcare, Retail, Food & drink, Sports, Biotech & pharma, Marketing & advertising, Internet & apps, Consumer goods https://newsworthy.ai/news/202610223065/agereverse-resurge-now-available-on-onelavicom Boca Raton, Florida Thursday Oct 22, 2026 @ 5:00 AM Eastern — AgeReverse, a Canadian longevity company focused on healthy aging and cellular vitality, today announced that its flagship RESURGE formulation is now available to U.S. consumers through OneLavi.com, marking another milestone in the company's expanding U.S. retail presence. The One Lavi launch follows the recent availability of RESURGE on Amazon and reflects AgeReverse's strategy to build a broader U.S. distribution network through multiple retail and e-commerce channels. "Expanding our availability through OneLavi is another important step in introducing AgeReverse to more consumers across the United States," said Kubi Turkmen, Founder and CEO of AgeReverse. "Our goal is to make RESURGE accessible through established retail destinations while continuing to build awareness of our comprehensive approach to healthy aging." AgeReverse developed RESURGE around the scientific framework of the 12 Hallmarks of Aging, which describes interconnected biological processes associated with aging. Rather than emphasizing a single ingredient or isolated wellness benefit, the company designed its flagship formulation to bring together multiple ingredients in a simplified daily regimen. The 90-capsule RESURGE formulation includes NMN, Resveratrol, Quercetin, Fisetin, CoQ10, Astragalus Extract, Hyaluronic Acid, Aronia Extract and Noni Berry. Key features of RESURGE include: Developed around the scientific concept of the 12 Hallmarks of Aging Combines multiple ingredients associated with antioxidant support and everyday wellness Supports nutrient metabolism, cardiovascular health and immune function Helps support collagen formation, connective tissue development and joint health Simplifies what the company describes as 12 or more individual products and 15 or more capsules per day into a three-capsule daily regimen Manufactured in GMP-certified facilities in Ontario, Canada using vegan capsules Registered as a Natural Health Product with Health Canada under NPN 80130202 The expansion onto OneLavi comes as AgeReverse continues developing its presence in the U.S. longevity and healthy aging market. The company recently participated in the ECRM Vitamin, Weight Management & Sports Nutrition Session in Palm Beach Gardens, Florida, where it introduced RESURGE and its broader product strategy during scheduled meetings with retail buyers across health, specialty, food, drug and mass retail channels. Beyond RESURGE, AgeReverse is developing a range of products focused on both internal wellness and external skin aging. Its broader plans include biological age testing, daily skincare, professional aesthetic formulations and non-invasive mesotherapy technology. "Our long-term strategy is about more than a single product or sales channel," Turkmen added. "We are building a complete range of healthy aging solutions while expanding the ways consumers can access the AgeReverse brand." The OneLavi availability represents another step in that strategy, complementing the company's existing Amazon presence and its ongoing efforts to develop additional U.S. retail relationships. RESURGE is now available on OneLavi.com and Amazon. Visit the AgeReverse Website and follow the company on Instagram and LinkedIn. About AgeReverse AgeReverse is a Canada-based longevity wellness company focused on developing science-driven products designed to support healthy aging and cellular vitality. Founded by Kubi Turkmen, who has more than 30 years of experience in anti-aging innovation, the company’s approach combines longevity research, telomere science, and wellness innovation to create comprehensive healthy aging solutions. The company’s expanding AgeReverse platform includes longevity supplements and other wellness technologies designed to support multiple biological pathways associated with aging and long-term vitality. Products are manufactured in GMP-certified facilities in Ontario, Canada. Learn more at the company’s website.  FDA Disclaimer These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. ———————————————————————————————————————————————————————————— Prilenia and Ferrer Announce Authorization for EU Initiation of Confirmatory PRECISE-HD Study of Pridopidine in Huntington's Disease 2026-10-22 · Business Wire · Healthcare, Biotech & pharma, Jobs & workplace https://finance.yahoo.com/healthcare/articles/prilenia-ferrer-announce-authorization-eu-083400162.html Recruitment is expected to start this month, rolling out to upwards of 31 sites across nine EU countries, and joining the ongoing enrollment in the US and UK, with Canada set to follow Prilenia and Ferrer will share new data analyses and clinical trial updates at the European Huntington's Disease Network (EHDN) Clinical R ———————————————————————————————————————————————————————————— Form 8.3 - [ADVANCED MEDICAL SOLUTIONS GROUP PLC - 21 10 2026] - (CGWL) 2026-10-22 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/22/3386078/0/en/form-8-3-advanced-medical-solutions-group-plc-21-10-2026-cgwl.html FORM 8.3 ———————————————————————————————————————————————————————————— OCTAVE Living hosts Women's Vitality Forum, launches two retreat programs in Suzhou 2026-10-22 · MarketersMEDIA · Healthcare https://news.marketersmedia.com/octave-living-hosts-womens-vitality-forum-launches-two-retreat-programs-in-suzhou/89206943 -- OCTAVE Living introduced two retreat programs focused on perimenopause and menopause at a women's vitality forum held Oct. 18 at SANGHA Retreat by OCTAVE in Suzhou, China. The event brought together health professionals, women entrepreneurs and brand representatives to discuss women's health needs at different life stages. Titled “Her Future, A New Chapter of Life,” the forum was part of the Suzhou edition of the ———————————————————————————————————————————————————————————— Ice-T, Mario & Courtney Lopez, Jack Osbourne and More Join Dr. Drew for New Episodes of “Health Uncensored" 2026-10-22 · EIN Presswire · Healthcare, Entertainment https://www.einpresswire.com/article/951284057/ice-t-mario-courtney-lopez-jack-osbourne-and-more-join-dr-drew-for-new-episodes-of-health-uncensored Montell Jordan and Dr. Drew Pinsky Hilaria Baldwin Airing Oct. 25 on Fox Business, the series combines candid celebrity conversations and health professionals exploring today's most relevant wellness topics. HOLLYWOOD, FL, UNITED STATES, October 22, 2026 / EINPresswire.com / -- From the personal health journeys of some of entertainment's most recognizable personalities to new innovations shaping the future of wellnes ———————————————————————————————————————————————————————————— Monitoring of Economic Community of West African States (ECOWAS) Interventions in Benin: The Resident Representation and the ECOWAS National Office Conduct a Joint Monitoring Mission of ECOWAS Projects and Programs in Benin 2026-10-22 · APO Group · Healthcare, Food & drink, Sustainability, Government & policy, Agriculture https://www.africa-newsroom.com/press/monitoring-of-ecowas-interventions-in-benin-the-resident-representation-and-the-ecowas-national-office-conduct-a-joint-monitoring-mission-of-ecowas-projects-and-programs-in-benin?lang=en From August 31 to September 5, 2026, the Resident Representation of the Economic Community of West African States (ECOWAS) in Benin, in collaboration with the ECOWAS National Office of Benin, conducted a field monitoring mission to assess the progress of projects and programs funded by ECOWAS Agencies and Institutions, identify challenges encountered, and enhance their coordination. Organized into two teams covering the Northern and Southern regions of the country, the mission carried out 20 site visits across 7 interventions in 17 municipalities, as well as 18 institutional audiences with local and prefectural authorities. The visits covered a diverse portfolio of interventions, including revitalizing the local dairy sector, developing forage production, building youth skills and employability in the agricultural and agro-sylvo-pastoral sectors, agroecological training, health, and cross-border cooperation. Field observations highlighted several tangible achievements, particularly improved production and processing capacities for certain dairy units, enhanced technical and entrepreneurial skills among youth, as well as the completion of infrastructure and provision of equipment to support local economic activities. These accomplishments contribute to improving working conditions, strengthening beneficiary capacities, and fostering the growth of production and training activities. The mission also identified challenges related to equipment availability, post-training support for beneficiaries, inter-stakeholder coordination, and the sustainability of achievements. Discussions with municipal authorities emphasized the need to strengthen their involvement in monitoring interventions and to increase the visibility of ECOWAS support among local populations. At the conclusion of the mission, the Resident Representation and the ECOWAS National Office, drawing on their findings, formulated recommendations to strengthen close-range monitoring, improve intervention coordination, and promote the sustainability of results for the benefit of the Beninese population. This effort aligns with the momentum of ECOWAS Vision 2050, which envisions an “ECOWAS of Peoples: Fully Integrated, Peaceful, and Prosperous,” as operationalized in the 2023–2027 Community Strategic Framework. Distributed by APO Group on behalf of Economic Community of West African States (ECOWAS). ———————————————————————————————————————————————————————————— Quality Management Software Market Forecast 2033: Opportunities and Challenges 2026-10-22 · Express Press Release · Healthcare, Software & IT https://express-press-release.net/news/2026/10/22/1778035 Market Overview and Projections The quality management software market is growing because companies want audit management, document control, non-conformance tracking, environmental health and safety, training [read full press release...] ———————————————————————————————————————————————————————————— Latin America’s Quiet Rise: Argentina and Brazil Enter the Biosimilars Market Spotlight 2026-10-22 · Express Press Release · Healthcare, Biotech & pharma https://express-press-release.net/news/2026/10/22/1778029 Biologic drugs transformed the treatment of cancer, autoimmune disease, and diabetes, but their cost has kept many patients and health systems from benefiting fully. Biosimilars [read full press release...] ———————————————————————————————————————————————————————————— Chronic Obstructive Pulmonary Disease Market is Expanding at a 4.44% CAGR Through 2034 2026-10-22 · PR News Releaser · Healthcare https://www.prnewsreleaser.com/news/475973 Chronic Obstructive Pulmonary Disease (COPD) remains one of the most significant global health challenges, affecting millions of people worldwide and placing a substantial burden on healthcare systems. Characterized by persistent airflow limitation, breathing difficulties, chronic cough, and reduced lung function, ... Read more ———————————————————————————————————————————————————————————— Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy 2026-10-22 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/22/3386063/0/en/nxera-pharma-submits-marketing-authorization-application-for-vamorolone-in-south-korea-for-the-treatment-of-duchenne-muscular-dystrophy.html Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy. ———————————————————————————————————————————————————————————— Rapid Physiocare Reinforces Evidence-Informed Physiotherapy Approach 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951438969/rapid-physiocare-reinforces-evidence-informed-physiotherapy-approach Founder and CEO Singapore physiotherapy provider highlights assessment, clinical reasoning and individual treatment goals. SINGAPORE, SINGAPORE, SINGAPORE, October 22, 2026 / EINPresswire.com / -- Rapid Physiocare is reaffirming its focus on evidence-informed physiotherapy and individualised musculoskeletal rehabilitation across its Singapore clinics. The group emphasises careful patient history, physical examination ———————————————————————————————————————————————————————————— RAPIDÉ Outlines Corporate Musculoskeletal Wellbeing Programme Concept 2026-10-22 · EIN Presswire · Healthcare, Education https://www.einpresswire.com/article/951438351/rapid-outlines-corporate-musculoskeletal-wellbeing-programme-concept Proposed employer offering combines education, appropriate assessments and curated recovery experiences. SINGAPORE, SINGAPORE, October 22, 2026 / EINPresswire.com / -- RAPIDÉ is outlining a proposed clinician-led corporate wellbeing programme for Singapore employers and benefits partners. The proposed framework includes musculoskeletal education, appropriate clinical assessments or referrals, and selected recovery ex ———————————————————————————————————————————————————————————— Poland's Ministry of Health Signs Agreement with HealthAI, Advancing Responsible AI Governance in Health Across Europe 2026-10-22 · EIN Presswire · AI, Healthcare, Education, Government & policy https://www.einpresswire.com/article/950978186/poland-s-ministry-of-health-signs-agreement-with-healthai-advancing-responsible-ai-governance-in-health-across-europe (from left to right) Dr. Ricardo Baptista Leite, CEO of HealthAI, and Mr. Tomasz Maciejewski, Deputy Minister of Health of the Republic of Poland, meet at the AIMed 2026 Conference in Kraków - one of Central Europe's leading gatherings on artificial intel Poland signs MoU with HealthAI, charting course for Poland's full membership in the GRN and reinforcing Europe's growing commitment to responsible AI in health. Pol ———————————————————————————————————————————————————————————— "All Access Hosted by Andy Garcia" Explores How Nanomix Group Unlocks the Potential of Silicon 2026-10-22 · PR Newswire · Healthcare, Agriculture https://www.prnewswire.com/news-releases/all-access-hosted-by-andy-garcia-explores-how-nanomix-group-unlocks-the-potential-of-silicon-302916132.html The upcoming segment explores the second most abundant element on earth and why its bioavailable form is critical to living organisms across agriculture, animal health, and human wellness. LOS ANGELES, Oct. 22, 2026 -- An upcoming feature will showcase Nanomix Group and its... ———————————————————————————————————————————————————————————— Warner & Fitzmartin Adds Senior Litigation Attorney Bruce Kleinberg 2026-10-22 · 24-7 Press Release · Healthcare, Legal https://www.24-7pressrelease.com/press-release/539815/warner-fitzmartin-adds-senior-litigation-attorney-bruce-kleinberg Board Certified Trial Lawyer Brings a Medical Degree to Injury Cases ———————————————————————————————————————————————————————————— Grayhawk Safety Provides OSHA Expert Witness and Workplace Accident Investigation Services for Serious Incidents and Litigation 2026-10-22 · MarketersMEDIA · Healthcare, Legal, Jobs & workplace https://news.marketersmedia.com/grayhawk-safety-provides-osha-expert-witness-and-workplace-accident-investigation-services-for-serious-incidents-and-litigation/89206910 Grayhawk Safety & Health Consulting provides OSHA expert witness and workplace accident investigation services for serious incidents and litigation. Led by Randy Gray, with 25 years of OSHA experience, the company offers impartial investigations, technical analysis, and litigation support for both plaintiff and defense counsel. -- When a serious workplace accident occurs, determining what happened, why it happened an ———————————————————————————————————————————————————————————— VitroVivo Biotech LLC Highlights Tissue Analysis Capabilities for Biomedical Researchers Through Specialized Laboratory Services 2026-10-22 · ACCESS Newswire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/vitrovivo-biotech-llc-highlights-tissue-065000606.html ROCKVILLE, MD / October 22, 2026 / VitroVivo Biotech LLC, a Maryland-based provider of histology and molecular histopathology services, is highlighting its laboratory capabilities for researchers requiring detailed tissue examination, specialized cell isolation, and reliable specimen preparation. The com ———————————————————————————————————————————————————————————— Auddia Announces Completion of LT350 Phase 1 Feasibility Study and Advancement to Phase 2/3 Engineering with Fresh Consulting 2026-10-22 · PressReach · Finance, AI, Healthcare https://pressreach.com/auddia-announces-completion-of-lt350-phase-1-feasibility-study-and-advancement-to-phase-2-3-engineering-with-fresh-consulting Phase 1 Validates LT350’s Canopy and Modular Cartridge Architecture Across All Engineering Domains Engagement Expands to Full Design/Engineering and Pilot Ready Deployment Timeline Supports Breaking Ground on First LT350 Canopy at Texas Hospital in Q3 2027 BOULDER, Colo., Oct. 21, 2026 — Auddia Inc. (NASDAQ: AUUD) (“Auddia” or the “Company”), an AI-first technology … Continue reading "Auddia Announces Completion of LT350 Phase 1 Feasibility Study and Advancement to Phase 2/3 Engineering with Fresh Consulting" ———————————————————————————————————————————————————————————— John Abraham Advocates Clinician-Led Healthcare Leadership in Singapore 2026-10-22 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951428892/john-abraham-advocates-clinician-led-healthcare-leadership-in-singapore The changemaker Rapid Group founder highlights patient-centred decisions, professional accountability and sustainable healthcare leadership. Healthcare leadership must begin with the patient. Commercial growth should never come at the expense of clinical integrity.” — John Abraham, Founder and CEO, Rapid Group SINGAPORE, SINGAPORE, SINGAPORE, October 22, 2026 / EINPresswire.com / -- John Abraham, a practising physiot ———————————————————————————————————————————————————————————— Indegene Receives Frost & Sullivan's 2026 Global Enabling Technology Leadership Recognition for AI-Powered Pharma Commercialization 2026-10-22 · PR Newswire · AI, Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/indegene-receives-frost--sullivans-2026-global-enabling-technology-leadership-recognition-for-ai-powered-pharma-commercialization-302910803.html Indegene is recognized for combining domain-led AI, knowledge orchestration, and integrated execution to transform pharmaceutical commercialization workflows. SAN ANTONIO, Oct. 22, 2026 -- Frost & Sullivan is pleased to announce that Indegene has received the 2026 Global... ———————————————————————————————————————————————————————————— [Ad hoc announcement pursuant to Art. 53 LR] Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 2026-10-22 · Roche · Finance, AI, SaaS, Healthcare, Real estate, Automotive, Food & drink, Industrial, Biotech & pharma, Sustainability, Investing & markets, Legal, Government & policy, Jobs & workplace, Marketing & advertising, Software & IT, Medical devices https://www.roche.com/media/releases/med-cor-2026-10-22 Ad hoc announcement pursuant to Art. 53 LR Basel, 22 October 2026 Roche continues strong momentum in the third quarter with sales growth of +7% at constant exchange rates (CER) and +8% in CHF; Group sales increase +6% (CER), +1% in CHF, in the first nine months of 2026 Group sales were +6% at constant exchange rates (CER)1, +1% when reported in CHF and +7% in USD2, in the first nine months of 2026, driven by high demand for our innovative medicines and diagnostics. In the third quarter, sales grew +7% (CER) and +8% in CHF (+7% in USD), as exchange rates stabilised. Pharmaceuticals Division sales were +7% at CER, +2% when reported in CHF and +8% in USD, in the first nine months, due to continued high demand for medicines to treat severe diseases; Xolair (chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases) were the top growth drivers. Diagnostics Division sales were +4% at CER, stable when reported in CHF and +6% in USD, in the first nine months, as demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Highlights: US approval for Tecentriq for the adjuvant treatment of stage-III DNA mismatch repair colon cancer, Gazyva/Gazyvaro for reducing the risk of relapse in patients 2 years of age and older with frequently relapsing or steroid-dependent childhood-onset idiopathic nephrotic syndrome and Enspryng in thyroid eye disease US Priority Reviews for fenebrutinib in both relapsing and primary progressive multiple sclerosis and Enspryng in MOGAD, an autoimmune disease; vamikibart filing acceptance in uveitic macular edema, a leading cause of vision loss EU approval for Susvimo in neovascular age-related macular degeneration (nAMD), a severe eye disease, and Ocrevus in paediatric relapsing multiple sclerosis; EMA validation of application for Enspryng in MOGAD in Europe Positive data for: sefaxersen in an autoimmune condition affecting kidney function (phase III), Lunsumio in blood cancer (phase III), Tam-Peli in relapsed small-cell lung cancer (phase III) as well as enicepatide and petrelintide in overweight or obesity and type 2 diabetes (both phase II) US clearance for Elecsys pTau217 test, providing clinicians across primary and specialty care with a single-biomarker blood test to aid in identifying amyloid pathology associated with Alzheimer’s disease Launch of two new, real-time PCR tests to support public health epidemic response to the US outbreak of the Cyclospora cayetanensis parasite Delivery of molecular tests to support the Democratic Republic of the Congo health ministry-led response to the Ebola outbreak Manufacturing and R&D capacity expansion: Hillsboro injectable medicines facility and Innovation Center Boston for cardiovascular, renal and metabolic diseases in the US and small molecules facility in Basel, Switzerland Outlook for 2026 confirmed Roche CEO Thomas Schinecker: “In the third quarter, we delivered strong sales growth of +7% at constant exchange rates and +8% in Swiss francs. Most importantly, we continued to make meaningful progress for patients. We advanced another five potential new medicines into the final stage of development this year and now aim to bring up to 20 new medicines to patients by 2030. The US FDA granted Priority Review for fenebrutinib in both relapsing and primary progressive multiple sclerosis, bringing us closer to delivering the first high-efficacy, brain-penetrant oral therapy to patients. Giredestrant is also under FDA Priority Review in both early-stage and advanced breast cancer, and we are fully prepared to launch later this year, pending approval. In Diagnostics, we received US FDA clearance for Elecsys pTau217, the first and only FDA-cleared single-biomarker blood test for Alzheimer’s disease that supports both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings.  We confirm our full-year outlook.” Outlook for 2026 Roche (SIX: RO, ROP; OTCQX: RHHBY) expects an increase in Group sales in the mid single digit range (CER) for 2026. Core earnings per share are targeted to develop in the high single digit range (CER). Roche expects to further increase its dividend in Swiss francs. SalesCHF millionsAs % of sales% change January–September 2026202520262025At CERIn CHFIn USD Group 46,49345,862100.0100.0+6+1+7          Pharmaceuticals Division36,21235,55577.977.5+7+2+8 United States18,71218,79840.241.0+50  Europe6,8196,81814.714.9+20  Japan2,3522,1395.14.7+25+10  International8,3297,80017.916.9+10+7           Diagnostics Division10,28110,30722.122.5+40+6 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Group sales In the first nine months of 2026, Roche sales were +6% at CER, +1% when reported in CHF, to CHF 46.5 billion due to strong demand for pharmaceutical products and diagnostic solutions. The appreciation of the Swiss franc against most currencies, notably the US dollar, had a significant impact on the results reported in Swiss francs compared to constant exchange rates. This currency impact reversed in the third quarter. Sales growth in the Pharmaceuticals Division was +7% at CER, +2% when reported in CHF, to CHF 36.2 billion, with medicines for severe diseases continuing their strong growth. The top five growth drivers – Xolair, Hemlibra, Ocrevus, Phesgo and Vabysmo – achieved total sales of CHF 16.8 billion, an increase of +12% at CER, or +6% in CHF, compared to the first nine months of 2025. Sales of products with expired patents (Avastin, Herceptin, MabThera/Rituxan, Lucentis and Actemra/RoActemra) decreased by a combined CHF 0.4 billion at CER, or CHF 0.6 billion in CHF. In the United States, sales were +5% at CER, stable when reported in CHF, due to continued growth of Xolair, Hemlibra, Ocrevus, Polivy (blood cancer) and Tecentriq (cancer immunotherapy). This growth more than compensated for the lower sales of Kadcyla (breast cancer) and Perjeta (breast cancer). Sales in Europe were +2% at CER, stable when reported in CHF, as the growing demand for Ocrevus, Phesgo and Evrysdi (spinal muscular atrophy) more than offset the impact of biosimilar competition on Actemra/RoActemra and the conversion to Phesgo on Perjeta. In Japan, sales were +25% at CER, +10% when reported in CHF, mainly due to product supply to third parties and continued growth of Lunsumio (blood cancer), Hemlibra, Polivy, Elevidys (Duchenne muscular dystrophy) and Vabysmo. There was also a positive impact of timing effects related to the implementation of a new enterprise resource planning (ERP) system. Sales in the International region were +10% at CER, +7% when reported in CHF, led by higher sales of Phesgo, Vabysmo, Hemlibra, Ocrevus and Evrysdi. In China, sales were stable at CER and when reported in CHF, driven by continued growth of Phesgo, Vabysmo, Alecensa and Polivy. The increase was partially offset by lower sales of Perjeta due to the conversion to Phesgo and Xofluza due to a milder flu season in 2025. The Diagnostics Division’s sales were +4% at CER, stable when reported in CHF, to CHF 10.3 billion as growth in demand for core lab and pathology solutions more than offset the impact of healthcare pricing reforms in China. Sales in the Europe, Middle East and Africa (EMEA) region were +3% at CER, unchanged when reported in CHF, driven by higher sales of clinical chemistry and immunodiagnostic products. In North America, sales were +9% at CER, +3% when reported in CHF, with growth across the Core Lab, Pathology Lab and Molecular Lab customer areas. Sales in Asia-Pacific were -4% at CER, or -8% when reported in CHF, due to the healthcare pricing reforms in China. In Latin America, sales growth was +12% at CER, or +11% when reported in CHF. Pharmaceuticals: key developments CompoundMilestone Regulatory Enspryng Thyroid eye diseaseFDA approves Enspryng, a first-in-class IL-6R inhibitor, as the first and only at-home subcutaneous treatment option for thyroid eye disease (TED) FDA approval based on phase III SatraGO-1 and -2 studies, with SatraGO-2 demonstrating a significant reduction in eye bulging (proptosis) and improvement in diplopia (double vision), with a favourable safety profile, regardless of TED activity or duration. Enspryng (satralizumab) represents an important advance for people with TED, offering the first at-home subcutaneous treatment option every four weeks during maintenance phase, allowing for greater flexibility in how treatment is administered. Enspryng is an anti-IL-6R monoclonal antibody using novel recycling antibody technology designed to inhibit IL-6 signalling upstream of autoantibody-driven pathology. TED is a rare autoimmune disease affecting approximately 155 out of every 100,000 people in the US that can lead to facial disfigurement and vision-threatening complications if left untreated. More information: Media Release, 16 October 2026 Tecentriq Different types of cancerFDA approves Tecentriq in combination with a fluoropyrimidine and oxaliplatin for the adjuvant treatment of a certain type of stage III colon cancer The approval is based on results from the landmark phase III ATOMIC study, published in The New England Journal of Medicine, which showed Tecentriq plus chemotherapy reduced the risk of disease recurrence or death by 50% compared to chemotherapy alone. It is the first approved adjuvant immunotherapy regimen for stage III dMMR colon cancer, positioning Tecentriq as a new post-surgery standard of care. Nearly 25% of all colon cancers are diagnosed at stage III, and almost one in three patients with stage III colon cancer experience a recurrence within five years. Approval marks the twelfth indication for Tecentriq in the US. More information: Media Release, 9 October 2026 Fenebrutinib Multiple sclerosisFenebrutinib is the first BTK inhibitor to receive US FDA filing acceptance in both relapsing and primary progressive multiple sclerosis Fenebrutinib cut relapses by 51% and 58% vs teriflunomide in phase III RMS trials (FENhance 1 and 2) while showing a consistent, positive trend in delaying disability. Fenebrutinib became the first investigational medicine in more than a decade to slow disability progression in a phase III PPMS trial (FENtrepid), with numerical benefit vs Ocrevus. Fenebrutinib is designed to address two drivers of MS – acute inflammation causing relapses and chronic brain inflammation driving disability progression. If approved, fenebrutinib would become the first BTK inhibitor and first high-efficacy oral treatment for both RMS and PPMS, offering a new option for the nearly 1 million people living with MS in the US. More information: Media Release, 30 September 2026 Susvimo Severe eye diseasesEuropean Commission approves Susvimo for the treatment of neovascular age-related macular degeneration   By continuously delivering medicine into the eye through the Contivue refillable implant, Susvimo is the first and only continuous delivery treatment that offers an alternative to standard-of-care eye injections for nAMD. Susvimo helps people with nAMD maintain their vision with as few as two treatments per year. Data from the phase III Archway study showed that Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections. nAMD is a leading cause of vision loss in adults over 60 and affects approximately 1.7 million people across the European Union. More information: Media Release, 21 September 2026 Enspryng MOGADFDA grants Priority Review for Enspryng for MOGAD, an autoimmune disease with no approved treatments If approved, Enspryng would be the first and only disease-modifying therapy for MOGAD (myelin oligodendrocyte glycoprotein antibody-associated disease). The filing acceptance is based on the phase III METEOROID study showing that Enspryng reduced the risk of relapses by 68%. The European Medicines Agency (EMA) has validated the application for Enspryng for MOGAD in Europe, with a decision expected in Q3 2027. More information: Media Release, 10 September 2026 Phase III, pivotal and other key read-outs Sefaxersen IgA nephropathyPositive interim data shows sefaxersen significantly reduces proteinuria in people with IgA nephropathy (IgAN) In the phase III IMAgINATION study, sefaxersen demonstrated statistically significant and clinically meaningful reductions in proteinuria versus placebo at 37 weeks, showing best-in-class potential. Sefaxersen inhibits complement factor B production at its primary source in the liver, thus blocking a key driver of IgAN-related kidney damage. Interim data will be presented at an upcoming medical meeting and shared with health authorities. More information: Media Release, 23 September 2026 Enicepatide ObesityRoche announces positive phase II results for dual GLP-1/GIP receptor agonist enicepatide in people living with type 2 diabetes and overweight or obesity At the highest dose (24 mg), enicepatide achieved a mean HbA1c reduction of 2.65% at 48 weeks, highlighting its potential for best-in-disease glycaemic control. By week 48, 90% of patients in the 24 mg enicepatide arm met the type-2-diabetes glycaemic target of ≤6.5% HbA1c, while 62% achieved normoglycaemia (HbA1c <5.7%). At the highest 24 mg dose, enicepatide achieved a mean weight loss of 15.5% at 48 weeks, without a weight loss plateau. More information: Media Release, 22 September 2026 Lunsumio Blood cancerRegimen based on Lunsumio significantly improves progression-free survival in follicular lymphoma in phase III CELESTIMO study Phase III CELESTIMO study met its primary endpoint at the interim analysis demonstrating a statistically significant and clinically meaningful reduction in the risk of disease progression in people with follicular lymphoma who have received at least one prior line of treatment. Data reinforce the potential of this regimen based on Lunsumio to improve clinical outcomes, while offering a tolerable safety profile, a simple dosing schedule and outpatient administration. CELESTIMO is the confirmatory study required to convert the accelerated approval / conditional marketing authorisation of Lunsumio monotherapy for third-line or later (3L+) follicular lymphoma to full approval, as well as to secure an indication in second-line or later (2L+) follicular lymphoma. Data will be submitted to health authorities and presented at an upcoming medical meeting. More information: Media Release, 17 September 2026 Tam-Peli Lung cancerRoche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%. The novel B7-H3-targeted antibody-drug conjugate with a dual release mechanism of the payload is based on MediLink’s proprietary TMALIN platform, designed to maximise antitumour activity while minimising off-target toxicity. Roche is developing and commercialising Tam-Peli outside mainland China, Hong Kong and Macau across multiple tumour types, with plans to rapidly initiate global trials. Tam-Peli has received US FDA and China CDE Breakthrough Therapy Designations for relapsed small-cell lung cancer. More information: Media Release, 13 September 2026 Vabysmo Severe eye diseasesVabysmo demonstrates sustained two-year results in a difficult-to-treat form of nAMD The SALWEEN study showed significant improvements in vision and retinal health. More than 60% of Asian patients with polypoidal choroidal vasculopathy (PCV), an aggressive subtype of nAMD, treated with Vabysmo showed no signs of polypoidal lesions. By the end of year two, more than 60% of patients were on an extended 20-week treatment interval, reducing treatment burden. More information: Media Release, 28 August 2026 Other ESMO presentation Lung and breast cancer portfolio Roche to present pivotal data at ESMO 2026, showcasing advances across its lung and breast cancer late-stage portfolio Phase III Krascendo 1 results demonstrated divarasib’s superiority over current standard-of-care, first-generation KRAS G12C inhibitors in previously treated advanced G12C-mutated non-small cell lung cancer. Patient-reported outcomes from phase III lidERA study showed that improved efficacy of giredestrant over standard endocrine therapy is achieved without compromising tolerability and health-related quality of life in early-stage breast cancer. Phase III results in Chinese patients with metastatic nasopharyngeal carcinoma demonstrate the potential of Tam-Peli, a next-generation B7-H3-targeted ADC, to deliver robust efficacy with a favourable safety profile in high-unmet-need solid tumours.   More information: Media Release, 19 October 2026 Vamikibart Uveitic macular edemaRoche presents new phase III one-year data for vamikibart in uveitic macular edema (UME), a serious cause of vision loss In the MEERKAT and SANDCAT studies, vamikibart demonstrated sustained improvements in vision and reductions in macular thickness in patients with UME at 52 weeks. UME is the leading cause of moderate and severe vision loss in patients with uveitis, posing a significant risk of blindness if left untreated. The FDA has accepted Roche’s Biologics License Application (BLA), with an approval decision expected by July 2027. More information: Media Release, 10 October 2026 Vabysmo Severe eye diseasesRoche presents new data at EURETINA, highlighting the real-world effectiveness and safety of Vabysmo across major retinal conditions New real-world results for Vabysmo in nAMD, diabetic macular edema and retinal vein occlusion reinforce robust effectiveness and durability across previously untreated and treated eyes, with no new safety signals. Advanced AI-enabled analysis of imaging confirms rapid and meaningful anatomical drying supporting Vabysmo as a standard-of-care therapy in routine clinical care. With more than 5,000 patients enrolled, VOYAGER is the largest, prospective, non-interventional real-world dataset evaluating Vabysmo across diverse clinical practice settings worldwide.   More information: Media Release, 1 October 2026 Giredestrant Breast cancerGiredestrant combination significantly improved progression-free survival in ER-positive advanced breast cancer in phase III evERA data published in The New England Journal of Medicine Giredestrant plus everolimus reduced the risk of disease progression or death by 44% and 62% in ITT and ESR1-mutated populations, respectively, versus standard endocrine therapy plus everolimus. By targeting resistance to endocrine treatments, the giredestrant combination seeks to delay disease progression and improve overall patient outcomes. The FDA has set a PDUFA goal date for giredestrant in early-stage breast cancer of 30 November 2026 and in advanced disease of 18 December 2026. More information: Media Release, 1 October 2026 Board of Directors nominationRoche proposes Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to its Board of Directors at the 2027 Annual General Meeting Roche’s Board of Directors has approved to propose Dr Christophe Weber, former CEO of Takeda Pharmaceuticals, for election to the Board at the Annual General Meeting on 9 March 2027. Roche Chairman Severin Schwan highlighted Dr Weber’s extensive healthcare industry knowledge and leadership experience as valuable assets for the Board. Roche continues its commitment to transformative medicines and diagnostics, focusing on major disease areas and global healthcare challenges. More information: Media Release, 23 September 2026 Innovation Center BostonRoche announces grand opening of its Innovation Center Boston to drive advancements in cardiovascular, renal and metabolic diseases The centre will be a hub for Roche and Genentech, bringing together expertise in cardiovascular, renal and metabolic diseases, as well as for data science and AI specialists to drive innovation in drug discovery and development. It will expand Roche’s and Genentech’s presence in Boston, reflecting a long-term commitment to one of the world’s leading life sciences hubs. This is part of Roche and Genentech’s USD 50 billion investment in US manufacturing and R&D, building on recent investments and manufacturing milestones in Holly Springs, North Carolina, and Hillsboro, Oregon. More information: Media Release, 17 September 2026 Hillsboro facilityGenentech, Roche’s US subsidiary, announces a USD 750 million manufacturing expansion in Hillsboro, Oregon The new facility in Hillsboro, Oregon for the assembly of injectable medicines and delivery devices will further advance end-to-end US drug manufacturing capabilities. Approximately USD 750 million investment will double the size of the existing facility and is expected to create an additional 250 specialised manufacturing jobs. Flexible manufacturing capacity will support advanced drug delivery devices that can provide patients with more convenient ways to receive treatment. More information: Media Release, 20 August 2026 Pharmaceuticals sales SalesCHF millionsAs % of sales% change January–September2026202520262025At CERIn CHF Pharmaceuticals Division36,21235,555100.0100.0+7+2 United States18,71218,79851.752.9+50 Europe6,8196,81818.819.2+20 Japan2,3522,1396.56.0+25+10 International8,3297,80023.021.9+10+7 International: Asia-Pacific, CEETRIS (Central Eastern Europe, Türkiye, Russia and Indian subcontinent), Latin America, Middle East, Africa, Canada, others Top 20 best-selling pharmaceuticals (% change at CER1)TotalUnited StatesEuropeJapanInternational CHF m%CHF m%CHF m%CHF m%CHF m% Ocrevus Multiple sclerosis5,317+73,581+51,136+9--600+21 Hemlibra Haemophilia A3,750+122,006+9769+5291+20684+23 Vabysmo Eye diseases (nAMD, DME, RVO)3,196+102,060+2585+7131+41420+65 Tecentriq Cancer immunotherapy2,615+51,243+8626-2245+6501+9 Xolair3 Chronic hives, food allergies2,521+202,521+20------ Phesgo Breast cancer2,064+18486-1657+11152+24769+43 Perjeta3 Breast cancer2,040-8824-10361-1338-20817-3 Actemra/RoActemra3 RA, COVID-191,621-10795-9328-26232+14266-4 Evrysdi Spinal muscular atrophy1,470+18497+12504+1465+7404+33 Kadcyla3 Breast cancer1,339-9442-19370-565+9462-2 Polivy Blood cancer1,302+24606+29204-9176+30316+44 Alecensa Lung cancer1,213+6391-1189-3154+15479+15 MabThera/Rituxan3 Blood cancer, RA919+3605+1294-88-16212-10 Activase/TNKase3 Cardiac diseases830+6792+5----38+12 Gazyva/Gazyvaro3 Blood cancer, lupus nephritis751+7369+4176-228+28178+25 Herceptin3 Breast and gastric cancer695-12140-15205-63-35347-13 Avastin3 Various cancer types639-12195-856+556-43332-9 Columvi Blood cancer327+67146+2492+113--89+167 Enspryng Acute inflammation of brain, spinal cord and optic nerves319+2879+1834+18138+3068+42 Pulmozyme3 Cystic fibrosis303-12214-1143-111+3845-18 DME: diabetic macular edema / nAMD: neovascular or ‘wet’ age-related macular degeneration / RVO: retinal vein occlusion / RA: rheumatoid arthritis Diagnostics key developments ProductMilestone Elecsys pTau217 Alzheimer’s diseaseRoche receives FDA clearance for Elecsys pTau217, advancing Alzheimer’s disease assessment across primary and specialty care It is the first and only FDA-cleared, single-biomarker blood test supporting both rule-in and rule-out assessment of amyloid pathology across primary and specialty care settings. The test delivers consistency across clinical settings by using the same validated cut-offs in primary and specialty care. It is designed for broad implementation across Roche’s installed base of more than 4,500 cobas laboratory instruments in the US supporting access through existing laboratory infrastructure.   More information: Investor Update, 24 August 2026 Diagnostics sales SalesCHF millionsAs % of sales% change January–September2026202520262025At CERIn CHF Diagnostics Division10,28110,307100.0100.0+40 Customer areas       Core Lab5,7555,68856.055.2+5+1 Molecular Lab1,8361,86117.918.1+3-1 Near Patient Care1,3481,47713.114.3-5-9 Pathology Lab1,3421,28113.012.4+10+5 Regions       Europe, Middle East, Africa3,6983,68636.035.8+30 North America3,3893,30532.932.1+9+3 Asia-Pacific2,3432,54722.824.7-4-8 Latin America8517698.37.4+12+11 More information on Roche’s performance in the first nine months of 2026: 9M 2026 presentation Appendix with tables  About Roche Roche (SIX: RO, ROP; OTCQX: RHHBY) is a healthcare company uniquely placed to prevent, stop and cure diseases by uniting leading science and technology across diagnostics, medicines and digital solutions. Roche was founded in Basel, Switzerland in 1896 and today is a leading provider of transformative medicines and diagnostics for millions of people in over 150 countries around the world. It is dedicated to tackling healthcare challenges that place the greatest strain on patients, families, communities and healthcare systems. Across its Diagnostics and Pharmaceuticals Divisions, Roche focuses on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology with the aim of providing real and positive change for patients, the people they love and the professionals who care for them. Genentech in the United States is a fully owned subsidiary in the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, a major innovator in the Japanese therapeutic antibody market. For more information, please visit www.roche.com. All trademarks used or mentioned in this release are protected by law. References [1] CER (Constant Exchange Rates). The percentage changes at constant exchange rates are calculated using simulations by reconsolidating both the 2026 and 2025 results at constant exchange rates (the average rates for the year ended 31 December 2025). For the definition of CER, see page 178 of the Roche Finance Report 2025. [2] USD (US dollars). The percentage changes for selected sales figures at US dollars are calculated by translating both the 2026 and 2025 sales figures at the respective average US dollar exchange rate for the period in question. This supplementary information is provided to assist readers when assessing comparability with other companies. [3] Products launched before 2015. Cautionary statement regarding forward-looking statements This document contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this document, such as: (1) pricing and product initiatives of competitors; (2) legislative and regulatory developments and economic conditions; (3) delay or inability in obtaining regulatory approvals or bringing products to market; (4) fluctuations in currency exchange rates and general financial market conditions; (5) uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side effects of pipeline or marketed products; (6) increased government pricing pressures; (7) interruptions in production; (8) loss of or inability to obtain adequate protection for intellectual property rights; (9) litigation; (10) loss of key executives or other employees; and (11) adverse publicity and news coverage. The statement regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. Roche Global Media Relations Phone: +41 61 688 88 88 / e-mail: media.relations@roche.com Tristan Schmitz Phone: +41 79 529 70 35Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915Karsten Kleine Phone: +41 79 461 86 83 Kirti Pandey Phone: +41 79 398 38 53Yvette Petillon Phone: +41 79 961 92 50 Irène Stephan Phone: +41 79 377 83 75Albert Thottiyil Phone: +41 79 775 66 12 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 687 5 284 e-mail: bruno.eschli@roche.comDr Sabine Borngräber Phone: +41 61 688 80 27 e-mail: sabine.borngraeber@roche.com Dr Birgit Masjost Phone: +41 61 688 48 14 e-mail: birgit.masjost@roche.com  Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: kalm.loren@gene.com   Attachments Communications appendix tables_YTD Sep 2026_Sales_02102026 Media Investor Release Roche Q3 2026 English ———————————————————————————————————————————————————————————— After Doctors Told Her to Prepare for Death, Kristin Whitcomb Shares Her Illness Journey in International Bestseller 2026-10-22 · EIN Presswire · Healthcare, Energy https://www.einpresswire.com/article/951384488/after-doctors-told-her-to-prepare-for-death-kristin-whitcomb-shares-her-illness-journey-in-international-bestseller The Moment We Rise Best-Selling Author Kristin Whitcomb Colorado sound and energy healer shares how a life-threatening illness, unanswered medical questions, and a mold-related diagnosis reshaped her view of healing. RED FEATHER LAKES, CO, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Kristin Whitcomb is one of 15 contributing authors featured in * The Moment We Rise : Stories of Healing, Purpose, and the C ———————————————————————————————————————————————————————————— SignalWealth Launches CRM and Content Studio Where AI Builds but Never Sends 2026-10-22 · EIN Presswire · AI, Healthcare, Media, Insurance, Software & IT https://www.einpresswire.com/article/951384123/signalwealth-launches-crm-and-content-studio-where-ai-builds-but-never-sends SignalWealth puts an advisor's client book and content in one login, under the firm's own brand. The SignalWealth CRM dashboard: today's tasks and meetings, pipeline value and an AI read on pipeline health. In the Studio, advisors edit and approve every short before it posts. Shown here under The Income Standard's brand. One login for financial advisors and insurance agents: a branded CRM plus a studio that turns rec ———————————————————————————————————————————————————————————— Sony Semiconductor Solutions Announces 1 mm Square Image Sensor for Medical Single-Use Endoscopes, Featuring Industry's First [*1] 5 m Digital Transmission and High Image Quality 2026-10-22 · PR Newswire · Healthcare, Semiconductors, Consumer electronics https://www.prnewswire.com/news-releases/sony-semiconductor-solutions-announces-1-mm-square-image-sensor-for-medical-single-use-endoscopes-featuring-industrys-first-1-5-m-digital-transmission-and-high-image-quality-302899093.html Providing stable transmission of high-definition images for thin endoscopes ATSUGI, Japan, Oct. 22, 2026 -- Sony Semiconductor Solutions Corporation (Sony) today announced the upcoming release of the IMX742, a CMOS image sensor with approximately 0.51 effective megapixels*2... ———————————————————————————————————————————————————————————— Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock 2026-10-22 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/arcus-biosciences-announces-pricing-250-025300974.html HAYWARD, Calif., October 22, 2026--Arcus Biosciences, Inc. (NYSE: RCUS), a late clinical-stage biopharmaceutical company focused on developing differentiated molecules and combinations for the treatment of cancer and immune diseases, today announced the pricing of an underwritten public offering of 14, ———————————————————————————————————————————————————————————— Computer Task Group Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Exposure of Social Security Numbers and Health Data 2026-10-22 · PR Newswire · Healthcare, Cybersecurity, Legal https://www.prnewswire.com/news-releases/computer-task-group-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-exposure-of-social-security-numbers-and-health-data-302916253.html National class action law firm offers free, confidential case evaluations to Computer Task Group employees, contractors, clients, and others whose information may have been exposed. NEWTOWN, Pa., Oct. 21, 2026 -- Edelson Lechtzin LLP, a national class action law firm, is... ———————————————————————————————————————————————————————————— STS Aviation Group Data Breach Investigation: Edelson Lechtzin LLP Probes Class Action Claims After Exposure of Social Security Numbers, Financial, and Medical Data 2026-10-22 · PR Newswire · Healthcare, Aerospace & defense, Cybersecurity, Legal https://www.prnewswire.com/news-releases/sts-aviation-group-data-breach-investigation-edelson-lechtzin-llp-probes-class-action-claims-after-exposure-of-social-security-numbers-financial-and-medical-data-302916251.html National class action law firm offers free, confidential case evaluations to STS Aviation Group customers, employees, and others whose personal information may have been exposed in the data breach. NEWTOWN, Pa., Oct. 21, 2026 -- Edelson Lechtzin LLP, a national class action... ———————————————————————————————————————————————————————————— Top-Journal Breakthrough (IF=81.2): Cloud-Clone AGE ELISA Kit Helps Uncover Protein Glycation Modification 2026-10-22 · EIN Presswire · SaaS, Healthcare, Biotech & pharma https://www.einpresswire.com/article/951394243/top-journal-breakthrough-if-81-2-cloud-clone-age-elisa-kit-helps-uncover-protein-glycation-modification CEB353Ge kit delivers critical molecular evidence for phase 3 clinical trial evaluating recombinant human serum albumin for cirrhotic ascites HUSTON, TX, UNITED STATES, October 22, 2026 / EINPresswire.com / -- Against the backdrop of rapid advances in biomedical science, landmark publications in high-impact academic journals define cutting-edge research directions worldwide. On 10 September 2026, a research team from ———————————————————————————————————————————————————————————— TheraConnect.net Launches Mental Care Discovery Platform Designed to Help People Find the Right Professional for Their Needs 2026-10-22 · MarketersMEDIA · SaaS, Healthcare https://news.marketersmedia.com/theraconnectnet-launches-mental-care-discovery-platform-designed-to-help-people-find-the-right-professional-for-their-needs/89206903 The professional directory connects people with mental care providers while helping practitioners showcase their services and receive inquiries directly. -- TheraConnect.net has announced the launch of its mental care discovery and professional directory platform, designed to help people find therapists, counselors, psychologists, mental-health coaches, and other mental care professionals. The platform also gives pro ———————————————————————————————————————————————————————————— Sony Semiconductor Solutions Announces 1 mm Square Image Sensor for Medical Single-Use Endoscopes, Featuring Industry's First*¹5 m Digital Transmission and High Image Quality 2026-10-22 · PR Newswire · Healthcare, Semiconductors, Consumer electronics https://www.prnewswire.com/news-releases/sony-semiconductor-solutions-announces-1-mm-square-image-sensor-for-medical-single-use-endoscopes-featuring-industrys-first5-m-digital-transmission-and-high-image-quality-302916055.html Providing stable transmission of high-definition images for thin endoscopes ATSUGI, Japan, Oct. 21, 2026 -- Sony Semiconductor Solutions Corporation (Sony) today announced the upcoming release of the IMX742, a CMOS image sensor with approximately 0.51 effective megapixels*2... ———————————————————————————————————————————————————————————— NUH WINS GOLD AT IHF AWARDS 2026 FOR GREEN OPERATING THEATRE PROGRAMME 2026-10-22 · PR Newswire · Healthcare, Sustainability, Government & policy https://www.prnewswire.com/news-releases/nuh-wins-gold-at-ihf-awards-2026-for-green-operating-theatre-programme-302916198.html NUH won Gold and received an Honourable Mention for its sustainability efforts at the International Hospital Federation Awards 2026, alongside presentations of its green surgical initiatives, digital health and organisational improvement initiatives at the World Hospital Congress.... ———————————————————————————————————————————————————————————— What Makes Dr. Rajeev Sood a Top Choice for Complex Renal Transplant Surgeries 2026-10-22 · freePRnow · Healthcare http://www.freePRnow.com/pr/what-makes-dr-rajeev-sood-a-top-choice-for-complex-renal-transplant-surgeries Dr. Rajeev Sood provides advanced renal transplant and urological care with expertise, precision, technology, and patient-centered treatment. ———————————————————————————————————————————————————————————— Unicycive Therapeutics Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission and PDUFA Date of March 25, 2027 2026-10-22 · ACN Newswire · Finance, Healthcare, Food & drink, Industrial, Biotech & pharma, Legal, Nonprofits, Internet & apps https://www.acnnewswire.com/press-release/english/110981/ Mountain View, CA, 21 Oct, 2026 - Unicycive Therapeutics, Inc. ("Unicycive" or the "Company") (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that the U.S. Food and Drug Administration (FDA) has accepted the resubmission of its New Drug Application (NDA) for oxylanthanum carbonate (OLC), the Company's investigational oral phosphate binder for the treatment of hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. The NDA was resubmitted following a Complete Response Letter (CRL) received in June 2026. The FDA has deemed the OLC resubmission a Class II with a six-month review period from the resubmission date, and set a Prescription Drug User Fee Act (PDUFA) target action date of March 25, 2027. Unicycive Therapeutics, Inc. is a B2i Digital Featured Company. See the company's in-depth profile at: https://b2idigital.com/unicycive-therapeutics. "We are pleased that the FDA has accepted the resubmission of our NDA for OLC and assigned a PDUFA date," said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. "This resubmission includes CMC data from a new third-party drug product manufacturing vendor. The new vendor's facility was last inspected by the FDA in March 2024 and received 'No Action Indicated' status. We hope to continue working with the FDA toward potential approval of this important medication to patients with CKD on dialysis who need additional treatment options for managing hyperphosphatemia." The Company does not know whether the FDA will decide to conduct a pre-approval inspection of the new third-party DP vendor. Additionally, if the original third-party manufacturing vendor is inspected in the near term and finds that its facility complies with current Good Manufacturing Practice (cGMP), the Company plans to seek FDA alignment on a shorter approval timeline. The Company resubmitted the NDA following the second CRL, which cited deficiencies previously identified at the original third-party manufacturer of the drug product, which the FDA had not been able to re-inspect during the prior submission review. The timing and outcome of any FDA inspection of the original third-party vendor will be determined solely by the FDA. The NDA is supported by data from three clinical studies (a Phase 1 study in healthy volunteers, a bioequivalence study in healthy volunteers, and a tolerability study of OLC in CKD patients on dialysis), multiple preclinical studies, as well as CMC data. The FDA did not raise any concerns regarding OLC's preclinical or clinical data, including safety data, included in the original NDA submission. About Oxylanthanum Carbonate OLC is an investigational oral phosphate binder that leverages proprietary nanoparticle technology to deliver high phosphate binding potency, reducing the number and size of pills that patients must take to treat hyperphosphatemia in patients with chronic kidney disease (CKD) on dialysis. Its potential best-in-class profile may have meaningful patient adherence benefits over currently available treatment options as it requires a lower pill burden. Unicycive is seeking FDA approval of OLC via the 505(b)(2) regulatory pathway. OLC is protected by a strong global patent portfolio including issued patents on composition of matter with exclusivity until 2031, and with the potential for patent term extension until 2035. About Hyperphosphatemia Hyperphosphatemia is a serious medical condition that occurs in nearly all patients with End Stage Renal Disease (ESRD). Annually there are over 450,000 individuals in the U.S. that require medication to control their phosphate levels.[1] Uncontrolled hyperphosphatemia is strongly associated with increased death and hospitalization for CKD patients on dialysis. Treatment of hyperphosphatemia is aimed at lowering serum phosphate levels via two means: (1) restricting dietary phosphorus intake; and (2) using, on a daily basis, and with each meal, oral phosphate binding drugs that facilitate fecal elimination of dietary phosphate rather than its absorption from the gastrointestinal tract into the bloodstream. [1] Flythe JE. Dialysis-Past, Present, and Future: A Kidney360 Perspectives Series. Kidney360. 2023 May 1;4(5):567-568. doi: 10.34067/KID.0000000000000145. About Unicycive Therapeutics Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive's lead investigational treatment is oxylanthanum carbonate, a novel phosphate binding agent for the treatment of hyperphosphatemia in patients with chronic kidney disease who are on dialysis. Unicycive’s second investigational treatment UNI-494 is intended for the treatment of conditions related to acute kidney injury. It has been granted orphan drug designation (ODD) by the FDA for the prevention of Delayed Graft Function (DGF) in kidney transplant patients and has completed a Phase 1 dose-ranging safety study in healthy volunteers. For more information, please visit Unicycive.com. Forward-looking statements Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as "anticipate," "believe," "forecast," "estimated" and "intend" or other similar terms or expressions that concern Unicycive's expectations, strategy, plans or intentions. These forward-looking statements are based on Unicycive's current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; Unicycive's clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidates; Unicycive's dependence on third parties for manufacturing; the possibility that FDA may require inspection of any vendor prior to approval, which could delay or prevent approval of its NDA; the risk that the inspection of the original or new third-party manufacturing vendor may not occur within a timeframe that benefits its regulatory timeline, or may result in adverse findings; risks related to business interruptions, which could seriously harm its financial condition and increase its costs and expenses; dependence on key personnel; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; market acceptance of its products; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and other factors described more fully in the section entitled 'Risk Factors' in Unicycive's Annual Report on Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. Any forward-looking statements contained in this press release speak only as of the date hereof, and Unicycive specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Investor Contacts: Kevin Gardner, LifeSci Advisors, kgardner@lifesciadvisors.com Media Contact: Unicycive Therapeutics, media@unicycive.com Additional Contact: David Shapiro, B2i Digital, Inc., +1 212-579-4844, david@b2idigital.com B2i Digital Social Media: LinkedIn X Facebook Instagram YouTube TikTok Stocktwits Reddit Pinterest Threads To learn more about the B2i Digital Media Network, visit:  https://b2idigital.com/media-network SOURCE: Unicycive Therapeutics, Inc. ———————————————————————————————————————————————————————————— Oklahoma HB 3127: Medical Marijuana Doctor Advises Patients on Workplace Drug Rules 2026-10-22 · Newsworthy.ai · Finance, AI, SaaS, Healthcare, Real estate, Energy, Automotive, Industrial, Biotech & pharma https://newsworthy.ai/news/202610223081/oklahoma-hb-3127-medical-marijuana-doctor-advises-patients-on-workplace-drug-rules OKLAHOMA CITY Wednesday Oct 21, 2026 @ 7:00 PM Central — An active Oklahoma medical marijuana license has never been an absolute guarantee of job security. Starting November 1, 2026, that legal distinction becomes significantly more critical. According to a statewide patient advisory issued by Medical Marijuana Doctor Oklahoma, licensed cardholders face substantial shifts under House Bill 3127, which allows employers to take adverse employment action following a positive marijuana test if the action is carried out under a lawful written drug and alcohol testing policy. Signed by Governor Kevin Stitt on April 17, 2026, HB 3127 amends 63 O.S. § 427.8 of the Oklahoma Medical Marijuana and Patient Protection Act. While the legislation preserves the foundational rule that employers cannot penalize someone solely for being a registered Oklahoma Medical Marijuana Authority (OMMA) license holder, it substantially narrows the positive-test protections that many working patients currently rely on. Before November 1: How Existing Law Protected Positive Tests Under current OMMA patient-rights guidance, an employer generally cannot refuse to hire, discipline, or terminate a licensed patient solely because of a positive drug screen for marijuana components or metabolites. Existing law permits exceptions only when: The individual does not hold a valid, active OMMA license; The employee possesses, consumes, or is under the influence of marijuana at work or during work hours; The individual holds a position with safety-sensitive job duties; or State protection is preempted by federal law or where compliance is required to maintain federal funding or contracts. As detailed in the enrolled HB 3127 legislative history, the amendment does not eliminate all patient safeguards, but it fundamentally rewrites the positive-test exception. A Compliant Written Policy Becomes the New Dividing Line Beginning November 1, an employer may act solely on a positive marijuana test result when that action is taken pursuant to a written drug and alcohol testing policy adopted and enforced in accordance with the Oklahoma Standards for Workplace Drug and Alcohol Testing Act. This statutory change means a valid patient license may no longer defeat an adverse employment decision based on a drug screen. However, Medical Marijuana Doctor Oklahoma emphasizes that employers do not receive unchecked authority simply because they possess an internal document labeled "drug policy." As noted in recent workplace legal analysis by Crowe & Dunlevy, an employer’s policy and testing workflow must comply strictly with state testing standards, which govern: advance written notice to employees; clearly articulated testing criteria (who, when, and what substances are tested); certified collection and laboratory procedures; employee rights to explain or rebut a positive result; and strict statutory confidentiality protections. Safety-Sensitive Jobs Move to Mandatory Zero Tolerance HB 3127 creates an explicit statutory rule for safety-sensitive positions: applicants and employees in those roles "shall be subject to a zero-tolerance drug and alcohol standard," even if the employer applies an impairment-based or more flexible rule to non-safety staff. Crucially, the amendment eliminates the former statutory wording that permitted employers to designate positions as safety-sensitive based merely on what management "reasonably believes" could impact health and safety. Under 63 O.S. § 427.8, the law ties the classification directly to actual performed duties, including: Handling, storing, disposing of, or transporting hazardous, volatile, flammable, or combustible materials; Operating a motor vehicle, machinery, equipment, or power tools; Repairing or monitoring equipment or manufacturing processes whose failure could cause personal injury or property damage; Firefighting; Operating or overseeing utilities and critical public infrastructure; Dispensing pharmaceuticals; Carrying a firearm; or Providing direct patient care or direct child care. While this statutory list is not exhaustive, it restricts employers from applying arbitrary, self-created safety-sensitive labels. Because HB 3127 does not define every operational detail of "zero tolerance," patients in potentially qualifying roles should inspect their formal job descriptions, company policies, and applicable federal regulations. Core Safeguards and Legal Remedies That Survive Unchanged Despite the expansion of employer authority, two vital legal protections remain in force: Status Discrimination Ban: Unless mandated by federal statute or federal funding agreements, an employer may not penalize an applicant or employee solely because they hold an OMMA patient card. Civil Legal Remedy for Willful Violations: Patients subjected to unlawful adverse actions retain legal recourse. The statute maintains remedies under the Oklahoma workplace testing act, which authorizes civil actions within one year of an alleged willful violation (40 O.S. § 563). At the same time, state law reiterates that medical cannabis licenses do not authorize workplace consumption. Employers maintain the absolute right to prohibit possession, use, sale, transfer, and impairment on company property or while performing job functions. What Oklahoma Patients Must Do Before November 1 Medical Marijuana Doctor Oklahoma recommends that cardholders take immediate proactive steps: Request the Written Policy: Obtain and review your employer's current written drug and alcohol testing policy to verify that it complies with the Oklahoma testing act. Review Real Job Duties: Compare your daily tasks against the statutory list of safety-sensitive functions to evaluate your risk level. Never Assume Automatic Protection: Do not assume that off-duty therapeutic use, an active card, or the lack of visible impairment will shield your employment after November 1. Preserve Documentation: Retain dated copies of testing notices, chain-of-custody documentation, laboratory results, and written employer correspondence. Seek Timely Counsel: If facing an adverse employment action that appears non-compliant, consult a qualified Oklahoma employment attorney immediately to preserve statutory claims within the one-year limitations window under 40 O.S. § 563. This advisory provides general educational information, not legal advice. Oklahoma law and workplace policies can change, and federal rules may produce a different result. Verify current requirements through the Oklahoma Legislature, the Oklahoma Medical Marijuana Authority, and qualified legal counsel. ———————————————————————————————————————————————————————————— INVESTOR NOTICE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline - HIMS 2026-10-21 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/investor-notice-hims--hers-health-inc-investors-with-substantial-losses-have-opportunity-to-lead-class-action-lawsuit-before-november-2-2026-deadline---hims-302916026.html SAN DIEGO, Oct. 21, 2026 -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Hims & Hers Health, Inc. (NYSE: HIMS) securities between August 4, 2025 and July 29, 2026, inclusive (the "Class Period"), have until Monday, November 2,... ———————————————————————————————————————————————————————————— Untrained and Injured, Ryan Beckmann Runs 115 Miles in 24 Hours on a Treadmill for SLEEPLESS 2026-10-21 · EIN Presswire · Healthcare https://www.einpresswire.com/article/951357891/untrained-and-injured-ryan-beckmann-runs-115-miles-in-24-hours-on-a-treadmill-for-sleepless He has never run a marathon. Now he is training for a run from Mexico to California for mental health and addiction recovery, then the Moab 240 COSTA MESA, CA, UNITED STATES, October 21, 2026 / EINPresswire.com / -- Ryan Beckmann has never run a marathon. He doesn't follow a training plan, and he will tell you he isn't in running shape. Yet on Oct. 16 and 17 he ran 115.20 miles in 24 hours on a treadmill at Motion Fi ———————————————————————————————————————————————————————————— Materna Medical Announces New Benchmark for Measuring Meaningful Improvement in Vaginismus 2026-10-21 · PRWeb · Healthcare https://www.prweb.com/releases/materna-medical-announces-new-benchmark-for-measuring-meaningful-improvement-in-vaginismus-302916072.html Study data presented at The Menopause Society 2026 Annual Meeting give researchers and clinicians a shared way to tell whether a treatment truly helps women with painful penetration MOUNTAIN VIEW, Calif., Oct. 21, 2026 -- An interim three-month analysis from the Materna... ———————————————————————————————————————————————————————————— Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™ 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/fresenius-medical-care-brings-kidney-care-innovation-to-critical-care-patients-with-us-launch-of-multifiltratepro-302916083.html Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment... ———————————————————————————————————————————————————————————— From Turkey to NYC: Peak Hair Restoration Brings Advanced Hair Restoration Techniques, the Science of Hair, and the Power of Confidence 2026-10-21 · ACCESS Newswire · Healthcare https://finance.yahoo.com/healthcare/articles/turkey-nyc-peak-hair-restoration-215500339.html Co-Founder and CEO Mustafa Onur Bostan discusses personalized care, physician-led treatment, and the emotional side of hair restoration. NEW YORK, NY / October 21, 2026 / Peak Hair Restoration is highlighting an approach to hair restoration that brings together individualized clinical assessment, patient ———————————————————————————————————————————————————————————— Unicycive Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027 2026-10-21 · FinanceWire · Healthcare https://financewire.com/2026/10/21/unicycive-announces-fda-acceptance-of-oxylanthanum-carbonate-nda-resubmission-pdufa-date-of-march-25-2027/ Mountain View, California, 21st October 2026, FinanceWire … Read More The post Unicycive Announces FDA Acceptance of Oxylanthanum Carbonate NDA Resubmission, PDUFA Date of March 25, 2027 appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Kane Engages Independent Trading Group as Market Maker 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385955/0/en/kane-engages-independent-trading-group-as-market-maker.html Agreement intended to support an orderly market and improve liquidity in Kane Biotech’s common shares Agreement intended to support an orderly market and improve liquidity in Kane Biotech’s common shares ———————————————————————————————————————————————————————————— Dorsata, Inc. Notifies Patients of Metabase Data Security Incident 2026-10-21 · PR Newswire · Healthcare, Cybersecurity https://www.prnewswire.com/news-releases/dorsata-inc-notifies-patients-of-metabase-data-security-incident-302916007.html CHARLOTTESVILLE, Va., Oct. 21, 2026 -- Dorsata, Inc. has become aware of a data security incident involving the Metabase third-party software it uses that may have involved the protected health information belonging to patients. Dorsata is sending letters to potentially... ———————————————————————————————————————————————————————————— Protect Yourself and Your Community: Accordia Health Encourages the Public to Get Annual Flu Vaccine 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/protect-yourself-and-your-community-accordia-health-encourages-the-public-to-get-annual-flu-vaccine-302915862.html MOBILE, Ala., Oct. 21, 2026 -- As flu season gets underway, Accordia Health encourages everyone eligible to get the annual flu vaccine. Influenza, commonly known as the flu, is more than just a seasonal inconvenience. It can cause serious illness, lead to hospitalization,... ———————————————————————————————————————————————————————————— eHealth, Inc. to Hold Third Quarter 2026 Earnings Call on November 4 at 5:00 p.m. Eastern Time 2026-10-21 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/ehealth-inc-to-hold-third-quarter-2026-earnings-call-on-november-4-at-500-pm-eastern-time-302915951.html INDIANAPOLIS, Oct. 21, 2026 -- eHealth, Inc. (Nasdaq: EHTH), a leading private online health insurance marketplace, today announced that the company plans to release third quarter 2026 financial results on November 4, 2026. The company will hold an earnings conference call... ———————————————————————————————————————————————————————————— Mexico Precision Medicine Market Size, Share, Trends, and Forecast 2026-2034 | Genomics and Digital Health to Drive 7.97% CAGR, Reaching USD 2.72 Billion 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385911/28124/en/mexico-precision-medicine-market-size-share-trends-and-forecast-2026-2034-genomics-and-digital-health-to-drive-7-97-cagr-reaching-usd-2-72-billion.html Genomics advances, digital health adoption and personalized care drive opportunities across oncology, diagnostics and rare disease management in Mexico. Genomics advances, digital health adoption and personalized care drive opportunities across oncology, diagnostics and rare disease management in Mexico. ———————————————————————————————————————————————————————————— Helus Pharma Highlights Clinical Program Advancements at Investor Presentation Held on October 21, 2026 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385903/0/en/helus-pharma-highlights-clinical-program-advancements-at-investor-presentation-held-on-october-21-2026.html Topline data readout from APPROACH Phase 3 study of HLP003 in development for the potential adjunctive treatment of major depressive disorder (“MDD”) on track for Q4 20261,2 ———————————————————————————————————————————————————————————— Placenta Accreta Spectrum is Life-Threatening and Becoming More Common, Says Intermountain Health 2026-10-21 · PRUnderground · Healthcare https://prunderground.com/placenta-accreta-spectrum-is-life-threatening-and-becoming-more-common-says-inte/cmvif26bs000f07jq896kkhaa Rare, Life-Threatening Condition is Best Treated by Maternal Fetal Medicine Specialists The post Placenta Accreta Spectrum is Life-Threatening and Becoming More Common, Says Intermountain Health first appeared on ———————————————————————————————————————————————————————————— Paul "Bear" Bryant Awards Announce 2026 Coach of the Year Award Watch List 2026-10-21 · NewMediaWire · Finance, Healthcare, Education, Sports https://www.newmediawire.com/news/paul-bear-bryant-awards-announce-2026-coach-of-the-year-award-watch-list-7090779 HOUSTON - October 21, 2026 - Twenty-eight football coaches make up the American Heart Association’s 2026 Paul “Bear” Bryant Coach of the Year Award watch list, a list of current coaches in consideration for the annual top honor. The award is given each January to a college football coach for contributions that make the sport better for athletes and fans alike by demonstrating grit, integrity and a winning approach to coaching and life - both on and off the field. This award is the only college football coaching honor given after the National Champion has been determined. The American Heart Association, a relentless force changing the future of health for everyone everywhere, presents the Bear Bryant Awards annually to celebrate excellence in coaching, to honor coach Bryant’s legacy and to raise awareness and critical funds for its mission. The coaching legend died from a heart attack in 1983, just 28 days after his final victory and retirement. Since its inception, the awards have united the football community in support of the Association's lifesaving work. The watch list, finalists and Coach of the Year recipient are voted on by the National Sports Media Association and the Paul “Bear” Bryant Awards Executive Leadership Team, comprised of members of the Bryant family and community leaders who come together to support the campaign. The 2026 Watch List includes (in alphabetical order): David Braun, Northwestern University (Big Ten Conference) Troy Calhoun, Air Force (Mountain West Conference) Bob Chesney, UCLA (Big Ten Conference) Curt Cignetti, Indiana University (Big Ten Conference) Mario Cristobal, University of Miami (Atlantic Coast Conference) Spencer Danielson, Boise State University (Pac-12 Conference) Ryan Day, Ohio State University (Big Ten Conference) Kalen DeBoer, University of Alabama (Southeastern Conference) Jake Dickert, Wake Forest University (Atlantic Coast Conference) Eli Drinkwitz, University of Missouri (Southeastern Conference) Jason Eck, University of New Mexico (Mountain West Conference) Kirk Ferentz, University of Iowa (Big Ten Conference) Marcus Freeman, University of Notre Dame (Independent) Willie Fritz, University of Houston (Big 12 Conference) Pete Golding, University of Mississippi (Southeastern Conference) Josh Heupel, University of Tennessee (Southeastern Conference) Charles Huff, University of Memphis (American Conference) Rhett Lashlee, Southern Methodist University (Atlantic Coast Conference) Joey McGuire, Texas Tech University (Big 12 Conference) Eric Morris, Oklahoma State University (Big 12 Conference) Billy Napier, James Madison University (Sun Belt Conference) Tim Polasek, North Dakota State University (Mountain West Conference) Lincoln Riley, USC (Big Ten Conference) Steve Sarkisian, University of Texas (Southeastern Conference) Morgan Scalley, University of Utah (Big 12 Conference) Kalani Sitake, BYU (Big 12 Conference) Kirby Smart, University of Georgia (Southeastern Conference) Will Stein, University of Kentucky (Southeastern Conference) In addition to the Coach of the Year, the Paul “Bear” Bryant Awards will also present Conference Coach of the Year Awards from each of the Power Four collegiate athletic conferences (Atlantic Coast Conference, Big Ten, Big 12 and Southeastern Conference) and one from the combined Group of Six conferences (American Conference, Conference USA, Mid-American Conference, Mountain West Conference, Pac-12 conference, and Sun Belt Conference) and Independent teams. The National Coach of the Year Award is one of five honors presented annually during the Paul “Bear” Bryant Awards Ceremony, presented by Memorial Hermann Health System in Houston, Texas. This year’s ceremony, in its 41st year, will be held on Wednesday, January 27, 2027, in Houston and will air on CBS Sports Network. Bruce Arians, NFL Super Bowl winning and college head coach, has been selected as the Heart of a Champion Award winner and Jackie Sherrill, two-time NCAA national championship head coach, has been named the Lifetime Achievement Award recipient, while the Fan Favorite and Newcomer Coach of the Year Awards will be announced live at the show. The Paul “Bear” Bryant Awards support the American Heart Association by raising funds and awareness to advance lifesaving research and improve cardiovascular health. Fans can follow the Paul “Bear” Bryant Awards and track progress of the awards at  facebook.com/bryantawards, Paul "Bear" Bryant Awards (@bryantawards) on X or by following the hashtag #BryantAwards. To attend an exclusive virtual, VIP experience for the Bryant Awards, contact 832-918-4009 or visit bryantawards.org. About the American Heart Association The American Heart Association is a relentless force for a world of longer, healthier lives. Dedicated to ensuring equitable health in all communities, the organization has been a leading source of health information for more than one hundred years. Supported by more than 35 million volunteers globally, we fund groundbreaking research, advocate for the public’s health, and provide critical resources to save and improve lives affected by cardiovascular disease and stroke. By driving breakthroughs and implementing proven solutions in science, policy, and care, we work tirelessly to advance health and transform lives every day. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.    For Media Inquiries: Paul Smith: paul.smith@heart.org Steven Embree: steven.embree@heart.org For Public Inquiries: 1-800-AHA-USA1 (242-8721) heart.org and stroke.org ———————————————————————————————————————————————————————————— VERAXA Biotech (VRXA) Expands Human-Relevant Testing Strategy to Advance Antibody-Based Cancer Pipeline 2026-10-21 · NewMediaWire · Finance, AI, Healthcare, Media, Biotech & pharma https://www.newmediawire.com/news/veraxa-biotech-vrxa-expands-human-relevant-testing-strategy-to-advance-antibody-based-cancer-pipeline-7090778 VERAXA is implementing FDA-aligned New Approach Methodologies (“NAMs”) across its preclinical research programs, aiming to improve the relevance of experimental findings to human biology while reducing animal testing. The strategy supports development of the company’s BiTAC(R) T-cell engagers, BiTAC-based antibody-drug conjugates and bispecific antibody-drug conjugates for the treatment of cancer. New three-dimensional spheroid data reportedly reinforce the ability of VERAXA’s models to assess the dual-target specificity of its lead T-cell engager candidates. An ex vivo study involving 10 low-passage patient-derived xenograft models of non-small cell lung cancer required about 10 mice, compared with an estimated 200 or more for comparable in vivo efficacy studies. The company says its lead BiTAC candidate induced potent T-cell-mediated tumor-cell killing across the tested models, while relevant controls showed minimal activity. LOS ANGELES, CA - October 21, 2026 - VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, is expanding its use of human-relevant testing methods across its oncology research programs, seeking to generate more clinically informative preclinical data while reducing the number of animals required for drug development. In an October 7, 2026, company announcement, the Switzerland-based biotechnology company, with a key financial and regulatory presence in the U.S., outlined its implementation of New Approach Methodologies (“NAMs”), a collection of non-animal research techniques that includes cell-based assays, computational modeling and… Read More Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer The latest news and updates relating to VRXA are available in the company’s newsroom at https://ibn.fm/VRXA Forward Looking Statements Certain statements in this article are forward-looking, as defined in the Private Securities Litigation Reform Act of 1995. These statements involve risks, uncertainties, and other factors that may cause actual results to differ materially from the information expressed or implied by these forward-looking statements and may not be indicative of future results. These forward-looking statements are subject to a number of risks and uncertainties, including, among others, various factors beyond management's control, including the risks set forth under the heading "Risk Factors" discussed under the caption "Item 1A. Risk Factors" in Part I of the Company's most recent Annual Report on Form 10-K or any updates discussed under the caption "Item 1A. Risk Factors" in Part II of the Company's Quarterly Reports on Form 10-Q and in the Company's other filings with the SEC. Undue reliance should not be placed on the forward-looking statements in this article in making an investment decision, which are based on information available to us on the date hereof. All parties undertake no duty to update this information unless required by law. ———————————————————————————————————————————————————————————— Greenberg Traurig Advises OPKO Health on $722M+ Agreement to Sell Select BioReference Health Assets to Labcorp 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/greenberg-traurig-advises-opko-health-on-722m-agreement-to-sell-select-bioreference-health-assets-to-labcorp-302915762.html MIAMI, Oct. 21, 2026 -- Global law firm Greenberg Traurig, P.A. advised OPKO Health, Inc., a multinational biopharmaceutical company, on its agreement to sell select assets of its wholly owned subsidiary, BioReference Health, LLC, to Labcorp. The purchase price for the... ———————————————————————————————————————————————————————————— Antidote Health Expands into Texas and Georgia, Bringing Affordable Coverage and $0 Virtual Care to New ACA Shoppers 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/antidote-health-expands-texas-georgia-182900023.html NEW YORK, October 21, 2026--Antidote Health expands to Texas and Georgia for 2027 with ACA individual plans, plus small group coverage for Texas employers. ———————————————————————————————————————————————————————————— ACQC and AHF Dedicate Rockaway Beach HIV Healthcare and Service Center 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/acqc-ahf-dedicate-rockaway-beach-180100146.html Ribbon-cutting Thursday, October 22 nd - 3:00 p.m. Patient-centered model allows for utmost discretion and one-to-one care ROCKAWAY BEACH, N.Y., October 21, 2026--AIDS Healthcare Foundation (AHF) and AIDS Center of Queens County (ACQC) are pleased to announce the relocation of its Far Rockaway AHF Hea ———————————————————————————————————————————————————————————— Breakthrough T1D Funded Clinical Trial Testing Islet Cell Transplantation with Eledon's Tegoprubart Expands to Include People with Type 1 Diabetes and Kidney Disease 2026-10-21 · PR Newswire · Healthcare, Biotech & pharma https://www.prnewswire.com/news-releases/breakthrough-t1d-funded-clinical-trial-testing-islet-cell-transplantation-with-eledons-tegoprubart-expands-to-include-people-with-type-1-diabetes-and-kidney-disease-302915841.html NEW YORK, Oct. 21, 2026 -- A new clinical trial funded by Breakthrough T1D recently launched and is testing islet cell transplantation paired with Eledon Pharmaceuticals' investigational immunosuppression therapy tegoprubart in people living with type 1 diabetes (T1D) and... ———————————————————————————————————————————————————————————— Hand to Hold Announces 2026 National NICU Mental Health Conference Program, Invites Parents and Healthcare Professionals to Attend 2026-10-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/hand-to-hold-announces-2026-national-nicu-mental-health-conference-program-invites-parents-and-healthcare-professionals-to-attend-302915833.html November 4–5 virtual conference features sessions on trauma-informed care, caregiver burnout, grief and family-centered support led by experts and parents with lived experiences; registration is free for NICU parents. AUSTIN, Texas, Oct. 21, 2026 -- Hand to Hold, a national... ———————————————————————————————————————————————————————————— Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) 2026-10-21 · FinanceWire · Finance, Healthcare, Biotech & pharma https://financewire.com/2026/10/21/big-pharmas-obesity-shopping-spree-is-moving-beyond-glp-1s-palatin-may-fit-the-pattern-nasdaq-ptn/ WSW, NY, 21st October 2026, FinanceWire … Read More The post Big Pharma’s Obesity Shopping Spree Is Moving Beyond GLP-1s. Palatin May Fit the Pattern (NASDAQ: PTN) appeared first on FinanceWire - Financial Press Release Distribution, Finance PR. ———————————————————————————————————————————————————————————— Savara Presented New Data Showing Molgramostim Inhalation Solution (Molgramostim) Treatment Effects in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Patients with Mild Diffusion Impairment 2026-10-21 · Business Wire · Finance, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/savara-presented-data-showing-molgramostim-171000667.html -- Post-Hoc Analysis of the Phase 2/3 IMPALA Clinical Trial Presented in a Poster Presentation at the CHEST 2026 Annual Meeting -- YARDLEY, Pa., October 21, 2026--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, presented a post ———————————————————————————————————————————————————————————— The Inner Circle acknowledges Amy Salanty, MSN, RN, PMHNP-BC as a Pinnacle Lifetime Member 2026-10-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/the-inner-circle-acknowledges-amy-salanty-msn-rn-pmhnp-bc-as-a-pinnacle-lifetime-member-302915732.html HOLLYWOOD, Fla., Oct. 21, 2026 -- Prominently featured in The Inner Circle, Amy Salanty, MSN, RN, PMHNP-BC is acknowledged as a Pinnacle Lifetime Member for her contributions to Psychiatric Mental Health and Patient Centered Care. Amy Salanty, MSN, RN, PMHNP-BC, is an... ———————————————————————————————————————————————————————————— TRUE RX HEALTH STRATEGISTS BECOMES FIRST PBM TO BRING INSTACART HEALTH FRESH FUNDS TO EMPLOYER PHARMACY BENEFITS 2026-10-21 · PR Newswire · Healthcare, Food & drink https://www.prnewswire.com/news-releases/true-rx-health-strategists-becomes-first-pbm-to-bring-instacart-health-fresh-funds-to-employer-pharmacy-benefits-302915665.html Employers can now fund nutritious food stipends through Instacart for employees in True Rx's dietitian-led weight and diabetes programs INDIANAPOLIS, Oct. 21, 2026 -- True Rx Health Strategists, the family-owned, pharmacist-led pharmacy benefit manager (PBM) based in Indiana,... ———————————————————————————————————————————————————————————— Global Oral Drugs Market is Predicted to Surpass USD 1 Trillion Mark by 2034 | DelveInsight 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385792/0/en/global-oral-drugs-market-is-predicted-to-surpass-usd-1-trillion-mark-by-2034-delveinsight.html The global oral drugs market is experiencing steady growth, driven by the increasing prevalence of chronic diseases and the growing demand for convenient, patient-friendly treatment options. The expansion of oral therapies across therapeutic areas such as oncology, diabetes, cardiovascular diseases, and neurological disorders is further supporting market development. In addition, the availability of generic and branded oral drugs, expanding healthcare access, and rising pharmaceutical R&D investments are contributing to market expansion. The global oral drugs market is experiencing steady growth, driven by the increasing prevalence of chronic diseases and the growing demand for convenient, patient-friendly treatment options. The expansion of oral therapies across therapeutic areas such as oncology, diabetes, cardiovascular diseases, and neurological disorders is further supporting market development. In addition, the availability of generic and branded oral drugs, expanding healthcare access, and rising pharmaceutical R&D investments are contributing to market expansion. ———————————————————————————————————————————————————————————— Tebra Announces "Grow Into 2027" Offer, Giving New and Growing Practices its EHR+ Platform at No Cost for the Remainder of the Year 2026-10-21 · Business Wire · SaaS, Healthcare https://finance.yahoo.com/healthcare/articles/tebra-announces-grow-2027-offer-170000931.html Grow Into 2027 offer gives new customers 90 days of Tebra's All-in-One EHR, Billing, and Patient Experience platform NEWPORT BEACH, Calif., October 21, 2026--Tebra today announced Grow Into 2027, an offer giving both new and expanding practices 90 days of its all-in-one EHR platform free. Practices tha ———————————————————————————————————————————————————————————— William Blair Expands Biotech Research as Veteran Analyst Alethia Young Initiates Coverage 2026-10-21 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/william-blair-expands-biotech-research-163000938.html CHICAGO, October 21, 2026--William Blair today announced that Alethia Young has initiated coverage of 13 biotechnology companies, marking the next step in the firm's continued expansion of its biotech offering. Young joined William Blair in May 2026 as part of a broader investment in the firm's equitie ———————————————————————————————————————————————————————————— Before the ambulance arrives: How AI is helping the NHS rethink patient care 2026-10-21 · Microsoft · AI, Healthcare https://news.microsoft.com/source/emea/features/before-the-ambulance-arrives-how-ai-is-helping-the-nhs-rethink-patient-care/ The post Before the ambulance arrives: How AI is helping the NHS rethink patient care appeared first on Source. ———————————————————————————————————————————————————————————— Populus Financial Group, Inc. and Netspend Corporation Donate More Than $590,000 to National Breast Cancer Foundation 2026-10-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/populus-financial-group-inc-and-netspend-corporation-donate-more-than-590-000-to-national-breast-cancer-foundation-302915692.html DALLAS, Oct. 21, 2026 -- Populus Financial Group, Inc. (Populus) and Netspend Corporation (Netspend) have announced a $591,730 donation to National Breast Cancer Foundation, Inc.® (NBCF). Breast cancer is one of the leading health crises for women in the United States, with... ———————————————————————————————————————————————————————————— HIMS 12-DAY DEADLINE ALERT: Hims & Hers Health Faces Securities Fraud Class Action, Investors with Losses Encouraged to Contact Hagens Berman 2026-10-21 · PR Newswire · Finance, Healthcare https://www.prnewswire.com/news-releases/hims-12-day-deadline-alert-hims--hers-health-faces-securities-fraud-class-action-investors-with-losses-encouraged-to-contact-hagens-berman-302915599.html SAN FRANCISCO, Oct. 21, 2026 -- Hims & Hers Health, Inc. (NYSE: HIMS) and certain company executives now face a securities class action lawsuit stemming from the FTC's sweeping federal complaint against the company in which the Commission accuses Hims of serious business... ———————————————————————————————————————————————————————————— Kisha Davis, MD, MPH, FAAFP, Installed as AAFP President, Bringing Expertise in Public Health, Advocacy 2026-10-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/kisha-davis-md-mph-faafp-installed-as-aafp-president-bringing-expertise-in-public-health-advocacy-302913729.html NASHVILLE, Tenn., Oct. 21, 2026 -- The American Academy of Family Physicians (AAFP) today installed Kisha Davis, MD, MPH, FAAFP, as its new president. As a family physician and public health advocate, Davis brings a deep commitment to advancing health equity, strengthening... ———————————————————————————————————————————————————————————— Premier’s AI-First Supply Chain and Quality Intelligence Products Enter Real-World Member Workflows 2026-10-21 · Business Wire · AI, Healthcare, Logistics https://finance.yahoo.com/healthcare/articles/premier-ai-first-supply-chain-160000007.html Six months after announcing its multi-year technology investment, Premier moves from promise to proof, as health systems begin using and refining AI-enabled capabilities ahead of broader availability. CHARLOTTE, N.C., October 21, 2026--At its 2026 Breakthroughs Conference, Premier's President and CEO, ———————————————————————————————————————————————————————————— OOG Enters Content Agreement with the New England Journal of Medicine to Support Clinician Lifelong Learning 2026-10-21 · Business Wire · AI, SaaS, Healthcare, Media, Education https://finance.yahoo.com/healthcare/articles/oog-enters-content-agreement-england-160000150.html Agreement brings evidence from the trusted medical research of NEJM to OOG's AI-powered Continuing Education platform for verified healthcare professionals SANTA MONICA, Calif., October 21, 2026--OOG , the AI-powered learning platform built for verified healthcare professionals, today announced a content license agreement providing access to content published in the New England Journal of Medicin ———————————————————————————————————————————————————————————— Future Health and Bridge for Billions to Launch Programme Strengthening Health Entrepreneurship in Emerging Markets 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/future-health-bridge-billions-launch-155000719.html New programme will support locally rooted health entrepreneurs to build stronger ventures and deepen their impact in the communities they serve The programme responds to persistent gaps in capital and specialist support for promising health innovation across emerging markets First phase will target around 50 entrepreneurs ———————————————————————————————————————————————————————————— Median Technologies to Showcase iCRO’s Central and AI-Powered Imaging Services for Oncology Clinical Trials at ESMO 2026 2026-10-21 · Business Wire · AI, Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/median-technologies-showcase-icro-central-154500262.html Median Technologies is a leading provider of central imaging services and AI-powered image analysis for oncology clinical trials The Company will host an interactive session on the implementation of RANO 2.0 in central imaging review for neuro-oncology trials at booth #1098 The Company will also present an ePoster on the ———————————————————————————————————————————————————————————— ACGME Announces 2027 Graduate Medical Education Awardees 2026-10-21 · GlobeNewswire · Healthcare, Education https://www.globenewswire.com/news-release/2026/10/21/3385732/0/en/acgme-announces-2027-graduate-medical-education-awardees.html Chicago, IL, Oct. 21, 2026 -- The Accreditation Council for Graduate Medical Education (ACGME) is honored to recognize the 2027 recipients of the ACGME Awards, which recognize notable designated institutional officials (DIOs), program directors, coordinators, programs, institutions, organizations, residents, and fellows for their outstanding work and contributions to graduate medical education (GME). ———————————————————————————————————————————————————————————— Immunis Wins Grand Prize in National Academy of Medicine Healthy Longevity Global Competition 2026-10-21 · Business Wire · Healthcare, Biotech & pharma https://finance.yahoo.com/healthcare/articles/immunis-wins-grand-prize-national-150200149.html Grand Prize recognizes IMM01-STEM and its potential to restore muscle function, metabolic health and quality of life as people age IRVINE, Calif., October 21, 2026--Immunis, Inc., a clinical-stage biotechnology company developing first-in-class multi-active biologics for muscle health and healthy agin ———————————————————————————————————————————————————————————— Alignment Health Expands Medicare Advantage Plan to Nye County for 2027 2026-10-21 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/21/3385723/0/en/alignment-health-expands-medicare-advantage-plan-to-nye-county-for-2027.html Expansion extends Alignment’s Nevada presence to three counties, home to more than 554,000 Medicare beneficiaries Expansion extends Alignment’s Nevada presence to three counties, home to more than 554,000 Medicare beneficiaries ———————————————————————————————————————————————————————————— Watchfire Announces Winners of 12th Annual LED Sign Awards 2026-10-21 · PRWeb · Healthcare https://www.prweb.com/releases/watchfire-announces-winners-of-12th-annual-led-sign-awards-302912509.html Signworks, Inc. earns Grand Prize for Riverview Health Arena at Innovation Mile installation in Noblesville, Indiana. DANVILLE, Ill., Oct. 21, 2026 -- Watchfire today announced the winners of its annual LED Sign Awards. Now in its 12th year, the Watchfire LED Sign... ———————————————————————————————————————————————————————————— Progyny, Inc. Announces Details for Its Third Quarter 2026 Results Report 2026-10-21 · GlobeNewswire · Finance, Healthcare https://www.globenewswire.com/news-release/2026/10/21/3385709/0/en/progyny-inc-announces-details-for-its-third-quarter-2026-results-report.html NEW YORK, Oct. 21, 2026 -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended September 30, 2026, after the close of the market on Wednesday, November 4, 2026. ———————————————————————————————————————————————————————————— Spark® Wild Plum Fusion’s LTO Launches Today 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/spark-wild-plum-fusion-lto-143300146.html More Flavor Firepower Ahead This Year RICHARDSON, Texas, October 21, 2026--AdvoCare International, LLC, a leader in health and wellness products, is turning up the flavor dial once again with the launch of Spark® Wild Plum Fusion , a bold, juicy, limited‑time flavor crafted for fans who crave something ———————————————————————————————————————————————————————————— QuantalX Named Finalist in the 2026 Digital Health & AI Awards 2026-10-21 · Business Wire · AI, Healthcare https://finance.yahoo.com/healthcare/articles/quantalx-named-finalist-2026-digital-143100493.html NEW YORK, October 21, 2026--QuantalX™ Neuroscience , the company translating brain signals into better care, today announced that it has been named a finalist in the 2026 Digital Health & AI Awards in the Rising Star – Brain Health category. The Digital Health & AI Awards recognize innovations shaping ———————————————————————————————————————————————————————————— SOBX2 and Green Bronx Machine Announce Strategic Partnership To Expand National Impact 2026-10-21 · 3BL Media · Healthcare, Media, Education, Travel, Food & drink, Sustainability https://www.3blmedia.com/news/sobx2-and-green-bronx-machine-announce-strategic-partnership-expand-national-impact SOBX2 and Green Bronx Machine Announce Strategic Partnership To Expand National Impact Wed, 10/21/2026 - 10:45 Subheader Partnership will help GROW awareness and access to award-winning agricultural education, curriculum, and growing technology for schools and communities nationwide. Body NEW YORK, October 21, 2026 - Green Bronx Machine (GBM) is pleased to announce a strategic partnership with SOBX2 Strategic Operations & Business Consulting to help GROW the national reach and impact of its award-winning agricultural education curriculum, resources, and innovative growing technologies. Founded in 2011 by educator Stephen Ritz, Green Bronx Machine has grown from an innovative school-based program in the South Bronx into a nationally and internationally recognized model for using food, agriculture, and hands-on learning to strengthen students, schools, and communities. Green Bronx Machine's approach goes far beyond growing vegetables. Its comprehensive model, including acclaimed whole-school curriculum, incorporates the art and science of growing food as the point of entry for all learning. Their unique project-based learning model connects food cultivation and preparation, science and academic learning, health and wellness, life skills, and workforce development—helping students better understand where food comes from while developing healthier and more meaningful relationships with food. Image Today, Green Bronx Machine's K–12+ model integrates urban agriculture into standards-based academic instruction while supporting healthier students, stronger schools, and more resilient communities in over 1,100 schools across the nation, with 100% teacher satisfaction. Green Bronx Machine was named a “Top Ten Health and Wellness Program in the Nation” by the Harkin Institute and a Fast Company Most Innovative Company. Recently dubbed “The Miracle in the Bronx” by New York Weekly, the new partnership will make its public debut at The Council of School Supervisors and Administrators (CSA) NYC Conference on Saturday, October 24, 2026, at the New York Hilton Midtown. Through this strategic partnership, SOBX2 will bring its extensive experience in institutional management, strategic planning, school foodservice, partnerships, business development, and operational improvement to support Green Bronx Machine's continued growth. "Green Bronx Machine demonstrates what is possible when food, education, health, and community development come together," said Stephen O'Brien, Founder and President of SOBX2. "This partnership is about helping more schools and communities discover these incredible resources and giving educators practical tools to connect students with food, agriculture, learning, and future opportunities. We are excited to help GROW something greater." Aligned to the conference theme “Leading with Purpose: Innovate, Engage, Transform,” together, SOBX2 and Green Bronx Machine will work to increase awareness of Green Bronx Machine's curriculum, educational resources, growing technologies, and whole-school approach while identifying opportunities to bring the model to additional schools, districts, institutions, and communities across the country. “We could not be more excited about this partnership, and we welcome Stephen to the Bronx with open arms, open minds, open ears, and grateful hearts, ready and eager to work with him,” states Lizette B. Ritz, Executive Director of Green Bronx Machine. She adds, “Stephen O’Brien is the ultimate professional, in a class by himself, bringing decades of proven leadership and experience, in the largest school system in America, in our own backyard, to the front and center of our organization. His experience and wisdom are second to none and provide us with exactly what we need to properly and effectively scale our mission, vision, and impact.” “For years, I’ve watched Stephen O’Brien with awe, respect, and admiration, not only for what he does, but for how he does it, the results he achieves, and most importantly, how he makes people feel in the process,” says Stephen Ritz, who adds, “Stephen is the consummate professional who understands people, processes, systems, accountability, organizational needs, planning, innovation, and implementation. Stephen’s skills and strengths compliment and support Green Bronx Machine’s relentless innovation and bring tremendous validation, credibility, and gravitas to our work and our organization. I’m the first to admit that two Stephens are better than one. Together, with Lizette and the rest of Team GBM, we are a dedicated tour de force – with service and satisfaction built into our DNA - who are determined to make epic happen and we could not be more excited to do so.”  About Green Bronx Machine: www.greenbronxmachine.org. Green Bronx Machine is an award-winning, impact-driven nonprofit organization dedicated to building healthy, equitable, and resilient communities through inspired education, local food systems, and 21st-century workforce development. Its school-based model uses urban agriculture and hands-on learning to help grow healthy students, high-performing schools, and thriving communities. To date, Green Bronx Machine has trained over 13,000 teachers and impacts over 400,000 students daily. Green Bronx Machine offers curriculum, growing technologies, and multiple opportunities to bring their program to your school or community, Contact: Stephen Ritz, 917.873.6449, stephen.ritz@greenbronxmachine.org   About SOBX2 Strategic Operations & Business Consulting: www.SOBX2.com. SOBX2 Strategic Operations & Business Consulting works with organizations, institutions, nonprofits, school districts, and businesses to turn ideas into actionable strategies and sustainable results. SOBX2 brings extensive experience in institutional operations, strategic partnerships, foodservice, procurement, sustainability, business development, and organizational improvement. Contact: Stephen O’Brien, 917.565.7725, sobfood2@gmail.com   #schoolfood #health #wellness #innovation #leadership #education #sustainability #culinary #publiceducation #school #nutrition #operations #foodservice #schoolgarden #towergarden #stem #children Featured Image Type of Content Press Release ———————————————————————————————————————————————————————————— Nobel Laureates Join China’s Brain-Health Conversation: Michael Levitt and May-Britt Moser 2026-10-21 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/21/3385690/0/en/nobel-laureates-join-china-s-brain-health-conversation-michael-levitt-and-may-britt-moser.html From Molecular Research to Neuroscience: Connecting International Academic Perspectives with China’s Biomanufacturing Practice From Molecular Research to Neuroscience: Connecting International Academic Perspectives with China’s Biomanufacturing Practice ———————————————————————————————————————————————————————————— ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact Levi & Korsinsky 2026-10-21 · PR Newswire · Healthcare https://www.prnewswire.com/news-releases/ardx-investor-alert-ardelyx-inc-securities-class-action-notice---contact-levi--korsinsky-302915119.html Important Notice Regarding Alleged Payer Access and Reimbursement Misrepresentations: the lawsuit contends Ardelyx pointed investors toward $1.75 billion in combined peak sales while payer utilization-management barriers were allegedly restricting patient starts for IBSRELA and XPHOZAH.... ———————————————————————————————————————————————————————————— Union: "Health care workers are exhausted, and NLHS still wants more." 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/union-health-care-workers-exhausted-140300373.html St. John's, NL, October 21, 2026--Today, unions gathered with Newfoundland and Labrador Health Services, government representatives, and representatives from Deloitte, to hear the results of the Core Staffing Review carried out over the last year. "While some of the recommendations like creating a ment ———————————————————————————————————————————————————————————— Jackson Healthcare Named to Fortune® Best Workplaces in Health Care™ List for Ninth Consecutive Year 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/jackson-healthcare-named-fortune-best-140200284.html Organization Recognized Among Top 10 for Exceptional Workplace Culture Based on Employee Feedback ATLANTA, October 21, 2026--Jackson Healthcare ® , the trusted authority in healthcare talent and workforce solutions, today announced it has been named to the newly published 2026 Fortune ® Best Workplace ———————————————————————————————————————————————————————————— World Health Organization (WHO) supports Nigeria after first Ebola case confirmed 2026-10-21 · APO Group · Healthcare, Travel, Biotech & pharma https://www.africa-newsroom.com/press/world-health-organization-who-supports-nigeria-after-first-ebola-case-confirmed?lang=en The patient is a woman who recently travelled from Uganda and began showing symptoms on 7 October, four days after her arrival.  The woman sought care at a private health facility in the capital, Abuja, on 11 October; laboratory testing confirmed the diagnosis on 20 October.  She remains in isolation and is receiving medical care as investigations continue to determine the likely source of her infection and reconstruct her full travel and exposure history.   Contact tracing underway  WHO said the Nigerian health authorities have so far identified 44 contacts who are being monitored amid intensified efforts to find other people who may have been exposed.  Infection prevention and control measures are being ramped up in the private health facility where the woman sought care.   Cases in five countries  Nigeria is the fifth country to detect Ebola Bundibugyo virus disease since an outbreak was declared in the Democratic Republic of the Congo (DRC) in mid-May – the deadliest in the country’s history.  More than 9,500 cases and more than 4,200 deaths were recorded as of 18 October, according to latest data from the Congolese health authorities. There is currently no vaccine to treat the virus.  Uganda also faced a deadly outbreak which was officially declared over in late August, while nine cases have been reported in Kenya and one in the Netherlands that are linked to the DRC.  Containing virus spread   The Nigeria Centre for Disease Control and Prevention has activated its incident management system to coordinate response efforts, WHO said.  The UN agency stressed that rapid identification of cases, timely follow-up of contacts and effective infection prevention and control are critical to contain the spread of the virus.   WHO and partners are working closely with the Nigerian health authorities to strengthen control measures, including case investigation, contact tracing, infection prevention and control. The agency is also assisting with the provision of essential supplies including personal protective equipment for health workers.   Meanwhile, WHO has advised all countries in the region to sustain a high level of readiness as the DRC outbreak continues to evolve.   Governments are also advised to maintain strong disease surveillance and ensure that laboratories can safely test suspected cases, among other measures.  WHO has not recommended any restrictions regarding travel and trade with affected countries.  Distributed by APO Group on behalf of UN News. ———————————————————————————————————————————————————————————— AdvaMed Welcomes New White House Women's Health Initiative 2026-10-21 · WebWire · Healthcare https://www.webwire.com/ViewPressRel.asp?aId=363132 Scott Whitaker, president and CEO of AdvaMed, the Medtech Association, welcomed the executive order from President Trump launching a new women's health initiative, “Advancing Women's Health to Improve Outcomes in All Phases of Life.” Whitaker made the following comment on the initiative. - - “I want to thank President Trump for his commitment to improving women's health. From conditions that have historically been under-recognized to well-known diseases like breast cancer, medtech is gi... Read the full story at https://www.webwire.com/ViewPressRel.asp?aId=363132 ———————————————————————————————————————————————————————————— NeOnc Deepens Abu Dhabi Research Ties as Its Brain Cancer Story Moves Forward 2026-10-21 · GlobeNewswire · Finance, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385643/0/en/neonc-deepens-abu-dhabi-research-ties-as-its-brain-cancer-story-moves-forward.html NeOnc (Nasdaq: NTHI) signed a MoU with the Department of Health – Abu Dhabi to support research and clinical capability in oncology and CNS ———————————————————————————————————————————————————————————— Refined Beauty in Boise Named a Top 1% Galderma Practice Nationwide, Adds Women's Health Division and New Laser Technology 2026-10-21 · PRWeb · Healthcare https://www.prweb.com/releases/refined-beauty-in-boise-named-a-top-1-galderma-practice-nationwide-adds-womens-health-division-and-new-laser-technology-302912350.html The women-owned medical aesthetics practice, led by national Galderma trainer Rachel Ryan, FNP-C, joins the top one percent of Galderma accounts in the country and expands its team and treatment menu BOISE, Idaho, Oct. 21, 2026 -- Refined Beauty, a women-owned medical... ———————————————————————————————————————————————————————————— Sagility and Inovaare Partner to Deliver Audit-Ready Appeals and Grievances Operations for Medicare Advantage and Medicaid Health Plans 2026-10-21 · PRWeb · AI, SaaS, Healthcare https://www.prweb.com/releases/sagility-and-inovaare-partner-to-deliver-audit-ready-appeals-and-grievances-operations-for-medicare-advantage-and-medicaid-health-plans-302915216.html • The partnership combines Inovaare's AI-native HealthCloud platform for regulated payer workflows — including appeals and grievances, compliance reporting, and member and provider services — with Sagility's technology-led business operations model to provide health plans with a more... ———————————————————————————————————————————————————————————— Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder 2026-10-21 · Newswire.com · Healthcare, Biotech & pharma https://www.newswire.com/news/jaguar-health-s-crofelemer-shows-benefit-for-intestinal-failure-if-in-third Mutation of the GUCY2C gene is the third IF-related congenital enteropathy, in addition to microvillus inclusion disease (MVID) and short bowel syndrome (SBS-IF), for which crofelemer has demonstrated benefit in reducing parenteral support needs in pediatric patients Company plans to file NDA for crofelemer for MVID in mid-2027 to obtain FDA approval ———————————————————————————————————————————————————————————— Golden Cariboo Completes Property Purchase for Camp in Hixon, B.C. to Support Year-Round Exploration 2026-10-21 · NewMediaWire · Finance, Healthcare, Real estate https://www.newmediawire.com/news/golden-cariboo-completes-property-purchase-for-camp-in-hixon-b-c-to-support-year-round-exploration-7090776 VANCOUVER, BC - October 21, 2026 - Golden Cariboo Resources Ltd. (the “Company”) (CSE:GCC) (OTC:GCCFF) (WKN:A402CQ) (FSE:3TZ) announces that it has completed the purchase of a property located in Hixon, British Columbia which was the subject of its May 19, 2026 news release. The 5.36 acre freehold property comprises two adjacent lots situated on Highway 97 and has been acquired for a total purchase price of $300,000CAD. The Company now holds title to the property (the “camp”). The acquisition represents a key investment in the Company's operational readiness and long-term capacity. The Hixon-based camp will play an important role in supporting continuous exploration and development activities at Golden Cariboo's nearby Quesnelle Gold Quartz Mine Property, enabling the Company to operate 12 months a year. The Company has mobilized its Atco 5 unit skid-mounted trailers to the camp, to provide near future accommodation and operational support infrastructure for field personnel and contractors. Company President and CEO J. Frank Callaghan stated: “Being able to work 12 months a year sets Golden Cariboo apart from many peer group companies. This acquisition will support those efforts and the Company’s focus on building upon and expanding its inaugural NI 43-101 Mineral Resource Estimate announced on September 30, 2026.” Water studies, permitting and engineered plans are currently in progress to assist with the installation of camp infrastructure. Aqua Tech Ltd from Kelowna and Western Water Associates Ltd out of nearby Prince George have been onsite to complete water testing and water quality analysis, which includes review by Northern Health. Results are pending. Either the existing water licence at the camp will be transferred to the Company or a new licence may need to be applied for. Additionally, Golden Cariboo has engaged with Prince George based L&M Engineering Ltd. to complete engineering plans and permitting for either an upgraded or new septic system to support the camp. This work ensures the site will be fully functional and compliant with applicable regulations. About Golden Cariboo Resources Ltd. Golden Cariboo Resources Ltd. is rediscovering the Cariboo Gold Rush by proceeding with highly targeted drilling and trenching programs on its Quesnelle Gold Quartz Mine property which is bordered by Osisko Gold Group Inc., partly intertwined with them at the north end of the Cariboo Gold Project, and located along a favourable corridor adjacent to the Spanish and Eureka thrust faults over a 96,183 hectare (237,673 acre) area. Historically, over 101 placer gold creeks on the 90-kilometer (56 mile) trend, from the Cariboo Hudson mine north to the Quesnelle Gold Quartz Mine property, have recorded production with successful placer mining continuing to this day. Golden Cariboo’s Quesnelle Gold Quartz Mine property is 4 kilometers (2.5 miles) northeast of, and road accessible from, Hixon in central British Columbia. The Property includes the Quesnelle Quartz gold-silver deposit, which was discovered in 1865 and developed over a footprint of about 150m x 150m (less than 6 acres) at the Main zone straddling Hixon Creek. Overall, the geological setting of the gold mineralization at the Company’s Quesnelle Gold Quartz Mine property shows strong similarities with the Spanish Mountain gold deposit, situated 120 km (75 miles) towards the southeast along the same geological trend. As a sediment-hosted vein (SHV) deposit, the Spanish Mountain deposit is considered to belong to the epizonal orogenic subclass of gold deposits which include some of the world’s largest deposits such as Muruntau, Uzbekistan and Bendigo, Australia. For further information please contact: GOLDEN CARIBOO RESOURCES LTD “J. Frank Callaghan” J. Frank Callaghan, President & CEO Tel: 604-669-6463 VISIT OUR WEBSITE FOR MORE DETAILS www.goldencariboo.com LIKE AND FOLLOW Instagram, Facebook, X (Twitter), LinkedIn Neither the “CSE” Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release. Cautionary Statements: This news release contains statements which constitute “forward-looking information” within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of the Company with respect to future business activities and plans of the Company. Forward-looking information is often identified by the words “may”, “would”, “could”, “should”, “will”, “intend”, “plan”, “anticipate”, “believe”, “estimate”, “expect” or similar expressions and includes information regarding; the expectation that the Company will receive all necessary exemptions and approvals to complete the Offering; the expectation that the Company will complete the Offering on the terms disclosed, or at all; the expectation that the proceeds will be used for property exploration and for general working capital; the Company’s exploration plans with respect to its Quesnelle Gold Quartz Mine property; and the anticipated participation of the insider in the Offering. Such forward-looking statements are based on a number of assumptions of management, including, without limitation, that the Company will receive all necessary exemptions and approvals to complete the Offering; that the Company will complete the Offering on the terms disclosed, or at all; that the proceeds will be used for property exploration and for general working capital; that the Company will have the resources required to proceed with its exploration plans; that the Company will not run into regulatory or other barriers in carrying out its business plans; that the insider will participate in the Offering, on the terms and conditions and in the amount currently expected by management; and that the Company will be able to rely on the exemption from the formal valuation and minority shareholder approval requirements on the basis anticipated. Additionally, forward-looking information involve a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of the Company to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: that the Company will not receive the necessary exemptions and approvals to complete the Offering; that the Company will not complete the Offering on the terms disclosed, or at all; that the Company will be unable to use the proceeds for property exploration and for general working capital; that the Company may incur unanticipated costs; that the Company may not have the resources required to pursue its exploration plans; that the Company’s operations could be adversely affected by possible future government legislation policies and controls or by changes in applicable laws and regulations; that the insider may not participate in the Offering on the terms and conditions and in the amount currently expected by management, or at all; and that the Company may not be able to rely on the exemption from the formal valuation and minority shareholder approval requirements on the basis currently expected. Such forward-looking information represents management’s best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. Neither the Company nor any of its representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this news release. Neither the Company nor any of its representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this news release by you or any of your representatives or for omissions from the information in this news release. The forward-looking statements herein speak only as of the date they were originally made. The Company has no intention and undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. ———————————————————————————————————————————————————————————— Medical Care Technologies Inc. (OTCID:MDCE) Transitions From Selling AI Software to Also Providing AI Model Training Consulting 2026-10-21 · Newswire.com · AI, Healthcare https://www.newswire.com/news/medical-care-technologies-inc-otcid-mdce-transitions-from-selling-ai-software Company Adds Enterprise Consulting Services Alongside First $250,000 Software Agreement and Six-Figure Collectibles Partnership Activity ———————————————————————————————————————————————————————————— Angkor Resources Presents Its Proposed 2027 Work Program For Block Viii to The Cambodian Government at the Joint Review Committee 2026-10-21 · NewMediaWire · Healthcare, Real estate, Energy, Media, Logistics https://www.newmediawire.com/news/angkor-resources-presents-its-proposed-2027-work-program-for-block-viii-to-the-cambodian-government-at-the-joint-review-committee-7090775 GRANDE PRAIRIE, ALBERTA - October 21, 2026 - ANGKOR RESOURCES CORP. (TSXV: ANK OTCQB: ANKOF) (“ANGKOR” OR “THE COMPANY”) announces that its Cambodian energy subsidiary, EnerCam Resources Co., Ltd. (“EnerCam”), presented its 2026 work program results and its proposed 2027 work program for Block VIII to the Royal Government of Cambodia at a Joint Review Committee (“JRC”) meeting held October 6, 2026 at the Ministry of Mines and Energy (“MME”) in Phnom Penh. Under the terms of EnerCam’s Production Sharing Contract (“PSC”), the Joint Review Committee meets twice each year to review progress on Block VIII with the government. The EnerCam team delivered technical, administrative and logistics presentations covering geology, geophysics, drilling, the Environmental Impact Assessment (“EIA”) and corporate social responsibility (“CSR”) programs, along with the proposed 2027 budget. Mike Weeks, President of EnerCam, commented: “Twice a year we sit down with the Ministry and walk through everything - the geology, the seismic, the well design, the environment work and what we’ve done in the communities. The feedback from the Ministry was positive, and the questions were the right ones for a project getting close to the drill bit. We’re now updating the 2027 budget and the 2026 actuals, so the Ministry has the full picture as we move to the tender and to drilling Cambodia’s first onshore wells.” EnerCam was represented in person by Mike Weeks, President, Mads Braemer, CFO, and Country Manager Bunchhay Yun, with technical team members Dr. David Johnson, Keith Edwards and John Koch, and Angkor CEO Delayne Weeks joining by video link. THE MEETING AT A GLANCE EnerCam reported its 2026 activities against the approved 2026 work program and proposed its program for Exploration Stage 1 - Year 3, running January 1 to December 31, 2027. The 2027 program targets the start of exploration drilling in 2027, with North Bokor planned as the first well. Three approvals were received in 2026: the CSR Program, approved by MME on May 13; the Health, Safety and Environment Manual, approved by MME on August 24; and the drilling EIA, approved by the Ministry of Environment on September 15. EnerCam is now updating its 2027 budget and its 2026 budget-to-actual comparison for MME. Click here to see Figure 1: EnerCam presents its drilling and testing procedures to the Block VIII Joint Review Committee, October 6, 2026. 2026 WORK PRESENTED TO THE COMMITTEE Geology. Oil seep samples collected in 2025 were analyzed in 2026, and the results are consistent with the 2015 Schlumberger evaluation, indicating a thermogenic source. A surface coal sample analyzed by the Institute for Energy Technology (IFE) in Norway indicates the source rock is within the early to peak oil generation window. Field studies carried out with students at the Institute of Technology of Cambodia (“ITC”) helped define the trend and plunge of the northern axis of the North Bokor anticline and identified quartz arenite sandstones at surface with 13–14% porosity. Geophysics. The team completed interpretation of the two key unconformity surfaces, the Indosinian 1 and Indosinian 3 horizons, converted seismic sections to depth, and ran seismic attribute and pre-stack amplitude analysis. Proposed drilling locations were selected to sit within closure, intersect the strongest seismic amplitudes, and test fractured Permian carbonates below the Indosinian 1 surface. Drilling. EnerCam completed the engineering design and detailed program for the drilling, completion, stimulation and testing of its exploration wells. Each well is designed to be completed in a full production configuration, flow-tested for four weeks, and then shut in for a 12-week pressure build-up, so that the test yields a definitive answer on the commerciality of the reservoir. During 2026 the team made two visits to China to meet three potential drilling service providers, and hosted site visits to Block VIII by two potential drilling contractors. Environment and CSR. The drilling EIA, prepared by Cambodian consultant Green Assessment Co., Ltd., was submitted to the Ministry of Environment on May 12, 2026, reviewed at an inter-ministerial meeting of five Ministries and three provinces on July 14, and approved on September 15. Under its previously approved CSR Program, EnerCam promised and did install playgrounds at 11 primary schools in three provinces, benefiting approximately 3,900 students, and has installed latrines for selected poor families in one district, with further installations being coordinated with local authorities. Four ITC students completed three-month internships with EnerCam in geoscience departments. THE 2027 PROGRAM With drill targets identified in 2025 and confirmed with drilling detail in 2026 during years 1 and 2, EnerCam proposed that Year 3 of Exploration Stage 1 be directed to prepare for exploratory drilling. The schedule presented to the Committee includes: preparation of the drilling tender document, followed by government review and approval before the tender is published to bidders; bid selection in early 2027, followed by drill pad construction and mobilization of the rig, services, casing and wellheads; import permits for downhole perforating charges and for the radioactive sources used in well logging, with EnerCam’s request for an MME support letter for the perforating charges planned for October 2026; drilling of the North Bokor well, which, as previously reported, has the largest of the three mapped Bokor closures at a mean area of 100 square kilometers, followed by a second well; a field program of seep and source-rock sampling and laboratory analysis to further test the elements of the petroleum system; and processing of additional seismic data recorded on adjacent lines during the 2025 survey, giving denser coverage over the South and Central Bokor locations. As Cambodia imports 100% of its hydrocarbon-based energy products, discovering a national domestic supply of oil and gas remains a high priority. The Company will continue providing further updates on the drilling tender, drilling contractors and well-planning progress at regular intervals. ABOUT ANGKOR RESOURCES CORP. ANGKOR Resources Corp. is a public company, listed on the TSX-Venture Exchange, and is a leading resource explorer and developer in Cambodia working towards mineral and energy solutions across the country. The Company’s mineral subsidiary, Angkor Gold Corp. Co., Ltd., currently holds two mineral exploration licenses in Cambodia with multiple prospects in copper and gold. Both licenses are in their first two-year renewal term. Angkor’s Cambodian energy subsidiary, EnerCam Resources Co., Ltd., was granted an onshore oil and gas license in the southwest quadrant of Cambodia called Block VIII. The license covers an area of approximately 4095 square kilometers. EnerCam is actively advancing oil and gas exploration activities onshore to meet its mission to prove Cambodia as a nation with its own oil and gas resources. The Company completed 2D-seismic in 2025 and has identified multiple drill targets with multiple target zones. The Company plans to follow with drilling Cambodia’s first privately financed onshore exploratory oil and gas wells under a Production Sharing Contract. CONTACT: Delayne Weeks - CEO Email:- info@angkorresources.com Website:angkorresources.com Telephone: +1 (780) 831-8722 Please follow @AngkorResources on LinkedIn, Facebook, Twitter, Instagram and YouTube. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.  Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to oil and gas risks of the seismic interpretation uncertainty and the preliminary nature of structural closure estimates; drilling risk and the absence of a drilled well on the Concession; reservoir and fluid uncertainty; PSC compliance obligations and the risk of relinquishment for non-performance; oil price exposure; and Cambodia-specific sovereign and regulatory risk. As well, additional uncertainties on the mineral projects exist regarding the potential for gold and/or other minerals at any of the Company’s properties, the prospective nature of any claims comprising the Company’s property interests, the impact of general economic conditions, industry conditions, dependence upon regulatory approvals, uncertainty of sample results, timing and results of future exploration, and the availability of financing. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. ———————————————————————————————————————————————————————————— Today in the UK, I saw how the Yorkshire Ambulance Service NHS Trust is using Copilot to cut down on administrative work and make better use of its data, and ultimately provide a better experience for medical personnel and patients. [Read more] 2026-10-21 · Microsoft · Healthcare https://www.linkedin.com/feed/update/urn:li:activity:7518622101692436482/ The post Today in the UK, I saw how the Yorkshire Ambulance Service NHS Trust is using Copilot to cut down on administrative work and make better use of its data, and ultimately provide a better experience for medical personnel and patients. [Read more] appeared first on Source. ———————————————————————————————————————————————————————————— As AI Makes Faces Easier to Misuse, ImageShield® Expands Likeness Protection for Personal Cybersecurity 2026-10-21 · PRWeb · AI, Healthcare, Cybersecurity https://www.prweb.com/releases/as-ai-makes-faces-easier-to-misuse-imageshield-expands-likeness-protection-for-personal-cybersecurity-302915235.html Launching during Cybersecurity Awareness Month, the new ImageShield combines a free educational assessment, personalized Likeness Health Score℠ and ongoing monitoring to help people understand and strengthen their likeness protection FAIRFAX, Va., Oct. 21, 2026 --... ———————————————————————————————————————————————————————————— AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE 2026-10-21 · Business Wire · Finance, Healthcare https://finance.yahoo.com/healthcare/articles/angiodynamics-announces-publication-direct-study-123000520.html Prospective, multicenter FDA IDE study found an IRE-based treatment strategy was associated with longer overall survival in Stage III pancreatic cancer; new Category I CPT code for open pancreatic IRE takes effect January 1, 2027 LATHAM, N.Y., October 21, 2026--AngioDynamics, Inc. (NASDAQ: ANGO), a lea ———————————————————————————————————————————————————————————— Southwest General Expands Relationship with Oracle to Connect Care, Finance, and Operations 2026-10-21 · Oracle · Healthcare https://www.prnewswire.com/news-releases/southwest-general-expands-relationship-with-oracle-to-connect-care-finance-and-operations-302914621.html Southwest General, a private, not-for-profit, acute care hospital in Middleburg Heights, Ohio, is expanding its relationship with Oracle. Building on ... ———————————————————————————————————————————————————————————— Santa Ana Bio to Present Preclinical Data on SAB05, a CD40-Targeted Glucocorticoid Antibody-Drug Conjugate, at ACR Convergence 2026 2026-10-21 · GlobeNewswire · Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385497/0/en/santa-ana-bio-to-present-preclinical-data-on-sab05-a-cd40-targeted-glucocorticoid-antibody-drug-conjugate-at-acr-convergence-2026.html ALAMEDA, Calif., Oct. 21, 2026 -- Santa Ana Bio, a clinical-stage precision immunology company, today announced that preclinical data on SAB05, its CD40-targeted glucocorticoid antibody-drug conjugate (ADC), will be presented in a poster at ACR Convergence 2026, the annual meeting of the American College of Rheumatology (ACR), taking place November 6–11, 2026, in Orlando, Florida. ———————————————————————————————————————————————————————————— Inspire and PatientPartner Announce Partnership to Expand Patient Mentorship and Community Support 2026-10-21 · GlobeNewswire · Healthcare https://www.globenewswire.com/news-release/2026/10/21/3385493/0/en/inspire-and-patientpartner-announce-partnership-to-expand-patient-mentorship-and-community-support.html This partnership creates new opportunities for patients to share their stories, support others, and connect with peers navigating similar health conditions. This partnership creates new opportunities for patients to share their stories, support others, and connect with peers navigating similar health conditions. ———————————————————————————————————————————————————————————— VivoSim Labs Extends NAMkind Platform with Human Disease Models for Efficacy Testing and Mechanistic Biomarker Profiling 2026-10-21 · GlobeNewswire · SaaS, Healthcare, Biotech & pharma https://www.globenewswire.com/news-release/2026/10/21/3385494/37000/en/vivosim-labs-extends-namkind-platform-with-human-disease-models-for-efficacy-testing-and-mechanistic-biomarker-profiling.html Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials Patient-derived liver and intestinal disease models are designed to help drug developers test whether a candidate reduces human disease in tissue before it reaches clinical trials ———————————————————————————————————————————————————————————— NOR Healthcare Systems Corp. Expands Mobile Patient Access Across Six Hospitals with Altera Digital Health's Sunrise CarePath 2026-10-21 · Business Wire · Healthcare https://finance.yahoo.com/healthcare/articles/nor-healthcare-systems-corp-expands-120100193.html Southern California hospital network will be the fourth Sunrise client to empower patients with added self-management and communication capabilities NIAGARA FALLS, N.Y., October 21, 2026--Altera Digital Health , a global health IT leader, today announced that NOR Healthcare Systems Corp. (NOR) will im